AU2001257413A1 - Arylmethylamine derivatives for use as tryptase inhibitors - Google Patents
Arylmethylamine derivatives for use as tryptase inhibitorsInfo
- Publication number
- AU2001257413A1 AU2001257413A1 AU2001257413A AU2001257413A AU2001257413A1 AU 2001257413 A1 AU2001257413 A1 AU 2001257413A1 AU 2001257413 A AU2001257413 A AU 2001257413A AU 2001257413 A AU2001257413 A AU 2001257413A AU 2001257413 A1 AU2001257413 A1 AU 2001257413A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- phenyl
- aryl
- piperidin
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002750 tryptase inhibitor Substances 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims description 395
- 238000000034 method Methods 0.000 claims description 239
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- 229910052739 hydrogen Inorganic materials 0.000 claims description 96
- 125000003118 aryl group Chemical group 0.000 claims description 95
- -1 hydroxy, ureido Chemical group 0.000 claims description 90
- 125000001072 heteroaryl group Chemical group 0.000 claims description 89
- 239000001257 hydrogen Substances 0.000 claims description 58
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000005843 halogen group Chemical group 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 32
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 31
- 102000001400 Tryptase Human genes 0.000 claims description 29
- 108060005989 Tryptase Proteins 0.000 claims description 29
- 150000002431 hydrogen Chemical group 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 125000001041 indolyl group Chemical group 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 150000001204 N-oxides Chemical class 0.000 claims description 18
- 206010003246 arthritis Diseases 0.000 claims description 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 17
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 17
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 16
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 16
- 208000006673 asthma Diseases 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 125000002252 acyl group Chemical group 0.000 claims description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 15
- 239000003246 corticosteroid Substances 0.000 claims description 15
- 239000000556 agonist Substances 0.000 claims description 14
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 14
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 125000001544 thienyl group Chemical group 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000003435 aroyl group Chemical group 0.000 claims description 12
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 12
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 12
- 125000004104 aryloxy group Chemical group 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000002541 furyl group Chemical group 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 10
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 9
- 230000001668 ameliorated effect Effects 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 8
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 8
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 210000000845 cartilage Anatomy 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 208000018937 joint inflammation Diseases 0.000 claims description 7
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims description 6
- 230000036783 anaphylactic response Effects 0.000 claims description 6
- 208000003455 anaphylaxis Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 230000001969 hypertrophic effect Effects 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 208000028169 periodontal disease Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 231100000241 scar Toxicity 0.000 claims description 6
- 230000004614 tumor growth Effects 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 5
- 201000004404 Neurofibroma Diseases 0.000 claims description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
- 206010048873 Traumatic arthritis Diseases 0.000 claims description 5
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 5
- 125000006383 alkylpyridyl group Chemical group 0.000 claims description 5
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 5
- PZCWEEOFDCYLCR-MBUXBYMASA-N ethyl (3s,4r)-4-[3-(aminomethyl)phenyl]-1-[5-(2-phenylethyl)pyridine-3-carbonyl]piperidine-3-carboxylate;dihydrochloride Chemical compound Cl.Cl.C1([C@@H]2CCN(C[C@H]2C(=O)OCC)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=CC=CC(CN)=C1 PZCWEEOFDCYLCR-MBUXBYMASA-N 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 201000005404 rubella Diseases 0.000 claims description 5
- VOBWLFNYOWWARN-UHFFFAOYSA-N thiophen-3-one Chemical compound O=C1CSC=C1 VOBWLFNYOWWARN-UHFFFAOYSA-N 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 201000005539 vernal conjunctivitis Diseases 0.000 claims description 5
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 4
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 claims description 4
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 4
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 4
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 4
- 229960000265 cromoglicic acid Drugs 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 4
- 229960001022 fenoterol Drugs 0.000 claims description 4
- 229960000676 flunisolide Drugs 0.000 claims description 4
- 229960002848 formoterol Drugs 0.000 claims description 4
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229960002259 nedocromil sodium Drugs 0.000 claims description 4
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 4
- 229960002052 salbutamol Drugs 0.000 claims description 4
- 229960000195 terbutaline Drugs 0.000 claims description 4
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 4
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 4
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 3
- UTMHTSVCUOVUSH-UHFFFAOYSA-N 4-[3-(aminomethyl)phenyl]-1-[5-(2-phenylethyl)pyridine-3-carbonyl]piperidine-4-carbonitrile;[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3,4-dichlorophenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(Cl)C(Cl)=CC=2)=C1.NCC1=CC=CC(C2(CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)C#N)=C1 UTMHTSVCUOVUSH-UHFFFAOYSA-N 0.000 claims description 3
- MCQWELVDXSSVNE-UHFFFAOYSA-N 4-[3-(aminomethyl)phenyl]piperidine-1-carboxylic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(O)=O)=C1 MCQWELVDXSSVNE-UHFFFAOYSA-N 0.000 claims description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 3
- BMGUQSJLWYQHHA-UHFFFAOYSA-N 1-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-3-methylsulfanyl-6,7-dihydro-5h-2-benzothiophen-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=12CCCC(=O)C2=C(SC)SC=1C(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 BMGUQSJLWYQHHA-UHFFFAOYSA-N 0.000 claims description 2
- HHKGATDJOAYQSW-UHFFFAOYSA-N 4-[3-(aminomethyl)phenyl]-n-(3,4-dichlorophenyl)piperidine-1-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)NC=2C=C(Cl)C(Cl)=CC=2)=C1 HHKGATDJOAYQSW-UHFFFAOYSA-N 0.000 claims description 2
- UEMUFZHSNOUPKR-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3-bromo-5-iodophenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(I)C=C(Br)C=2)=C1 UEMUFZHSNOUPKR-UHFFFAOYSA-N 0.000 claims description 2
- SGSBBQAXTBXELX-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-(2-phenylethyl)phenyl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=CC=2)=C1 SGSBBQAXTBXELX-UHFFFAOYSA-N 0.000 claims description 2
- KMXXSMSBPCYYHI-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[2-(6-aminopyridin-3-yl)ethyl]phenyl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=NC(N)=CC=3)C=CC=2)=C1 KMXXSMSBPCYYHI-UHFFFAOYSA-N 0.000 claims description 2
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical group N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims 4
- 208000011906 peptic ulcer disease Diseases 0.000 claims 3
- OJBYFYZTTBGOCP-UHFFFAOYSA-N 1-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-3-propan-2-ylsulfanyl-6,7-dihydro-5h-2-benzothiophen-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=12CCCC(=O)C2=C(SC(C)C)SC=1C(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 OJBYFYZTTBGOCP-UHFFFAOYSA-N 0.000 claims 1
- HEUJWNJDXIRLFV-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[2-(2-fluorophenyl)ethyl]phenyl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C(=CC=CC=3)F)C=CC=2)=C1 HEUJWNJDXIRLFV-UHFFFAOYSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 254
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 209
- 239000007787 solid Substances 0.000 description 153
- 239000000203 mixture Substances 0.000 description 123
- 239000000243 solution Substances 0.000 description 117
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 99
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 82
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 73
- 235000019439 ethyl acetate Nutrition 0.000 description 70
- 229940093499 ethyl acetate Drugs 0.000 description 69
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
- 238000005160 1H NMR spectroscopy Methods 0.000 description 63
- 150000002500 ions Chemical class 0.000 description 63
- 239000007921 spray Substances 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 58
- 239000011541 reaction mixture Substances 0.000 description 54
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
- 238000006243 chemical reaction Methods 0.000 description 46
- 239000003921 oil Substances 0.000 description 46
- 235000019198 oils Nutrition 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 34
- 239000000741 silica gel Substances 0.000 description 34
- 229910002027 silica gel Inorganic materials 0.000 description 34
- 239000000463 material Substances 0.000 description 33
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 32
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 31
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- 235000019341 magnesium sulphate Nutrition 0.000 description 29
- WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 27
- 239000011347 resin Substances 0.000 description 27
- 229920005989 resin Polymers 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000012230 colorless oil Substances 0.000 description 24
- 238000009472 formulation Methods 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 22
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- 239000002253 acid Substances 0.000 description 21
- XMHNLZXYPAULDF-UHFFFAOYSA-N 4-bromo-1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1CBr XMHNLZXYPAULDF-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- 238000004587 chromatography analysis Methods 0.000 description 20
- QYRFJLLXPINATB-UHFFFAOYSA-N hydron;2,4,5,6-tetrafluorobenzene-1,3-diamine;dichloride Chemical compound Cl.Cl.NC1=C(F)C(N)=C(F)C(F)=C1F QYRFJLLXPINATB-UHFFFAOYSA-N 0.000 description 20
- 125000006239 protecting group Chemical group 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 18
- DXJZBANECHYHRT-UHFFFAOYSA-N 5-(2-phenylethynyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(C#CC=2C=CC=CC=2)=C1 DXJZBANECHYHRT-UHFFFAOYSA-N 0.000 description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 17
- 238000000105 evaporative light scattering detection Methods 0.000 description 17
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 15
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 14
- 239000012442 inert solvent Substances 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 14
- YUEPFPUBEDTMTC-UHFFFAOYSA-N 3-methylsulfanyl-4-oxo-6,7-dihydro-5h-2-benzothiophene-1-carboxylic acid Chemical compound C1CCC(=O)C2=C(SC)SC(C(O)=O)=C21 YUEPFPUBEDTMTC-UHFFFAOYSA-N 0.000 description 13
- 239000012298 atmosphere Substances 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 238000010511 deprotection reaction Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- GHTDODSYDCPOCW-UHFFFAOYSA-N 1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CNC2=C1 GHTDODSYDCPOCW-UHFFFAOYSA-N 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 11
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 11
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 11
- 239000012312 sodium hydride Substances 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- PJENQPVQJVVCAP-UHFFFAOYSA-N [3-[4-[3-[[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]piperidine-1-carbonyl]phenyl]carbamic acid Chemical compound C(C)(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC=1C=C(C=CC1)C1CCN(CC1)C(=O)C=1C=C(C=CC1)NC(O)=O PJENQPVQJVVCAP-UHFFFAOYSA-N 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 8
- 239000002480 mineral oil Substances 0.000 description 8
- 235000010446 mineral oil Nutrition 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 235000017550 sodium carbonate Nutrition 0.000 description 8
- 229940001593 sodium carbonate Drugs 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 229940086542 triethylamine Drugs 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- TVVLDCQYTBYDPD-UHFFFAOYSA-N 5-(2-phenylethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(CCC=2C=CC=CC=2)=C1 TVVLDCQYTBYDPD-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 235000011056 potassium acetate Nutrition 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000003875 Wang resin Substances 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 229940014259 gelatin Drugs 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- IMNOWEMCWIDYNW-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]-n-[(3-piperidin-4-ylphenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(C2CCNCC2)=C1 IMNOWEMCWIDYNW-UHFFFAOYSA-N 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- RFHZBPMSLDVPGS-UHFFFAOYSA-N (3-piperidin-4-ylphenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=CC(C2CCNCC2)=C1 RFHZBPMSLDVPGS-UHFFFAOYSA-N 0.000 description 4
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical group CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- XIWBSOUNZWSFKU-UHFFFAOYSA-N ethyl piperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCNC1 XIWBSOUNZWSFKU-UHFFFAOYSA-N 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- XCAQIUOFDMREBA-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=O)OC(C)(C)C XCAQIUOFDMREBA-UHFFFAOYSA-N 0.000 description 4
- WPXFKOSNDNRKIL-UHFFFAOYSA-N tert-butyl n-[(3-bromo-4-fluorophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(F)C(Br)=C1 WPXFKOSNDNRKIL-UHFFFAOYSA-N 0.000 description 4
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- RZJGKPNCYQZFGR-UHFFFAOYSA-N 1-(bromomethyl)naphthalene Chemical compound C1=CC=C2C(CBr)=CC=CC2=C1 RZJGKPNCYQZFGR-UHFFFAOYSA-N 0.000 description 3
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 3
- 238000004293 19F NMR spectroscopy Methods 0.000 description 3
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- VICGWDSJFIOZOO-UHFFFAOYSA-N 6-bromopyridine-3-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=C(Br)N=C1 VICGWDSJFIOZOO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- ATVRWPXACFDNID-UHFFFAOYSA-N [4-[3-(1-aminoethyl)phenyl]piperidin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone;dihydrochloride Chemical compound Cl.Cl.CC(N)C1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 ATVRWPXACFDNID-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000005530 alkylenedioxy group Chemical group 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 3
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 3
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- CANLSXRPXMCFAA-UHFFFAOYSA-N benzyl-[3-[4-[3-[[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]piperidine-1-carbonyl]phenyl]carbamic acid Chemical compound C(C1=CC=CC=C1)N(C(O)=O)C1=CC(=CC=C1)C(=O)N1CCC(CC1)C1=CC(=CC=C1)CN(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C CANLSXRPXMCFAA-UHFFFAOYSA-N 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 239000011257 shell material Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- UBGQFNJKGIILPI-UHFFFAOYSA-N tert-butyl n-[3-[4-[3-[[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]piperidine-1-carbonyl]phenyl]-n-[(4-bromophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)N(CC=2C=CC(Br)=CC=2)C(=O)OC(C)(C)C)=C1 UBGQFNJKGIILPI-UHFFFAOYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- WIRTWOIWFFCEPB-UHFFFAOYSA-N (3-bromo-4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C(Br)=C1 WIRTWOIWFFCEPB-UHFFFAOYSA-N 0.000 description 2
- QLIJEXONEGCCON-UHFFFAOYSA-N (3-bromo-4-phenylmethoxyphenyl)methylcarbamic acid Chemical compound BrC1=CC(CNC(=O)O)=CC=C1OCC1=CC=CC=C1 QLIJEXONEGCCON-UHFFFAOYSA-N 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 2
- XPEIJWZLPWNNOK-UHFFFAOYSA-N (4-phenylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=CC=CC=C1 XPEIJWZLPWNNOK-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- ZPCJPJQUVRIILS-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)benzene Chemical compound BrCC1=CC=CC(Br)=C1 ZPCJPJQUVRIILS-UHFFFAOYSA-N 0.000 description 2
- TWVUTEBEOYXQDC-UHFFFAOYSA-N 1-ethylindole-3-carboxylic acid Chemical compound C1=CC=C2N(CC)C=C(C(O)=O)C2=C1 TWVUTEBEOYXQDC-UHFFFAOYSA-N 0.000 description 2
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 2
- IMSGLFSCCSFDAS-UHFFFAOYSA-N 2-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]-1-(4-hydroxyphenyl)ethanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CC(=O)C=3C=CC(O)=CC=3)C=CC=2)=C1 IMSGLFSCCSFDAS-UHFFFAOYSA-N 0.000 description 2
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 2
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- WSUJOBUFWOMRNC-UHFFFAOYSA-N 2-trimethylsilylethyl 4-(3-cyanophenyl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OCC[Si](C)(C)C)CCC(C=2C=C(C=CC=2)C#N)=C1 WSUJOBUFWOMRNC-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- VPHHJAOJUJHJKD-UHFFFAOYSA-N 3,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(Cl)=C1 VPHHJAOJUJHJKD-UHFFFAOYSA-N 0.000 description 2
- UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 2
- SAPAUOFSCLCQJB-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C(O)=O)=C1 SAPAUOFSCLCQJB-UHFFFAOYSA-N 0.000 description 2
- IZXDUYXMTBSKJR-UHFFFAOYSA-N 3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-1h-quinolin-4-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C(=C3C=CC=CC3=NC=2)O)=C1 IZXDUYXMTBSKJR-UHFFFAOYSA-N 0.000 description 2
- AJQDEUJYFUHVHS-UHFFFAOYSA-N 3-bromo-5-(bromomethyl)pyridine Chemical compound BrCC1=CN=CC(Br)=C1 AJQDEUJYFUHVHS-UHFFFAOYSA-N 0.000 description 2
- VOIZNVUXCQLQHS-UHFFFAOYSA-N 3-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC(Br)=C1 VOIZNVUXCQLQHS-UHFFFAOYSA-N 0.000 description 2
- OGZUGPOTBGMCLE-UHFFFAOYSA-N 4-(2-phenylethynyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C#CC1=CC=CC=C1 OGZUGPOTBGMCLE-UHFFFAOYSA-N 0.000 description 2
- JVGIFSLDPGHONA-UHFFFAOYSA-N 4-(3-cyanophenyl)-4-hydroxypiperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1(O)C1=CC=CC(C#N)=C1 JVGIFSLDPGHONA-UHFFFAOYSA-N 0.000 description 2
- ADFVZNLMCBKCPR-UHFFFAOYSA-N 4-hydroxy-4-[3-(phenylmethoxycarbonylaminomethyl)phenyl]piperidine-1-carboxylic acid Chemical compound C(C1=CC=CC=C1)OC(=O)NCC=1C=C(C=CC1)C1(CCN(CC1)C(=O)O)O ADFVZNLMCBKCPR-UHFFFAOYSA-N 0.000 description 2
- MIOGAEMLGAPYFB-UHFFFAOYSA-N 5-(2-phenylethynyl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C#CC1=CC=CC=C1 MIOGAEMLGAPYFB-UHFFFAOYSA-N 0.000 description 2
- QTMFBTMLLNVUPT-UHFFFAOYSA-N 5-(3-chlorophenyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(C=2C=C(Cl)C=CC=2)=C1 QTMFBTMLLNVUPT-UHFFFAOYSA-N 0.000 description 2
- KOKMNLWZMSIVQZ-UHFFFAOYSA-N 5-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CN=CC(C(O)=O)=C1 KOKMNLWZMSIVQZ-UHFFFAOYSA-N 0.000 description 2
- UYQIRJWFRMCAID-UHFFFAOYSA-N 6-chloroquinoline-3-carboxylic acid Chemical compound C1=CC(Cl)=CC2=CC(C(=O)O)=CN=C21 UYQIRJWFRMCAID-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- FFXUIJZNIZJKJN-UHFFFAOYSA-N [3-bromo-5-(bromomethyl)phenoxy]-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC1=CC(Br)=CC(CBr)=C1 FFXUIJZNIZJKJN-UHFFFAOYSA-N 0.000 description 2
- UNGMAHWVYMKIID-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(1-ethylindol-3-yl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC=CC=C2N(CC)C=C1C(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 UNGMAHWVYMKIID-UHFFFAOYSA-N 0.000 description 2
- OLJQTVNTKSNOOS-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-(2-phenylethynyl)phenyl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 OLJQTVNTKSNOOS-UHFFFAOYSA-N 0.000 description 2
- CIDNHVFHZRKZAK-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-(benzylamino)phenyl]methanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NCC=3C=CC=CC=3)C=CC=2)=C1 CIDNHVFHZRKZAK-UHFFFAOYSA-N 0.000 description 2
- ZHVADSSWGSUNSP-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-(phenoxymethyl)phenyl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(COC=3C=CC=CC=3)C=CC=2)=C1 ZHVADSSWGSUNSP-UHFFFAOYSA-N 0.000 description 2
- QEPNLRHOQHDVNN-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[(4-bromophenyl)methylamino]phenyl]methanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NCC=3C=CC(Br)=CC=3)C=CC=2)=C1 QEPNLRHOQHDVNN-UHFFFAOYSA-N 0.000 description 2
- ORAOCMSYWTWBRY-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[2-(6-aminopyridin-3-yl)ethyl]phenyl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=NC(N)=CC=3)C=CC=2)=C1 ORAOCMSYWTWBRY-UHFFFAOYSA-N 0.000 description 2
- DRXCAFOYVAOADS-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 DRXCAFOYVAOADS-UHFFFAOYSA-N 0.000 description 2
- UHWMJEVMTNBERU-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-phenylmethanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=CC=CC=2)=C1 UHWMJEVMTNBERU-UHFFFAOYSA-N 0.000 description 2
- XCFIMNBRUIZTTA-UHFFFAOYSA-N [4-[5-(aminomethyl)-2-hydroxyphenyl]piperidin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=C(O)C(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 XCFIMNBRUIZTTA-UHFFFAOYSA-N 0.000 description 2
- DVOLGTSDPBCKOL-UHFFFAOYSA-N [4-[5-(aminomethyl)-2-methylphenyl]piperidin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone;dihydrochloride Chemical compound Cl.Cl.CC1=CC=C(CN)C=C1C1CCN(C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)CC1 DVOLGTSDPBCKOL-UHFFFAOYSA-N 0.000 description 2
- MWIVVJKNMNXLBB-UHFFFAOYSA-N [4-[5-(aminomethyl)pyridin-3-yl]piperidin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone;trihydrochloride Chemical compound Cl.Cl.Cl.NCC1=CN=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 MWIVVJKNMNXLBB-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000005239 aroylamino group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- NCIWZVBJGPWNGA-UHFFFAOYSA-N benzyl n-[[3-(4-cyanopiperidin-4-yl)phenyl]methyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NCC(C=1)=CC=CC=1C1(C#N)CCNCC1 NCIWZVBJGPWNGA-UHFFFAOYSA-N 0.000 description 2
- DOOWLMXJOWQLER-UHFFFAOYSA-N benzyl n-[[3-[4-cyano-1-[5-(2-phenylethyl)pyridine-3-carbonyl]piperidin-4-yl]phenyl]methyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NCC(C=1)=CC=CC=1C(CC1)(C#N)CCN1C(=O)C(C=1)=CN=CC=1CCC1=CC=CC=C1 DOOWLMXJOWQLER-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000003523 bronchorelaxing effect Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- PZCWEEOFDCYLCR-OKOKNOAKSA-N ethyl (3R,4R)-4-[3-(aminomethyl)phenyl]-1-[5-(2-phenylethyl)pyridine-3-carbonyl]piperidine-3-carboxylate dihydrochloride Chemical compound Cl.Cl.C1([C@@H]2CCN(C[C@@H]2C(=O)OCC)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=CC=CC(CN)=C1 PZCWEEOFDCYLCR-OKOKNOAKSA-N 0.000 description 2
- AQFMAWLPWUGVKP-UHFFFAOYSA-N ethyl 6-chloroquinoline-3-carboxylate Chemical compound C1=CC(Cl)=CC2=CC(C(=O)OCC)=CN=C21 AQFMAWLPWUGVKP-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 2
- 229940060367 inert ingredients Drugs 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 150000003893 lactate salts Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- VVKGPGIOVJYAHI-UHFFFAOYSA-N methyl 1-ethylindole-3-carboxylate Chemical compound C1=CC=C2N(CC)C=C(C(=O)OC)C2=C1 VVKGPGIOVJYAHI-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 150000003873 salicylate salts Chemical class 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- MHXRBUKPQNITJB-UHFFFAOYSA-N tert-butyl n-[(3-bromophenyl)methyl]-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(Br)=C1 MHXRBUKPQNITJB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LVMPWFJVYMXSNY-UHFFFAOYSA-N (2,3-dimethoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1OC LVMPWFJVYMXSNY-UHFFFAOYSA-N 0.000 description 1
- IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
- RSFNYNQGERWCMT-UHFFFAOYSA-N (3-bromo-4-fluorophenyl)methylazanium;chloride Chemical compound Cl.NCC1=CC=C(F)C(Br)=C1 RSFNYNQGERWCMT-UHFFFAOYSA-N 0.000 description 1
- NPPPVEBBUIBPQA-UHFFFAOYSA-N (3-bromo-4-phenylmethoxyphenyl)methanamine Chemical compound BrC1=CC(CN)=CC=C1OCC1=CC=CC=C1 NPPPVEBBUIBPQA-UHFFFAOYSA-N 0.000 description 1
- KJBOBQDNPJSPRN-UHFFFAOYSA-N (3-bromo-5-methylphenoxy)-tert-butyl-dimethylsilane Chemical compound CC1=CC(Br)=CC(O[Si](C)(C)C(C)(C)C)=C1 KJBOBQDNPJSPRN-UHFFFAOYSA-N 0.000 description 1
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
- NEBWDEKBEYUNLV-UHFFFAOYSA-N (3-piperidin-4-ylphenyl)methanamine Chemical compound NCC1=CC=CC(C2CCNCC2)=C1 NEBWDEKBEYUNLV-UHFFFAOYSA-N 0.000 description 1
- CNQRHSZYVFYOIE-UHFFFAOYSA-N (4-iodophenyl)methanol Chemical compound OCC1=CC=C(I)C=C1 CNQRHSZYVFYOIE-UHFFFAOYSA-N 0.000 description 1
- PDKBJZGGXHTHNC-UHFFFAOYSA-N (5-bromo-2-fluorophenyl)methanamine Chemical compound NCC1=CC(Br)=CC=C1F PDKBJZGGXHTHNC-UHFFFAOYSA-N 0.000 description 1
- WDVDHJLKXYCOFS-UHFFFAOYSA-N (5-bromopyridin-3-yl)methanol Chemical compound OCC1=CN=CC(Br)=C1 WDVDHJLKXYCOFS-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- JYAQYXOVOHJRCS-UHFFFAOYSA-N 1-(3-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Br)=C1 JYAQYXOVOHJRCS-UHFFFAOYSA-N 0.000 description 1
- GAUUDQVOPUKGJD-UHFFFAOYSA-N 1-(bromomethyl)-2-chloro-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C(Cl)=C1 GAUUDQVOPUKGJD-UHFFFAOYSA-N 0.000 description 1
- JDNPUJCKXLOHOW-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(CBr)C=C1 JDNPUJCKXLOHOW-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UFWFLXATWHFHKG-UHFFFAOYSA-N 1-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]indol-1-yl]ethanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC=CC=C2N(C(=O)C)C=C1C(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 UFWFLXATWHFHKG-UHFFFAOYSA-N 0.000 description 1
- CHVLHFHSDQYPSM-UHFFFAOYSA-N 1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-naphthalen-2-ylsulfanylpropan-1-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)CCSC=2C=C3C=CC=CC3=CC=2)=C1 CHVLHFHSDQYPSM-UHFFFAOYSA-N 0.000 description 1
- CTBHKLOYRNYMJD-UHFFFAOYSA-N 1-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-3-propylsulfanyl-6,7-dihydro-5h-2-benzothiophen-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=12CCCC(=O)C2=C(SCCC)SC=1C(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 CTBHKLOYRNYMJD-UHFFFAOYSA-N 0.000 description 1
- GHLPNUSFQJHAPG-UHFFFAOYSA-N 1-acetylindole-3-carboxylic acid Chemical compound C1=CC=C2N(C(=O)C)C=C(C(O)=O)C2=C1 GHLPNUSFQJHAPG-UHFFFAOYSA-N 0.000 description 1
- DYSJMQABFPKAQM-UHFFFAOYSA-N 1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-N 0.000 description 1
- MPEOPBCQHNWNFB-UHFFFAOYSA-N 1-chloro-2-iodobenzene Chemical compound ClC1=CC=CC=C1I MPEOPBCQHNWNFB-UHFFFAOYSA-N 0.000 description 1
- GWQSENYKCGJTRI-UHFFFAOYSA-N 1-chloro-4-iodobenzene Chemical compound ClC1=CC=C(I)C=C1 GWQSENYKCGJTRI-UHFFFAOYSA-N 0.000 description 1
- TYHUGKGZNOULKD-UHFFFAOYSA-N 1-fluoro-2-iodobenzene Chemical compound FC1=CC=CC=C1I TYHUGKGZNOULKD-UHFFFAOYSA-N 0.000 description 1
- VSKSBSORLCDRHS-UHFFFAOYSA-N 1-fluoro-3-iodobenzene Chemical compound FC1=CC=CC(I)=C1 VSKSBSORLCDRHS-UHFFFAOYSA-N 0.000 description 1
- KGNQDBQYEBMPFZ-UHFFFAOYSA-N 1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1 KGNQDBQYEBMPFZ-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- IGZGUYVVBABKOY-UHFFFAOYSA-N 1-iodo-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1I IGZGUYVVBABKOY-UHFFFAOYSA-N 0.000 description 1
- RINOYHWVBUKAQE-UHFFFAOYSA-N 1-iodo-2-methylbenzene Chemical compound CC1=CC=CC=C1I RINOYHWVBUKAQE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HVRCLXXJIQTXHC-UHFFFAOYSA-N 1-methylindole-3-carboxylic acid Chemical compound C1=CC=C2N(C)C=C(C(O)=O)C2=C1 HVRCLXXJIQTXHC-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- MNJWEKZIPYSEGV-UHFFFAOYSA-N 1-o-benzyl 5-o-ethyl 4-hydroxy-3,6-dihydro-2h-pyridine-1,5-dicarboxylate Chemical compound C1C(C(=O)OCC)=C(O)CCN1C(=O)OCC1=CC=CC=C1 MNJWEKZIPYSEGV-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- FTLHGQOBAPTEHE-UHFFFAOYSA-N 2,3,5,6-tetrafluoro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=C(F)C(F)=C(O)C(F)=C1F FTLHGQOBAPTEHE-UHFFFAOYSA-N 0.000 description 1
- ZHXUWDPHUQHFOV-UHFFFAOYSA-N 2,5-dibromopyridine Chemical compound BrC1=CC=C(Br)N=C1 ZHXUWDPHUQHFOV-UHFFFAOYSA-N 0.000 description 1
- KVHGJAKTBPFFNV-UHFFFAOYSA-N 2-(1-hydroxyundecyl)-1-(4-nitroanilino)-6-phenyl-4a,7a-dihydro-2h-pyrrolo[3,4-b]pyridine-5,7-dione Chemical compound CCCCCCCCCCC(O)C1C=CC(C(N(C2=O)C=3C=CC=CC=3)=O)C2N1NC1=CC=C([N+]([O-])=O)C=C1 KVHGJAKTBPFFNV-UHFFFAOYSA-N 0.000 description 1
- TULDPXYHBFBRGW-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-yl)acetic acid Chemical compound C1=CC=C2CC(CC(=O)O)CC2=C1 TULDPXYHBFBRGW-UHFFFAOYSA-N 0.000 description 1
- ZOUPGSMSNQLUNW-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(Cl)=C1 ZOUPGSMSNQLUNW-UHFFFAOYSA-N 0.000 description 1
- WEPVZDHUQUUGBH-UHFFFAOYSA-N 2-(5-chloropyridin-3-yl)oxyacetic acid Chemical compound OC(=O)COC1=CN=CC(Cl)=C1 WEPVZDHUQUUGBH-UHFFFAOYSA-N 0.000 description 1
- HWDFNPNQSKZHKJ-UHFFFAOYSA-N 2-(6-chloropyridin-2-yl)oxyacetic acid Chemical compound OC(=O)COC1=CC=CC(Cl)=N1 HWDFNPNQSKZHKJ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ICXKVCNMBQHTHD-UHFFFAOYSA-N 2-[2-[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-3-yl]ethynyl]pyridine-3-carboxylic acid Chemical compound C1=NC(NC(=O)OC(C)(C)C)=CC=C1C#CC1=NC=CC=C1C(O)=O ICXKVCNMBQHTHD-UHFFFAOYSA-N 0.000 description 1
- BOXBITJAYWJXPC-UHFFFAOYSA-N 2-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]-1-(4-hydroxyphenyl)ethanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CC(=O)C=3C=CC(O)=CC=3)C=CC=2)=C1 BOXBITJAYWJXPC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- LWQPVINTIOVYLW-UHFFFAOYSA-N 2-bromo-4-(bromomethyl)-1-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1Br LWQPVINTIOVYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 1
- KQDJTBPASNJQFQ-UHFFFAOYSA-N 2-iodophenol Chemical compound OC1=CC=CC=C1I KQDJTBPASNJQFQ-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- ACMLKANOGIVEPB-UHFFFAOYSA-N 2-oxo-2H-chromene-3-carboxylic acid Chemical compound C1=CC=C2OC(=O)C(C(=O)O)=CC2=C1 ACMLKANOGIVEPB-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- GDPBMHREQFDTQF-UHFFFAOYSA-N 2-trimethylsilylethyl 4-[3-(aminomethyl)phenyl]piperidine-1-carboxylate;2-trimethylsilylethyl 4-(3-cyanophenyl)-3,6-dihydro-2h-pyridine-1-carboxylate;hydrochloride Chemical compound Cl.C1CN(C(=O)OCC[Si](C)(C)C)CCC1C1=CC=CC(CN)=C1.C1N(C(=O)OCC[Si](C)(C)C)CCC(C=2C=C(C=CC=2)C#N)=C1 GDPBMHREQFDTQF-UHFFFAOYSA-N 0.000 description 1
- MFUVCHZWGSJKEQ-UHFFFAOYSA-N 3,4-dichlorphenylisocyanate Chemical compound ClC1=CC=C(N=C=O)C=C1Cl MFUVCHZWGSJKEQ-UHFFFAOYSA-N 0.000 description 1
- YEVDJWVEYDOQQC-UHFFFAOYSA-N 3-(4-chlorothiophen-2-yl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC(Cl)=CS1 YEVDJWVEYDOQQC-UHFFFAOYSA-N 0.000 description 1
- JAFVPRMULXJDEN-UHFFFAOYSA-N 3-(5-chlorothiophen-2-yl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=C(Cl)S1 JAFVPRMULXJDEN-UHFFFAOYSA-N 0.000 description 1
- OQKZSMMMKYJQJP-UHFFFAOYSA-N 3-(cyanomethyl)benzonitrile Chemical compound N#CCC1=CC=CC(C#N)=C1 OQKZSMMMKYJQJP-UHFFFAOYSA-N 0.000 description 1
- URLYREZIPSJJQU-UHFFFAOYSA-N 3-(phenoxymethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(COC=2C=CC=CC=2)=C1 URLYREZIPSJJQU-UHFFFAOYSA-N 0.000 description 1
- LZPNXAULYJPXEH-AATRIKPKSA-N 3-Methoxycinnamic acid Chemical compound COC1=CC=CC(\C=C\C(O)=O)=C1 LZPNXAULYJPXEH-AATRIKPKSA-N 0.000 description 1
- RHKYEHRKNBWIDK-MDZDMXLPSA-N 3-[(e)-2-phenylethenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(\C=C\C=2C=CC=CC=2)=C1 RHKYEHRKNBWIDK-MDZDMXLPSA-N 0.000 description 1
- SOXXAUYJGNTYAW-UHFFFAOYSA-N 3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]chromen-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C(OC3=CC=CC=C3C=2)=O)=C1 SOXXAUYJGNTYAW-UHFFFAOYSA-N 0.000 description 1
- XUCLYZJGCSJDTF-UHFFFAOYSA-N 3-[[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]anilino]methyl]benzonitrile;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NCC=3C=C(C=CC=3)C#N)C=CC=2)=C1 XUCLYZJGCSJDTF-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- FTKDCOINUAYGTC-UHFFFAOYSA-N 3-ethoxythiophene-2-carboxylic acid Chemical compound CCOC=1C=CSC=1C(O)=O FTKDCOINUAYGTC-UHFFFAOYSA-N 0.000 description 1
- PHPIMLZTBYCDSX-UHFFFAOYSA-N 3-ethynylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C#C)=C1 PHPIMLZTBYCDSX-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- NSQNHJRGWHJONB-UHFFFAOYSA-N 3-methylsulfanyl-6,7-dihydro-2-benzothiophene-1-carboxylic acid Chemical compound C1CC=CC2=C(SC)SC(C(O)=O)=C21 NSQNHJRGWHJONB-UHFFFAOYSA-N 0.000 description 1
- HXBFYPGUFUUNLO-UHFFFAOYSA-N 3-methylsulfanyl-6,7-dihydro-5h-2-benzothiophen-4-one Chemical compound C1CCC(=O)C2=C(SC)SC=C21 HXBFYPGUFUUNLO-UHFFFAOYSA-N 0.000 description 1
- XMQJAJQNGNSZFY-UHFFFAOYSA-N 3-naphthalen-2-ylsulfanylpropanoic acid Chemical compound C1=CC=CC2=CC(SCCC(=O)O)=CC=C21 XMQJAJQNGNSZFY-UHFFFAOYSA-N 0.000 description 1
- CISXCTKEQYOZAM-UHFFFAOYSA-N 3-phenylmethoxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OCC=2C=CC=CC=2)=C1 CISXCTKEQYOZAM-UHFFFAOYSA-N 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical group C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- ZBNTUDLPJCXPNF-UHFFFAOYSA-N 4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid Chemical compound C1CCCC2=C(C(=O)O)SC=C21 ZBNTUDLPJCXPNF-UHFFFAOYSA-N 0.000 description 1
- VTFKGQSKBNUQNK-UHFFFAOYSA-N 4-(2-phenylethyl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC(CCC=2C=CC=CC=2)=C1 VTFKGQSKBNUQNK-UHFFFAOYSA-N 0.000 description 1
- OEUNNRBHTDTPBR-UHFFFAOYSA-N 4-(2-phenylethynyl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC(C#CC=2C=CC=CC=2)=C1 OEUNNRBHTDTPBR-UHFFFAOYSA-N 0.000 description 1
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 1
- QYBXZYYECZFQRX-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)benzoic acid Chemical class C1=CC(C(=O)O)=CC=C1CN1CCOCC1 QYBXZYYECZFQRX-UHFFFAOYSA-N 0.000 description 1
- PUVJFTXSTOQWHY-UHFFFAOYSA-N 4-[3-(aminomethyl)phenyl]-4-hydroxypiperidine-1-carboxylic acid Chemical compound NCC1=CC=CC(C2(O)CCN(CC2)C(O)=O)=C1 PUVJFTXSTOQWHY-UHFFFAOYSA-N 0.000 description 1
- JJGJEDNZKYLCNL-UHFFFAOYSA-N 4-[3-(aminomethyl)phenyl]-n-(3,4-dichlorophenyl)piperidine-1-carboxamide Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)NC=2C=C(Cl)C(Cl)=CC=2)=C1 JJGJEDNZKYLCNL-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- NANALAOSHGYIEJ-UHFFFAOYSA-N 4-bromo-2-(bromomethyl)thiophene Chemical compound BrCC1=CC(Br)=CS1 NANALAOSHGYIEJ-UHFFFAOYSA-N 0.000 description 1
- PDONIKHDXYHTLS-UHFFFAOYSA-N 4-bromothiophene-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=C1 PDONIKHDXYHTLS-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- ILNJBIQQAIIMEY-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CN=C21 ILNJBIQQAIIMEY-UHFFFAOYSA-N 0.000 description 1
- NLSIIPKSANRIGS-UHFFFAOYSA-N 4-pyrrol-1-ylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1C=CC=C1 NLSIIPKSANRIGS-UHFFFAOYSA-N 0.000 description 1
- HFYACYZCOUYIFR-UHFFFAOYSA-N 5-(2-phenylethynyl)furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1C#CC1=CC=CC=C1 HFYACYZCOUYIFR-UHFFFAOYSA-N 0.000 description 1
- FQIUCPGDKPXSLL-UHFFFAOYSA-N 5-bromopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Br)=C1 FQIUCPGDKPXSLL-UHFFFAOYSA-N 0.000 description 1
- PKIXUVKUGMYKRU-UHFFFAOYSA-N 5-chloro-1-benzothiophene-2-carboxylic acid Chemical compound ClC1=CC=C2SC(C(=O)O)=CC2=C1 PKIXUVKUGMYKRU-UHFFFAOYSA-N 0.000 description 1
- FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 description 1
- IVILGUFRMDBUEQ-UHFFFAOYSA-N 5-iodopyridin-2-amine Chemical compound NC1=CC=C(I)C=N1 IVILGUFRMDBUEQ-UHFFFAOYSA-N 0.000 description 1
- NQAXCWZGYZFOGC-UHFFFAOYSA-N 5-methoxy-1-methylindole-3-carboxylic acid Chemical compound COC1=CC=C2N(C)C=C(C(O)=O)C2=C1 NQAXCWZGYZFOGC-UHFFFAOYSA-N 0.000 description 1
- GUXKBDHITFXEJG-UHFFFAOYSA-N 5-methoxycarbonylpyridine-3-carboxylic acid Chemical compound COC(=O)C1=CN=CC(C(O)=O)=C1 GUXKBDHITFXEJG-UHFFFAOYSA-N 0.000 description 1
- LNTBEMJFYFIVCQ-UHFFFAOYSA-N 5-oxo-2,3-dihydro-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid Chemical compound O=C1C(C(=O)O)=CN=C2SCCN21 LNTBEMJFYFIVCQ-UHFFFAOYSA-N 0.000 description 1
- FTZBWZOVJFPPOG-UHFFFAOYSA-N 5h-2-benzothiophen-4-one Chemical compound O=C1CC=CC2=CSC=C12 FTZBWZOVJFPPOG-UHFFFAOYSA-N 0.000 description 1
- AVAGKGZNBMZOLD-UHFFFAOYSA-N 6-chloro-1-benzothiophene-2-carboxylic acid Chemical compound C1=C(Cl)C=C2SC(C(=O)O)=CC2=C1 AVAGKGZNBMZOLD-UHFFFAOYSA-N 0.000 description 1
- YWOVTMQPFPHCEP-UHFFFAOYSA-N 6-chloroquinoline-3-carboxylic acid;ethyl 6-chloroquinoline-3-carboxylate Chemical compound C1=CC(Cl)=CC2=CC(C(=O)O)=CN=C21.C1=CC(Cl)=CC2=CC(C(=O)OCC)=CN=C21 YWOVTMQPFPHCEP-UHFFFAOYSA-N 0.000 description 1
- UFGMOMJMGBYKBN-UHFFFAOYSA-N 6-phenylquinoline-3-carboxylic acid Chemical compound C=1C2=CC(C(=O)O)=CN=C2C=CC=1C1=CC=CC=C1 UFGMOMJMGBYKBN-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- KLPMSROOCJMQJH-UHFFFAOYSA-N OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.NCc1cccc(c1)C1CCN(CC1)C(=O)c1cccc(CCc2ccc(N)nc2)c1 Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.NCc1cccc(c1)C1CCN(CC1)C(=O)c1cccc(CCc2ccc(N)nc2)c1 KLPMSROOCJMQJH-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XUQXGGNQTVLVHI-UHFFFAOYSA-N [3-[4-[3-[[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]piperidine-1-carbonyl]phenyl]-(pyridin-2-ylmethyl)carbamic acid Chemical compound C(C)(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC=1C=C(C=CC=1)C1CCN(CC1)C(=O)C=1C=C(C=CC=1)N(C(O)=O)CC1=NC=CC=C1 XUQXGGNQTVLVHI-UHFFFAOYSA-N 0.000 description 1
- VDBFSRCCFIUMAV-UHFFFAOYSA-N [3-[4-[3-[[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]piperidine-1-carbonyl]phenyl]-(pyridin-3-ylmethyl)carbamic acid Chemical compound C(C)(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC=1C=C(C=CC=1)C1CCN(CC1)C(=O)C=1C=C(C=CC=1)N(C(O)=O)CC=1C=NC=CC=1 VDBFSRCCFIUMAV-UHFFFAOYSA-N 0.000 description 1
- CBCAGGPBCZWBAH-UHFFFAOYSA-N [4-[3-(aminomethyl)-4-fluorophenyl]piperidin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone;dihydrochloride Chemical compound Cl.Cl.C1=C(F)C(CN)=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 CBCAGGPBCZWBAH-UHFFFAOYSA-N 0.000 description 1
- ZZPJXGWXKKHBRJ-UHFFFAOYSA-N [4-[3-(aminomethyl)-5-hydroxyphenyl]piperidin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC(O)=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 ZZPJXGWXKKHBRJ-UHFFFAOYSA-N 0.000 description 1
- ZIPGFTLBRITSHA-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(1-benzothiophen-2-yl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2SC3=CC=CC=C3C=2)=C1 ZIPGFTLBRITSHA-UHFFFAOYSA-N 0.000 description 1
- SDXRQZKFUGAQCY-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(1-methylindol-3-yl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC=CC=C2N(C)C=C1C(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 SDXRQZKFUGAQCY-UHFFFAOYSA-N 0.000 description 1
- OCBLHVOVZOVDBU-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(1h-indol-6-yl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C3NC=CC3=CC=2)=C1 OCBLHVOVZOVDBU-UHFFFAOYSA-N 0.000 description 1
- OUWSXMYYPYHLTF-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(1h-indol-6-yl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C3NC=CC3=CC=2)=C1 OUWSXMYYPYHLTF-UHFFFAOYSA-N 0.000 description 1
- IBCQONBZMVLJSZ-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(2,3-dihydro-1-benzofuran-5-yl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C3CCOC3=CC=2)=C1 IBCQONBZMVLJSZ-UHFFFAOYSA-N 0.000 description 1
- OJQVYOZIFFUCPA-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(2-phenoxyphenyl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C(=CC=CC=2)OC=2C=CC=CC=2)=C1 OJQVYOZIFFUCPA-UHFFFAOYSA-N 0.000 description 1
- NPVJQRRJEWBUOI-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3,4-dichlorophenyl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(Cl)C(Cl)=CC=2)=C1 NPVJQRRJEWBUOI-UHFFFAOYSA-N 0.000 description 1
- JXIJLJZBOLCXGH-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3-bromo-4-fluorophenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(Br)C(F)=CC=2)=C1 JXIJLJZBOLCXGH-UHFFFAOYSA-N 0.000 description 1
- OLRUKLGIKCVLDG-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3-chlorophenyl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(Cl)C=CC=2)=C1 OLRUKLGIKCVLDG-UHFFFAOYSA-N 0.000 description 1
- OFYYSULZHUAKKX-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3-phenylmethoxyphenyl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 OFYYSULZHUAKKX-UHFFFAOYSA-N 0.000 description 1
- ACRDVZRILDMTPH-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(4,5,6,7-tetrahydro-2-benzothiophen-1-yl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C2=C3CCCCC3=CS2)=C1 ACRDVZRILDMTPH-UHFFFAOYSA-N 0.000 description 1
- FSHXWQZJTABAKV-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(4-phenylphenyl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 FSHXWQZJTABAKV-UHFFFAOYSA-N 0.000 description 1
- LSPBMRUHDVYMBZ-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(5,6-dichloropyridin-3-yl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(Cl)C(Cl)=NC=2)=C1 LSPBMRUHDVYMBZ-UHFFFAOYSA-N 0.000 description 1
- BIKLKFZWHXLGOP-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(5-methoxy-1-methylindol-3-yl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC(OC)=CC=C2N(C)C=C1C(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 BIKLKFZWHXLGOP-UHFFFAOYSA-N 0.000 description 1
- NNGCBBPXPDJTOV-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(6-bromopyridin-3-yl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=NC(Br)=CC=2)=C1 NNGCBBPXPDJTOV-UHFFFAOYSA-N 0.000 description 1
- LMYKIKBTWBBLFK-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(6-chloroquinolin-3-yl)methanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C3C=C(Cl)C=CC3=NC=2)=C1 LMYKIKBTWBBLFK-UHFFFAOYSA-N 0.000 description 1
- QRHNJSKMZRTYGS-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(6-phenylquinolin-3-yl)methanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C3C=C(C=CC3=NC=2)C=2C=CC=CC=2)=C1 QRHNJSKMZRTYGS-UHFFFAOYSA-N 0.000 description 1
- MRYNWCFQVYVGQG-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-(1,3-benzoxazol-2-yl)phenyl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C=2OC3=CC=CC=C3N=2)=C1 MRYNWCFQVYVGQG-UHFFFAOYSA-N 0.000 description 1
- SOMSQYXCFSAMIH-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-(2-phenylethyl)phenyl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=CC=2)=C1 SOMSQYXCFSAMIH-UHFFFAOYSA-N 0.000 description 1
- KTNGMRXGBOFRTM-UEIGIMKUSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[(e)-2-phenylethenyl]phenyl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(\C=C\C=3C=CC=CC=3)C=CC=2)=C1 KTNGMRXGBOFRTM-UEIGIMKUSA-N 0.000 description 1
- FTLAPCYRDYOODY-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[2-(2-chlorophenyl)ethynyl]phenyl]methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C#CC=2C(=CC=CC=2)Cl)=C1 FTLAPCYRDYOODY-UHFFFAOYSA-N 0.000 description 1
- VHVIIBRDQHUVJJ-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[2-(2-fluorophenyl)ethyl]phenyl]methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C(=CC=CC=3)F)C=CC=2)=C1 VHVIIBRDQHUVJJ-UHFFFAOYSA-N 0.000 description 1
- GPQTVSALFPGLGU-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[2-(6-aminopyridin-3-yl)ethynyl]phenyl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C#CC=2C=NC(N)=CC=2)=C1 GPQTVSALFPGLGU-UHFFFAOYSA-N 0.000 description 1
- SLCDTVPQJYPVKW-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[2-[2-(trifluoromethyl)phenyl]ethynyl]phenyl]methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C#CC=2C(=CC=CC=2)C(F)(F)F)=C1 SLCDTVPQJYPVKW-UHFFFAOYSA-N 0.000 description 1
- OSUSVUMPNQVASN-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[2-[4-(hydroxymethyl)phenyl]ethynyl]phenyl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C#CC=2C=CC(CO)=CC=2)=C1 OSUSVUMPNQVASN-UHFFFAOYSA-N 0.000 description 1
- ZXBFFHBCFFORDY-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[4-(2-phenylethyl)thiophen-2-yl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2SC=C(CCC=3C=CC=CC=3)C=2)=C1 ZXBFFHBCFFORDY-UHFFFAOYSA-N 0.000 description 1
- SILUEIFUXCSRSY-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[4-(2-phenylethynyl)thiophen-2-yl]methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2SC=C(C=2)C#CC=2C=CC=CC=2)=C1 SILUEIFUXCSRSY-UHFFFAOYSA-N 0.000 description 1
- ZNFYZUWSVOCXBT-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[4-(dimethylamino)phenyl]methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(N(C)C)=CC=C1C(=O)N1CCC(C=2C=C(CN)C=CC=2)CC1 ZNFYZUWSVOCXBT-UHFFFAOYSA-N 0.000 description 1
- HKPWBHWNFDDGLH-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-(2-phenylethyl)thiophen-2-yl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2SC(CCC=3C=CC=CC=3)=CC=2)=C1 HKPWBHWNFDDGLH-UHFFFAOYSA-N 0.000 description 1
- NHBWICHXSWDPQY-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-(2-phenylethyl)thiophen-2-yl]methanone;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2SC(CCC=3C=CC=CC=3)=CC=2)=C1 NHBWICHXSWDPQY-UHFFFAOYSA-N 0.000 description 1
- YPVSDOKGNYAHFF-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-(2-phenylethynyl)pyridin-3-yl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1 YPVSDOKGNYAHFF-UHFFFAOYSA-N 0.000 description 1
- QZVFRAUFSOTXRX-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-(2-phenylethynyl)pyridin-3-yl]methanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1 QZVFRAUFSOTXRX-UHFFFAOYSA-N 0.000 description 1
- RFVHHKAPSRZFEV-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-(2-phenylethynyl)thiophen-2-yl]methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2SC(=CC=2)C#CC=2C=CC=CC=2)=C1 RFVHHKAPSRZFEV-UHFFFAOYSA-N 0.000 description 1
- SUNQZTABQKFSPI-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-(benzylamino)pyridin-3-yl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NCC=3C=CC=CC=3)C=NC=2)=C1 SUNQZTABQKFSPI-UHFFFAOYSA-N 0.000 description 1
- QBFKBTDWESCACY-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-(pyridin-2-ylmethylamino)pyridin-3-yl]methanone;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NCC=3N=CC=CC=3)C=NC=2)=C1 QBFKBTDWESCACY-UHFFFAOYSA-N 0.000 description 1
- LCDAITYMUVMCNG-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-(pyridin-3-ylmethylamino)pyridin-3-yl]methanone;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NCC=3C=NC=CC=3)C=NC=2)=C1 LCDAITYMUVMCNG-UHFFFAOYSA-N 0.000 description 1
- LIFIMZLLTHPMKK-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[5-[[4-(trifluoromethoxy)phenyl]methylamino]pyridin-3-yl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NCC=3C=CC(OC(F)(F)F)=CC=3)C=NC=2)=C1 LIFIMZLLTHPMKK-UHFFFAOYSA-N 0.000 description 1
- UINMHPMZTPDGKB-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-naphthalen-2-ylmethanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C3C=CC=CC3=CC=2)=C1 UINMHPMZTPDGKB-UHFFFAOYSA-N 0.000 description 1
- LGPPRANHCTYVBG-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-quinolin-3-ylmethanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C3C=CC=CC3=NC=2)=C1 LGPPRANHCTYVBG-UHFFFAOYSA-N 0.000 description 1
- DFMZVXSYIZHQRN-UHFFFAOYSA-N [4-[5-(aminomethyl)-2-(hydroxymethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone Chemical compound NCC1=CC=C(CO)C(C=2CCN(CC=2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 DFMZVXSYIZHQRN-UHFFFAOYSA-N 0.000 description 1
- YUGDGJMIWBUZRZ-UHFFFAOYSA-N [4-[5-(aminomethyl)-2-fluorophenyl]piperidin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone;dihydrochloride Chemical compound Cl.Cl.NCC1=CC=C(F)C(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 YUGDGJMIWBUZRZ-UHFFFAOYSA-N 0.000 description 1
- RXAIQOFXFZDMBO-UHFFFAOYSA-N [4-[5-(aminomethyl)pyridin-3-yl]piperidin-1-yl]-[5-(2-phenylethyl)pyridin-3-yl]methanone Chemical compound NCC1=CN=CC(C2CCN(CC2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 RXAIQOFXFZDMBO-UHFFFAOYSA-N 0.000 description 1
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 1
- ZVDDJPSHRNMSKV-UHFFFAOYSA-N acetaldehyde;hydrochloride Chemical compound Cl.CC=O ZVDDJPSHRNMSKV-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- VNEMVKOXLBIWTB-UHFFFAOYSA-N aminomethyl benzoate Chemical class NCOC(=O)C1=CC=CC=C1 VNEMVKOXLBIWTB-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 150000007962 benzene acetonitriles Chemical class 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- OOMGRWNPCPICJN-UHFFFAOYSA-N benzyl (2,5-dioxopyrrolidin-3-yl) carbonate Chemical compound C1C(=O)NC(=O)C1OC(=O)OCC1=CC=CC=C1 OOMGRWNPCPICJN-UHFFFAOYSA-N 0.000 description 1
- VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- HQLOJWVJHLZFSB-UHFFFAOYSA-N benzyl n-[[3-[4-hydroxy-1-[5-(2-phenylethyl)pyridine-3-carbonyl]piperidin-4-yl]phenyl]methyl]carbamate Chemical compound C1CC(O)(C=2C=C(CNC(=O)OCC=3C=CC=CC=3)C=CC=2)CCN1C(=O)C(C=1)=CN=CC=1CCC1=CC=CC=C1 HQLOJWVJHLZFSB-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- PGGQCHVPWSXPSI-UHFFFAOYSA-N diethyl pyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=CN=CC(C(=O)OCC)=C1 PGGQCHVPWSXPSI-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- YZBOYNARHHAGLV-UHFFFAOYSA-N ethyl 3-cyano-6,6-dimethyl-4-oxo-5,7-dihydro-2-benzothiophene-1-carboxylate Chemical compound C1C(C)(C)CC(=O)C=2C1=C(C(=O)OCC)SC=2C#N YZBOYNARHHAGLV-UHFFFAOYSA-N 0.000 description 1
- BSSNTDZRVNQGDF-UHFFFAOYSA-N ethyl 4,6-dichloroquinoline-3-carboxylate Chemical compound C1=CC(Cl)=CC2=C(Cl)C(C(=O)OCC)=CN=C21 BSSNTDZRVNQGDF-UHFFFAOYSA-N 0.000 description 1
- LVWYWXLMDBCCKZ-UHFFFAOYSA-N ethyl 4-oxo-3-propylsulfanyl-6,7-dihydro-5h-2-benzothiophene-1-carboxylate Chemical compound C1CCC(=O)C2=C(SCCC)SC(C(=O)OCC)=C21 LVWYWXLMDBCCKZ-UHFFFAOYSA-N 0.000 description 1
- RTYXWLMQWSFXNI-UHFFFAOYSA-N ethyl 4-oxopiperidin-1-ium-3-carboxylate;chloride Chemical compound Cl.CCOC(=O)C1CNCCC1=O RTYXWLMQWSFXNI-UHFFFAOYSA-N 0.000 description 1
- VBSTYSSJSVEODP-UHFFFAOYSA-N ethyl 5-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=CC(NC(=O)OC(C)(C)C)=C1 VBSTYSSJSVEODP-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005835 indanylene group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- JTEDVYBZBROSJT-UHFFFAOYSA-N indole-3-butyric acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229950006462 lauromacrogol 400 Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- XHDHEDITROOBDC-UHFFFAOYSA-N methyl 3-(2h-tetrazol-5-yl)benzoate Chemical compound COC(=O)C1=CC=CC(C2=NNN=N2)=C1 XHDHEDITROOBDC-UHFFFAOYSA-N 0.000 description 1
- DGCDOLUIZCGQES-UHFFFAOYSA-N methyl 3-ethylsulfanyl-6,6-dimethyl-4-oxo-5,7-dihydro-2-benzothiophene-1-carboxylate Chemical compound C1C(C)(C)CC(=O)C2=C(SCC)SC(C(=O)OC)=C21 DGCDOLUIZCGQES-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- RRIWSQXXBIFKQM-UHFFFAOYSA-N monomeric N-benzylcarbamic acid Natural products OC(=O)NCC1=CC=CC=C1 RRIWSQXXBIFKQM-UHFFFAOYSA-N 0.000 description 1
- LPWAKYISHIZIPO-UHFFFAOYSA-N morpholin-4-ylmethyl benzoate Chemical class C=1C=CC=CC=1C(=O)OCN1CCOCC1 LPWAKYISHIZIPO-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- VFBILHPIHUPBPZ-UHFFFAOYSA-N n-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide Chemical compound CCOC1=CC=CC=C1C(=O)NCC1=COC(C=2C=C(OC(C)C)C(OC(F)F)=CC=2)=N1 VFBILHPIHUPBPZ-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000023837 negative regulation of proteolysis Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- JQKIHHHTOFFTAM-UHFFFAOYSA-N piperidin-4-one;hydrate Chemical compound O.O=C1CCNCC1 JQKIHHHTOFFTAM-UHFFFAOYSA-N 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108010052605 prostromelysin Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- HDNSUSJVQINPAN-UHFFFAOYSA-N tert-butyl 4-[3-(aminomethyl)phenyl]-4-hydroxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)C1=CC=CC(CN)=C1 HDNSUSJVQINPAN-UHFFFAOYSA-N 0.000 description 1
- UQADQTBQNVARAP-UHFFFAOYSA-N tert-butyl 4-cyanopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#N)CC1 UQADQTBQNVARAP-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- YZLXIVKPYUFJPN-UHFFFAOYSA-N tert-butyl n-(5-iodopyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(I)C=N1 YZLXIVKPYUFJPN-UHFFFAOYSA-N 0.000 description 1
- GIEJFEGUGASWCU-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]-n-[[3-[1-[3-[(2-methylpropan-2-yl)oxycarbonylamino]benzoyl]piperidin-4-yl]phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C(=O)N2CCC(CC2)C=2C=C(CN(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C=CC=2)=C1 GIEJFEGUGASWCU-UHFFFAOYSA-N 0.000 description 1
- VFWYMSSTHYUYEF-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]-n-[[3-[1-[5-(2-phenylethynyl)pyridine-3-carbonyl]piperidin-4-yl]phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1 VFWYMSSTHYUYEF-UHFFFAOYSA-N 0.000 description 1
- XHWJNCKBFHDQSK-UHFFFAOYSA-N tert-butyl n-[3-[4-[3-[[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]piperidine-1-carbonyl]phenyl]-n-(pyridin-4-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)N(CC=2C=CN=CC=2)C(=O)OC(C)(C)C)=C1 XHWJNCKBFHDQSK-UHFFFAOYSA-N 0.000 description 1
- OOSLJWVJVHVDPA-UHFFFAOYSA-N tert-butyl n-[[3-[1-(3-ethynylbenzoyl)piperidin-4-yl]phenyl]methyl]-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C#C)=C1 OOSLJWVJVHVDPA-UHFFFAOYSA-N 0.000 description 1
- UBZBWULSZURMAR-UHFFFAOYSA-N tert-butyl n-[[3-[1-[(3,4-dichlorophenyl)carbamoyl]piperidin-4-yl]phenyl]methyl]-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(C2CCN(CC2)C(=O)NC=2C=C(Cl)C(Cl)=CC=2)=C1 UBZBWULSZURMAR-UHFFFAOYSA-N 0.000 description 1
- WSADFGYTNCASNM-UHFFFAOYSA-N tert-butyl n-[[4-fluoro-3-[1-[5-(2-phenylethyl)pyridine-3-carbonyl]-3,6-dihydro-2h-pyridin-4-yl]phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(F)C(C=2CCN(CC=2)C(=O)C=2C=C(CCC=3C=CC=CC=3)C=NC=2)=C1 WSADFGYTNCASNM-UHFFFAOYSA-N 0.000 description 1
- IXEXFUPGYJKXNQ-UHFFFAOYSA-N tert-butyl n-benzyl-n-[3-[4-[3-[[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]piperidine-1-carbonyl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)N(CC=2C=CC=CC=2)C(=O)OC(C)(C)C)=C1 IXEXFUPGYJKXNQ-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229930195727 α-lactose Natural products 0.000 description 1
Description
ARY METHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS
FIELD OF THE INVENTION This invention is directed to substituted arylmethylamines>, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of tryptase.
BACKGROUND OF THE INVENTION Tryptase is stored in mast cell secretory granules and is the major secretory protease of human mast cells. Tryptase has been implicated in a variety of biological processes, including degradation of vasodilating and bronchorelaxing neuropeptides (Caughey, et al., J. Pharmacol. Exp. Ther., 1988, 244, pages 133-137; Franconi, et al., J. Pharmacol. Exp. Ther., 1988, 248, pages 947-951; and Tam, et al., Am. J. Respir. Cell Mol. Biol., 1990, 3, pages 27-32) and modulation of bronchial responsiveness to histamine (Sekizawa, et al., J. Clin. Invest., 1989, 83, pages 175-179). As a result, tryptase inhibitors may be useful as anti-inflammatory agents (K Rice, P.A. Sprengler, Current Opinion in Drug Discovery and Development, 1999, 2(5), pages 463-474) particularly in the treatment of chronic asthma (M.Q. Zhang, H. Timmerman, Mediators Inflamm., 1997, 112, pages 311-317) and may also be useful in treating or preventing allergic rhinitis (S. J. Wilson et al, Clin. Exp. Allergy, 1998, 28, pages 220-227), inflammatory bowel disease (S.C. Bischoff et al, Histopathology, 1996, 28, pages 1- 13), psoriasis (A. Naukkarinen et al, Arch. Dermatol. Res., 1993, 285, pages 341-346), conjunctivitis (A.A.Irani et al, J. Allergy Clin. Immunol., 1990, 86, pages 34-40), atopic dermatitis (A. Jarvikallio et al, Br. J. Dermatol., 1997, 136, pages 871-877), rheumatoid arthritis (L.C Tetlow et al, Ann. Rheum. Dis., 1998, 54, pages 549-555), osteoarthritis (M.G. Buckley et al, J. Pathol., 1998, 186, pages 67-74), gouty arthritis, rheumatoid spondylitis, and diseases of joint cartilage destruction.
In addition, tryptase has been shown to be a potent mitogen for fibroblasts, suggesting its involvement in the pulmonary fibrosis in asthma and interstitial lung diseases (Ruoss et al., J. Clin. Invest., 1991, 88, pages 493-499). Therefore, tryptase inhibitors may be useful in treating or preventing fibrotic conditions (J.A. Cairns and A.F. Walls, J. Clin. Invest., 1997, 99, pages 1313-1321) for example,
fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fϊbrosis, neurofibromas and hypertrophic scars.
Additionally, tryptase inhibitors may be useful in treating or preventing myocardial infarction, stroke, angina and other consequences of atherosclerotic plaque rupture (M. Jeziorska et al, J. Pathol., 1997, 182, pages 115-122). Tryptase has also been discovered to activate prostromelysin that in turn activates collagenase, thereby initiating the destruction of cartilage and periodontal connective tissue, respectively. Therefore, tryptase inhibitors could be useful in the treatment or prevention of arthritis, periodontal disease, diabetic retinopathy, and tumor growth (WJ. Beil et al, Exp. Hematol., (1998) 26, pages 158-169). Also, tryptase inhibitors may be useful in the treatment of anaphylaxis (L.B. Schwarz et al, J. Clin. Invest., 1995, 96, pages 2702-2710), multiple sclerosis (M. Steinhoff et al, Nat. Med. (N. Y.), 2000, 6(2), pages 151-158), peptic ulcers and syncytial viral infections.
Mast cell mediated inflammatory conditions, in particular asthma, are a growing public health concern. Asthma is frequently characterized by progressive development of hyper-responsiveness of the trachea and bronchi to both immunospecific allergens and generalized chemical or physical stimuli, which lead to the onset of chronic inflammation. Leukocytes containing IgE receptors, notably mast cells and basophils, are present in the epithelium and underlying smooth muscle tissues of bronchi. These leukocytes initially become activated by binding of specific inhaled antigens to the IgE receptors and then release a number of chemical mediators. For example, degranulation of mast cells leads to the release of proteoglycans, peroxidase, arylsulfatase B, tryptase and chymase, which results in bronchiole constriction.
Accordingly, what is needed is a novel and useful group of compounds having valuable pharmaceutical properties, particularly, the ability to inhibit tryptase. Such compounds readily have utility in treating a patient suffering condition that can be ameliorated by the administration of an inhibitor of tryptase, e.g., mast cell mediated inflammatory conditions, inflammation, and diseases or disorders related to the degradation of vasodilating and bronchorelaxing neuropeptides. Particular examples of such conditions are described infra.
The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.
SUMMARYOF THE INVETNION
Broadly, the present invention extends to a compound of formula (I):-
such that Ar is an aryl group or a heteroa
ryl group, and the group is beta to the s
T ^ group on the aryl, wherein:- is a single or a double bond; Ri and R2 are each independently hydrogen or lower alkyl;
R3 is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R", -OR^, -S(0)mR^ or
-C(=0)-R6;
R4 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=0)-NYlγ2 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, -S(0)m-alkyl or -NYΪY2;
R is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, trifluoromethyl, -C(=0)-NY1Y2, -NY!Y2, -Z1-C2.6alkylene-R7 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido, -C(=0)-NY1Y2, -SO2-NY1 Y2, -S(0)m-alkyl or - Y!γ2;
R" is aryl or heteroaryl;
R7 is hydroxy, alkoxy, ureido, -C(=0)-NY1Y2, -S0 -NY1Y2, -S(0)m-alkyl or -NYΪY2;
R^ is hydrogen or lower alkyl;
γl and Y2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; or the group -NY*Y2 may form a cyclic amine; Zl is O, S(0)m or NR8; m is zero or an integer 1 to 2; n is zero or an integer 1 to 4; an N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, and a hydrate of said compound.
Furthermore, the present invention extends to a compound of formula (la): -
wherein:- is a single or a double bond;
R1 and R2 are each independently hydrogen or lower alkyl;
R3 is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R6, -OR6, -S(0)mR6 or
-C(=0)-R6;
R4 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=0)-NY Y2 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy,
-S(0)m-alkyl or -NY^2;
R is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, trifluoromethyl, -C(=0)-NY1Y2, -lST^Y2, -Zi-C^alkylene-R7 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido, -C(=0)-NY1Y2, -S02-NY1Y2, -S(0)m-alkyl or -NY1 Y2;
R6 is aryl or heteroaryl;
R7 is hydroxy, alkoxy, ureido, -C(=0)-NY1Y2, -S02-NY1Y2, -S(O)m-alkyl or -Nγ!γ2;
R° is hydrogen or lower alkyl; γl and Y2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; or the group -Nγ!γ2 may form a cyclic amine;
Z1 is O, S(0)m or NR8; m is zero or an integer 1 to 2; n is zero or an integer 1 to 4; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
2. In another embodiment, the present invention extends to a compound of formula (lb):
wherein
R3 is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R6, -OR6, -S(0)mR6 or -C(=0)-R6;
R4 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=0)-Nγlγ2 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, -S(0)m-alkyl or -NYXY2; and
~R is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, trifluoromethyl, -C(=0)-NY1Y2, -Nγ!γ2, -Z1-C2-6alkylene-R7 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido,
-C(=0)-NY]Y2, -SO2-NY!γ2, -S(0)m-alkyl or - Y^2' and> a corresponding N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, an N-oxides and prodrugs.
Particular examples of such compounds are described infra.
Furthermore, the present invention extends to a pharmaceutical composition comprising a compound of the present invention, as described above, and a pharmaceutically acceptable carrier thereof. Numerous examples of pharmaceutical carriers having applications in the present invention are described infra.
In addition, the present invention extends to a method for treating a patient suffering from a condition that can be ameliorated by the administration of an inhibitor of tryptase, comprising administering an effective amount of a compound of a compound of the present invention. An example of a condition that can be treated with a compound of the present invention includes, but certainly is not limited to inflammatory diseases, e.g., joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, and other chronic inflammatory joint diseases. Other examples of conditions that can be treated with a method of the present invention include diseases of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung diseases, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas, hypertrophic scars, various dermatological conditions, for example, atopic dermatitis and psoriasis, myocardial infarction, stroke, angina and other consequences of atherosclerotic plaque rupture, as well as periodontal disease, diabetic retinopathy, tumor growth, anaphylaxis, multiple sclerosis, peptic ulcers, and syncytial viral infections, to name only a few.
In a particular embodiment, the present invention extends to a method of treating a subject suffering from asthma, comprising administering to the subject an effective amount of a compound of the present invention.
In another embodiment, the present invention extends to a method for treating a patient suffering from joint inflammation, comprising administering to the patient an effective amount of a compound of the present invention.
In addition, the present invention extends to a pharmaceutical comprising a compound of the present invention, a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent, and a pharmaceutically acceptable carrier thereof. Particular inflammatory diseases or disorders that can be treated with such a pharmaceutical composition includes, but certainly is not limited to asthma.
Moreover, the present invention extends to a method for treating a patient suffering from an inflammatory disorder, comprising administering to the patient a compound of the present invention and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent. In such a method of the present invention, a compound of the present invention can be administered to the patient before a second compound, a second compound can be administered to the patient before a compound of the present invention, or a compound of the present invention and a second compound can be administered concurrently. Particular examples of andrenergic agonists, anticholinergics, anti- inflammatory corticosteroids, and anti-inflammatory agents having applications in a method of the present invention are described infra.
Accordingly, it is a principal object to provide compounds having an anti-tryptase activity. Such compounds can readily be used to treat a condition that can be ameliorated by the administration of an inhibitor of tryptase.
It is another object of the present invention to provide pharmaceutical compositions for treating a condition that can be ameliorated by the administration of an inhibitor of tryptase.
It is yet another object of the present invention to provide pharmaceutical compositions comprising a compound of the present invention.
These and other aspects of the present invention will be better appreciated by reference to the following Detailed Description.
DETAILED DESCRIPTION
As used above, and throughout the instant specification and appending claims, the following terms, unless otherwise indicated, shall be understood to have the following meanings:-
As used herein, the term "compounds of the present invention", and equivalent expressions, are meant to embrace compounds of formulae (I), (la), or (lb) as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.
As used herein, the term "treatment" includes prophylactic therapy as well as treatment of an established condition.
"Patient" includes both human and other mammals.
"Effective amount" is meant to describe an amount of compound of the present invention effective in inhibiting tryptase and thus producing the desired therapeutic effect.
"Acyl" means an H-CO- or alkyl-CO- group in which the alkyl group is as described herein.
"Acylamino" is an acyl-NH- group wherein acyl is as defined herein.
"Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. "Branched", as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain that may be straight or branched. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl and decenyl.
"Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and heptoxy.
"Alkyloxycarbonyl" means an alkyl-0-C(=0)- group in which the alkyl group is as described herein. Exemplary alkyloxycarbonyl groups include methoxy- and ethoxycarbonyl.
"Alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 15 carbon atoms in the chain optionally substituted by alkoxy or by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. "Lower alkyl" as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, 3 -pentyl, heptyl, octyl, nonyl, decyl and dodecyl.
"Alkylcarbonylamino" means an alkyl-C(=0)-NH- group in which the alkyl group is as described herein. Exemplary alkylcarbonylamino groups include acetamido and propionamido.
"Alkylene" means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein. Exemplary alkylene radicals include methylene, ethylene and trimethylene.
"Alkylenedioxy" means an -O-alkyl-O- group in which the alkyl group is as defined above. Exemplary alkylenedioxy groups include methylenedioxy and ethylenedioxy.
"Alkylsulfinyl" means an alkyl-SO- group in which the alkyl group is as previously described. Preferred alkylsulfinyl groups are those in which the alkyl group is Cι_4alkyl.
"Alkylsulfonyl" means an alkyl-S02- group in which the alkyl group is as previously described.
Preferred alkylsulfonyl groups are those in which the alkyl group is Cι_4alkyl.
"Alkylsulfonylamino" means an alkyl-S02-NH- group in which the alkyl group is as described herein.
Exemplary alkylsulfonylamino groups include methanesulfonamido and ethanesulfonamido.
"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, isopropylthio and heptylthio.
"Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3- methylbut-2-ynyl, and n-pentynyl.
"Aroyl" means an aryl-CO- group in which the aryl group is as described herein. Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.
"Aroylamino" is an aroyl-NH- group wherein aroyl is as previously defined.
"Aryl" as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to fonn a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Aryl groups may be substituted with one or more aryl group substituents which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkyloxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkenyl, arylalkynyl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxyalkyl, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkenyl, heteroarylalkynyl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heteroaryloxyalkyl, hydroxy, nitro, trifluoromethyl, -NY^Y2,
-CONY1 Y2, -S02NY1Y2, -Z2-C2.6alkylene-NY1Y2 {where Z2 is O, NR8 or S(0)m},
-NY1-(C=0)alkyl, -NY1-S0 alkyl or alkyl optionally substituted with alkoxy, aroyl, aryl, aryloxy, heteroaryl, hydroxy, or - Y^2.
"Arylalkenyl" means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Preferred arylalkenyls contain a lower alkenyl moiety. Exemplary arylalkenyl groups include styryl and phenylallyl.
"Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C^alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.
"Arylalkyloxy" means an arylalkyl-O- group in which the arylalkyl groups is as previously described. Exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
"Arylalkyloxycarbonyl" means an arylalkyl-O-CO- group in which the arylalkyl groups is as previously described. An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.
"Arylalkylthio" means an arylalkyl-S- group in which the arylalkyl group is as previously described. An exemplary arylalkylthio group is benzylthio.
"Arylalkynyl" means an aryl-alkynyl- group in which the aryl and alkynyl are as previously described. Exemplary arylalkynyl groups include phenylethynyl and 3-phenylbut-2-ynyl.
"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Exemplary aryloxy groups include optionally substituted phenoxy and naphthoxy.
"Aryloxyalkyl" means an aryl-O-alkyl- group in which the aryl and alkyl groups are as previously described. Exemplary aryloxyalkyl groups include phenoxymethyl and 1- or 2-naphthyloxymethyl.
"Aryloxycarbonyl" means an aryl-O-C(=0)- group in which the aryl group is as previously described. Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.
"Arylsulfϊnyl" means an aryl-SO- group in which the aryl group is as previously described.
"Arylsulfonyl" means an aryl-S0 - group in which the aryl group is as previously described.
"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Exemplary arylthio groups include phenylthio and naphthylthio.
"Azaheteroaryl" means an aromatic carbocyclic moiety of about 5 to about 10 ring members in which one of the ring members is nitrogen and the other ring members are chosen from carbon, oxygen, sulfur, or nitrogen. Examples of azaheteroaryl groups include benzimidazolyl, imidazolyl, isoquinolinyl, isoxazolyl, pyrazolopyrimidinyl, pyridyl, pyrimidinyl, quinolinyl, quinazolinyl and thiazolyl.
"Cyclic amine" means a 3 to 8 membered monocyclic cycloalkyl ring system where one of the ring carbon atoms is replaced by nitrogen and which (i) may optionally contain an additional heteroatom selected from O, S or NY3 (where Y3 is hydrogen, alkyl, arylalkyl, and aryl) and (ii) may be fused to additional aryl or heteroaryl ring to form a bicyclic ring system. Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline and pyrindoline.
"Cycloalkenyl" means a cycloalkyl group containing at least one carbon-carbon double bond.
Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl.
"Cycloalkyl" means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms optionally substituted by oxo, alkyl, aryl or -C(=0)- NY^2. Exemplary monocyclic cycloalkyl rings include C3_gcycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.
"Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.
"Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred are fluoro or chloro.
"Heteroaroyl" means a heteroaryl-C(=0)- group in which the heteroaryl group is as described herein. Exemplary groups include pyridylcarbonyl.
"Heteroaroylamino" means a heteroaroyl-NH- group in which the heteroaryl moiety are as previously described.
"Heteroaryl" as a group or part of a group denotes: (i) an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur (examples of such groups include benzimidazolyl, benzthiazolyl, benzthiophenyl, furyl, imidazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups, optionally substituted by one or more aryl group substituents as defined above); (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which a heteroaryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure (examples of such groups include pyrindanyl groups). Optional substituents include one or more "aryl group substituents" as defined above.
"Aryldiyl" means an optionally substituted bivalent radical derived from an aryl group as defined herein. Exemplary aryldiyl groups include optionally substituted phenylene, naphthylene and indanylene. Suitable substituents include one or more "aryl group substituents" as defined above, particularly halogen, methyl or methoxy.
"Heteroaryldiyl" means a bivalent radical derived from a heteroaryl group as defined below.
"Heteroarylalkenyl" means a heteroaryl-alkenyl- group in which the heteroaryl and alkenyl moieties are as previously described. Preferred heteroarylalkenyl groups contain a lower alkenyl moiety. Exemplary heteroarylalkenyl groups include pyridylethenyl and pyridylallyl.
"Heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a Ci _4alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.
"Heteroarylalkyloxy" means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.
"Heteroarylalkynyl" means a heteroaryl-alkynyl- group in which the heteroaryl and alkynyl moieties are as previously described. Exemplary heteroarylalkenyl groups include pyridylethynyl and 3-pyridylbut-2-ynyl.
"Heteroaryloxy" means an heteroaryl-O- group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.
"Heteroaryloxyalkyl" means an heteroaryl-O-alkyl- group in which the heteroaryl and alkyl groups are as previously described. Exemplary heteroaryloxyalkyl groups include pyridyoxymethyl and 2-, 3- or 4-quinolinyloxymethyl.
"Heterocycloalkenyl" means a cycloalkenyl group of about 3 to 7 ring members which contains one or more heteroatoms selected from O, S or NY^ (where Y^ is hydrogen, alkyl, aryl, arylalkyl, and alkyloxycarbonyl). Exemplary heterocycloalkenyl groups include 1,2,3,6-tetrahydro-pyridine.
"Heterocycloalkyl" means: (i) a cycloalkyl group of about 3 to 7 ring members which contains one or more heteroatoms selected from O, S or NY^ (where γ4 is hydrogen, alkyl, aryl, arylalkyl, and alkyloxycarbonyl) and which may optionally be substituted by oxo (examples of such groups include piperidinyl, pyrrolidinyl, morpholinyl, tetrahydropyranyl and tetrahydrothiophenyl; (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which one or more aryl (or heteroaryl) rings and a cycloalkyl group of about 3 to 7 ring members, which contains one or more heteroatoms selected from O, S or NY^ and which may optionally be substituted by oxo, are fused together to form a cyclic structure (examples of such groups include chromanyl, dihydrobenzofuranyl, indolinyl and pyrindolinyl groups).
"Heterocycloalkylalkyl" means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.
"Heterocycloalkylalkyloxy" means a heterocycloalkyl-alkyl-O- group in which the heterocycloalkyl and alkyl moieties are as previously described.
"Heterocycloalkyloxy" means a heterocycloalkyl-O- group in which the heterocycloalkyl is as previously described.
"Prodrug" means a compound which is suitable for administration to a patient without undue toxicity, irritation, allergic response, and the like, and is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of the present invention, including N-oxides thereof. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A. C. S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. For example an ester of a compound of the present invention containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule. Alternatively an ester of a compound of the present invention containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.
Suitable esters of compounds of present invention containing a hydroxy group, are for example acetates, citrates, lactates, tartxates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-β-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.
An especially useful class of esters of compounds of the present invention containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et al., J. Med. Chem., 1989, 32, page 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-l-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-l-yl)benzoates.
Suitable esters of compounds of the present invention containing a carboxy group, are for example those described by FJ.Leinweber, Drug Metab. Res., 1987, 18, page 379.
The compounds of the present invention are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.
Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g. hydrochlorides and hydrobromides, sulfates, phosphates, nitrates, sulfamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.
As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.
With reference to formula (la) above, the following are particular and preferred groupings:
R1 may particularly represent hydrogen.
R2 may particularly represent hydrogen.
R3 may particularly represent aryl, such as optionally substituted phenyl or optionally substituted naphthyl, especially substituted phenyl. Exemplary optional substituents include one or more halo atoms or alkyl substituted by aryl, alkyl substituted by aryloxy, alkyl substituted by aroyl, alkyl substituted by heteroaryl, arylalkynyl, heteroarylalkynyl, aryl, heteroaryl, arylalkenyl or arylalkyloxy,
in which the aryl or heteroaryl groups may be further substituted by one or more aryl group substituents.
R3 may also particularly represent heteroaryl, such as optionally substituted pyridyl, optionally substituted quinolinyl, optionally substituted thienyl, optionally substituted furanyl or optionally substituted indolyl, especially substituted thienyl, substituted pyridyl or indolyl. Exemplary optional substituents include alkyl substituted by aryl, alkyl substituted by aryloxy, alkyl substituted by aroyl, alkyl substituted heteroaryl, arylalkynyl, heteroarylalkynyl, heteroaryl, arylalkenyl or arylalkyloxy, in which the aryl or heteroaryl groups are further substituted by one or more aryl group substituents.
R4 may particularly represent hydrogen.
R4 may also particularly represent cyano, especially when attached to the tertiary ring carbon atom.
R5 may particularly represent hydrogen.
R^ may also particularly represent lower alkyl (e.g. methyl) or halo (e.g. fluoro).
may particularly represent a single bond.
n may particularly represent 2.
It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.
A particular group of compounds of the invention are compounds of formula (lb):-
(lb)
in which R3, R^ and R^ are as hereinbefore defined and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
Compounds of formula (lb) in which R3 represents aryl, such as optionally substituted phenyl or optionally substituted naphthyl, especially substituted phenyl, are preferred. Preferred optional substituents include one or more halo atoms or alkyl substituted by aryl or alkyl substituted heteroaryl, in which the aryl or heteroaryl groups may be further substituted by one or more aryl group substituents. R3 especially represents dichlorophenyl [e.g. 3,4-dichlorophenyl], phenylCi . alkylphenyl [e.g. phenethyl], hydroxyphenylC^alkylphenyl [e.g.
4-hydroxyphenylethylphenyl] and aminopyridylC^alkylphenyl [e.g. (4-amino-pyrid-3- yl)ethylphenyl].
Compounds of formula (lb) in which R3 represents heteroaryl, such as optionally substituted pyridyl, optionally substituted quinolinyl, optionally substituted thienyl, optionally substituted furanyl or optionally substituted indolyl, especially substituted thienyl, substituted pyridyl or indolyl, are preferred. Preferred optional substituents include alkyl substituted by aryl and alkyl substituted heteroaryl in which the aryl or heteroaryl groups are further substituted by one or more aryl group substituents. R3 especially represents phenylC 1. alky lpyridyl [e.g. 5-phenylethyl-pyrid-3-yl], phenylC 1.3 alky lthienyl [e.g. 5-phenylethyl-thien-2-yl] and indolyl [e.g. indol-6-yl].
Compounds of formula (lb) in which R^ represents hydrogen are preferred.
Compounds of formula (lb) in which R^ represents cyano are also preferred. R^ is preferably attached at the 4 position of the piperidine ring.
Compounds of formula (lb) in which R^ represents hydrogen are preferred.
Compounds of formula (lb) in which R^ represents lower alkyl (e.g. methyl) or halo (e.g. fluoro), are also preferred. R is preferably attached to the phenyl ring in the position para to the -CH2NH2 group.
A preferred group of compounds of the invention are compounds of formula (lb) in which:- R3 is substituted phenyl [especially 3,4-dichlorophenyl, phenethyl, 4-hydroxyphenylefhylphenyl and (4- a ino-pyrid-3-yl)ethylphenyl] or optionally substituted heteroaryl [ especially 5-phenylethyl-pyrid-3- yl, 5-phenylethyl-thien-2-yl or indol-6-yl]; R^ is hydrogen, or cyano attached at the 4 position of the piperidine ring; R^ is hydrogen, or lower alkyl (e.g. methyl) or halo (e.g. fluoro) attached to the phenyl ring in the position para to the -CH2NH2 group; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
Particular compounds of the invention are selected from the compounds formed by joining the carbon atom (C*) of one of the fragments (Al to AlO) shown in Table 1 to the carbon atom (C*) of one of the fragments (Bl to B12) shown in Table 2, and joining the nitrogen atom (N*) of one of the fragments (Bl to B12) shown in Table 2 to the carbon atom (C*) of one of the acidic fragments (CI to C103) depicted in Table 3.
TABLE 1
TABLE 2
TABLE 3
Particularly preferred examples of fragments "A", "B", and "C" are illustrated in Table 4 below
TABLE 4
A1-B1-C1 A1-B1-C2 A1-B1-C3 A1-B1-C4 A1-B1-C5 A1-B1-C6
A1-B1-C7 A1-B1-C8 A1-B1-C9 A1-B1-C10 A1-B1-C1 1 A1-B1-C12
A1-B1-C13 A1-B1-C14 A1-B1-C15 A1-B1-C16 A1-B1-C17 A1-B1-C18
A1-B1-C19 A1-B1-C20 A1-B1-C21 A1-B1-C22 A1-B1-C23 A1-B1-C24
A1-B1-C25 A1-B1-C26 A1-B1-C27 A1-B1-C28 A1-B1-C29 A1-B1-C30
A1-B1-C31 A1-B1-C32 A1-B1-C33 A1-B1-C34 A1-B1-C35 A1-B1-C36
A1-B1-C37 A1-B1-C38 A1-B1-C39 A1-B1-C40 A1-B1-C41 A1-B1-C42
A1-B1-C43 A1-B1-C44 A1-B1-C45 A1-B1-C46 A1-B1-C47 A1-B1-C48
A1-B1-C49 A1-B1-C50 A1-B1-C51 A1-B1-C52 A1-B1-C53 A1-B1-C54
A1-B1-C55 A1-B1-C56 A1-B1-C57 A1-B1-C58 A1-B1-C59 A1-B1-C60
A1-B1-C61 A1-B1-C62 A1-B1-C63 A1-B1-C64 A1-B1-C65 A1-B1-C66
A1-B1-C67 A1-B1-C68 A1-B1-C69 A1-B1-C70 A1-B1-C71 A1-B1-C72
A1-B1-C73 A1-B1-C74 A1-B1-C75 A1-B1-C76 A1-B1-C77 A1-B1-C78
A1-B1-C79 A1-B1-C80 A1-B1-C81 A1-B1-C82 A1-B1-C83 A1-B1-C84
A1-B1-C85 A1-B1-C86 A1-B1-C87 A1-B1-C88 A1-B1-C89 A1-B1-C90
A1-B1-C91 A1-B1-C92 A1-B1-C93 A1-B1-C94 A1-B1-C95 A1-B1-C96
A1-B1-C97 A1-B1-C98 A1-B1-C99 A1-B1-C100 A1-B1-C101 Al-Bl-cl02
A1-B1-C103 A1-B1-C104 A1-B1-C105 A1-B1-C106 A1-B1-C107 A1-B1-C108
A1-B1-C109 A1-B1-C110 A1-B1-C111 A1-B1-C112 A1-B1-C113 A1-B1-C114
A1-B1-C115 A1-B1-C1 16 A1-B1-C117 A1-B1-C118 A1-B1-C119 A1-B1-C120
A1-B1-C121 A1-B1-C122 A1-B1-C123 A1-B1-C124 A1-B1-C125 A1-B1-C126
A1-B1-C127 A1-B1-C128 A1-B1-C129 A1-B1-C130 A1-B1-C131 A1-B1-C132
A1-B1-C133 A1-B1-C134 A1-B1-C135 A1-B1-C136 A1-B1-C137 A1-B1-C138
A1-B1-C139 A1-B1-C140 BLANK BLANK BLANK BLANK
A1-B2-C1 A1-B2-C2 A1-B2-C3 A1-B2-C4 A1-B2-C5 A1-B2-C6
A1-B2-C7 A1-B2-C8 A1-B2-C9 A1-B2-C10 A1-B2-C11 A1-B2-C12
A1-B2-C13 A1-B2-C14 A1-B2-C15 A1-B2-C16 A1-B2-C17 A1-B2-C18
A1-B2-C19 A1-B2-C20 A1-B2-C21 A1-B2-C22 A1-B2-C23 A1-B2-C24
A1-B2-C25 A1-B2-C26 A1-B2-C27 A1-B2-C28 A1-B2-C29 A1-B2-C30
A1-B2-C31 A1-B2-C32 A1-B2-C33 A1-B2-C34 A1-B2-C35 A1-B2-C36
A1-B2-C37 A1-B2-C38 A1-B2-C39 A1-B2-C40 A1-B2-C41 A1-B2-C42
A1-B2-C43 A1-B2-C44 A1-B2-C45 A1-B2-C46 A1-B2-C47 A1-B2-C48
A1-B2-C49 A1-B2-C50 A1-B2-C51 A1-B2-C52 A1-B2-C53 A1-B2-C54
A1-B2-C55 A1-B2-C56 A1-B2-C57 A1-B2-C58 A1-B2-C59 A1-B2-C60
A1-B2-C61 A1-B2-C62 A1-B2-C63 A1-B2-C64 A1-B2-C65 A1-B2-C66
A1-B2-C67 A1-B2-C68 A1-B2-C69 A1-B2-C70 A1-B2-C71 A1-B2-C72
A1-B2-C73 A1-B2-C74 A1-B2-C75 A1-B2-C76 A1-B2-C77 A1-B2-C78
A1-B2-C79 A1-B2-C80 A1-B2-C81 A1-B2-C82 A1-B2-C83 A1-B2-C84
A1-B2-C85 A1-B2-C86 A1-B2-C87 A1-B2-C88 A1-B2-C89 A1-B2-C90
A1-B2-C91 A1-B2-C92 A1-B2-C93 A1-B2-C94 A1-B2-C95 A1-B2-C96
A1-B2-C97 A1-B2-C98 A1-B2-C99 A1-B2-C100 A1-B2-C101 A1-B2-C102
A1-B2-C103 A1-B2-C104 A1-B2-C105 A1-B2-C106 A1-B2-C107 A1-B2-C108
A1-B2-C109 A1-B2-C110 A1-B2-C111 A1-B2-C112 A1-B2-C113 A1-B2-C114
A1-B2-C115 A1-B2-C116 A1-B2-C117 A1-B2-C118 A1-B2-C119 A1-B2-C120
A1-B2-C121 A1-B2-C122 A1-B2-C123 A1-B2-C124 A1-B2-C125 A1-B2-C126
A1-B2-C127 A1-B2-C128 A1-B2-C129 A1-B2-C130 A1-B2-C131 A1-B2-C132
A1-B2-C133 A1-B2-C134 A1-B2-C135 A1-B2-C136 A1-B2-C137 A1-B2-C138
A1-B2-C139 A1-B2-C140 BLANK BLANK BLANK BLANK
A1-B3-C1 A1-B3-C2 A1-B3-C3 A1-B3-C4 A1-B3-C5 A1-B3-C6
A1-B3-C7 A1-B3-C8 A1-B3-C9 A1-B3-C10 A1-B3-C11 A1-B3-C12
A1-B3-C13 A1-B3-C14 A1-B3-C15 A1-B3-C16 A1-B3-C17 A1-B3-C18
A1-B3-C19 A1-B3-C20 A1-B3-C21 A1-B3-C22 A1-B3-C23 A1-B3-C24
A1-B3-C25 A1-B3-C26 A1-B3-C27 A1-B3-C28 A1-B3-C29 A1-B3-C30
A1-B3-C31 A1-B3-C32 A1-B3-C33 A1-B3-C34 A1-B3-C35 A1-B3-C36
A1-B3-C37 A1-B3-C38 A1-B3-C39 A1-B3-C40 A1-B3-C41 A1-B3-C42
A1-B3-C43 A1-B3-C44 A1-B3-C45 A1-B3-C46 A1-B3-C47 A1-B3-C48
A1-B3-C49 A1-B3-C50 A1-B3-C51 A1-B3-C52 A1-B3-C53 A1-B3-C54 A1-B3-C55 A1-B3-C56 A1-B3-C57 A1-B3-C58 A1-B3-C59 A1-B3-C60 A1-B3-C61 A1-B3-C62 A1-B3-C63 A1-B3-C64 A1-B3-C65 A1-B3-C66 A1-B3-C67 A1-B3-C68 A1-B3-C69 A1-B3-C70 A1-B3-C71 A1-B3-C72 A1-B3-C73 A1-B3-C74 A1-B3-C75 A1-B3-C76 A1-B3-C77 A1-B3-C78 A1-B3-C79 A1-B3-C80 A1-B3-C81 A1-B3-C82 A1-B3-C83 A1-B3-C84 A1-B3-C85 A1-B3-C86 A1-B3-C87 A1-B3-C88 A1-B3-C89 A1-B3-C90 A1-B3-C91 A1-B3-C92 A1-B3-C93 A1-B3-C94 A1-B3-C95 A1-B3-C96 A1-B3-C97 A1-B3-C98 A1-B3-C99 A1-B3-C100 A1-B3-C101 A1-B3-C102 A1-B3-C103 A1-B3-C104 A1-B3-C105 A1-B3-C106 A1-B3-C107 A1-B3-C108 A1-B3-C109 A1-B3-C110 A1-B3-C111 A1-B3-C112 A1-B3-C113 A1-B3-C114 A1-B3-C115 A1-B3-C116 A1-B3-C117 A1-B3-C118 A1-B3-C119 A1-B3-C120 A1-B3-C121 A1-B3-C122 A1-B3-C123 A1-B3-C124 A1-B3-C125 A1-B3-C126 A1-B3-C127 A1-B3-C128 A1-B3-C129 A1-B3-C130 A1-B3-C131 A1-B3-C132 A1-B3-C133 A1-B3-C134 A1-B3-C135 A1-B3-C136 A1-B3-C137 A1-B3-C138 A1-B3-C139 A1-B3-C140 BLANK BLANK BLANK BLANK A1-B4-C1 A1-B4-C2 • A1-B4-C3 A1-B4-C4 A1-B4-C5 A1-B4-C6 A1-B4-C7 A1-B4-C8 A1-B4-C9 A1-B4-C10 A1-B4-C11 A1-B4-C12 A1-B4-C13 A1-B4-C14 A1-B4-C15 A1-B4-C16 A1-B4-C17 A1-B4-C18 A1-B4-C19 A1-B4-C20 A1-B4-C21 A1-B4-C22 A1-B4-C23 A1-B4-C24 A1-B4-C25 A1-B4-C26 A1-B4-C27 A1-B4-C28 A1-B4-C29 A1-B4-C30 A1-B4-C31 A1-B4-C32 A1-B4-C33 A1-B4-C34 A1-B4-C35 A1-B4-C36 A1-B4-C37 A1-B4-C38 A1-B4-C39 A1-B4-C40 A1-B4-C41 A1-B4-C42 A1-B4-C43 A1-B4-C44 A1-B4-C45 A1-B4-C46 A1-B4-C47 A1-B4-C48 A1-B4-C49 A1-B4-C50 A1-B4-C51 A1-B4-C52 A1-B4-C53 A1-B4-C54 A1-B4-C55 A1-B4-C56 A1-B4-C57 A1-B4-C58 A1-B4-C59 A1-B4-C60 A1-B4-C61 A1-B4-C62 A1-B4-C63 A1-B4-C64 A1-B4-C65 A1-B4-C66 A1-B4-C67 A1-B4-C68 A1-B4-C69 A1-B4-C70 A1-B4-C71 A1-B4-C72 A1-B4-C73 A1-B4-C74 A1-B4-C75 A1-B4-C76 A1-B4-C77 A1-B4-C78 A1-B4-C79 A1-B4-C80 A1-B4-C81 A1-B4-C82 A1-B4-C83 A1-B4-C84 A1-B4-C85 A1-B4-C86 A1-B4-C87 A1-B4-C88 A1-B4-C89 A1-B4-C90 A1-B4-C91 A1-B4-C92 A1-B4-C93 A1-B4-C94 A1-B4-C95 A1-B4-C96 A1-B4-C97 A1-B4-C98 A1-B4-C99 A1-B4-C100 A1-B4-C101 A1-B4-C102 A1-B4-C103 A1-B4-C104 A1-B4-C105 A1-B4-C106 A1-B4-C107 A1-B4-C108 A1-B4-C109 A1-B4-C110 A1-B4-C1 11 A1-B4-C112 A1-B4-C113 A1-B4-C114 A1-B4-C115 A1-B4-C116 A1-B4-C117 A1-B4-C118 A1-B4-C119 A1-B4-C120 A1-B4-C121 A1-B4-C122 A1-B4-C123 A1-B4-C124 A1-B4-C125 A1-B4-C126
A1-B4-C127 A1-B4-C128 A1-B4-C129 A1-B4-C130 A1-B4-C131 A1-B4-C132
A1-B4-C133 A1-B4-C134 A1-B4-C135 A1-B4-C136 A1-B4-C137 A1-B4-C138
A1-B4-C139 A1-B4-C140 BLANK BLANK BLANK BLANK
A1-B5-C1 A1-B5-C2 A1-B5-C3 A1-B5-C4 A1-B5-C5 A1-B5-C6
A1-B5-C7 A1-B5-C8 A1-B5-C9 A1-B5-C10 A1-B5-C11 A1-B5-C12
A1-B5-C13 A1-B5-C14 A1-B5-C15 A1-B5-C16 A1-B5-C17 A1-B5-C18
A1-B5-C19 A1-B5-C20 A1-B5-C21 A1-B5-C22 A1-B5-C23 A1-B5-C24
A1-B5-C25 A1-B5-C26 A1-B5-C27 A1-B5-C28 A1-B5-C29 A1-B5-C30
A1-B5-C31 A1-B5-C32 A1-B5-C33 A1-B5-C34 A1-B5-C35 A1-B5-C36
A1-B5-C37 A1-B5-C38 A1-B5-C39 A1-B5-C40 A1-B5-C41 A1-B5-C42
A1-B5-C43 A1-B5-C44 A1-B5-C45 A1-B5-C46 A1-B5-C47 A1-B5-C48
A1-B5-C49 A1-B5-C50 A1-B5-C51 A1-B5-C52 A1-B5-C53 A1-B5-C54
A1-B5-C55 A1-B5-C56 A1-B5-C57 A1-B5-C58 A1-B5-C59 A1-B5-C60
A1-B5-C61 A1-B5-C62 A1-B5-C63 A1-B5-C64 A1-B5-C65 A1-B5-C66
A1-B5-C67 A1-B5-C68 A1-B5-C69 A1-B5-C70 A1-B5-C71 A1-B5-C72
A1-B5-C73 A1-B5-C74 A1-B5-C75 A1-B5-C76 A1-B5-C77 A1-B5-C78
A1-B5-C79 A1-B5-C80 A1-B5-C81 A1-B5-C82 A1-B5-C83 A1-B5-C84
A1-B5-C85 A1-B5-C86 A1-B5-C87 A1-B5-C88 A1-B5-C89 A1-B5-C90
A1-B5-C91 A1-B5-C92 A1-B5-C93 A1-B5-C94 A1-B5-C95 A1-B5-C96
A1-B5-C97 A1-B5-C98 A1-B5-C99 A1-B5-C100 A1-B5-C101 A1-B5-C102
A1-B5-C103 A1-B5-C104 A1-B5-C105 A1-B5-C106 A1-B5-C107 A1-B5-C108
A1-B5-C109 A1-B5-C110 A1-B5-C111 A1-B5-C112 A1-B5-C113 A1-B5-C114
A1-B5-C115 A1-B5-C116 A1-B5-C117 A1-B5-C118 A1-B5-C119 A1-B5-C120
A1-B5-C121 A1-B5-C122 A1-B5-C123 A1-B5-C124 A1-B5-C125 A1-B5-C126
A1-B5-C127 A1-B5-C128 A1-B5-C129 A1-B5-C130 A1-B5-C131 A1-B5-C132
A1-B5-C133 A1-B5-C134 A1-B5-C135 A1-B5-C136 A1-B5-C137 A1-B5-C138
A1-B5-C139 A1-B5-C140 BLANK BLANK BLANK BLANK
A1-B6-C1 A1-B6-C2 A1-B6-C3 A1-B6-C4 A1-B6-C5 A1-B6-C6
A1-B6-C7 A1-B6-C8 A1-B6-C9 A1-B6-C10 A1-B6-C11 A1-B6-C12
A1-B6-C13 A1-B6-C14 A1-B6-C15 A1-B6-C16 A1-B6-C17 A1-B6-C18
A1-B6-C19 A1-B6-C20 A1-B6-C21 A1-B6-C22 A1-B6-C23 A1-B6-C24
A1-B6-C25 A1-B6-C26 A1-B6-C27 A1-B6-C28 A1-B6-C29 A1-B6-C30
A1-B6-C31 A1-B6-C32 A1-B6-C33 A1-B6-C34 A1-B6-C35 A1-B6-C36
A1-B6-C37 A1-B6-C38 A1-B6-C39 A1-B6-C40 A1-B6-C41 A1-B6-C42
A1-B6-C43 A1-B6-C44 A1-B6-C45 A1-B6-C46 A1-B6-C47 A1-B6-C48
A1-B6-C49 A1-B6-C50 A1-B6-C51 A1-B6-C52 A1-B6-C53 A1-B6-C54
A1-B6-C55 A1-B6-C56 A1-B6-C57 A1-B6-C58 A1-B6-C59 A1-B6-C60
A1-B6-C61 A1-B6-C62 A1-B6-C63 A1-B6-C64 A1-B6-C65 A1-B6-C66
A1-B6-C67 A1-B6-C68 A1-B6-C69 A1-B6-C70 A1-B6-C71 A1-B6-C72
A1-B6-C73 A1-B6-C74 A1-B6-C75 A1-B6-C76 A1-B6-C77 A1-B6-C78
A1-B6-C79 A1-B6-C80 A1-B6-C81 A1-B6-C82 A1-B6-C83 A1-B6-C84
A1-B6-C85 A1-B6-C86 A1-B6-C87 A1-B6-C88 A1-B6-C89 A1-B6-C90
A1-B6-C91 A1-B6-C92 A1-B6-C93 A1-B6-C94 A1-B6-C95 A1-B6-C96
A1-B6-C97 A1-B6-C98 A1-B6-C99 A1-B6-C100 A1-B6-C101 A1-B6-C102
A1-B6-C103 A1-B6-C104 A1-B6-C105 A1-B6-C106 A1-B6-C107 A1-B6-C108
A1-B6-C109 A1-B6-C110 A1-B6-C111 A1-B6-C112 A1-B6-C113 A1-B6-C114
A1-B6-C1 15 A1-B6-C116 A1-B6-C117 A1-B6-C118 A1-B6-C119 A1-B6-C120
A1-B6-C121 A1-B6-C122 A1-B6-C123 A1-B6-C124 A1-B6-C125 A1-B6-C126
A1-B6-C127 A1-B6-C128 A1-B6-C129 A1-B6-C130 A1-B6-C131 A1-B6-C132
A1-B6-C133 A1-B6-C134 A1-B6-C135 A1-B6-C136 A1-B6-C137 A1-B6-C138
A1-B6-C139 A1-B6-C140 BLANK BLANK BLANK BLANK
A1-B7-C1 A1-B7-C2 A1-B7-C3 A1-B7-C4 A1-B7-C5 A1-B7-C6
A1-B7-C7 A1-B7-C8 A1-B7-C9 A1-B7-C10 A1-B7-C11 A1-B7-C12
A1-B7-C13 A1-B7-C14 A1-B7-C15 A1-B7-C16 A1-B7-C17 A1-B7-C18
A1-B7-C19 A1-B7-C20 A1-B7-C21 A1-B7-C22 A1-B7-C23 A1-B7-C24
A1-B7-C25 A1-B7-C26 A1-B7-C27 A1-B7-C28 A1-B7-C29 A1-B7-C30
A1-B7-C31 A1-B7-C32 A1-B7-C33 A1-B7-C34 A1-B7-C35 A1-B7-C36
A1-B7-C37 A1-B7-C38 A1-B7-C39 A1-B7-C40 A1-B7-C41 A1-B7-C42
A1-B7-C43 A1-B7-C44 A1-B7-C45 A1-B7-C46 A1-B7-C47 A1-B7-C48
A1-B7-C49 A1-B7-C50 A1-B7-C51 A1-B7-C52 A1-B7-C53 A1-B7-C54
A1-B7-C55 A1-B7-C56 A1-B7-C57 A1-B7-C58 A1-B7-C59 A1-B7-C60
A1-B7-C61 A1-B7-C62 A1-B7-C63 A1-B7-C64 A1-B7-C65 A1-B7-C66
A1-B7-C67 A1-B7-C68 A1-B7-C69 A1-B7-C70 A1-B7-C71 A1-B7-C72
A1-B7-C73 A1-B7-C74 A1-B7-C75 A1-B7-C76 A1-B7-C77 A1-B7-C78
A1-B7-C79 A1-B7-C80 A1-B7-C81 A1-B7-C82 A1-B7-C83 A1-B7-C84
A1-B7-C85 A1-B7-C86 A1-B7-C87 A1-B7-C88 A1-B7-C89 A1-B7-C90
A1-B7-C91 A1-B7-C92 A1-B7-C93 A1-B7-C94 A1-B7-C95 A1-B7-C96
A1-B7-C97 A1-B7-C98 A1-B7-C99 A1-B7-C100 A1-B7-C101 A1-B7-C102
A1-B7-C103 A1-B7-C104 A1-B7-C105 A1-B7-C106 A1-B7-C107 A1-B7-C108
A1-B7-C109 A1-B7-C110 A1-B7-C111 A1-B7-C112 A1-B7-C113 A1-B7-C114
A1-B7-C115 A1-B7-C116 A1-B7-C117 A1-B7-C118 A1-B7-C119 A1-B7-C120
A1-B7-C121 A1-B7-C122 A1-B7-C123 A1-B7-C124 A1-B7-C125 A1-B7-C126
A1-B7-C127 A1-B7-C128 A1-B7-C129 A1-B7-C130 A1-B7-C131 A1-B7-C132
A1-B7-C133 A1-B7-C134 A1-B7-C135 A1-B7-C136 A1-B7-C137 A1-B7-C138
A1-B7-C139 A1-B7-C140 BLANK BLANK BLANK BLANK
A1-B8-C1 A1-B8-C2 A1-B8-C3 A1-B8-C4 A1-B8-C5 A1-B8-C6
A1-B8-C7 A1-B8-C8 A1-B8-C9 A1-B8-C10 A1-B8-C1 1 A1-B8-C12
A1-B8-C13 A1-B8-C14 A1-B8-C15 A1-B8-C16 A1-B8-C17 A1-B8-C18
A1-B8-C19 A1-B8-C20 A1-B8-C21 A1-B8-C22 A1-B8-C23 A1-B8-C24
A1-B8-C25 A1-B8-C26 A1-B8-C27 A1-B8-C28 A1-B8-C29 A1-B8-C30
A1-B8-C31 A1-B8-C32 A1-B8-C33 A1-B8-C34 A1-B8-C35 A1-B8-C36
A1-B8-C37 A1-B8-C38 A1-B8-C39 A1-B8-C40 A1-B8-C41 A1-B8-C42
A1-B8-C43 A1-B8-C44 A1-B8-C45 A1-B8-C46 A1-B8-C47 A1-B8-C48
A1-B8-C49 A1-B8-C50 A1-B8-C51 A1-B8-C52 A1-B8-C53 A1-B8-C54
A1-B8-C55 A1-B8-C56 A1-B8-C57 A1-B8-C58 A1-B8-C59 A1-B8-C60
A1-B8-C61 A1-B8-C62 A1-B8-C63 A1-B8-C64 A1-B8-C65 A1-B8-C66
A1-B8-C67 A1-B8-C68 A1-B8-C69 A1-B8-C70 A1-B8-C71 A1-B8-C72
A1-B8-C73 A1-B8-C74 A1-B8-C75 A1-B8-C76 A1-B8-C77 A1-B8-C78
A1-B8-C79 A1-B8-C80 A1-B8-C81 A1-B8-C82 A1-B8-C83 A1-B8-C84
A1-B8-C85 A1-B8-C86 A1-B8-C87 A1-B8-C88 A1-B8-C89 A1-B8-C90
A1-B8-C91 A1-B8-C92 A1-B8-C93 A1-B8-C94 A1-B8-C95 A1-B8-C96
A1-B8-C97 A1-B8-C98 A1-B8-C99 A1-B8-C100 A1-B8-C101 A1-B8-C102
A1-B8-C103 A1-B8-C104 A1-B8-C105 A1-B8-C106 A1-B8-C107 A1-B8-C108
A1-B8-C109 A1-B8-C110 A1-B8-C111 A1-B8-C112 A1-B8-C113 A1-B8-C114
A1-B8-C115 A1-B8-C116 A1-B8-C117 A1-B8-C118 A1-B8-C119 A1-B8-C120
A1-B8-C121 A1-B8-C122 A1-B8-C123 A1-B8-C124 A1-B8-C125 A1-B8-C126
A1-B8-C127 A1-B8-C128 A1-B8-C129 A1-B8-C130 A1-B8-C131 A1-B8-C132
A1-B8-C133 A1-B8-C134 A1-B8-C135 A1-B8-C136 A1-B8-C137 A1-B8-C138
A1-B8-C139 A1-B8-C140 BLANK BLANK BLANK BLANK
A1-B9-C1 A1-B9-C2 A1-B9-C3 A1-B9-C4 A1-B9-C5 A1-B9-C6
A1-B9-C7 A1-B9-C8 A1-B9-C9 A1-B9-C10 A1-B9-C11 A1-B9-C12
A1-B9-C13 A1-B9-C14 A1-B9-C15 A1-B9-C16 A1-B9-C17 A1-B9-C18
A1-B9-C19 A1-B9-C20 A1-B9-C21 A1-B9-C22 A1-B9-C23 A1-B9-C24
A1-B9-C25 A1-B9-C26 A1-B9-C27 A1-B9-C28 A1-B9-C29 A1-B9-C30
A1-B9-C31 A1-B9-C32 A1-B9-C33 A1-B9-C34 A1-B9-C35 A1-B9-C36
A1-B9-C37 A1-B9-C38 A1-B9-C39 A1-B9-C40 A1-B9-C41 A1-B9-C42
A1-B9-C43 A1-B9-C44 A1-B9-C45 A1-B9-C46 A1-B9-C47 A1-B9-C48
A1-B9-C49 A1-B9-C50 A1-B9-C51 A1-B9-C52 A1-B9-C53 A1-B9-C54
A1-B9-C55 A1-B9-C56 A1-B9-C57 A1-B9-C58 A1-B9-C59 A1-B9-C60
A1-B9-C61 A1-B9-C62 A1-B9-C63 A1-B9-C64 A1-B9-C65 A1-B9-C66
A1-B9-C67 A1-B9-C68 A1-B9-C69 A1-B9-C70 A1-B9-C71 A1-B9-C72
A1-B9-C73 A1-B9-C74 A1-B9-C75 A1-B9-C76 A1-B9-C77 A1-B9-C78
A1-B9-C79 A1-B9-C80 A1-B9-C81 A1-B9-C82 A1-B9-C83 A1-B9-C84
A1-B9-C85 A1-B9-C86 A1-B9-C87 A1-B9-C88 A1-B9-C89 A1-B9-C90
A1-B9-C91 A1-B9-C92 A1-B9-C93 A1-B9-C94 A1-B9-C95 A1-B9-C96
A1-B9-C97 A1-B9-C98 A1-B9-C99 A1-B9-C100 A1-B9-C101 A1-B9-C102
A1-B9-C103 A1-B9-C104 A1-B9-C105 A1-B9-C106 A1-B9-C107 A1-B9-C108
A1-B9-C109 A1-B9-C110 A1-B9-C111 A1-B9-C112 A1-B9-C113 A1-B9-C1 14
A1-B9-C115 A1-B9-C116 A1-B9-C117 A1-B9-C118 A1-B9-C119 A1-B9-C120
A1-B9-C121 A1-B9-C122 A1-B9-C123 A1-B9-C124 A1-B9-C125 A1-B9-C126
A1-B9-C127 A1-B9-C128 A1-B9-C129 A1-B9-C130 A1-B9-C131 A1-B9-C132
A1-B9-C133 A1-B9-C134 A1-B9-C135 A1-B9-C136 A1-B9-C137 A1-B9-C138
A1-B9-C139 A1-B9-C140 BLANK BLANK BLANK BLANK
A1-B10-C1 A1-B10-C2 A1-B10-C3 A1-B10-C4 A1-B10-C5 A1-B10-C6
A1-B10-C7 A1-B10-C8 A1-B10-C9 A1-B10-C10 A1-B10-C11 A1-B10-C12
A1-B10-C13 A1-B10-C14 A1-B10-C15 A1-B10-C16 A1-B10-C17 A1-B10-C18
A1-B10-C19 A1-B10-C20 A1-B10-C21 A1-B10-C22 A1-B10-C23 A1-B10-C24
A1-B10-C25 A1-B10-C26 A1-B10-C27 A1-B10-C28 A1-B10-C29 A1-B10-C30
A1-B10-C31 A1-B10-C32 A1-B10-C33 A1-B10-C34 A1-B10-C35 A1-B10-C36
A1-B10-C37 A1-B10-C38 A1-B10-C39 A1-B10-C40 A1-B10-C41 A1-B10-C42
A1-B10-C43 A1-B10-C44 A1-B10-C45 A1-B10-C46 A1-B10-C47 A1-B10-C48
A1-B10-C49 A1-B10-C50 A1-B10-C51 A1-B10-C52 A1-B10-C53 A1-B10-C54
A1-B10-C55 A1-B10-C56 A1-B10-C57 A1-B10-C58 A1-B10-C59 A1-B10-C60
A1-B10-C61 A1-B10-C62 A1-B10-C63 A1-B10-C64 A1-B10-C65 A1-B10-C66
A1-B10-C67 A1-B10-C68 A1-B10-C69 A1-B10-C70 A1-B10-C71 A1-B10-C72
A1-B10-C73 A1-B10-C74 A1-B10-C75 A1-B10-C76 A1-B10-C77 A1-B10-C78
A1-B10-C79 A1-B10-C80 A1-B10-C81 A1-B10-C82 A1-B10-C83 A1-B10-C84
A1-B10-C85 A1-B10-C86 A1-B10-C87 A1-B10-C88 A1-B10-C89 A1-B10-C90
A1-B10-C91 A1-B10-C92 A1-B10-C93 A1-B10-C94 A1-B10-C95 A1-B10-C96
A1-B10-C97 A1-B10-C98 A1-B10-C99 A1-B10-C100 A1-B10-C101 A1-B10-C102
A1-B10-C103 A1-B10-C104 A1-B10-C105 A1-B10-C106 A1-B10-C107 A1-B10-C108
A1-B10-C109 A1-B10-C110 A1-B10-C111 A1-B10-C112 A1-B10-C113 A1-B10-C114
A1-B10-C115 A1-B10-C116 A1-B10-C117 A1-B10-C118 A1-B10-C119 A1-B10-C120
A1-B10-C121 A1-B10-C122 A1-B10-C123 A1-B10-C124 A1-B10-C125 A1-B10-C126
A1-B10-C127 A1-B10-C128 A1-B10-C129 A1-B10-C130 A1-B10-C131 A1-B10-C132
A1-B10-C133 A1-B10-C134 A1-B10-C135 A1-B10-C136 A1-B10-C137 A1-B10-C138
A1-B10-C139 A1-B10-C140 BLANK BLANK BLANK BLANK
A1-B11-C1 A1-B11-C2 A1-B11-C3 A1-B11-C4 A1-B11-C5 A1-B11-C6
A1-B11-C7 A1-B11-C8 A1-B11-C9 A1-B11-C10 A1-B11-C11 A1-B11-C12
A1-B11-C13 A1-B11-C14 A1-B11-C15 A1-B11-C16 A1-B11-C17 A1-B11-C18
A1-B11-C19 A1-B11-C20 A1-B11-C21 A1-B11-C22 A1-B11-C23 A1-B11-C24
A1-B11-C25 A1-B11-C26 A1-B11-C27 A1-B11-C28 A1-B11-C29 A1-B11-C30 A1-B11-C31 A1-B11-C32 A1-B11-C33 A1-B11-C34 A1-B11-C35 A1-B11-C36
A1-B11-C37 A1-B11-C38 A1-B11-C39 A1-B11-C40 A1-B11-C41 A1-B11-C42
A1-B11-C43 A1-B11-C44 A1-B11-C45 A1-B11-C46 A1-B11-C47 A1-B11-C48
A1-B11-C49 A1-B11-C50 A1-B11-C51 A1-B11-C52 A1-B11-C53 A1-B11-C54
A1-B11-C55 A1-B11-C56 A1-B11-C57 A1-B11-C58 A1-B11-C59 A1-B11-C60 A1-B11-C61 A1-B11-C62 A1-B11-C63 A1-B11-C64 A1-B11-C65 A1-B11-C66
A1-B11-C67 A1-B11-C68 A1-B11-C69 A1-B11-C70 A1-B11-C71 A1-B11-C72
A1-B11-C73 A1-B11-C74 A1-B11-C75 A1-B11-C76 A1-B11-C77 A1-B11-C78
A1-B11-C79 A1-B11-C80 A1-B11-C81 A1-B11-C82 A1-B11-C83 A1-B11-C84
A1-B11-C85 A1-B11-C86 A1-B11-C87 A1-B11-C88 A1-B11-C89 A1-B11-C90 A1-B11-C91 A1-B11-C92 A1-B11-C93 A1-B11-C94 A1-B11-C95 A1-B11-C96
A1-B11-C97 A1-B11-C98 A1-B11-C99 A1-B11-C100 A1-B11-C101 A1-B11-C102
A1-B11-C103 A1-B11-C104 A1-B11-C105 A1-B11-C106 A1-B11-C107 A1-B11-C108
A1-B11-C109 A1-B11-C110 Al-Bl l-Cl l l A1-B11-C112 A1-B11-C113 A1-B11-C114
A1-B11-C115 A1-B11-C116 A1-B11-C117 A1-B11-C118 A1-B11-C119 A1-B11-C120 A1-B11-C121 A1-B11-C122 A1-B11-C123 A1-B11-C124 A1-B11-C125 A1-B11-C126
A1-B11-C127 A1-B11-C128 A1-B11-C129 A1-B11-C130 A1-B11-C131 A1-B11-C132
A1-B11-C133 A1-B11-C134 A1-B11-C135 A1-B11-C136 A1-B11-C137 A1-B11-C138
A1-B11-C139 A1-B11-C140 BLANK BLANK BLANK BLANK
A1-B12-C1 A1-B12-C2 A1-B12-C3 A1-B12-C4 A1-B12-C5 A1-B12-C6 A1-B12-C7 A1-B12-C8 A1-B12-C9 A1-B12-C10 A1-B12-C11 A1-B12-C12
A1-B12-C13 A1-B12-C14 A1-B12-C15 A1-B12-C16 A1-B12-C17 A1-B12-C18
A1-B12-C19 A1-B12-C20 A1-B12-C21 A1-B12-C22 A1-B12-C23 A1-B12-C24
A1-B12-C25 A1-B12-C26 A1-B12-C27 A1-B12-C28 A1-B12-C29 A1-B12-C30
A1-B12-C31 A1-B12-C32 A1-B12-C33 A1-B12-C34 A1-B12-C35 A1-B12-C36 A1-B12-C37 A1-B12-C38 A1-B12-C39 A1-B12-C40 A1-B12-C41 A1-B12-C42
A1-B12-C43 A1-B12-C44 A1-B12-C45 A1-B12-C46 A1-B12-C47 A1-B12-C48
A1-B12-C49 A1-B12-C50 A1-B12-C51 A1-B12-C52 A1-B12-C53 A1-B12-C54
A1-B12-C55 A1-B12-C56 A1-B12-C57 A1-B12-C58 A1-B12-C59 A1-B12-C60
A1-B12-C61 A1-B12-C62 A1-B12-C63 A1-B12-C64 A1-B12-C65 A1-B12-C66 A1-B12-C67 A1-B12-C68 A1-B12-C69 A1-B12-C70 A1-B12-C71 A1-B12-C72
A1-B12-C73 A1-B12-C74 A1-B12-C75 A1-B12-C76 A1-B12-C77 A1-B12-C78
A1-B12-C79 A1-B12-C80 A1-B12-C81 A1-B12-C82 A1-B12-C83 A1-B12-C84
A1-B12-C85 A1-B12-C86 A1-B12-C87 A1-B12-C88 A1-B12-C89 A1-B12-C90
A1-B12-C91 A1-B12-C92 A1-B12-C93 A1-B12-C94 A1-B12-C95 A1-B12-C96
A1-B12-C97 A1-B12-C98 A1-B12-C99 A1-B12-C100 A1-B12-C101 A1-B12-C102
A1-B12-C103 A1-B12-C104 A1-B12-C105 A1-B12-C106 A1-B12-C107 A1-B12-C108 A1-B12-C109 A1-B12-C110 A1-B12-C111 A1-B12-C1 12 A1-B12-C113 A1-B12-C114
A1-B12-C115 A1-B12-C116 A1-B12-C117 A1-B12-C118 A1-B12-C119 A1-B12-C120
A1-B12-C121 A1-B12-C122 A1-B12-C123 A1-B12-C124 A1-B12-C125 A1-B12-C126
A1-B12-C127 A1-B12-C128 A1-B12-C129 A1-B12-C130 A1-B12-C131 A1-B12-C132
A1-B12-C133 A1-B12-C134 A1-B12-C135 A1-B12-C136 A1-B12-C137 A1-B12-C138 A1-B12-C139 A1-B12-C140 BLANK BLANK BLANK BLANK
A1-B13-C1 A1-B13-C2 A1-B13-C3 A1-B13-C4 A1-B13-C5 A1-B13-C6
A1-B13-C7 A1-B13-C8 A1-B13-C9 A1-B13-C10 A1-B13-C11 A1-B13-C12
A1-B13-C13 A1-B13-C14 A1-B13-C15 A1-B13-C16 A1-B13-C17 A1-B13-C18
A1-B13-C19 A1-B13-C20 A1-B13-C21 A1-B13-C22 A1-B13-C23 A1-B13-C24 A1-B13-C25 A1-B13-C26 A1-B13-C27 A1-B13-C28 A1-B13-C29 A1-B13-C30
A1-B13-C31 A1-B13-C32 A1-B13-C33 A1-B13-C34 A1-B13-C35 A1-B13-C36
A1-B13-C37 A1-B13-C38 A1-B13-C39 A1-B13-C40 A1-B13-C41 A1-B13-C42
A1-B13-C43 A1-B13-C44 A1-B13-C45 A1-B13-C46 A1-B13-C47 A1-B13-C48
A1-B13-C49 A1-B13-C50 A1-B13-C51 A1-B13-C52 A1-B13-C53 A1-B13-C54 A1-B13-C55 A1-B13-C56 A1-B13-C57 A1-B13-C58 A1-B13-C59 A1-B13-C60
A1-B13-C61 A1-B13-C62 A1-B13-C63 A1-B13-C64 A1-B13-C65 A1-B13-C66
A1-B13-C67 A1-B13-C68 A1-B13-C69 A1-B13-C70 A1-B13-C71 A1-B13-C72
A1-B13-C73 A1-B13-C74 A1-B13-C75 A1-B13-C76 A1-B13-C77 A1-B13-C78
A1-B13-C79 A1-B13-C80 A1-B13-C81 A1-B13-C82 A1-B13-C83 A1-B13-C84 A1-B13-C85 A1-B13-C86 A1-B13-C87 A1-B13-C88 A1-B13-C89 A1-B13-C90
A1-B13-C91 A1-B13-C92 A1-B13-C93 A1-B13-C94 A1-B13-C95 A1-B13-C96
A1-B13-C97 A1-B13-C98 A1-B13-C99 A1-B13-C100 A1-B13-C101 A1-B13-C102
A1-B13-C103 A1-B13-C104 A1-B13-C105 A1-B13-C106 A1-B13-C107 A1-B13-C108
A1-B13-C109 A1-B13-C110 A1-B13-C111 A1-B13-C112 A1-B13-C113 A1-B13-C114 A1-B13-C115 A1-B13-C116 A1-B13-C117 A1-B13-C118 A1-B13-C119 A1-B13-C120
A1-B13-C121 A1-B13-C122 A1-B13-C123 A1-B13-C124 A1-B13-C125 A1-B13-C126
A1-B13-C127 A1-B13-C128 A1-B13-C129 A1-B13-C130 A1-B13-C131 A1-B13-C132
A1-B13-C133 A1-B13-C134 A1-B13-C135 A1-B13-C136 A1-B13-C137 A1-B13-C138
A1-B13-C139 A1-B13-C140 BLANK BLANK BLANK BLANK A2-B1-C1 A2-B1-C2 A2-B1-C3 A2-B1-C4 A2-B1-C5 A2-B1-C6
A2-B1-C7 A2-B1-C8 A2-B1-C9 A2-B1-C10 A2-B1-C11 A2-B1-C12
A2-B1-C13 A2-B1-C14 A2-B1-C15 A2-B1-C16 A2-B1-C17 A2-B1-C18
A2-B1-C19 A2-B1-C20 A2-B1-C21 A2-B1-C22 A2-B1-C23 A2-B1-C24
A2-B1-C25 A2-B1-C26 A2-B1-C27 A2-B1-C28 A2-B1-C29 A2-B1-C30
A2-B1-C31 A2-B1-C32 A2-B1-C33 A2-B1-C34 A2-B1-C35 A2-B1-C36
A2-B1-C37 A2-B1-C38 A2-B1-C39 A2-B1-C40 A2-B1-C41 A2-B1-C42
A2-B1-C43 A2-B1-C44 A2-B1-C45 A2-B1-C46 A2-B1-C47 A2-B1-C48
A2-B1-C49 A2-B1-C50 A2-B1-C51 A2-B1-C52 A2-B1-C53 A2-B1-C54
A2-B1-C55 A2-B1-C56 A2-B1-C57 A2-B1-C58 A2-B1-C59 A2-B1-C60
A2-B1-C61 A2-B1-C62 A2-B1-C63 A2-B1-C64 A2-B1-C65 A2-B1-C66
A2-B1-C67 A2-B1-C68 A2-B1-C69 A2-B1-C70 A2-B1-C71 A2-B1-C72
A2-B1-C73 A2-B1-C74 A2-B1-C75 A2-B1-C76 A2-B1-C77 A2-B1-C78
A2-B1-C79 A2-B1-C80 A2-B1-C81 A2-B1-C82 A2-B1-C83 A2-B1-C84
A2-B1-C85 A2-B1-C86 A2-B1-C87 A2-B1-C88 A2-B1-C89 A2-B1-C90
A2-B1-C91 A2-B1-C92 A2-B1-C93 A2-B1-C94 A2-B1-C95 A2-B1-C96
A2-B1-C97 A2-B1-C98 A2-B1-C99 A2-B1-C100 A2-B1-C101 A2-B1-C102
A2-B1-C103 A2-B1-C104 A2-B1-C105 A2-B1-C106 A2-B1-C107 A2-B1-C108
A2-B1-C109 A2-B1-C110 A2-B1-C111 A2-B1-C112 A2-B1-C113 A2-B1-C114
A2-B1-C115 A2-B1-C116 A2-B1-C117 A2-B1-C118 A2-B1-C119 A2-B1-C120
A2-B1-C121 A2-B1-C122 A2-B1-C123 A2-B1-C124 A2-B1-C125 A2-B1-C126
A2-B1-C127 A2-B1-C128 A2-B1-C129 A2-B1-C130 A2-B1-C131 A2-B1-C132
A2-B1-C133 A2-B1-C134 A2-B1-C135 A2-B1-C136 A2-B1-C137 A2-B1-C138
A2-B1-C139 A2-B1-C140 BLANK BLANK BLANK BLANK
A2-B2-C1 A2-B2-C2 A2-B2-C3 A2-B2-C4 A2-B2-C5 A2-B2-C6
A2-B2-C7 A2-B2-C8 A2-B2-C9 A2-B2-C10 A2-B2-C11 A2-B2-C12
A2-B2-C13 A2-B2-C14 A2-B2-C15 A2-B2-C16 A2-B2-C17 A2-B2-C18
A2-B2-C19 A2-B2-C20 A2-B2-C21 A2-B2-C22 A2-B2-C23 A2-B2-C24
A2-B2-C25 A2-B2-C26 A2-B2-C27 A2-B2-C28 A2-B2-C29 A2-B2-C30
A2-B2-C31 A2-B2-C32 A2-B2-C33 A2-B2-C34 A2-B2-C35 A2-B2-C36
A2-B2-C37 A2-B2-C38 A2-B2-C39 A2-B2-C40 A2-B2-C41 A2-B2-C42
A2-B2-C43 A2-B2-C44 A2-B2-C45 A2-B2-C46 A2-B2-C47 A2-B2-C48
A2-B2-C49 A2-B2-C50 A2-B2-C51 A2-B2-C52 A2-B2-C53 A2-B2-C54
A2-B2-C55 A2-B2-C56 A2-B2-C57 A2-B2-C58 A2-B2-C59 A2-B2-C60
A2-B2-C61 A2-B2-C62 A2-B2-C63 A2-B2-C64 A2-B2-C65 A2-B2-C66
A2-B2-C67 A2-B2-C68 A2-B2-C69 A2-B2-C70 A2-B2-C71 A2-B2-C72
A2-B2-C73 A2-B2-C74 A2-B2-C75 A2-B2-C76 A2-B2-C77 A2-B2-C78
A2-B2-C79 A2-B2-C80 A2-B2-C81 A2-B2-C82 A2-B2-C83 A2-B2-C84
A2-B2-C85 A2-B2-C86 A2-B2-C87 A2-B2-C88 A2-B2-C89 A2-B2-C90
A2-B2-C91 A2-B2-C92 A2-B2-C93 A2-B2-C94 A2-B2-C95 A2-B2-C96
A2-B2-C97 A2-B2-C98 A2-B2-C99 A2-B2-C100 A2-B2-C101 A2-B2-C102
A2-B2-C103 A2-B2-C104 A2-B2-C105 A2-B2-C106 A2-B2-C107 A2-B2-C108
A2-B2-C109 A2-B2-C1 10 A2-B2-C111 A2-B2-C112 A2-B2-C1 13 A2-B2-C114
A2-B2-C115 A2-B2-C1 16 A2-B2-C117 A2-B2-C118 A2-B2-C119 A2-B2-C120
A2-B2-C121 A2-B2-C122 A2-B2-C123 A2-B2-C124 A2-B2-C125 A2-B2-C126
A2-B2-C127 A2-B2-C128 A2-B2-C129 A2-B2-C130 A2-B2-C131 A2-B2-C132
A2-B2-C133 A2-B2-C134 A2-B2-C135 A2-B2-C136 A2-B2-C137 A2-B2-C138
A2-B2-C139 A2-B2-C140 BLANK BLANK BLANK BLANK
A2-B3-C1 A2-B3-C2 A2-B3-C3 A2-B3-C4 A2-B3-C5 A2-B3-C6
A2-B3-C7 A2-B3-C8 A2-B3-C9 A2-B3-C10 A2-B3-C11 A2-B3-C12
A2-B3-C13 A2-B3-C14 A2-B3-C15 A2-B3-C16 A2-B3-C17 A2-B3-C18
A2-B3-C19 A2-B3-C20 A2-B3-C21 A2-B3-C22 A2-B3-C23 A2-B3-C24
A2-B3-C25 A2-B3-C26 A2-B3-C27 A2-B3-C28 A2-B3-C29 A2-B3-C30
A2-B3-C31 A2-B3-C32 A2-B3-C33 A2-B3-C34 A2-B3-C35 A2-B3-C36
A2-B3-C37 A2-B3-C38 A2-B3-C39 A2-B3-C40 A2-B3-C41 A2-B3-C42
A2-B3-C43 A2-B3-C44 A2-B3-C45 A2-B3-C46 A2-B3-C47 A2-B3-C48
A2-B3-C49 A2-B3-C50 A2-B3-C51 A2-B3-C52 A2-B3-C53 A2-B3-C54
A2-B3-C55 A2-B3-C56 A2-B3-C57 A2-B3-C58 A2-B3-C59 A2-B3-C60
A2-B3-C61 A2-B3-C62 A2-B3-C63 A2-B3-C64 A2-B3-C65 A2-B3-C66
A2-B3-C67 A2-B3-C68 A2-B3-C69 A2-B3-C70 A2-B3-C71 A2-B3-C72
A2-B3-C73 A2-B3-C74 A2-B3-C75 A2-B3-C76 A2-B3-C77 A2-B3-C78
A2-B3-C79 A2-B3-C80 A2-B3-C81 A2-B3-C82 A2-B3-C83 A2-B3-C84
A2-B3-C85 A2-B3-C86 A2-B3-C87 A2-B3-C88 A2-B3-C89 A2-B3-C90
A2-B3-C91 A2-B3-C92 A2-B3-C93 A2-B3-C94 A2-B3-C95 A2-B3-C96
A2-B3-C97 A2-B3-C98 A2-B3-C99 A2-B3-C100 A2-B3-C101 A2-B3-C102
A2-B3-C103 A2-B3-C104 A2-B3-C105 A2-B3-C106 A2-B3-C107 A2-B3-C108
A2-B3-C109 A2-B3-C110 A2-B3-C111 A2-B3-C112 A2-B3-C113 A2-B3-C114
A2-B3-C115 A2-B3-C116 A2-B3-C117 A2-B3-C118 A2-B3-C119 A2-B3-C120
A2-B3-C121 A2-B3-C122 A2-B3-C123 A2-B3-C124 A2-B3-C125 A2-B3-C126
A2-B3-C127 A2-B3-C128 A2-B3-C129 A2-B3-C130 A2-B3-C131 A2-B3-C132
A2-B3-C133 A2-B3-C134 A2-B3-C135 A2-B3-C136 A2-B3-C137 A2-B3-C138
A2-B3-C139 A2-B3-C140 BLANK BLANK BLANK BLANK
A2-B4-C1 A2-B4-C2 A2-B4-C3 A2-B4-C4 A2-B4-C5 A2-B4-C6
A2-B4-C7 A2-B4-C8 A2-B4-C9 A2-B4-C10 A2-B4-C11 A2-B4-C12
A2-B4-C13 A2-B4-C14 A2-B4-C15 A2-B4-C16 A2-B4-C17 A2-B4-C18
A2-B4-C19 A2-B4-C20 A2-B4-C21 A2-B4-C22 A2-B4-C23 A2-B4-C24
A2-B4-C25 A2-B4-C26 A2-B4-C27 A2-B4-C28 A2-B4-C29 A2-B4-C30
A2-B4-C31 A2-B4-C32 A2-B4-C33 A2-B4-C34 A2-B4-C35 A2-B4-C36
A2-B4-C37 A2-B4-C38 A2-B4-C39 A2-B4-C40 A2-B4-C41 A2-B4-C42
A2-B4-C43 A2-B4-C44 A2-B4-C45 A2-B4-C46 A2-B4-C47 A2-B4-C48
A2-B4-C49 A2-B4-C50 A2-B4-C51 A2-B4-C52 A2-B4-C53 A2-B4-C54
A2-B4-C55 A2-B4-C56 A2-B4-C57 A2-B4-C58 A2-B4-C59 A2-B4-C60
A2-B4-C61 A2-B4-C62 A2-B4-C63 A2-B4-C64 A2-B4-C65 A2-B4-C66
A2-B4-C67 A2-B4-C68 A2-B4-C69 A2-B4-C70 A2-B4-C71 A2-B4-C72
A2-B4-C73 A2-B4-C74 A2-B4-C75 A2-B4-C76 A2-B4-C77 A2-B4-C78
A2-B4-C79 A2-B4-C80 A2-B4-C81 A2-B4-C82 A2-B4-C83 A2-B4-C84
A2-B4-C85 A2-B4-C86 A2-B4-C87 A2-B4-C88 A2-B4-C89 A2-B4-C90
A2-B4-C91 A2-B4-C92 A2-B4-C93 A2-B4-C94 A2-B4-C95 A2-B4-C96
A2-B4-C97 A2-B4-C98 A2-B4-C99 A2-B4-C100 A2-B4-C101 A2-B4-C102
A2-B4-C103 A2-B4-C104 A2-B4-C105 A2-B4-C106 A2-B4-C107 A2-B4-C108
A2-B4-C109 A2-B4-C110 A2-B4-C111 A2-B4-C112 A2-B4-C113 A2-B4-C114
A2-B4-C115 A2-B4-C116 A2-B4-C117 A2-B4-C118 A2-B4-C119 A2-B4-C120
A2-B4-C121 A2-B4-C122 A2-B4-C123 A2-B4-C124 A2-B4-C125 A2-B4-C126
A2-B4-C127 A2-B4-C128 A2-B4-C129 A2-B4-C130 A2-B4-C131 A2-B4-C132
A2-B4-C133 A2-B4-C134 A2-B4-C135 A2-B4-C136 A2-B4-C137 A2-B4-C138
A2-B4-C139 A2-B4-C140 BLANK BLANK BLANK BLANK
A2-B5-C1 A2-B5-C2 A2-B5-C3 A2-B5-C4 A2-B5-C5 A2-B5-C6
A2-B5-C7 A2-B5-C8 A2-B5-C9 A2-B5-C10 A2-B5-C11 A2-B5-C12
A2-B5-C13 A2-B5-C14 A2-B5-C15 A2-B5-C16 A2-B5-C17 A2-B5-C18
A2-B5-C19 A2-B5-C20 A2-B5-C21 A2-B5-C22 A2-B5-C23 A2-B5-C24
A2-B5-C25 A2-B5-C26 A2-B5-C27 A2-B5-C28 A2-B5-C29 A2-B5-C30
A2-B5-C31 A2-B5-C32 A2-B5-C33 A2-B5-C34 A2-B5-C35 A2-B5-C36
A2-B5-C37 A2-B5-C38 A2-B5-C39 A2-B5-C40 A2-B5-C41 A2-B5-C42
A2-B5-C43 A2-B5-C44 A2-B5-C45 A2-B5-C46 A2-B5-C47 A2-B5-C48
A2-B5-C49 A2-B5-C50 A2-B5-C51 A2-B5-C52 A2-B5-C53 A2-B5-C54
A2-B5-C55 A2-B5-C56 A2-B5-C57 A2-B5-C58 A2-B5-C59 A2-B5-C60
A2-B5-C61 A2-B5-C62 A2-B5-C63 A2-B5-C64 A2-B5-C65 A2-B5-C66
A2-B5-C67 A2-B5-C68 A2-B5-C69 A2-B5-C70 A2-B5-C71 A2-B5-C72
A2-B5-C73 A2-B5-C74 A2-B5-C75 A2-B5-C76 A2-B5-C77 A2-B5-C78
A2-B5-C79 A2-B5-C80 A2-B5-C81 A2-B5-C82 A2-B5-C83 A2-B5-C84
A2-B5-C85 A2-B5-C86 A2-B5-C87 A2-B5-C88 A2-B5-C89 A2-B5-C90
A2-B5-C91 A2-B5-C92 A2-B5-C93 A2-B5-C94 A2-B5-C95 A2-B5-C96
A2-B5-C97 A2-B5-C98 A2-B5-C99 A2-B5-C100 A2-B5-C101 A2-B5-C102
A2-B5-C103 A2-B5-C104 A2-B5-C105 A2-B5-C106 A2-B5-C107 A2-B5-C108
A2-B5-C109 A2-B5-C110 A2-B5-C111 A2-B5-C112 A2-B5-C113 A2-B5-C114
A2-B5-C115 A2-B5-C116 A2-B5-C117 A2-B5-C118 A2-B5-C119 A2-B5-C120
A2-B5-C121 A2-B5-C122 A2-B5-C123 A2-B5-C124 A2-B5-C125 A2-B5-C126
A2-B5-C127 A2-B5-C128 A2-B5-C129 A2-B5-C130 A2-B5-C131 A2-B5-C132
A2-B5-C133 A2-B5-C134 A2-B5-C135 A2-B5-C136 A2-B5-C137 A2-B5-C138
A2-B5-C139 A2-B5-C140 BLANK BLANK BLANK BLANK
A2-B6-C1 A2-B6-C2 A2-B6-C3 A2-B6-C4 A2-B6-C5 A2-B6-C6
A2-B6-C7 A2-B6-C8 A2-B6-C9 A2-B6-C10 A2-B6-C11 A2-B6-C12
A2-B6-C13 A2-B6-C14 A2-B6-C15 A2-B6-C16 A2-B6-C17 A2-B6-C18
A2-B6-C19 A2-B6-C20 A2-B6-C21 A2-B6-C22 A2-B6-C23 A2-B6-C24
A2-B6-C25 A2-B6-C26 A2-B6-C27 A2-B6-C28 A2-B6-C29 A2-B6-C30
A2-B6-C31 A2-B6-C32 A2-B6-C33 A2-B6-C34 A2-B6-C35 A2-B6-C36
A2-B6-C37 A2-B6-C38 A2-B6-C39 A2-B6-C40 A2-B6-C41 A2-B6-C42
A2-B6-C43 A2-B6-C44 A2-B6-C45 A2-B6-C46 A2-B6-C47 A2-B6-C48
A2-B6-C49 A2-B6-C50 A2-B6-C51 A2-B6-C52 A2-B6-C53 A2-B6-C54
A2-B6-C55 A2-B6-C56 A2-B6-C57 A2-B6-C58 A2-B6-C59 A2-B6-C60
A2-B6-C61 A2-B6-C62 A2-B6-C63 A2-B6-C64 A2-B6-C65 A2-B6-C66
A2-B6-C67 A2-B6-C68 A2-B6-C69 A2-B6-C70 A2-B6-C71 A2-B6-C72
A2-B6-C73 A2-B6-C74 A2-B6-C75 A2-B6-C76 A2-B6-C77 A2-B6-C78
A2-B6-C79 A2-B6-C80 A2-B6-C81 A2-B6-C82 A2-B6-C83 A2-B6-C84
A2-B6-C85 A2-B6-C86 A2-B6-C87 A2-B6-C88 A2-B6-C89 A2-B6-C90
A2-B6-C91 A2-B6-C92 A2-B6-C93 A2-B6-C94 A2-B6-C95 A2-B6-C96
A2-B6-C97 A2-B6-C98 A2-B6-C99 A2-B6-C100 A2-B6-C101 A2-B6-C102
A2-B6-C103 A2-B6-C104 A2-B6-C105 A2-B6-C106 A2-B6-C107 A2-B6-C108
A2-B6-C109 A2-B6-C110 A2-B6-C11 1 A2-B6-C112 A2-B6-C113 A2-B6-C114
A2-B6-C115 A2-B6-C116 A2-B6-C117 A2-B6-C118 A2-B6-C119 A2-B6-C120
A2-B6-C121 A2-B6-C122 A2-B6-C123 A2-B6-C124 A2-B6-C125 A2-B6-C126
A2-B6-C127 A2-B6-C128 A2-B6-C129 A2-B6-C130 A2-B6-C131 A2-B6-C132
A2-B6-C133 A2-B6-C134 A2-B6-C135 A2-B6-C136 A2-B6-C137 A2-B6-C138
A2-B6-C139 A2-B6-C140 BLANK BLANK BLANK BLANK
A2-B7-C1 A2-B7-C2 A2-B7-C3 A2-B7-C4 A2-B7-C5 A2-B7-C6
A2-B7-C7 A2-B7-C8 A2-B7-C9 A2-B7-C10 A2-B7-C11 A2-B7-C12
A2-B7-C13 A2-B7-C14 A2-B7-C15 A2-B7-C16 A2-B7-C17 A2-B7-C18
A2-B7-C19 A2-B7-C20 A2-B7-C21 A2-B7-C22 A2-B7-C23 A2-B7-C24
A2-B7-C25 A2-B7-C26 A2-B7-C27 A2-B7-C28 A2-B7-C29 A2-B7-C30
A2-B7-C31 A2-B7-C32 A2-B7-C33 A2-B7-C34 A2-B7-C35 A2-B7-C36
A2-B7-C37 A2-B7-C38 A2-B7-C39 A2-B7-C40 A2-B7-C41 A2-B7-C42
A2-B7-C43 A2-B7-C44 A2-B7-C45 A2-B7-C46 A2-B7-C47 A2-B7-C48 A2-B7-C49 A2-B7-C50 A2-B7-C51 A2-B7-C52 A2-B7-C53 A2-B7-C54 A2-B7-C55 A2-B7-C56 A2-B7-C57 A2-B7-C58 A2-B7-C59 A2-B7-C60 A2-B7-C61 A2-B7-C62 A2-B7-C63 A2-B7-C64 ■ A2-B7-C65 A2-B7-C66 A2-B7-C67 A2-B7-C68 A2-B7-C69 A2-B7-C70 A2-B7-C71 A2-B7-C72 A2-B7-C73 A2-B7-C74 A2-B7-C75 A2-B7-C76 A2-B7-C77 A2-B7-C78 A2-B7-C79 A2-B7-C80 A2-B7-C81 A2-B7-C82 A2-B7-C83 A2-B7-C84 A2-B7-C85 A2-B7-C86 A2-B7-C87 A2-B7-C88 A2-B7-C89 A2-B7-C90 A2-B7-C91 A2-B7-C92 A2-B7-C93 A2-B7-C94 A2-B7-C95 A2-B7-C96 A2-B7-C97 A2-B7-C98 A2-B7-C99 A2-B7-C100 A2-B7-C101 A2-B7-C102 A2-B7-C103 A2-B7-C104 A2-B7-C105 A2-B7-C106 A2-B7-C107 A2-B7-C108 A2-B7-C109 A2-B7-C110 A2-B7-C111 A2-B7-C112 A2-B7-C113 A2-B7-C114 A2-B7-C115 A2-B7-C116 A2-B7-C117 A2-B7-C118 A2-B7-C119 A2-B7-C120 A2-B7-C121 A2-B7-C122 A2-B7-C123 A2-B7-C124 A2-B7-C125 A2-B7-C126 A2-B7-C127 A2-B7-C128 A2-B7-C129 A2-B7-C130 A2-B7-C131 A2-B7-C132 A2-B7-C133 A2-B7-C134 A2-B7-C135 A2-B7-C136 A2-B7-C137 A2-B7-C138 A2-B7-C139 A2-B7-C140 BLANK BLANK BLANK BLANK A2-B8-C1 A2-B8-C2 A2-B8-C3 A2-B8-C4 A2-B8-C5 A2-B8-C6 A2-B8-C7 A2-B8-C8 A2-B8-C9 A2-B8-C10 A2-B8-C11 A2-B8-C12 A2-B8-C13 A2-B8-C14 A2-B8-C15 A2-B8-C16 A2-B8-C17 A2-B8-C18 A2-B8-C19 A2-B8-C20 A2-B8-C21 A2-B8-C22 A2-B8-C23 A2-B8-C24 A2-B8-C25 A2-B8-C26 A2-B8-C27 A2-B8-C28 A2-B8-C29 A2-B8-C30 A2-B8-C31 A2-B8-C32 A2-B8-C33 A2-B8-C34 A2-B8-C35 A2-B8-C36 A2-B8-C37 A2-B8-C38 A2-B8-C39 A2-B8-C40 A2-B8-C41 A2-B8-C42 A2-B8-C43 A2-B8-C44 A2-B8-C45 A2-B8-C46 A2-B8-C47 A2-B8-C48 A2-B8-C49 A2-B8-C50 A2-B8-C51 A2-B8-C52 A2-B8-C53 A2-B8-C54 A2-B8-C55 A2-B8-C56 A2-B8-C57 A2-B8-C58 A2-B8-C59 ' A2-B8-C60 A2-B8-C61 A2-B8-C62 A2-B8-C63 A2-B8-C64 A2-B8-C65 A2-B8-C66 A2-B8-C67 A2-B8-C68 A2-B8-C69 A2-B8-C70 A2-B8-C71 A2-B8-C72 A2-B8-C73 A2-B8-C74 A2-B8-C75 A2-B8-C76 A2-B8-C77 A2-B8-C78 A2-B8-C79 A2-B8-C80 A2-B8-C81 A2-B8-C82 A2-B8-C83 A2-B8-C84 A2-B8-C85 A2-B8-C86 A2-B8-C87 A2-B8-C88 A2-B8-C89 A2-B8-C90 A2-B8-C91 A2-B8-C92 A2-B8-C93 A2-B8-C94 A2-B8-C95 A2-B8-C96 A2-B8-C97 A2-B8-C98 A2-B8-C99 A2-B8-C100 A2-B8-C101 A2-B8-C102 A2-B8-C103 A2-B8-C104 A2-B8-C105 A2-B8-C106 A2-B8-C107 A2-B8-C108 A2-B8-C109 A2-B8-C110 A2-B8-C111 A2-B8-C112 A2-B8-C113 A2-B8-C114 A2-B8-C115 A2-B8-C116 A2-B8-C117 A2-B8-C118 A2-B8-C119 A2-B8-C120
A2-B8-C121 A2-B8-C122 A2-B8-C123 A2-B8-C124 A2-B8-C125 A2-B8-C126
A2-B8-C127 A2-B8-C128 A2-B8-C129 A2-B8-C130 A2-B8-C131 A2-B8-C132
A2-B8-C133 A2-B8-C134 A2-B8-C135 A2-B8-C136 A2-B8-C137 A2-B8-C138
A2-B8-C139 A2-B8-C140 BLANK BLANK BLANK BLANK
A2-B9-C1 A2-B9-C2 A2-B9-C3 A2-B9-C4 A2-B9-C5 A2-B9-C6
A2-B9-C7 A2-B9-C8 A2-B9-C9 A2-B9-C10 A2-B9-C1 1 A2-B9-C12
A2-B9-C13 A2-B9-C14 A2-B9-C15 A2-B9-C16 A2-B9-C17 A2-B9-C18
A2-B9-C19 A2-B9-C20 A2-B9-C21 A2-B9-C22 A2-B9-C23 A2-B9-C24
A2-B9-C25 A2-B9-C26 A2-B9-C27 A2-B9-C28 A2-B9-C29 A2-B9-C30
A2-B9-C31 A2-B9-C32 A2-B9-C33 A2-B9-C34 A2-B9-C35 A2-B9-C36
A2-B9-C37 A2-B9-C38 A2-B9-C39 A2-B9-C40 A2-B9-C41 A2-B9-C42
A2-B9-C43 A2-B9-C44 A2-B9-C45 A2-B9-C46 A2-B9-C47 A2-B9-C48
A2-B9-C49 A2-B9-C50 A2-B9-C51 A2-B9-C52 A2-B9-C53 A2-B9-C54
A2-B9-C55 A2-B9-C56 A2-B9-C57 A2-B9-C58 A2-B9-C59 A2-B9-C60
A2-B9-C61 A2-B9-C62 A2-B9-C63 A2-B9-C64 A2-B9-C65 A2-B9-C66
A2-B9-C67 A2-B9-C68 A2-B9-C69 A2-B9-C70 A2-B9-C71 A2-B9-C72
A2-B9-C73 A2-B9-C74 A2-B9-C75 A2-B9-C76 A2-B9-C77 A2-B9-C78
A2-B9-C79 A2-B9-C80 A2-B9-C81 A2-B9-C82 A2-B9-C83 A2-B9-C84
A2-B9-C85 A2-B9-C86 A2-B9-C87 A2-B9-C88 A2-B9-C89 A2-B9-C90
A2-B9-C91 A2-B9-C92 A2-B9-C93 A2-B9-C94 A2-B9-C95 A2-B9-C96
A2-B9-C97 A2-B9-C98 A2-B9-C99 A2-B9-C100 A2-B9-C101 A2-B9-C102
A2-B9-C103 A2-B9-C104 A2-B9-C105 A2-B9-C106 A2-B9-C107 A2-B9-C108
A2-B9-C109 A2-B9-C110 A2-B9-C111 A2-B9-C112 A2-B9-C113 A2-B9-C114
A2-B9-C115 A2-B9-C116 A2-B9-C117 A2-B9-C118 A2-B9-C119 A2-B9-C120
A2-B9-C121 A2-B9-C122 A2-B9-C123 A2-B9-C124 A2-B9-C125 A2-B9-C126
A2-B9-C127 A2-B9-C128 A2-B9-C129 A2-B9-C130 A2-B9-C131 A2-B9-C132
A2-B9-C133 A2-B9-C134 A2-B9-C135 A2-B9-C136 A2-B9-C137 A2-B9-C138
A2-B9-C139 A2-B9-C140 BLANK BLANK BLANK BLANK
A2-B10-C1 A2-B10-C2 A2-B10-C3 A2-B10-C4 A2-B10-C5 A2-B10-C6
A2-B10-C7 A2-B10-C8 A2-B10-C9 A2-B10-C10 A2-B10-C11 A2-B10-C12
A2-B10-C13 A2-B10-C14 A2-B10-C15 A2-B10-C16 A2-B10-C17 A2-B10-C18
A2-B10-C19 A2-B10-C20 A2-B10-C21 A2-B10-C22 A2-B10-C23 A2-B10-C24
A2-B10-C25 A2-B10-C26 A2-B10-C27 A2-B10-C28 A2-B10-C29 A2-B10-C30
A2-B10-C31 A2-B10-C32 A2-B10-C33 A2-B10-C34 A2-B10-C35 A2-B10-C36
A2-B10-C37 A2-B10-C38 A2-B10-C39 A2-B10-C40 A2-B10-C41 A2-B10-C42
A2-B10-C43 A2-B10-C44 A2-B10-C45 A2-B10-C46 A2-B10-C47 A2-B10-C48
A2-B10-C49 A2-B10-C50 A2-B10-C51 A2-B10-C52 A2-B10-C53 A2-B10-C54
A2-B10-C55 A2-B10-C56 A2-B10-C57 A2-B10-C58 A2-B10-C59 A2-B10-C60
A2-B10-C61 A2-B10-C62 A2-B10-C63 A2-B10-C64 A2-B10-C65 A2-B10-C66
A2-B10-C67 A2-B10-C68 A2-B10-C69 A2-B10-C70 A2-B10-C71 A2-B10-C72
A2-B10-C73 A2-B10-C74 A2-B10-C75 A2-B10-C76 A2-B10-C77 A2-B10-C78 A2-B10-C79 A2-B10-C80 A2-B10-C81 A2-B10-C82 A2-B10-C83 A2-B10-C84
A2-B10-C85 A2-B10-C86 A2-B10-C87 A2-B10-C88 A2-B10-C89 A2-B10-C90
A2-B10-C91 A2-B10-C92 A2-B10-C93 A2-B10-C94 A2-B10-C95 A2-B10-C96
A2-B10-C97 A2-B10-C98 A2-B10-C99 A2-B10-C100 A2-B10-C101 A2-B10-C102
A2-B10-C103 A2-B10-C104 A2-B10-C105 A2-B10-C106 A2-B10-C107 A2-B10-C108 A2-B10-C109 A2-B10-C110 A2-B10-C111 A2-B10-C112 A2-B10-C113 A2-B10-C114
A2-B10-C115 A2-B10-C116 A2-B10-C117 A2-B10-C118 A2-B10-C119 A2-B10-C120
A2-B10-C121 A2-B10-C122 A2-B10-C123 A2-B10-C124 A2-B10-C125 A2-B10-C126
A2-B10-C127 A2-B10-C128 A2-B10-C129 A2-B10-C130 A2-B10-C131 A2-B10-C132
A2-B10-C133 A2-B10-C134 A2-B10-C135 A2-B10-C136 A2-B10-C137 A2-B10-C138 A2-B10-C139 A2-B10-C140 BLANK BLANK BLANK BLANK
A2-B11-C1 A2-B11-C2 A2-B11-C3 A2-B11-C4 A2-B11-C5 A2-B11-C6
A2-B11-C7 A2-B11-C8 A2-B11-C9 A2-B11-C10 A2-B11-C11 A2-B1 1-C12
A2-B11-C13 A2-B11-C14 A2-B11-C15 A2-B11-C16 A2-B11-C17 A2-B1 1-C18
A2-B11-C19 A2-B11-C20 A2-B11-C21 A2-B11-C22 A2-B11-C23 A2-B11-C24 A2-B11-C25 A2-B11-C26 A2-B11-C27 A2-B11-C28 A2-B11-C29 A2-B1 1-C30
A2-B11-C31 A2-B11-C32 A2-B11-C33 A2-B11-C34 A2-B11-C35 A2-B11-C36
A2-B11-C37 A2-B11-C38 A2-B11-C39 A2-B11-C40 A2-B11-C41 A2-B 11-C42
A2-B11-C43 A2-B11-C44 A2-B11-C45 A2-B11-C46 A2-B11-C47 A2-B1 1-C48
A2-B11-C49 A2-B11-C50 A2-B11-C51 A2-B11-C52 A2-B11-C53 A2-B1 1-C54 A2-B11-C55 A2-B11-C56 A2-B11-C57 A2-B11-C58 A2-B11-C59 A2-B11-C60
A2-B11-C61 A2-B11-C62 A2-B11-C63 A2-B11-C64 A2-B11-C65 A2-B11-C66
A2-B11-C67 A2-B11-C68 A2-B11-C69 A2-B11-C70 A2-B11-C71 A2-B11-C72
A2-B11-C73 A2-B11-C74 A2-B11-C75 A2-B11-C76 A2-B11-C77 A2-B11-C78
A2-B11-C79 A2-B11-C80 A2-B11-C81 A2-B11-C82 A2-B11-C83 A2-B1 1-C84 A2-B11-C85 A2-B11-C86 A2-B11-C87 A2-B11-C88 A2-B11-C89 A2-B11-C90
A2-B11-C91 A2-B11-C92 A2-B11-C93 A2-B11-C94 A2-B11-C95 A2-B1 1-C96
A2-B11-C97 A2-B11-C98 A2-B11-C99 A2-B11-C100 A2-B11-C101 A2-B11-C102
A2-B11-C103 A2-B11-C104 A2-B11-C105 A2-B11-C106 A2-B11-C107 A2-B11-C108
A2-B11-C109 A2-B11-C110 A2-B11-C111 A2-B11-C112 A2-B11-C113 A2-B11-C114 A2-B11-C115 A2-B11-C116 A2-B11-C117 A2-B11-C118 A2-B11-C119 A2-B11-C120
A2-B11-C121 A2-B11-C122 A2-B11-C123 A2-B11-C124 A2-B11-C125 A2-B11-C126
A2-B11-C127 A2-B11-C128 A2-B11-C129 A2-B11-C130 A2-B11-C131 A2-B1 1-C132
A2-B11-C133 A2-B11-C134 A2-B11-C135 A2-B11-C136 A2-B11-C137 A2-B11-C138
A2-B11-C139 A2-B11-C140 BLANK BLANK BLANK BLANK
A2-B12-C1 A2-B12-C2 A2-B12-C3 A2-B12-C4 A2-B12-C5 A2-B12-C6
A2-B12-C7 A2-B12-C8 A2-B12-C9 A2-B12-C10 A2-B12-C11 A2-B12-C12 A2-B12-C13 A2-B12-C14 A2-B12-C15 A2-B12-C16 A2-B12-C17 A2-B12-C18
A2-B12-C19 A2-B12-C20 A2-B12-C21 A2-B12-C22 A2-B12-C23 A2-B12-C24
A2-B12-C25 A2-B12-C26 A2-B12-C27 A2-B12-C28 A2-B12-C29 A2-B12-C30
A2-B12-C31 A2-B12-C32 A2-B12-C33 A2-B12-C34 A2-B12-C35 A2-B12-C36
A2-B12-C37 A2-B12-C38 A2-B12-C39 A2-B12-C40 A2-B12-C41 A2-B12-C42 A2-B12-C43 A2-B12-C44 A2-B12-C45 A2-B12-C46 A2-B12-C47 A2-B12-C48
A2-B12-C49 A2-B12-C50 A2-B12-C51 A2-B12-C52 A2-B12-C53 A2-B12-C54
A2-B12-C55 A2-B12-C56 A2-B12-C57 A2-B12-C58 A2-B12-C59 A2-B12-C60
A2-B12-C61 A2-B12-C62 A2-B12-C63 A2-B12-C64 A2-B12-C65 A2-B12-C66
A2-B12-C67 A2-B12-C68 A2-B12-C69 A2-B12-C70 A2-B12-C71 A2-B12-C72 A2-B12-C73 A2-B12-C74 A2-B12-C75 A2-B12-C76 A2-B12-C77 A2-B12-C78
A2-B12-C79 A2-B12-C80 A2-B12-C81 A2-B12-C82 A2-B12-C83 A2-B12-C84
A2-B12-C85 A2-B12-C86 A2-B12-C87 A2-B12-C88 A2-B12-C89 A2-B12-C90
A2-B12-C91 A2-B12-C92 A2-B12-C93 A2-B12-C94 A2-B12-C95 A2-B12-C96
A2-B12-C97 A2-B12-C98 A2-B12-C99 A2-B12-C100 A2-B12-C101 A2-B12-C102 A2-B12-C103 A2-B12-C104 A2-B12-C105 A2-B12-C106 A2-B12-C107 A2-B12-C108
A2-B12-C109 A2-B12-C110 A2-B12-C111 A2-B12-C112 A2-B12-C113 A2-B12-C114
A2-B12-C115 A2-B12-C116 A2-B12-C117 A2-B12-C118 A2-B12-C119 A2-B12-C120
A2-B12-C121 A2-B12-C122 A2-B12-C123 A2-B12-C124 A2-B12-C125 A2-B12-C126
A2-B12-C127 A2-B12-C128 A2-B12-C129 A2-B12-C130 A2-B12-C131 A2-B12-C132 A2-B12-C133 A2-B12-C134 A2-B12-C135 A2-B12-C136 A2-B12-C137 A2-B12-C138
A2-B12-C139 A2-B12-C140 BLANK BLANK BLANK BLANK
A2-B13-C1 A2-B13-C2 A2-B13-C3 A2-B13-C4 A2-B13-C5 A2-B13-C6
A2-B13-C7 A2-B13-C8 A2-B13-C9 A2-B13-C10 A2-B13-C11 A2-B13-C12
A2-B13-C13 A2-B13-C14 A2-B13-C15 A2-B13-C16 A2-B13-C17 A2-B13-C18 A2-B13-C19 A2-B13-C20 A2-B13-C21 A2-B13-C22 A2-B13-C23 A2-B13-C24
A2-B13-C25 A2-B13-C26 A2-B13-C27 A2-B13-C28 A2-B13-C29 A2-B13-C30
A2-B13-C31 A2-B13-C32 A2-B13-C33 A2-B13-C34 A2-B13-C35 A2-B13-C36
A2-B13-C37 A2-B13-C38 A2-B13-C39 A2-B13-C40 A2-B13-C41 A2-B13-C42
A2-B13-C43 A2-B13-C44 A2-B13-C45 A2-B13-C46 A2-B13-C47 A2-B13-C48 A2-B13-C49 A2-B13-C50 A2-B13-C51 A2-B13-C52 A2-B13-C53 A2-B13-C54
A2-B13-C55 A2-B13-C56 A2-B13-C57 A2-B13-C58 A2-B13-C59 A2-B13-C60
A2-B13-C61 A2-B13-C62 A2-B13-C63 A2-B13-C64 A2-B13-C65 A2-B13-C66
A2-B13-C67 A2-B13-C68 A2-B13-C69 A2-B13-C70 A2-B13-C71 A2-B13-C72
A2-B13-C73 A2-B13-C74 A2-B13-C75 A2-B13-C76 A2-B13-C77 A2-B13-C78
A2-B13-C79 A2-B13-C80 A2-B13-C81 A2-B13-C82 A2-B13-C83 A2-B13-C84
A2-B13-C85 A2-B13-C86 A2-B13-C87 A2-B13-C88 A2-B13-C89 A2-B13-C90
A2-B13-C91 A2-B13-C92 A2-B13-C93 A2-B13-C94 A2-B13-C95 A2-B13-C96
A2-B13-C97 A2-B13-C98 A2-B13-C99 A2-B13-C100 A2-B13-C101 A2-B13-C102
A2-B13-C103 A2-B13-C104 A2-B13-C105 A2-B13-C106 A2-B13-C107 A2-B13-C108
A2-B13-C109 A2-B13-C110 A2-B13-C111 A2-B13-C112 A2-B13-C113 A2-B13-C114
A2-B13-C115 A2-B13-C116 A2-B13-C117 A2-B13-C118 A2-B13-C119 A2-B13-C120
A2-B13-C121 A2-B13-C122 A2-B13-C123 A2-B13-C124 A2-B13-C125 A2-B13^C126
A2-B13-C127 A2-B13-C128 A2-B13-C129 A2-B13-C130 A2-B13-C131 A2-B13-C132
A2-B13-C133 A2-B13-C134 A2-B13-C135 A2-B13-C136 A2-B13-C137 A2-B13-C138
A2-B13-C139 A2-B13-C140 BLANK BLANK BLANK BLANK
A3-B1-C1 A3-B1-C2 A3-B1-C3 A3-B1-C4 A3-B1-C5 A3-B1-C6
A3-B1-C7 A3-B1-C8 A3-B1-C9 A3-B1-C10 A3-B1-C11 A3-B1-C12
A3-B1-C13 A3-B1-C14 A3-B1-C15 A3-B1-C16 A3-B1-C17 A3-B1-C18
A3-B1-C19 A3-B1-C20 A3-B1-C21 A3-B1-C22 A3-B1-C23 A3-B1-C24
A3-B1-C25 A3-B1-C26 A3-B1-C27 A3-B1-C28 A3-B1-C29 A3-B1-C30
A3-B1-C31 A3-B1-C32 A3-B1-C33 A3-B1-C34 A3-B1-C35 A3-B1-C36
A3-B1-C37 A3-B1-C38 A3-B1-C39 A3-B1-C40 A3-B1-C41 A3-B1-C42
A3-B1-C43 A3-B1-C44 A3-B1-C45 A3-B1-C46 A3-B1-C47 A3-B1-C48
A3-B1-C49 A3-B1-C50 A3-B1-C51 A3-B1-C52 A3-B1-C53 A3-B1-C54
A3-B1-C55 A3-B1-C56 A3-B1-C57 A3-B1-C58 A3-B1-C59 A3-B1-C60
A3-B1-C61 A3-B1-C62 A3-B1-C63 A3-B1-C64 A3-B1-C65 A3-B1-C66
A3-B1-C67 A3-B1-C68 A3-B1-C69 A3-B1-C70 A3-B1-C71 A3-B1-C72
A3-B1-C73 A3-B1-C74 A3-B1-C75 A3-B1-C76 A3-B1-C77 A3-B1-C78
A3-B1-C79 A3-B1-C80 A3-B1-C81 A3-B1-C82 A3-B1-C83 A3-B1-C84
A3-B1-C85 A3-B1-C86 A3-B1-C87 A3-B1-C88 A3-B1-C89 A3-B1-C90
A3-B1-C91 A3-B1-C92 A3-B1-C93 A3-B1-C94 A3-B1-C95 A3-B1-C96
A3-B1-C97 A3-B1-C98 A3-B1-C99 A3-B1-C100 ' A3-B1-C101 A3-B1-C102
A3-B1-C103 A3-B1-C104 A3-B1-C105 A3-B1-C106 A3-B1-C107 A3-B1-C108
A3-B1-C109 A3-B1-C110 A3-B1-C111 A3-B1-C112 A3-B1-C113 A3-B1-C114
A3-B1-C115 A3-B1-C116 A3-B1-C117 A3-B1-C118 A3-B1-C119 A3-B1-C120
A3-B1-C121 A3-B1-C122 A3-B1-C123 A3-B1-C124 A3-B1-C125 A3-B1-C126
A3-B1-C127 A3-B1-C128 A3-B1-C129 A3-B1-C130 A3-B1-C131 A3-B1-C132
A3-B1-C133 A3-B1-C134 A3-B1-C135 A3-B1-C136 A3-B1-C137 A3-B1-C138
A3-B1-C139 A3-B1-C140 BLANK BLANK BLANK BLANK
A3-B2-C1 A3-B2-C2 A3-B2-C3 A3-B2-C4 A3-B2-C5 A3-B2-C6
A3-B2-C7 A3-B2-C8 A3-B2-C9 A3-B2-C10 A3-B2-C11 A3-B2-C12
A3-B2-C13 A3-B2-C14 A3-B2-C15 A3-B2-C16 A3-B2-C17 A3-B2-C18
A3-B2-C19 A3-B2-C20 A3-B2-C21 A3-B2-C22 A3-B2-C23 A3-B2-C24
A3-B2-C25 A3-B2-C26 A3-B2-C27 A3-B2-C28 A3-B2-C29 A3-B2-C30
A3-B2-C31 A3-B2-C32 A3-B2-C33 A3-B2-C34 A3-B2-C35 A3-B2-C36
A3-B2-C37 A3-B2-C38 A3-B2-C39 A3-B2-C40 A3-B2-C41 A3-B2-C42
A3-B2-C43 A3-B2-C44 A3-B2-C45 A3-B2-C46 A3-B2-C47 A3-B2-C48
A3-B2-C49 A3-B2-C50 A3-B2-C51 A3-B2-C52 A3-B2-C53 A3-B2-C54
A3-B2-C55 A3-B2-C56 A3-B2-C57 A3-B2-C58 A3-B2-C59 A3-B2-C60
A3-B2-C61 A3-B2-C62 A3-B2-C63 A3-B2-C64 A3-B2-C65 A3-B2-C66
A3-B2-C67 A3-B2-C68 A3-B2-C69 A3-B2-C70 A3-B2-C71 A3-B2-C72
A3-B2-C73 A3-B2-C74 A3-B2-C75 A3-B2-C76 A3-B2-C77 A3-B2-C78
A3-B2-C79 A3-B2-C80 A3-B2-C81 A3-B2-C82 A3-B2-C83 A3-B2-C84
A3-B2-C85 A3-B2-C86 A3-B2-C87 A3-B2-C88 A3-B2-C89 A3-B2-C90
A3-B2-C91 A3-B2-C92 A3-B2-C93 A3-B2-C94 A3-B2-C95 A3-B2-C96
A3-B2-C97 A3-B2-C98 A3-B2-C99 A3-B2-C1 0 A3-B2-C101 A3-B2-C102
A3-B2-C103 A3-B2-C104 A3-B2-C105 A3-B2-C106 A3-B2-C107 A3-B2-C108
A3-B2-C109 A3-B2-C110 A3-B2-C111 A3-B2-C112 A3-B2-C113 A3-B2-C114
A3-B2-C115 A3-B2-C116 A3-B2-C117 A3-B2-C118 A3-B2-C119 A3-B2-C120
A3-B2-C121 A3-B2-C122 A3-B2-C123 A3-B2-C124 A3-B2-C125 A3-B2-C126
A3-B2-C127 A3-B2-C128 A3-B2-C129 A3-B2-C130 A3-B2-C131 A3-B2-C132
A3-B2-C133 A3-B2-C134 A3-B2-C135 A3-B2-C136 A3-B2-C137 A3-B2-C138
A3-B2-C139 A3-B2-C140 BLANK BLANK BLANK BLANK
A3-B3-C1 A3-B3-C2 A3-B3-C3 A3-B3-C4 A3-B3-C5 A3-B3-C6
A3-B3-C7 A3-B3-C8 A3-B3-C9 A3-B3-C10 A3-B3-C11 A3-B3-C12
A3-B3-C13 A3-B3-C14 A3-B3-C15 A3-B3-C16 A3-B3-C17 A3-B3-C18
A3-B3-C19 A3-B3-C20 A3-B3-C21 A3-B3-C22 A3-B3-C23 A3-B3-C24
A3-B3-C25 A3-B3-C26 A3-B3-C27 A3-B3-C28 A3-B3-C29 A3-B3-C30
A3-B3-C31 A3-B3-C32 A3-B3-C33 A3-B3-C34 A3-B3-C35 A3-B3-C36
A3-B3-C37 A3-B3-C38 A3-B3-C39 A3-B3-C40 A3-B3-C41 A3-B3-C42
A3-B3-C43 A3-B3-C44 A3-B3-C45 A3-B3-C46 A3-B3-C47 A3-B3-C48
A3-B3-C49 A3-B3-C50 A3-B3-C51 A3-B3-C52 A3-B3-C53 A3-B3-C54
A3-B3-C55 A3-B3-C56 A3-B3-C57 A3-B3-C58 A3-B3-C59 A3-B3-C60
A3-B3-C61 A3-B3-C62 A3-B3-C63 A3-B3-C64 A3-B3-C65 A3-B3-C66
A3-B3-C67 A3-B3-C68 A3-B3-C69 A3-B3-C70 A3-B3-C71 A3-B3-C72
A3-B3-C73 A3-B3-C74 A3-B3-C75 A3-B3-C76 A3-B3-C77 A3-B3-C78
A3-B3-C79 A3-B3-C80 A3-B3-C81 A3-B3-C82 A3-B3-C83 A3-B3-C84
A3-B3-C85 A3-B3-C86 A3-B3-C87 A3-B3-C88 A3-B3-C89 A3-B3-C90
A3-B3-C91 A3-B3-C92 A3-B3-C93 A3-B3-C94 A3-B3-C95 A3-B3-C96
A3-B3-C97 A3-B3-C98 A3-B3-C99 A3-B3-C100 A3-B3-C101 A3-B3-C102
A3-B3-C103 A3-B3-C104 A3-B3-C105 A3-B3-C106 A3-B3-C107 A3-B3-C108
A3-B3-C109 A3-B3-C110 A3-B3-C111 A3-B3-C112 A3-B3-C1 13 A3-B3-C114
A3-B3-C115 A3-B3-C116 A3-B3-C117 A3-B3-C118 A3-B3-C119 A3-B3-C120
A3-B3-C121 A3-B3-C122 A3-B3-C123 A3-B3-C124 A3-B3-C125 A3-B3-C126
A3-B3-C127 A3-B3-C128 A3-B3-C129 A3-B3-C130 A3-B3-C131 A3-B3-C132
A3-B3-C133 A3-B3-C134 A3-B3-C135 A3-B3-C136 A3-B3-C137 A3-B3-C138
A3-B3-C139 A3-B3-C140 BLANK BLANK BLANK BLANK
A3-B4-C1 A3-B4-C2 A3-B4-C3 A3-B4-C4 A3-B4-C5 A3-B4-C6
A3-B4-C7 A3-B4-C8 A3-B4-C9 A3-B4-C10 A3-B4-C11 A3-B4-C12
A3-B4-C13 A3-B4-C14 A3-B4-C15 A3-B4-C16 A3-B4-C17 A3-B4-C18
A3-B4-C19 A3-B4-C20 A3-B4-C21 A3-B4-C22 A3-B4-C23 A3-B4-C24
A3-B4-C25 A3-B4-C26 A3-B4-C27 A3-B4-C28 A3-B4-C29 A3-B4-C30
A3-B4-C31 A3-B4-C32 A3-B4-C33 A3-B4-C34 A3-B4-C35 A3-B4-C36
A3-B4-C37 A3-B4-C38 A3-B4-C39 A3-B4-C40 A3-B4-C41 A3-B4-C42
A3-B4-C43 A3-B4-C44 A3-B4-C45 A3-B4-C46 A3-B4-C47 A3-B4-C48
A3-B4-C49 A3-B4-C50 A3-B4-C51 A3-B4-C52 A3-B4-C53 A3-B4-C54
A3-B4-C55 A3-B4-C56 A3-B4-C57 A3-B4-C58 A3-B4-C59 A3-B4-C60
A3-B4-C61 A3-B4-C62 A3-B4-C63 A3-B4-C64 A3-B4-C65 A3-B4-C66
A3-B4-C67 A3-B4-C68 A3-B4-C69 A3-B4-C70 A3-B4-C71 A3-B4-C72
A3-B4-C73 A3-B4-C74 A3-B4-C75 A3-B4-C76 A3-B4-C77 A3-B4-C78
A3-B4-C79 A3-B4-C80 A3-B4-C81 A3-B4-C82 A3-B4-C83 A3-B4-C84
A3-B4-C85 A3-B4-C86 A3-B4-C87 A3-B4-C88 A3-B4-C89 A3-B4-C90
A3-B4-C91 A3-B4-C92 A3-B4-C93 A3-B4-C94 A3-B4-C95 A3-B4-C96
A3-B4-C97 A3-B4-C98 A3-B4-C99 A3-B4-C100 A3-B4-C101 A3-B4-C102
A3-B4-C103 A3-B4-C104 A3-B4-C105 A3-B4-C106 A3-B4-C107 A3-B4-C108
A3-B4-C109 A3-B4-C110 A3-B4-C111 A3-B4-C112 A3-B4-C113 A3-B4-C114
A3-B4-C115 A3-B4-C116 A3-B4-C117 A3-B4-C118 A3-B4-C119 A3-B4-C120
A3-B4-C121 A3-B4-C122 A3-B4-C123 A3-B4-C124 A3-B4-C125 A3-B4-C126
A3-B4-C127 A3-B4-C128 A3-B4-C129 A3-B4-C130 A3-B4-C131 A3-B4-C132
A3-B4-C133 A3-B4-C134 A3-B4-C135 A3-B4-C136 A3-B4-C137 A3-B4-C138
A3-B4-C139 A3-B4-C140 BLANK BLANK BLANK BLANK
A3-B5-C1 A3-B5-C2 A3-B5-C3 A3-B5-C4 A3-B5-C5 A3-B5-C6
A3-B5-C7 A3-B5-C8 A3-B5-C9 A3-B5-C10 A3-B5-C11 A3-B5-C12
A3-B5-C13 A3-B5-C14 A3-B5-C15 A3-B5-C16 A3-B5-C17 A3-B5-C18
A3-B5-C19 A3-B5-C20 A3-B5-C21 A3-B5-C22 A3-B5-C23 A3-B5-C24
A3-B5-C25 A3-B5-C26 A3-B5-C27 A3-B5-C28 A3-B5-C29 A3-B5-C30
A3-B5-C31 A3-B5-C32 A3-B5-C33 A3-B5-C34 A3-B5-C35 A3-B5-C36
A3-B5-C37 A3-B5-C38 A3-B5-C39 A3-B5-C40 A3-B5-C41 A3-B5-C42
A3-B5-C43 A3-B5-C44 A3-B5-C45 A3-B5-C46 A3-B5-C47 A3-B5-C48
A3-B5-C49 A3-B5-C50 A3-B5-C51 A3-B5-C52 A3-B5-C53 A3-B5-C54
A3-B5-C55 A3-B5-C56 A3-B5-C57 A3-B5-C58 A3-B5-C59 A3-B5-C60
A3-B5-C61 A3-B5-C62 A3-B5-C63 A3-B5-C64 A3-B5-C65 A3-B5-C66
A3-B5-C67 A3-B5-C68 A3-B5-C69 A3-B5-C70 A3-B5-C71 A3-B5-C72
A3-B5-C73 A3-B5-C74 A3-B5-C75 A3-B5-C76 A3-B5-C77 A3-B5-C78
A3-B5-C79 A3-B5-C80 A3-B5-C81 A3-B5-C82 A3-B5-C83 A3-B5-C84
A3-B5-C85 A3-B5-C86 A3-B5-C87 A3-B5-C88 A3-B5-C89 A3-B5-C90
A3-B5-C91 A3-B5-C92 A3-B5-C93 A3-B5-C94 A3-B5-C95 A3-B5-C96
A3-B5-C97 A3-B5-C98 A3-B5-C99 A3-B5-C100 A3-B5-C101 A3-B5-C102
A3-B5-C103 A3-B5-C104 A3-B5-C105 A3-B5-C106 A3-B5-C107 A3-B5-C108
A3-B5-C109 A3-B5-C110 A3-B5-C111 A3-B5-C112 A3-B5-C113 A3-B5-C1 14
A3-B5-C115 A3-B5-C116 A3-B5-C117 A3-B5-C118 A3-B5-C119 A3-B5-C120
A3-B5-C121 A3-B5-C122 A3-B5-C123 A3-B5-C124 A3-B5-C125 A3-B5-C126
A3-B5-C127 A3-B5-C128 A3-B5-C129 A3-B5-C130 A3-B5-C131 A3-B5-C132
A3-B5-C133 A3-B5-C134 A3-B5-C135 A3-B5-C136 A3-B5-C137 A3-B5-C138
A3-B5-C139 A3-B5-C140 BLANK BLANK BLANK BLANK
A3-B6-C1 A3-B6-C2 A3-B6-C3 A3-B6-C4 A3-B6-C5 A3-B6-C6
A3-B6-C7 A3-B6-C8 A3-B6-C9 A3-B6-C10 A3-B6-C11 A3-B6-C12
A3-B6-C13 A3-B6-C14 A3-B6-C15 A3-B6-C16 A3-B6-C17 A3-B6-C18
A3-B6-C19 A3-B6-C20 A3-B6-C21 A3-B6-C22 A3-B6-C23 A3-B6-C24
A3-B6-C25 A3-B6-C26 A3-B6-C27 A3-B6-C28 A3-B6-C29 A3-B6-C30
A3-B6-C31 A3-B6-C32 A3-B6-C33 A3-B6-C34 A3-B6-C35 A3-B6-C36
A3-B6-C37 A3-B6-C38 A3-B6-C39 A3-B6-C40 A3-B6-C41 A3-B6-C42
A3-B6-C43 A3-B6-C44 A3-B6-C45 A3-B6-C46 A3-B6-C47 A3-B6-C48
A3-B6-C49 A3-B6-C50 A3-B6-C51 A3-B6-C52 A3-B6-C53 A3-B6-C54
A3-B6-C55 A3-B6-C56 A3-B6-C57 A3-B6-C58 A3-B6-C59 A3-B6-C60
A3-B6-C61 A3-B6-C62 A3-B6-C63 A3-B6-C64 A3-B6-C65 A3-B6-C66
A3-B6-C67 A3-B6-C68 A3-B6-C69 A3-B6-C70 A3-B6-C71 A3-B6-C72
A3-B6-C73 A3-B6-C74 A3-B6-C75 A3-B6-C76 A3-B6-C77 A3-B6-C78
A3-B6-C79 A3-B6-C80 A3-B6-C81 A3-B6-C82 A3-B6-C83 A3-B6-C84
A3-B6-C85 A3-B6-C86 A3-B6-C87 A3-B6-C88 A3-B6-C89 A3-B6-C90
A3-B6-C91 A3-B6-C92 A3-B6-C93 A3-B6-C94 A3-B6-C95 A3-B6-C96
A3-B6-C97 A3-B6-C98 A3-B6-C99 A3-B6-C100 A3-B6-C101 A3-B6-C102
A3-B6-C103 A3-B6-C104 A3-B6-C105 A3-B6-C106 A3-B6-C107 A3-B6-C108
A3-B6-C109 A3-B6-C110 A3-B6-C111 A3-B6-C112 A3-B6-C113 A3-B6-C114
A3-B6-C115 A3-B6-C116 A3-B6-C117 A3-B6-C118 A3-B6-C119 A3-B6-C120
A3-B6-C121 A3-B6-C122 A3-B6-C123 A3-B6-C124 A3-B6-C125 A3-B6-C126
A3-B6-C127 A3-B6-C128 A3-B6-C129 A3-B6-C130 A3-B6-C131 A3-B6-C132
A3-B6-C133 A3-B6-C134 A3-B6-C135 A3-B6-C136 A3-B6-C137 A3-B6-C138
A3-B6-C139 A3-B6-C140 BLANK BLANK BLANK BLANK
A3-B7-C1 A3-B7-C2 A3-B7-C3 A3-B7-C4 A3-B7-C5 A3-B7-C6
A3-B7-C7 A3-B7-C8 A3-B7-C9 A3-B7-C10 A3-B7-C11 A3-B7-C12
A3-B7-C13 A3-B7-C14 A3-B7-C15 A3-B7-C16 A3-B7-C17 A3-B7-C18
A3-B7-C19 A3-B7-C20 A3-B7-C21 A3-B7-C22 A3-B7-C23 A3-B7-C24
A3-B7-C25 A3-B7-C26 A3-B7-C27 A3-B7-C28 A3-B7-C29 A3-B7-C30
A3-B7-C31 A3-B7-C32 A3-B7-C33 A3-B7-C34 A3-B7-C35 A3-B7-C36
A3-B7-C37 A3-B7-C38 A3-B7-C39 A3-B7-C40 A3-B7-C41 A3-B7-C42
A3-B7-C43 A3-B7-C44 A3-B7-C45 A3-B7-C46 A3-B7-C47 A3-B7-C48
A3-B7-C49 A3-B7-C50 A3-B7-C51 A3-B7-C52 A3-B7-C53 A3-B7-C54
A3-B7-C55 A3-B7-C56 A3-B7-C57 A3-B7-C58 A3-B7-C59 A3-B7-C60
A3-B7-C61 A3-B7-C62 A3-B7-C63 A3-B7-C64 A3-B7-C65 A3-B7-C66
A3-B7-C67 A3-B7-C68 A3-B7-C69 A3-B7-C70 A3-B7-C71 A3-B7-C72
A3-B7-C73 A3-B7-C74 A3-B7-C75 A3-B7-C76 A3-B7-C77 A3-B7-C78
A3-B7-C79 A3-B7-C80 A3-B7-C81 A3-B7-C82 A3-B7-C83 A3-B7-C84
A3-B7-C85 A3-B7-C86 A3-B7-C87 A3-B7-C88 A3-B7-C89 A3-B7-C90
A3-B7-C91 A3-B7-C92 A3-B7-C93 A3-B7-C94 A3-B7-C95 A3-B7-C96
A3-B7-C97 A3-B7-C98 A3-B7-C99 A3-B7-C100 A3-B7-C101 A3-B7-C102
A3-B7-C103 A3-B7-C104 A3-B7-C105 A3-B7-C106 A3-B7-C107 A3-B7-C108
A3-B7-C109 A3-B7-C110 A3-B7-C111 A3-B7-C112 A3-B7-C113 A3-B7-C114
A3-B7-C115 A3-B7-C116 A3-B7-C117 A3-B7-C118 A3-B7-C119 A3-B7-C120
A3-B7-C121 A3-B7-C122 A3-B7-C123 A3-B7-C124 A3-B7-C125 A3-B7-C126
A3-B7-C127 A3-B7-C128 A3-B7-C129 A3-B7-C130 A3-B7-C131 A3-B7-C132
A3-B7-C133 A3-B7-C134 A3-B7-C135 A3-B7-C136 A3-B7-C137 A3-B7-C138
A3-B7-C139 A3-B7-C140 BLANK BLANK BLANK BLANK
A3-B8-C1 A3-B8-C2 A3-B8-C3 A3-B8-C4 A3-B8-C5 A3-B8-C6
A3-B8-C7 A3-B8-C8 A3-B8-C9 A3-B8-C10 A3-B8-C11 A3-B8-C12
A3-B8-C13 A3-B8-C14 A3-B8-C15 A3-B8-C16 A3-B8-C17 A3-B8-C18
A3-B8-C19 A3-B8-C20 A3-B8-C21 A3-B8-C22 A3-B8-C23 A3-B8-C24
A3-B8-C25 A3-B8-C26 A3-B8-C27 A3-B8-C28 A3-B8-C29 A3-B8-C30
A3-B8-C31 A3-B8-C32 A3-B8-C33 A3-B8-C34 A3-B8-C35 A3-B8-C36
A3-B8-C37 A3-B8-C38 A3-B8-C39 A3-B8-C40 A3-B8-C41 A3-B8-C42
A3-B8-C43 A3-B8-C44 A3-B8-C45 A3-B8-C46 A3-B8-C47 A3-B8-C48
A3-B8-C49 A3-B8-C50 A3-B8-C51 A3-B8-C52 A3-B8-C53 A3-B8-C54
A3-B8-C55 A3-B8-C56 A3-B8-C57 A3-B8-C58 A3-B8-C59 A3-B8-C60
A3-B8-C61 A3-B8-C62 A3-B8-C63 A3-B8-C64 A3-B8-C65 A3-B8-C66
A3-B8-C67 A3-B8-C68 A3-B8-C69 A3-B8-C70 A3-B8-C71 A3-B8-C72
A3-B8-C73 A3-B8-C74 A3-B8-C75 A3-B8-C76 A3-B8-C77 A3-B8-C78
A3-B8-C79 A3-B8-C80 A3-B8-C81 A3-B8-C82 A3-B8-C83 A3-B8-C84
A3-B8-C85 A3-B8-C86 A3-B8-C87 A3-B8-C88 A3-B8-C89 A3-B8-C90
A3-B8-C91 A3-B8-C92 A3-B8-C93 A3-B8-C94 A3-B8-C95 A3-B8-C96
A3-B8-C97 A3-B8-C98 A3-B8-C99 A3-B8-C100 A3-B8-C101 A3-B8-C102
A3-B8-C103 A3-B8-C104 A3-B8-C105 A3-B8-C106 A3-B8-C107 A3-B8-C108
A3-B8-C109 A3-B8-C110 A3-B8-C111 A3-B8-C112 A3-B8-C113 A3-B8-C114
A3-B8-C115 A3-B8-C116 A3-B8-C117 A3-B8-C118 A3-B8-C119 A3-B8-C120
A3-B8-C121 A3-B8-C122 A3-B8-C123 A3-B8-C124 A3-B8-C125 A3-B8-C126
A3-B8-C127 A3-B8-C128 A3-B8-C129 A3-B8-C130 A3-B8-C131 A3-B8-C132
A3-B8-C133 A3-B8-C134 A3-B8-C135 A3-B8-C136 A3-B8-C137 A3-B8-C138
A3-B8-C139 A3-B8-C140 BLANK BLANK BLANK BLANK
A3-B9-C1 A3-B9-C2 A3-B9-C3 A3-B9-C4 A3-B9-C5 A3-B9-C6
A3-B9-C7 A3-B9-C8 A3-B9-C9 A3-B9-C10 A3-B9-C11 A3-B9-C12
A3-B9-C13 A3-B9-C14 A3-B9-C15 A3-B9-C16 A3-B9-C17 A3-B9-C18
A3-B9-C19 A3-B9-C20 A3-B9-C21 A3-B9-C22 A3-B9-C23 A3-B9-C24
A3-B9-C25 A3-B9-C26 A3-B9-C27 A3-B9-C28 A3-B9-C29 A3-B9-C30
A3-B9-C31 A3-B9-C32 A3-B9-C33 A3-B9-C34 A3-B9-C35 A3-B9-C36
A3-B9-C37 A3-B9-C38 A3-B9-C39 A3-B9-C40 A3-B9-C41 A3-B9-C42
A3-B9-C43 A3-B9-C44 A3-B9-C45 A3-B9-C46 A3-B9-C47 A3-B9-C48
A3-B9-C49 A3-B9-C50 A3-B9-C51 A3-B9-C52 A3-B9-C53 A3-B9-C54
A3-B9-C55 A3-B9-C56 A3-B9-C57 A3-B9-C58 A3-B9-C59 A3-B9-C60
A3-B9-C61 A3-B9-C62 A3-B9-C63 A3-B9-C64 A3-B9-C65 A3-B9-C66
A3-B9-C67 A3-B9-C68 A3-B9-C69 A3-B9-C70 A3-B9-C71 A3-B9-C72
A3-B9-C73 A3-B9-C74 A3-B9-C75 A3-B9-C76 A3-B9-C77 A3-B9-C78
A3-B9-C79 A3-B9-C80 A3-B9-C81 A3-B9-C82 A3-B9-C83 A3-B9-C84
A3-B9-C85 A3-B9-C86 A3-B9-C87 A3-B9-C88 A3-B9-C89 A3-B9-C90
A3-B9-C91 A3-B9-C92 A3-B9-C93 A3-B9-C94 A3-B9-C95 ' A3-B9-C96
A3-B9-C97 A3-B9-C98 A3-B9-C99 A3-B9-C100 A3-B9-C101 A3-B9-C102
A3-B9-C103 A3-B9-C104 A3-B9-C105 A3-B9-C106 A3-B9-C107 A3-B9-C108
A3-B9-C109 A3-B9-C110 A3-B9-C111 A3-B9-C112 A3-B9-C113 A3-B9-C114
A3-B9-C115 A3-B9-C116 A3-B9-C117 A3-B9-C118 A3-B9-C119 A3-B9-C120
A3-B9-C121 A3-B9-C122 A3-B9-C123 A3-B9-C124 A3-B9-C125 A3-B9-C126 A3-B9-C127 A3-B9-C128 A3-B9-C129 A3-B9-C130 A3-B9-C131 A3-B9-C132
A3-B9-C133 A3-B9-C134 A3-B9-C135 A3-B9-C136 A3-B9-C137 A3-B9-C138
A3-B9-C139 A3-B9-C140 BLANK BLANK BLANK BLANK
A3-B10-C1 A3-B10-C2 A3-B10-C3 A3-B10-C4 A3-B10-C5 A3-B10-C6
A3-B10-C7 A3-B10-C8 A3-B10-C9 A3-B10-C10 A3-B10-C11 A3-B10-C12 A3-B10-C13 A3-B10-C14 A3-B10-C15 A3-B10-C16 A3-B10-C17 A3-B10-C18
A3-B10-C19 A3-B10-C20 A3-B10-C21 A3-B10-C22 A3-B10-C23 A3-B10-C24
A3-B10-C25 A3-B10-C26 A3-B10-C27 A3-B10-C28 A3-B10-C29 A3-B10-C30
A3-B10-C31 A3-B10-C32 A3-B10-C33 A3-B10-C34 A3-B10-C35 A3-B10-C36
A3-B10-C37 A3-B10-C38 A3-B10-C39 A3-B10-C40 A3-B10-C41 A3-B10-C42 A3-B10-C43 A3-B10-C44 A3-B10-C45 A3-B10-C46 A3-B10-C47 A3-B10-C48
A3-B10-C49 A3-B10-C50 A3-B10-C51 A3-B10-C52 A3-B10-C53 A3-B10-C54
A3-B10-C55 A3-B10-C56 A3-B10-C57 A3-B10-C58 A3-B10-C59 A3-B10-C60
A3-B10-C61 A3-B10-C62 A3-B10-C63 A3-B10-C64 A3-B10-C65 A3-B10-C66
A3-B10-C67 A3-B10-C68 A3-B10-C69 A3-B10-C70 A3-B10-C71 A3-B10-C72 A3-B10-C73 A3-B10-C74 A3-B10-C75 A3-B10-C76 A3-B10-C77 A3-B10-C78
A3-B10-C79 A3-B10-C80 A3-B10-C81 A3-B10-C82 A3-B10-C83 A3-B10-C84
A3-B10-C85 A3-B10-C86 A3-B10-C87 A3-B10-C88 A3-B10-C89 A3-B10-C90
A3-B10-C91 A3-B10-C92 A3-B10-C93 A3-B10-C94 A3-B10-C95 A3-B10-C96
A3-B10-C97 A3-B10-C98 A3-B10-C99 A3-B10-C100 A3-B10-C101 A3-B10-C102 A3-B10-C103 A3-B10-C104 A3-B10-C105 A3-B10-C106 A3-B10-C107 A3-B10-C108
A3-B10-C109 A3-B10-C110 A3-B10-C111 A3-B10-C112 A3-B10-C113 A3-B10-C114
A3-B10-C115 A3-B10-C116 A3-B10-C117 A3-B10-C118 A3-B10-C119 A3-B10-C120
A3-B10-C121 A3-B10-C122 A3-B10-C123 A3-B10-C124 A3-B10-C125 A3-B10-C126
A3-B10-C127 A3-B10-C128 A3-B10-C129 A3-B10-C130 A3-B10-C131 A3-B10-C132 A3-B10-C133 A3-B10-C134 A3-B10-C135 A3-B10-C136 A3-B10-C137 A3-B10-C138
A3-B10-C139 A3-B10-C140 BLANK BLANK BLANK BLANK
A3-B11-C1 A3-B11-C2 A3-B11-C3 A3-B11-C4 A3-B11-C5 A3-B11-C6
A3-B11-C7 A3-B11-C8 A3-B11-C9 A3-B11-C10 A3-B11-C11 A3-B11-C12
A3-B11-C13 A3-B11-C14 A3-B11-C15 A3-B11-C16 A3-B11-C17 A3-B11-C18 A3-B11-C19 A3-B11-C20 A3-B11-C21 A3-B11-C22 A3-B11-C23 A3-B11-C24
A3-B11-C25 A3-B11-C26 A3-B11-C27 A3-B11-C28 A3-B11-C29 A3-B11-C30
A3-B11-C31 A3-B11-C32 A3-B11-C33 A3-B11-C34 A3-B11-C35 A3-B11-C36
A3-B11-C37 A3-B11-C38 A3-B11-C39 A3-B11-C40 A3-B1 1-C41 A3-B1 1-C42
A3-B11-C43 A3-B1 1-C44 A3-B11-C45 A3-B11-C46 A3-B11-C47 A3-B11-C48
A3-B11-C49 A3-B1 1-C50 A3-B11-C51 A3-B11-C52 A3-B1 1-C53 A3-B1 1-C54
A3-B11-C55 A3-B11-C56 A3-B11-C57 A3-B11-C58 A3-B11-C59 A3-B11-C60 A3-B11-C61 A3-B1 1-C62 A3-B11-C63 A3-B11-C64 A3-B11-C65 A3-B11-C66
A3-B11-C67 A3-BU-C68 A3-B11-C69 A3-B11-C70 A3-B11-C71 A3-B11-C72
A3-B11-C73 A3-B11-C74 A3-B11-C75 A3-B11-C76 A3-B11-C77 A3-B11-C78
A3-B11-C79 A3-B11-C80 A3-B11-C81 A3-B11-C82 A3-B11-C83 A3-B11-C84
A3-B11-C85 A3-B11-C86 A3-B11-C87 A3-B11-C88 A3-B11-C89 A3-B11-C90 A3-B11-C91 A3-B11-C92 A3-B11-C93 A3-B11-C94 A3-B11-C95 A3-B11-C96
A3-B11-C97 A3-B11-C98 A3-B11-C99 A3-B11-C100 A3-B11-C101 A3-B11-C102
A3-B11-C103 A3-B11-C104 A3-B11-C105 A3-B11-C106 A3-B11-C107 A3-B11-C108
A3-B11-C109 A3-B11-C110 A3-B11-C111 A3-B11-C112 A3-B11-C113 A3-B11-C114
A3-B11-C115 A3-B11-C116 A3-B11-C117 A3-B11-C118 A3-B11-C119 A3-B11-C120 A3-B11-C121 A3-B11-C122 A3-B11-C123 A3-B11-C124 A3-B11-C125 A3-B11-C126
A3-B11-C127 A3-B11-C128 A3-B11-C129 A3-B11-C130 A3-B11-C131 A3-B11-C132
A3-B11-C133 A3-B11-C134 A3-B11-C135 A3-B11-C136 A3-B11-C137 A3-B11-C138
A3-B11-C139 A3-B11-C140 BLANK BLANK BLANK BLANK
A3-B12-C1 A3-B12-C2 A3-B12-C3 A3-B12-C4 A3-B12-C5 A3-B12-C6 A3-B12-C7 A3-B12-C8 A3-B12-C9 A3-B12-C10 A3-B12-C11 A3-B12-C12
A3-B12-C13 A3-B12-C14 A3-B12-C15 A3-B12-C16 A3-B12-C17 A3-B 12-C18
A3-B12-C19 A3-B12-C20 A3-B12-C21 A3-B12-C22 A3-B12-C23 A3-B12-C24
A3-B12-C25 A3-B12-C26 A3-B12-C27 A3-B12-C28 A3-B12-C29 A3-B12-C30
A3-B12-C31 A3-B12-C32 A3-B12-C33 A3-B12-C34 A3-B12-C35 A3-B12-C36 A3-B12-C37 A3-B12-C38 A3-B12-C39 A3-B12-C40 A3-B12-C41 A3-B12-C42
A3-B12-C43 A3-B12-C44 A3-B12-C45 A3-B12-C46 A3-B12-C47 A3-B12-C48
A3-B12-C49 A3-B12-C50 A3-B12-C51 A3-B12-C52 A3-B12-C53 A3-B12-C54
A3-B12-C55 A3-B12-C56 A3-B12-C57 A3-B12-C58 A3-B12-C59 A3-B12-C60
A3-B12-C61 A3-B12-C62 A3-B12-C63 A3-B12-C64 A3-B12-C65 A3-B12-C66 A3-B12-C67 A3-B12-C68 A3-B12-C69 A3-B12-C70 A3-B12-C71 A3-B12-C72
A3-B12-C73 A3-B12-C74 A3-B12-C75 A3-B12-C76 A3-B12-C77 A3-B12-C78
A3-B12-C79 A3-B12-C80 A3-B12-C81 A3-B12-C82 A3-B12-C83 A3-B12-C84
A3-B12-C85 A3-B12-C86 A3-B12-C87 A3-B12-C88 A3-B12-C89 A3-B12-C90
A3-B12-C91 A3-B12-C92 A3-B12-C93 A3-B12-C94 A3-B12-C95 A3-B12-C96 A3-B12-C97 A3-B12-C98 A3-B12-C99 A3-B12-C100 A3-B12-C101 A3-B12-C102
A3-B12-C103 A3-B12-C104 , A3-B12-C105 A3-B12-C106 A3-B12-C107 A3-B12-C108
A3-B12-C109 A3-B12-C110 A3-B12-C111 A3-B12-C112 A3-B12-C113 A3-B12-C114
A3-B12-C115 A3-B12-C116 A3-B12-C117 A3-B12-C118 A3-B12-C119 A3-B12-C120
A3-B12-C121 A3-B12-C122 A3-B12-C123 A3-B12-C124 A3-B12-C125 A3-B12-C126
A3-B12-C127 A3-B12-C128 A3-B12-C129 A3-B12-C130 A3-B12-C131 A3-B12-C132
A3-B12-C133 A3-B12-C134 A3-B12-C135 A3-B12-C136 A3-B12-C137 A3-B12-C138 A3-B12-C139 A3-B12-C140 BLANK BLANK BLANK BLANK
A3-B13-C1 A3-B13-C2 A3-B13-C3 A3-B13-C4 A3-B13-C5 A3-B13-C6
A3-B13-C7 A3-B13-C8 A3-B13-C9 A3-B13-C10 A3-B13-C11 A3-B13-C12
A3-B13-C13 A3-B13-C14 A3-B13-C15 A3-B13-C16 A3-B13-C17 A3-B13-C18
A3-B13-C19 A3-B13-C20 A3-B13-C21 A3-B13-C22 A3-B13-C23 A3-B13-C24 A3-B13-C25 A3-B13-C26 A3-B13-C27 A3-B13-C28 A3-B13-C29 A3-B13-C30
A3-B13-C31 A3-B13-C32 A3-B13-C33 A3-B13-C34 A3-B13-C35 A3-B13-C36
A3-B13-C37 A3-B13-C38 A3-B13-C39 A3-B13-C40 A3-B13-C41 A3-B13-C42
A3-B13-C43 A3-B13-C44 A3-B13-C45 A3-B13-C46 A3-B13-C47 A3-B13-C48
A3-B13-C49 A3-B13-C50 A3-B13-C51 A3-B13-C52 A3-B13-C53 A3-B13-C54 A3-B13-C55 A3-B13-C56 A3-B13-C57 A3-B13-C58 A3-B13-C59 A3-B13-C60
A3-B13-C61 A3-B13-C62 A3-B13-C63 A3-B13-C64 A3-B13-C65 A3-B13-C66
A3-B13-C67 A3-B13-C68 A3-B13-C69 A3-B13-C70 A3-B13-C71 A3-B13-C72
A3-B13-C73 A3-B13-C74 A3-B13-C75 A3-B13-C76 A3-B13-C77 A3-B13-C78
A3-B13-C79 A3-B13-C80 A3-B13-C81 A3-B13-C82 A3-B13-C83 A3-B13-C84 A3-B13-C85 A3-B13-C86 A3-B13-C87 A3-B13-C88 A3-B13-C89 A3-B13-C90
A3-B13-C91 A3-B13-C92 A3-B13-C93 A3-B13-C94 A3-B13-C95 A3-B13-C96
A3-B13-C97 A3-B13-C98 A3-B13-C99 A3-B13-C100 A3-B13-C101 A3-B13-C102
A3-B13-C103 A3-B13-C104 A3-B13-C105 A3-B13-C106 A3-B13-C107 A3-B13-C108
A3-B13-C109 A3-B13-C110 A3-B13-C111 A3-B13-C112 A3-B13-C113 A3-B13-C114 A3-B13-C115 A3-B13-C116 A3-B13-C117 A3-B13-C118 A3-B13-C119 A3-B13-C120
A3-B13-C121 A3-B13-C122 A3-B13-C123 A3-B13-C124 A3-B13-C125 A3-B13-C126
A3-B13-C127 A3-B13-C128 A3-B13-C129 A3-B13-C130 A3-B13-C131 A3-B13-C132
A3-B13-C133 A3-B13-C134 A3-B13-C135 A3-B13-C136 A3-B13-C137 A3-B13-C138
A3-B13-C139 A3-B13-C140 BLANK BLANK BLANK BLANK A4-B1-C1 A4-B1-C2 A4-B1-C3 A4-B1-C4 A4-B1-C5 A4-B1-C6
A4-B1-C7 A4-B1-C8 A4-B1-C9 A4-B1-C10 A4-B1-C11 A4-B1-C12
A4-B1-C13 A4-B1-C14 A4-B1-C15 A4-B1-C16 A4-B1-C17 A4-B1-C18
A4-B1-C19 A4-B1-C20 A4-B1-C21 A4-B1-C22 A4-B1-C23 A4-B1-C24
A4-B1-C25 A4-B1-C26 A4-B1-C27 A4-B1-C28 A4-B1-C29 A4-B1-C30 A4-B1-C31 A4-B1-C32 A4-B1-C33 A4-B1-C34 A4-B1-C35 A4-B1-C36
A4-B1-C37 A4-B1-C38 A4-B1-C39 A4-B1-C40 A4-B1-C41 A4-B1-C42
A4-B1-C43 A4-B1-C44 A4-B1-C45 A4-B1-C46 A4-B1-C47 A4-B1-C48
A4-B1-C49 A4-B1-C50 A4-B1-C51 A4-B1-C52 A4-B1-C53 A4-B1-C54
A4-B1-C55 A4-B1-C56 A4-B1-C57 A4-B1-C58 A4-B1-C59 A4-B1-C60
A4-B1-C61 A4-B1-C62 A4-B1-C63 A4-B1-C64 A4-B1-C65 A4-B1-C66
A4-B1-C67 A4-B1-C68 A4-B1-C69 A4-B1-C70 A4-B1-C71 A4-B1-C72
A4-B1-C73 A4-B1-C74 A4-B1-C75 A4-B1-C76 A4-B1-C77 A4-B1-C78
A4-B1-C79 A4-B1-C80 A4-B1-C81 A4-B1-C82 A4-B1-C83 A4-B1-C84
A4-B1-C85 A4-B1-C86 A4-B1-C87 A4-B1-C88 A4-B1-C89 A4-B1-C90
A4-B1-C91 A4-B1-C92 A4-B1-C93 A4-B1-C94 A4-B1-C95 A4-B1-C96
A4-B1-C97 A4-B1-C98 A4-B1-C99 A4-B1-C100 A4-B1-C101 A4-B1-C102
A4-B1-C103 A4-B1-C104 A4-B1-C105 A4-B1-C106 A4-B1-C107 A4-B1-C108
A4-B1-C109 A4-B1-C110 A4-B1-C111 A4-B1-C112 A4-B1-C113 A4-B1-C114
A4-B1-C115 A4-B1-C116 A4-B1-C117 A4-B1-C118 A4-B1-C119 A4-B1-C120
A4-B1-C121 A4-B1-C122 A4-B1-C123 A4-B1-C124 A4-B1-C125 A4-B1-C126
A4-B1-C127 A4-B1-C128 A4-B1-C129 A4-B1-C130 A4-B1-C131 A4-B1-C132
A4-B1-C133 A4-B1-C134 A4-B1-C135 A4-B1-C136 A4-B1-C137 A4-B1-C138
A4-B1-C139 A4-B1-C140 BLANK BLANK BLANK BLANK
A4-B2-C1 A4-B2-C2 A4-B2-C3 A4-B2-C4 A4-B2-C5 A4-B2-C6
A4-B2-C7 A4-B2-C8 A4-B2-C9 A4-B2-C10 A4-B2-C11 A4-B2-C12
A4-B2-C13 A4-B2-C14 A4-B2-C15 A4-B2-C16 A4-B2-C17 A4-B2-C18
A4-B2-C19 A4-B2-C20 A4-B2-C21 A4-B2-C22 A4-B2-C23 A4-B2-C24
A4-B2-C25 A4-B2-C26 A4-B2-C27 A4-B2-C28 A4-B2-C29 A4-B2-C30
A4-B2-C31 A4-B2-C32 A4-B2-C33 A4-B2-C34 A4-B2-C35 A4-B2-C36
A4-B2-C37 A4-B2-C38 A4-B2-C39 A4-B2-C40 A4-B2-C41 A4-B2-C42
A4-B2-C43 A4-B2-C44 A4-B2-C45 A4-B2-C46 A4-B2-C47 A4-B2-C48
A4-B2-C49 A4-B2-C50 A4-B2-C51 A4-B2-C52 A4-B2-C53 A4-B2-C54
A4-B2-C55 A4-B2-C56 A4-B2-C57 A4-B2-C58 A4-B2-C59 A4-B2-C60
A4-B2-C61 A4-B2-C62 A4-B2-C63 A4-B2-C64 A4-B2-C65 A4-B2-C66
A4-B2-C67 A4-B2-C68 A4-B2-C69 A4-B2-C70 A4-B2-C71 A4-B2-C72
A4-B2-C73 A4-B2-C74 A4-B2-C75 A4-B2-C76 A4-B2-C77 A4-B2-C78
A4-B2-C79 A4-B2-C80 A4-B2-C81 A4-B2-C82 A4-B2-C83 A4-B2-C84
A4-B2-C85 A4-B2-C86 A4-B2-C87 A4-B2-C88 A4-B2-C89 A4-B2-C90
A4-B2-C91 A4-B2-C92 A4-B2-C93 A4-B2-C94 A4-B2-C95 A4-B2-C96
A4-B2-C97 A4-B2-C98 A4-B2-C99 A4-B2-C100 A4-B2-C101 A4-B2-C102
A4-B2-C103 A4-B2-C104 A4-B2-C105 A4-B2-C106 A4-B2-C107 A4-B2-C108
A4-B2-C109 A4-B2-C110 A4-B2-C111 A4-B2-C112 A4-B2-C113 A4-B2-C114
A4-B2-C115 A4-B2-C116 A4-B2-C117 A4-B2-C118 A4-B2-C119 A4-B2-C120
A4-B2-C121 A4-B2-C122 A4-B2-C123 A4-B2-C124 A4-B2-C125 A4-B2-C126
A4-B2-C127 A4-B2-C128 A4-B2-C129 A4-B2-C130 A4-B2-C131 A4-B2-C132
A4-B2-C133 A4-B2-C134 A4-B2-C135 A4-B2-C136 A4-B2-C137 A4-B2-C138
A4-B2-C139 A4-B2-C140 BLANK BLANK BLANK BLANK
A4-B3-C1 A4-B3-C2 A4-B3-C3 A4-B3-C4 A4-B3-C5 A4-B3-C6
A4-B3-C7 A4-B3-C8 A4-B3-C9 A4-B3-C10 A4-B3-C11 A4-B3-C12
A4-B3-C13 A4-B3-C14 A4-B3-C15 A4-B3-C16 A4-B3-C17 A4-B3-C18
A4-B3-C19 A4-B3-C20 A4-B3-C21 A4-B3-C22 A4-B3-C23 A4-B3-C24
A4-B3-C25 A4-B3-C26 A4-B3-C27 A4-B3-C28 A4-B3-C29 A4-B3-C30
A4-B3-C31 A4-B3-C32 A4-B3-C33 A4-B3-C34 A4-B3-C35 A4-B3-C36
A4-B3-C37 A4-B3-C38 A4-B3-C39 A4-B3-C40 A4-B3-C41 A4-B3-C42
A4-B3-C43 A4-B3-C44 A4-B3-C45 A4-B3-C46 A4-B3-C47 A4-B3-C48
A4-B3-C49 A4-B3-C50 A4-B3-C51 A4-B3-C52 A4-B3-C53 A4-B3-C54
A4-B3-C55 A4-B3-C56 A4-B3-C57 A4-B3-C58 A4-B3-C59 A4-B3-C60
A4-B3-C61 A4-B3-C62 A4-B3-C63 A4-B3-C64 A4-B3-C65 A4-B3-C66
A4-B3-C67 A4-B3-C68 A4-B3-C69 A4-B3-C70 A4-B3-C71 A4-B3-C72
A4-B3-C73 A4-B3-C74 A4-B3-C75 A4-B3-C76 A4-B3-C77 A4-B3-C78
A4-B3-C79 A4-B3-C80 A4-B3-C81 A4-B3-C82 A4-B3-C83 A4-B3-C84
A4-B3-C85 A4-B3-C86 A4-B3-C87 A4-B3-C88 A4-B3-C89 A4-B3-C90
A4-B3-C91 A4-B3-C92 A4-B3-C93 A4-B3-C94 A4-B3-C95 A4-B3-C96
A4-B3-C97 A4-B3-C98 A4-B3-C99 A4-B3-C100 A4-B3-C101 A4-B3-C102
A4-B3-C103 A4-B3-C104 A4-B3-C105 A4-B3-C106 A4-B3-C107 A4-B3-C108
A4-B3-C109 A4-B3-C110 A4-B3-C111 A4-B3-C1 12 A4-B3-C113 A4-B3-C114
A4-B3-C115 A4-B3-C116 A4-B3-C117 A4-B3-C118 A4-B3-C119 A4-B3-C120
A4-B3-C121 A4-B3-C122 A4-B3-C123 A4-B3-C124 A4-B3-C125 A4-B3-C126
A4-B3-C127 A4-B3-C128 A4-B3-C129 A4-B3-C130 A4-B3-C131 A4-B3-C132
A4-B3-C133 A4-B3-C134 A4-B3-C135 A4-B3-C136 A4-B3-C137 A4-B3-C138
A4-B3-C139 A4-B3-C140 BLANK BLANK BLANK BLANK
A4-B4-C1 A4-B4-C2 A4-B4-C3 A4-B4-C4 A4-B4-C5 A4-B4-C6
A4-B4-C7 A4-B4-C8 A4-B4-C9 A4-B4-C10 A4-B4-C11 A4-B4-C12
A4-B4-C13 A4-B4-C14 A4-B4-C15 A4-B4-C16 A4-B4-C17 A4-B4-C18
A4-B4-C19 A4-B4-C20 A4-B4-C21 A4-B4-C22 A4-B4-C23 A4-B4-C24
A4-B4-C25 A4-B4-C26 A4-B4-C27 A4-B4-C28 A4-B4-C29 A4-B4-C30
A4-B4-C31 A4-B4-C32 A4-B4-C33 A4-B4-C34 A4-B4-C35 A4-B4-C36
A4-B4-C37 A4-B4-C38 A4-B4-C39 A4-B4-C40 A4-B4-C41 A4-B4-C42
A4-B4-C43 A4-B4-C44 A4-B4-C45 A4-B4-C46 A4-B4-C47 A4-B4-C48
A4-B4-C49 A4-B4-C50 A4-B4-C51 A4-B4-C52 A4-B4-C53 A4-B4-C54
A4-B4-C55 A4-B4-C56 A4-B4-C57 A4-B4-C58 A4-B4-C59 A4-B4-C60
A4-B4-C61 A4-B4-C62 A4-B4-C63 A4-B4-C64 A4-B4-C65 A4-B4-C66
A4-B4-C67 A4-B4-C68 A4-B4-C69 A4-B4-C70 A4-B4-C71 A4-B4-C72
A4-B4-C73 A4-B4-C74 A4-B4-C75 A4-B4-C76 A4-B4-C77 A4-B4-C78
A4-B4-C79 A4-B4-C80 A4-B4-C81 A4-B4-C82 A4-B4-C83 A4-B4-C84
A4-B4-C85 A4-B4-C86 A4-B4-C87 A4-B4-C88 A4-B4-C89 A4-B4-C90
A4-B4-C91 A4-B4-C92 A4-B4-C93 A4-B4-C94 A4-B4-C95 A4-B4-C96
A4-B4-C97 A4-B4-C98 A4-B4-C99 A4-B4-C100 A4-B4-C101 A4-B4-C102
A4-B4-C103 A4-B4-C104 A4-B4-C105 A4-B4-C106 A4-B4-C107 A4-B4-C108
A4-B4-C109 A4-B4-C110 A4-B4-C111 A4-B4-C112 A4-B4-C113 A4-B4-C114
A4-B4-C115 A4-B4-C116 A4-B4-C117 A4-B4-C118 A4-B4-C1 19 A4-B4-C120
A4-B4-C121 A4-B4-C122 A4-B4-C123 A4-B4-C124 A4-B4-C125 A4-B4-C126
A4-B4-C127 A4-B4-C128 A4-B4-C129 A4-B4-C130 A4-B4-C131 A4-B4-C132
A4-B4-C133 A4-B4-C134 A4-B4-C135 A4-B4-C136 A4-B4-C137 A4-B4-C138
A4-B4-C139 A4-B4-C140 BLANK BLANK BLANK BLANK
A4-B5-C1 A4-B5-C2 A4-B5-C3 A4-B5-C4 A4-B5-C5 A4-B5-C6
A4-B5-C7 A4-B5-C8 A4-B5-C9 A4-B5-C10 A4-B5-C11 A4-B5-C12
A4-B5-C13 A4-B5-C14 A4-B5-C15 A4-B5-C16 A4-B5-C17 A4-B5-C18
A4-B5-C19 A4-B5-C20 A4-B5-C21 A4-B5-C22 A4-B5-C23 A4-B5-C24
A4-B5-C25 A4-B5-C26 A4-B5-C27 A4-B5-C28 A4-B5-C29 A4-B5-C30
A4-B5-C31 A4-B5-C32 A4-B5-C33 A4-B5-C34 A4-B5-C35 A4-B5-C36
A4-B5-C37 A4-B5-C38 A4-B5-C39 A4-B5-C40 A4-B5-C41 A4-B5-C42
A4-B5-C43 A4-B5-C44 A4-B5-C45 A4-B5-C46 A4-B5-C47 A4-B5-C48
A4-B5-C49 A4-B5-C50 A4-B5-C51 A4-B5-C52 A4-B5-C53 A4-B5-C54
A4-B5-C55 A4-B5-C56 A4-B5-C57 A4-B5-C58 A4-B5-C59 A4-B5-C60
A4-B5-C61 A4-B5-C62 A4-B5-C63 A4-B5-C64 A4-B5-C65 A4-B5-C66
A4-B5-C67 A4-B5-C68 A4-B5-C69 A4-B5-C70 A4-B5-C71 A4-B5-C72
A4-B5-C73 A4-B5-C74 A4-B5-C75 A4-B5-C76 A4-B5-C77 A4-B5-C78
A4-B5-C79 A4-B5-C80 A4-B5-C81 A4-B5-C82 A4-B5-C83 A4-B5-C84
A4-B5-C85 A4-B5-C86 A4-B5-C87 A4-B5-C88 A4-B5-C89 A4-B5-C90
A4-B5-C91 A4-B5-C92 A4-B5-C93 A4-B5-C94 A4-B5-C95 A4-B5-C96
A4-B5-C97 A4-B5-C98 A4-B5-C99 A4-B5-C100 A4-B5-C101 A4-B5-C102
A4-B5-C103 A4-B5-C104 A4-B5-C105 A4-B5-C106 A4-B5-C107 A4-B5-C108
A4-B5-C109 A4-B5-C110 A4-B5-C111 A4-B5-C112 A4-B5-C113 A4-B5-C114
A4-B5-C115 A4-B5-C116 A4-B5-C117 A4-B5-C118 A4-B5-C119 A4-B5-C120
A4-B5-C121 A4-B5-C122 A4-B5-C123 A4-B5-C124 A4-B5-C125 A4-B5-C126
A4-B5-C127 A4-B5-C128 A4-B5-C129 A4-B5-C130 A4-B5-C131 A4-B5-C132
A4-B5-C133 A4-B5-C134 A4-B5-C135 A4-B5-C136 A4-B5-C137 A4-B5-C138
A4-B5-C139 A4-B5-C140 BLANK BLANK BLANK BLANK
A4-B6-C1 A4-B6-C2 A4-B6-C3 A4-B6-C4 A4-B6-C5 A4-B6-C6
A4-B6-C7 A4-B6-C8 A4-B6-C9 A4-B6-C10 A4-B6-C11 A4-B6-C12
A4-B6-C13 A4-B6-C14 A4-B6-C15 A4-B6-C16 A4-B6-C17 A4-B6-C18
A4-B6-C19 A4-B6-C20 A4-B6-C21 A4-B6-C22 A4-B6-C23 A4-B6-C24
A4-B6-C25 A4-B6-C26 A4-B6-C27 A4-B6-C28 A4-B6-C29 A4-B6-C30
A4-B6-C31 A4-B6-C32 A4-B6-C33 A4-B6-C34 A4-B6-C35 A4-B6-C36
A4-B6-C37 A4-B6-C38 A4-B6-C39 A4-B6-C40 A4-B6-C41 A4-B6-C42
A4-B6-C43 A4-B6-C44 A4-B6-C45 A4-B6-C46 A4-B6-C47 A4-B6-C48
A4-B6-C49 A4-B6-C50 A4-B6-C51 A4-B6-C52 A4-B6-C53 A4-B6-C54
A4-B6-C55 A4-B6-C56 A4-B6-C57 A4-B6-C58 A4-B6-C59 A4-B6-C60
A4-B6-C61 A4-B6-C62 A4-B6-C63 A4-B6-C64 A4-B6-C65 A4-B6-C66
A4-B6-C67 A4-B6-C68 A4-B6-C69 A4-B6-C70 A4-B6-C71 A4-B6-C72
A4-B6-C73 A4-B6-C74 A4-B6-C75 A4-B6-C76 A4-B6-C77 A4-B6-C78
A4-B6-C79 A4-B6-C80 A4-B6-C81 A4-B6-C82 A4-B6-C83 A4-B6-C84
A4-B6-C85 A4-B6-C86 A4-B6-C87 A4-B6-C88 A4-B6-C89 A4-B6-C90
A4-B6-C91 A4-B6-C92 A4-B6-C93 A4-B6-C94 A4-B6-C95 A4-B6-C96
A4-B6-C97 A4-B6-C98 A4-B6-C99 A4-B6-C100 A4-B6-C101 A4-B6-C102
A4-B6-C103 A4-B6-C104 A4-B6-C105 A4-B6-C106 A4-B6-C107 A4-B6-C108
A4-B6-C109 A4-B6-C110 A4-B6-C111 A4-B6-C112 A4-B6-C113 A4-B6-C114
A4-B6-C115 A4-B6-C116 A4-B6-C117 A4-B6-C118 A4-B6-C119 A4-B6-C120
A4-B6-C121 A4-B6-C122 A4-B6-C123 A4-B6-C124 A4-B6-C125 A4-B6-C126
A4-B6-C127 A4-B6-C128 A4-B6-C129 A4-B6-C130 A4-B6-C131 A4-B6-C132
A4-B6-C133 A4-B6-C134 A4-B6-C135 A4-B6-C136 A4-B6-C137 A4-B6-C138
A4-B6-C139 A4-B6-C140 BLANK BLANK BLANK BLANK
A4-B7-C1 A4-B7-C2 A4-B7-C3 A4-B7-C4 A4-B7-C5 A4-B7-C6
A4-B7-C7 A4-B7-C8 A4-B7-C9 A4-B7-C10 A4-B7-C11 A4-B7-C12
A4-B7-C13 A4-B7-C14 A4-B7-C15 A4-B7-C16 A4-B7-C17 A4-B7-C18
A4-B7-C19 A4-B7-C20 A4-B7-C21 A4-B7-C22 A4-B7-C23 A4-B7-C24
A4-B7-C25 A4-B7-C26 A4-B7-C27 A4-B7-C28 A4-B7-C29 A4-B7-C30
A4-B7-C31 A4-B7-C32 A4-B7-C33 A4-B7-C34 A4-B7-C35 A4-B7-C36
A4-B7-C37 A4-B7-C38 A4-B7-C39 A4-B7-C40 A4-B7-C41 A4-B7-C42
A4-B7-C43 A4-B7-C44 A4-B7-C45 A4-B7-C46 A4-B7-C47 A4-B7-C48
A4-B7-C49 A4-B7-C50 A4-B7-C51 A4-B7-C52 A4-B7-C53 A4-B7-C54
A4-B7-C55 A4-B7-C56 A4-B7-C57 A4-B7-C58 A4-B7-C59 A4-B7-C60
A4-B7-C61 A4-B7-C62 A4-B7-C63 A4-B7-C64 A4-B7-C65 A4-B7-C66
A4-B7-C67 A4-B7-C68 A4-B7-C69 A4-B7-C70 A4-B7-C71 A4-B7-C72
A4-B7-C73 A4-B7-C74 A4-B7-C75 A4-B7-C76 A4-B7-C77 A4-B7-C78
A4-B7-C79 A4-B7-C80 A4-B7-C81 A4-B7-C82 A4-B7-C83 A4-B7-C84
A4-B7-C85 A4-B7-C86 A4-B7-C87 A4-B7-C88 A4-B7-C89 A4-B7-C90
A4-B7-C91 A4-B7-C92 A4-B7-C93 A4-B7-C94 A4-B7-C95 A4-B7-C96
A4-B7-C97 A4-B7-C98 A4-B7-C99 A4-B7-C100 A4-B7-C101 A4-B7-C102
A4-B7-C103 A4-B7-C104 A4-B7-C105 A4-B7-C106 A4-B7-C107 A4-B7-C108
A4-B7-C109 A4-B7-C110 A4-B7-C111 A4-B7-C112 A4-B7-C113 A4-B7-C114
A4-B7-C115 A4-B7-C116 A4-B7-C117 A4-B7-C118 A4-B7-C119 A4-B7-C120
A4-B7-C121 A4-B7-C122 A4-B7-C123 A4-B7-C124 A4-B7-C125 A4-B7-C126
A4-B7-C127 A4-B7-C128 A4-B7-C129 A4-B7-C130 A4-B7-C131 A4-B7-C132
A4-B7-C133 A4-B7-C134 A4-B7-C135 A4-B7-C136 A4-B7-C137 A4-B7-C138
A4-B7-C139 A4-B7-C140 BLANK BLANK BLANK BLANK
A4-B8-C1 A4-B8-C2 A4-B8-C3 A4-B8-C4 A4-B8-C5 A4-B8-C6
A4-B8-C7 A4-B8-C8 A4-B8-C9 A4-B8-C10 A4-B8-C11 A4-B8-C12
A4-B8-C13 A4-B8-C14 A4-B8-C15 A4-B8-C16 A4-B8-C17 A4-B8-C18
A4-B8-C19 A4-B8-C20 A4-B8-C21 A4-B8-C22 A4-B8-C23 A4-B8-C24
A4-B8-C25 A4-B8-C26 A4-B8-C27 A4-B8-C28 A4-B8-C29 A4-B8-C30
A4-B8-C31 A4-B8-C32 A4-B8-C33 A4-B8-C34 A4-B8-C35 A4-B8-C36
A4-B8-C37 A4-B8-C38 A4-B8-C39 A4-B8-C40 A4-B8-C41 A4-B8-C42
A4-B8-C43 A4-B8-C44 A4-B8-C45 A4-B8-C46 A4-B8-C47 A4-B8-C48
A4-B8-C49 A4-B8-C50 A4-B8-C51 A4-B8-C52 A4-B8-C53 A4-B8-C54
A4-B8-C55 A4-B8-C56 A4-B8-C57 A4-B8-C58 A4-B8-C59 A4-B8-C60
A4-B8-C61 A4-B8-C62 A4-B8-C63 A4-B8-C64 A4-B8-C65 A4-B8-C66
A4-B8-C67 A4-B8-C68 A4-B8-C69 A4-B8-C70 A4-B8-C71 A4-B8-C72
A4-B8-C73 A4-B8-C74 A4-B8-C75 A4-B8-C76 A4-B8-C77 A4-B8-C78
A4-B8-C79 A4-B8-C80 A4-B8-C81 A4-B8-C82 A4-B8-C83 A4-B8-C84
A4-B8-C85 A4-B8-C86 A4-B8-C87 A4-B8-C88 A4-B8-C89 A4-B8-C90
A4-B8-C91 A4-B8-C92 A4-B8-C93 A4-B8-C94 A4-B8-C95 A4-B8-C96
A4-B8-C97 A4-B8-C98 A4-B8-C99 A4-B8-C100 A4-B8-C101 A4-B8-C102
A4-B8-C103 A4-B8-C104 A4-B8-C105 A4-B8-C106 A4-B8-C107 A4-B8-C108
A4-B8-C109 A4-B8-C110 A4-B8-C111 A4-B8-C112 A4-B8-C113 A4-B8-C114
A4-B8-C115 A4-B8-C116 A4-B8-C117 A4-B8-C118 A4-B8-C119 A4-B8-C120
A4-B8-C121 A4-B8-C122 A4-B8-C123 A4-B8-C124 A4-B8-C125 A4-B8-C126
A4-B8-C127 A4-B8-C128 A4-B8-C129 A4-B8-C130 A4-B8-C131 A4-B8-C132
A4-B8-C133 A4-B8-C134 A4-B8-C135 A4-B8-C136 A4-B8-C137 A4-B8-C138
A4-B8-C139 A4-B8-C140 BLANK BLANK BLANK BLANK
A4-B9-C1 A4-B9-C2 A4-B9-C3 A4-B9-C4 A4-B9-C5 A4-B9-C6
A4-B9-C7 A4-B9-C8 A4-B9-C9 A4-B9-C10 A4-B9-C11 A4-B9-C12
A4-B9-C13 A4-B9-C14 A4-B9-C15 A4-B9-C16 A4-B9-C17 A4-B9-C18
A4-B9-C19 A4-B9-C20 A4-B9-C21 A4-B9-C22 A4-B9-C23 A4-B9-C24
A4-B9-C25 A4-B9-C26 A4-B9-C27 A4-B9-C28 A4-B9-C29 A4-B9-C30
A4-B9-C31 A4-B9-C32 A4-B9-C33 A4-B9-C34 A4-B9-C35 A4-B9-C36
A4-B9-C37 A4-B9-C38 A4-B9-C39 A4-B9-C40 A4-B9-C41 A4-B9-C42
A4-B9-C43 A4-B9-C44 A4-B9-C45 A4-B9-C46 A4-B9-C47 A4-B9-C48
A4-B9-C49 A4-B9-C50 A4-B9-C51 A4-B9-C52 A4-B9-C53 A4-B9-C54
A4-B9-C55 A4-B9-C56 A4-B9-C57 A4-B9-C58 A4-B9-C59 A4-B9-C60
A4-B9-C61 A4-B9-C62 A4-B9-C63 A4-B9-C64 A4-B9-C65 A4-B9-C66
A4-B9-C67 A4-B9-C68 A4-B9-C69 A4-B9-C70 A4-B9-C71 A4-B9-C72
A4-B9-C73 A4-B9-C74 A4-B9-C75 A4-B9-C76 A4-B9-C77 A4-B9-C78
A4-B9-C79 A4-B9-C80 A4-B9-C81 A4-B9-C82 A4-B9-C83 A4-B9-C84
A4-B9-C85 A4-B9-C86 A4-B9-C87 A4-B9-C88 A4-B9-C89 A4-B9-C90
A4-B9-C91 A4-B9-C92 A4-B9-C93 A4-B9-C94 A4-B9-C95 A4-B9-C96
A4-B9-C97 A4-B9-C98 A4-B9-C99 A4-B9-C100 A4-B9-C101 A4-B9-C102
A4-B9-C103 A4-B9-C104 A4-B9-C105 A4-B9-C106 A4-B9-C107 A4-B9-C108
A4-B9-C109 A4-B9-C110 A4-B9-C11 1 A4-B9-C112 A4-B9-C113 A4-B9-C114
A4-B9-C115 A4-B9-C116 A4-B9-C117 A4-B9-C118 A4-B9-C119 A4-B9-C120
A4-B9-C121 A4-B9-C122 A4-B9-C123 A4-B9-C124 A4-B9-C125 A4-B9-C126
A4-B9-C127 A4-B9-C128 A4-B9-C129 A4-B9-C130 A4-B9-C131 A4-B9-C132
A4-B9-C133 A4-B9-C134 A4-B9-C135 A4-B9-C136 A4-B9-C137 A4-B9-C138
A4-B9-C139 A4-B9-C140 BLANK BLANK BLANK BLANK
A4-B10-C1 , A4-B10-C2 A4-B10-C3 A4-B10-C4 A4-B10-C5 A4-B10-C6
A4-B10-C7 A4-B10-C8 A4-B10-C9 A4-B10-C10 A4-B10-C11 A4-B10-C12
A4-B10-C13 A4-B10-C14 A4-B10-C15 A4-B10-C16 A4-B10-C17 A4-B10-C18
A4-B10-C19 A4-B10-C20 A4-B10-C21 A4-B10-C22 A4-B10-C23 A4-B10-C24
A4-B10-C25 A4-B10-C26 A4-B10-C27 A4-B10-C28 A4-B10-C29 A4-B10-C30
A4-B10-C31 A4-B10-C32 A4-B10-C33 A4-B10-C34 A4-B10-C35 A4-B10-C36
A4-B10-C37 A4-B10-C38 A4-B10-C39 A4-B10-C40 A4-B10-C41 A4-B10-C42
A4-B10-C43 A4-B10-C44 A4-B10-C45 A4-B10-C46 A4-B10-C47 A4-B10-C48
A4-B10-C49 A4-B10-C50 A4-B10-C51 A4-B10-C52 A4-B10-C53 A4-B10-C54
A4-B10-C55 A4-B10-C56 A4-B10-C57 A4-B10-C58 A4-B10-C59 A4-B10-C60
A4-B10-C61 A4-B10-C62 A4-B10-C63 A4-B10-C64 A4-B10-C65 A4-B10-C66
A4-B10-C67 A4-B10-C68 A4-B10-C69 A4-B10-C70 A4-B10-C71 A4-B10-C72
A4-B10-C73 A4-B10-C74 A4-B10-C75 A4-B10-C76 A4-B10-C77 A4-B10-C78
A4-B10-C79 A4-B10-C80 A4-B10-C81 A4-B10-C82 A4-B10-C83 A4-B10-C84
A4-B10-C85 A4-B10-C86 A4-B10-C87 A4-B10-C88 A4-B10-C89 A4-B10-C90
A4-B10-C91 A4-B10-C92 A4-B10-C93 A4-B10-C94 A4-B10-C95 A4-B10-C96
A4-B10-C97 A4-B10-C98 A4-B10-C99 A4-B10-C100 A4-B10-C101 A4-B10-C102
A4-B10-C103 A4-B10-C104 A4-B10-C105 A4-B10-C106 A4-B10-C107 A4-B10-C108 A4-B10-C109 A4-B10-C110 A4-B10-C111 A4-B10-C112 A4-B10-C113 A4-B10-C114
A4-B10-C115 A4-B10-C116 A4-B10-C117 A4-B10-C118 A4-B10-C119 A4-B10-C120
A4-B10-C121 A4-B10-C122 A4-B10-C123 A4-B10-C124 A4-B10-C125 A4-B10-C126
A4-B10-C127 A4-B10-C128 A4-B10-C129 A4-B10-C130 A4-B10-C131 A4-B10-C132
A4-B10-C133 A4-B10-C134 A4-B10-C135 A4-B10-C136 A4-B10-C137 A4-B10-C138 A4-B10-C139 A4-B10-C140 BLANK BLANK BLANK BLANK
A4-B11-C1 A4-B11-C2 A4-B11-C3 A4-B1 1-C4 A4-B11-C5 A4-B11-C6
A4-B11-C7 A4-B11-C8 A4-B11-C9 A4-B1 1-C10 A4-B11-C11 A4-B11-C12
A4-B11-C13 A4-B11-C14 A4-B11-C15 A4-B11-C16 A4-B11-C17 A4-B11-C18
A4-B11-C19 A4-B11-C20 A4-B11-C21 A4-B1 1-C22 A4-B11-C23 A4-B11-C24 A4-B11-C25 A4-B11-C26 A4-B11-C27 A4-B1 1-C28 A4-B11-C29 A4-B11-C30
A4-B11-C31 A4-B11-C32 A4-B11-C33 A4-B11-C34 A4-B11-C35 A4-B11-C36
A4-B11-C37 A4-B11-C38 A4-B11-C39 A4-B11-C40 A4-B11-C41 A4-B11-C42
A4-B11-C43 A4-B11-C44 A4-B11-C45 A4-B11-C46 A4-B11-C47 A4-B11-C48
A4-B11-C49 A4-B11-C50 A4-B11-C51 A4-B1 1-C52 A4-B11-C53 A4-B11-C54 A4-B11-C55 A4-B11-C56 A4-B11-C57 A4-B1 1-C58 A4-B11-C59 A4-B11-C60
A4-B11-C61 A4-B11-C62 A4-B11-C63 A4-B11-C64 A4-B11-C65 A4-B11-C66
A4-B11-C67 A4-B11-C68 A4-B11-C69 A4-B1 1-C70 A4-B11-C71 A4-B11-C72
A4-B11-C73 A4-B11-C74 A4-B11-C75 A4-B11-C76 A4-B11-C77 A4-B11-C78
A4-B11-C79 A4-B11-C80 A4-B11-C81 A4-B1 1-C82 A4-B11-C83 A4-B11-C84 A4-BU-C85 A4-B11-C86 A4-B11-C87 A4-B11-C88 A4-B11-C89 A4-B11-C90
A4-B11-C91 A4-B11-C92 A4-B11-C93 A4-B11-C94 A4-B11-C95 A4-B11-C96
A4-B11-C97 A4-B11-C98 A4-B11-C99 A4-B11-C100 A4-B11-C101 A4-B11-C102
A4-B11-C103 A4-B11-C104 A4-B11-C105 A4-B11-C106 A4-B11-C107 A4-B11-C108
A4-B11-C109 A4-B11-C110 A4-B11-C111 A4-B11-C112 A4-B11-C113 A4-B11-C114 A4-B11-C115 A4-B11-C116 A4-B11-C117 A4-B11-C118 A4-B11-C119 A4-B11-C120
A4-B11-C121 A4-B11-C122 A4-B11-C123 A4-B11-C124 A4-B11-C125 A4-B11-C126
A4-B11-C127 A4-B11-C128 A4-B11-C129 A4-B11-C130 A4-B11-C131 A4-B11-C132
A4-B11-C133 A4-B11-C134 A4-B11-C135 A4-B1 1-C136 A4-B11-C137 A4-B11-C138
A4-B11-C139 A4-B11-C140 BLANK BLANK BLANK BLANK A4-B12-C1 A4-B12-C2 A4-B12-C3 A4-B12-C4 A4-B12-C5 A4-B12-C6
A4-B12-C7 A4-B12-C8 A4-B12-C9 A4-B12-C10 A4-B12-C11 A4-B12-C12
A4-B12-C13 A4-B12-C14 A4-B12-C15 A4-B12-C16 A4-B12-C17 A4-B12-C18
A4-B12-C19 A4-B12-C20 A4-B12-C21 A4-B12-C22 A4-B12-C23 A4-B12-C24
A4-B12-C25 A4-B12-C26 A4-B12-C27 A4-B12-C28 A4-B12-C29 A4-B12-C30
A4-B12-C31 A4-B12-C32 A4-B12-C33 A4-B12-C34 A4-B12-C35 A4-B12-C36
A4-B12-C37 A4-B12-C38 A4-B12-C39 A4-B12-C40 A4-B12-C41 A4-B12-C42 A4-B12-C43 A4-B12-C44 A4-B12-C45 A4-B12-C46 A4-B12-C47 A4-B12-C48
A4-B12-C49 A4-B12-C50 A4-B12-C51 A4-B12-C52 A4-B12-C53 A4-B12-C54
A4-B12-C55 A4-B12-C56 A4-B12-C57 A4-B12-C58 A4-B12-C59 A4-B12-C60
A4-B12-C61 A4-B12-C62 A4-B12-C63 A4-B12-C64 A4-B12-C65 A4-B12-C66
A4-B12-C67 A4-B12-C68 A4-B12-C69 A4-B12-C70 A4-B12-C71 A4-B12-C72 A4-B12-C73 A4-B12-C74 A4-B12-C75 A4-B12-C76 A4-B12-C77 A4-B12-C78
A4-B12-C79 A4-B12-C80 A4-B12-C81 A4-B12-C82 A4-B12-C83 A4-B12-C84
A4-B12-C85 A4-B12-C86 A4-B12-C87 A4-B12-C88 A4-B12-C89 A4-B12-C90
A4-B12-C91 A4-B12-C92 A4-B12-C93 A4-B12-C94 A4-B12-C95 A4-B12-C96
A4-B12-C97 A4-B12-C98 A4-B12-C99 A4-B12-C100 A4-B12-C101 A4-B12-C102 A4-B12-C103 A4-B12-C104 A4-B12-C105 A4-B12-C106 A4-B12-C107 A4-B12-C108
A4-B12-C109 A4-B12-C110 A4-B12-C111 A4-B12-C112 A4-B12-C1 13 A4-B12-C114
A4-B12-C115 A4-B12-C116 A4-B12-C117 A4-B12-C118 A4-B12-C1 19 A4-B12-C120
A4-B12-C121 A4-B12-C122 A4-B12-C123 A4-B12-C124 A4-B12-C125 A4-B12-C126
A4-B12-C127 A4-B12-C128 A4-B12-C129 A4-B12-C130 A4-B12-C131 A4-B12-C132 A4-B12-C133 A4-B12-C134 A4-B12-C135 A4-B12-C136 A4-B12-C137 A4-B12-C138
A4-B12-C139 A4-B12-C140 BLANK BLANK BLANK BLANK
A4-B13-C1 A4-B13-C2 A4-B13-C3 A4-B13-C4 A4-B13-C5 A4-B13-C6
A4-B13-C7 A4-B13-C8 A4-B13-C9 A4-B13-C10 A4-B13-C11 A4-B13-C12
A4-B13-C13 A4-B13-C14 A4-B13-C15 A4-B13-C16 A4-B13-C17 A4-B13-C18 A4-B13-C19 A4-B13-C20 A4-B13-C21 A4-B13-C22 A4-B13-C23 A4-B13-C24
A4-B13-C25 A4-B13-C26 A4-B13-C27 A4-B13-C28 A4-B13-C29 A4-B13-C30
A4-B13-C31 A4-B13-C32 A4-B13-C33 A4-B13-C34 A4-B13-C35 A4-B13-C36
A4-B13-C37 A4-B13-C38 A4-B13-C39 A4-B13-C40 A4-B13-C41 A4-B13-C42
A4-B13-C43 A4-B13-C44 A4-B13-C45 A4-B13-C46 A4-B13-C47 A4-B13-C48 A4-B13-C49 A4-B13-C50 A4-B13-C51 A4-B13-C52 A4-B13-C53 A4-B13-C54
A4-B13-C55 A4-B13-C56 A4-B13-C57 A4-B13-C58 A4-B13-C59 A4-B13-C60
A4-B13-C61 A4-B13-C62 A4-B13-C63 A4-B13-C64 A4-B13-C65 A4-B13-C66
A4-B13-C67 A4-B13-C68 A4-B13-C69 A4-B13-C70 A4-B13-C71 A4-B13-C72
A4-B13-C73 A4-B13-C74 A4-B13-C75 A4-B13-C76 A4-B13-C77 A4-B13-C78 A4-B13-C79 A4-B13-C80 A4-B13-C81 A4-B13-C82 A4-B13-C83 A4-B13-C84
A4-B13-C85 A4-B13-C86 A4-B13-C87 A4-B13-C88 A4-B13-C89 A4-B13-C90
A4-B13-C91 A4-B13-C92 A4-B13-C93 A4-B13-C94 A4-B13-C95 A4-B13-C96
A4-B13-C97 A4-B13-C98 A4-B13-C99 A4-B13-C100 A4-B13-C101 A4-B13-C102
A4-B13-C103 A4-B13-C104 A4-B13-C105 A4-B13-C106 A4-B13-C107 A4-B13-C108
A4-B13-C109 A4-B13-C110 A4-B13-C111 A4-B13-C112 A4-B13-C113 A4-B13-C114
A4-B13-C115 A4-B13-C116 A4-B13-C117 A4-B13-C118 A4-B13-C119 A4-B13-C120
A4-B13-C121 A4-B13-C122 A4-B13-C123 A4-B13-C124 A4-B13-C125 A4-B13-C126
A4-B13-C127 A4-B13-C128 A4-B13-C129 A4-B13-C130 A4-B13-C131 A4-B13-C132
A4-B13-C133 A4-B13-C134 A4-B13-C135 A4-B13-C136 A4-B13-C137 A4-B13-C138
A4-B13-C139 A4-B13-C140 BLANK BLANK BLANK BLANK
A5-B1-C1 A5-B1-C2 A5-B1-C3 A5-B1-C4 A5-B1-C5 A5-B1-C6
A5-B1-C7 A5-B1-C8 A5-B1-C9 A5-B1-C10 A5-B1-C11 A5-B1-C12
A5-B1-C13 A5-B1-C14 A5-B1-C15 A5-B1-C16 A5-B1-C17 A5-B1-C18
A5-B1-C19 A5-B1-C20 A5-B1-C21 A5-B1-C22 A5-B1-C23 A5-B1-C24
A5-B1-C25 A5-B1-C26 A5-B1-C27 A5-B1-C28 A5-B1-C29 A5-B1-C30
A5-B1-C31 A5-B1-C32 A5-B1-C33 A5-B1-C34 A5-B1-C35 A5-B1-C36
A5-B1-C37 A5-B1-C38 A5-B1-C39 A5-B1-C40 A5-B1-C41 A5-B1-C42
A5-B1-C43 A5-B1-C44 A5-B1-C45 A5-B1-C46 A5-B1-C47 A5-B1-C48
A5-B1-C49 A5-B1-C50 A5-B1-C51 A5-B1-C52 A5-B1-C53 A5-B1-C54
A5-B1-C55 A5-B1-C56 A5-B1-C57 A5-B1-C58 A5-B1-C59 A5-B1-C60
A5-B1-C61 A5-B1-C62 A5-B1-C63 A5-B1-C64 A5-B1-C65 A5-B1-C66
A5-B1-C67 A5-B1-C68 A5-B1-C69 A5-B1-C70 A5-B1-C71 A5-B1-C72
A5-B1-C73 A5-B1-C74 A5-B1-C75 A5-B1-C76 A5-B1-C77 A5-B1-C78
A5-B1-C79 A5-B1-C80 A5-B1-C81 A5-B1-C82 A5-B1-C83 A5-B1-C84
A5-B1-C85 A5-B1-C86 A5-B1-C87 A5-B1-C88 A5-B1-C89 A5-B1-C90
A5-B1-C91 A5-B1-C92 A5-B1-C93 A5-B1-C94 A5-B1-C95 A5-B1-C96
A5-B1-C97 A5-B1-C98 A5-B1-C99 A5-B1-C100 A5-B1-C101 A5-B1-C102
A5-B1-C103 A5-B1-C104 A5-B1-C105 A5-B1-C106 A5-B1-C107 A5-B1-C108
A5-B1-C109 A5-B1-C110 A5-B1-C111 A5-B1-C112 A5-B1-C113 A5-B1-C114
A5-B1-C115 A5-B1-C116 A5-B1-C117 A5-B1-C118 A5-B1-C119 A5-B1-C120
A5-B1-C121 A5-B1-C122 A5-B1-C123 A5-B1-C124 A5-B1-C125 A5-B1-C126
A5-B1-C127 A5-B1-C128 A5-B1-C129 A5-B1-C130 A5-B1-C131 A5-B1-C132
A5-B1-C133 A5-B1-C134 A5-B1-C135 A5-B1-C136 A5-B1-C137 A5-B1-C138
A5-B1-C139 A5-B1-C140 BLANK BLANK BLANK BLANK
A5-B2-C1 A5-B2-C2 A5-B2-C3 A5-B2-C4 A5-B2-C5 A5-B2-C6
A5-B2-C7 A5-B2-C8 A5-B2-C9 A5-B2-C10 A5-B2-C11 A5-B2-C12
A5-B2-C13 A5-B2-C14 A5-B2-C15 A5-B2-C16 A5-B2-C17 A5-B2-C18
A5-B2-C19 A5-B2-C20 A5-B2-C21 A5-B2-C22 A5-B2-C23 A5-B2-C24
A5-B2-C25 A5-B2-C26 A5-B2-C27 A5-B2-C28 A5-B2-C29 A5-B2-C30
A5-B2-C31 A5-B2-C32 A5-B2-C33 A5-B2-C34 A5-B2-C35 A5-B2-C36
A5-B2-C37 A5-B2-C38 A5-B2-C39 A5-B2-C40 A5-B2-C41 A5-B2-C42
A5-B2-C43 A5-B2-C44 A5-B2-C45 A5-B2-C46 A5-B2-C47 A5-B2-C48
A5-B2-C49 A5-B2-C50 A5-B2-C51 A5-B2-C52 A5-B2-C53 A5-B2-C54
A5-B2-C55 A5-B2-C56 A5-B2-C57 A5-B2-C58 A5-B2-C59 A5-B2-C60
A5-B2-C61 A5-B2-C62 A5-B2-C63 A5-B2-C64 A5-B2-C65 A5-B2-C66
A5-B2-C67 A5-B2-C68 A5-B2-C69 A5-B2-C70 A5-B2-C71 A5-B2-C72
A5-B2-C73 A5-B2-C74 A5-B2-C75 A5-B2-C76 A5-B2-C77 A5-B2-C78
A5-B2-C79 A5-B2-C80 A5-B2-C81 A5-B2-C82 A5-B2-C83 A5-B2-C84
A5-B2-C85 A5-B2-C86 A5-B2-C87 A5-B2-C88 A5-B2-C89 A5-B2-C90
A5-B2-C91 A5-B2-C92 A5-B2-C93 A5-B2-C94 A5-B2-C95 A5-B2-C96
A5-B2-C97 A5-B2-C98 A5-B2-C99 A5-B2-C100 A5-B2-C101 A5-B2-C102
A5-B2-C103 A5-B2-C104 A5-B2-C105 A5-B2-C106 A5-B2-C107 A5-B2-C108
A5-B2-C109 A5-B2-C110 A5-B2-C111 A5-B2-C112 A5-B2-C113 A5-B2-C114
A5-B2-C115 A5-B2-C116 A5-B2-C117 A5-B2-C118 A5-B2-C119 A5-B2-C120
A5-B2-C121 A5-B2-C122 A5-B2-C123 A5-B2-C124 A5-B2-C125 A5-B2-C126
A5-B2-C127 A5-B2-C128 A5-B2-C129 A5-B2-C130 A5-B2-C131 A5-B2-C132
A5-B2-C133 A5-B2-C134 A5-B2-C135 A5-B2-C136 A5-B2-C137 A5-B2-C138
A5-B2-C139 A5-B2-C140 BLANK BLANK BLANK BLANK
A5-B3-C1 A5-B3-C2 A5-B3-C3 A5-B3-C4 A5-B3-C5 A5-B3-C6
A5-B3-C7 A5-B3-C8 A5-B3-C9 A5-B3-C10 A5-B3-C11 A5-B3-C12
A5-B3-C13 A5-B3-C14 A5-B3-C15 A5-B3-C16 A5-B3-C17 A5-B3-C18
A5-B3-C19 A5-B3-C20 A5-B3-C21 A5-B3-C22 A5-B3-C23 A5-B3-C24
A5-B3-C25 A5-B3-C26 A5-B3-C27 A5-B3-C28 A5-B3-C29 A5-B3-C30
A5-B3-C31 A5-B3-C32 A5-B3-C33 A5-B3-C34 A5-B3-C35 A5-B3-C36
A5-B3-C37 A5-B3-C38 A5-B3-C39 A5-B3-C40 A5-B3-C41 A5-B3-C42
A5-B3-C43 A5-B3-C44 A5-B3-C45 A5-B3-C46 A5-B3-C47 A5-B3-C48
A5-B3-C49 A5-B3-C50 A5-B3-C51 A5-B3-C52 A5-B3-C53 A5-B3-C54
A5-B3-C55 A5-B3-C56 A5-B3-C57 A5-B3-C58 A5-B3-C59 A5-B3-C60
A5-B3-C61 A5-B3-C62 A5-B3-C63 A5-B3-C64 A5-B3-C65 A5-B3-C66
A5-B3-C67 A5-B3-C68 A5-B3-C69 A5-B3-C70 A5-B3-C71 A5-B3-C72
A5-B3-C73 A5-B3-C74 A5-B3-C75 A5-B3-C76 A5-B3-C77 A5-B3-C78
A5-B3-C79 A5-B3-C80 A5-B3-C81 A5-B3-C82 A5-B3-C83 A5-B3-C84
A5-B3-C85 A5-B3-C86 A5-B3-C87 A5-B3-C88 A5-B3-C89 A5-B3-C90
A5-B3-C91 A5-B3-C92 A5-B3-C93 A5-B3-C94 A5-B3-C95 A5-B3-C96
A5-B3-C97 A5-B3-C98 A5-B3-C99 A5-B3-C100 A5-B3-C101 A5-B3-C102
A5-B3-C103 A5-B3-C104 A5-B3-C105 A5-B3-C106 A5-B3-C107 A5-B3-C108
A5-B3-C109 A5-B3-C110 A5-B3-C111 A5-B3-C112 A5-B3-C113 A5-B3-C114
A5-B3-C115 A5-B3-C116 A5-B3-C117 A5-B3-C118 A5-B3-C119 A5-B3-C120
A5-B3-C121 A5-B3-C122 A5-B3-C123 A5-B3-C124 A5-B3-C125 A5-B3-C126
A5-B3-C127 A5-B3-C128 A5-B3-C129 A5-B3-C130 A5-B3-C131 A5-B3-C132
A5-B3-C133 A5-B3-C134 A5-B3-C135 A5-B3-C136 A5-B3-C137 A5-B3-C138
A5-B3-C139 A5-B3-C140 BLANK BLANK BLANK BLANK
A5-B4-C1 A5-B4-C2 A5-B4-C3 A5-B4-C4 A5-B4-C5 A5-B4-C6
A5-B4-C7 A5-B4-C8 A5-B4-C9 A5-B4-C10 A5-B4-C11 A5-B4-C12
A5-B4-C13 A5-B4-C14 A5-B4-C15 A5-B4-C16 A5-B4-C17 A5-B4-C18
A5-B4-C19 A5-B4-C20 A5-B4-C21 A5-B4-C22 A5-B4-C23 A5-B4-C24
A5-B4-C25 A5-B4-C26 A5-B4-C27 A5-B4-C28 A5-B4-C29 A5-B4-C30
A5-B4-C31 A5-B4-C32 A5-B4-C33 A5-B4-C34 A5-B4-C35 A5-B4-C36
A5-B4-C37 A5-B4-C38 A5-B4-C39 A5-B4-C40 A5-B4-C41 A5-B4-C42
A5-B4-C43 A5-B4-C44 A5-B4-C45 A5-B4-C46 A5-B4-C47 A5-B4-C48
A5-B4-C49 A5-B4-C50 A5-B4-C51 A5-B4-C52 A5-B4-C53 A5-B4-C54
A5-B4-C55 A5-B4-C56 A5-B4-C57 A5-B4-C58 A5-B4-C59 A5-B4-C60
A5-B4-C61 A5-B4-C62 A5-B4-C63 A5-B4-C64 A5-B4-C65 A5-B4-C66
A5-B4-C67 A5-B4-C68 A5-B4-C69 A5-B4-C70 A5-B4-C71 A5-B4-C72
A5-B4-C73 A5-B4-C74 A5-B4-C75 A5-B4-C76 A5-B4-C77 A5-B4-C78
A5-B4-C79 A5-B4-C80 A5-B4-C81 A5-B4-C82 A5-B4-C83 A5-B4-C84
A5-B4-C85 A5-B4-C86 A5-B4-C87 A5-B4-C88 A5-B4-C89 A5-B4-C90
A5-B4-C91 A5-B4-C92 A5-B4-C93 A5-B4-C94 A5-B4-C95 A5-B4-C96
A5-B4-C97 A5-B4-C98 A5-B4-C99 A5-B4-C100 A5-B4-C101 A5-B4-C102
A5-B4-C103 A5-B4-C104 A5-B4-C105 A5-B4-C106 A5-B4-C107 A5-B4-C108
A5-B4-C109 A5-B4-C110 A5-B4-C111 A5-B4-C112 A5-B4-C113 A5-B4-CU4
A5-B4-C115 A5-B4-C116 A5-B4-C117 A5-B4-C118 A5-B4-C119 A5-B4-C120
A5-B4-C121 A5-B4-C122 A5-B4-C123 A5-B4-C124 A5-B4-C125 A5-B4-C126
A5-B4-C127 A5-B4-C128 A5-B4-C129 A5-B4-C130 A5-B4-C131 A5-B4-C132
A5-B4-C133 A5-B4-C134 A5-B4-C135 A5-B4-C136 A5-B4-C137 A5-B4-C138
A5-B4-C139 A5-B4-C140 BLANK BLANK BLANK BLANK
A5-B5-C1 A5-B5-C2 A5-B5-C3 A5-B5-C4 A5-B5-C5 A5-B5-C6
A5-B5-C7 A5-B5-C8 A5-B5-C9 A5-B5-C10 A5-B5-C11 A5-B5-C12
A5-B5-C13 A5-B5-C14 A5-B5-C15 A5-B5-C16 A5-B5-C17 A5-B5-C18
A5-B5-C19 A5-B5-C20 A5-B5-C21 A5-B5-C22 A5-B5-C23 A5-B5-C24
A5-B5-C25 A5-B5-C26 A5-B5-C27 A5-B5-C28 A5-B5-C29 A5-B5-C30
A5-B5-C31 A5-B5-C32 A5-B5-C33 A5-B5-C34 A5-B5-C35 A5-B5-C36
A5-B5-C37 A5-B5-C38 A5-B5-C39 A5-B5-C40 A5-B5-C41 A5-B5-C42
A5-B5-C43 A5-B5-C44 A5-B5-C45 A5-B5-C46 A5-B5-C47 A5-B5-C48 A5-B5-C49 A5-B5-C50 A5-B5-C51 A5-B5-C52 A5-B5-C53 A5-B5-C54 A5-B5-C55 A5-B5-C56 A5-B5-C57 A5-B5-C58 A5-B5-C59 A5-B5-C60 A5-B5-C61 A5-B5-C62 A5-B5-C63 A5-B5-C64 A5-B5-C65 A5-B5-C66 A5-B5-C67 A5-B5-C68 A5-B5-C69 A5-B5-C70 A5-B5-C71 A5-B5-C72 A5-B5-C73 A5-B5-C74 A5-B5-C75 A5-B5-C76 A5-B5-C77 A5-B5-C78 A5-B5-C79 A5-B5-C80 A5-B5-C81 A5-B5-C82 A5-B5-C83 A5-B5-C84 A5-B5-C85 A5-B5-C86 A5-B5-C87 A5-B5-C88 A5-B5-C89 A5-B5-C90 A5-B5-C91 A5-B5-C92 A5-B5-C93 A5-B5-C94 A5-B5-C95 A5-B5-C96 A5-B5-C97 A5-B5-C98 A5-B5-C99 A5-B5-C100 A5-B5-C101 A5-B5-C102 A5-B5-C103 A5-B5-C104 A5-B5-C105 A5-B5-C106 A5-B5-C107 A5-B5-C108 A5-B5-C109 A5-B5-C110 A5-B5-C111 A5-B5-C112 A5-B5-C113 A5-B5-C114 A5-B5-C115 A5-B5-C116 A5-B5-C117 A5-B5-C118 A5-B5-C119 A5-B5-C120 A5-B5-C121 A5-B5-C122 A5-B5-C123 A5-B5-C124 A5-B5-C125 A5-B5-C126 A5-B5-C127 A5-B5-C128 A5-B5-C129 A5-B5-C130 A5-B5-C131 A5-B5-C132 A5-B5-C133 A5-B5-C134 A5-B5-C135 A5-B5-C136 A5-B5-C137 A5-B5-C138 A5-B5-C139 A5-B5-C140 BLANK BLANK BLANK BLANK A5-B6-C1 A5-B6-C2 A5-B6-C3 A5-B6-C4 A5-B6-C5 A5-B6-C6 A5-B6-C7 A5-B6-C8 A5-B6-C9 A5-B6-C10 A5-B6-C11 A5-B6-C12 A5-B6-C13 A5-B6-C14 A5-B6-C15 A5-B6-C16 A5-B6-C17 A5-B6-C18 A5-B6-C19 A5-B6-C20 A5-B6-C21 A5-B6-C22 A5-B6-C23 A5-B6-C24 A5-B6-C25 A5-B6-C26 A5-B6-C27 A5-B6-C28 A5-B6-C29 A5-B6-C30 A5-B6-C31 A5-B6-C32 A5-B6-C33 A5-B6-C34 A5-B6-C35 A5-B6-C36 A5-B6-C37 A5-B6-C38 A5-B6-C39 A5-B6-C40 A5-B6-C41 A5-B6-C42 A5-B6-C43 A5-B6-C44 A5-B6-C45 A5-B6-C46 A5-B6-C47 A5-B6-C48 A5-B6-C49 A5-B6-C50 A5-B6-C51 A5-B6-C52 A5-B6-C53 A5-B6-C54 A5-B6-C55 A5-B6-C56 A5-B6-C57 A5-B6-C58 A5-B6-C59 A5-B6-C60 A5-B6-C61 A5-B6-C62 A5-B6-C63 A5-B6-C64 A5-B6-C65 A5-B6-C66 A5-B6-C67 A5-B6-C68 A5-B6-C69 A5-B6-C70 A5-B6-C71 A5-B6-C72 A5-B6-C73 A5-B6-C74 A5-B6-C75 A5-B6-C76 A5-B6-C77 A5-B6-C78 A5-B6-C79 A5-B6-C80 A5-B6-C81 A5-B6-C82 A5-B6-C83 A5-B6-C84 A5-B6-C85 A5-B6-C86 A5-B6-C87 A5-B6-C88 A5-B6-C89 A5-B6-C90 A5-B6-C91 A5-B6-C92 A5-B6-C93 A5-B6-C94 A5-B6-C95 A5-B6-C96 A5-B6-C97 A5-B6-C98 A5-B6-C99 A5-B6-C100 A5-B6-C101 A5-B6-C102 A5-B6-C103 A5-B6-C104 A5-B6-C105 A5-B6-C106 A5-B6-C107 A5-B6-C108 A5-B6-C109 A5-B6-C110 A5-B6-C111 A5-B6-C112 A5-B6-C113 A5-B6-C114 A5-B6-C115 A5-B6-C116 A5-B6-C117 A5-B6-C118 A5-B6-C119 A5-B6-C120
A5-B6-C121 A5-B6-C122 A5-B6-C123 A5-B6-C124 A5-B6-C125 A5-B6-C126
A5-B6-C127 A5-B6-C128 A5-B6-C129 A5-B6-C130 A5-B6-C131 A5-B6-C132
A5-B6-C133 A5-B6-C134 A5-B6-C135 A5-B6-C136 A5-B6-C137 A5-B6-C138
A5-B6-C139 A5-B6-C140 BLANK BLANK BLANK BLANK
A5-B7-C1 A5-B7-C2 A5-B7-C3 A5-B7-C4 A5-B7-C5 A5-B7-C6
A5-B7-C7 A5-B7-C8 A5-B7-C9 A5-B7-C10 A5-B7-C1 1 A5-B7-C12
A5-B7-C13 A5-B7-C14 A5-B7-C15 A5-B7-C16 A5-B7-C17 A5-B7-C18
A5-B7-C19 A5-B7-C20 A5-B7-C21 A5-B7-C22 A5-B7-C23 A5-B7-C24
A5-B7-C25 A5-B7-C26 A5-B7-C27 A5-B7-C28 A5-B7-C29 A5-B7-C30
A5-B7-C31 A5-B7-C32 A5-B7-C33 A5-B7-C34 A5-B7-C35 A5-B7-C36
A5-B7-C37 A5-B7-C38 A5-B7-C39 A5-B7-C40 A5-B7-C41 A5-B7-C42
A5-B7-C43 A5-B7-C44 A5-B7-C45 A5-B7-C46 A5-B7-C47 A5-B7-C48
A5-B7-C49 A5-B7-C50 A5-B7-C51 A5-B7-C52 A5-B7-C53 A5-B7-C54
A5-B7-C55 A5-B7-C56 A5-B7-C57 A5-B7-C58 A5-B7-C59 A5-B7-C60
A5-B7-C61 A5-B7-C62 A5-B7-C63 A5-B7-C64 A5-B7-C65 A5-B7-C66
A5-B7-C67 A5-B7-C68 A5-B7-C69 A5-B7-C70 A5-B7-C71 A5-B7-C72
A5-B7-C73 A5-B7-C74 A5-B7-C75 A5-B7-C76 A5-B7-C77 A5-B7-C78
A5-B7-C79 A5-B7-C80 A5-B7-C81 A5-B7-C82 A5-B7-C83 A5-B7-C84
A5-B7-C85 A5-B7-C86 A5-B7-C87 A5-B7-C88 A5-B7-C89 A5-B7-C90
A5-B7-C91 A5-B7-C92 A5-B7-C93 A5-B7-C94 A5-B7-C95 A5-B7-C96
A5-B7-C97 A5-B7-C98 A5-B7-C99 A5-B7-C100 A5-B7-C101 A5-B7-C102
A5-B7-C103 A5-B7-C104 A5-B7-C105 A5-B7-C106 A5-B7-C107 A5-B7-C108
A5-B7-C109 A5-B7-C110 A5-B7-C111 A5-B7-C112 A5-B7-C113 A5-B7-C114
A5-B7-C115 A5-B7-C116 A5-B7-C117 A5-B7-C118 A5-B7-C119 A5-B7-C120
A5-B7-C121 A5-B7-C122 A5-B7-C123 A5-B7-C124 A5-B7-C125 A5-B7-C126
A5-B7-C127 A5-B7-C128 A5-B7-C129 A5-B7-C130 A5-B7-C131 A5-B7-C132
A5-B7-C133 A5-B7-C134 A5-B7-C135 A5-B7-C136 A5-B7-C137 A5-B7-C138
A5-B7-C139 A5-B7-C140 BLANK BLANK BLANK BLANK
A5-B8-C1 A5-B8-C2 A5-B8-C3 A5-B8-C4 A5-B8-C5 A5-B8-C6
A5-B8-C7 A5-B8-C8 A5-B8-C9 A5-B8-C10 A5-B8-C11 A5-B8-C12
A5-B8-C13 A5-B8-C14 A5-B8-C15 A5-B8-C16 A5-B8-C17 A5-B8-C18
A5-B8-C19 A5-B8-C20 A5-B8-C21 A5-B8-C22 A5-B8-C23 A5-B8-C24
A5-B8-C25 A5-B8-C26 A5-B8-C27 A5-B8-C28 A5-B8-C29 A5-B8-C30
A5-B8-C31 A5-B8-C32 A5-B8-C33 A5-B8-C34 A5-B8-C35 A5-B8-C36
A5-B8-C37 A5-B8-C38 A5-B8-C39 A5-B8-C40 A5-B8-C41 A5-B8-C42
A5-B8-C43 A5-B8-C44 A5-B8-C45 A5-B8-C46 A5-B8-C47 A5-B8-C48
A5-B8-C49 A5-B8-C50 A5-B8-C51 A5-B8-C52 A5-B8-C53 A5-B8-C54
A5-B8-C55 A5-B8-C56 A5-B8-C57 A5-B8-C58 A5-B8-C59 A5-B8-C60 A5-B8-C61 A5-B8-C62 A5-B8-C63 A5-B8-C64 A5-B8-C65 A5-B8-C66 A5-B8-C67 A5-B8-C68 A5-B8-C69 A5-B8-C70 A5-B8-C71 A5-B8-C72 A5-B8-C73 A5-B8-C74 A5-B8-C75 A5-B8-C76 A5-B8-C77 A5-B8-C78 A5-B8-C79 A5-B8-C80 A5-B8-C81 A5-B8-C82 A5-B8-C83 A5-B8-C84 A5-B8-C85 A5-B8-C86 A5-B8-C87 A5-B8-C88 A5-B8-C89 A5-B8-C90 A5-B8-C91 A5-B8-C92 A5-B8-C93 A5-B8-C94 A5-B8-C95 A5-B8-C96 A5-B8-C97 A5-B8-C98 A5-B8-C99 A5-B8-C100 A5-B8-C101 A5-B8-C102 A5-B8-C103 A5-B8-C104 A5-B8-C105 A5-B8-C106 A5-B8-C107 A5-B8-C108 A5-B8-C109 A5-B8-C110 A5-B8-C111 A5-B8-C112 A5-B8-C113 A5-B8-C114 A5-B8-C115 A5-B8-C116 A5-B8-C117 A5-B8-C118 A5-B8-C119 A5-B8-C120 A5-B8-C121 A5-B8-C122 A5-B8-C123 A5-B8-C124 A5-B8-C125 A5-B8-C126 A5-B8-C127 A5-B8-C128 A5-B8-C129 A5-B8-C130 A5-B8-C131 A5-B8-C132 A5-B8-C133 A5-B8-C134 A5-B8-C135 A5-B8-C136 A5-B8-C137 A5-B8-C138 A5-B8-C139 A5-B8-C140 BLANK BLANK BLANK BLANK A5-B9-C1 A5-B9-C2 A5-B9-C3 A5-B9-C4 A5-B9-C5 A5-B9-C6 A5-B9-C7 A5-B9-C8 A5-B9-C9 A5-B9-C10 A5-B9-C11 A5-B9-C12 A5-B9-C13 A5-B9-C14 A5-B9-C15 A5-B9-C16 A5-B9-C17 A5-B9-C18 A5-B9-C19 A5-B9-C20 A5-B9-C21 A5-B9-C22 A5-B9-C23 A5-B9-C24 A5-B9-C25 A5-B9-C26 A5-B9-C27 A5-B9-C28 A5-B9-C29 A5-B9-C30 A5-B9-C31 A5-B9-C32 A5-B9-C33 A5-B9-C34 A5-B9-C35 A5-B9-C36 A5-B9-C37 A5-B9-C38 A5-B9-C39 A5-B9-C40 A5-B9-C41 A5-B9-C42 A5-B9-C43 A5-B9-C44 A5-B9-C45 A5-B9-C46 A5-B9-C47 A5-B9-C48 A5-B9-C49 A5-B9-C50 A5-B9-C51 A5-B9-C52 A5-B9-C53 A5-B9-C54 A5-B9-C55 A5-B9-C56 A5-B9-C57 A5-B9-C58 A5-B9-C59 A5-B9-C60 A5-B9-C61 A5-B9-C62 A5-B9-C63 A5-B9-C64 A5-B9-C65 A5-B9-C66 A5-B9-C67 A5-B9-C68 A5-B9-C69 A5-B9-C70 A5-B9-C71 A5-B9-C72 A5-B9-C73 A5-B9-C74 A5-B9-C75 A5-B9-C76 A5-B9-C77 A5-B9-C78 A5-B9-C79 A5-B9-C80 A5-B9-C81 A5-B9-C82 A5-B9-C83 A5-B9-C84 A5-B9-C85 A5-B9-C86 A5-B9-C87 A5-B9-C88 A5-B9-C89 A5-B9-C90 A5-B9-C91 A5-B9-C92 A5-B9-C93 A5-B9-C94 A5-B9-C95 A5-B9-C96 A5-B9-C97 A5-B9-C98 A5-B9-C99 A5-B9-C100 A5-B9-C101 A5-B9-C102 A5-B9-C103 A5-B9-C104 A5-B9-C105 A5-B9-C106 A5-B9-C107 A5-B9-C108 A5-B9-C109 A5-B9-C110 A5-B9-C111 A5-B9-C112 A5-B9-C113 A5-B9-C114 A5-B9-C115 A5-B9-C116 A5-B9-C117 A5-B9-C118 A5-B9-C119 A5-B9-C120 A5-B9-C121 A5-B9-C122 A5-B9-C123 A5-B9-C124 A5-B9-C125 A5-B9-C126 A5-B9-C127 A5-B9-C128 A5-B9-C129 A5-B9-C130 A5-B9-C131 A5-B9-C132
A5-B9-C133 A5-B9-C134 A5-B9-C135 A5-B9-C136 A5-B9-C137 A5-B9-C138
A5-B9-C139 A5-B9-C140 BLANK BLANK BLANK BLANK
A5-B10-C1 A5-B10-C2 A5-B10-C3 A5-B10-C4 A5-B10-C5 A5-B10-C6
A5-B10-C7 A5-B10-C8 A5-B10-C9 A5-B10-C10 A5-B10-C11 A5-B10-C12
A5-B10-C13 A5-B10-C14 A5-B10-C15 A5-B10-C16 A5-B10-C17 A5-B10-C18
A5-B10-C19 A5-B10-C20 A5-B10-C21 A5-B10-C22 A5-B10-C23 A5-B10-C24
A5-B10-C25 A5-B10-C26 A5-B10-C27 A5-B10-C28 A5-B10-C29 A5-B10-C30
A5-B10-C31 A5-B10-C32 A5-B10-C33 A5-B10-C34 A5-B10-C35 A5-B10-C36
A5-B10-C37 A5-B10-C38 A5-B10-C39 A5-B10-C40 A5-B10-C41 A5-B10-C42
A5-B10-C43 A5-B10-C44 A5-B10-C45 A5-B10-C46 A5-B10-C47 A5-B10-C48
A5-B10-C49 A5-B10-C50 A5-B10-C51 A5-B10-C52 A5-B10-C53 A5-B10-C54
A5-B10-C55 A5-B10-C56 A5-B10-C57 A5-B10-C58 A5-B10-C59 A5-B10-C60
A5-B10-C61 A5-B10-C62 A5-B10-C63 A5-B10-C64 A5-B10-C65 A5-B10-C66
A5-B10-C67 A5-B10-C68 A5-B10-C69 A5-B10-C70 A5-B10-C71 A5-B10-C72
A5-B10-C73 A5-B10-C74 A5-B10-C75 A5-B10-C76 A5-B10-C77 A5-B10-C78
A5-B10-C79 A5-B10-C80 A5-B10-C81 A5-B10-C82 A5-B10-C83 A5-B10-C84
A5-B10-C85 A5-B10-C86 A5-B10-C87 A5-B10-C88 A5-B10-C89 A5-B10-C90
A5-B10-C91 A5-B10-C92 A5-B10-C93 A5-B10-C94 A5-B10-C95 A5-B10-C96
A5-B10-C97 A5-B10-C98 A5-B10-C99 A5-B10-C100 A5-B10-C101 A5-B10-C102
A5-B10-C103 A5-B10-C104 A5-B10-C105 A5-B10-C106 A5-B10-C107 A5-B10-C108
A5-B10-C109 A5-B10-C110 A5-B10-C111 A5-B10-C112 A5-B10-C113 A5-B10-C114
A5-B10-C115 A5-B10-C116 A5-B10-C117 A5-B10-C118 A5-B10-C119 A5-B10-C120
A5-B10-C121 A5-B10-C122 A5-B10-C123 A5-B10-C124 A5-B10-C125 A5-B10-C126
A5-B10-C127 A5-B10-C128 A5-B10-C129 A5-B10-C130 A5-B10-C131 A5-B10-C132
A5-B10-C133 A5-B10-C134 A5-B10-C135 A5-B10-C136 A5-B10-C137 A5-B10-C138
A5-B10-C139 A5-B10-C140 BLANK BLANK BLANK BLANK
A5-B11-C1 A5-B11-C2 A5-B11-C3 A5-B11-C4 A5-B11-C5 A5-B11-C6
A5-B11-C7 A5-B11-C8 A5-B11-C9 A5-B11-C10 A5-B11-C11 A5-B11-C12
A5-B11-C13 A5-B11-C14 A5-B11-C15 A5-B11-C16 A5-B11-C17 A5-B11-C18
A5-B11-C19 A5-B11-C20 A5-B11-C21 A5-B11-C22 A5-B11-C23 A5-B11-C24
A5-B11-C25 A5-B11-C26 A5-B11-C27 A5-B11-C28 A5-B11-C29 A5-B11-C30
A5-B11-C31 A5-B11-C32 A5-B11-C33 A5-B11-C34 A5-B11-C35 A5-B11-C36
A5-B11-C37 A5-B11-C38 A5-B11-C39 A5-B11-C40 A5-B11-C41 A5-B11-C42
A5-B11-C43 A5-B11-C44 A5-B11-C45 A5-B11-C46 A5-B11-C47 A5-B11-C48
A5-B11-C49 A5-B11-C50 A5-B11-C51 A5-B11-C52 A5-B11-C53 A5-B11-C54
A5-B11-C55 A5-B11-C56 A5-B11-C57 A5-B11-C58 A5-B11-C59 A5-B11-C60
A5-B11-C61 A5-B11-C62 A5-B11-C63 A5-B11-C64 A5-B11-C65 A5-B11-C66
A5-B11-C67 A5-B11-C68 A5-B11-C69 A5-B11-C70 A5-B11-C71 A5-B11-C72
A5-B11-C73 A5-B11-C74 A5-B11-C75 A5-B11-C76 A5-B11-C77 A5-B11-C78
A5-B11-C79 A5-B11-C80 A5-B11-C81 A5-B1 1-C82 A5-B11-C83 A5-B11-C84
A5-B11-C85 A5-B11-C86 A5-B11-C87 A5-B11-C88 A5-B11-C89 A5-B11-C90 A5-B11-C91 A5-B11-C92 A5-B11-C93 A5-B11-C94 A5-B11-C95 A5-B11-C96
A5-B11-C97 A5-B11-C98 A5-B11-C99 A5-B11-C100 A5-B11-C101 A5-B11-C102
A5-B11-C103 A5-B11-C104 A5-B11-C105 A5-B11-C106 A5-B11-C107 A5-B11-C108
A5-B11-C109 A5-B11-C110 A5-B11-C111 A5-B11-C112 A5-B11-C113 A5-B11-C114
A5-B11-C115 A5-B11-C116 A5-B11-C117 A5-B11-C118 A5-B11-C119 A5-B11-C120 A5-B11-C121 A5-B11-C122 A5-B11-C123 A5-B11-C124 A5-B11-C125 A5-B11-C126
A5-B11-C127 A5-B11-C128 A5-B11-C129 A5-B11-C130 A5-B11-C131 A5-B11-C132
A5-B11-C133 A5-B11-C134 A5-B11-C135 A5-B11-C136 A5-B11-C137 A5-B11-C138
A5-B11-C139 A5-B11-C140 BLANK BLANK BLANK BLANK
A5-B12-C1 A5-B12-C2 A5-B12-C3 A5-B12-C4 A5-B12-C5 A5-B12-C6 A5-B12-C7 A5-B12-C8 A5-B12-C9 A5-B12-C10 A5-B12-C11 A5-B12-C12
A5-B12-C13 A5-B12-C14 A5-B12-C15 A5-B12-C16 A5-B12-C17 A5-B12-C18
A5-B12-C19 A5-B12-C20 A5-B12-C21 A5-B12-C22 A5-B12-C23 A5-B12-C24
A5-B12-C25 A5-B12-C26 A5-B12-C27 A5-B12-C28 A5-B12-C29 A5-B12-C30
A5-B12-C31 A5-B12-C32 A5-B12-C33 A5-B12-C34 A5-B12-C35 A5-B12-C36 A5-B12-C37 A5-B12-C38 A5-B12-C39 A5-B12-C40 A5-B12-C41 A5-B12-C42
A5-B12-C43 A5-B12-C44 A5-B12-C45 A5-B12-C46 A5-B12-C47 A5-B12-C48
A5-B12-C49 A5-B12-C50 A5-B12-C51 A5-B12-C52 A5-B12-C53 A5-B12-C54
A5-B12-C55 A5-B12-C56 A5-B12-C57 A5-B12-C58 A5-B12-C59 A5-B12-C60
A5-B12-C61 A5-B12-C62 A5-B12-C63 A5-B12-C64 A5-B12-C65 A5-B12-C66 A5-B12-C67 A5-B12-C68 A5-B12-C69 A5-B12-C70 A5-B12-C71 A5-B12-C72
A5-B12-C73 A5-B12-C74 A5-B12-C75 A5-B12-C76 A5-B12-C77 A5-B12-C78
A5-B12-C79 A5-B12-C80 A5-B12-C81 A5-B12-C82 A5-B12-C83 A5-B12-C84
A5-B12-C85 A5-B12-C86 A5-B12-C87 A5-B12-C88 A5-B12-C89 A5-B12-C90
A5-B12-C91 A5-B12-C92 A5-B12-C93 A5-B12-C94 A5-B12-C95 A5-B12-C96 A5-B12-C97 A5-B12-C98 A5-B12-C99 A5-B12-C100 A5-B12-C101 A5-B12-C102
A5-B12-C103 A5-B12-C104 A5-B12-C105 A5-B12-C106 A5-B12-C107 A5-B12-C108
A5-B12-C109 A5-B12-C110 A5-B12-C111 A5-B12-C112 A5-B12-C113 A5-B12-C114
A5-B12-C115 A5-B12-C116 A5-B12-C117 A5-B12-C118 A5-B12-C119 A5-B12-C120
A5-B12-C121 A5-B12-C122 A5-B12-C123 A5-B12-C124 A5-B12-C125 A5-B12-C126 A5-B12-C127 A5-B12-C128 A5-B12-C129 A5-B12-C130 A5-B12-C131 A5-B12-C132
A5-B12-C133 A5-B12-C134 A5-B12-C135 A5-B12-C136 A5-B12-C137 A5-B12-C138
A5-B12-C139 A5-B12-C140 BLANK BLANK BLANK BLANK
A5-B13-C1 A5-B13-C2 A5-B13-C3 A5-B13-C4 A5-B13-C5 A5-B13-C6
A5-B13-C7 A5-B13-C8 A5-B13-C9 A5-B13-C10 A5-B13-C11 A5-B13-C12
A5-B13-C13 A5-B13-C14 A5-B13-C15 A5-B13-C16 A5-B13-C17 A5-B13-C18
A5-B13-C19 A5-B13-C20 A5-B13-C21 A5-B13-C22 A5-B13-C23 A5-B13-C24 A5-B13-C25 A5-B13-C26 A5-B13-C27 A5-B13-C28 A5-B13-C29 A5-B13-C30
A5-B13-C31 A5-B13-C32 A5-B13-C33 A5-B13-C34 A5-B13-C35 A5-B13-C36
A5-B13-C37 A5-B13-C38 A5-B13-C39 A5-B13-C40 A5-B13-C41 A5-B13-C42
A5-B13-C43 A5-B13-C44 A5-B13-C45 A5-B13-C46 A5-B13-C47 A5-B13-C48
A5-B13-C49 A5-B13-C50 A5-B13-C51 A5-B13-C52 A5-B13-C53 A5-B13-C54 A5-B13-C55 A5-B13-C56 A5-B13-C57 A5-B13-C58 A5-B13-C59 A5-B13-C60
A5-B13-C61 A5-B13-C62 A5-B13-C63 A5-B13-C64 A5-B13-C65 A5-B13-C66
A5-B13-C67 A5-B13-C68 A5-B13-C69 A5-B13-C70 A5-B13-C71 A5-B13-C72
A5-B13-C73 A5-B13-C74 A5-B13-C75 A5-B13-C76 A5-B13-C77 A5-B13-C78
A5-B13-C79 A5-B13-C80 A5-B13-C81 A5-B13-C82 A5-B13-C83 A5-B13-C84 A5-B13-C85 A5-B13-C86 A5-B13-C87 A5-B13-C88 A5-B13-C89 A5-B13-C90
A5-B13-C91 A5-B13-C92 A5-B13-C93 A5-B13-C94 A5-B13-C95 A5-B13-C96
A5-B13-C97 A5-B13-C98 A5-B13-C99 A5-B13-C100 A5-B13-C101 A5-B13-C102
A5-B13-C103 A5-B13-C104 A5-B13-C105 A5-B13-C106 A5-B13-C107 A5-B13-C108
A5-B13-C109 A5-B13-C110 A5-B13-C111 A5-B13-C112 A5-B13-C113 A5-B13-C114 A5-B13-C115 A5-B13-C116 A5-B13-C117 A5-B13-C118 A5-B13-C119 A5-B13-C120
A5-B13-C121 A5-B13-C122 A5-B13-C123 A5-B13-C124 A5-B13-C125 A5-B13-C126
A5-B13-C127 A5-B13-C128 A5-B13-C129 A5-B13-C130 A5-B13-C131 A5-B13-C132
A5-B13-C133 A5-B13-C134 A5-B13-C135 A5-B13-C136 A5-B13-C137 A5-B13-C138
A5-B13-C139 A5-B13-C140 BLANK BLANK BLANK BLANK A6-B1-C1 A6-B1-C2 A6-B1-C3 A6-B1-C4 A6-B1-C5 A6-B1-C6
A6-B1-C7 A6-B1-C8 A6-B1-C9 A6-B1-C10 A6-B1-C11 A6-B1-C12
A6-B1-C13 A6-B1-C14 A6-B1-C15 A6-B1-C16 A6-B1-C17 A6-B1-C18
A6-B1-C19 A6-B1-C20 A6-B1-C21 A6-B1-C22 A6-B1-C23 A6-B1-C24
A6-B1-C25 A6-B1-C26 A6-B1-C27 A6-B1-C28 A6-B1-C29 A6-B1-C30 A6-B1-C31 A6-B1-C32 A6-B1-C33 A6-B1-C34 A6-B1-C35 A6-B1-C36
A6-B1-C37 A6-B1-C38 A6-B1-C39 A6-B1-C40 A6-B1-C41 A6-B1-C42
A6-B1-C43 A6-B1-C44 A6-B1-C45 A6-B1-C46 A6-B1-C47 A6-B1-C48
A6-B1-C49 A6-B1-C50 A6-B1-C51 A6-B1-C52 A6-B1-C53 A6-B1-C54
A6-B1-C55 A6-B1-C56 A6-B1-C57 A6-B1-C58 A6-B1-C59 A6-B1-C60 A6-B1-C61 A6-B1-C62 A6-B1-C63 A6-B1-C64 A6-B1-C65 A6-B1-C66
A6-B1-C67 A6-B1-C68 A6-B1-C69 A6-B1-C70 A6-B1-C71 A6-B1-C72
A6-B1-C73 A6-B1-C74 A6-B1-C75 A6-B1-C76 A6-B1-C77 A6-B1-C78
A6-B1-C79 A6-B1-C80 A6-B1-C81 A6-B1-C82 A6-B1-C83 A6-B1-C84
A6-B1-C85 A6-B1-C86 A6-B1-C87 A6-B1-C88 A6-B1-C89 A6-B1-C90
A6-B1-C91 A6-B1-C92 A6-B1-C93 A6-B1-C94 A6-B1-C95 A6-B1-C96
A6-B1-C97 A6-B1-C98 A6-B1-C99 A6-B1-C100 A6-B1-C101 A6-B1-C102
A6-B1-C103 A6-B1-C104 A6-B1-C105 A6-B1-C106 A6-B1-C107 A6-B1-C108
A6-B1-C109 A6-B1-C1 10 A6-B1-C111 A6-B1-C112 A6-B1-C113 A6-B1-C114
A6-B1-C115 A6-B1-C116 A6-B1-C117 A6-B1-C118 A6-B1-C119 A6-B1-C120
A6-B1-C121 A6-B1-C122 A6-B1-C123 A6-B1-C124 A6-B1-C125 A6-B1-C126
A6-B1-C127 A6-B1-C128 A6-B1-C129 A6-B1-C130 A6-B1-C131 A6-B1-C132
A6-B1-C133 A6-B1-C134 A6-B1-C135 A6-B1-C136 A6-B1-C137 A6-B1-C138
A6-B1-C139 A6-B1-C140 BLANK BLANK BLANK BLANK
A6-B2-C1 A6-B2-C2 A6-B2-C3 A6-B2-C4 A6-B2-C5 A6-B2-C6
A6-B2-C7 A6-B2-C8 A6-B2-C9 A6-B2-C10 A6-B2-C11 A6-B2-C12
A6-B2-C13 A6-B2-C14 A6-B2-C15 A6-B2-C16 A6-B2-C17 A6-B2-C18
A6-B2-C19 A6-B2-C20 A6-B2-C21 A6-B2-C22 A6-B2-C23 A6-B2-C24
A6-B2-C25 A6-B2-C26 A6-B2-C27 A6-B2-C28 A6-B2-C29 A6-B2-C30
A6-B2-C31 A6-B2-C32 A6-B2-C33 A6-B2-C34 A6-B2-C35 A6-B2-C36
A6-B2-C37 A6-B2-C38 A6-B2-C39 A6-B2-C40 A6-B2-C41 A6-B2-C42
A6-B2-C43 A6-B2-C44 A6-B2-C45 A6-B2-C46 A6-B2-C47 A6-B2-C48
A6-B2-C49 A6-B2-C50 A6-B2-C51 A6-B2-C52 A6-B2-C53 A6-B2-C54
A6-B2-C55 A6-B2-C56 A6-B2-C57 A6-B2-C58 A6-B2-C59 A6-B2-C60
A6-B2.-C61 A6-B2-C62 A6-B2-C63 A6-B2-C64 A6-B2-C65 A6-B2-C66
A6-B2-C67 A6-B2-C68 A6-B2-C69 A6-B2-C70 A6-B2-C71 A6-B2-C72
A6-B2-C73 A6-B2-C74 A6-B2-C75 A6-B2-C76 A6-B2-C77 A6-B2-C78
A6-B2-C79 A6-B2-C80 A6-B2-C81 A6-B2-C82 A6-B2-C83 A6-B2-C84
A6-B2-C85 A6-B2-C86 A6-B2-C87 A6-B2-C88 A6-B2-C89 A6-B2-C90
A6-B2-C91 A6-B2-C92 A6-B2-C93 A6-B2-C94 A6-B2-C95 A6-B2-C96
A6-B2-C97 A6-B2-C98 A6-B2-C99 A6-B2-C100 A6-B2-C101 A6-B2-C102
A6-B2-C103 A6-B2-C104 A6-B2-C105 A6-B2-C106 A6-B2-C107 A6-B2-C108
A6-B2-C109 A6-B2-C110 A6-B2-C111 A6-B2-C112 A6-B2-C113 A6-B2-C114
A6-B2-C115 A6-B2-C116 A6-B2-C117 A6-B2-C118 A6-B2-C119 A6-B2-C120
A6-B2-C121 A6-B2-C122 A6-B2-C123 A6-B2-C124 A6-B2-C125 A6-B2-C126
A6-B2-C127 A6-B2-C128 A6-B2-C129 A6-B2-C130 A6-B2-C131 A6-B2-C132
A6-B2-C133 A6-B2-C134 A6-B2-C135 A6-B2-C136 A6-B2-C137 A6-B2-C138
A6-B2-C139 A6-B2-C140 BLANK BLANK BLANK BLANK
A6-B3-C1 A6-B3-C2 A6-B3-C3 A6-B3-C4 A6-B3-C5 A6-B3-C6
A6-B3-C7 A6-B3-C8 A6-B3-C9 A6-B3-C10 A6-B3-C11 A6-B3-C12
A6-B3-C13 A6-B3-C14 A6-B3-C15 A6-B3-C16 A6-B3-C17 A6-B3-C18
A6-B3-C19 A6-B3-C20 A6-B3-C21 A6-B3-C22 A6-B3-C23 A6-B3-C24
A6-B3-C25 A6-B3-C26 A6-B3-C27 A6-B3-C28 A6-B3-C29 A6-B3-C30
A6-B3-C31 A6-B3-C32 A6-B3-C33 A6-B3-C34 A6-B3-C35 A6-B3-C36
A6-B3-C37 A6-B3-C38 A6-B3-C39 A6-B3-C40 A6-B3-C41 A6-B3-C42
A6-B3-C43 A6-B3-C44 A6-B3-C45 A6-B3-C46 A6-B3-C47 A6-B3-C48
A6-B3-C49 A6-B3-C50 A6-B3-C51 A6-B3-C52 A6-B3-C53 A6-B3-C54
A6-B3-C55 A6-B3-C56 A6-B3-C57 A6-B3-C58 A6-B3-C59 A6-B3-C60
A6-B3-C61 A6-B3-C62 A6-B3-C63 A6-B3-C64 A6-B3-C65 A6-B3-C66
A6-B3-C67 A6-B3-C68 A6-B3-C69 A6-B3-C70 A6-B3-C71 A6-B3-C72
A6-B3-C73 A6-B3-C74 A6-B3-C75 A6-B3-C76 A6-B3-C77 A6-B3-C78
A6-B3-C79 A6-B3-C80 A6-B3-C81 A6-B3-C82 A6-B3-C83 A6-B3-C84
A6-B3-C85 A6-B3-C86 A6-B3-C87 A6-B3-C88 A6-B3-C89 A6-B3-C90
A6-B3-C91 A6-B3-C92 A6-B3-C93 A6-B3-C94 A6-B3-C95 A6-B3-C96
A6-B3-C97 A6-B3-C98 A6-B3-C99 A6-B3-C100 A6-B3-C101 A6-B3-C102
A6-B3-C103 A6-B3-C104 A6-B3-C105 A6-B3-C106 A6-B3-C107 A6-B3-C108
A6-B3-C109 A6-B3-C110 A6-B3-C111 A6-B3-C112 A6-B3-C113 A6-B3-C114
A6-B3-C115 A6-B3-C116 A6-B3-C117 A6-B3-C118 A6-B3-C119 A6-B3-C120
A6-B3-C121 A6-B3-C122 A6-B3-C123 A6-B3-C124 A6-B3-C125 A6-B3-C126
A6-B3-C127 A6-B3-C128 A6-B3-C129 A6-B3-C130 A6-B3-C131 A6-B3-C132
A6-B3-C133 A6-B3-C134 A6-B3-C135 A6-B3-C136 A6-B3-C137 A6-B3-C138
A6-B3-C139 A6-B3-C140 BLANK BLANK BLANK BLANK
A6-B4-C1 A6-B4-C2 A6-B4-C3 A6-B4-C4 A6-B4-C5 A6-B4-C6
A6-B4-C7 A6-B4-C8 A6-B4-C9 A6-B4-C10 A6-B4-C11 A6-B4-C12
A6-B4-C13 A6-B4-C14 A6-B4-C15 A6-B4-C16 A6-B4-C17 A6-B4-C18
A6-B4-C19 A6-B4-C20 A6-B4-C21 A6-B4-C22 A6-B4-C23 A6-B4-C24
A6-B4-C25 A6-B4-C26 A6-B4-C27 A6-B4-C28 A6-B4-C29 A6-B4-C30
A6-B4-C31 A6-B4-C32 A6-B4-C33 A6-B4-C34 A6-B4-C35 A6-B4-C36
A6-B4-C37 A6-B4-C38 A6-B4-C39 A6-B4-C40 A6-B4-C41 A6-B4-C42.
A6-B4-C43 A6-B4-C44 A6-B4-C45 A6-B4-C46 A6-B4-C47 A6-B4-C48
A6-B4-C49 A6-B4-C50 A6-B4-C51 A6-B4-C52 A6-B4-C53 A6-B4-C54
A6-B4-C55 A6-B4-C56 A6-B4-C57 A6-B4-C58 A6-B4-C59 A6-B4-C60
A6-B4-C61 A6-B4-C62 A6-B4-C63 A6-B4-C64 A6-B4-C65 A6-B4-C66
A6-B4-C67 A6-B4-C68 A6-B4-C69 A6-B4-C70 A6-B4-C71 A6-B4-C72
A6-B4-C73 A6-B4-C74 A6-B4-C75 A6-B4-C76 A6-B4-C77 A6-B4-C78
A6-B4-C79 A6-B4-C80 A6-B4-C81 A6-B4-C82 A6-B4-C83 A6-B4-C84
A6-B4-C85 A6-B4-C86 A6-B4-C87 A6-B4-C88 A6-B4-C89 A6-B4-C90
A6-B4-C91 A6-B4-C92 A6-B4-C93 A6-B4-C94 A6-B4-C95 A6-B4-C96
A6-B4-C97 A6-B4-C98 A6-B4-C99 A6-B4-C100 A6-B4-C101 A6-B4-C102
A6-B4-C103 A6-B4-C104 A6-B4-C105 A6-B4-C106 A6-B4-C107 A6-B4-C108
A6-B4-C109 A6-B4-C110 A6-B4-C1 11 A6-B4-C112 A6-B4-C113 A6-B4-C114
A6-B4-C115 A6-B4-C116 A6-B4-C117 A6-B4-C118 A6-B4-C119 A6-B4-C120
A6-B4-C121 A6-B4-C122 A6-B4-C123 A6-B4-C124 A6-B4-C125 A6-B4-C126
A6-B4-C127 A6-B4-C128 A6-B4-C129 A6-B4-C130 A6-B4-C131 A6-B4-C132
A6-B4-C133 A6-B4-C134 A6-B4-C135 A6-B4-C136 A6-B4-C137 A6-B4-C138
A6-B4-C139 A6-B4-C140 BLANK BLANK BLANK BLANK
A6-B5-C1 A6-B5-C2 A6-B5-C3 A6-B5-C4 A6-B5-C5 A6-B5-C6
A6-B5-C7 A6-B5-C8 A6-B5-C9 A6-B5-C10 A6-B5-C11 A6-B5-C12
A6-B5-C13 A6-B5-C14 A6-B5-C15 A6-B5-C16 A6-B5-C17 A6-B5-C18
A6-B5-C19 A6-B5-C20 A6-B5-C21 A6-B5-C22 A6-B5-C23 A6-B5-C24
A6-B5-C25 A6-B5-C26 A6-B5-C27 A6-B5-C28 A6-B5-C29 A6-B5-C30
A6-B5-C31 A6-B5-C32 A6-B5-C33 A6-B5-C34 A6-B5-C35 A6-B5-C36
A6-B5-C37 A6-B5-C38 A6-B5-C39 A6-B5-C40 A6-B5-C41 A6-B5-C42
A6-B5-C43 A6-B5-C44 A6-B5-C45 A6-B5-C46 A6-B5-C47 A6-B5-C48
A6-B5-C49 A6-B5-C50 A6-B5-C51 A6-B5-C52 A6-B5-C53 A6-B5-C54
A6-B5-C55 A6-B5-C56 A6-B5-C57 A6-B5-C58 A6-B5-C59 A6-B5-C60
A6-B5-C61 A6-B5-C62 A6-B5-C63 A6-B5-C64 A6-B5-C65 A6-B5-C66
A6-B5-C67 A6-B5-C68 A6-B5-C69 A6-B5-C70 A6-B5-C71 A6-B5-C72
A6-B5-C73 A6-B5-C74 A6-B5-C75 A6-B5-C76 A6-B5-C77 A6-B5-C78
A6-B5-C79 A6-B5-C80 A6-B5-C81 A6-B5-C82 A6-B5-C83 A6-B5-C84
A6-B5-C85 A6-B5-C86 A6-B5-C87 A6-B5-C88 A6-B5-C89 A6-B5-C90
A6-B5-C91 A6-B5-C92 A6-B5-C93 A6-B5-C94 A6-B5-C95 A6-B5-C96
A6-B5-C97 A6-B5-C98 A6-B5-C99 A6-B5-C100 A6-B5-C101 A6-B5-C102
A6-B5-C103 A6-B5-C104 A6-B5-C105 A6-B5-C106 A6-B5-C107 A6-B5-C108
A6-B5-C109 A6-B5-C110 A6-B5-C111 A6-B5-C112 A6-B5-C113 A6-B5-C114
A6-B5-C115 A6-B5-C116 A6-B5-C117 A6-B5-C118 A6-B5-C119 A6-B5-C120
A6-B5-C121 A6-B5-C122 A6-B5-C123 A6-B5-C124 A6-B5-C125 A6-B5-C126
A6-B5-C127 A6-B5-C128 A6-B5-C129 A6-B5-C130 A6-B5-C131 A6-B5-C132
A6-B5-C133 A6-B5-C134 A6-B5-C135 A6-B5-C136 A6-B5-C137 A6-B5-C138
A6-B5-C139 A6-B5-C140 BLANK BLANK BLANK BLANK
A6-B6-C1 A6-B6-C2 A6-B6-C3 A6-B6-C4 A6-B6-C5 A6-B6-C6
A6-B6-C7 A6-B6-C8 A6-B6-C9 A6-B6-C10 A6-B6-C11 A6-B6-C12
A6-B6-C13 A6-B6-C14 A6-B6-C15 A6-B6-C16 A6-B6-C17 A6-B6-C18
A6-B6-C19 A6-B6-C20 A6-B6-C21 A6-B6-C22 A6-B6-C23 A6-B6-C24
A6-B6-C25 A6-B6-C26 A6-B6-C27 A6-B6-C28 A6-B6-C29 A6-B6-C30
A6-B6-C31 A6-B6-C32 A6-B6-C33 A6-B6-C34 A6-B6-C35 A6-B6-C36
A6-B6-C37 A6-B6-C38 A6-B6-C39 A6-B6-C40 A6-B6-C41 A6-B6-C42
A6-B6-C43 A6-B6-C44 A6-B6-C45 A6-B6-C46 A6-B6-C47 A6-B6-C48
A6-B6-C49 A6-B6-C50 A6-B6-C51 A6-B6-C52 A6-B6-C53 A6-B6-C54
A6-B6-C55 A6-B6-C56 A6-B6-C57 A6-B6-C58 A6-B6-C59 A6-B6-C60
A6-B6-C61 A6-B6-C62 A6-B6-C63 A6-B6-C64 A6-B6-C65 A6-B6-C66
A6-B6-C67 A6-B6-C68 A6-B6-C69 A6-B6-C70 A6-B6-C71 A6-B6-C72
A6-B6-C73 A6-B6-C74 A6-B6-C75 A6-B6-C76 A6-B6-C77 A6-B6-C78
A6-B6-C79 A6-B6-C80 A6-B6-C81 A6-B6-C82 A6-B6-C83 A6-B6-C84
A6-B6-C85 A6-B6-C86 A6-B6-C87 A6-B6-C88 A6-B6-C89 A6-B6-C90
A6-B6-C91 A6-B6-C92 A6-B6-C93 A6-B6-C94 A6-B6-C95 A6-B6-C96
A6-B6-C97 A6-B6-C98 A6-B6-C99 A6-B6-C100 A6-B6-C101 A6-B6-C102
A6-B6-C103 A6-B6-C104 A6-B6-C105 A6-B6-C106 A6-B6-C107 A6-B6-C108
A6-B6-C109 A6-B6-C110 A6-B6-C111 A6-B6-C1 12 A6-B6-C113 A6-B6-C114
A6-B6-C115 A6-B6-C116 A6-B6-C117 A6-B6-C1 18 A6-B6-C119 A6-B6-C120
A6-B6-C121 A6-B6-C122 A6-B6-C123 A6-B6-C124 A6-B6-C125 A6-B6-C126
A6-B6-C127 A6-B6-C128 A6-B6-C129 A6-B6-C130 A6-B6-C131 A6-B6-C132
A6-B6-C133 A6-B6-C134 A6-B6-C135 A6-B6-C136 A6-B6-C137 A6-B6-C138
A6-B6-C139 A6-B6-C140 BLANK BLANK BLANK BLANK
A6-B7-C1 A6-B7-C2 A6-B7-C3 A6-B7-C4 A6-B7-C5 A6-B7-C6
A6-B7-C7 A6-B7-C8 A6-B7-C9 A6-B7-C10 A6-B7-C11 A6-B7-C12
A6-B7-C13 A6-B7-C14 A6-B7-C15 A6-B7-C16 A6-B7-C17 A6-B7-C18
A6-B7-C19 A6-B7-C20 A6-B7-C21 A6-B7-C22 A6-B7-C23 A6-B7-C24
A6-B7-C25 A6-B7-C26 A6-B7-C27 A6-B7-C28 A6-B7-C29 A6-B7-C30
A6-B7-C31 A6-B7-C32 A6-B7-C33 A6-B7-C34 A6-B7-C35 A6-B7-C36
A6-B7-C37 A6-B7-C38 A6-B7-C39 A6-B7-C40 A6-B7-C41 A6-B7-C42
A6-B7-C43 A6-B7-C44 A6-B7-C45 A6-B7-C46 A6-B7-C47 A6-B7-C48
A6-B7-C49 A6-B7-C50 A6-B7-C51 A6-B7-C52 A6-B7-C53 A6-B7-C54
A6-B7-C55 A6-B7-C56 A6-B7-C57 A6-B7-C58 A6-B7-C59 A6-B7-C60
A6-B7-C61 A6-B7-C62 A6-B7-C63 A6-B7-C64 A6-B7-C65 A6-B7-C66
A6-B7-C67 A6-B7-C68 A6-B7-C69 A6-B7-C70 A6-B7-C71 A6-B7-C72
A6-B7-C73 A6-B7-C74 A6-B7-C75 A6-B7-C76 A6-B7-C77 A6-B7-C78
A6-B7-C79 A6-B7-C80 A6-B7-C81 A6-B7-C82 A6-B7-C83 A6-B7-C84
A6-B7-C85 A6-B7-C86 A6-B7-C87 A6-B7-C88 A6-B7-C89 A6-B7-C90
A6-B7-C91 A6-B7-C92 A6-B7-C93 A6-B7-C94 A6-B7-C95 A6-B7-C96
A6-B7-C97 A6-B7-C98 A6-B7-C99 A6-B7-C100 A6-B7-C101 A6-B7-C102
A6-B7-C103 A6-B7-C104 A6-B7-C105 A6-B7-C106 A6-B7-C107 A6-B7-C108
A6-B7-C109 A6-B7-C110 A6-B7-C111 A6-B7-C112 A6-B7-C1 13 A6-B7-C114
A6-B7-C1 15 A6-B7-C116 A6-B7-C117 A6-B7-C118 A6-B7-C119 A6-B7-C120
A6-B7-C121 A6-B7-C122 A6-B7-C123 A6-B7-C124 A6-B7-C125 A6-B7-C126
A6-B7-C127 A6-B7-C128 A6-B7-C129 A6-B7-C130 A6-B7-C131 A6-B7-C132
A6-B7-C133 A6-B7-C134 A6-B7-C135 A6-B7-C136 A6-B7-C137 A6-B7-C138
A6-B7-C139 A6-B7-C140 BLANK BLANK BLANK BLANK
A6-B8-C1 A6-B8-C2 A6-B8-C3 A6-B8-C4 A6-B8-C5 A6-B8-C6
A6-B8-C7 A6-B8-C8 A6-B8-C9 A6-B8-C10 A6-B8-C11 A6-B8-C12
A6-B8-C13 A6-B8-C14 A6-B8-C15 A6-B8-C16 A6-B8-C17 A6-B8-C18
A6-B8-C19 A6-B8-C20 A6-B8-C21 A6-B8-C22 A6-B8-C23 A6-B8-C24
A6-B8-C25 A6-B8-C26 A6-B8-C27 A6-B8-C28 A6-B8-C29 A6-B8-C30
A6-B8-C31 A6-B8-C32 A6-B8-C33 A6-B8-C34 A6-B8-C35 A6-B8-C36
A6-B8-C37 A6-B8-C38 A6-B8-C39 A6-B8-C40 A6-B8-C41 A6-B8-C42
A6-B8-C43 A6-B8-C44 A6-B8-C45 A6-B8-C46 A6-B8-C47 A6-B8-C48
A6-B8-C49 A6-B8-C50 A6-B8-C51 A6-B8-C52 A6-B8-C53 A6-B8-C54
A6-B8-C55 A6-B8-C56 A6-B8-C57 A6-B8-C58 A6-B8-C59 A6-B8-C60
A6-B8-C61 A6-B8-C62 A6-B8-C63 A6-B8-C64 A6-B8-C65 A6-B8-C66
A6-B8-C67 A6-B8-C68 A6-B8-C69 A6-B8-C70 A6-B8-C71 A6-B8-C72
A6-B8-C73 A6-B8-C74 A6-B8-C75 A6-B8-C76 A6-B8-C77 A6-B8-C78
A6-B8-C79 A6-B8-C80 A6-B8-C81 A6-B8-C82 A6-B8-C83 A6-B8-C84
A6-B8-C85 A6-B8-C86 A6-B8-C87 A6-B8-C88 A6-B8-C89 A6-B8-C90
A6-B8-C91 A6-B8-C92 A6-B8-C93 A6-B8-C94 A6-B8-C95 A6-B8-C96
A6-B8-C97 A6-B8-C98 A6-B8-C99 A6-B8-C100 A6-B8-C101 A6-B8-C102
A6-B8-C103 A6-B8-C104 A6-B8-C105 A6-B8-C106 A6-B8-C107 A6-B8-C108
A6-B8-C109 A6-B8-C110 A6-B8-C111 A6-B8-C112 A6-B8-C113 A6-B8-C114
A6-B8-C115 A6-B8-C116 A6-B8-C117 A6-B8-C118 A6-B8-C119 A6-B8-C120
A6-B8-C121 A6-B8-C122 A6-B8-C123 A6-B8-C124 A6-B8-C125 A6-B8-C126
A6-B8-C127 A6-B8-C128 A6-B8-C129 A6-B8-C130 A6-B8-C131 A6-B8-C132
A6-B8-C133 A6-B8-C134 A6-B8-C135 A6-B8-C136 A6-B8-C137 A6-B8-C138
A6-B8-C139 A6-B8-C140 BLANK BLANK BLANK BLANK
A6-B9-C1 A6-B9-C2 A6-B9-C3 A6-B9-C4 A6-B9-C5 A6-B9-C6
A6-B9-C7 A6-B9-C8 A6-B9-C9 A6-B9-C10 A6-B9-C11 A6-B9-C12
A6-B9-C13 A6-B9-C14 A6-B9-C15 A6-B9-C16 A6-B9-C17 A6-B9-C18
A6-B9-C19 A6-B9-C20 A6-B9-C21 A6-B9-C22 A6-B9-C23 A6-B9-C24
A6-B9-C25 A6-B9-C26 A6-B9-C27 A6-B9-C28 A6-B9-C29 A6-B9-C30
A6-B9-C31 A6-B9-C32 A6-B9-C33 A6-B9-C34 A6-B9-C35 A6-B9-C36
A6-B9-C37 A6-B9-C38 A6-B9-C39 A6-B9-C40 A6-B9-C41 A6-B9-C42
A6-B9-C43 A6-B9-C44 A6-B9-C45 A6-B9-C46 A6-B9-C47 A6-B9-C48
A6-B9-C49 A6-B9-C50 A6-B9-C51 A6-B9-C52 A6-B9-C53 A6-B9-C54
A6-B9-C55 A6-B9-C56 A6-B9-C57 A6-B9-C58 A6-B9-C59 A6-B9-C60 A6-B9-C61 A6-B9-C62 A6-B9-C63 A6-B9-C64 A6-B9-C65 A6-B9-C66
A6-B9-C67 A6-B9-C68 A6-B9-C69 A6-B9-C70 A6-B9-C71 A6-B9-C72
A6-B9-C73 A6-B9-C74 A6-B9-C75 A6-B9-C76 A6-B9-C77 A6-B9-C78
A6-B9-C79 A6-B9-C80 A6-B9-C81 A6-B9-C82 A6-B9-C83 A6-B9-C84
A6-B9-C85 A6-B9-C86 A6-B9-C87 A6-B9-C88 A6-B9-C89 A6-B9-C90 A6-B9-C91 A6-B9-C92 A6-B9-C93 A6-B9-C94 A6-B9-C95 A6-B9-C96
A6-B9-C97 A6-B9-C98 A6-B9-C99 A6-B9-C100 A6-B9-C101 A6-B9-C102
A6-B9-C103 A6-B9-C104 A6-B9-C105 A6-B9-C106 A6-B9-C107 A6-B9-C108
A6-B9-C109 A6-B9-C110 A6-B9-C111 A6-B9-C112 A6-B9-C113 A6-B9-C114
A6-B9-C115 A6-B9-C116 A6-B9-C117 A6-B9-C118 A6-B9-C119 A6-B9-C120 A6-B9-C121 A6-B9-C122 A6-B9-C123 A6-B9-C124 A6-B9-C125 A6-B9-C126
A6-B9-C127 A6-B9-C128 A6-B9-C129 A6-B9-C130 A6-B9-C131 A6-B9-C132
A6-B9-C133 A6-B9-C134 A6-B9-C135 A6-B9-C136 A6-B9-C137 A6-B9-C138
A6-B9-C139 A6-B9-C140 BLANK BLANK BLANK BLANK
A6-B10-C1 A6-B10-C2 A6-B10-C3 A6-B10-C4 A6-B10-C5 A6-B10-C6 A6-B10-C7 A6-B10-C8 A6-B10-C9 A6-B10-C10 A6-B10-C11 A6-B10-C12
A6-B10-C13 A6-B10-C14 A6-B10-C15 A6-B10-C16 A6-B10-C17 A6-B10-C18
A6-B10-C19 A6-B10-C20 A6-B10-C21 A6-B10-C22 A6-B10-C23 A6-B10-C24
A6-B10-C25 A6-B10-C26 A6-B10-C27 A6-B10-C28 A6-B10-C29 A6-B10-C30
A6-B10-C31 A6-B10-C32 A6-B10-C33 A6-B10-C34 A6-B10-C35 A6-B10-C36 A6-B10-C37 A6-B10-C38 A6-B10-C39 A6-B10-C40 A6-B10-C41 A6-B10-C42
A6-B10-C43 A6-B10-C44 A6-B10-C45 A6-B10-C46 A6-B10-C47 A6-B10-C48
A6-B10-C49 A6-B10-C50 A6-B10-C51 A6-B10-C52 A6-B10-C53 A6-B10-C54
A6-B10-C55 A6-B10-C56 A6-B10-C57 A6-B10-C58 A6-B10-C59 A6-B10-C60
A6-B10-C61 A6-B10-C62 A6-B10-C63 A6-B10-C64 A6-B10-C65 A6-B10-C66 A6-B10-C67 A6-B10-C68 A6-B10-C69 A6-B10-C70 A6-B10-C71 A6-B10-C72
A6-B10-C73 A6-B10-C74 A6-B10-C75 A6-B10-C76 A6-B10-C77 A6-B10-C78
A6-B10-C79 A6-B10-C80 A6-B10-C81 A6-B10-C82 A6-B10-C83 A6-B10-C84
A6-B10-C85 A6-B10-C86 A6-B10-C87 A6-B10-C88 A6-B10-C89 A6-B10-C90
A6-B10-C91 A6-B10-C92 A6-B10-C93 A6-B10-C94 A6-B10-C95 A6-B10-C96 A6-B10-C97 A6-B10-C98 A6-B10-C99 A6-B10-C100 A6-B10-C101 A6-B10-C102
A6-B10-C103 A6-B10-C104 A6-B10-C105 A6-B10-C106 A6-B10-C107 A6-B10-C108
A6-B10-C109 A6-B10-C1 10 A6-B10-C111 A6-B10-C112 A6-B10-C113 A6-B10-C114
A6-B10-C115 A6-B10-C116 A6-B10-C117 A6-B10-C118 A6-B10-C119 A6-B10-C120
A6-B10-C121 A6-B10-C122 A6-B10-C123 A6-B10-C124 A6-B10-C125 A6-B10-C126
A6-B10-C127 A6-B10-C128 A6-B10-C129 A6-B10-C130 A6-B10-C131 A6-B10-C132
A6-B10-C133 A6-B10-C134 A6-B10-C135 A6-B10-C136 A6-B10-C137 A6-B10-C138 A6-B10-C139 A6-B10-C140 BLANK BLANK BLANK BLANK
A6-B11-C1 A6-B11-C2 A6-B11-C3 A6-B11-C4 A6-B11-C5 A6-B11-C6
A6-B11-C7 A6-B11-C8 A6-B11-C9 A6-B11-C10 A6-B11-C11 A6-B11-C12
A6-B11-C13 A6-B11-C14 A6-B11-C15 A6-B11-C16 A6-B11-C17 A6-B11-C18
A6-B11-C19 A6-B11-C20 A6-B11-C21 A6-B11-C22 A6-B11-C23 A6-B11-C24 A6-B11-C25 A6-B11-C26 A6-B11-C27 A6-B11-C28 A6-B11-C29 A6-B11-C30
A6-B11-C31 A6-B11-C32 A6-B11-C33 A6-B11-C34 A6-B11-C35 A6-B11-C36
A6-B11-C37 A6-B11-C38 A6-B11-C39 A6-B11-C40 A6-B11-C41 A6-B11-C42
A6-B11-C43 A6-B11-C44 A6-B11-C45 A6-B11-C46 A6-B11-C47 A6-B11-C48
A6-B11-C49 A6-B11-C50 A6-B11-C51 A6-B11-C52 A6-B11-C53 A6-B11-C54 A6-B11-C55 A6-B11-C56 A6-B11-C57 A6-B11-C58 A6-B11-C59 A6-B11-C60
A6-B11-C61 A6-B11-C62 A6-B11-C63 A6-B11-C64 A6-B11-C65 A6-B11-C66
A6-B11-C67 A6-B11-C68 A6-B11-C69 A6-B11-C70 A6-B11-C71 A6-B11-C72
A6-B11-C73 A6-B11-C74 A6-B11-C75 A6-B11-C76 A6-B11-C77 A6-B11-C78
A6-B11-C79 A6-B11-C80 A6-B11-C81 A6-B11-C82 A6-B11-C83 A6-B11-C84 A6-B11-C85 A6-B11-C86 A6-B11-C87 A6-B11-C88 A6-B11-C89 A6-B11-C90
A6-B11-C91 A6-B11-C92 A6-B11-C93 A6-B11-C94 A6-B11-C95 A6-B11-C96
A6-B11-C97 A6-B11-C98 A6-B11-C99 A6-B11-C100 A6-B11-C101 A6-B11-C102
A6-B11-C103 A6-B11-C104 A6-B11-C105 A6-B11-C106 A6-B11-C107 A6-B11-C108
A6-B11-C109 A6-B11-C110 A6-B11-C111 A6-B11-C112 A6-B11-C113 A6-B11-C1 14 A6-B11-C115 A6-B11-C116 A6-B11-C117 A6-B11-C118 A6-B11-C119 A6-B11-C120
A6-B11-C121 A6-B11-C122 A6-B11-C123 A6-B11-C124 A6-B11-C125 A6-B11-C126
A6-B11-C127 A6-B11-C128 A6-B11-C129 A6-B11-C130 A6-B11-C131 A6-B11-C132
A6-B11-C133 A6-B11-C134 A6-B11-C135 A6-B11-C136 A6-B11-C137 A6-B11-C138
A6-B11-C139 A6-B11-C140 BLANK BLANK BLANK BLANK A6-B12-C1 A6-B12-C2 A6-B12-C3 A6-B12-C4 A6-B12-C5 A6-B12-C6
A6-B12-C7 A6-B12-C8 A6-B12-C9 A6-B12-C10 A6-B12-C11 A6-B12-C12
A6-B12-C13 A6-B12-C14 A6-B12-C15 A6-B12-C16 A6-B12-C17 A6-B12-C18
A6-B12-C19 A6-B12-C20 A6-B12-C21 A6-B12-C22 A6-B12-C23 A6-B12-C24
A6-B12-C25 A6-B12-C26 A6-B12-C27 A6-B12-C28 A6-B12-C29 A6-B12-C30 A6-B12-C31 A6-B12-C32 A6-B12-C33 A6-B12-C34 A6-B12-C35 A6-B12-C36
A6-B12-C37 A6-B12-C38 A6-B12-C39 A6-B12-C40 A6-B12-C41 A6-B12-C42
A6-B12-C43 A6-B12-C44 A6-B12-C45 A6-B12-C46 A6-B12-C47 A6-B12-C48
A6-B12-C49 A6-B12-C50 A6-B12-C51 A6-B12-C52 A6-B12-C53 A6-B12-C54
A6-B12-C55 A6-B12-C56 A6-B12-C57 A6-B12-C58 A6-B12-C59 A6-B12-C60
A6-B12-C61 A6-B12-C62 A6-B12-C63 A6-B12-C64 A6-B12-C65 A6-B12-C66
A6-B12-C67 A6-B12-C68 A6-B12-C69 A6-B12-C70 A6-B12-C71 A6-B12-C72 A6-B12-C73 A6-B12-C74 A6-B12-C75 A6-B12-C76 A6-B12-C77 A6-B12-C78
A6-B12-C79 A6-B12-C80 A6-B12-C81 A6-B12-C82 A6-B12-C83 A6-B12-C84
A6-B12-C85 A6-B12-C86 A6-B12-C87 A6-B12-C88 A6-B12-C89 A6-B12-C90
A6-B12-C91 A6-B12-C92 A6-B12-C93 A6-B12-C94 A6-B12-C95 A6-B12-C96
A6-B12-C97 A6-B12-C98 A6-B12-C99 A6-B12-C100 A6-B12-C101 A6-B12-C102 A6-B12-C103 A6-B12-C104 A6-B12-C105 A6-B12-C106 A6-B12-C107 A6-B12-C108
A6-B12-C109 A6-B12-C110 A6-B12-C111 A6-B12-C112 A6-B12-C113 A6-B12-C114
A6-B12-C115 A6-B12-C116 A6-B12-C117 A6-B12-C118 A6-B12-C119 A6-B12-C120
A6-B12-C121 A6-B12-C122 A6-B12-C123 A6-B12-C124 A6-B12-C125 A6-B12-C126
A6-B12-C127 A6-B12-C128 A6-B12-C129 A6-B12-C130 A6-B12-C131 A6-B12-C132 A6-B12-C133 A6-B12-C134 A6-B12-C135 A6-B12-C136 A6-B12-C137 A6-B12-C138
A6-B12-C139 A6-B12-C140 BLANK BLANK BLANK BLANK
A6-B13-C1 A6-B13-C2 A6-B13-C3 A6-B13-C4 A6-B13-C5 A6-B13-C6
A6-B13-C7 A6-B13-C8 A6-B13-C9 A6-B13-C10 A6-B13-C11 A6-B13-C12
A6-B13-C13 A6-B13-C14 A6-B13-C15 A6-B13-C16 A6-B13-C17 A6-B13-C18 A6-B13-C19 A6-B13-C20 A6-B13-C21 A6-B13-C22 A6-B13-C23 A6-B13-C24
A6-B13-C25 A6-B13-C26 A6-B13-C27 A6-B13-C28 A6-B13-C29 A6-B13-C30
A6-B13-C31 A6-B13-C32 A6-B13-C33 A6-B13-C34 A6-B13-C35 A6-B13-C36
A6-B13-C37 A6-B13-C38 A6-B13-C39 A6-B13-C40 A6-B13-C41 A6-B13-C42
A6-B13-C43 A6-B13-C44 A6-B13-C45 A6-B13-C46 A6-B13-C47 A6-B13-C48 A6-B13-C49 A6-B13-C50 A6-B13-C51 A6-B13-C52 A6-B13-C53 A6-B13-C54
A6-B13-C55 A6-B13-C56 A6-B13-C57 A6-B13-C58 A6-B13-C59 A6-B13-C60
A6-B13-C61 A6-B13-C62 A6-B13-C63 A6-B13-C64 A6-B13-C65 A6-B13-C66
A6-B13-C67 A6-B13-C68 A6-B13-C69 A6-B13-C70 A6-B13-C71 A6-B13-C72
A6-B13-C73 A6-B13-C74 A6-B13-C75 A6-B13-C76 A6-B13-C77 A6-B13-C78 A6-B13-C79 A6-B13-C80 A6-B13-C81 A6-B13-C82 A6-B13-C83 A6-B13-C84
A6-B13-C85 A6-B13-C86 A6-B13-C87 A6-B13-C88 A6-B13-C89 A6-B13-C90
A6-B13-C91 A6-B13-C92 A6-B13-C93 A6-B13-C94 A6-B13-C95 A6-B13-C96
A6-B13-C97 A6-B13-C98 A6-B13-C99 A6-B13-C100 A6-B13-C101 A6-B13-C102
A6-B13-C103 A6-B13-C104 A6-B13-C105 A6-B13-C106 A6-B13-C107 A6-B13-C108 A6-B13-C109 A6-B13-C110 A6-B13-C111 A6-B13-C112 A6-B13-C113 A6-B13-C114
A6-B13-C115 A6-B13-C116 A6-B13-C117 A6-B13-C118 A6-B13-C119 A6-B13-C120
A6-B13-C121 A6-B13-C122 A6-B13-C123 A6-B13-C124 A6-B13-C125 A6-B13-C126
A6-B13-C127 A6-B13-C128 A6-B13-C129 A6-B13-C130 A6-B13-C131 A6-B13-C132
A6-B13-C133 A6-B13-C134 A6-B13-C135 A6-B13-C136 A6-B13-C137 A6-B13-C138
A6-B13-C139 A6-B13-C140 BLANK BLANK BLANK BLANK
A7-B1-C1 A7-B1-C2 A7-B1-C3 A7-B1-C4 A7-B1-C5 A7-B1-C6
A7-B1-C7 A7-B1-C8 A7-B1-C9 A7-B1-C10 A7-B1-C11 A7-B1-C12
A7-B1-C13 A7-B1-C14 A7-B1-C15 A7-B1-C16 A7-B1-C17 A7-B1-C18
A7-B1-C19 A7-B1-C20 A7-B1-C21 A7-B1-C22 A7-B1-C23 A7-B1-C24
A7-B1-C25 A7-B1-C26 A7-B1-C27 A7-B1-C28 A7-B1-C29 A7-B1-C30
A7-B1-C31 A7-B1-C32 A7-B1-C33 A7-B1-C34 A7-B1-C35 A7-B1-C36
A7-B1-C37 A7-B1-C38 A7-B1-C39 A7-B1-C40 A7-B1-C41 A7-B1-C42
A7-B1-C43 A7-B1-C44 A7-B1-C45 A7-B1-C46 A7-B1-C47 A7-B1-C48
A7-B1-C49 A7-B1-C50 A7-B1-C51 A7-B1-C52 A7-B1-C53 A7-B1-C54
A7-B1-C55 A7-B1-C56 A7-B1-C57 A7-B1-C58 A7-B1-C59 A7-B1-C60
A7-B1-C61 A7-B1-C62 A7-B1-C63 A7-B1-C64 A7-B1-C65 A7-B1-C66
A7-B1-C67 A7-B1-C68 A7-B1-C69 A7-B1-C70 A7-B1-C71 A7-B1-C72
A7-B1-C73 A7-B1-C74 A7-B1-C75 A7-B1-C76 A7-B1-C77 A7-B1-C78
A7-B1-C79 A7-B1-C80 A7-B1-C81 A7-B1-C82 A7-B1-C83 A7-B1-C84
A7-B1-C85 A7-B1-C86 A7-B1-C87 A7-B1-C88 A7-B1-C89 A7-B1-C90
A7-B1-C91 A7-B1-C92 A7-B1-C93 A7-B1-C94 A7-B1-C95 A7-B1-C96
A7-B1-C97 A7-B1-C98 A7-B1-C99 A7-B1-C100 A7-B1-C101 A7-B1-C102
A7-B1-C103 A7-B1-C104 A7-B1-C105 A7-B1-C106 A7-B1-C107 A7-B1-C108
A7-B1-C109 A7-B1-C110 A7-B1-C111 A7-B1-C112 A7-B1-C113 A7-B1-C114
A7-B1-C115 A7-B1-C116 A7-B1-C117 A7-B1-C118 A7-B1-C119 A7-B1-C120
A7-B1-C121 A7-B1-C122 A7-B1-C123 A7-B1-C124 A7-B1-C125 A7-B1-C126
A7-B1-C127 A7-B1-C128 A7-B1-C129 A7-B1-C130 A7-B1-C131 A7-B1-C132
A7-B1-C133 A7-B1-C134 A7-B1-C135 A7-B1-C136 A7-B1-C137 A7-B1-C138
A7-B1-C139 A7-B1-C140 BLANK BLANK BLANK BLANK
A7-B2-C1 A7-B2-C2 A7-B2-C3 A7-B2-C4 A7-B2-C5 A7-B2-C6
A7-B2-C7 A7-B2-C8 A7-B2-C9 A7-B2-C10 A7-B2-C11 A7-B2-C12
A7-B2-C13 A7-B2-C14 A7-B2-C15 A7-B2-C16 A7-B2-C17 A7-B2-C18
A7-B2-C19 A7-B2-C20 A7-B2-C21 A7-B2-C22 A7-B2-C23 A7-B2-C24
A7-B2-C25 A7-B2-C26 A7-B2-C27 A7-B2-C28 A7-B2-C29 A7-B2-C30
A7-B2-C31 A7-B2-C32 A7-B2-C33 A7-B2-C34 A7-B2-C35 A7-B2-C36
A7-B2-C37 A7-B2-C38 A7-B2-C39 A7-B2-C40 A7-B2-C41 A7-B2-C42
A7-B2-C43 A7-B2-C44 A7-B2-C45 A7-B2-C46 A7-B2-C47 A7-B2-C48
A7-B2-C49 A7-B2-C50 A7-B2-C51 A7-B2-C52 A7-B2-C53 A7-B2-C54
A7-B2-C55 A7-B2-C56 A7-B2-C57 A7-B2-C58 A7-B2-C59 A7-B2-C60
A7-B2-C61 A7-B2-C62 A7-B2-C63 A7-B2-C64 A7-B2-C65 A7-B2-C66
A7-B2-C67 A7-B2-C68 A7-B2-C69 A7-B2-C70 A7-B2-C71 A7-B2-C72
A7-B2-C73 A7-B2-C74 A7-B2-C75 A7-B2-C76 A7-B2-C77 A7-B2-C78
A7-B2-C79 A7-B2-C80 A7-B2-C81 A7-B2-C82 A7-B2-C83 A7-B2-C84
A7-B2-C85 A7-B2-C86 A7-B2-C87 A7-B2-C88 A7-B2-C89 A7-B2-C90
A7-B2-C91 A7-B2-C92 A7-B2-C93 A7-B2-C94 A7-B2-C95 A7-B2-C96
A7-B2-C97 A7-B2-C98 A7-B2-C99 A7-B2-C100 A7-B2-C101 A7-B2-C102
A7-B2-C103 A7-B2-C104 A7-B2-C105 A7-B2-C106 A7-B2-C107 A7-B2-C108
A7-B2-C109 A7-B2-C110 A7-B2-C111 A7-B2-C112 A7-B2-C113 A7-B2-C114
A7-B2-C115 A7-B2-C116 A7-B2-C117 A7-B2-C118 A7-B2-C119 A7-B2-C120
A7-B2-C121 A7-B2-C122 A7-B2-C123 A7-B2-C124 A7-B2-C125 A7-B2-C126
A7-B2-C127 A7-B2-C128 A7-B2-C129 A7-B2-C130 A7-B2-C131 A7-B2-C132
A7-B2-C133 A7-B2-C134 A7-B2-C135 A7-B2-C136 A7-B2-C137 A7-B2-C138
A7-B2-C139 A7-B2-C140 BLANK BLANK BLANK BLANK
A7-B3-C1 A7-B3-C2 A7-B3-C3 A7-B3-C4 A7-B3-C5 A7-B3-C6
A7-B3-C7 A7-B3-C8 A7-B3-C9 A7-B3-C10 A7-B3-C11 A7-B3-C12
A7-B3-C13 A7-B3-C14 A7-B3-C15 A7-B3-C16 A7-B3-C17 A7-B3-C18
A7-B3-C19 A7-B3-C20 A7-B3-C21 A7-B3-C22 A7-B3-C23 A7-B3-C24
A7-B3-C25 A7-B3-C26 A7-B3-C27 A7-B3-C28 A7-B3-C29 A7-B3-C30
A7-B3-C31 A7-B3-C32 A7-B3-C33 A7-B3-C34 A7-B3-C35 A7-B3-C36
A7-B3-C37 A7-B3-C38 A7-B3-C39 A7-B3-C40 A7-B3-C41 A7-B3-C42
A7-B3-C43 A7-B3-C44 A7-B3-C45 A7-B3-C46 A7-B3-C47 A7-B3-C48
A7-B3-C49 A7-B3-C50 A7-B3-C51 A7-B3-C52 A7-B3-C53 A7-B3-C54
A7-B3-C55 A7-B3-C56 A7-B3-C57 A7-B3-C58 A7-B3-C59 A7-B3-C60
A7-B3-C61 A7-B3-C62 A7-B3-C63 A7-B3-C64 A7-B3-C65 A7-B3-C66
A7-B3-C67 A7-B3-C68 A7-B3-C69 A7-B3-C70 A7-B3-C71 A7-B3-C72
A7-B3-C73 A7-B3-C74 A7-B3-C75 A7-B3-C76 A7-B3-C77 A7-B3-C78
A7-B3-C79 A7-B3-C80 A7-B3-C81 A7-B3-C82 A7-B3-C83 A7-B3-C84
A7-B3-C85 A7-B3-C86 A7-B3-C87 A7-B3-C88 A7-B3-C89 A7-B3-C90
A7-B3-C91 A7-B3-C92 A7-B3-C93 A7-B3-C94 A7-B3-C95 A7-B3-C96
A7-B3-C97 A7-B3-C98 A7-B3-C99 A7-B3-C100 A7-B3-C101 A7-B3-C102
A7-B3-C103 A7-B3-C104 A7-B3-C105 A7-B3-C106 A7-B3-C107 A7-B3-C108
A7-B3-C109 A7-B3-C110 A7-B3-C111 A7-B3-C112 A7-B3-C113 A7-B3-C114
A7-B3-C115 A7-B3-C116 A7-B3-C117 A7-B3-C118 A7-B3-C119 A7-B3-C120
A7-B3-C121 A7-B3-C122 A7-B3-C123 A7-B3-C124 A7-B3-C125 A7-B3-C126
A7-B3-C127 A7-B3-C128 A7-B3-C129 A7-B3-C130 A7-B3-C131 A7-B3-C132
A7-B3-C133 A7-B3-C134 A7-B3-C135 A7-B3-C136 A7-B3-C137 A7-B3-C138
A7-B3-C139 A7-B3-C140 BLANK BLANK BLANK BLANK
A7-B4-C1 A7-B4-C2 A7-B4-C3 A7-B4-C4 A7-B4-C5 A7-B4-C6
A7-B4-C7 A7-B4-C8 A7-B4-C9 A7-B4-C10 A7-B4-C11 A7-B4-C12
A7-B4-C13 A7-B4-C14 A7-B4-C15 A7-B4-C16 A7-B4-C17 A7-B4-C18
A7-B4-C19 A7-B4-C20 A7-B4-C21 A7-B4-C22 A7-B4-C23 A7-B4-C24
A7-B4-C25 A7-B4-C26 A7-B4-C27 A7-B4-C28 A7-B4-C29 A7-B4-C30
A7-B4-C31 A7-B4-C32 A7-B4-C33 A7-B4-C34 A7-B4-C35 A7-B4-C36
A7-B4-C37 A7-B4-C38 A7-B4-C39 A7-B4-C40 A7-B4-C41 A7-B4-C42
A7-B4-C43 A7-B4-C44 A7-B4-C45 A7-B4-C46 A7-B4-C47 A7-B4-C48
A7-B4-C49 A7-B4-C50 A7-B4-C51 A7-B4-C52 A7-B4-C53 A7-B4-C54
A7-B4-C55 A7-B4-C56 A7-B4-C57 A7-B4-C58 A7-B4-C59 A7-B4-C60
A7-B4-C61 A7-B4-C62 A7-B4-C63 A7-B4-C64 A7-B4-C65 A7-B4-C66
A7-B4-C67 A7-B4-C68 A7-B4-C69 A7-B4-C70 A7-B4-C71 A7-B4-C72
A7-B4-C73 A7-B4-C74 A7-B4-C75 A7-B4-C76 A7-B4-C77 A7-B4-C78
A7-B4-C79 A7-B4-C80 A7-B4-C81 A7-B4-C82 A7-B4-C83 A7-B4-C84
A7-B4-C85 A7-B4-C86 A7-B4-C87 A7-B4-C88 A7-B4-C89 A7-B4-C90
A7-B4-C91 A7-B4-C92 A7-B4-C93 A7-B4-C94 A7-B4-C95 A7-B4-C96
A7-B4-C97 A7-B4-C98 A7-B4-C99 A7-B4-C100 A7-B4-C101 A7-B4-C102
A7-B4-C103 A7-B4-C104 A7-B4-C105 A7-B4-C106 A7-B4-C107 A7-B4-C108
A7-B4-C109 A7-B4-C110 A7-B4-C111 A7-B4-C112 A7-B4-C113 A7-B4-C114
A7-B4-C115 A7-B4-C116 A7-B4-C117 A7-B4-C118 A7-B4-C119 A7-B4-C120
A7-B4-C121 A7-B4-C122 A7-B4-C123 A7-B4-C124 A7-B4-C125 A7-B4-C126
A7-B4-C127 A7-B4-C128 A7-B4-C129 A7-B4-C130 A7-B4-C131 A7-B4-C132
A7-B4-C133 A7-B4-C134 A7-B4-C135 A7-B4-C136 A7-B4-C137 A7-B4-C138
A7-B4-C139 A7-B4-C140 BLANK BLANK BLANK BLANK
A7-B5-C1 A7-B5-C2 A7-B5-C3 A7-B5-C4 A7-B5-C5 A7-B5-C6
A7-B5-C7 A7-B5-C8 A7-B5-C9 A7-B5-C10 A7-B5-C11 A7-B5-C12
A7-B5-C13 A7-B5-C14 A7-B5-C15 A7-B5-C16 A7-B5-C17 A7-B5-C18
A7-B5-C19 A7-B5-C20 A7-B5-C21 A7-B5-C22 A7-B5-C23 A7-B5-C24
A7-B5-C25 A7-B5-C26 A7-B5-C27 A7-B5-C28 A7-B5-C29 A7-B5-C30
A7-B5-C31 A7-B5-C32 A7-B5-C33 A7-B5-C34 A7-B5-C35 A7-B5-C36
A7-B5-C37 A7-B5-C38 A7-B5-C39 A7-B5-C40 A7-B5-C41 A7-B5-C42
A7-B5-C43 A7-B5-C44 A7-B5-C45 A7-B5-C46 A7-B5-C47 A7-B5-C48
A7-B5-C49 A7-B5-C50 A7-B5-C51 A7-B5-C52 A7-B5-C53 A7-B5-C54
A7-B5-C55 A7-B5-C56 A7-B5-C57 A7-B5-C58 A7-B5-C59 A7-B5-C60
A7-B5-C61 A7-B5-C62 A7-B5-C63 A7-B5-C64 A7-B5-C65 A7-B5-C66
A7-B5-C67 A7-B5-C68 A7-B5-C69 A7-B5-C70 A7-B5-C71 A7-B5-C72
A7-B5-C73 A7-B5-C74 A7-B5-C75 A7-B5-C76 A7-B5-C77 A7-B5-C78
A7-B5-C79 A7-B5-C80 A7-B5-C81 A7-B5-C82 A7-B5-C83 A7-B5-C84
A7-B5-C85 A7-B5-C86 A7-B5-C87 A7-B5-C88 A7-B5-C89 A7-B5-C90
A7-B5-C91 A7-B5-C92 A7-B5-C93 A7-B5-C94 A7-B5-C95 A7-B5-C96
A7-B5-C97 A7-B5-C98 A7-B5-C99 A7-B5-C100 A7-B5-C101 A7-B5-C102
A7-B5-C103 A7-B5-C104 A7-B5-C105 A7-B5-C106 A7-B5-C107 A7-B5-C108
A7-B5-C109 A7-B5-C110 A7-B5-C111 A7-B5-C112 A7-B5-C113 A7-B5-C114
A7-B5-C115 A7-B5-C116 A7-B5-C1 17 A7-B5-C118 A7-B5-C119 A7-B5-C120
A7-B5-C121 A7-B5-C122 A7-B5-C123 A7-B5-C124 A7-B5-C125 A7-B5-C126
A7-B5-C127 A7-B5-C128 A7-B5-C129 A7-B5-C130 A7-B5-C131 A7-B5-C132
A7-B5-C133 A7-B5-C134 A7-B5-C135 A7-B5-C136 A7-B5-C137 A7-B5-C138
A7-B5-C139 A7-B5-C140 BLANK BLANK BLANK BLANK
A7-B6-C1 A7-B6-C2 A7-B6-C3 A7-B6-C4 A7-B6-C5 A7-B6-C6
A7-B6-C7 A7-B6-C8 A7-B6-C9 A7-B6-C10 A7-B6-C11 A7-B6-C12
A7-B6-C13 A7-B6-C14 A7-B6-C15 A7-B6-C16 A7-B6-C17 A7-B6-C18
A7-B6-C19 A7-B6-C20 A7-B6-C21 A7-B6-C22 A7-B6-C23 A7-B6-C24
A7-B6-C25 A7-B6-C26 A7-B6-C27 A7-B6-C28 A7-B6-C29 A7-B6-C30
A7-B6-C31 A7-B6-C32 A7-B6-C33 A7-B6-C34 A7-B6-C35 A7-B6-C36
A7-B6-C37 A7-B6-C38 A7-B6-C39 A7-B6-C40 A7-B6-C41 A7-B6-C42
A7-B6-C43 A7-B6-C44 A7-B6-C45 A7-B6-C46 A7-B6-C47 A7-B6-C48
A7-B6-C49 A7-B6-C50 A7-B6-C51 A7-B6-C52 A7-B6-C53 A7-B6-C54
A7-B6-C55 A7-B6-C56 A7-B6-C57 A7-B6-C58 A7-B6-C59 A7-B6-C60
A7-B6-C61 A7-B6-C62 A7-B6-C63 A7-B6-C64 A7-B6-C65 A7-B6-C66
A7-B6-C67 A7-B6-C68 A7-B6-C69 A7-B6-C70 A7-B6-C71 A7-B6-C72
A7-B6-C73 A7-B6-C74 A7-B6-C75 A7-B6-C76 A7-B6-C77 A7-B6-C78
A7-B6-C79 A7-B6-C80 A7-B6-C81 A7-B6-C82 A7-B6-C83 A7-B6-C84
A7-B6-C85 A7-B6-C86 A7-B6-C87 A7-B6-C88 A7-B6-C89 A7-B6-C90
A7-B6-C91 A7-B6-C92 A7-B6-C93 A7-B6-C94 A7-B6-C95 A7-B6-C96
A7-B6-C97 A7-B6-C98 A7-B6-C99 A7-B6-C100 A7-B6-C101 A7-B6-C102
A7-B6-C103 A7-B6-C104 A7-B6-C105 A7-B6-C106 A7-B6-C107 A7-B6-C108
A7-B6-C109 A7-B6-C110 A7-B6-C111 A7-B6-C112 A7-B6-C113 A7-B6-C114
A7-B6-C115 A7-B6-C116 A7-B6-C117 A7-B6-C118 A7-B6-C119 A7-B6-C120
A7-B6-C121 A7-B6-C122 A7-B6-C123 A7-B6-C124 A7-B6-C125 A7-B6-C126
A7-B6-C127 A7-B6-C128 A7-B6-C129 A7-B6-C130 A7-B6-C131 A7-B6-C132
A7-B6-C133 A7-B6-C134 A7-B6-C135 A7-B6-C136 A7-B6-C137 A7-B6-C138
A7-B6-C139 A7-B6-C140 BLANK BLANK BLANK BLANK
A7-B7-C1 A7-B7-C2 A7-B7-C3 A7-B7-C4 A7-B7-C5 A7-B7-C6
A7-B7-C7 A7-B7-C8 A7-B7-C9 A7-B7-C10 A7-B7-C11 A7-B7-C12
A7-B7-C13 A7-B7-C14 A7-B7-C15 A7-B7-C16 A7-B7-C17 A7-B7-C18
A7-B7-C19 A7-B7-C20 A7-B7-C21 A7-B7-C22 A7-B7-C23 A7-B7-C24
A7-B7-C25 A7-B7-C26 A7-B7-C27 A7-B7-C28 A7-B7-C29 A7-B7-C30
A7-B7-C31 A7-B7-C32 A7-B7-C33 A7-B7-C34 A7-B7-C35 A7-B7-C36
A7-B7-C37 A7-B7-C38 A7-B7-C39 A7-B7-C40 A7-B7-C41 A7-B7-C42
A7-B7-C43 A7-B7-C44 A7-B7-C45 A7-B7-C46 A7-B7-C47 A7-B7-C48
A7-B7-C49 A7-B7-C50 A7-B7-C51 A7-B7-C52 A7-B7-C53 A7-B7-C54
A7-B7-C55 A7-B7-C56 A7-B7-C57 A7-B7-C58 A7-B7-C59 A7-B7-C60
A7-B7-C61 A7-B7-C62 A7-B7-C63 A7-B7-C64 A7-B7-C65 A7-B7-C66
A7-B7-C67 A7-B7-C68 A7-B7-C69 A7-B7-C70 A7-B7-C71 A7-B7-C72
A7-B7-C73 A7-B7-C74 A7-B7-C75 A7-B7-C76 A7-B7-C77 A7-B7-C78
A7-B7-C79 A7-B7-C80 A7-B7-C81 A7-B7-C82 A7-B7-C83 A7-B7-C84
A7-B7-C85 A7-B7-C86 A7-B7-C87 A7-B7-C88 A7-B7-C89 A7-B7-C90
A7-B7-C91 A7-B7-C92 A7-B7-C93 A7-B7-C94 A7-B7-C95 A7-B7-C96
A7-B7-C97 A7-B7-C98 A7-B7-C99 A7-B7-C100 A7-B7-C101 A7-B7-C102
A7-B7-C103 A7-B7-C104 A7-B7-C105 A7-B7-C106 A7-B7-C107 A7-B7-C108
A7-B7-C109 A7-B7-C110 A7-B7-C111 A7-B7-C112 A7-B7-C113 A7-B7-C114
A7-B7-C115 A7-B7-C116 A7-B7-C117 A7-B7-C118 A7-B7-C119 A7-B7-C120
A7-B7-C121 A7-B7-C122 A7-B7-C123 A7-B7-C124 A7-B7-C125 A7-B7-C126
A7-B7-C127 A7-B7-C128 A7-B7-C129 A7-B7-C130 A7-B7-C131 A7-B7-C132
A7-B7-C133 A7-B7-C134 A7-B7-C135 A7-B7-C136 A7-B7-C137 A7-B7-C138
A7-B7-C139 A7-B7-C140 BLANK BLANK BLANK BLANK
A7-B8-C1 A7-B8-C2 A7-B8-C3 A7-B8-C4 A7-B8-C5 A7-B8-C6
A7-B8-C7 A7-B8-C8 A7-B8-C9 A7-B8-C10 A7-B8-C11 A7-B8-C12
A7-B8-C13 A7-B8-C14 A7-B8-C15 A7-B8-C16 A7-B8-C17 A7-B8-C18
A7-B8-C19 A7-B8-C20 A7-B8-C21 A7-B8-C22 A7-B8-C23 A7-B8-C24
A7-B8-C25 A7-B8-C26 A7-B8-C27 A7-B8-C28 A7-B8-C29 A7-B8-C30
A7-B8-C31 A7-B8-C32 A7-B8-C33 A7-B8-C34 A7-B8-C35 A7-B8-C36
A7-B8-C37 A7-B8-C38 A7-B8-C39 A7-B8-C40 A7-B8-C41 A7-B8-C42
A7-B8-C43 A7-B8-C44 A7-B8-C45 A7-B8-C46 A7-B8-C47 A7-B8-C48
A7-B8-C49 A7-B8-C50 A7-B8-C51 A7-B8-C52 A7-B8-C53 A7-B8-C54
A7-B8-C55 A7-B8-C56 A7-B8-C57 A7-B8-C58 A7-B8-C59 A7-B8-C60
A7-B8-C61 A7-B8-C62 A7-B8-C63 A7-B8-C64 A7-B8-C65 A7-B8-C66
A7-B8-C67 A7-B8-C68 A7-B8-C69 A7-B8-C70 A7-B8-C71 A7-B8-C72
A7-B8-C73 A7-B8-C74 A7-B8-C75 A7-B8-C76 A7-B8-C77 A7-B8-C78
A7-B8-C79 A7-B8-C80 A7-B8-C81 A7-B8-C82 A7-B8-C83 A7-B8-C84
A7-B8-C85 A7-B8-C86 A7-B8-C87 A7-B8-C88 A7-B8-C89 A7-B8-C90
A7-B8-C91 A7-B8-C92 A7-B8-C93 A7-B8-C94 A7-B8-C95 A7-B8-C96
A7-B8-C97 A7-B8-C98 A7-B8-C99 A7-B8-C100 A7-B8-C101 A7-B8-C102
A7-B8-C103 A7-B8-C104 A7-B8-C105 A7-B8-C106 A7-B8-C107 A7-B8-C108
A7-B8-C109 A7-B8-C110 A7-B8-C111 A7-B8-C112 A7-B8-C1 13 A7-B8-C114
A7-B8-C115 A7-B8-C116 A7-B8-C117 A7-B8-C118 A7-B8-C119 A7-B8-C120
A7-B8-C121 A7-B8-C122 A7-B8-C123 A7-B8-C124 A7-B8-C125 A7-B8-C126
A7-B8-C127 A7-B8-C128 A7-B8-C129 A7-B8-C130 A7-B8-C131 A7-B8-C132
A7-B8-C133 A7-B8-C134 A7-B8-C135 A7-B8-C136 A7-B8-C137 A7-B8-C138
A7-B8-C139 A7-B8-C140 BLANK BLANK BLANK BLANK
A7-B9-C1 A7-B9-C2 A7-B9-C3 A7-B9-C4 A7-B9-C5 A7-B9-C6
A7-B9-C7 A7-B9-C8 A7-B9-C9 A7-B9-C10 A7-B9-C11 A7-B9-C12
A7-B9-C13 A7-B9-C14 A7-B9-C15 A7-B9-C16 A7-B9-C17 A7-B9-C18
A7-B9-C19 A7-B9-C20 A7-B9-C21 A7-B9-C22 A7-B9-C23 A7-B9-C24
A7-B9-C25 A7-B9-C26 A7-B9-C27 A7-B9-C28 A7-B9-C29 A7-B9-C30
A7-B9-C31 A7-B9-C32 A7-B9-C33 A7-B9-C34 A7-B9-C35 A7-B9-C36
A7-B9-C37 A7-B9-C38 A7-B9-C39 A7-B9-C40 A7-B9-C41 A7-B9-C42
A7-B9-C43 A7-B9-C44 A7-B9-C45 A7-B9-C46 A7-B9-C47 A7-B9-C48
A7-B9-C49 A7-B9-C50 A7-B9-C51 A7-B9-C52 A7-B9-C53 A7-B9-C54
A7-B9-C55 A7-B9-C56 A7-B9-C57 A7-B9-C58 A7-B9-C59 A7-B9-C60
A7-B9-C61 A7-B9-C62 A7-B9-C63 A7-B9-C64 A7-B9-C65 A7-B9-C66
A7-B9-C67 A7-B9-C68 A7-B9-C69 A7-B9-C70 A7-B9-C71 A7-B9-C72
A7-B9-C73 A7-B9-C74 A7-B9-C75 A7-B9-C76 A7-B9-C77 A7-B9-C78
A7-B9-C79 A7-B9-C80 A7-B9-C81 A7-B9-C82 A7-B9-C83 A7-B9-C84
A7-B9-C85 A7-B9-C86 A7-B9-C87 A7-B9-C88 A7-B9-C89 A7-B9-C90
A7-B9-C91 A7-B9-C92 A7-B9-C93 A7-B9-C94 A7-B9-C95 A7-B9-C96
A7-B9-C97 A7-B9-C98 A7-B9-C99 A7-B9-C100 A7-B9-C101 A7-B9-C102
A7-B9-C103 A7-B9-C104 A7-B9-C105 A7-B9-C106 A7-B9-C107 A7-B9-C108
A7-B9-C109 A7-B9-C110 A7-B9-C111 A7-B9-C112 A7-B9-C113 A7-B9-C114
A7-B9-C115 A7-B9-C116 A7-B9-C117 A7-B9-C118 A7-B9-C119 A7-B9-C120
A7-B9-C121 A7-B9-C122 A7-B9-C123 A7-B9-C124 A7-B9-C125 A7-B9-C126
A7-B9-C127 A7-B9-C128 A7-B9-C129 A7-B9-C130 A7-B9-C131 A7-B9-C132
A7-B9-C133 A7-B9-C134 A7-B9-C135 A7-B9-C136 A7-B9-C137 A7-B9-C138
A7-B9-C139 A7-B9-C140 BLANK BLANK BLANK BLANK
A7-B10-C1 A7-B10-C2 A7-B10-C3 A7-B10-C4 A7-B10 C5 A7-B10-C6
A7-B10-C7 A7-B10-C8 A7-B10-C9 A7-B10-C10 A7-B10-C11 A7-B10-C12
A7-B10-C13 A7-B10-C14 A7-B10-C15 A7-B10-C16 A7-B10-C17 A7-B10-C18
A7-B10-C19 A7-B10-C20 A7-B10-C21 A7-B10-C22 A7-B10-C23 A7-B10-C24
A7-B10-C25 A7-B10-C26 A7-B10-C27 A7-B10-C28 A7-B10-C29 A7-B10-C30
A7-B10-C31 A7-B10-C32 A7-B10-C33 A7-B10-C34 A7-B10-C35 A7-B10-C36
A7-B10-C37 A7-B10-C38 A7-B10-C39 A7-B10-C40 A7-B10-C41 A7-B10-C42 A7-B10-C43 A7-B10-C44 A7-B10-C45 A7-B10-C46 A7-B10-C47 A7-B10-C48
A7-B10-C49 A7-B10-C50 A7-B10-C51 A7-B10-C52 A7-B10-C53 A7-B10-C54
A7-B10-C55 A7-B10-C56 A7-B10-C57 A7-B10-C58 A7-B10-C59 A7-B10-C60
A7-B10-C61 A7-B10-C62 A7-B10-C63 A7-B10-C64 A7-B10-C65 A7-B10-C66
A7-B10-C67 A7-B10-C68 A7-B10-C69 A7-B10-C70 A7-B10-C71 A7-B10-C72 A7-B10-C73 A7-B10-C74 A7-B10-C75 A7-B10-C76 A7-B10-C77 A7-B10-C78
A7-B10-C79 A7-B10-C80 A7-B10-C81 A7-B10-C82 A7-B10-C83 A7-B10-C84
A7-B10-C85 A7-B10-C86 A7-B10-C87 A7-B10-C88 . A7-B10-C89 A7-B10-C90
A7-B10-C91 A7-B10-C92 A7-B10-C93 A7-B10-C94 A7-B10-C95 A7-B10-C96
A7-B10-C97 A7-B10-C98 A7-B10-C99 A7-B10-C100 A7-B10-C101 A7-B10-C102 A7-B10-C103 A7-B10-C104 A7-B10-C105 A7-B10-C106 A7-B10-C107 A7-B10-C108
A7-B10-C109 A7-B10-C110 A7-B10-C111 A7-B10-C112 A7-B10-C113 A7-B10-C114
A7-B10-C115 A7-B10-C116 A7-B10-C117 A7-B10-C118 A7-B10-C119 A7-B10-C120
A7-B10-C121 A7-B10-C122 A7-B10-C123 A7-B10-C124 A7-B10-C125 A7-B10-C126
A7-B10-C127 A7-B10-C128 A7-B10-C129 A7-B10-C130 A7-B10-C131 A7-B10-C132 A7-B10-C133 A7-B10-C134 A7-B10-C135 A7-B10-C136 A7-B10-C137 A7-B10-C138
A7-B10-C139 A7-B10-C140 BLANK BLANK BLANK BLANK
A7-B11-C1 A7-B11-C2 A7-B11-C3 A7-B11-C4 A7-B11-C5 A7-B11-C6
A7-B11-C7 A7-B11-C8 A7-B11-C9 A7-B11-C10 A7-B11-C11 A7-B11-C12
A7-B11-C13 A7-B1 1-C14 A7-B11-C15 A7-B11-C16 A7JB11-C17 A7-B11-C18 A7-B11-C19 A7-B11-C20 A7-B11-C21 A7-B11-C22 A7-B11-C23 A7-B11-C24
A7-B11-C25 A7-B11-C26 A7-B11-C27 A7-B11-C28 A7-B11-C29 A7-B11-C30
A7-B11-C31 A7-B11-C32 A7-B11-C33 A7-B11-C34 A7-B11-C35 A7-B11-C36
A7-B11-C37 A7-B11-C38 A7-B11-C39 A7-B11-C40 A7-B11-C41 A7-B11-C42
A7-B11-C43 A7-B11-C44 A7-B11-C45 A7-B11-C46 A7-B11-C47 A7-B11-C48 A7-B11-C49 A7-B11-C50 A7-B11-C51 A7-B11-C52 A7-B11-C53 A7-B11-C54
A7-B11-C55 A7-B11-C56 A7-B11-C57 A7-B11-C58 A7-B11-C59 A7-B11-C60
A7-B11-C61 A7-B11-C62 A7-B11-C63 A7-B11-C64 A7-B11-C65 A7-B11-C66
A7-B11-C67 A7-B11-C68 A7-B11-C69 A7-B11-C70 A7-B11-C71 A7-B11-C72
A7-B11-C73 A7-B11-C74 A7-B11-C75 A7-B11-C76 A7-B11-C77 A7-B11-C78 A7-B11-C79 A7-B11-C80 A7-B11-C81 A7-B11-C82 A7-B11-C83 A7-B11-C84
A7-B11-C85 A7-B11-C86 A7-B11-C87 A7-B11-C88 A7-B11-C89 A7-B11-C90
A7-B11-C91 A7-B11-C92 A7-B11-C93 A7-B11-C94 A7-B11-C95 A7-B11-C96
A7-B11-C97 A7-B11-C98 A7-B11-C99 A7-B11-C100 A7-B11-C101 A7-B11-C102
A7-B11-C103 A7-B11-C104 A7-B11-C105 A7-B11-C106 A7-B11-C107 A7-B11-C108
A7-B11-C109 A7-B11-C110 A7-B11-C111 A7-B11-C112 A7-B11-C113 A7-B11-C1 14
A7-B11-C115 A7-B11-C116 A7-B11-C117 A7-B11-C118 A7-B11-C119 A7-B11-C120 A7-B11-C121 A7-B11-C122 A7-B11-C123 A7-B11-C124 A7-B11-C125 A7-B11-C126
A7-B11-C127 A7-B11-C128 A7-B11-C129 A7-B11-C130 A7-B11-C131 A7-B11-C132
A7-B11-C133 A7-B11-C134 A7-B11-C135 A7-B11-C136 A7-B11-C137 A7-B11-C138
A7-B11-C139 A7-B11-C140 BLANK BLANK BLANK BLANK
A7-B12-C1 A7-B12-C2 A7-B12-C3 A7-B12-C4 A7-B12-C5 A7-B12-C6 A7-B12-C7 A7-B12-C8 A7-B12-C9 A7-B12-C10 A7-B12-C11 A7-B12-C12
A7-B12-C13 A7-B12-C14 A7-B12-C15 A7-B12-C16 A7-B12-C17 A7-B12-C18
A7-B12-C19 A7-B12-C20 A7-B12-C21 A7-B12-C22 A7-B12-C23 A7-B12-C24
A7-B12-C25 A7-B12-C26 A7-B12-C27 A7-B12-C28 A7-B12-C29 A7-B12-C30
A7-B12-C31 A7-B12-C32 A7-B12-C33 A7-B12-C34 A7-B12-C35 A7-B12-C36 A7-B12-C37 A7-B12-C38 A7-B12-C39 A7-B12-C40 A7-B12-C41 A7-B12-C42
A7-B12-C43 A7-B12-C44 A7-B12-C45 A7-B12-C46 A7-B12-C47 A7-B12-C48
A7-B12-C49 A7-B12-C50 A7-B12-C51 A7-B12-C52 A7-B12-C53 A7-B12-C54
A7-B12-C55 A7-B12-C56 A7-B12-C57 A7-B12-C58 A7-B12-C59 A7-B12-C60
A7-B12-C61 A7-B12-C62 A7-B12-C63 A7-B12-C64 A7-B12-C65 A7-B12-C66 A7-B12-C67 A7-B12-C68 A7-B12-C69 A7-B12-C70 A7-B12-C71 A7-B12-C72
A7-B12-C73 A7-B12-C74 A7-B12-C75 A7-B12-C76 A7-B12-C77 A7-B12-C78
A7-B12-C79 A7-B12-C80 A7-B12-C81 A7-B12-C82 A7-B12-C83 A7-B12-C84
A7-B12-C85 A7-B12-C86 A7-B12-C87 A7-B12-C88 A7-B12-C89 A7-B12-C90
A7-B12-C91 A7-B12-C92 A7-B12-C93 A7-B12-C94 A7-B12-C95 A7-B12-C96 A7-B12-C97 A7-B12-C98 A7-B12-C99 A7-B12-C100 A7-B12-C101 A7-B12-C102
A7-B12-C103 A7-B12-C104 A7-B12-C105 A7-B12-C106 A7-B12-C107 A7-B12-C108
A7-B12-C109 A7-B12-C110 A7-B12-C111 A7-B12-C112 A7-B12-C113 A7-B12-C114
A7-B12-C115 A7-B12-C116 A7-B12-C117 A7-B12-C118 A7-B12-C119 A7-B12-C120
A7-B12-C121 A7-B12-C122 A7-B12-C123 A7-B12-C124 A7-B12-C125 A7-B12-C126 A7-B12-C127 A7-B12-C128 A7-B12-C129 A7-B12-C130 A7-B12-C131 A7-B12-C132
A7-B12-C133 A7-B12-C134 A7-B12-C135 A7-B12-C136 A7-B12-C137 A7-B12-C138
A7-B12-C139 A7-B12-C140 BLANK BLANK BLANK BLANK
A7-B13-C1 A7-B13-C2 A7-B13-C3 A7-B13-C4 A7-B13-C5 A7-B13-C6
A7-B13-C7 A7-B13-C8 A7-B13-C9 A7-B13-C10 A7-B13-C11 A7-B13-C12 A7-B13-C13 A7-B13-C14 A7-B13-C15 A7-B13-C16 A7-B13-C17 A7-B13-C18
A7-B13-C19 A7-B13-C20 A7-B13-C21 A7-B13-C22 A7-B13-C23 A7-B13-C24
A7-B13-C25 A7-B13-C26 A7-B13-C27 A7-B13-C28 A7-B13-C29 A7-B13-C30
A7-B13-C31 A7-B13-C32 A7-B13-C33 A7-B13-C34 A7-B13-C35 A7-B13-C36
A7-B13-C37 A7-B13-C38 A7-B13-C39 A7-B13-C40 A7-B13-C41 A7-B13-C42
A7-B13-C43 A7-B13-C44 A7-B13-C45 A7-B13-C46 A7-B13-C47 A7-B13-C48
A7-B13-C49 A7-B13-C50 A7-B13-C51 A7-B13-C52 A7-B13-C53 A7-B13-C54 A7-B13-C55 A7-B13-C56 A7-B13-C57 A7-B13-C58 A7-B13-C59 A7-B13-C60
A7-B13-C61 A7-B13-C62 A7-B13-C63 A7-B13-C64 A7-B13-C65 A7-B13-C66
A7-B13-C67 A7-B13-C68 A7-B13-C69 A7-B13-C70 A7-B13-C71 A7-B13-C72
A7-B13-C73 A7-B13-C74 A7-B13-C75 A7-B13-C76 A7-B13-C77 A7-B13-C78
A7-B13-C79 A7-B13-C80 A7-B13-C81 A7-B13-C82 A7-B13-C83 A7-B13-C84 A7-B13-C85 A7-B13-C86 A7-B13-C87 A7-B13-C88 A7-B13-C89 A7-B13-C90
A7-B13-C91 A7-B13-C92 A7-B13-C93 A7-B13-C94 A7-B13-C95 A7-B13-C96
A7-B13-C97 A7-B13-C98 A7-B13-C99 A7-B13-C100 A7-B13-C101 A7-B13-C102
A7-B13-C103 A7-B13-C104 A7-B13-C105 A7-B13-C106 A7-B13-C107 A7-B13-C108
A7-B13-C109 A7-B13-C110 A7-B13-C111 A7-B13-C112 A7-B13-C113 A7-B13-C114 A7-B13-C115 A7-B13-C116 A7-B13-C117 A7-B13-C118 A7-B13-C119 A7-B13-C120
A7-B13-C121 A7-B13-C122 A7-B13-C123 A7-B13-C124 A7-B13-C125 A7-B13-C126
A7-B13-C127 A7-B13-C128 A7-B13-C129 A7-B13-C130 A7-B13-C131 A7-B13-C132
A7-B13-C133 A7-B13-C134 A7-B13-C135 A7-B13-C136 A7-B13-C137 A7-B13-C138
A7-B13-C139 A7-B13-C140 BLANK BLANK BLANK BLANK A8-B1-C1 A8-B1-C2 A8-B1-C3 A8-B1-C4 A8-B1-C5 A8-B1-C6
A8-B1-C7 A8-B1-C8 A8-B1-C9 A8-B1-C10 A8-B1-C11 A8-B1-C12
A8-B1-C13 A8-B1-C14 A8-B1-C15 A8-B1-C16 A8-B1-C17 A8-B1-C18
A8-B1-C19 A8-B1-C20 A8-B1-C21 A8-B1-C22 A8-B1-C23 A8-B1-C24
A8-B1-C25 A8-B1-C26 A8-B1-C27 A8-B1-C28 A8-B1-C29 A8-B1-C30 A8-B1-C31 A8-B1-C32 A8-B1-C33 A8-B1-C34 A8-B1-C35 A8-B1-C36
A8-B1-C37 A8-B1-C38 A8-B1-C39 A8-B1-C40 A8-B1-C41 A8-B1-C42
A8-B1-C43 A8-B1-C44 A8-B1-C45 A8-B1-C46 A8-B1-C47 A8-B1-C48
A8-B1-C49 A8-B1-C50 A8-B1-C51 A8-B1-C52 A8-B1-C53 A8-B1-C54
A8-B1-C55 A8-B1-C56 A8-B1-C57 A8-B1-C58 A8-B1-C59 A8-B1-C60 A8-B1-C61 A8-B1-C62 A8-B1-C63 A8-B1-C64 A8-B1-C65 A8-B1-C66
A8-B1-C67 A8-B1-C68 A8-B1-C69 A8-B1-C70 A8-B1-C71 A8-B1-C72
A8-B1-C73 A8-B1-C74 A8-B1-C75 A8-B1-C76 A8-B1-C77 A8-B1-C78
A8-B1-C79 A8-B1-C80 A8-B1-C81 A8-B1-C82 A8-B1-C83 A8-B1-C84
A8-B1-C85 A8-B1-C86 A8-B1-C87 A8-B1-C88 A8-B1-C89 A8-B1-C90 A8-B1-C91 A8-B1-C92 A8-B1-C93 A8-B1-C94 A8-B1-C95 A8-B1-C96
A8-B1-C97 A8-B1-C98 A8-B1-C99 A8-B1-C100 A8-B1-C101 A8-B1-C102
A8-B1-C103 A8-B1-C104 A8-B1-C105 A8-B1-C106 A8-B1-C107 A8-B1-C108
A8-B1-C109 A8-B1-C110 A8-B1-C111 A8-B1-C112 A8-B1-C113 A8-B1-C114
A8-B1-C1 15 A8-B1-C116 A8-B1-C117 A8-B1-C1 18 A8-B1-C119 A8-B1-C120
A8-B1-C121 A8-B1-C122 A8-B1-C123 A8-B1-C124 A8-B1-C125 A8-B1-C126
A8-B1-C127 A8-B1-C128 A8-B1-C129 A8-B1-C130 A8-B1-C131 A8-B1-C132
A8-B1-C133 A8-B1-C134 A8-B1-C135 A8-B1-C136 A8-B1-C137 A8-B1-C138
A8-B1-C139 A8-B1-C140 BLANK BLANK BLANK BLANK
A8-B2-C1 A8-B2-C2 A8-B2-C3 A8-B2-C4 A8-B2-C5 A8-B2-C6
A8-B2-C7 A8-B2-C8 A8-B2-C9 A8-B2-C10 A8-B2-C11 A8-B2-C12
A8-B2-C13 A8-B2-C14 A8-B2-C15 A8-B2-C16 A8-B2-C17 A8-B2-C18
A8-B2-C19 A8-B2-C20 A8-B2-C21 A8-B2-C22 A8-B2-C23 A8-B2-C24
A8-B2-C25 A8-B2-C26 A8-B2-C27 A8-B2-C28 A8-B2-C29 A8-B2-C30
A8-B2-C31 A8-B2-C32 A8-B2-C33 A8-B2-C34 A8-B2-C35 A8-B2-C36
A8-B2-C37 A8-B2-C38 A8-B2-C39 A8-B2-C40 A8-B2-C41 A8-B2-C42
A8-B2-C43 A8-B2-C44 A8-B2-C45 A8-B2-C46 A8-B2-C47 A8-B2-C48
A8-B2-C49 A8-B2-C50 A8-B2-C51 A8-B2-C52 A8-B2-C53 A8-B2-C54
A8-B2-C55 A8-B2-C56 A8-B2-C57 A8-B2-C58 A8-B2-C59 A8-B2-C60
A8-B2-C61 A8-B2-C62 A8-B2-C63 A8-B2-C64 A8-B2-C65 A8-B2-C66
A8-B2-C67 A8-B2-C68 A8-B2-C69 A8-B2-C70 A8-B2-C71 A8-B2-C72
A8-B2-C73 A8-B2-C74 A8-B2-C75 A8-B2-C76 A8-B2-C77 A8-B2-C78
A8-B2-C79 A8-B2-C80 A8-B2-C81 A8-B2-C82 A8-B2-C83 A8-B2-C84
A8-B2-C85 A8-B2-C86 A8-B2-C87 A8-B2-C88 A8-B2-C89 A8-B2-C90
A8-B2-C91 A8-B2-C92 A8-B2-C93 A8-B2-C94 A8-B2-C95 A8-B2-C96
A8-B2-C97 A8-B2-C98 A8-B2-C99 A8-B2-C100 A8-B2-C101 A8-B2-C102
A8-B2-C103 A8-B2-C104 A8-B2-C105 A8-B2-C106 A8-B2-C107 A8-B2-C108
A8-B2-C109 A8-B2-C110 A8-B2-C111 A8-B2-C112 A8-B2-C113 A8-B2-C114
A8-B2-C115 A8-B2-C116 A8-B2-C117 A8-B2-C118 A8-B2-C119 A8-B2-C120
A8-B2-C121 A8-B2-C122 A8-B2-C123 A8-B2-C124 A8-B2-C125 A8-B2-C126
A8-B2-C127 A8-B2-C128 A8-B2-C129 A8-B2-C130 A8-B2-C131 A8-B2-C132
A8-B2-C133 A8-B2-C134 A8-B2-C135 A8-B2-C136 A8-B2-C137 A8-B2-C138
A8-B2-C139 A8-B2-C140 BLANK BLANK BLANK BLANK
A8-B3-C1 A8-B3-C2 A8-B3-C3 A8-B3-C4 A8-B3-C5 A8-B3-C6
A8-B3-C7 A8-B3-C8 A8-B3-C9 A8-B3-C10 A8-B3-C11 A8-B3-C12
A8-B3-C13 A8-B3-C14 A8-B3-C15 A8-B3-C16 A8-B3-C17 A8-B3-C18
A8-B3-C19 A8-B3-C20 A8-B3-C21 A8-B3-C22 A8-B3-C23 A8-B3-C24
A8-B3-C25 A8-B3-C26 A8-B3-C27 A8-B3-C28 A8-B3-C29 A8-B3-C30
A8-B3-C31 A8-B3-C32 A8-B3-C33 A8-B3-C34 A8-B3-C35 A8-B3-C36
A8-B3-C37 A8-B3-C38 A8-B3-C39 A8-B3-C40 A8-B3-C41 A8-B3-C42
A8-B3-C43 A8-B3-C44 A8-B3-C45 A8-B3-C46 A8-B3-C47 A8-B3-C48
A8-B3-C49 A8-B3-C50 A8-B3-C51 A8-B3-C52 A8-B3-C53 A8-B3-C54
A8-B3-C55 A8-B3-C56 A8-B3-C57 A8-B3-C58 A8-B3-C59 A8-B3-C60
A8-B3-C61 A8-B3-C62 A8-B3-C63 A8-B3-C64 A8-B3-C65 A8-B3-C66
A8-B3-C67 A8-B3-C68 A8-B3-C69 A8-B3-C70 A8-B3-C71 A8-B3-C72
A8-B3-C73 A8-B3-C74 A8-B3-C75 A8-B3-C76 A8-B3-C77 A8-B3-C78
A8-B3-C79 A8-B3-C80 A8-B3-C81 A8-B3-C82 A8-B3-C83 A8-B3-C84
A8-B3-C85 A8-B3-C86 A8-B3-C87 A8-B3-C88 A8-B3-C89 A8-B3-C90
A8-B3-C91 A8-B3-C92 A8-B3-C93 A8-B3-C94 A8-B3-C95 A8-B3-C96
A8-B3-C97 A8-B3-C98 A8-B3-C99 A8-B3-C100 A8-B3-C101 A8-B3-C102
A8-B3-C103 A8-B3-C104 A8-B3-C105 A8-B3-C106 A8-B3-C107 A8-B3-C108
A8-B3-C109 A8-B3-C110 A8-B3-C111 A8-B3-C112 A8-B3-C113 A8-B3-C114
A8-B3-C115 A8-B3-C116 A8-B3-C117 A8-B3-C118 A8-B3-C119 A8-B3-C120
A8-B3-C121 A8-B3-C122 A8-B3-C123 A8-B3-C124 A8-B3-C125 A8-B3-C126
A8-B3-C127 A8-B3-C128 A8-B3-C129 A8-B3-C130 A8-B3-C131 A8-B3-C132
A8-B3-C133 A8-B3-C134 A8-B3-C135 A8-B3-C136 A8-B3-C137 A8-B3-C138
A8-B3-C139 A8-B3-C140 BLANK BLANK BLANK BLANK
A8-B4-C1 A8-B4-C2 A8-B4-C3 A8-B4-C4 A8-B4-C5 A8-B4-C6
A8-B4-C7 A8-B4-C8 A8-B4-C9 A8-B4-C10 A8-B4-C1 1 A8-B4-C12
A8-B4-C13 A8-B4-C14 A8-B4-C15 A8-B4-C16 A8-B4-C17 A8-B4-C18
A8-B4-C19 A8-B4-C20 A8-B4-C21 A8-B4-C22 A8-B4-C23 A8-B4-C24
A8-B4-C25 A8-B4-C26 A8-B4-C27 A8-B4-C28 A8-B4-C29 A8-B4-C30
A8-B4-C31 A8-B4-C32 A8-B4-C33 A8-B4-C34 A8-B4-C35 A8-B4-C36
A8-B4-C37 A8-B4-C38 A8-B4-C39 A8-B4-C40 A8-B4-C41 A8-B4-C42
A8-B4-C43 A8-B4-C44 A8-B4-C45 A8-B4-C46 A8-B4-C47 A8-B4-C48
A8-B4-C49 A8-B4-C50 A8-B4-C51 A8-B4-C52 A8-B4-C53 A8-B4-C54
A8-B4-C55 A8-B4-C56 A8-B4-C57 A8-B4-C58 A8-B4-C59 A8-B4-C60
A8-B4-C61 A8-B4-C62 A8-B4-C63 A8-B4-C64 A8-B4-C65 A8-B4-C66
A8-B4-C67 A8-B4-C68 A8-B4-C69 A8-B4-C70 A8-B4-C71 A8-B4-C72
A8-B4-C73 A8-B4-C74 A8-B4-C75 A8-B4-C76 A8-B4-C77 A8-B4-C78
A8-B4-C79 A8-B4-C80 A8-B4-C81 A8-B4-C82 A8-B4-C83 A8-B4-C84
A8-B4-C85 A8-B4-C86 A8-B4-C87 A8-B4-C88 A8-B4-C89 A8-B4-C90
A8-B4-C91 A8-B4-C92 A8-B4-C93 A8-B4-C94 A8-B4-C95 A8-B4-C96
A8-B4-C97 A8-B4-C98 A8-B4-C99 A8-B4-C100 A8-B4-C101 A8-B4-C102
A8-B4-C103 A8-B4-C104 A8-B4-C105 A8-B4-C106 A8-B4-C107 A8-B4-C108
A8-B4-C109 A8-B4-C110 A8-B4-C111 A8-B4-C112 A8-B4-C113 A8-B4-C114
A8-B4-C115 A8-B4-C116 A8-B4-C117 A8-B4-C118 A8-B4-C119 A8-B4-C120
A8-B4-C121 A8-B4-C122 A8-B4-C123 A8-B4-C124 A8-B4-C125 A8-B4-C126
A8-B4-C127 A8-B4-C128 A8-B4-C129 A8-B4-C130 A8-B4-C131 A8-B4-C132
A8-B4-C133 A8-B4-C134 A8-B4-C135 A8-B4-C136 A8-B4-C137 A8-B4-C138
A8-B4-C139 A8-B4-C140 BLANK BLANK BLANK BLANK
A8-B5-C1 A8-B5-C2 A8-B5-C3 A8-B5-C4 A8-B5-C5 A8-B5-C6
A8-B5-C7 A8-B5-C8 A8-B5-C9 A8-B5-C10 A8-B5-C11 A8-B5-C12
A8-B5-C13 A8-B5-C14 A8-B5-C15 A8-B5-C16 A8-B5-C17 A8-B5-C18
A8-B5-C19 A8-B5-C20 A8-B5-C21 A8-B5-C22 A8-B5-C23 A8-B5-C24
A8-B5-C25 A8-B5-C26 A8-B5-C27 A8-B5-C28 A8-B5-C29 A8-B5-C30
A8-B5-C31 A8-B5-C32 A8-B5-C33 A8-B5-C34 A8-B5-C35 A8-B5-C36
A8-B5-C37 A8-B5-C38 A8-B5-C39 A8-B5-C40 A8-B5-C41 A8-B5-C42
A8-B5-C43 A8-B5-C44 A8-B5-C45 A8-B5-C46 A8-B5-C47 A8-B5-C48
A8-B5-C49 A8-B5-C50 A8-B5-C51 A8-B5-C52 A8-B5-C53 A8-B5-C54
A8-B5-C55 A8-B5-C56 A8-B5-C57 A8-B5-C58 A8-B5-C59 A8-B5-C60
A8-B5-C61 A8-B5-C62 A8-B5-C63 A8-B5-C64 A8-B5-C65 A8-B5-C66
A8-B5-C67 A8-B5-C68 A8-B5-C69 A8-B5-C70 A8-B5-C71 A8-B5-C72
A8-B5-C73 A8-B5-C74 A8-B5-C75 A8-B5-C76 A8-B5-C77 A8-B5-C78
A8-B5-C79 A8-B5-C80 A8-B5-C81 A8-B5-C82 A8-B5-C83 A8-B5-C84
A8-B5-C85 A8-B5-C86 A8-B5-C87 A8-B5-C88 A8-B5-C89 A8-B5-C90
A8-B5-C91 A8-B5-C92 A8-B5-C93 A8-B5-C94 A8-B5-C95 A8-B5-C96
A8-B5-C97 A8-B5-C98 A8-B5-C99 A8-B5-C100 A8-B5-C101 A8-B5-C102
A8-B5-C103 A8-B5-C104 A8-B5-C105 A8-B5-C106 A8-B5-C107 A8-B5-C108
A8-B5-C109 A8-B5-C110 A8-B5-C111 A8-B5-C112 A8-B5-C113 A8-B5-C114
A8-B5-C115 A8-B5-C116 A8-B5-C117 A8-B5-C118 A8-B5-C119 A8-B5-C120
A8-B5-C121 A8-B5-C122 A8-B5-C123 A8-B5-C124 A8-B5-C125 A8-B5-C126
A8-B5-C127 A8-B5-C128 A8-B5-C129 A8-B5-C130 A8-B5-C131 A8-B5-C132
A8-B5-C133 A8-B5-C134 A8-B5-C135 A8-B5-C136 A8-B5-C137 A8-B5-C138
A8-B5-C139 A8-B5-C140 BLANK BLANK BLANK BLANK
A8-B6-C1 A8-B6-C2 A8-B6-C3 A8-B6-C4 A8-B6-C5 A8-B6-C6
A8-B6-C7 A8-B6-C8 A8-B6-C9 A8-B6-C10 A8-B6-C11 A8-B6-C12
A8-B6-C13 A8-B6-C14 A8-B6-C15 A8-B6-C16 A8-B6-C17 A8-B6-C18
A8-B6-C19 A8-B6-C20 A8-B6-C21 A8-B6-C22 A8-B6-C23 A8-B6-C24
A8-B6-C25 A8-B6-C26 A8-B6-C27 A8-B6-C28 A8-B6-C29 A8-B6-C30
A8-B6-C31 A8-B6-C32 A8-B6-C33 A8-B6-C34 A8-B6-C35 A8-B6-C36
A8-B6-C37 A8-B6-C38 A8-B6-C39 A8-B6-C40 A8-B6-C41 A8-B6-C42
A8-B6-C43 A8-B6-C44 A8-B6-C45 A8-B6-C46 A8-B6-C47 A8-B6-C48
A8-B6-C49 A8-B6-C50 A8-B6-C51 A8-B6-C52 A8-B6-C53 A8-B6-C54
A8-B6-C55 A8-B6-C56 A8-B6-C57 A8-B6-C58 A8-B6-C59 A8-B6-C60
A8-B6-C61 A8-B6-C62 A8-B6-C63 A8-B6-C64 A8-B6-C65 A8-B6-C66
A8-B6-C67 A8-B6-C68 A8-B6-C69 A8-B6-C70 A8-B6-C71 A8-B6-C72
A8-B6-C73 A8-B6-C74 A8-B6-C75 A8-B6-C76 A8-B6-C77 A8-B6-C78
A8-B6-C79 A8-B6-C80 A8-B6-C81 A8-B6-C82 A8-B6-C83 A8-B6-C84
A8-B6-C85 A8-B6-C86 A8-B6-C87 A8-B6-C88 A8-B6-C89 A8-B6-C90
A8-B6-C91 A8-B6-C92 A8-B6-C93 A8-B6-C94 A8-B6-C95 A8-B6-C96
A8-B6-C97 A8-B6-C98 A8-B6-C99 A8-B6-C100 A8-B6-C101 A8-B6-C102
A8-B6-C103 A8-B6-C104 A8-B6-C105 A8-B6-C106 A8-B6-C107 A8-B6-C108
A8-B6-C109 A8-B6-C110 A8-B6-C111 A8-B6-C112 A8-B6-C113 A8-B6-C114
A8-B6-C115 A8-B6-C116 A8-B6-C117 A8-B6-C118 A8-B6-C119 A8-B6-C120
A8-B6-C121 A8-B6-C122 A8-B6-C123 A8-B6-C124 A8-B6-C125 A8-B6-C126
A8-B6-C127 A8-B6-C128 A8-B6-C129 A8-B6-C130 A8-B6-C131 A8-B6-C132
A8-B6-C133 A8-B6-C134 A8-B6-C135 A8-B6-C136 A8-B6-C137 A8-B6-C138
A8-B6-C139 A8-B6-C140 BLANK BLANK BLANK BLANK
A8-B7-C1 A8-B7-C2 A8-B7-C3 A8-B7-C4 A8-B7-C5 A8-B7-C6
A8-B7-C7 A8-B7-C8 A8-B7-C9 A8-B7-C10 A8-B7-C11 A8-B7-C12
A8-B7-C13 A8-B7-C14 A8-B7-C15 A8-B7-C16 A8-B7-C17 A8-B7-C18
A8-B7-C19 A8-B7-C20 A8-B7-C21 A8-B7-C22 A8-B7-C23 A8-B7-C24
A8-B7-C25 A8-B7-C26 A8-B7-C27 A8-B7-C28 A8-B7-C29 A8-B7-C30
A8-B7-C31 A8-B7-C32 A8-B7-C33 A8-B7-C34 A8-B7-C35 A8-B7-C36
A8-B7-C37 A8-B7-C38 A8-B7-C39 A8-B7-C40 A8-B7-C41 A8-B7-C42
A8-B7-C43 A8-B7-C44 A8-B7-C45 A8-B7-C46 A8-B7-C47 A8-B7-C48
A8-B7-C49 A8-B7-C50 A8-B7-C51 A8-B7-C52 A8-B7-C53 A8-B7-C54
A8-B7-C55 A8-B7-C56 A8-B7-C57 A8-B7-C58 A8-B7-C59 A8-B7-C60
A8-B7-C61 A8-B7-C62 A8-B7-C63 A8-B7-C64 A8-B7-C65 A8-B7-C66
A8-B7-C67 A8-B7-C68 A8-B7-C69 A8-B7-C70 A8-B7-C71 A8-B7-C72
A8-B7-C73 A8-B7-C74 A8-B7-C75 A8-B7-C76 A8-B7-C77 A8-B7-C78
A8-B7-C79 A8-B7-C80 A8-B7-C81 A8-B7-C82 A8-B7-C83 A8-B7-C84
A8-B7-C85 A8-B7-C86 A8-B7-C87 A8-B7-C88 A8-B7-C89 A8-B7-C90
A8-B7-C91 A8-B7-C92 A8-B7-C93 A8-B7-C94 A8-B7-C95 A8-B7-C96
A8-B7-C97 A8-B7-C98 A8-B7-C99 A8-B7-C100 A8-B7-C101 A8-B7-C102
A8-B7-C103 A8-B7-C104 A8-B7-C105 A8-B7-C106 A8-B7-C107 A8-B7-C108
A8-B7-C109 A8-B7-C110 A8-B7-C111 A8-B7-C112 A8-B7-C113 A8-B7-C114
A8-B7-C115 A8-B7-C116 A8-B7-C117 A8-B7-C118 A8-B7-C119 A8-B7-C120
A8-B7-C121 A8-B7-C122 A8-B7-C123 A8-B7-C124 A8-B7-C125 A8-B7-C126
A8-B7-C127 A8-B7-C128 A8-B7-C129 A8-B7-C130 A8-B7-C131 A8-B7-C132
A8-B7-C133 A8-B7-C134 A8-B7-C135 A8-B7-C136 A8-B7-C137 A8-B7-C138
A8-B7-C139 A8-B7-C140 BLANK BLANK BLANK BLANK
A8-B8-C1 A8-B8-C2 A8-B8-C3 A8-B8-C4 A8-B8-C5 A8-B8-C6
A8-B8-C7 A8-B8-C8 A8-B8-C9 A8-B8-C10 A8-B8-C11 A8-B8-C12
A8-B8-C13 A8-B8-C14 A8-B8-C15 A8-B8-C16 A8-B8-C17 A8-B8-C18
A8-B8-C19 A8-B8-C20 A8-B8-C21 A8-B8-C22 A8-B8-C23 A8-B8-C24
A8-B8-C25 A8-B8-C26 A8-B8-C27 A8-B8-C28 A8-B8-C29 A8-B8-C30
A8-B8-C31 A8-B8-C32 A8-B8-C33 A8-B8-C34 A8-B8-C35 A8-B8-C36
A8-B8-C37 A8-B8-C38 A8-B8-C39 A8-B8-C40 A8-B8-C41 A8-B8-C42
A8-B8-C43 A8-B8-C44 A8-B8-C45 A8-B8-C46 A8-B8-C47 A8-B8-C48
A8-B8-C49 A8-B8-C50 A8-B8-C51 A8-B8-C52 A8-B8-C53 A8-B8-C54
A8-B8-C55 A8-B8-C56 A8-B8-C57 A8-B8-C58 A8-B8-C59 A8-B8-C60
A8-B8-C61 A8-B8-C62 A8-B8-C63 A8-B8-C64 A8-B8-C65 A8-B8-C66
A8-B8-C67 A8-B8-C68 A8-B8-C69 A8-B8-C70 A8-B8-C71 A8-B8-C72
A8-B8-C73 A8-B8-C74 A8-B8-C75 A8-B8-C76 A8-B8-C77 A8-B8-C78
A8-B8-C79 A8-B8-C80 A8-B8-C81 A8-B8-C82 A8-B8-C83 A8-B8-C84
A8-B8-C85 A8-B8-C86 A8-B8-C87 A8-B8-C88 A8-B8-C89 A8-B8-C90
A8-B8-C91 A8-B8-C92 A8-B8-C93 A8-B8-C94 A8-B8-C95 A8-B8-C96
A8-B8-C97 A8-B8-C98 A8-B8-C99 A8-B8-C100 A8-B8-C101 A8-B8-C102
A8-B8-C103 A8-B8-C104 A8-B8-C105 A8-B8-C106 A8-B8-C107 A8-B8-C108
A8-B8-C109 A8-B8-C110 A8-B8-C111 A8-B8-C112 A8-B8-C113 A8-B8-C114
A8-B8-C115 A8-B8-C116 A8-B8-C117 A8-B8-C118 A8-B8-C119 A8-B8-C120
A8-B8-C121 A8-B8-C122 A8-B8-C123 A8-B8-C124 A8-B8-C125 A8-B8-C126
A8-B8-C127 A8-B8-C128 A8-B8-C129 A8-B8-C130 A8-B8-C131 A8-B8-C132
A8-B8-C133 A8-B8-C134 A8-B8-C135 A8-B8-C136 A8-B8-C137 A8-B8-C138
A8-B8-C139 A8-B8-C140 BLANK BLANK BLANK BLANK
A8-B9-C1 A8-B9-C2 A8-B9-C3 A8-B9-C4 A8-B9-C5 A8-B9-C6
A8-B9-C7 A8-B9-C8 A8-B9-C9 A8-B9-C10 A8-B9-C11 A8-B9-C12
A8-B9-C13 A8-B9-C14 A8-B9-C15 A8-B9-C16 A8-B9-C17 A8-B9-C18
A8-B9-C19 A8-B9-C20 A8-B9-C21 A8-B9-C22 A8-B9-C23 A8-B9-C24
A8-B9-C25 A8-B9-C26 A8-B9-C27 A8-B9-C28 A8-B9-C29 A8-B9-C30
A8-B9-C31 A8-B9-C32 A8-B9-C33 A8-B9-C34 A8-B9-C35 A8-B9-C36
A8-B9-C37 A8-B9-C38 A8-B9-C39 A8-B9-C40 A8-B9-C41 A8-B9-C42
A8-B9-C43 A8-B9-C44 A8-B9-C45 A8-B9-C46 A8-B9-C47 A8-B9-C48
A8-B9-C49 A8-B9-C50 A8-B9-C51 A8-B9-C52 A8-B9-C53 A8-B9-C54
A8-B9-C55 A8-B9-C56 A8-B9-C57 A8-B9-C58 A8-B9-C59 A8-B9-C60
A8-B9-C61 A8-B9-C62 A8-B9-C63 A8-B9-C64 A8-B9-C65 A8-B9-C66
A8-B9-C67 A8-B9-C68 A8-B9-C69 A8-B9-C70 A8-B9-C71 A8-B9-C72
A8-B9-C73 A8-B9-C74 A8-B9-C75 A8-B9-C76 A8-B9-C77 A8-B9-C78
A8-B9-C79 A8-B9-C80 A8-B9-C81 A8-B9-C82 A8-B9-C83 A8-B9-C84
A8-B9-C85 A8-B9-C86 A8-B9-C87 A8-B9-C88 A8-B9-C89 A8-B9-C90
A8-B9-C91 A8-B9-C92 A8-B9-C93 A8-B9-C94 A8-B9-C95 A8-B9-C96
A8-B9-C97 A8-B9-C98 A8-B9-C99 A8-B9-C100 A8-B9-C101 A8-B9-C102
A8-B9-C103 A8-B9-C104 A8-B9-C105 A8-B9-C106 A8-B9-C107 A8-B9-C108
A8-B9-C109 A8-B9-C110 A8-B9-C111 A8-B9-C112 A8-B9-C113 A8-B9-C114
A8-B9-C115 A8-B9-C116 A8-B9-C117 A8-B9-C118 A8-B9-C119 A8-B9-C120
A8-B9-C121 A8-B9-C122 A8-B9-C123 A8-B9-C124 A8-B9-C125 A8-B9-C126
A8-B9-C127 A8-B9-C128 A8-B9-C129 A8-B9-C130 A8-B9-C131 A8-B9-C132
A8-B9-C133 A8-B9-C134 A8-B9-C135 A8-B9-C136 A8-B9-C137 A8-B9-C138
A8-B9-C139 A8-B9-C140 BLANK BLANK BLANK BLANK
A8-B10-C1 A8-B10-C2 A8-B10-C3 A8-B10-C4 A8-B10-C5 A8-B10-C6
A8-B10-C7 A8-B10-C8 A8-B10-C9 A8-B10-C10 A8-B10-C11 A8-B10-C12
A8-B10-C13 A8-B10-C14 A8-B10-C15 A8-B10-C16 A8-B10-C17 A8-B10-C18
A8-B10-C19 A8-B10-C20 A8-B10-C21 A8-B10-C22 A8-B10-C23 A8-B10-C24
A8-B10-C25 A8-B10-C26 A8-B10-C27 A8-B10-C28 A8-B10-C29 A8-B10-C30
A8-B10-C31 A8-B10-C32 A8-B10-C33 A8-B10-C34 A8-B10-C35 A8-B10-C36
A8-B10-C37 A8-B10-C38 A8-B10-C39 A8-B10-C40 A8-B10-C41 A8-B10-C42
A8-B10-C43 A8-B10-C44 A8-B10-C45 A8-B10-C46 A8-B10-C47 A8-B10-C48
A8-B10-C49 A8-B10-C50 A8-B10-C51 A8-B10-C52 A8-B10-C53 A8-B10-C54
A8-B10-C55 A8-B10-C56 A8-B10-C57 A8-B10-C58 A8-B10-C59 A8-B10-C60
A8-B10-C61 A8-B10-C62 A8-B10-C63 A8-B10-C64 A8-B10-C65 A8-B10-C66
A8-B10-C67 A8-B10-C68 A8-B10-C69 A8-B10-C70 A8-B10-C71 A8-B10-C72
A8-B10-C73 A8-B10-C74 A8-B10-C75 A8-B10-C76 A8-B10-C77 A8-B10-C78
A8-B10-C79 A8-B10-C80 A8-B10-C81 A8-B10-C82 A8-B10-C83 A8-B10-C84
A8-B10-C85 A8-B10-C86 A8-B10-C87 A8-B10-C88 A8-B10-C89 A8-B10-C90
A8-B10-C91 A8-B10-C92 A8-B10-C93 A8-B10-C94 A8-B10-C95 A8-B10-C96
A8-B10-C97 A8-B10-C98 A8-B10-C99 A8-B10-C100 A8-B10-C101 A8-B10-C102
A8-B10-C103 A8-B10-C104 A8-B10-C105 A8-B10-C106 A8-B10-C107 A8-B10-C108
A8-B10-C109 A8-B10-C110 A8-B10-C111 A8-B10-C112 A8-B10-C113 A8-B10-C114
A8-B10-C115 A8-B10-C116 A8-B10-C117 A8-B10-C118 A8-B10-C119 A8-B10-C120
A8-B10-C121 A8-B10-C122 A8-B10-C123 A8-B10-C124 A8-B10-C125 A8-B10-C126
A8-B10-C127 A8-B10-C128 A8-B10-C129 A8-B10-C130 A8-B10-C131 A8-B10-C132
A8-B10-C133 A8-B10-C134 A8-B10-C135 A8-B10-C136 A8-B10-C137 A8-B10-C138
A8-B10-C139 A8-B10-C140 BLANK BLANK BLANK BLANK
A8-B11-C1 A8-B11-C2 A8-B11-C3 A8-B11-C4 A8-B11-C5 A8-B11-C6
A8-B11-C7 A8-B11-C8 A8-B11-C9 A8-B11-C10 A8-B11-C11 A8-B11-C12
A8-B11-C13 A8-B11-C14 A8-B11-C15 A8-B11-C16 A8-B11-C17 A8-B11-C18
A8-B11-C19 A8-B11-C20 A8-B11-C21 A8-B11-C22 A8-B11-C23 A8-B11-C24 A8-B11-C25 A8-B11-C26 A8-B11-C27 A8-B11-C28 A8-B11-C29 A8-B11-C30
A8-B11-C31 A8-B11-C32 A8-B11-C33 A8-B11-C34 A8-B11-C35 A8-B11-C36
A8-B11-C37 A8-B11-C38 A8-B11-C39 A8-B11-C40 A8-B11-C41 A8-B11-C42
A8-B11-C43 A8-B11-C44 A8-B11-C45 A8-B11-C46 A8-B11-C47 A8-B11-C48
A8-B11-C49 A8-B11-C50 A8-B11-C51 A8-B11-C52 A8-B11-C53 A8-B11-C54 A8-B11-C55 A8-B11-C56 A8-B11-C57 A8-B11-C58 A8-B11-C59 A8-B11-C60
A8-B11-C61 A8-B11-C62 A8-B11-C63 A8-B11-C64 A8-B11-C65 A8-B11-C66
A8-B11-C67 A8-B11-C68 A8-B11-C69 A8-B11-C70 A8-B11-C71 A8-B11-C72
A8-B11-C73 A8-B11-C74 A8-B11-C75 A8-B11-C76 A8-B11-C77 A8-B11-C78
A8-B11-C79 A8-B11-C80 A8-B11-C81 A8-B11-C82 A8-B11-C83 A8-B11-C84 A8-B11-C85 A8-B11-C86 A8-B11-C87 A8-B11-C88 A8-B11-C89 A8-B11-C90
A8-B11-C91 A8-B11-C92 A8-B11-C93 A8-B11-C94 A8-B11-C95 A8-B11-C96
A8-B11-C97 A8-B11-C98 A8-B11-C99 A8-B11-C100 A8-B11-C101 A8-B11-C102
A8-B11-C103 A8-B11-C104 A8-B11-C105 A8-B11-C106 A8-B11-C107 A8-B11-C108
A8-B11-C109 A8-B11-C110 A8-B11-C111 A8-B11-C112 A8-B11-C113 A8-B11-C114 A8-B11-C115 A8-B11-C116 A8-B11-C117 A8-B11-C118 A8-B11-C119 A8-B11-C120
A8-B11-C121 A8-B11-C122 A8-B11-C123 A8-B11-C124 A8-B11-C125 A8-B11-C126
A8-B11-C127 A8-B11-C128 A8-B11-C129 A8-B11-C130 A8-B11-C131 A8-B11-C132
A8-B11-C133 A8-B11-C134 A8-B11-C135 A8-B11-C136 A8-B11-C137 A8-B11-C138
A8-B11-C139 A8-B11-C140 BLANK BLANK BLANK BLANK A8-B12-C1 A8-B12-C2 A8-B12-C3 A8-B12-C4 A8-B12-C5 A8-B12-C6
A8-B12-C7 A8-B12-C8 A8-B12-C9 A8-B12-C10 A8-B12-C11 A8-B12-C12
A8-B12-C13 A8-B12-C14 A8-B12-C15 A8-B12-C16 A8-B12-C17 A8-B12-C18
A8-B12-C19 A8-B12-C20 A8-B12-C21 A8-B12-C22 A8-B12-C23 A8-B12-C24
A8-B12-C25 A8-B12-C26 A8-B12-C27 A8-B12-C28 A8-B12-C29 A8-B12-C30 A8-B12-C31 A8-B12-C32 A8-B12-C33 A8-B12-C34 A8-B12-C35 A8-B12-C36
A8-B12-C37 A8-B12-C38 A8-B12-C39 A8-B12-C40 A8-B12-C41 A8-B12-C42
A8-B12-C43 A8-B12-C44 A8-B12-C45 A8-B12-C46 A8-B12-C47 A8-B12-C48
A8-B12-C49 A8-B12-C50 A8-B12-C51 A8-B12-C52 A8-B12-C53 A8-B12-C54
A8-B12-C55 A8-B12-C56 A8-B12-C57 A8-B12-C58 A8-B12-C59 A8-B12-C60 A8-B12-C61 A8-B12-C62 A8-B12-C63 A8-B12-C64 A8-B12-C65 A8-B12-C66
A8-B12-C67 A8-B12-C68 A8-B12-C69 A8-B12-C70 A8-B12-C71 A8-B12-C72
A8-B12-C73 A8-B12-C74 A8-B12-C75 A8-B12-C76 A8-B12-C77 A8-B12-C78
A8-B12-C79 A8-B12-C80 A8-B12-C81 A8-B12-C82 A8-B12-C83 A8-B12-C84
A8-B12-C85 A8-B12-C86 A8-B12-C87 A8-B12-C88 A8-B12-C89 A8-B12-C90
A8-B12-C91 A8-B12-C92 A8-B12-C93 A8-B12-C94 A8-B12-C95 A8-B12-C96
A8-B12-C97 A8-B12-C98 A8-B12-C99 A8-B12-C100 A8-B12-C101 A8-B12-C102 A8-B12-C103 A8-B12-C104 A8-B12-C105 A8-B12-C106 A8-B12-C107 A8-B12-C108
A8-B12-C109 A8-B12-C110 A8-B12-C111 A8-B12-C112 A8-B12-C113 A8-B12-C114
A8-B12-C115 A8-B12-C116 A8-B12-C117 A8-B12-C118 A8-B12-C119 A8-B12-C120
A8-B12-C121 A8-B12-C122 A8-B12-C123 A8-B12-C124 A8-B12-C125 A8-B12-C126
A8-B12-C127 A8-B12-C128 A8-B12-C129 A8-B12-C130 A8-B12-C131 A8-B12-C132 A8-B12-C133 A8-B12-C134 A8-B12-C135 A8-B12-C136 A8-B12-C137 A8-B12-C138
A8-B12-C139 A8-B12-C140 BLANK BLANK BLANK BLANK
A8-B13-C1 A8-B13-C2 A8-B13-C3 A8-B13-C4 A8-B13-C5 A8-B13-C6
A8-B13-C7 A8-B13-C8 A8-B13-C9 A8-B13-C10 A8-B13-C11 A8-B13-C12
A8-B13-C13 A8-B13-C14 A8-B13-C15 A8-B13-C16 A8-B13-C17 A8-B13-C18 A8-B13-C19 A8-B13-C20 A8-B13-C21 A8-B13-C22 A8-B13-C23 A8-B13-C24
A8-B13-C25 A8-B13-C26 A8-B13-C27 A8-B13-C28 A8-B13-C29 A8-B13-C30
A8-B13-C31 A8-B13-C32 A8-B13-C33 A8-B13-C34 A8-B13-C35 A8-B13-C36
A8-B13-C37 A8-B13-C38 A8-B13-C39 A8-B13-C40 A8-B13-C41 A8-B13-C42
A8-B13-C43 A8-B13-C44 A8-B13-C45 A8-B13-C46 A8-B13-C47 A8-B13-C48 A8-B13-C49 A8-B13-C50 A8-B13-C51 A8-B13-C52 A8-B13-C53 A8-B13-C54
A8-B13-C55 A8-B13-C56 A8-B13-C57 A8-B13-C58 A8-B13-C59 A8-B13-C60
A8-B13-C61 A8-B13-C62 A8-B13-C63 A8-B13-C64 A8-B13-C65 A8-B13-C66
A8-B13-C67 A8-B13-C68 A8-B13-C69 A8-B13-C70 A8-B13-C71 A8-B13-C72
A8-B13-C73 A8-B13-C74 A8-B13-C75 A8-B13-C76 A8-B13-C77 A8-B13-C78 A8-B13-C79 A8-B13-C80 A8-B13-C81 A8-B13-C82 A8-B13-C83 A8-B13-C84
A8-B13-C85 A8-B13-C86 A8-B13-C87 A8-B13-C88 A8-B13-C89 A8-B13-C90
A8-B13-C91 A8-B13-C92 A8-B13-C93 A8-B13-C94 A8-B13-C95 A8-B13-C96
A8-B13-C97 A8-B13-C98 A8-B13-C99 A8-B13-C100 A8-B13-C101 A8-B13-C102
A8-B13-C103 A8-B13-C104 A8-B13-C105 A8-B13-C106 A8-B13-C107 A8-B13-C108 A8-B13-C109 A8-B13-C110 A8-B13-C111 A8-B13-C112 A8-B13-C113 A8-B13-C114
A8-B13-C115 A8-B13-C116 A8-B13-C117 A8-B13-C118 A8-B13-C119 A8-B13-C120 A8-B13-C121 A8-B13-C122 A8-B13-C123 A8-B13-C124 A8-B13-C125 A8-B13-C126
A8-B13-C127 A8-B13-C128 A8-B13-C129 A8-B13-C130 A8-B13-C131 A8-B13-C132
A8-B13-C133 A8-B13-C134 A8-B13-C135 A8-B13-C136 A8-B13-C137 A8-B13-C138 A8-B13-C139 A8-B13-C140 BLANK BLANK BLANK BLANK
A9-B1-C1 A9-B1-C2 A9-B1-C3 A9-B1-C4 A9-B1-C5 A9-B1-C6
A9-B1-C7 A9-B1-C8 A9-B1-C9 A9-B1-C10 A9-B1-C11 A9-B1-C12
A9-B1-C13 A9-B1-C14 A9-B1-C15 A9-B1-C16 A9-B1-C17 A9-B1-C18
A9-B1-C19 A9-B1-C20 A9-B1-C21 A9-B1-C22 A9-B1-C23 A9-B1-C24
A9-B1-C25 A9-B1-C26 A9-B1-C27 A9-B1-C28 A9-B1-C29 A9-B1-C30
A9-B1-C31 A9-B1-C32 A9-B1-C33 A9-B1-C34 A9-B1-C35 A9-B1-C36
A9-B1-C37 A9-B1-C38 A9-B1-C39 A9-B1-C40 A9-B1-C41 A9-B1-C42
A9-B1-C43 A9-B1-C44 A9-B1-C45 A9-B1-C46 A9-B1-C47 A9-B1-C48
A9-B1-C49 A9-B1-C50 A9-B1-C51 A9-B1-C52 A9-B1-C53 A9-B1-C54
A9-B1-C55 A9-B1-C56 A9-B1-C57 A9-B1-C58 A9-B1-C59 A9-B1-C60
A9-B1-C61 A9-B1-C62 A9-B1-C63 A9-B1-C64 A9-B1-C65 A9-B1-C66
A9-B1-C67 A9-B1-C68 A9-B1-C69 A9-B1-C70 A9-B1-C71 A9-B1-C72
A9-B1-C73 A9-B1-C74 A9-B1-C75 A9-B1-C76 A9-B1-C77 A9-B1-C78
A9-B1-C79 A9-B1-C80 A9-B 1-C81 A9-B1-C82 A9-B1-C83 A9-B1-C84
A9-B1-C85 A9-B1-C86 A9-B1-C87 A9-B1-C88 A9-B1-C89 A9-B1-C90
A9-B1-C91 A9-B1-C92 A9-B1-C93 A9-B1-C94 A9-B1-C95 A9-B1-C96
A9-B1-C97 A9-B1-C98 A9-B1-C99 A9-B1-C100 A9-B1-C101 A9-B1-C102
A9-B1-C103 A9-B1-C104 A9-B1-C105 A9-B1-C106 A9-B1-C107 A9-B1-C108
A9-B1-C109 A9-B1-C110 A9-B1-C1 1 1 A9-B1-C112 A9-B1-C113 A9-B1-C114
A9-B1-C115 A9-B1-C116 A9-B1-C117 A9-B1-C118 A9-B1-C119 A9-B1-C120
A9-B1-C121 A9-B1-C122 A9-B1-C123 A9-B1-C124 A9-B1-C125 A9-B1-C126
A9-B1-C127 A9-B1-C128 A9-B1-C129 A9-B1-C130 A9-B1-C131 A9-B1-C132
A9-B1-C133 A9-B1-C134 A9-B1-C135 A9-B1-C136 A9-B1-C137 A9-B1-C138
A9-B1-C139 A9-B1-C140 BLANK BLANK BLANK BLANK
A9-B2-C1 A9-B2-C2 A9-B2-C3 A9-B2-C4 A9-B2-C5 A9-B2-C6
A9-B2-C7 A9-B2-C8 A9-B2-C9 A9-B2-C10 A9-B2-C11 A9-B2-C12
A9-B2-C13 A9-B2-C14 A9-B2-C15 A9-B2-C16 A9-B2-C17 A9-B2-C18
A9-B2-C19 A9-B2-C20 A9-B2-C21 A9-B2-C22 A9-B2-C23 A9-B2-C24
A9-B2-C25 A9-B2-C26 A9-B2-C27 A9-B2-C28 A9-B2-C29 A9-B2-C30
A9-B2-C31 A9-B2-C32 A9-B2-C33 A9-B2-C34 A9-B2-C35 A9-B2-C36
A9-B2-C37 A9-B2-C38 A9-B2-C39 A9-B2-C40 A9-B2-C41 A9-B2-C42
A9-B2-C43 A9-B2-C44 A9-B2-C45 A9-B2-C46 A9-B2-C47 A9-B2-C48
A9-B2-C49 A9-B2-C50 A9-B2-C51 A9-B2-C52 A9-B2-C53 A9-B2-C54
A9-B2-C55 A9-B2-C56 A9-B2-C57 A9-B2-C58 A9-B2-C59 A9-B2-C60
A9-B2-C61 A9-B2-C62 A9-B2-C63 A9-B2-C64 A9-B2-C65 A9-B2-C66
A9-B2-C67 A9-B2-C68 A9-B2-C69 A9-B2-C70 A9-B2-C71 A9-B2-C72
A9-B2-C73 A9-B2-C74 A9-B2-C75 A9-B2-C76 A9-B2-C77 A9-B2-C78
A9-B2-C79 A9-B2-C80 A9-B2-C81 A9-B2-C82 A9-B2-C83 A9-B2-C84
A9-B2-C85 A9-B2-C86 A9-B2-C87 A9-B2-C88 A9-B2-C89 A9-B2-C90
A9-B2-C91 A9-B2-C92 A9-B2-C93 A9-B2-C94 A9-B2-C95 A9-B2-C96
A9-B2-C97 A9-B2-C98 A9-B2-C99 A9-B2-C100 A9-B2-C101 A9-B2-C102
A9-B2-C103 A9-B2-C104 A9-B2-C105 A9-B2-C106 A9-B2-C107 A9-B2-C108
A9-B2-C109 A9-B2-C110 A9-B2-C111 A9-B2-C112 A9-B2-C113 A9-B2-C114
A9-B2-C115 A9-B2-C116 A9-B2-C117 A9-B2-C118 A9-B2-C119 A9-B2-C120
A9-B2-C121 A9-B2-C122 A9-B2-C123 A9-B2-C124 A9-B2-C125 A9-B2-C126
A9-B2-C127 A9-B2-C128 A9-B2-C129 A9-B2-C130 A9-B2-C131 A9-B2-C132
A9-B2-C133 A9-B2-C134 A9-B2-C135 A9-B2-C136 A9-B2-C137 A9-B2-C138
A9-B2-C139 A9-B2-C140 BLANK BLANK BLANK BLANK
A9-B3-C1 A9-B3-C2 A9-B3-C3 A9-B3-C4 A9-B3-C5 A9-B3-C6
A9-B3-C7 A9-B3-C8 A9-B3-C9 A9-B3-C10 A9-B3-C11 A9-B3-C12
A9-B3-C13 A9-B3-C14 A9-B3-C15 A9-B3-C16 A9-B3-C17 A9-B3-C18
A9-B3-C19 A9-B3-C20 A9-B3-C21 A9-B3-C22 A9-B3-C23 A9-B3-C24
A9-B3-C25 A9-B3-C26 A9-B3-C27 A9-B3-C28 A9-B3-C29 A9-B3-C30
A9-B3-C31 A9-B3-C32 A9-B3-C33 A9-B3-C34 A9-B3-C35 A9-B3-C36
A9-B3-C37 A9-B3-C38 A9-B3-C39 A9-B3-C40 A9-B3-C41 A9-B3-C42
A9-B3-C43 A9-B3-C44 A9-B3-C45 A9-B3-C46 A9-B3-C47 A9-B3-C48
A9-B3-C49 A9-B3-C50 A9-B3-C51 A9-B3-C52 A9-B3-C53 A9-B3-C54
A9-B3-C55 A9-B3-C56 A9-B3-C57 A9-B3-C58 A9-B3-C59 A9-B3-C60
A9-B3-C61 A9-B3-C62 A9-B3-C63 A9-B3-C64 A9-B3-C65 A9-B3-C66
A9-B3-C67 A9-B3-C68 A9-B3-C69 A9-B3-C70 A9-B3-C71 A9-B3-C72
A9-B3-C73 A9-B3-C74 A9-B3-C75 A9-B3-C76 A9-B3-C77 A9-B3-C78
A9-B3-C79 A9-B3-C80 A9-B3-C81 A9-B3-C82 A9-B3-C83 A9-B3-C84
A9-B3-C85 A9-B3-C86 A9-B3-C87 A9-B3-C88 A9-B3-C89 A9-B3-C90
A9-B3-C91 A9-B3-C92 A9-B3-C93 A9-B3-C94 A9-B3-C95 A9-B3-C96
A9-B3-C97 A9-B3-C98 A9-B3-C99 A9-B3-C100 A9-B3-C101 A9-B3-C102
A9-B3-C103 A9-B3-C104 A9-B3-C105 A9-B3-C106 A9-B3-C107 A9-B3-C108
A9-B3-C109 A9-B3-C110 A9-B3-C111 A9-B3-C112 A9-B3-C113 A9-B3-C114
A9-B3-C115 A9-B3-C116 A9-B3-C117 A9-B3-C118 A9-B3-C119 A9-B3-C120
A9-B3-C121 A9-B3-C122 A9-B3-C123 A9-B3-C124 A9-B3-C125 A9-B3-C126
A9-B3-C127 A9-B3-C128 A9-B3-C129 A9-B3-C130 A9-B3-C131 A9-B3-C132
A9-B3-C133 A9-B3-C134 A9-B3-C135 A9-B3-C136 A9-B3-C137 A9-B3-C138
A9-B3-C139 A9-B3-C140 BLANK BLANK BLANK BLANK
A9-B4-C1 A9-B4-C2 A9-B4-C3 A9-B4-C4 A9-B4-C5 A9-B4-C6
A9-B4-C7 A9-B4-C8 A9-B4-C9 A9-B4-C10 A9-B4-C11 A9-B4-C12
A9-B4-C13 A9-B4-C14 A9-B4-C15 A9-B4-C16 A9-B4-C17 A9-B4-C18
A9-B4-C19 A9-B4-C20 A9-B4-C21 A9-B4-C22 A9-B4-C23 A9-B4-C24
A9-B4-C25 A9-B4-C26 A9-B4-C27 A9-B4-C28 A9-B4-C29 A9-B4-C30
A9-B4-C31 A9-B4-C32 A9-B4-C33 A9-B4-C34 A9-B4-C35 A9-B4-C36
A9-B4-C37 A9-B4-C38 A9-B4-C39 A9-B4-C40 A9-B4-C41 A9-B4-C42
A9-B4-C43 A9-B4-C44 A9-B4-C45 A9-B4-C46 A9-B4-C47 A9-B4-C48
A9-B4-C49 A9-B4-C50 A9-B4-C51 A9-B4-C52 A9-B4-C53 A9-B4-C54
A9-B4-C55 A9-B4-C56 A9-B4-C57 A9-B4-C58 A9-B4-C59 A9-B4-C60
A9-B4-C61 A9-B4-C62 A9-B4-C63 A9-B4-C64 A9-B4-C65 A9-B4-C66
A9-B4-C67 A9-B4-C68 A9-B4-C69 A9-B4-C70 A9-B4-C71 A9-B4-C72
A9-B4-C73 A9-B4-C74 A9-B4-C75 A9-B4-C76 A9-B4-C77 A9-B4-C78
A9-B4-C79 A9-B4-C80 A9-B4-C81 A9-B4-C82 A9-B4-C83 A9-B4-C84
A9-B4-C85 A9-B4-C86 A9-B4-C87 A9-B4-C88 A9-B4-C89 A9-B4-C90
A9-B4-C91 A9-B4-C92 A9-B4-C93 A9-B4-C94 A9-B4-C95 A9-B4-C96
A9-B4-C97 A9-B4-C98 A9-B4-C99 A9-B4-C100 A9-B4-C101 A9-B4-C102
A9-B4-C103 A9-B4-C104 A9-B4-C105 A9-B4-C106 A9-B4-C107 A9-B4-C108
A9-B4-C109 A9-B4-C110 A9-B4-C111 A9-B4-C112 A9-B4-C113 A9-B4-C114
A9-B4-C115 A9-B4-C116 A9-B4-C117 A9-B4-C118 A9-B4-C119 A9-B4-C120
A9-B4-C121 A9-B4-C122 A9-B4-C123 A9-B4-C124 A9-B4-C125 A9-B4-C126
A9-B4-C127 A9-B4-C128 A9-B4-C129 A9-B4-C130 A9-B4-C131 A9-B4-C132
A9-B4-C133 A9-B4-C134 A9-B4-C135 A9-B4-C136 A9-B4-C137 A9-B4-C138
A9-B4-C139 A9-B4-C140 BLANK BLANK BLANK BLANK
A9-B5-C1 A9-B5-C2 A9-B5-C3 A9-B5-C4 A9-B5-C5 A9-B5-C6
A9-B5-C7 A9-B5-C8 A9-B5-C9 A9-B5-C10 A9-B5-C11 A9-B5-C12
A9-B5-C13 A9-B5-C14 A9-B5-C15 A9-B5-C16 A9-B5-C17 A9-B5-C18
A9-B5-C19 A9-B5-C20 A9-B5-C21 A9-B5-C22 A9-B5-C23 A9-B5-C24
A9-B5-C25 A9-B5-C26 A9-B5-C27 A9-B5-C28 A9-B5-C29 A9-B5-C30
A9-B5-C31 A9-B5-C32 A9-B5-C33 A9-B5-C34 A9-B5-C35 A9-B5-C36
A9-B5-C37 A9-B5-C38 A9-B5-C39 A9-B5-C40 A9-B5-C41 A9-B5-C42
A9-B5-C43 A9-B5-C44 A9-B5-C45 A9-B5-C46 A9-B5-C47 A9-B5-C48
A9-B5-C49 A9-B5-C50 A9-B5-C51 A9-B5-C52 A9-B5-C53 A9-B5-C54
A9-B5-C55 A9-B5-C56 A9-B5-C57 A9-B5-C58 A9-B5-C59 A9-B5-C60
A9-B5-C61 A9-B5-C62 A9-B5-C63 A9-B5-C64 A9-B5-C65 A9-B5-C66
A9-B5-C67 A9-B5-C68 A9-B5-C69 A9-B5-C70 A9-B5-C71 A9-B5-C72
A9-B5-C73 A9-B5-C74 A9-B5-C75 A9-B5-C76 A9-B5-C77 A9-B5-C78
A9-B5-C79 A9-B5-C80 A9-B5-C81 A9-B5-C82 A9-B5-C83 A9-B5-C84
A9-B5-C85 A9-B5-C86 A9-B5-C87 A9-B5-C88 A9-B5-C89 A9-B5-C90
A9-B5-C91 A9-B5-C92 A9-B5-C93 A9-B5-C94 A9-B5-C95 A9-B5-C96
A9-B5-C97 A9-B5-C98 A9-B5-C99 A9-B5-C100 A9-B5-C101 A9-B5-C102
A9-B5-C103 A9-B5-C104 A9-B5-C105 A9-B5-C106 A9-B5-C107 A9-B5-C108
A9-B5-C109 A9-B5-C110 A9-B5-C111 A9-B5-C112 A9-B5-C113 A9-B5-C114
A9-B5-C115 A9-B5-C116 A9-B5-C117 A9-B5-C118 A9-B5-C119 A9-B5-C120
A9-B5-C121 A9-B5-C122 A9-B5-C123 A9-B5-C124 A9-B5-C125 A9-B5-C126
A9-B5-C127 A9-B5-C128 A9-B5-C129 A9-B5-C130 A9-B5-C131 A9-B5-C132
A9-B5-C133 A9-B5-C134 A9-B5-C135 A9-B5-C136 A9-B5-C137 A9-B5-C138
A9-B5-C139 A9-B5-C140 BLANK BLANK BLANK BLANK
A9-B6-C1 A9-B6-C2 A9-B6-C3 A9-B6-C4 A9-B6-C5 A9-B6-C6
A9-B6-C7 A9-B6-C8 A9-B6-C9 A9-B6-C10 A9-B6-C11 A9-B6-C12
A9-B6-C13 A9-B6-C14 A9-B6-C15 A9-B6-C16 A9-B6-C17 A9-B6-C18
A9-B6-C19 A9-B6-C20 A9-B6-C21 A9-B6-C22 A9-B6-C23 A9-B6-C24
A9-B6-C25 A9-B6-C26 A9-B6-C27 A9-B6-C28 A9-B6-C29 A9-B6-C30
A9-B6-C31 A9-B6-C32 A9-B6-C33 A9-B6-C34 A9-B6-C35 A9-B6-C36
A9-B6-C37 A9-B6-C38 A9-B6-C39 A9-B6-C40 A9-B6-C41 A9-B6-C42
A9-B6-C43 A9-B6-C44 A9-B6-C45 A9-B6-C46 A9-B6-C47 A9-B6-C48
A9-B6-C49 A9-B6-C50 A9-B6-C51 A9-B6-C52 A9-B6-C53 A9-B6-C54
A9-B6-C55 A9-B6-C56 A9-B6-C57 A9-B6-C58 A9-B6-C59 A9-B6-C60
A9-B6-C61 A9-B6-C62 A9-B6-C63 A9-B6-C64 A9-B6-C65 A9-B6-C66
A9-B6-C67 A9-B6-C68 A9-B6-C69 A9-B6-C70 A9-B6-C71 A9-B6-C72
A9-B6-C73 A9-B6-C74 A9-B6-C75 A9-B6-C76 A9-B6-C77 A9-B6-C78
A9-B6-C79 A9-B6-C80 A9-B6-C81 A9-B6-C82 A9-B6-C83 A9-B6-C84
A9-B6-C85 A9-B6-C86 A9-B6-C87 A9-B6-C88 A9-B6-C89 A9-B6-C90
A9-B6-C91 A9-B6-C92 A9-B6-C93 A9-B6-C94 A9-B6-C95 A9-B6-C96
A9-B6-C97 A9-B6-C98 A9-B6-C99 A9-B6-C100 A9-B6-C101 A9-B6-C102
A9-B6-C103 A9-B6-C104 A9-B6-C105 A9-B6-C106 A9-B6-C107 A9-B6-C108
A9-B6-C109 A9-B6-C110 A9-B6-C111 A9-B6-C112 A9-B6-C113 A9-B6-C114
A9-B6-C115 A9-B6-C116 A9-B6-C117 A9-B6-C118 A9-B6-C119 A9-B6-C120
A9-B6-C121 A9-B6-C122 A9-B6-C123 A9-B6-C124 A9-B6-C125 A9-B6-C126
A9-B6-C127 A9-B6-C128 A9-B6-C129 A9-B6-C130 A9-B6-C131 A9-B6-C132
A9-B6-C133 A9-B6-C134 A9-B6-C135 A9-B6-C136 A9-B6-C137 A9-B6-C138
A9-B6-C139 A9-B6-C140 BLANK BLANK BLANK BLANK
A9-B7-C1 A9-B7-C2 A9-B7-C3 A9-B7-C4 A9-B7-C5 A9-B7-C6
A9-B7-C7 A9-B7-C8 A9-B7-C9 A9-B7-C10 A9-B7-C11 A9-B7-C12
A9-B7-C13 A9-B7-C14 A9-B7-C15 A9-B7-C16 A9-B7-C17 A9-B7-C18
A9-B7-C19 A9-B7-C20 A9-B7-C21 A9-B7-C22 A9-B7-C23 A9-B7-C24
A9-B7-C25 A9-B7-C26 A9-B7-C27 A9-B7-C28 A9-B7-C29 A9-B7-C30
A9-B7-C31 A9-B7-C32 A9-B7-C33 A9-B7-C34 A9-B7-C35 A9-B7-C36
A9-B7-C37 A9-B7-C38 A9-B7-C39 A9-B7-C40 A9-B7-C41 A9-B7-C42
A9-B7-C43 A9-B7-C44 A9-B7-C45 A9-B7-C46 A9-B7-C47 A9-B7-C48
A9-B7-C49 A9-B7-C50 A9-B7-C51 A9-B7-C52 A9-B7-C53 A9-B7-C54
A9-B7-C55 A9-B7-C56 A9-B7-C57 A9-B7-C58 A9-B7-C59 A9-B7-C60
A9-B7-C61 A9-B7-C62 A9-B7-C63 A9-B7-C64 A9-B7-C65 A9-B7-C66
A9-B7-C67 A9-B7-C68 A9-B7-C69 A9-B7-C70 A9-B7-C71 A9-B7-C72
A9-B7-C73 A9-B7-C74 A9-B7-C75 A9-B7-C76 A9-B7-C77 A9-B7-C78
A9-B7-C79 A9-B7-C80 A9-B7-C81 A9-B7-C82 A9-B7-C83 A9-B7-C84
A9-B7-C85 A9-B7-C86 A9-B7-C87 A9-B7-C88 A9-B7-C89 A9-B7-C90
A9-B7-C91 A9-B7-C92 A9-B7-C93 A9-B7-C94 A9-B7-C95 A9-B7-C96
A9-B7-C97 A9-B7-C98 A9-B7-C99 A9-B7-C100 A9-B7-C101 A9-B7-C102
A9-B7-C103 A9-B7-C104 A9-B7-C105 A9-B7-C106 A9-B7-C107 A9-B7-C108
A9-B7-C109 A9-B7-C110 A9-B7-C111 A9-B7-C112 A9-B7-C113 A9-B7-C114
A9-B7-C115 A9-B7-C116 A9-B7-C117 A9-B7-C118 A9-B7-C119 A9-B7-C120
A9-B7-C121 A9-B7-C122 A9-B7-C123 A9-B7-C124 A9-B7-C125 A9-B7-C126
A9-B7-C127 A9-B7-C128 A9-B7-C129 A9-B7-C130 A9-B7-C131 A9-B7-C132
A9-B7-C133 A9-B7-C134 A9-B7-C135 A9-B7-C136 A9-B7-C137 A9-B7-C138
A9-B7-C139 A9-B7-C140 BLANK BLANK BLANK BLANK
A9-B8-C1 A9-B8-C2 A9-B8-C3 A9-B8-C4 A9-B8-C5 A9-B8-C6
A9-B8-C7 A9-B8-C8 A9-B8-C9 A9-B8-C10 A9-B8-C11 A9-B8-C12
A9-B8-C13 A9-B8-C14 A9-B8-C15 A9-B8-C16 A9-B8-C17 A9-B8-C18
A9-B8-C19 A9-B8-C20 A9-B8-C21 A9-B8-C22 A9-B8-C23 A9-B8-C24
A9-B8-C25 A9-B8-C26 A9-B8-C27 A9-B8-C28 A9-B8-C29 A9-B8-C30
A9-B8-C31 A9-B8-C32 A9-B8-C33 A9-B8-C34 A9-B8-C35 A9-B8-C36
A9-B8-C37 A9-B8-C38 A9-B8-C39 A9-B8-C40 A9-B8-C41 A9-B8-C42
A9-B8-C43 A9-B8-C44 A9-B8-C45 A9-B8-C46 A9-B8-C47 A9-B8-C48
A9-B8-C49 A9-B8-C50 A9-B8-C51 A9-B8-C52 A9-B8-C53 A9-B8-C54
A9-B8-C55 A9-B8-C56 A9-B8-C57 A9-B8-C58 A9-B8-C59 A9-B8-C60
A9-B8-C61 A9-B8-C62 A9-B8-C63 A9-B8-C64 A9-B8-C65 A9-B8-C66
A9-B8-C67 A9-B8-C68 A9-B8-C69 A9-B8-C70 A9-B8-C71 A9-B8-C72
A9-B8-C73 A9-B8-C74 A9-B8-C75 A9-B8-C76 A9-B8-C77 A9-B8-C78
A9-B8-C79 A9-B8-C80 A9-B8-C81 A9-B8-C82 A9-B8-C83 A9-B8-C84
A9-B8-C85 A9-B8-C86 A9-B8-C87 A9-B8-C88 A9-B8-C89 A9-B8-C90
A9-B8-C91 A9-B8-C92 A9-B8-C93 A9-B8-C94 A9-B8-C95 A9-B8-C96
A9-B8-C97 A9-B8-C98 A9-B8-C99 A9-B8-C100 A9-B8-C101 A9-B8-C102
A9-B8-C103 A9-B8-C104 A9-B8-C105 A9-B8-C106 A9-B8-C107 A9-B8-C108
A9-B8-C109 A9-B8-C110 A9-B8-C111 A9-B8-C112 A9-B8-C113 A9-B8-C114
A9-B8-C115 A9-B8-C116 A9-B8-C117 A9-B8-C118 A9-B8-C119 A9-B8-C120
A9-B8-C121 A9-B8-C122 A9-B8-C123 A9-B8-C124 A9-B8-C125 A9-B8-C126
A9-B8-C127 A9-B8-C128 A9-B8-C129 A9-B8-C130 A9-B8-C131 A9-B8-C132
A9-B8-C133 A9-B8-C134 A9-B8-C135 A9-B8-C136 A9-B8-C137 A9-B8-C138
A9-B8-C139 A9-B8-C140 BLANK BLANK BLANK BLANK
A9-B9-C1 A9-B9-C2 A9-B9-C3 A9-B9-C4 A9-B9-C5 A9-B9-C6
A9-B9-C7 A9-B9-C8 A9-B9-C9 A9-B9-C10 A9-B9-C11 A9-B9-C12
A9-B9-C13 A9-B9-C14 A9-B9-C15 A9-B9-C16 A9-B9-C17 A9-B9-C18
A9-B9-C19 A9-B9-C20 A9-B9-C21 A9-B9-C22 A9-B9-C23 A9-B9-C24
A9-B9-C25 A9-B9-C26 A9-B9-C27 A9-B9-C28 A9-B9-C29 A9-B9-C30
A9-B9-C31 A9-B9-C32 A9-B9-C33 A9-B9-C34 A9-B9-C35 A9-B9-C36
A9-B9-C37 A9-B9-C38 A9-B9-C39 A9-B9-C40 A9-B9-C41 A9-B9-C42
A9-B9-C43 A9-B9-C44 A9-B9-C45 A9-B9-C46 A9-B9-C47 A9-B9-C48
A9-B9-C49 A9-B9-C50 A9-B9-C51 A9-B9-C52 A9-B9-C53 A9-B9-C54
A9-B9-C55 A9-B9-C56 A9-B9-C57 A9-B9-C58 A9-B9-C59 A9-B9-C60
A9-B9-C61 A9-B9-C62 A9-B9-C63 A9-B9-C64 A9-B9-C65 A9-B9-C66
A9-B9-C67 A9-B9-C68 A9-B9-C69 A9-B9-C70 A9-B9-C71 A9-B9-C72
A9-B9-C73 A9-B9-C74 A9-B9-C75 A9-B9-C76 A9-B9-C77 A9-B9-C78
A9-B9-C79 A9-B9-C80 A9-B9-C81 A9-B9-C82 A9-B9-C83 A9-B9-C84
A9-B9-C85 A9-B9-C86 A9-B9-C87 A9-B9-C88 A9-B9-C89 A9-B9-C90
A9-B9-C91 A9-B9-C92 A9-B9-C93 A9-B9-C94 A9-B9-C95 A9-B9-C96
A9-B9-C97 A9-B9-C98 A9-B9-C99 A9-B9-C100 A9-B9-C101 A9-B9-C102
A9-B9-C103 A9-B9-C104 A9-B9-C105 A9-B9-C106 A9-B9-C107 A9-B9-C108
A9-B9-C109 A9-B9-C110 A9-B9-C111 A9-B9-C112 A9-B9-C113 A9-B9-C114
A9-B9-C115 A9-B9-C116 A9-B9-C117 A9-B9-C118 A9-B9-C119 A9-B9-C120
A9-B9-C121 A9-B9-C122 A9-B9-C123 A9-B9-C124 A9-B9-C125 A9-B9-C126
A9-B9-C127 A9-B9-C128 A9-B9-C129 A9-B9-C130 A9-B9-C131 A9-B9-C132
A9-B9-C133 A9-B9-C134 A9-B9-C135 A9-B9-C136 A9-B9-C137 A9-B9-C138
A9-B9-C139 A9-B9-C140 BLANK BLANK BLANK BLANK
A9-B10-C1 A9-B10-C2 A9-B10-C3 A9-B10-C4 A9-B10-C5 A9-B10-C6
A9-B10-C7 A9-B10-C8 A9-B10-C9 A9-B10-C10 A9-B10-C11 A9-B10-C12
A9-B10-C13 A9-B10-C14 A9-B10-C15 A9-B10-C16 A9-B10-C17 A9-B10-C18
A9-B10-C19 A9-B10-C20 A9-B10-C21 A9-B10-C22 A9-B10-C23 A9-B10-C24
A9-B10-C25 A9-B10-C26 A9-B10-C27 A9-B10-C28 A9-B10-C29 A9-B10-C30
A9-B10-C31 A9-B10-C32 A9-B10-C33 A9-B10-C34 A9-B10-C35 A9-B10-C36
A9-B10-C37 A9-B10-C38 A9-B10-C39 A9-B10-C40 A9-B10-C41 A9-B10-C42
A9-B10-C43 A9-B10-C44 A9-B10-C45 A9-B10-C46 A9-B10-C47 A9-B10-C48
A9-B10-C49 A9-B10-C50 A9-B10-C51 A9-B10-C52 A9-B10-C53 A9-B10-C54
A9-B10-C55 A9-B10-C56 A9-B10-C57 A9-B10-C58 A9-B10-C59 A9-B10-C60
A9-B10-C61 A9-B10-C62 A9-B10-C63 A9-B10-C64 A9-B10-C65 A9-B10-C66
A9-B10-C67 A9-B10-C68 A9-B10-C69 A9-B10-C70 A9-B10-C71 A9-B10-C72 A9-B10-C73 A9-B10-C74 A9-B10-C75 A9-B10-C76 A9-B10-C77 A9-B10-C78
A9-B10-C79 A9-B10-C80 A9-B10-C81 A9-B10-C82 A9-B10-C83 A9-B10-C84
A9-B10-C85 A9-B10-C86 A9-B10-C87 A9-B10-C88 A9-B10-C89 A9-B10-C90
A9-B10-C91 A9-B10-C92 A9-B10-C93 A9-B10-C94 A9-B10-C95 A9-B10-C96
A9-B10-C97 A9-B10-C98 A9-B10-C99 A9-B10-C100 A9-B10-C101 A9-B10-C102 A9-B10-C103 A9-B10-C104 A9-B10-C105 A9-B10-C106 A9-B10-C107 A9-B10-C108
A9-B10-C109 A9-B10-C110 A9-B10-C111 A9-B10-C112 A9-B10-C113 A9-B10-C114
A9-B10-C115 A9-B10-C116 A9-B10-C117 A9-B10-C118 A9-B10-C119 A9-B10-C120
A9-B10-C121 A9-B10-C122 A9-B10-C123 A9-B10-C124 A9-B10-C125 A9-B10-C126
A9-B10-C127 A9-B10-C128 A9-B10-C129 A9-B10-C130 A9-B10-C131 A9-B10-C132 A9-B10-C133 A9-B10-C134 A9-B10-C135 A9-B10-C136 A9-B10-C137 A9-B10-C138
A9-B10-C139 A9-B10-C140 BLANK BLANK BLANK BLANK
A9-B11-C1 A9-B11-C2 A9-B11-C3 A9-B11-C4 A9-B11-C5 A9-B11-C6
A9-B11-C7 A9-B11-C8 A9-B11-C9 A9-B11-C10 A9-B11-C11 A9-B11-C12
A9-B11-C13 A9-B11-C14 A9-B11-C15 A9-B11-C16 A9-B11-C17 A9-B11-C18 A9-B11-C19 A9-B11-C20 A9-B11-C21 A9-B11-C22 A9-B11-C23 A9-B11-C24
A9-B11-C25 A9-B11-C26 A9-B11-C27 A9-B11-C28 A9-B11-C29 A9-B11-C30
A9-B11-C31 A9-B11-C32 A9-B11-C33 A9-B11-C34 A9-B11-C35 A9-B11-C36
A9-B11-C37 A9-B11-C38 A9-B11-C39 A9-B11-C40 A9-B11-C41 A9-B11-C42
A9-B11-C43 A9-B11-C44 A9-B11-C45 A9-B11-C46 A9-B11-C47 A9-B11-C48 A9-B11-C49 A9-B11-C50 A9-B11-C51 A9-B11-C52 A9-B11-C53 A9-B11-C54
A9-B11-C55 A9-B11-C56 A9-B11-C57 A9-B11-C58 A9-B11-C59 A9-B11-C60
A9-B11-C61 A9-B11-C62 A9-B11-C63 A9-B11-C64 A9-B11-C65 A9-B11-C66
A9-B11-C67 A9-B11-C68 A9-B11-C69 A9-B11-C70 A9-B11-C71 A9-B11-C72
A9-B11-C73 A9-B11-C74 A9-B11-C75 A9-B11-C76 A9-B11-C77 A9-B11-C78 A9-B11-C79 A9-B11-C80 A9-B11-C81 A9-B11-C82 A9-B11-C83 A9-B11-C84
A9-B11-C85 A9-B11-C86 A9-B11-C87 A9-B11-C88 A9-B11-C89 A9-B11-C90
A9-B11-C91 A9-B11-C92 A9-B11-C93 A9-B11-C94 A9-B11-C95 A9-B11-C96
A9-B11-C97 A9-B11-C98 A9-B11-C99 A9-B11-C100 A9-B11-C101 A9-B11-C102
A9-B11-C103 A9-B11-C104 A9-B11-C105 A9-B11-C106 A9-B11-C107 A9-B11-C108 A9-B11-C109 A9-B11-C110 A9-B11-C111 A9-B11-C112 A9-B11-C113 A9-B11-C114
A9-B11-C115 A9-B11-C116 A9-B11-C117 A9-B11-C118 A9-B11-C119 A9-B11-C120
A9-B11-C121 A9-B11-C122 A9-B11-C123 A9-B11-C124 A9-B11-C125 A9-B11-C126
A9-B11-C127 A9-B11-C128 A9-B11-C129 A9-B11-C130 A9-B1 1-C131 A9-B11-C132
A9-B11-C133 A9-B11-C134 A9-B11-C135 A9-B11-C136 A9-B11-C137 A9-B11-C138
A9-B11-C139 A9-B11-C140 BLANK BLANK BLANK BLANK
A9-B12-C1 A9-B12-C2 A9-B12-C3 A9-B12-C4 A9-B12-C5 A9-B12-C6 A9-B12-C7 A9-B12-C8 A9-B12-C9 A9-B12-C10 A9-B12-C11 A9-B12-C12
A9-B12-C13 A9-B12-C14 A9-B12-C15 A9-B12-C16 A9-B12-C17 A9-B12-C18
A9-B12-C19 A9-B12-C20 A9-B12-C21 A9-B12-C22 A9-B12-C23 A9-B12-C24
A9-B12-C25 A9-B12-C26 A9-B12-C27 A9-B12-C28 A9-B12-C29 A9-B12-C30
A9-B12-C31 A9-B12-C32 A9-B12-C33 A9-B12-C34 A9-B12-C35 A9-B12-C36 A9-B12-C37 A9-B12-C38 A9-B12-C39 A9-B12-C40 A9-B12-C41 A9-B12-C42
A9-B12-C43 A9-B12-C44 A9-B12-C45 A9-B12-C46 A9-B12-C47 A9-B12-C48
A9-B12-C49 A9-B12-C50 A9-B12-C51 A9-B12-C52 A9-B12-C53 A9-B12-C54
A9-B12-C55 A9-B12-C56 A9-B12-C57 A9-B12-C58 A9-B12-C59 A9-B12-C60
A9-B12-C61 A9-B12-C62 A9-B12-C63 A9-B12-C64 A9-B12-C65 A9-B12-C66 A9-B12-C67 A9-B12-C68 A9-B12-C69 A9-B12-C70 A9-B12-C71 A9-B12-C72
A9-B12-C73 A9-B12-C74 A9-B12-C75 A9-B12-C76 A9-B12-C77 A9-B12-C78
A9-B12-C79 A9-B12-C80 A9-B12-C81 A9-B12-C82 A9-B12-C83 A9-B12-C84
A9-B12-C85 A9-B12-C86 A9-B12-C87 A9-B12-C88 A9-B12-C89 A9-B12-C90
A9-B12-C91 A9-B12-C92 A9-B12-C93 A9-B12-C94 A9-B12-C95 A9-B12-C96 A9-B12-C97 A9-B12-C98 A9-B12-C99 A9-B12-C100 A9-B12-C101 A9-B12-C102
A9-B12-C103 A9-B12-C104 A9-B12-C105 A9-B12-C106 A9-B12-C107 A9-B12-C108
A9-B12-C109 A9-B12-C110 A9-B12-C111 A9-B12-C112 A9-B12-C113 A9-B12-C114
A9-B12-C115 A9-B12-C116 A9-B12-C117 A9-B12-C118 A9-B12-C119 A9-B12-C120
A9-B12-C121 A9-B12-C122 A9-B12-C123 A9-B12-C124 A9-B12-C125 A9-B12-C126 A9-B12-C127 A9-B12-C128 A9-B12-C129 A9-B12-C130 A9-B12-C131 A9-B12-C132
A9-B12-C133 A9-B12-C134 A9-B12-C135 A9-B12-C136 A9-B12-C137 A9-B12-C138
A9-B12-C139 A9-B12-C140 BLANK BLANK BLANK BLANK
A9-B13-C1 A9-B13-C2 A9-B13-C3 A9-B13-C4 A9-B13-C5 A9-B13-C6
A9-B13-C7 A9-B13-C8 A9-B13-C9 A9-B13-C10 A9-B13-C11 A9-B13-C12 A9-B13-C13 A9-B13-C14 A9-B13-C15 A9-B13-C16 A9-B13-C17 A9-B13-C18
A9-B13-C19 A9-B13-C20 A9-B13-C21 A9-B13-C22 A9-B13-C23 A9-B13-C24
A9-B13-C25 A9-B13-C26 A9-B13-C27 A9-B13-C28 A9-B13-C29 A9-B13-C30
A9-B13-C31 A9-B13-C32 A9-B13-C33 A9-B13-C34 A9-B13-C35 A9-B13-C36
A9-B13-C37 A9-B13-C38 A9-B13-C39 A9-B13-C40 A9-B13-C41 A9-B13-C42 A9-B13-C43 A9-B13-C44 A9-B13-C45 A9-B13-C46 A9-B13-C47 A9-B13-C48
A9-B13-C49 A9-B13-C50 A9-B13-C51 A9-B13-C52 A9-B13-C53 A9-B13-C54
A9-B13-C55 A9-B13-C56 A9-B13-C57 A9-B13-C58 A9-B13-C59 A9-B13-C60
A9-B13-C61 A9-B13-C62 A9-B13-C63 A9-B13-C64 A9-B13-C65 A9-B13-C66
A9-B13-C67 A9-B13-C68 A9-B13-C69 A9-B13-C70 A9-B13-C71 A9-B13-C72
A9-B13-C73 A9-B13-C74 A9-B13-C75 A9-B13-C76 A9-B13-C77 A9-B13-C78
A9-B13-C79 A9-B13-C80 A9-B13-C81 A9-B13-C82 A9-B13-C83 A9-B13-C84 A9-B13-C85 A9-B13-C86 A9-B13-C87 A9-B13-C88 A9-B13-C89 A9-B13-C90
A9-B13-C91 A9-B13-C92 A9-B13-C93 A9-B13-C94 A9-B13-C95 A9-B13-C96
A9-B13-C97 A9-B13-C98 A9-B13-C99 A9-B13-C100 A9-B13-C101 A9-B13-C102
A9-B13-C103 A9-B13-C104 A9-B13-C105 A9-B13-C106 A9-B13-C107 A9-B13-C108
A9-B13-C109 A9-B13-C110 A9-B13-C111 A9-B13-C112 A9-B13-C113 A9-B13-C114 A9-B13-C115 A9-B13-C116 A9-B13-C117 A9-B13-C118 A9-B13-C119 A9-B13-C120
A9-B13-C121 A9-B13-C122 A9-B13-C123 A9-B13-C124 A9-B13-C125 A9-B13-C126
A9-B13-C127 A9-B13-C128 A9-B13-C129 A9-B13-C130 A9-B13-C131 A9-B13-C132
A9-B13-C133 A9-B13-C134 A9-B13-C135 A9-B13-C136 A9-B13-C137 A9-B13-C138
A9-B13-C139 A9-B13-C140 BLANK BLANK BLANK BLANK A10-B1-C1 A10-B1-C2 A10-B1-C3 A10-B1-C4 A10-B1-C5 A10-B1-C6
A10-B1-C7 A10-B1-C8 A10-B1-C9 A10-B1-C10 A10-B1-C11 A10-B1-C12
A10-B1-C13 A10-B1-C14 A10-B1-C15 A10-B1-C16 A10-B1-C17 A10-B1-C18
A10-B1-C19 A10-B1-C20 A10-B1-C21 A10-B1-C22 A10-B1-C23 A10-B1-C24
A10-B1-C25 A10-B1-C26 A10-B1-C27 A10-B1-C28 A10-B1-C29 A10-B1-C30 A10-B1-C31 A10-B1-C32 A10-B1-C33 A10-B1-C34 A10-B1-C35 A10-B1-C36
A10-B1-C37 A10-B1-C38 A10-B1-C39 A10-B1-C40 A10-B1-C41 A10-B1-C42
A10-B1-C43 A10-B1-C44 A10-B1-C45 A10-B1-C46 A10-B1-C47 A10-B1-C48
A10-B1-C49 A10-B1-C50 A10-B1-C51 A10-B1-C52 A10-B1-C53 A10-B1-C54
A10-B1-C55 A10-B1-C56 A10-B1-C57 A10-B1-C58 A10-B1-C59 A10-B1-C60 A10-B1-C61 A10-B1-C62 A10-B1-C63 A10-B1-C64 A10-B1-C65 A10-B1-C66
A10-B1-C67 A10-B1-C68 A10-B1-C69 A10-B1-C70 A10-B1-C71 A10-B1-C72
A10-B1-C73 A10-B1-C74 A10-B1-C75 A10-B1-C76 A10-B1-C77 A10-B1-C78
A10-B1-C79 A10-B1-C80 A10-B1-C81 A10-B1-C82 A10-B1-C83 A10-B1-C84
A10-B1-C85 A10-B1-C86 A10-B1-C87 A10-B1-C88 A10-B1-C89 A10-B1-C90 A10-B1-C91 A10-B1-C92 A10-B1-C93 A10-B1-C94 A10-B1-C95 A10-B1-C96
A10-B1-C97 A10-B1-C98 A10-B1-C99 A10-B1-C100 A10-B1-C101 A10-B1-C102
A10-B1-C103 A10-B1-C104 A10-B1-C105 A10-B1-C106 A10-B1-C107 A10-B1-C108
A10-B1-C109 A10-B1-C110 AlO-Bl-Clll A10-B1-C112 A10-B1-C113 A10-B1-C114
A10-B1-C115 A10-B1-C116 A10-B1-C117 A10-B1-C118 A10-B1-C119 A10-B1-C120 A10-B1-C121 A10-B1-C122 A10-B1-C123 A10-B1-C124 A10-B1-C125 A10-B1-C126
A10-B1-C127 A10-B1-C128 A10-B1-C129 A10-B1-C130 A10-B1-C131 A10-B1-C132
A10-B1-C133 A10-B1-C134 A10-B1-C135 A10-B1-C136 A10-B1-C137 A10-B1-C138
A10-B1-C139 A10-B1-C140 BLANK BLANK BLANK BLANK
A10-B2-C1 A10-B2-C2 A10-B2-C3 A10-B2-C4 A10-B2-C5 A10-B2-C6
A10-B2-C7 A10-B2-C8 A10-B2-C9 A10-B2-C10 A10-B2-C11 A10-B2-C12
A10-B2-C13 A10-B2-C14 A10-B2-C15 A10-B2-C16 A10-B2-C17 A10-B2-C18 A10-B2-C19 A10-B2-C20 A10-B2-C21 A10-B2-C22 A10-B2-C23 A10-B2-C24
A10-B2-C25 A10-B2-C26 A10-B2-C27 A10-B2-C28 A10-B2-C29 A10-B2-C30
A10-B2-C31 A10-B2-C32 A10-B2-C33 A10-B2-C34 A10-B2-C35 A10-B2-C36
A10-B2-C37 A10-B2-C38 A10-B2-C39 A10-B2-C40 A10-B2-C41 A10-B2-C42
A10-B2-C43 A10-B2-C44 A10-B2-C45 A10-B2-C46 A10-B2-C47 A10-B2-C48 A10-B2-C49 A10-B2-C50 A10-B2-C51 A10-B2-C52 A10-B2-C53 A10-B2-C54
A10-B2-C55 A10-B2-C56 A10-B2-C57 A10-B2-C58 A10-B2-C59 A10-B2-C60
A10-B2-C61 A10-B2-C62 A10-B2-C63 A10-B2-C64 A10-B2-C65 A10-B2-C66
A10-B2-C67 A10-B2-C68 A10-B2-C69 A10-B2-C70 A10-B2-C71 A10-B2-C72
A10-B2-C73 A10-B2-C74 A10-B2-C75 A10-B2-C76 A10-B2-C77 A10-B2-C78 A10-B2-C79 A10-B2-C80 A10-B2-C81 A10-B2-C82 A10-B2-C83 A10-B2-C84
A10-B2-C85 A10-B2-C86 A10-B2-C87 A10-B2-C88 A10-B2-C89 A10-B2-C90
A10-B2-C91 A10-B2-C92 A10-B2-C93 A10-B2-C94 A10-B2-C95 A10-B2-C96
A10-B2-C97 A10-B2-C98 A10-B2-C99 A10-B2-C100 A10-B2-C101 A10-B2-C102
A10-B2-C103 A10-B2-C104 A10-B2-C105 A10-B2-C106 A10-B2-C107 A10-B2-C108 A10-B2-C109 A10-B2-C110 A10-B2-C111 A10-B2-C112 A10-B2-C113 A10-B2-C114
A10-B2-C115 A10-B2-C116 A10-B2-C117 A10-B2-C118 A10-B2-C119 A10-B2-C120
A10-B2-C121 A10-B2-C122 A10-B2-C123 A10-B2-C124 A10-B2-C125 A10-B2-C126
A10-B2-C127 A10-B2-C128 A10-B2-C129 A10-B2-C130 A10-B2-C131 A10-B2-C132
A10-B2-C133 A10-B2-C134 A10-B2-C135 A10-B2-C136 A10-B2-C137 A10-B2-C138 A10-B2-C139 A10-B2-C140 BLANK BLANK BLANK BLANK
A10-B3-C1 A10-B3-C2 A10-B3-C3 A10-B3-C4 A10-B3-C5 A10-B3-C6
A10-B3-C7 A10-B3-C8 A10-B3-C9 A10-B3-C10 A10-B3-C11 A10-B3-C12
A10-B3-C13 A10-B3-C14 A10-B3-C15 A10-B3-C16 A10-B3-C17 A10-B3-C18
A10-B3-C19 A10-B3-C20 A10-B3-C21 A10-B3-C22 A10-B3-C23 A10-B3-C24 A10-B3-C25 A10-B3-C26 A10-B3-C27 A10-B3-C28 A10-B3-C29 A10-B3-C30
A10-B3-C31 A10-B3-C32 A10-B3-C33 A10-B3-C34 A10-B3-C35 A10-B3-C36
A10-B3-C37 A10-B3-C38 A10-B3-C39 A10-B3-C40 A10-B3-C41 A10-B3-C42
A10-B3-C43 A10-B3-C44 A10-B3-C45 A10-B3-C46 A10-B3-C47 A10-B3-C48
A10-B3-C49 A10-B3-C50 A10-B3-C51 A10-B3-C52 A10-B3-C53 A10-B3-C54 A10-B3-C55 A10-B3-C56 A10-B3-C57 A10-B3-C58 A10-B3-C59 A10-B3-C60
A10-B3-C61 A10-B3-C62 A10-B3-C63 A10-B3-C64 A10-B3-C65 A10-B3-C66
A10-B3-C67 A10-B3-C68 A10-B3-C69 A10-B3-C70 A10-B3-C71 A10-B3-C72
A10-B3-C73 A10-B3-C74 A10-B3-C75 A10-B3-C76 A10-B3-C77 A10-B3-C78
A10-B3-C79 A10-B3-C80 A10-B3-C81 A10-B3-C82 A10-B3-C83 A10-B3-C84
A10-B3-C85 A10-B3-C86 A10-B3-C87 A10-B3-C88 A10-B3-C89 A10-B3-C90
A10-B3-C91 A10-B3-C92 A10-B3-C93 A10-B3-C94 A10-B3-C95 A10-B3-C96 A10-B3-C97 A10-B3-C98 A10-B3-C99 A10-B3-C100 A10-B3-C101 A10-B3-C102
A10-B3-C103 A10-B3-C104 A10-B3-C105 A10-B3-C106 A10-B3-C107 A10-B3-C108
A10-B3-C109 A10-B3-C110 A10-B3-C111 A10-B3-C112 A10-B3-C113 A10-B3-C114
A10-B3-C115 A10-B3-C116 A10-B3-C117 A10-B3-C118 A10-B3-C119 A10-B3-C120
A10-B3-C121 A10-B3-C122 A10-B3-C123 A10-B3-C124 A10-B3-C125 A10-B3-C126 A10-B3-C127 A10-B3-C128 A10-B3-C129 A10-B3-C130 A10-B3-C131 A10-B3-C132
A10-B3-C133 A10-B3-C134 A10-B3-C135 A10-B3-C136 A10-B3-C137 A10-B3-C138
A10-B3-C139 A10-B3-C140 BLANK BLANK BLANK BLANK
A10-B4-C1 A10-B4-C2 A10-B4-C3 A10-B4-C4 A10-B4-C5 A10-B4-C6
A10-B4-C7 A10-B4-C8 A10-B4-C9 A10-B4-C10 A10-B4-C11 A10-B4-C12 A10-B4-C13 A10-B4-C14 A10-B4-C15 A10-B4-C16 A10-B4-C17 A10-B4-C18
A10-B4-C19 A10-B4-C20 A10-B4-C21 A10-B4-C22 A10-B4-C23 A10-B4-C24
A10-B4-C25 A10-B4-C26 A10-B4-C27 A10-B4-C28 A10-B4-C29 A10-B4-C30
A10-B4-C31 A10-B4-C32 A10-B4-C33 A10-B4-C34 A10-B4-C35 A10-B4-C36
A10-B4-C37 A10-B4-C38 A10-B4-C39 A10-B4-C40 A10-B4-C41 A10-B4-C42 A10-B4-C43 A10-B4-C44 A10-B4-C45 A10-B4-C46 A10-B4-C47 A10-B4-C48
A10-B4-C49 A10-B4-C50 A10-B4-C51 A10-B4-C52 A10-B4-C53 A10-B4-C54
A10-B4-C55 A10-B4-C56 A10-B4-C57 A10-B4-C58 A10-B4-C59 A10-B4-C60
A10-B4-C61 A10-B4-C62 A10-B4-C63 A10-B4-C64 A10-B4-C65 A10-B4-C66
A10-B4-C67 A10-B4-C68 A10-B4-C69 A10-B4-C70 A10-B4-C71 A10-B4-C72 A10-B4-C73 A10-B4-C74 A10-B4-C75 A10-B4-C76 A10-B4-C77 A10-B4-C78
A10-B4-C79 A10-B4-C80 A10-B4-C81 A10-B4-C82 A10-B4-C83 A10-B4-C84
A10-B4-C85 A10-B4-C86 A10-B4-C87 A10-B4-C88 A10-B4-C89 A10-B4-C90
A10-B4-C91 A10-B4-C92 A10-B4-C93 A10-B4-C94 A10-B4-C95 A10-B4-C96
A10-B4-C97 A10-B4-C98 A10-B4-C99 A10-B4-C100 A10-B4-C101 A10-B4-C102 A10-B4-C103 A10-B4-C104 A10-B4-C105 A10-B4-C106 A10-B4-C107 A10-B4-C108
A10-B4-C109 A10-B4-C110 A10-B4-C111 A10-B4-C112 A10-B4-C113 A10-B4-C114
A10-B4-C115 A10-B4-C116 A10-B4-C117 A10-B4-C118 A10-B4-C119 A10-B4-C120
A10-B4-C121 A10-B4-C122 A10-B4-C123 A10-B4-C124 A10-B4-C125 A10-B4-C126
A10-B4-C127 A10-B4-C128 A10-B4-C129 A10-B4-C130 A10-B4-C131 A10-B4-C132 A10-B4-C133 A10-B4-C134 A10-B4-C135 A10-B4-C136 A10-B4-C137 A10-B4-C138
A10-B4-C139 A10-B4-C140 BLANK BLANK BLANK BLANK
A10-B5-C1 A10-B5-C2 A10-B5-C3 A10-B5-C4 A10-B5-C5 A10-B5-C6
A10-B5-C7 A10-B5-C8 A10-B5-C9 A10-B5-C10 A10-B5-C11 A10-B5-C12
A10-B5-C13 A10-B5-C14 A10-B5-C15 A10-B5-C16 A10-B5-C17 A10-B5-C18
A10-B5-C19 A10-B5-C20 A10-B5-C21 A10-B5-C22 A10-B5-C23 A10-B5-C24
A10-B5-C25 A10-B5-C26 A10-B5-C27 A10-B5-C28 A10-B5-C29 A10-B5-C30 A10-B5-C31 A10-B5-C32 A10-B5-C33 A10-B5-C34 A10-B5-C35 A10-B5-C36
A10-B5-C37 A10-B5-C38 A10-B5-C39 A10-B5-C40 A10-B5-C41 A10-B5-C42
A10-B5-C43 A10-B5-C44 A10-B5-C45 A10-B5-C46 A10-B5-C47 A10-B5-C48
A10-B5-C49 A10-B5-C50 A10-B5-C51 A10-B5-C52 A10-B5-C53 A10-B5-C54
A10-B5-C55 A10-B5-C56 A10-B5-C57 A10-B5-C58 A10-B5-C59 A10-B5-C60 A10-B5-C61 A10-B5-C62 A10-B5-C63 A10-B5-C64 A10-B5-C65 A10-B5-C66
A10-B5-C67 A10-B5-C68 A10-B5-C69 A10-B5-C70 A10-B5-C71 A10-B5-C72
A10-B5-C73 A10-B5-C74 A10-B5-C75 A10-B5-C76 A10-B5-C77 A10-B5-C78
A10-B5-C79 A10-B5-C80 A10-B5-C81 A10-B5-C82 A10-B5-C83 A10-B5-C84
A10-B5-C85 A10-B5-C86 A10-B5-C87 A10-B5-C88 A10-B5-C89 A10-B5-C90 A10-B5-C91 A10-B5-C92 A10-B5-C93 A10-B5-C94 A10-B5-C95 A10-B5-C96
A10-B5-C97 A10-B5-C98 A10-B5-C99 A10-B5-C100 A10-B5-C101 A10-B5-C102
A10-B5-C103 A10-B5-C104 A10-B5-C105 A10-B5-C106 A10-B5-C107 A10-B5-C108
A10-B5-C109 A10-B5-C110 A10-B5-C111 A10-B5-C112 A10-B5-C113 A10-B5-C114
A10-B5-C115 A10-B5-C116 A10-B5-C117 A10-B5-C118 A10-B5-C119 A10-B5-C120 A10-B5-C121 A10-B5-C122 A10-B5-C123 A10-B5-C124 A10-B5-C125 A10-B5-C126
A10-B5-C127 A10-B5-C128 A10-B5-C129 A10-B5-C130 A10-B5-C131 A10-B5-C132
A10-B5-C133 A10-B5-C134 A10-B5-C135 A10-B5-C136 A10-B5-C137 A10-B5-C138
A10-B5-C139 A10-B5-C140 BLANK BLANK BLANK BLANK
A10-B6-C1 A10-B6-C2 A10-B6-C3 A10-B6-C4 A10-B6-C5 A10-B6-C6 A10-B6-C7 A10-B6-C8 A10-B6-C9 A10-B6-C10 A10-B6-C11 A10-B6-C12
A10-B6-C13 A10-B6-C14 A10-B6-C15 A10-B6-C16 A10-B6-C17 A10-B6-C18
A10-B6-C19 A10-B6-C20 A10-B6-C21 A10-B6-C22 A10-B6-C23 A10-B6-C24
A10-B6-C25 A10-B6-C26 A10-B6-C27 A10-B6-C28 A10-B6-C29 A10-B6-C30
A10-B6-C31 A10-B6-C32 A10-B6-C33 A10-B6-C34 A10-B6-C35 A10-B6-C36 A10-B6-C37 A10-B6-C38 A10-B6-C39 A10-B6-C40 A10-B6-C41 A10-B6-C42
A10-B6-C43 A10-B6-C44 A10-B6-C45 A10-B6-C46 A10-B6-C47 A10-B6-C48
A10-B6-C49 A10-B6-C50 A10-B6-C51 A10-B6-C52 A10-B6-C53 A10-B6-C54
A10-B6-C55 A10-B6-C56 A10-B6-C57 A10-B6-C58 A10-B6-C59 A10-B6-C60
A10-B6-C61 A10-B6-C62 A10-B6-C63 A10-B6-C64 A10-B6-C65 A10-B6-C66 A10-B6-C67 A10-B6-C68 A10-B6-C69 A10-B6-C70 A10-B6-C71 A10-B6-C72
A10-B6-C73 A10-B6-C74 A10-B6-C75 A10-B6-C76 A10-B6-C77 A10-B6-C78
A10-B6-C79 A10-B6-C80 A10-B6-C81 A10-B6-C82 A10-B6-C83 A10-B6-C84
A10-B6-C85 A10-B6-C86 A10-B6-C87 A10-B6-C88 A10-B6-C89 A10-B6-C90
A10-B6-C91 A10-B6-C92 A10-B6-C93 A10-B6-C94 A10-B6-C95 A10-B6-C96
A10-B6-C97 A10-B6-C98 A10-B6-C99 A10-B6-C100 A10-B6-C101 A10-B6-C102
A10-B6-C103 A10-B6-C104 A10-B6-C105 A10-B6-C106 A10-B6-C107 A10-B6-C108 A10-B6-C109 A10-B6-C110 A10-B6-C111 A10-B6-C112 A10-B6-C113 A10-B6-C114
A10-B6-C115 A10-B6-C116 A10-B6-C117 A10-B6-C118 A10-B6-C119 A10-B6-C120
A10-B6-C121 A10-B6-C122 A10-B6-C123 A10-B6-C124 A10-B6-C125 A10-B6-C126
A10-B6-C127 A10-B6-C128 A10-B6-C129 A10-B6-C130 A10-B6-C131 A10-B6-C132
A10-B6-C133 A10-B6-C134 A10-B6-C135 A10-B6-C136 A10-B6-C137 A10-B6-C138 A10-B6-C139 A10-B6-C140 BLANK BLANK BLANK BLANK
A10-B7-C1 A10-B7-C2 A10-B7-C3 A10-B7-C4 A10-B7-C5 A10-B7-C6
A10-B7-C7 A10-B7-C8 A10-B7-C9 A10-B7-C10 A10-B7-C11 A10-B7-C12
A10-B7-C13 A10-B7-C14 A10-B7-C15 A10-B7-C16 A10-B7-C17 A10-B7-C18
A10-B7-C19 A10-B7-C20 A10-B7-C21 A10-B7-C22 A10-B7-C23 A10-B7-C24 A10-B7-C25 A10-B7-C26 A10-B7-C27 A10-B7-C28 A10-B7-C29 A10-B7-C30
A10-B7-C31 A10-B7-C32 A10-B7-C33 A10-B7-C34 A10-B7-C35 A10-B7-C36
A10-B7-C37 A10-B7-C38 A10-B7-C39 A10-B7-C40 A10-B7-C41 A10-B7-C42
A10-B7-C43 A10-B7-C44 A10-B7-C45 A10-B7-C46 A10-B7-C47 A10-B7-C48
A10-B7-C49 A10-B7-C50 A10-B7-C51 A10-B7-C52 A10-B7-C53 A10-B7-C54 A10-B7-C55 A10-B7-C56 A10-B7-C57 A10-B7-C58 A10-B7-C59 A10-B7-C60
A10-B7-C61 A10-B7-C62 A10-B7-C63 A10-B7-C64 A10-B7-C65 A10-B7-C66
A10-B7-C67 A10-B7-C68 A10-B7-C69 A10-B7-C70 A10-B7-C71 A10-B7-C72
A10-B7-C73 A10-B7-C74 A10-B7-C75 A10-B7-C76 A10-B7-C77 A10-B7-C78
A10-B7-C79 A10-B7-C80 A10-B7-C81 A10-B7-C82 A10-B7-C83 A10-B7-C84 A10-B7-C85 A10-B7-C86 A10-B7-C87 A10-B7-C88 A10-B7-C89 A10-B7-C90
A10-B7-C91 A10-B7-C92 A10-B7-C93 A10-B7-C94 A10-B7-C95 A10-B7-C96
A10-B7-C97 A10-B7-C98 A10-B7-C99 A10-B7-C100 A10-B7-C101 A10-B7-C102
A10-B7-C103 A10-B7-C104 A10-B7-C105 A10-B7-C106 A10-B7-C107 A10-B7-C108
A10-B7-C109 A10-B7-C110 A10-B7-C111 A10-B7-C112 A10-B7-C113 A10-B7-C114 A10-B7-C115 A10-B7-C116 A10-B7-C117 A10-B7-C118 A10-B7-C119 A10-B7-C120
A10-B7-C121 A10-B7-C122 A10-B7-C123 A10-B7-C124 A10-B7-C125 A10-B7-C126
A10-B7-C127 A10-B7-C128 A10-B7-C129 A10-B7-C130 A10-B7-C131 A10-B7-C132
A10-B7-C133 A10-B7-C134 A10-B7-C135 A10-B7-C136 A10-B7-C137 A10-B7-C138
A10-B7-C139 A10-B7-C140 BLANK BLANK BLANK BLANK A10-B8-C1 A10-B8-C2 A10-B8-C3 A10-B8-C4 A10-B8-C5 A10-B8-C6
A10-B8-C7 A10-B8-C8 A10-B8-C9 A10-B8-C10 A10-B8-C11 A10-B8-C12
A10-B8-C13 A10-B8-C14 A10-B8-C15 A10-B8-C16 A10-B8-C17 A10-B8-C18
A10-B8-C19 A10-B8-C20 A10-B8-C21 A10-B8-C22 A10-B8-C23 A10-B8-C24
A10-B8-C25 A10-B8-C26 A10-B8-C27 A10-B8-C28 A10-B8-C29 A10-B8-C30
A10-B8-C31 A10-B8-C32 A10-B8-C33 A10-B8-C34 A10-B8-C35 A10-B8-C36
A10-B8-C37 A10-B8-C38 A10-B8-C39 A10-B8-C40 A10-B8-C41 A10-B8-C42 A10-B8-C43 A10-B8-C44 A10-B8-C45 A10-B8-C46 A10-B8-C47 A10-B8-C48
A10-B8-C49 A10-B8-C50 A10-B8-C51 A10-B8-C52 A10-B8-C53 A10-B8-C54
A10-B8-C55 A10-B8-C56 A10-B8-C57 A10-B8-C58 A10-B8-C59 A10-B8-C60
A10-B8-C61 A10-B8-C62 A10-B8-C63 A10-B8-C64 A10-B8-C65 A10-B8-C66
A10-B8-C67 A10-B8-C68 A10-B8-C69 A10-B8-C70 A10-B8-C71 A10-B8-C72 A10-B8-C73 A10-B8-C74 A10-B8-C75 A10-B8-C76 A10-B8-C77 A10-B8-C78
A10-B8-C79 A10-B8-C80 A10-B8-C81 A10-B8-C82 A10-B8-C83 A10-B8-C84
A10-B8-C85 A10-B8-C86 A10-B8-C87 A10-B8-C88 A10-B8-C89 A10-B8-C90
A10-B8-C91 A10-B8-C92 A10-B8-C93 A10-B8-C94 A10-B8-C95 A10-B8-C96
A10-B8-C97 A10-B8-C98 A10-B8-C99 A10-B8-C100 A10-B8-C101 A10-B8-C102 A10-B8-C103 A10-B8-C104 A10-B8-C105 A10-B8-C106 A10-B8-C107 A10-B8-C108
A10-B8-C109 A10-B8-C110 A10-B8-C111 A10-B8-C112 A10-B8-C113 A10-B8-C114
A10-B8-C115 A10-B8-C116 A10-B8-C117 A10-B8-C118 A10-B8-C119 A10-B8-C120
A10-B8-C121 A10-B8-C122 A10-B8-C123 A10-B8-C124 A10-B8-C125 A10-B8-C126
A10-B8-C127 A10-B8-C128 A10-B8-C129 A10-B8-C130 A10-B8-C131 A10-B8-C132 A10-B8-C133 A10-B8-C134 A10-B8-C135 A10-B8-C136 A10-B8-C137 A10-B8-C138
A10-B8-C139 A10-B8-C140 BLANK BLANK BLANK BLANK
A10-B9-C1 A10-B9-C2 A10-B9-C3 A10-B9-C4 A10-B9-C5 A10-B9-C6
A10-B9-C7 A10-B9-C8 A10-B9-C9 A10-B9-C10 A10-B9-C11 A10-B9-C12
A10-B9-C13 A10-B9-C14 A10-B9-C15 A10-B9-C16 A10-B9-C17 A10-B9-C18 A10-B9-C19 A10-B9-C20 A10-B9-C21 A10-B9-C22 A10-B9-C23 A10-B9-C24
A10-B9-C25 A10-B9-C26 A10-B9-C27 A10-B9-C28 A10-B9-C29 A10-B9-C30
A10-B9-C31 A10-B9-C32 A10-B9-C33 A10-B9-C34 A10-B9-C35 A10-B9-C36
A10-B9-C37 A10-B9-C38 A10-B9-C39 A10-B9-C40 A10-B9-C41 A10-B9-C42
A10-B9-C43 A10-B9-C44 A10-B9-C45 A10-B9-C46 A10-B9-C47 A10-B9-C48 A10-B9-C49 A10-B9-C50 A10-B9-C51 A10-B9-C52 A10-B9-C53 A10-B9-C54
A10-B9-C55 A10-B9-C56 A10-B9-C57 A10-B9-C58 A10-B9-C59 A10-B9-C60
A10-B9-C61 A10-B9-C62 A10-B9-C63 A10-B9-C64 A10-B9-C65 A10-B9-C66
A10-B9-C67 A10-B9-C68 A10-B9-C69 A10-B9-C70 A10-B9-C71 A10-B9-C72
A10-B9-C73 A10-B9-C74 A10-B9-C75 A10-B9-C76 A10-B9-C77 A10-B9-C78 A10-B9-C79 A10-B9-C80 A10-B9-C81 A10-B9-C82 A10-B9-C83 A10-B9-C84
A10-B9-C85 A10-B9-C86 A10-B9-C87 A10-B9-C88 A10-B9-C89 A10-B9-C90
A10-B9-C91 A10-B9-C92 A10-B9-C93 A10-B9-C94 A10-B9-C95 A10-B9-C96
A10-B9-C97 A10-B9-C98 A10-B9-C99 A10-B9-C100 A10-B9-C101 A10-B9-C102
A10-B9-C103 A10-B9-C104 A10-B9-C105 A10-B9-C106 A10-B9-C107 A10-B9-C108
A10-B9-C109 A10-B9-C110 A10-B9-C111 A10-B9-C112 A10-B9-C113 A10-B9-C114
A10-B9-C115 A10-B9-C116 A10-B9-C117 A10-B9-C118 A10-B9-C119 A10-B9-C120 A10-B9-C121 A10-B9-C122 A10-B9-C123 A10-B9-C124 A10-B9-C125 A10-B9-C126
A10-B9-C127 A10-B9-C128 A10-B9-C129 A10-B9-C130 A10-B9-C131 A10-B9-C132
A10-B9-C133 A10-B9-C134 A10-B9-C135 A10-B9-C136 A10-B9-C137 A10-B9-C138
A10-B9-C139 A10-B9-C140 BLANK BLANK BLANK BLANK
A10-B10-C1 A10-B10-C2 A10-B10-C3 A10-B10-C4 A10-B10-C5 A10-B10-C6 A10-B10-C7 A10-B10-C8 A10-B10-C9 A10-B10-C10 A10-B10-C11 A10-B10-C12
A10-B10-C13 A10-B10-C14 A10-B10-C15 A10-B10-C16 A10-B10-C17 A10-B10-C18
A10-B10-C19 A10-B10-C20 A10-B10-C21 A10-B10-C22 A10-B10-C23 A10-B10-C24
A10-B10-C25 A10-B10-C26 A10-B10-C27 A10-B10-C28 A10-B10-C29 A10-B10-C30
A10-B10-C31 A10-B10-C32 A10-B10-C33 A10-B10-C34 A10-B10-C35 A10-B10-C36 A10-B10-C37 A10-B10-C38 A10-B10-C39 A10-B10-C40 A10-B10-C41 A10-B10-C42
A10-B10-C43 A10-B10-C44 A10-B10-C45 A10-B10-C46 A10-B10-C47 A10-B10-C48
A10-B10-C49 A10-B10-C50 A10-B10-C51 A10-B10-C52 A10-B10-C53 A10-B10-C54
A10-B10-C55 A10-B10-C56 A10-B10-C57 A10-B10-C58 A10-B10-C59 A10-B10-C60
A10-B10-C61 A10-B10-C62 A10-B10-C63 A10-B10-C64 A10-B10-C65 A10-B10-C66 A10-B10-C67 A10-B10-C68 A10-B10-C69 A10-B10-C70 A10-B10-C71 A10-B10-C72
A10-B10-C73 A10-B10-C74 A10-B10-C75 A10-B10-C76 A10-B10-C77 A10-B10-C78
A10-B10-C79 A10-B10-C80 A10-B10-C81 A10-B10-C82 A10-B10-C83 A10-B10-C84
A10-B10-C85 A10-B10-C86 A10-B10-C87 A10-B10-C88 A10-B10-C89 A10-B10-C90
A10-B10-C91 A10-B10-C92 A10-B10-C93 A10-B10-C94 A10-B10-C95 A10-B10-C96 A10-B10-C97 A10-B10-C98 A10-B10-C99 A10-B10-C100 AlO-BlO-ClOl A10-B10-C102
A10-B10-C103 A10-B10-C104 A10-B10-C105 A10-B10-C106 A10-B10-C107 A10-B10-C108
A10-B10-C109 AlO-BlO-Cl lO AlO-BlO-Cl l l A10-B10-C112 A10-B10-C113 A10-B10-C114
A10-B10-C115 A10-B10-C116 A10-B10-C117 A10-B10-C118 A10-B10-C119 A10-B10-C120
A10-B10-C121 A10-B10-C122 A10-B10-C123 A10-B10-C124 A10-B10-C125 A10-B10-C126 A10-B10-C127 A10-B10-C128 A10-B10-C129 A10-B10-C130 A10-B10-C131 A10-B10-C132
A10-B10-C133 A10-B10-C134 A10-B10-C135 A10-B10-C136 A10-B10-C137 A10-B10-C138
A10-B10-C139 A10-B10-C140 BLANK BLANK BLANK BLANK
A10-B11-C1 A10-B11-C2 A10-B1 1-C3 A10-B11-C4 A10-B11-C5 A10-B11-C6
A10-B11-C7 A10-B11-C8 A10-B11-C9 A10-B11-C10 A10-B11-C11 A10-B11-C12 A10-B11-C13 A10-B11-C14 A10-B11-C15 A10-B11-C16 A10-B11-C17 A10-B11-C18
A10-B11-C19 A10-B11-C20 A10-B1 1-C21 A10-B11-C22 A10-B11-C23 A10-B11-C24
A10-B11-C25 A10-B11-C26 A10-B1 1-C27 A10-B11-C28 A10-B11-C29 A10-B11-C30
A10-B11-C31 A10-B11-C32 A10-B11-C33 A10-B11-C34 A10-B11-C35 A10-B11-C36
A10-B11-C37 A10-B11-C38 A10-B11-C39 A10-B11-C40 A10-B11-C41 A10-B11-C42
A10-B11-C43 A10-B11-C44 A10-B11-C45 A10-B1 1-C46 A10-B11-C47 A10-B11-C48
A10-B11-C49 A10-B11-C50 A10-B11-C51 A10-B1 1-C52 A10-B11-C53 A10-B11-C54 A10-B11-C55 A10-B11-C56 A10-B11-C57 A10-B1 1-C58 A10-B11-C59 A10-B11-C60
A10-B11-C61 A10-B11-C62 A10-B11-C63 A10-B11-C64 A10-B11-C65 A10-B11-C66
A10-B11-C67 A10-B11-C68 A10-B11-C69 A10-B11-C70 A10-B11-C71 A10-B11-C72
A10-B11-C73 A10-B11-C74 A10-B11-C75 A10-B11-C76 A10-B11-C77 A10-B11-C78
A10-B11-C79 A10-B11-C80 A10-B11-C81 A10-B11-C82 A10-B11-C83 A10-B11-C84 A10-B11-C85 A10-B11-C86 A10-B11-C87 A10-B11-C88 A10-B11-C89 A10-B11-C90
A10-B11-C91 A10-B11-C92 A10-B11-C93 A10-B11-C94 A10-B11-C95 A10-B11-C96
A10-B11-C97 A10-B11-C98 A10-B11-C99 A10-B11-C100 A10-B11-C101 A10-B11-C102
A10-B11-C103 A10-B11-C104 A10-B11-C105 A10-B11-C106 A10-B11-C107 A10-B11-C108
A10-B11-C109 A10-B11-C110 A10-B11-C111 A10-B11-C112 A10-B11-C113 A10-B11-C114 A10-B11-C115 A10-B11-C116 A10-B11-C117 A10-B11-C118 A10-B11-C119 A10-B11-C120
A10-B11-C121 A10-B11-C122 A10-B11-C123 A10-B11-C124 A10-B11-C125 A10-B11-C126
A10-B11-C127 A10-B11-C128 A10-B11-C129 A10-B11-C130 A10-B11-C131 A10-B11-C132
A10-B11-C133 A10-B11-C134 A10-B11-C135 A10-B11-C136 A10-B11-C137 A10-B11-C138
A10-B11-C139 A10-B11-C140 BLANK BLANK BLANK BLANK A10-B12-C1 A10-B12-C2 A10-B12-C3 A10-B12-C4 A10-B12-C5 A10-B12-C6
A10-B12-C7 A10-B12-C8 A10-B12-C9 A10-B12-C10 A10-B12-C11 A10-B12-C12
A10-B12-C13 A10-B12-C14 A10-B12-C15 A10-B12-C16 A10-B12-C17 A10-B12-C18
A10-B12-C19 A10-B12-C20 A10-B12-C21 A10-B12-C22 A10-B12-C23 A10-B12-C24
A10-B12-C25 A10-B12-C26 A10-B12-C27 A10-B12-C28 A10-B12-C29 A10-B12-C30 A10-B12-C31 A10-B12-C32 A10-B12-C33 A10-B12-C34 A10-B12-C35 A10-B12-C36
A10-B12-C37 A10-B12-C38 A10-B12-C39 A10-B12-C40 A10-B12-C41 A10-B12-C42
A10-B12-C43 A10-B12-C44 A10-B12-C45 A10-B12-C46 A10-B12-C47 A10-B12-C48
A10-B12-C49 A10-B12-C50 A10-B12-C51 A10-B12-C52 A10-B12-C53 A10-B12-C54
A10-B12-C55 A10-B12-C56 A10-B12-C57 A10-B12-C58 A10-B12-C59 A10-B12-C60 A10-B12-C61 A10-B12-C62 A10-B12-C63 A10-B12-C64 A10-B12-C65 A10-B12-C66
A10-B12-C67 A10-B12-C68 A10-B12-C69 A10-B12-C70 A10-B12-C71 A10-B12-C72
A10-B12-C73 A10-B12-C74 A10-B12-C75 A10-B12-C76 A10-B12-C77 A10-B12-C78
A10-B12-C79 A10-B12-C80 A10-B12-C81 A10-B12-C82 A10-B12-C83 A10-B12-C84
A10-B12-C85 A10-B12-C86 A10-B12-C87 A10-B12-C88 A10-B12-C89 A10-B12-C90 A10-B12-C91 A10-B12-C92 A10-B12-C93 A10-B12-C94 A10-B12-C95 A10-B12-C96
A10-B12-C97 A10-B12-C98 A10-B12-C99 A10-B12-C100 A10-B12-C101 A10-B12-C102
A10-B12-C103 A10-B12-C104 A10-B12-C105 A10-B12-C106 A10-B12-C107 A10-B12-C108
A10-B12-C109 A10-B12-C110 A10-B12-C111 A10-B12-C112 A10-B12-C113 A10-B12-C114
A10-B12-C115 A10-B12-C116 A10-B12-C117 A10-B12-C1 18 A10-B12-C119 A10-B12-C120
A10-B12-C121 A10-B12-C122 A10-B12-C123 A10-B12-C124 A10-B12-C125 A10-B12-C126
A10-B12-C127 A10-B12-C128 A10-B12-C129 A10-B12-C130 A10-B12-C131 A10-B12-C132 A10-B12-C133 A10-B12-C134 A10-B12-C135 A10-B12-C136 A10-B12-C137 A10-B12-C138
A10-B12-C139 A10-B12-C140 BLANK BLANK BLANK BLANK
A10-B13-C1 A10-B13-C2 A10-B13-C3 A10-B13-C4 A10-B13-C5 A10-B13-C6
A10-B13-C7 A10-B13-C8 A10-B13-C9 A10-B13-C10 A10-B13-C11 A10-B13-C12
A10-B13-C13 A10-B13-C14 A10-B13-C15 A10-B13-C16 A10-B13-C17 A10-B13-C18 A10-B13-C19 A10-B13-C20 A10-B13-C21 A10-B13-C22 A10-B13-C23 A10-B13-C24
A10-B13-C25 A10-B13-C26 A10-B13-C27 A10-B13-C28 A10-B13-C29 A10-B13-C30
A10-B13-C31 A10-B13-C32 A10-B13-C33 A10-B13-C34 A10-B13-C35 A10-B13-C36
A10-B13-C37 A10-B13-C38 A10-B13-C39 A10-B13-C40 A10-B13-C41 A10-B13-C42
A10-B13-C43 A10-B13-C44 A10-B13-C45 A10-B13-C46 A10-B13-C47 A10-B13-C48 A10-B13-C49 A10-B13-C50 A10-B13-C51 A10-B13-C52 A10-B13-C53 A10-B13-C54
A10-B13-C55 A10-B13-C56 A10-B13-C57 A10-B13-C58 A10-B13-C59 A10-B13-C60
A10-B13-C61 A10-B13-C62 A10-B13-C63 A10-B13-C64 A10-B13-C65 A10-B13-C66
A10-B13-C67 A10-B13-C68 A10-B13-C69 A10-B13-C70 A10-B13-C71 A10-B13-C72
A10-B13-C73 A10-B13-C74 A10-B13-C75 A10-B13-C76 A10-B13-C77 A10-B13-C78 A10-B13-C79 A10-B13-C80 A10-B13-C81 A10-B13-C82 A10-B13-C83 A10-B13-C84
A10-B13-C85 A10-B13-C86 A10-B13-C87 A10-B13-C88 A10-B13-C89 A10-B13-C90
A10-B13-C91 A10-B13-C92 A10-B13-C93 A10-B13-C94 A10-B13-C95 A10-B13-C96
A10-B13-C97 A10-B13-C98 A10-B13-C99 A10-B13-C100 A10-B13-C101 A10-B13-C102
A10-B13-C103 A10-B13-C104 A10-B13-C105 A10-B13-C106 A10-B13-C107 A10-B13-C108 A10-B13-C109 A10-B13-C110 A10-B13-C111 A10-B13-C112 A10-B13-C113 A10-B13-C114
A10-B13-C115 A10-B13-C116 A10-B13-C117 A10-B13-C118 A10-B13-C119 A10-B13-C120
A10-B13-C121 A10-B13-C122 A10-B13-C123 A10-B13-C124 A10-B13-C125 A10-B13-C126
A10-B13-C127 A10-B13-C128 A10-B13-C129 A10-B13-C130 A10-B13-C131 A10-B13-C132
A10-B13-C133 A10-B13-C134 A10-B13-C135 A10-B13-C136 A10-B13-C137 A10-B13-C138 A10-B13-C139 A10-B13-C140 BLANK BLANK BLANK BLANK
A11-B1-C1 A11-B1-C2 A11-B1-C3 A11-B1-C4 A11-B1-C5 A11-B1-C6
A11-B1-C7 A11-B1-C8 A11-B1-C9 A11-B1-C10 A11-B1-C11 A11-B1-C12
AH-B1-C13 A11-B1-C14 A11-B1-C15 A11-B1-C16 A11-B1-C17 A11-B1-C18
AH-B1-C19 A11-B1-C20 A11-B1-C21 A11-B1-C22 A11-B1-C23 A11-B1-C24 AH-B1-C25 A11-B1-C26 A11-B1-C27 A11-B1-C28 A11-B1-C29 A11-B1-C30
A11-B1-C31 A11-B1-C32 A11-B1-C33 A11-B1-C34 A11-B1-C35 A11-B1-C36
AH-B1-C37 A11-B1-C38 A11-B1-C39 A11-B1-C40 A11-B1-C41 A11-B1-C42
A11-B1-C43 A11-B1-C44 A11-B1-C45 A11-B1-C46 A11-B1-C47 A11-B1-C48
A11-B1-C49 A11-B1-C50 A11-B1-C51 A11-B1-C52 A11-B1-C53 A11-B1-C54
A11-B1-C55 A11-B1-C56 A11-B1-C57 A11-B1-C58 A11-B1-C59 A11-B1-C60
A11-B1-C61 A1 1-B1-C62 A11-B1-C63 A11-B1-C64 A11-B1-C65 A11-B1-C66 A11-B1-C67 A1 1-B1-C68 A11-B1-C69 A11-B1-C70 A11-B1-C71 A11-B1-C72
A11-B1-C73 A11-B1-C74 A11-B1-C75 A11-B1-C76 A11-B1-C77 A11-B1-C78
A11-B1-C79 A1 1-B1-C80 A11-B1-C81 A11-B1-C82 A11-B1-C83 A11-B1-C84
A11-B1-C85 A11-B1-C86 A11-B1-C87 A11-B1-C88 A11-B1-C89 A11-B1-C90
A11-B1-C91 A1 1-B1-C92 A11-B1-C93 A11-B1-C94 A11-B1-C95 A11-B1-C96 A11-B1-C97 A11-B1-C98 A11-B1-C99 A11-B1-C100 A11-B1-C101 A11-B1-C102
A11-B1-C103 A11-B1-C104 A11-B1-C105 A11-B1-C106 A11-B1-C107 A11-B1-C108
A11-B1-C109 A11-B1-C110 All-Bl-Cll l A11-B1-C112 A11-B1-C113 A11-B1-C114
A11-B1-C115 A1 1-B1-C116 A11-B1-C117 A11-B1-C118 A11-B1-C119 A11-B1-C120
A11-B1-C121 A11-B1-C122 A11-B1-C123 A11-B1-C124 A11-B1-C125 A11-B1-C126 A11-B1-C127 A11-B1-C128 A11-B1-C129 A11-B1-C130 A11-B1-C131 A11-B1-C132
A11-B1-C133 A11-B1-C134 A11-B1-C135 A11-B1-C136 A11-B1-C137 A11-B1-C138
A11-B1-C139 A11-B1-C140 BLANK BLANK BLANK BLANK
A11-B2-C1 A11-B2-C2 A11-B2-C3 A11-B2-C4 A11-B2-C5 A11-B2-C6
A11-B2-C7 A11-B2-C8 A11-B2-C9 A11-B2-C10 A11-B2-C1 1 A11-B2-C12 A11-B2-C13 A11-B2-C14 A11-B2-C15 A11-B2-C16 A11-B2-C17 A11-B2-C18
A11-B2-C19 A11-B2-C20 A11-B2-C21 A11-B2-C22 A11-B2-C23 A11-B2-C24
A11-B2-C25 A11-B2-C26 A11-B2-C27 A11-B2-C28 A11-B2-C29 A11-B2-C30
A11-B2-C31 A11-B2-C32 A11-B2-C33 A11-B2-C34 A11-B2-C35 A11-B2-C36
A11-B2-C37 A11-B2-C38 A11-B2-C39 A11-B2-C40 A11-B2-C41 A11-B2-C42 A11-B2-C43 A11-B2-C44 A11-B2-C45 A11-B2-C46 A11-B2-C47 A11-B2-C48
A11-B2-C49 A11-B2-C50 A11-B2-C51 A11-B2-C52 A11-B2-C53 A11-B2-C54
A11-B2-C55 A11-B2-C56 A11-B2-C57 A11-B2-C58 A11-B2-C59 A11-B2-C60
A11-B2-C61 A11-B2-C62 A11-B2-C63 A11-B2-C64 A11-B2-C65 A11-B2-C66
A11-B2-C67 A11-B2-C68 A11-B2-C69 A11-B2-C70 A11-B2-C71 A11-B2-C72 A11-B2-C73 A11-B2-C74 A11-B2-C75 A11-B2-C76 A11-B2-C77 A11-B2-C78
A11-B2-C79 A11-B2-C80 A11-B2-C81 A11-B2-C82 A11-B2-C83 A11-B2-C84
A11-B2-C85 A11-B2-C86 A11-B2-C87 A11-B2-C88 A11-B2-C89 A11-B2-C90
AH-B2-C91 A11-B2-C92 A11-B2-C93 A11-B2-C94 A11-B2-C95 A11-B2-C96
A11-B2-C97 A11-B2-C98 A11-B2-C99 A11-B2-C100 A11-B2-C101 A11-B2-C102 AH-B2-C103 A11-B2-C104 A11-B2-C105 A11-B2-C106 A11-B2-C107 A11-B2-C108
A11-B2-C109 A11-B2-C110 A11-B2-C111 A11-B2-C112 A11-B2-C113 A11-B2-C114
A11-B2-C115 A11-B2-C116 A11-B2-C117 A11-B2-C118 A11-B2-C119 A11-B2-C120
A11-B2-C121 A11-B2-C122 A11-B2-C123 A11-B2-C124 A11-B2-C125 A11-B2-C126
A11-B2-C127 A11-B2-C128 A11-B2-C129 A11-B2-C130 A11-B2-C131 A11-B2-C132
A11-B2-C133 A11-B2-C134 A11-B2-C135 A11-B2-C136 A11-B2-C137 A11-B2-C138
A11-B2-C139 A11-B2-C140 BLANK BLANK BLANK BLANK A11-B3-C1 A11-B3-C2 A11-B3-C3 A11-B3-C4 A11-B3-C5 A11-B3-C6
A11-B3-C7 A11-B3-C8 A11-B3-C9 A11-B3-C10 A11-B3-C11 A11-B3-C12
A11-B3-C13 A11-B3-C14 A11-B3-C15 A11-B3-C16 A11-B3-C17 A11-B3-C18
A11-B3-C19 A11-B3-C20 A11-B3-C21 A11-B3-C22 A11-B3-C23 A11-B3-C24
A11-B3-C25 A11-B3-C26 A11-B3-C27 A11-B3-C28 A11-B3-C29 A11-B3-C30 A11-B3-C31 A11-B3-C32 A11-B3-C33 A11-B3-C34 A11-B3-C35 A11-B3-C36
A11-B3-C37 A11-B3-C38 A11-B3-C39 A11-B3-C40 A11-B3-C41 A11-B3-C42
A11-B3-C43 A11-B3-C44 A11-B3-C45 A11-B3-C46 A11-B3-C47 A11-B3-C48
A11-B3-C49 A11-B3-C50 A11-B3-C51 A11-B3-C52 A11-B3-C53 A11-B3-C54
A11-B3-C55 A11-B3-C56 A11-B3-C57 A11-B3-C58 A11-B3-C59 A11-B3-C60 A11-B3-C61 A11-B3-C62 A11-B3-C63 A11-B3-C64 A11-B3-C65 A11-B3-C66
A11-B3-C67 A11-B3-C68 A11-B3-C69 A11-B3-C70 A11-B3-C71 A11-B3-C72
A11-B3-C73 A11-B3-C74 A11-B3-C75 A11-B3-C76 A11-B3-C77 A11-B3-C78
A11-B3-C79 A11-B3-C80 A11-B3-C81 A11-B3-C82 A11-B3-C83 A11-B3-C84
A11-B3-C85 A11-B3-C86 A11-B3-C87 A11-B3-C88 A11-B3-C89 A11-B3-C90 A11-B3-C91 A11-B3-C92 A11-B3-C93 A11-B3-C94 A11-B3-C95 A11-B3-C96
A11-B3-C97 A11-B3-C98 A11-B3-C99 A11-B3-C100 A11-B3-C101 A11-B3-C102
A11-B3-C103 A11-B3-C104 A11-B3-C105 A11-B3-C106 A11-B3-C107 A11-B3-C108
A11-B3-C109 A11-B3-C110 A11-B3-C111 A11-B3-C112 A11-B3-C113 A11-B3-C114
A11-B3-C115 A11-B3-C116 A1T-B3-C117 A11-B3-C118 A11-B3-C119 A11-B3-C120 A11-B3-C121 A11-B3-C122 A11-B3-C123 A11-B3-C124 A11-B3-C125 A11-B3-C126
A11-B3-C127 A11-B3-C128 A11-B3-C129 A11-B3-C130 A11-B3-C131 A11-B3-C132
A11-B3-C133 A11-B3-C134 A11-B3-C135 A11-B3-C136 A11-B3-C137 A11-B3-C138 A11-B3-C139 A11-B3-C140 BLANK BLANK BLANK BLANK
A11-B4-C1 A11-B4-C2 A11-B4-C3 A11-B4-C4 A11-B4-C5 A11-B4-C6 A11-B4-C7 A11-B4-C8 A11-B4-C9 A11-B4-C10 A11-B4-C11 A11-B4-C12
A11-B4-C13 A11-B4-C14 A11-B4-C15 A11-B4-C16 A11-B4-C17 A11-B4-C18
AH-B4-C19 A11-B4-C20 A11-B4-C21 A11-B4-C22 A11-B4-C23 A11-B4-C24
AH-B4-C25 A11-B4-C26 A11-B4-C27 A11-B4-C28 A11-B4-C29 A11-B4-C30
AH-B4-C31 A11-B4-C32 A11-B4-C33 A11-B4-C34 A11-B4-C35 A11-B4-C36 AH-B4-C37 A11-B4-C38 A11-B4-C39 A11-B4-C40 A11-B4-C41 A11-B4-C42
AH-B4-C43 A11-B4-C44 A11-B4-C45 A11-B4-C46 A11-B4-C47 A11-B4-C48
AH-B4-C49 A11-B4-C50 A11-B4-C51 A11-B4-C52 A11-B4-C53 A11-B4-C54
A11-B4-C55 A11-B4-C56 A11-B4-C57 A11-B4-C58 A11-B4-C59 A11-B4-C60
A11-B4-C61 A11-B4-C62 A11-B4-C63 A11-B4-C64 A11-B4-C65 A11-B4-C66
A11-B4-C67 A11-B4-C68 A11-B4-C69 A11-B4-C70 A11-B4-C71 A11-B4-C72
A11-B4-C73 A11-B4-C74 A1 1-B4-C75 A11-B4-C76 A11-B4-C77 A11-B4-C78 A11-B4-C79 A11-B4-C80 A11-B4-C81 A11-B4-C82 A11-B4-C83 A11-B4-C84
A11-B4-C85 A11-B4-C86 A11-B4-C87 A11-B4-C88 A11-B4-C89 A11-B4-C90
A11-B4-C91 A11-B4-C92 A11-B4-C93 A11-B4-C94 A11-B4-C95 A11-B4-C96
A11-B4-C97 A11-B4-C98 A11-B4-C99 A11-B4-C100 A11-B4-C101 A11-B4-C102
A11-B4-C103 A11-B4-C104 A11-B4-C105 A11-B4-C106 A11-B4-C107 A11-B4-C108 A11-B4-C109 A11-B4-C110 A11-B4-C111 A11-B4-C112 A11-B4-C113 A11-B4-C114
A11-B4-C115 A11-B4-C116 A11-B4-C117 A11-B4-C118 A11-B4-C119 A11-B4-C120
A11-B4-C121 A11-B4-C122 A1 1-B4-C123 A11-B4-C124 A11-B4-C125 A11-B4-C126
A11-B4-C127 A11-B4-C128 A11-B4-C129 A11-B4-C130 A11-B4-C131 A11-B4-C132
A11-B4-C133 A11-B4-C134 A11-B4-C135 A11-B4-C136 A11-B4-C137 A11-B4-C138 A11-B4-C139 A11-B4-C140 BLANK BLANK BLANK BLANK
A11-B5-C1 A11-B5-C2 A11-B5-C3 A11-B5-C4 A11-B5-C5 A11-B5-C6
A11-B5-C7 A11-B5-C8 A11-B5-C9 A11-B5-C10 A11-B5-C11 A11-B5-C12
A11-B5-C13 A11-B5-C14 A1 1-B5-C15 A11-B5-C16 A11-B5-C17 A11-B5-C18
A11-B5-C19 A11-B5-C20 A11-B5-C21 A11-B5-C22 A11-B5-C23 A11-B5-C24 A11-B5-C25 A11-B5-C26 A11-B5-C27 A11-B5-C28 A11-B5-C29 A11-B5-C30
A11-B5-C31 A11-B5-C32 A11-B5-C33 A11-B5-C34 A11-B5-C35 A11-B5-C36
A11-B5-C37 A11-B5-C38 A11-B5-C39 A11-B5-C40 A11-B5-C41 A11-B5-C42
A11-B5-C43 A11-B5-C44 A11-B5-C45 A11-B5-C46 A11-B5-C47 A11-B5-C48
A11-B5-C49 A11-B5-C50 A1 1-B5-C51 A11-B5-C52 A11-B5-C53 A11-B5-C54 A11-B5-C55 A11-B5-C56 A11-B5-C57 A11-B5-C58 A11-B5-C59 A11-B5-C60
A11-B5-C61 A11-B5-C62 A11-B5-C63 A11-B5-C64 A11-B5-C65 A11-B5-C66
A11-B5-C67 A11-B5-C68 A11-B5-C69 A11-B5-C70 A11-B5-C71 A11-B5-C72
A11-B5-C73 A11-B5-C74 A11-B5-C75 A11-B5-C76 A11-B5-C77 A11-B5-C78
A11-B5-C79 A11-B5-C80 A11-B5-C81 A11-B5-C82 A11-B5-C83 A11-B5-C84 A11-B5-C85 A11-B5-C86 A11-B5-C87 A11-B5-C88 A11-B5-C89 A11-B5-C90
A11-B5-C91 A11-B5-C92 A11-B5-C93 A11-B5-C94 A11-B5-C95 A11-B5-C96
A11-B5-C97 A11-B5-C98 A11-B5-C99 A11-B5-C100 A11-B5-C101 A11-B5-C102
AH-B5-C103 A11-B5-C104 A1 1-B5-C105 A11-B5-C106 A11-B5-C107 A11-B5-C108
AH-B5-C109 A11-B5-C110 A11-B5-C111 A11-B5-C112 A11-B5-C113 A11-B5-C114 AH-B5-C115 A11-B5-C116 A11-B5-C117 A11-B5-C118 A11-B5-C119 A11-B5-C120
A11-B5-C121 A11-B5-C122 A11-B5-C123 A11-B5-C124 A11-B5-C125 A11-B5-C126
A11-B5-C127 A11-B5-C128 A11-B5-C129 A11-B5-C130 A11-B5-C131 A11-B5-C132
A11-B5-C133 A11-B5-C134 A11-B5-C135 A11-B5-C136 A11-B5-C137 A11-B5-C138
A11-B5-C139 A11-B5-C140 BLANK BLANK BLANK BLANK
A1 1-B6-C1 A11-B6-C2 A11-B6-C3 A1 1-B6-C4 A11-B6-C5 A11-B6-C6
A11-B6-C7 A11-B6-C8 A11-B6-C9 A11-B6-C10 A11-B6-C11 A11-B6-C12 A11-B6-C13 A11-B6-C14 A11-B6-C15 A11-B6-C16 A11-B6-C17 A11-B6-C18
A11-B6-C19 A11-B6-C20 A11-B6-C21 A11-B6-C22 A11-B6-C23 A11-B6-C24
A11-B6-C25 A11-B6-C26 A11-B6-C27 A11-B6-C28 A11-B6-C29 A11-B6-C30
A1 1-B6-C31 A11-B6-C32 A11-B6-C33 A11-B6-C34 A11-B6-C35 A11-B6-C36
A11-B6-C37 A11-B6-C38 A11-B6-C39 A11-B6-C40 A11-B6-C41 A11-B6-C42 A11-B6-C43 A11-B6-C44 A11-B6-C45 A11-B6-C46 A11-B6-C47 A11-B6-C48
A11-B6-C49 A11-B6-C50 A11-B6-C51 A11-B6-C52 A11-B6-C53 A11-B6-C54
A11-B6-C55 A11-B6-C56 A11-B6-C57 A11-B6-C58 A11-B6-C59 A11-B6-C60
A11-B6-C61 A11-B6-C62 A11-B6-C63 A11-B6-C64 A11-B6-C65 A11-B6-C66
A11-B6-C67 A11-B6-C68 A11-B6-C69 A1 1-B6-C70 A11-B6-C71 A11-B6-C72 A1 1-B6-C73 A11-B6-C74 A11-B6-C75 A1 1-B6-C76 A11-B6-C77 A11-B6-C78
A11-B6-C79 A11-B6-C80 A11-B6-C81 A11-B6-C82 A11-B6-C83 A11-B6-C84
A11-B6-C85 A11-B6-C86 A11-B6-C87 A11-B6-C88 A11-B6-C89 A11-B6-C90
A11-B6-C91 A11-B6-C92 A11-B6-C93 A11-B6-C94 A11-B6-C95 A11-B6-C96
A11-B6-C97 A11-B6-C98 A11-B6-C99 A1 1-B6-C100 A11-B6-C101 A11-B6-C102 A11-B6-C103 A11-B6-C104 A11-B6-C105 A11-B6-C106 A11-B6-C107 A11-B6-C108
A11-B6-C109 A11-B6-C110 A11-B6-C111 A11-B6-C112 A11-B6-C113 A11-B6-C114
A11-B6-C115 A11-B6-C116 A11-B6-C117 A11-B6-C118 A11-B6-C119 A11-B6-C120
A11-B6-C121 A11-B6-C122 A11-B6-C123 A11-B6-C124 A11-B6-C125 A11-B6-C126
A11-B6-C127 A11-B6-C128 A11-B6-C129 A11-B6-C130 A11-B6-C131 A11-B6-C132 A11-B6-C133 A11-B6-C134 A11-B6-C135 A11-B6-C136 A11-B6-C137 A11-B6-C138
A11-B6-C139 A11-B6-C140 BLANK BLANK BLANK BLANK
A11-B7-C1 A11-B7-C2 A11-B7-C3 A11-B7-C4 A11-B7-C5 A11-B7-C6
A11-B7-C7 A11-B7-C8 A11-B7-C9 A11-B7-C10 A11-B7-C11 A11-B7-C12
A11-B7-C13 A11-B7-C14 A11-B7-C15 A11-B7-C16 A11-B7-C17 A11-B7-C18 A11-B7-C19 A11-B7-C20 A11-B7-C21 A11-B7-C22 A11-B7-C23 A11-B7-C24
A11-B7-C25 A11-B7-C26 A11-B7-C27 A11-B7-C28 A11-B7-C29 A11-B7-C30
A11-B7-C31 A11-B7-C32 A11-B7-C33 A11-B7-C34 A11-B7-C35 A11-B7-C36
A11-B7-C37 A11-B7-C38 A11-B7-C39 A11-B7-C40 A11-B7-C41 A11-B7-C42
A11-B7-C43 A11-B7-C44 A11-B7-C45 A11-B7-C46 A11-B7-C47 A11-B7-C48 AH-B7-C49 A11-B7-C50 A11-B7-C51 A11-B7-C52 A11-B7-C53 A11-B7-C54
A11-B7-C55 A11-B7-C56 A11-B7-C57 A11-B7-C58 A11-B7-C59 A11-B7-C60
A11-B7-C61 A11-B7-C62 A11-B7-C63 A11-B7-C64 A11-B7-C65 A11-B7-C66
A11-B7-C67 A11-B7-C68 A11-B7-C69 A11-B7-C70 A11-B7-C71 A11-B7-C72
A11-B7-C73 A11-B7-C74 A11-B7-C75 A11-B7-C76 A11-B7-C77 A11-B7-C78
A11-B7-C79 A11-B7-C80 A11-B7-C81 A11-B7-C82 A11-B7-C83 A11-B7-C84
A11-B7-C85 A11-B7-C86 A11-B7-C87 A11-B7-C88 A11-B7-C89 A11-B7-C90 A11-B7-C91 A11-B7-C92 A11-B7-C93 A11-B7-C94 A11-B7-C95 A11-B7-C96
A11-B7-C97 A11-B7-C98 A11-B7-C99 A11-B7-C100 A11-B7-C101 A11-B7-C102
A11-B7-C103 A11-B7-C104 A11-B7-C105 A11-B7-C106 A11-B7-C107 A11-B7-C108
A11-B7-C109 A11-B7-C110 A11-B7-C111 A11-B7-C112 A11-B7-C113 A11-B7-C114
A11-B7-C115 A11-B7-C116 A11-B7-C117 A11-B7-C118 A11-B7-C119 A11-B7-C120 A11-B7-C121 A11-B7-C122 A11-B7-C123 A11-B7-C124 A11-B7-C125 A11-B7-C126
A11-B7-C127 A11-B7-C128 A11-B7-C129 A11-B7-C130 A11-B7-C131 A11-B7-C132
A11-B7-C133 A11-B7-C134 A11-B7-C135 A11-B7-C136 A11-B7-C137 A11-B7-C138
A11-B7-C139 A11-B7-C140 BLANK BLANK BLANK BLANK
A11-B8-C1 A11-B8-C2 A11-B8-C3 A11-B8-C4 A11-B8-C5 A11-B8-C6 A11-B8-C7 A11-B8-C8 A11-B8-C9 A11-B8-C10 A11-B8-C11 A11-B8-C12
A11-B8-C13 A11-B8-C14 A11-B8-C15 A11-B8-C16 A11-B8-C17 A11-B8-C18
A11-B8-C19 A11-B8-C20 A11-B8-C21 A11-B8-C22 A11-B8-C23 A11-B8-C24
A11-B8-C25 A11-B8-C26 A11-B8-C27 A11-B8-C28 A11-B8-C29 A11-B8-C30
A11-B8-C31 A11-B8-C32 A11-B8-C33 A11-B8-C34 A11-B8-C35 A11-B8-C36 A1 1-B8-C37 A11-B8-C38 A11-B8-C39 A11-B8-C40 A11-B8-C41 A11-B8-C42
A11-B8-C43 A11-B8-C44 A11-B8-C45 A11-B8-C46 A11-B8-C47 A11-B8-C48
A11-B8-C49 A11-B8-C50 A11-B8-C51 A11-B8-C52 A11-B8-C53 A11-B8-C54
A11-B8-C55 A11-B8-C56 A11-B8-C57 A11-B8-C58 A11-B8-C59 A11-B8-C60
A11-B8-C61 A11-B8-C62 A11-B8-C63 A11-B8-C64 A11-B8-C65 A11-B8-C66 A11-B8-C67 A11-B8-C68 A11-B8-C69 A11-B8-C70 A11-B8-C71 A11-B8-C72
A11-B8-C73 A11-B8-C74 A11-B8-C75 A11-B8-C76 A11-B8-C77 A11-B8-C78
A11-B8-C79 A11-B8-C80 A11-B8-C81 A11-B8-C82 A11-B8-C83 A11-B8-C84
A11-B8-C85 A11-B8-C86 A11-B8-C87 A11-B8-C88 A11-B8-C89 A11-B8-C90
A11-B8-C91 A11-B8-C92 A11-B8-C93 A11-B8-C94 A11-B8-C95 A11-B8-C96 A11-B8-C97 A11-B8-C98 A11-B8-C99 A11-B8-C100 A11-B8-C101 A11-B8-C102
A11-B8-C103 A11-B8-C104 A11-B8-C105 A11-B8-C106 A11-B8-C107 A11-B8-C108
A11-B8-C109 A11-B8-C110 A11-B8-C111 A11-B8-C112 A11-B8-C113 A11-B8-C114
A11-B8-C115 A11-B8-C116 A11-B8-C117 A11-B8-C118 A11-B8-C119 A11-B8-C120
A11-B8-C121 A11-B8-C122 A11-B8-C123 A11-B8-C124 A11-B8-C125 A11-B8-C126 A11-B8-C127 A11-B8-C128 A11-B8-C129 A11-B8-C130 A11-B8-C131 A11-B8-C132
A11-B8-C133 A11-B8-C134 A11-B8-C135 A11-B8-C136 A11-B8-C137 A11-B8-C138
A11-B8-C139 A11-B8-C140 BLANK BLANK BLANK BLANK
A11-B9-C1 A1 1-B9-C2 A11-B9-C3 A11-B9-C4 A11-B9-C5 A11-B9-C6
A11-B9-C7 A11-B9-C8 A11-B9-C9 A11-B9-C10 A11-B9-C11 A11-B9-C12
A11-B9-C13 A11-B9-C14 A11-B9-C15 A11-B9-C16 A11-B9-C17 A11-B9-C18
A11-B9-C19 A11-B9-C20 A11-B9-C21 A11-B9-C22 A11-B9-C23 A11-B9-C24 A11-B9-C25 A11-B9-C26 A11-B9-C27 A11-B9-C28 A11-B9-C29 A11-B9-C30
A11-B9-C31 A1 1-B9-C32 A11-B9-C33 A11-B9-C34 A11-B9-C35 A11-B9-C36
A11-B9-C37 A11-B9-C38 A11-B9-C39 A11-B9-C40 A11-B9-C41 A11-B9-C42
A11-B9-C43 A11-B9-C44 A11-B9-C45 A11-B9-C46 A11-B9-C47 A11-B9-C48
A11-B9-C49 A11-B9-C50 A11-B9-C51 A11-B9-C52 A11-B9-C53 A11-B9-C54 A11-B9-C55 A11-B9-C56 A11-B9-C57 A11-B9-C58 A11-B9-C59 A11-B9-C60
A11-B9-C61 A11-B9-C62 A11-B9-C63 A11-B9-C64 A11-B9-C65 A11-B9-C66
A11-B9-C67 A1 1-B9-C68 A11-B9-C69 A11-B9-C70 A11-B9-C71 A11-B9-C72
A11-B9-C73 A11-B9-C74 A11-B9-C75 A11-B9-C76 A11-B9-C77 A11-B9-C78
A11-B9-C79 A11-B9-C80 A11-B9-C81 A11-B9-C82 A11-B9-C83 A11-B9-C84 A11-B9-C85 A11-B9-C86 A11-B9-C87 A11-B9-C88 A11-B9-C89 A11-B9-C90
A11-B9-C91 A1 1-B9-C92 A11-B9-C93 A11-B9-C94 A11-B9-C95 A11-B9-C96
A11-B9-C97 A11-B9-C98 A11-B9-C99 A11-B9-C100 A11-B9-C101 A11-B9-C102
A11-B9-C103 A11-B9-C104 A11-B9-C105 A11-B9-C106 A1.1-B9-C107 A11-B9-C108
A11-B9-C109 A11-B9-C110 A11-B9-C111 A11-B9-C112 A11-B9-C113 A11-B9-C114 A11-B9-C115 A11-B9-C116 A11-B9-C117 A11-B9-C118 A11-B9-C119 A11-B9-C120
A11-B9-C121 A11-B9-C122 A11-B9-C123 A11-B9-C124 A11-B9-C125 A11-B9-C126
A11-B9-C127 A11-B9-C128 A11-B9-C129 A11-B9-C130 A11-B9-C131 A11-B9-C132
A11-B9-C133 A11-B9-C134 A11-B9-C135 A11-B9-C136 A11-B9-C137 A11-B9-C138
A11-B9-C139 A11-B9-C140 BLANK BLANK BLANK BLANK A11-B10-C1 A1 1-B10-C2 A11-B10-C3 A11-B10-C4 A11-B10-C5 A11-B10-C6
A11-B10-C7 A11-B10-C8 A11-B10-C9 A11-B10-C10 A11-B10-C11 A11-B10-C12
A11-B10-C13 A11-B10-C14 A11-B10-C15 A11-B10-C16 A11-B10-C17 A11-B10-C18
A11-B10-C19 A11-B10-C20 A11-B10-C21 A11-B10-C22 A11-B10-C23 A11-B10-C24
A11-B10-C25 A11-B10-C26 A11-B10-C27 A11-B10-C28 A11-B10-C29 A11-B10-C30 A11-B10-C31 A11-B10-C32 A11-B10-C33 A11-B10-C34 A11-B10-C35 A11-B10-C36
A11-B10-C37 A11-B10-C38 A11-B10-C39 A11-B10-C40 A11-B10-C41 A11-B10-C42
A11-B10-C43 A11-B10-C44 A11-B10-C45 A11-B10-C46 A11-B10-C47 A11-B10-C48
A11-B10-C49 A11-B10-C50 A11-B10-C51 A11-B10-C52 A11-B10-C53 A11-B10-C54
A11-B10-C55 A11-B10-C56 A11-B10-C57 A11-B10-C58 A11-B10-C59 A11-B10-C60 A11-B10-C61 A11-B10-C62 A11-B10-C63 A11-B10-C64 A11-B10-C65 A11-B10-C66
A11-B10-C67 A11-B10-C68 A11-B10-C69 A11-B10-C70 A11-B10-C71 A11-B10-C72
A11-B10-C73 A11-B10-C74 A11-B10-C75 A11-B10-C76 A11-B10-C77 A11-B10-C78
A11-B10-C79 A11-B10-C80 A11-B10-C81 A11-B10-C82 A11-B10-C83 A11-B10-C84
A11-B10-C85 A11-B10-C86 A11-B10-C87 A11-B10-C88 A11-B10-C89 A11-B10-C90
A11-B10-C91 A11-B10-C92 A1 1-B10-C93 A11-B10-C94 A11-B10-C95 A11-B10-C96
A11-B10-C97 A11-B10-C98 A11-B10-C99 A11-B10-C100 A11-B10-C101 A11-B10-C102 A11-B10-C103 A11-B10-C104 A11-B10-C105 A11-B10-C106 A11-B10-C107 A11-B10-C108
A11-B10-C109 A11-B10-C110 A1 1-B10-C111 A11-B10-C112 A11-B10-C113 A11-B10-C1 14
A11-B10-C115 A11-B10-C116 A11-B10-C117 A11-B10-C118 A11-B10-C119 A11-B10-C120
A11-B10-C121 A11-B10-C122 A11-B10-C123 A11-B10-C124 A11-B10-C125 A11-B10-C126
A11-B10-C127 A11-B10-C128 A11-B10-C129 A11-B10-C130 A11-B10-C131 A11-B10-C132 A11-B10-C133 A11-B10-C134 A11-B10-C135 A11-B10-C136 A11-B10-C137 A11-B10-C138
A11-B10-C139 A11-B10-C140 BLANK BLANK BLANK BLANK
A11-B11-C1 A11-B11-C2 A11-B11-C3 A11-B11-C4 A11-B11-C5 A11-B11-C6
A11-B11-C7 A11-B11-C8 A1 1-B11-C9 A11-B11-C10 A11-B11-C11 A11-B11-C12
A11-B11-C13 A11-B11-C14 A11-B11-C15 A11-B11-C16 A11-B11-C17 A11-B11-C18 A11-B11-C19 A11-B11-C20 A11-B11-C21 A11-B11-C22 A11-B11-C23 A11-B11-C24
A11-B11-C25 A11-B11-C26 A11-B11-C27 A11-B11-C28 A11-B11-C29 A11-B11-C30
A11-B11-C31 A11-B11-C32 A11-B11-C33 A11-B11-C34 A11-B11-C35 A11-B11-C36
A11-B11-C37 A11-B11-C38 A1 1-B11-C39 A11-B11-C40 A11-B11-C41 A11-B11-C42
A11-B11-C43 A11-B11-C44 A11-B11-C45 A11-B11-C46 A11-B11-C47 A11-B11-C48 A11-B11-C49 A11-B11-C50 A11-B11-C51 A11-B11-C52 A11-B11-C53 A11-B11-C54
A11-B11-C55 A11-B11-C56 A11-B11-C57 A11-B11-C58 A11-B11-C59 A11-B11-C60
A11-B11-C61 A11-B11-C62 A11-B11-C63 A11-B11-C64 A11-B11-C65 A11-B11-C66
A11-B11-C67 A11-B11-C68 A11-B11-C69 A11-B11-C70 A11-B11-C71 A11-B11-C72
A11-B11-C73 A11-B11-C74 A11-B11-C75 A11-B11-C76 A11-B11-C77 A11-B11-C78 A11-B11-C79 A11-B11-C80 A1 1-B11-C81 A11-B11-C82 A11-B11-C83 A11-B1 1-C84
A11-B11-C85 A11-B11-C86 A11-B11-C87 A11-B11-C88 A11-B11-C89 A11-B11-C90
A11-B11-C91 A11-B11-C92 A11-B11-C93 A11-B11-C94 A11-B11-C95 A11-B11-C96
A11-B11-C97 A11-B11-C98 A11-B11-C99 A11-B11-C100 A11-B11-C101 A11-B11-C102
A11-B11-C103 A11-B11-C104 A11-B11-C105 A11-B11-C106 A11-B11-C107 A11-B11-C108 A11-B11-C109 A11-B11-C110 A11-B11-C111 A11-B11-C112 A11-B11-C113 A11-B11-C114
A11-B11-C115 A11-B11-C116 A1 1-B1 1-C117 A11-B11-C118 A11-B11-C119 A11-B11-C120
A11-B11-C121 A11-B11-C122 A11-B11-C123 A11-B11-C124 A11-B11-C125 A11-B11-C126
A11-B11-C127 A11-B11-C128 A11-B11-C129 A11-B11-C130 A11-B11-C131 A11-B11-C132
A11-B11-C133 A11-B11-C134 A11-B11-C135 A11-B11-C136 A11-B11-C137 A11-B11-C138 A11-B11-C139 A11-B11-C140 BLANK BLANK BLANK BLANK
A11-B12-C1 A11-B12-C2 A11-B12-C3 A11-B12-C4 A11-B12-C5 A11-B12-C6
A11-B12-C7 A11-B12-C8 A11-B12-C9 A11-B12-C10 A11-B12-C11 A11-B12-C12
A11-B12-C13 A11-B12-C14 A11-B12-C15 A1 1-B12-C16 A11-B12-C17 A11-B12-C18
A11-B12-C19 A11-B12-C20 A11-B12-C21 A11-B12-C22 A11-B12-C23 A11-B12-C24
A11-B12-C25 A11-B12-C26 A11-B12-C27 A11-B12-C28 A11-B12-C29 A11-B12-C30
A11-B12-C31 A11-B12-C32 A11-B12-C33 A11-B12-C34 A11-B12-C35 A11-B12-C36 A11-B12-C37 A11-B12-C38 A11-B12-C39 A11-B12-C40 A11-B12-C41 A11-B12-C42
A11-B12-C43 A11-B12-C44 A11-B12-C45 A11-B12-C46 A11-B12-C47 A11-B12-C48
A11-B12-C49 A11-B12-C50 A11-B12-C51 A11-B12-C52 A11-B12-C53 A11-B12-C54
A11-B12-C55 A11-B12-C56 A11-B12-C57 A11-B12-C58 A11-B12-C59 A11-B12-C60
A11-B12-C61 A11-B12-C62 A11-B12-C63 A11-B12-C64 A11-B12-C65 A11-B12-C66 A11-B12-C67 A11-B12-C68 A11-B12-C69 A11-B12-C70 A11-B12-C71 A11-B12-C72
A11-B12-C73 A11-B12-C74 A11-B12-C75 A11-B12-C76 A11-B12-C77 A11-B12-C78
A11-B12-C79 A11-B12-C80 A11-B12-C81 A11-B12-C82 A11-B12-C83 A11-B12-C84
A11-B12-C85 A11-B12-C86 A11-B12-C87 A11-B12-C88 A11-B12-C89 A11-B12-C90
A11-B12-C91 A11-B12-C92 A11-B12-C93 A11-B12-C94 A11-B12-C95 A11-B12-C96 A11-B12-C97 A11-B12-C98 A11-B12-C99 A11-B12-C100 A11-B12-C101 A11-B12-C102
A11-B12-C103 A11-B12-C104 A11-B12-C105 A11-B12-C106 A11-B12-C107 A11-B12-C108
A11-B12-C109 A11-B12-C110 A11-B12-C111 A11-B12-C112 A11-B12-C113 A11-B12-C114
A11-B12-C115 A11-B12-C116 A11-B12-C117 A11-B12-C118 A11-B12-C119 A11-B12-C120
A11-B12-C121 A11-B12-C122 A11-B12-C123 A11-B12-C124 A11-B12-C125 A11-B12-C126 A11-B12-C127 A11-B12-C128 A11-B12-C129 A11-B12-C130 A11-B12-C131 A11-B12-C132
A11-B12-C133 A11-B12-C134 A11-B12-C135 A11-B12-C136 A11-B12-C137 A11-B12-C138
A11-B12-C139 A11-B12-C140 BLANK BLANK BLANK BLANK
A11-B13-C1 A11-B13-C2 A11-B13-C3 A11-B13-C4 A11-B13-C5 A11-B13-C6
A11-B13-C7 A11-B13-C8 A11-B13-C9 A11-B13-C10 A11-B13-C11 A11-B13-C12 A11-B13-C13 A11-B13-C14 A11-B13-C15 A11-B13-C16 A11-B13-C17 A11-B13-C18
A11-B13-C19 A11-B13-C20 A11-B13-C21 A11-B13-C22 A11-B13-C23 A11-B13-C24
A11-B13-C25 A11-B13-C26 A11-B13-C27 A11-B13-C28 A11-B13-C29 A11-B13-C30
A11-B13-C31 A11-B13-C32 A11-B13-C33 A11-B13-C34 A11-B13-C35 A11-B13-C36
A11-B13-C37 A11-B13-C38 A11-B13-C39 A11-B13-C40 A11-B13-C41 A11-B13-C42 A11-B13-C43 A11-B13-C44 A11-B13-C45 A11-B13-C46 A11-B13-C47 A11-B13-C48
A11-B13-C49 A11-B13-C50 A11-B13-C51 A11-B13-C52 A11-B13-C53 A11-B13-C54
A11-B13-C55 A11-B13-C56 A11-B13-C57 A11-B13-C58 A11-B13-C59 A11-B13-C60
A11-B13-C61 A11-B13-C62 A11-B13-C63 A11-B13-C64 A11-B13-C65 A11-B13-C66
A11-B13-C67 A11-B13-C68 A11-B13-C69 A11-B13-C70 A11-B13-C71 A11-B13-C72 A11-B13-C73 A11-B13-C74 A11-B13-C75 A11-B13-C76 A11-B13-C77 A11-B13-C78
A11-B13-C79 A11-B13-C80 A11-B13-C81 A11-B13-C82 A11-B13-C83 A11-B13-C84
A11-B13-C85 A11-B13-C86 A11-B13-C87 A11-B13-C88 A11-B13-C89 A11-B13-C90
A11-B13-.C91 A11-B13-C92 A11-B13-C93 A11-B13-C94 A11-B13-C95 A11-B13-C96 A11-B13-C97 A11-B13-C98 A11-B13-C99 A11-B13-C100 A11-B13-C101 A11-B13-C102 A1 1-B13-C103 A11-B13-C104 A11-B13-C105 A1 1-B13-C106 A11-B13-C107 A11-B13-C108 A1 1-B13-C109 A11-B13-C110 A11-B13-C111 A11-B13-C112 A11-B13-C113 A11-B13-C114 A11-B13-C115 A11-B13-C116 A11-B13-C117 A11-B13-C118 A11-B13-C119 A11-B13-C120 A11-B13-C121 A11-B13-C122 A11-B13-C123 A11-B13-C124 A11-B13-C125 A11-B13-C126 A11-B13-C127 A11-B13-C128 A11-B13-C129 A11-B13-C130 A11-B13-C131 A11-B13-C132 A11-B13-C133 A11-B13-C134 A11-B13-C135 A11-B13-C136 A11-B13-C137 A11-B13-C138 A11-B13-C139 A11-B13-C140 BLANK BLANK BLANK BLANK A12-B1-C1 A12-B1-C2 A12-B1-C3 A12-B1-C4 A12-B1-C5 A12-B1-C6 A12-B1-C7 A12-B1-C8 A12-B1-C9 A12-B1-C10 A12-B1-C11 A12-B1-C12 A12-B1-C13 A12-B1-C14 A12-B1-C15 A12-B1-C16 A12-B1-C17 A12-B1-C18 A12-B1-C19 A12-B1-C20 A12-B1-C21 A12-B1-C22 A12-B1-C23 A12-B1-C24 A12-B1-C25 A12-B1-C26 A12-B1-C27 A12-B1-C28 A12-B1-C29 A12-B1-C30 A12-B1-C31 A12-B1-C32 A12-B1-C33 A12-B1-C34 A12-B1-C35 A12-B1-C36 A12-B1-C37 A12-B1-C38 A12-B1-C39 A12-B1-C40 A12-B1-C41 A12-B1-C42 A12-B1-C43 A12-B1-C44 A12-B1-C45 A12-B1-C46 A12-B1-C47 A12-B1-C48 A12-B1-C49 A12-B1-C50 A12-B1-C51 A12-B1-C52 A12-B1-C53 A12-B1-C54 A12-B1-C55 A12-B1-C56 A12-B1-C57 A12-B1-C58 A12-B1-C59 A12-B1-C60 A12-B1-C61 A12-B1-C62 A12-B1-C63 A12-B1-C64 A12-B1-C65 A12-B1-C66 A12-B1-C67 A12-B1-C68 A12-B1-C69 A12-B1-C70 A12-B1-C71 A12-B1-C72 A12-B1-C73 A12-B1-C74 A12-B1-C75 A12-B1-C76 A12-B1-C77 A12-B1-C78 A12-B1-C79 A12-B1-C80 A12-B1-C81 A12-B1-C82 A12-B1-C83 A12-B1-C84 A12-B1-C85 A12-B1-C86 A12-B1-C87 A12-B1-C88 A12-B1-C89 A12-B1-C90 A12-B1-C91 A12-B1-C92 A12-B1-C93 A12-B1-C94 A12-B1-C95 A12-B1-C96 A12-B1-C97 A12-B1-C98 A12-B1-C99 A12-B1-C100 A12-B1-C101 A12-B1-C102 A12-B1-C103 A12-B1-C104 A12-B1-C105 A12-B1-C106 A12-B1-C107 A12-B1-C108 A12-B1-C109 A12-B1-C110 A12-B1-C111 A12-B1-C112 A12-B1-C113 A12-B1-C114 A12-B1-C115 A12-B1-C116 A12-B1-C117 A12-B1-C118 A12-B1-C119 A12-B1-C120 A12-B1-C121 A12-B1-C122 A12-B1-C123 A12-B1-C124 A12-B1-C125 A12-B1-C126 A12-B1-C127 A12-B1-C128 A12-B1-C129 A12-B1-C130 A12-B1-C131 A12-B1-C132 A12-B1-C133 A12-B1-C134 A12-B1-C135 A12-B1-C136 A12-B1-C137 A12-B1-C138 A12-B1-C139 A12-B1-C140 BLANK BLANK BLANK BLANK A12-B2-C1 A12-B2-C2 A12-B2-C3 A12-B2-C4 A12-B2-C5 A12-B2-C6 A12-B2-C7 A12-B2-C8 A12-B2-C9 A12-B2-C10 A12-B2-C11 A12-B2-C12 A12-B2-C13 A12-B2-C14 A12-B2-C15 A12-B2-C16 A12-B2-C17 A12-B2-C18 A12-B2-C19 A12-B2-C20 A12-B2-C21 A12-B2-C22 A12-B2-C23 A12-B2-C24
A12-B2-C25 A12-B2-C26 A12-B2-C27 A12-B2-C28 A12-B2-C29 A12-B2-C30
A12-B2-C31 A12-B2-C32 A12-B2-C33 A12-B2-C34 A12-B2-C35 A12-B2-C36
A12-B2-C37 A12-B2-C38 A12-B2-C39 A12-B2-C40 A12-B2-C41 A12-B2-C42
A12-B2-C43 A12-B2-C44 A12-B2-C45 A12-B2-C46 A12-B2-C47 A12-B2-C48 A12-B2-C49 A12-B2-C50 A12-B2-C51 A12-B2-C52 A12-B2-C53 A12-B2-C54
A12-B2-C55 A12-B2-C56 A12-B2-C57 A12-B2-C58 A12-B2-C59 A12-B2-C60
A12-B2-C61 A12-B2-C62 A12-B2-C63 A12-B2-C64 A12-B2-C65 A12-B2-C66
A12-B2-C67 A12-B2-C68 A12-B2-C69 A12-B2-C70 A12-B2-C71 A12-B2-C72
A12-B2-C73 A12-B2-C74 A12-B2-C75 A12-B2-C76 A12-B2-C77 A12-B2-C78 A12-B2-C79 A12-B2-C80 A12-B2-C81 A12-B2-C82 A12-B2-C83 A12-B2-C84
A12-B2-C85 A12-B2-C86 A12-B2-C87 A12-B2-C88 A12-B2-C89 A12-B2-C90
A12-B2-C91 A12-B2-C92 A12-B2-C93 A12-B2-C94 A12-B2-C95 A12-B2-C96
A12-B2-C97 A12-B2-C98 A12-B2-C99 A12-B2-C100 A12-B2-C101 A12-B2-C102
A12-B2-C103 A12-B2-C104 A12-B2-C105 A12-B2-C106 A12-B2-C107 A12-B2-C108 A12-B2-C109 A12-B2-C110 A12-B2-C111 A12-B2-C112 A12-B2-C113 A12-B2-C114
A12-B2-C115 A12-B2-C116 A12-B2-C117 A12-B2-C118 A12-B2-C119 A12-B2-C120
A12-B2-C121 A12-B2-C122 A12-B2-C123 A12-B2-C124 A12-B2-C125 A12-B2-C126
A12-B2-C127 A12-B2-C128 A12-B2-C129 A12-B2-C130 A12-B2-C131 A12-B2-C132
A12-B2-C133 A12-B2-C134 A12-B2-C135 A12-B2-C136 A12-B2-C137 A12-B2-C138 A12-B2-C139 A12-B2-C140 BLANK BLANK BLANK BLANK
A12-B3-C1 A12-B3-C2 A12-B3-C3 A12-B3-C4 A12-B3-C5 A12-B3-C6
A12-B3-C7 A12-B3-C8 A12-B3-C9 A12-B3-C10 A12-B3-C11 A12-B3-C12
A12-B3-C13 A12-B3-C14 A12-B3-C15 A12-B3-C16 A12-B3-C17 A12-B3-C18
A12-B3-C19 A12-B3-C20 A12-B3-C21 A12-B3-C22 A12-B3-C23 A12-B3-C24 A12-B3-C25 A12-B3-C26 A12-B3-C27 A12-B3-C28 A12-B3-C29 A12-B3-C30
A12-B3-C31 A12-B3-C32 A12-B3-C33 A12-B3-C34 A12-B3-C35 A12-B3-C36
A12-B3-C37 A12-B3-C38 A12-B3-C39 A12-B3-C40 A12-B3-C41 A12-B3-C42
A12-B3-C43 A12-B3-C44 A12-B3-C45 A12-B3-C46 A12-B3-C47 A12-B3-C48
A12-B3-C49 A12-B3-C50 A12-B3-C51 A12-B3-C52 A12-B3-C53 A12-B3-C54 A12-B3-C55 A12-B3-C56 A12-B3-C57 A12-B3-C58 A12-B3-C59 A12-B3-C60
A12-B3-C61 A12-B3-C62 A12-B3-C63 A12-B3-C64 A12-B3-C65 A12-B3-C66
A12-B3-C67 A12-B3-C68 A12-B3-C69 A12-B3-C70 A12-B3-C71 A12-B3-C72
A12-B3-C73 A12-B3-C74 A12-B3-C75 A12-B3-C76 A12-B3-C77 A12-B3-C78
A12-B3-C79 A12-B3-C80 A12-B3-C81 A12-B3-C82 A12-B3-C83 A12-B3-C84 A12-B3-C85 A12-B3-C86 A12-B3-C87 A12-B3-C88 A12-B3-C89 A12-B3-C90
A12-B3-C91 A12-B3-C92 A12-B3-C93 A12-B3-C94 A12-B3-C95 A12-B3-C96
A12-B3-C97 A12-B3-C98 A12-B3-C99 A12-B3-C100 A12-B3-C101 A12-B3-C102
A12-B3-C103 A12-B3-C104 A12-B3-C105 A12-B3-C106 A12-B3-C107 A12-B3-C108
A12-B3-C109 A12-B3-C1 10 A12-B3-C111 A12-B3-C112 A12-B3-C113 A12-B3-C114
A12-B3-C115 A12-B3-C1 16 A12-B3-C117 A12-B3-C118 A12-B3-C119 A12-B3-C120
A12-B3-C121 A12-B3-C122 A12-B3-C123 A12-B3-C124 A12-B3-C125 A12-B3-C126 A12-B3-C127 A12-B3-C128 A12-B3-C129 A12-B3-C130 A12-B3-C131 A12-B3-C132
A12-B3-C133 A12-B3-C134 A12-B3-C135 A12-B3-C136 A12-B3-C137 A12-B3-C138
A12-B3-C139 A12-B3-C140 BLANK BLANK BLANK BLANK
A12-B4-C1 A12-B4-C2 A12-B4-C3 A12-B4-C4 A12-B4-C5 A12-B4-C6
A12-B4-C7 A12-B4-C8 A12-B4-C9 A12-B4-C10 A12-B4-C11 A12-B4-C12 A12-B4-C13 A12-B4-C14 A12-B4-C15 A12-B4-C16 A12-B4-C17 A12-B4-C18
A12-B4-C19 A12-B4-C20 A12-B4-C21 A12-B4-C22 A12-B4-C23 A12-B4-C24
A12-B4-C25 A12-B4-C26 A12-B4-C27 A12-B4-C28 A12-B4-C29 A12-B4-C30
A12-B4-C31 A12-B4-C32 A12-B4-C33 A12-B4-C34 A12-B4-C35 A12-B4-C36
A12-B4-C37 A12-B4-C38 A12-B4-C39 A12-B4-C40 A12-B4-C41 A12-B4-C42 A12-B4-C43 A12-B4-C44 A12-B4-C45 A12-B4-C46 A12-B4-C47 A12-B4-C48
A12-B4-C49 A12-B4-C50 A12-B4-C51 A12-B4-C52 A12-B4-C53 A12-B4-C54
A12-B4-C55 A12-B4-C56 A12-B4-C57 A12-B4-C58 A12-B4-C59 A12-B4-C60
A12-B4-C61 A12-B4-C62 A12-B4-C63 A12-B4-C64 A12-B4-C65 A12-B4-C66
A12-B4-C67 A12-B4-C68 A12-B4-C69 A12-B4-C70 A12-B4-C71 A12-B4-C72 A12-B4-C73 A12-B4-C74 A12-B4-C75 A12-B4-C76 A12-B4-C77 A12-B4-C78
A12-B4-C79 A12-B4-C80 A12-B4-C81 A12-B4-C82 A12-B4-C83 A12-B4-C84
A12-B4-C85 A12-B4-C86 A12-B4-C87 A12-B4-C88 A12-B4-C89 A12-B4-C90
A12-B4-C91 A12-B4-C92 A12-B4-C93 A12-B4-C94 A12-B4-C95 A12-B4-C96
A12-B4-C97 A12-B4-C98 A12-B4-C99 A12-B4-C100 A12-B4-C101 A12-B4-C102 A12-B4-C103 A12-B4-C104 A12-B4-C105 A12-B4-C106 A12-B4-C107 A12-B4-C108
A12-B4-C109 A12-B4-C110 A12-B4-C111 A12-B4-C112 A12-B4-C113 A12-B4-C114
A12-B4-C115 A12-B4-C116 A12-B4-C117 A12-B4-C118 A12-B4-C119 A12-B4-C120
A12-B4-C121 A12-B4-C122 A12-B4-C123 A12-B4-C124 A12-B4-C125 A12-B4-C126
A12-B4-C127 A12-B4-C128 A12-B4-C129 A12-B4-C130 A12-B4-C131 A12-B4-C132 A12-B4-C133 A12-B4-C134 A12-B4-C135 A12-B4-C136 A12-B4-C137 A12-B4-C138
A12-B4-C139 A12-B4-C140 BLANK BLANK BLANK BLANK
A12-B5-C1 A12-B5-C2 A12-B5-C3 A12-B5-C4 A12-B5-C5 A12-B5-C6
A12-B5-C7 A12-B5-C8 A12-B5-C9 A12-B5-C10 A12-B5-C11 A12-B5-C12
A12-B5-C13 A12-B5-C14 A12-B5-C15 A12-B5-C16 A12-B5-C17 A12-B5-C18 A12-B5-C19 A12-B5-C20 A12-B5-C21 A12-B5-C22 A12-B5-C23 A12-B5-C24
A12-B5-C25 A12-B5-C26 A12-B5-C27 A12-B5-C28 A12-B5-C29 A12-B5-C30
A12-B5-C31 A12-B5-C32 A12-B5-C33 A12-B5-C34 A12-B5-C35 A12-B5-C36
A12-B5-C37 A12-B5-C38 A12-B5-C39 A12-B5-C40 A12-B5-C41 A12-B5-C42
A12-B5-C43 A12-B5-C44 A12-B5-C45 A12-B5-C46 A12-B5-C47 A12-B5-C48
A12-B5-C49 A12-B5-C50 A12-B5-C51 A12-B5-C52 A12-B5-C53 A12-B5-C54
A12-B5-C55 A12-B5-C56 A12-B5-C57 A12-B5-C58 A12-B5-C59 A12-B5-C60 A12-B5-C61 A12-B5-C62 A12-B5-C63 A12-B5-C64 A12-B5-C65 A12-B5-C66
A12-B5-C67 A12-B5-C68 A12-B5-C69 A12-B5-C70 A12-B5-C71 A12-B5-C72
A12-B5-C73 A12-B5-C74 A12-B5-C75 A12-B5-C76 A12-B5-C77 A12-B5-C78
A12-B5-C79 A12-B5-C80 A12-B5-C81 A12-B5-C82 A12-B5-C83 A12-B5-C84
A12-B5-C85 A12-B5-C86 A12-B5-C87 A12-B5-C88 A12-B5-C89 A12-B5-C90 A12-B5-C91 A12-B5-C92 A12-B5-C93 A12-B5-C94 A12-B5-C95 A12-B5-C96
A12-B5-C97 A12-B5-C98 A12-B5-C99 A12-B5-C100 A12-B5-C101 A12-B5-C102
A12-B5-C103 A12-B5-C104 A12-B5-C105 A12-B5-C106 A12-B5-C107 A12-B5-C108
A12-B5-C109 A12-B5-C110 A12-B5-C111 A12-B5-C112 A12-B5-C113 A12-B5-C114
A12-B5-C115 A12-B5-C116 A12-B5-C117 A12-B5-C118 A12-B5-C119 A12-B5-C120 A12-B5-C121 A12-B5-C122 A12-B5-C123 A12-B5-C124 A12-B5-C125 A12-B5-C126
A12-B5-C127 A12-B5-C128 A12-B5-C129 A12-B5-C130 A12-B5-C131 A12-B5-C132
A12-B5-C133 A12-B5-C134 A12-B5-C135 A12-B5-C136 A12-B5-C137 A12-B5-C138
A12-B5-C139 A12-B5-C140 BLANK BLANK BLANK BLANK
A12-B6-C1 A12-B6-C2 A12-B6-C3 A12-B6-C4 A12-B6-C5 A12-B6-C6 A12-B6-C7 A12-B6-C8 A12-B6-C9 A12-B6-C10 A12-B6-C11 A12-B6-C12
A12-B6-C13 A12-B6-C14 A12-B6-C15 A12-B6-C16 A12-B6-C17 A12-B6-C18
A12-B6-C19 A12-B6-C20 A12-B6-C21 A12-B6-C22 A12-B6-C23 A12-B6-C24
A12-B6-C25 A12-B6-C26 A12-B6-C27 A12-B6-C28 A12-B6-C29 A12-B6-C30
A12-B6-C31 A12-B6-C32 A12-B6-C33 A12-B6-C34 A12-B6-C35 A12-B6-C36 A12-B6-C37 A12-B6-C38 A12-B6-C39 A12-B6-C40 A12-B6-C41 A12-B6-C42
A12-B6-C43 A12-B6-C44 A12-B6-C45 A12-B6-C46 A12-B6-C47 A12-B6-C48
A12-B6-C49 A12-B6-C50 A12-B6-C51 A12-B6-C52 A12-B6-C53 A12-B6-C54
A12-B6-C55 A12-B6-C56 A12-B6-C57 A12-B6-C58 A12-B6-C59 A12-B6-C60
A12-B6-C61 A12-B6-C62 A12-B6-C63 A12-B6-C64 A12-B6-C65 A12-B6-C66 A12-B6-C67 A12-B6-C68 A12-B6-C69 A12-B6-C70 A12-B6-C71 A12-B6-C72
A12-B6-C73 A12-B6-C74 A12-B6-C75 A12-B6-C76 A12-B6-C77 A12-B6-C78
A12-B6-C79 A12-B6-C80 A12-B6-C81 A12-B6-C82 A12-B6-C83 A12-B6-C84
A12-B6-C85 A12-B6-C86 A12-B6-C87 A12-B6-C88 A12-B6-C89 A12-B6-C90
A12-B6-C91 A12-B6-C92 A12-B6-C93 A12-B6-C94 A12-B6-C95 A12-B6-C96 A12-B6-C97 A12-B6-C98 A12-B6-C99 A12-B6-C100 A12-B6-C101 A12-B6-C102
A12-B6-C103 A12-B6-C104 A12-B6-C105 A12-B6-C106 A12-B6-C107 A12-B6-C108
A12-B6-C109 A12-B6-C110 A12-B6-C111 A12-B6-C112 A12-B6-C113 A12-B6-C114
A12-B6-C115 A12-B6-C116 A12-B6-C117 A12-B6-C118 A12-B6-C119 A12-B6-C120
A12-B6-C121 A12-B6-C122 A12-B6-C123 A12-B6-C124 A12-B6-C125 A12-B6-C126
A12-B6-C127 A12-B6-C128 A12-B6-C129 A12-B6-C130 A12-B6-C131 A12-B6-C132
A12-B6-C133 A12-B6-C134 A12-B6-C135 A12-B6-C136 A12-B6-C137 A12-B6-C138 A12-B6-C139 A12-B6-C140 BLANK BLANK BLANK BLANK
A12-B7-C1 A12-B7-C2 A12-B7-C3 A12-B7-C4 A12-B7-C5 A12-B7-C6
A12-B7-C7 A12-B7-C8 A12-B7-C9 A12-B7-C10 A12-B7-C11 A12-B7-C12
A12-B7-C13 A12-B7-C14 A12-B7-C15 A12-B7-C16 A12-B7-C17 A12-B7-C18
A12-B7-C19 A12-B7-C20 A12-B7-C21 A12-B7-C22 A12-B7-C23 A12-B7-C24 A12-B7-C25 A12-B7-C26 A12-B7-C27 A12-B7-C28 A12-B7-C29 A12-B7-C30
A12-B7-C31 A12-B7-C32 A12-B7-C33 A12-B7-C34 A12-B7-C35 A12-B7-C36
A12-B7-C37 A12-B7-C38 A12-B7-C39 A12-B7-C40 A12-B7-C41 A12-B7-C42
A12-B7-C43 A12-B7-C44 A12-B7-C45 A12-B7-C46 A12-B7-C47 A12-B7-C48
A12-B7-C49 A12-B7-C50 A12-B7-C51 A12-B7-C52 A12-B7-C53 A12-B7-C54 A12-B7-C55 A12-B7-C56 A12-B7-C57 A12-B7-C58 A12-B7-C59 A12-B7-C60
A12-B7-C61 A12-B7-C62 A12-B7-C63 A12-B7-C64 A12-B7-C65 A12-B7-C66
A12-B7-C67 A12-B7-C68 A12-B7-C69 A12-B7-C70 A12-B7-C71 A12-B7-C72
A12-B7-C73 A12-B7-C74 A12-B7-C75 A12-B7-C76 A12-B7-C77 A12-B7-C78
A12-B7-C79 A12-B7-C80 A12-B7-C81 A12-B7-C82 A12-B7-C83 A12-B7-C84 A12-B7-C85 A12-B7-C86 A12-B7-C87 A12-B7-C88 A12-B7-C89 A12-B7-C90
A12-B7-C91 A12-B7-C92 A12-B7-C93 A12-B7-C94 A12-B7-C95 A12-B7-C96
A12-B7-C97 A12-B7-C98 A12-B7-C99 A12-B7-C100 A12-B7-C101 A12-B7-C102
A12-B7-C103 A12-B7-C104 A12-B7-C105 A12-B7-C106 A12-B7-C107 A12-B7-C108
A12-B7-C109 A12-B7-C110 A12-B7-C111 A12-B7-C112 A12-B7-C113 A12-B7-C114 A12-B7-C115 A12-B7-C116 A12-B7-C117 A12-B7-C118 A12-B7-C119 A12-B7-C120
A12-B7-C121 A12-B7-C122 A12-B7-C123 A12-B7-C124 A12-B7-C125 A12-B7-C126
A12-B7-C127 A12-B7-C128 A12-B7-C129 A12-B7-C130 A12-B7-C131 A12-B7-C132
A12-B7-C133 A12-B7-C134 A12-B7-C135 A12-B7-C136 A12-B7-C137 A12-B7-C138
A12-B7-C139 A12-B7-C140 BLANK BLANK BLANK BLANK A12-B8-C1 A12-B8-C2 A12-B8-C3 A12-B8-C4 A12-B8-C5 A12-B8-C6
A12-B8-C7 A12-B8-C8 A12-B8-C9 A12-B8-C10 A12-B8-C11 A12-B8-C12
A12-B8-C13 A12-B8-C14 A12-B8-C15 A12-B8-C16 A12-B8-C17 A12-B8-C18
A12-B8-C19 A12-B8-C20 A12-B8-C21 A12-B8-C22 A12-B8-C23 A12-B8-C24
A12-B8-C25 A12-B8-C26 A12-B8-C27 A12-B8-C28 A12-B8-C29 A12-B8-C30 A12-B8-C31 A12-B8-C32 A12-B8-C33 A12-B8-C34 A12-B8-C35 A12-B8-C36
A12-B8-C37 A12-B8-C38 A12-B8-C39 A12-B8-C40 A12-B8-C41 A12-B8-C42
A12-B8-C43 A12-B8-C44 A12-B8-C45 A12-B8-C46 A12-B8-C47 A12-B8-C48
A12-B8-C49 A12-B8-C50 A12-B8-C51 A12-B8-C52 A12-B8-C53 A12-B8-C54
A12-B8-C55 A12-B8-C56 A12-B8-C57 A12-B8-C58 A12-B8-C59 A12-B8-C60
A12-B8-C61 A12-B8-C62 A12-B8-C63 A12-B8-C64 A12-B8-C65 A12-B8-C66
A12-B8-C67 A12-B8-C68 A12-B8-C69 A12-B8-C70 A12-B8-C71 A12-B8-C72 A12-B8-C73 A12-B8-C74 A12-B8-C75 A12-B8-C76 A12-B8-C77 A12-B8-C78
A12-B8-C79 A12-B8-C80 A12-B8-C81 A12-B8-C82 A12-B8-C83 A12-B8-C84
A12-B8-C85 A12-B8-C86 A12-B8-C87 A12-B8-C88 A12-B8-C89 A12-B8-C90
A12-B8-C91 A12-B8-C92 A12-B8-C93 A12-B8-C94 A12-B8-C95 A12-B8-C96
A12-B8-C97 A12-B8-C98 A12-B8-C99 A12-B8-C100 A12-B8-C101 A12-B8-C102 A12-B8-C103 A12-B8-C104 A12-B8-C105 A12-B8-C106 A12-B8-C107 A12-B8-C108
A12-B8-C109 A12-B8-C110 A12-B8-C111 A12-B8-C112 A12-B8-C113 A12-B8-C114
A12-B8-C115 A12-B8-C116 A12-B8-C117 A12-B8-C118 A12-B8-C119 A12-B8-C120
A12-B8-C121 A12-B8-C122 A12-B8-C123 A12-B8-C124 A12-B8-C125 A12-B8-C126
A12-B8-C127 A12-B8-C128 A12-B8-C129 A12-B8-C130 A12-B8-C131 A12-B8-C132 A12-B8-C133 A12-B8-C134 A12-B8-C135 A12-B8-C136 A12-B8-C137 A12-B8-C138
A12-B8-C139 A12-B8-C140 BLANK BLANK BLANK BLANK
A12-B9-C1 A12-B9-C2 A12-B9-C3 A12-B9-C4 A12-B9-C5 A12-B9-C6
A12-B9-C7 A12-B9-C8 A12-B9-C9 A12-B9-C10 A12-B9-C11 A12-B9-C12
A12-B9-C13 A12-B9-C14 A12-B9-C15 A12-B9-C16 A12-B9-C17 A12-B9-C18 A12-B9-C19 A12-B9-C20 A12-B9-C21 A12-B9-C22 A12-B9-C23 A12-B9-C24
A12-B9-C25 A12-B9-C26 A12-B9-C27 A12-B9-C28 A12-B9-C29 A12-B9-C30
A12-B9-C31 A12-B9-C32 A12-B9-C33 A12-B9-C34 A12-B9-C35 A12-B9-C36
A12-B9-C37 A12-B9-C38 A12-B9-C39 A12-B9-C40 A12-B9-C41 A12-B9-C42
A12-B9-C43 A12-B9-C44 A12-B9-C45 A12-B9-C46 A12-B9-C47 A12-B9-C48 A12-B9-C49 A12-B9-C50 A12-B9-C51 A12-B9-C52 A12-B9-C53 A12-B9-C54
A12-B9-C55 A12-B9-C56 A12-B9-C57 A12-B9-C58 A12-B9-C59 A12-B9-C60
A12-B9-C61 A12-B9-C62 A12-B9-C63 A12-B9-C64 A12-B9-C65 A12-B9-C66
A12-B9-C67 A12-B9-C68 A12-B9-C69 A12-B9-C70 A12-B9-C71 A12-B9-C72
A12-B9-C73 A12-B9-C74 A12-B9-C75 A12-B9-C76 A12-B9-C77 A12-B9-C78 A12-B9-C79 A12-B9-C80 A12-B9-C81 A12-B9-C82 A12-B9-C83 A12-B9-C84
A12-B9-C85 A12-B9-C86 A12-B9-C87 A12-B9-C88 A12-B9-C89 A12-B9-C90
A12-B9-C91 A12-B9-C92 A12-B9-C93 A12-B9-C94 A12-B9-C95 A12-B9-C96
A12-B9-C97 A12-B9-C98 A12-B9-C99 A12-B9-C100 A12-B9-C101 A12-B9-C102
A12-B9-C103 A12-B9-C104 A12-B9-C105 A12-B9-C106 A12-B9-C107 A12-B9-C108 A12-B9-C109 A12-B9-C110 A12-B9-C111 A12-B9-C112 A12-B9-C113 A12-B9-C114
A12-B9-C115 A12-B9-C116 A12-B9-C117 A12-B9-C118 A12-B9-C119 A12-B9-C120
A12-B9-C121 A12-B9-C122 A12-B9-C123 A12-B9-C124 A12-B9-C125 A12-B9-C126
A12-B9-C127 A12-B9-C128 A12-B9-C129 A12-B9-C130 A12-B9-C131 A12-B9-C132
A12-B9-C133 A12-B9-C134 A12-B9-C135 A12-B9-C136 A12-B9-C137 A12-B9-C138
A12-B9-C139 A12-B9-C140 BLANK BLANK BLANK BLANK
A12-B10-C1 A12-B10-C2 A12-B10-C3 A12-B10-C4 A12-B10-C5 A12-B10-C6 A12-B10-C7 A12-B10-C8 A12-B10-C9 A12-B10-C10 A12-B10-C11 A12-B10-C12
A12-B10-C13 A12-B10-C14 A12-B10-C15 A12-B10-C16 A12-B10-C17 A12-B10-C18
A12-B10-C19 A12-B10-C20 A12-B10-C21 A12-B10-C22 A12-B10-C23 A12-B10-C24
A12-B10-C25 A12-B10-C26 A12-B10-C27 A12-B10-C28 A12-B10-C29 A12-B10-C30
A12-B10-C31 A12-B10-C32 A12-B10-C33 A12-B10-C34 A12-B10-C35 A12-B10-C36 A12-B10-C37 A12-B10-C38 A12-B10-C39 A12-B10-C40 A12-B10-C41 A12-B10-C42
A12-B10-C43 A12-B10-C44 A12-B10-C45 A12-B10-C46 A12-B10-C47 A12-B10-C48
A12-B10-C49 A12-B10-C50 A12-B10-C51 A12-B10-C52 A12-B10-C53 A12-B10-C54
A12-B10-C55 A12-B10-C56 A12-B10-C57 A12-B10-C58 A12-B10-C59 A12-B10-C60
A12-B10-C61 A12-B10-C62 A12-B10-C63 A12-B10-C64 A12-B10-C65 A12-B10-C66 A12-B10-C67 A12-B10-C68 A12-B10-C69 A12-B10-C70 A12-B10-C71 A12-B10-C72
A12-B10-C73 A12-B10-C74 A12-B10-C75 A12-B10-C76 A12-B10-C77 A12-B10-C78
A12-B10-C79 A12-B10-C80 A12-B10-C81 A12-B10-C82 A12-B10-C83 A12-B10-C84
A12-B10-C85 A12-B10-C86 A12-B10-C87 A12-B10-C88 A12-B10-C89 A12-B10-C90
A12-B10-C91 A12-B10-C92 A12-B10-C93 A12-B10-C94 A12-B10-C95 A12-B10-C96 A12-B10-C97 A12-B10-C98 A12-B10-C99 A12-B10-C100 A12-B10-C101 A12-B10-C102
A12-B10-C103 A12-B10-C104 A12-B10-C105 A12-B10-C106 A12-B10-C107 A12-B10-C108
A12-B10-C109 A12-B10-C110 A12-B10-C111 A12-B10-C112 A12-B10-C113 A12-B10-C114
A12-B10-C115 A12-B10-C116 A12-B10-C117 A12-B10-C118 A12-B10-C119 A12-B10-C120
A12-B10-C121 A12-B10-C122 A12-B10-C123 A12-B10-C124 A12-B10-C125 A12-B10-C126 A12-B10-C127 A12-B10-C128 A12-B10-C129 A12-B10-C130 A12-B10-C131 A12-B10-C132
A12-B10-C133 A12-B10-C134 A12-B10-C135 A12-B10-C136 A12-B10-C137 A12-B10-C138
A12-B10-C139 A12-B10-C140 BLANK BLANK BLANK BLANK
A12-B11-C1 A12-B11-C2 A12-B11-C3 A12-B11-C4 A12-B11-C5 A12-B11-C6
A12-B11-C7 A12-B11-C8 A12-B11-C9 A12-B11-C10 A12-B11-C11 A12-B11-C12 A12-B11-C13 A12-B11-C14 A12-B11-C15 A12-B11-C16 A12-B11-C17 A12-B11-C18
A12-B11-C19 A12-B11-C20 A12-B11-C21 A12-B11-C22 A12-B11-C23 A12-B11-C24
A12-B11-C25 A12-B11-C26 A12-B11-C27 A12-B11-C28 A12-B11-C29 A12-B11-C30
A12-B11-C31 A12-B11-C32 A12-B11-C33 A12-B11-C34 A12-B11-C35 A12-B11-C36
A12-B11-C37 A12-B11-C38 A12-B11-C39 A12-B11-C40 A12-B11-C41 A12-B11-C42 A12-B11-C43 A12-B11-C44 A12-B11-C45 A12-B11-C46 A12-B11-C47 A12-B11-C48
A12-B11-C49 A12-B11-C50 A12-B11-C51 A12-B11-C52 A12-B11-C53 A12-B11-C54
A12-B11-C55 A12-B11-C56 A12-B11-C57 A12-B11-C58 A12-B11-C59 A12-B11-C60
A12-B11-C61 A12-B11-C62 A12-B11-C63 A12-B11-C64 A12-B11-C65 A12-B11-C66
A12-B11-C67 A12-B11-C68 A12-B11-C69 A12-B11-C70 A12-B11-C71 A12-B1 1-C72
A12-B11-C73 A12-B11-C74 A12-B11-C75 A12-B11-C76 A12-B11-C77 A12-B1 1-C78
A12-B11-C79 A12-B11-C80 A12-B11-C81 A12-B11-C82 A12-B11-C83 A12-B1 1-C84 A12-B11-C85 A12-B11-C86 A12-B11-C87 A12-B11-C88 A12-B11-C89 A12-B11-C90
A12-B11-C91 A12-B11-C92 A12-B11-C93 A12-B11-C94 A12-B11-C95 A12-B11-C96
A12-B11-C97 A12-B11-C98 A12-B11-C99 A12-B11-C100 A12-B11-C101 A12-B11-C102
A12-B11-C103 A12-B11-C104 A12-B11-C105 A12-B11-C106 A12-B11-C107 A12-B11-C108
A12-B11-C109 A12-B11-C110 A12-B11-C111 A12-B11-C112 A12-B11-C113 A12-B11-C114 A12-B11-C115 A12-B11-C1 16 A12-B11-C117 A12-B11-C118 A12-B11-C119 A12-B1 1-C120
A12-B11-C121 A12-B11-C122 A12-B11-C123 A12-B11-C124 A12-B11-C125 A12-B11-C126
A12-B11-C127 A12-B11-C128 A12-B11-C129 A12-B11-C130 A12-B11-C131 A12-B11-C132
A12-B11-C133 A12-B11-C134 A12-B11-C135 A12-B11-C136 A12-B11-C137 A12-B1 1-C138
A12-B11-C139 A12-B11-C140 BLANK BLANK BLANK BLANK A12-B12-C1 A12-B12-C2 A12-B12-C3 A12-B12-C4 A12-B12-C5 A12-B12-C6
A12-B12-C7 A12-B12-C8 A12-B12-C9 A12-B12-C10 A12-B12-C11 A12-B12-C12
A12-B12-C13 A12-B12-C14 A12-B12-C15 A12-B12-C16 A12-B12-C17 A12-B12-C18
A12-B12-C19 A12-B12-C20 A12-B12-C21 A12-B12-C22 A12-B12-C23 A12-B12-C24
A12-B12-C25 A12-B12-C26 A12-B12-C27 A12-B12-C28 A12-B12-C29 A12-B12-C30 A12-B12-C31 A12-B12-C32 A12-B12-C33 A12-B12-C34 A12-B12-C35 A12-B12-C36
A12-B12-C37 A12-B12-C38 A12-B12-C39 A12-B12-C40 A12-B12-C41 A12-B12-C42
A12-B12-C43 A12-B12-C44 A12-B12-C45 A12-B12-C46 A12-B12-C47 A12-B12-C48
A12-B12-C49 A12-B12-C50 A12-B12-C51 A12-B12-C52 A12-B12-C53 A12-B12-C54
A12-B12-C55 A12-B12-C56 A12-B12-C57 A12-B12-C58 A12-B12-C59 A12-B12-C60 A12-B12-C61 A12-B12-C62 A12-B12-C63 A12-B12-C64 A12-B12-C65 A12-B12-C66
A12-B12-C67 A12-B12-C68 A12-B12-C69 A12-B12-C70 A12-B12-C71 A12-B12-C72
A12-B12-C73 A12-B12-C74 A12-B12-C75 A12-B12-C76 A12-B12-C77 A12-B12-C78
A12-B12-C79 A12-B12-C80 A12-B12-C81 A12-B12-C82 A12-B12-C83 A12-B12-C84
A12-B12-C85 A12-B12-C86 A12-B12-C87 A12-B12-C88 A12-B12-C89 A12-B12-C90 A12-B12-C91 A12-B12-C92 A12-B12-C93 A12-B12-C94 A12-B12-C95 A12-B12-C96
A12-B12-C97 A12-B12-C98 A12-B12-C99 A12-B12-C100 A12-B12-C101 A12-B12-C102
A12-B12-C103 A12-B12-C104 A12-B12-C105 A12-B12-C106 A12-B12-C107 A12-B12-C108
A12-B12-C109 A12-B12-C110 A12-B12-C111 A12-B12-C112 A12-B12-C113 A12-B12-C114
A12-B12-C115 A12-B12-C116 A12-B12-C117 A12-B12-C118 A12-B12-C119 A12-B12-C120 A12-B12-C121 A12-B12-C122 A12-B12-C123 A12-B12-C124 A12-B12-C125 A12-B12-C126
A12-B12-C127 A12-B12-C128 A12-B12-C129 A12-B12-C130 A12-B12-C131 A12-B12-C132
A12-B12-C133 A12-B12-C134 A12-B12-C135 A12-B12-C136 A12-B12-C137 A12-B12-C138
A12-B12-C139 A12-B12-C140 BLANK BLANK BLANK BLANK
A12-B13-C1 A12-B13-C2 A12-B13-C3 A12-B13-C4 A12-B13-C5 A12-B13-C6
A12-B13-C7 A12-B13-C8 A12-B13-C9 A12-B13-C10 A12-B13-C11 A12-B13-C12
A12-B13-C13 A12-B13-C14 A12-B13-C15 A12-B13-C16 A12-B13-C17 A12-B13-C18 A12-B13-C19 A12-B13-C20 A12-B13-C21 A12-B13-C22 A12-B13-C23 A12-B13-C24
A12-B13-C25 A12-B13-C26 A12-B13-C27 A12-B13-C28 A12-B13-C29 A12-B13-C30
A12-B13-C31 A12-B13-C32 A12-B13-C33 A12-B13-C34 A12-B13-C35 A12-B13-C36
A12-B13-C37 A12-B13-C38 A12-B13-C39 A12-B13-C40 A12-B13-C41 A12-B13-C42
A12-B13-C43 A12-B13-C44 A12-B13-C45 A12-B13-C46 A12-B13-C47 A12-B13-C48 A12-B13-C49 A12-B13-C50 A12-B13-C51 A12-B13-C52 A12-B13-C53 A12-B13-C54
A12-B13-C55 A12-B13-C56 A12-B13-C57 A12-B13-C58 A12-B13-C59 A12-B13-C60
A12-B13-C61 A12-B13-C62 A12-B13-C63 A12-B13-C64 A12-B13-C65 A12-B13-C66
A12-B13-C67 A12-B13-C68 A12-B13-C69 A12-B13-C70 A12-B13-C71 A12-B13-C72
A12-B13-C73 A12-B13-C74 A12-B13-C75 A12-B13-C76 A12-B13-C77 A12-B13-C78 A12-B13-C79 A12-B13-C80 A12-B13-C81 A12-B13-C82 A12-B13-C83 A12-B13-C84
A12-B13-C85 A12-B13-C86 A12-B13-C87 A12-B13-C88 A12-B13-C89 A12-B13-C90
A12-B13-C91 A12-B13-C92 A12-B13-C93 A12-B13-C94 A12-B13-C95 A12-B13-C96
A12-B13-C97 A12-B13-C98 A12-B13-C99 A12-B13-C100 A12-B13-C101 A12-B13-C102
A12-B13-C103 A12-B13-C104 A12-B13-C105 A12-B13-C106 A12-B13-C107 A12-B13-C108 A12-B13-C109 A12-B13-C110 A12-B13-C1 11 A12-B13-C112 A12-B13-C113 A12-B13-C114
A12-B13-C115 A12-B13-C116 A12-B13-C1 17 A12-B13-C118 A12-B13-C119 A12-B13-C120
A12-B13-C121 A12-B13-C122 A12-B13-C123 A12-B13-C124 A12-B13-C125 A12-B13-C126
A12-B13-C127 A12-B13-C128 A12-B13-C129 A12-B13-C130 A12-B13-C131 A12-B13-C132
A12-B13-C133 A12-B13-C134 A12-B13-C135 A12-B13-C136 A12-B13-C137 A12-B13-C138 A12-B13-C139 A12-B13-C140 BLANK BLANK BLANK BLANK.
Thus, for example, in the above list the compound denoted as A1-B1-C1 is the product of the combination of group Al in Table 1 and Bl in Table 2 and CI in Table 3, namely
Preferred compounds of the invention are selected from:
3-[l-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
3- [ 1 -(3-phenylethyl-benzoyl)-piperidin-4-yl]-benzylamine;
3-{l-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine;
3 - { 1 - [3 -(6-amino-pyridin-3 -yl)ethyl-benzoyl] -piperidin-4-yl} -benzylamine; 3 - [ 1 -(5-phenylethyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine;
4-fluoro-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
4-methyl-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
3 - [ 1 -(indole-6-carbonyl)-piperidin-4-yl]-benzylamine;
4-(3-aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile [4-(3-aminomethylphenyl)piperidin-l-yl]-(3,4-dichlorophenyl)methanone; l-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-methylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one trifluoroacetate;
1 - [4-(3 -Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 -(3 -methylsulfany 1-6,7-dihydro-benzo [cjthiophen- 1 - yl)-methanone trifluoroacetate; l-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-ethylsulfanyl-6,6-dimethyl-6,7- dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate; l-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-propylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one trifluoroacetate; l-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-isopropylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one trifluoroacetate;
1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 -benzo [b]thiophen-2-yl-methanone-trifluoroacetate;
l-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-l-yl]-l-(5-phenethyl-pyridin-3-yl)-methanone- ditrifluoroacetate;
1 - [4-(3- Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 -( 1 -methyl- 1 H-indol-3 -yl)-methanone-trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(2-fluoro-phenylethynyl)-phenyl]-methanone trifluoroacetate;
1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 - { 3 - [2-(2-fluoro-phenyl)-ethyl] -phenyl} -methanone trifluoroacetate;
1 -[4-(3-Aminomethyl-phenyl)-piperidin- 1-yl]- 1- {3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl}- methanone tri-trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(6-chloro-thieno[3,2-έ]thiophen-2-yl)-methanone trifluoroacetate;
(3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3- carboxylic acid ethyl ester dihydrochloride;
3-[l-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate; 4-(3-Aminomethyl-phenyl)-piperidine-l-carboxylic acid (3,4-dichloro-phenyl)-amide trifluoroacetate;
1 -[4-(3-Aminomethyl-phenyl)-piperidin- 1-yl]- l-(2,3-dihydro-benzofuran-5-yl)-methanone;
1 -[4-(3-Aminomethyl-phenyl)-piperidin- 1-yl]- l-(5,6-dichloro-pyridin-3-yl)-methanone;
1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl] - 1 -(3 -bromo-4-fluoro-phenyl)-methanone;
(E)-l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-(2-nitro-phenyl)-propenone; 1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 -(3 -bromo- 5 -iodo-phenyl)-methanone;
(E)-l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-phenyl-propenone; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-cyclohexyl-propan-l-one;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
Pharmaceutical Compositions As explained above, compounds of the present invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further aspect, compounds of the invention and pharmaceutical compositions containing compounds of the invention for use in therapy, wherein a pharmaceutical composition of the present invention comprising a compound of the present invention, and a pharmaceutically acceptable carrier thereof. As used herein, the term "pharmaceutically acceptable" preferably means approved by a regulatory agency of a government, in particular the Federal government or a state government, or listed in the U.S. Pharmacopeia or another generally recognized pharmacopeia for use in animals, and more
particularly in humans. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.
A pharmaceutical composition according to the present invention can be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavorings, colorings, or stabilizers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used. Such pharmaceutically acceptable carriers can also be sterile water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include ma nitol, human serum albumin (HSA), starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium carbonate, magnesium stearate, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. These compositions can take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained-release formulations and the like.
Naturally, a pharmaceutical composition of the present invention compositions will contain an effective diagnostic or therapeutic amount of the active compound together with a suitable amount of carrier so as to provide the form for proper administration to the patient. While intravenous injection is a very effective form of administration, other modes can be employed, such as by injection, or by oral, nasal or parenteral administration, which are discussed infra.
Methods of Treatment Compounds within the scope of the present invention possess tryptase inhibition activity according to tests described in the literature and described in vitro procedures hereinafter, and which test results are believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further embodiment, the present invention provides compounds of the invention and compositions containing compounds of the invention for use in the treatment of a patient suffering from, or subject to, conditions that can be ameliorated by the administration of an inhibitor of tryptase. For example, compounds of the present invention are useful in the treatment of inflammatory diseases, for example joint inflammation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, osteoarthritis and other chronic inflammatory joint diseases, or diseases of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung diseases, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofϊbromas, hypertrophic scars, various dermatological conditions, for example, atopic dermatitis and psoriasis, myocardial infarction, stroke, angina and other consequences of atherosclerotic plaque rupture, as well as periodontal disease, diabetic retinopathy, tumor growth, anaphylaxis, multiple sclerosis, peptic ulcers, and syncytial viral infections.
A special embodiment of the therapeutic methods of the present invention is the treating of asthma.
Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.
Another special embodiment of the therapeutic methods of the present invention is the treating of inflammatory bowel disease.
According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of tryptase, for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the invention. "Effective amount" is meant to describe an amount of compound of the present invention effective in inhibiting tryptase and thus producing the desired therapeutic effect.
Combination Therapy
As explained above, other pharmaceutically active agents can be employed in combination with the compounds of the invention depending upon the disease being treated. For example, in the treatment
of asthma, beta-adrenergic agonists such as albuterol, terbutaline, formoterol, fenoterol or prenaline can be included, as can anticholinergics such as ipratropium bromide, anti-inflammatory corticosteroids such as beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone, and anti-inflammatory agents such as sodium cromoglycate and nedocromil sodium. Thus, the present invention extends to a pharmaceutical composition comprising a compound of the present invention and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof. Particular pharmaceutical carriers having applications in this pharmaceutical composition are described herein.
Furthermore, the present invention extends to a method for treating a patient suffering from asthma, comprising administering the patient a compound of the present invention, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti- inflammatory corticosteroid, and an anti- inflammatory agent. In such a combination method, a compound of the present invention can be administered prior to the administration of the second compound, a compound of the present invention can be administered after administration of the second compound, or a compound of the present invention and the second compound can be administered concurrently.
Modes of Delivery
According to the invention, a compound of the present invention, or a pharmaceutical composition of the present invention, may be introduced parenterally, transmucosally, e.g., orally, nasally, pulmonarily, or rectally, or transdermally to a patient.
Oral Delivery
Contemplated for use herein are oral solid dosage forms, which are described generally in Remington's Pharmaceutical Sciences, 18th Ed.1990 (Mack Publishing Co. Easton PA 18042) at Chapter 89, which is herein incorporated by reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Patent No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Patent No. 5,013,556). A description of possible solid dosage forms for a therapeutic is given by Marshall, K. In: Modern Pharmaceutics Edited by G.S. Banker and CT. Rhodes Chapter 10, 1979, herein incorporated by reference. In general, the formulation will include a compound of the present invention, and inert ingredients which allow for protection against the stomach environment, and release of the biologically active material, i.e., a compound of the present invention, in the intestine.
Also specifically contemplated are oral dosage forms of a compound of the present invention. Such a compound may be chemically modified so that oral delivery is more efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the compound of the present invention, and increase in circulation time in the body. Examples of such moieties include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. Abuchowski and Davis, 1981, "Soluble Polymer-Enzyme Adducts" In: Enzymes as Drugs, Hocenberg and Roberts, eds.,
Wiley-Interscience, New York, NY, pp. 367-383; Newmark, et al., 1982, J. Appl. Biochem. 4:185-189. Other polymers that could be used are poly-l,3-dioxolane and poly-l,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are polyethylene glycol moieties.
For a compound of the present invention, the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations that will not dissolve in the stomach, yet will release the material in the duodenum or elsewhere in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the compound of the present invention, or by release of the compound beyond the stomach environment, such as in the intestine.
To ensure full gastric resistance a coating impermeable to at least pH 5.0 is essential. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and shellac. These coatings may be used as mixed films.
A coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings that make the tablet easier to swallow. Capsules may consist of a hard shell (such as gelatin) for delivery of dry therapeutic i.e. powder; for liquid forms, a soft gelatin shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.
The therapeutic can be included in the formulation as fine multi-particulates in the form of granules or pellets of particle size about 1 mm. The formulation of the material for capsule administration could
also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.
Colorants and flavoring agents may all be included. For example, the compound of the present invention may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.
One may dilute or increase the volume of the therapeutic with an inert material. These diluents could include carbohydrates, especially mannitol, α-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may be also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.
Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrates include, but are not limited to starch, including the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.
Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.
An anti-frictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.
Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.
To aid dissolution of the therapeutic into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethomium chloride. The list of potential non-ionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of a compound of the present invention either alone or as a mixture in different ratios.
Additives which potentially enhance uptake of a compound of the present invention are, for instance, the fatty acids oleic acid, linoleic acid and linolenic acid.
Controlled release oral formulation may be desirable. The drug could be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms, e.g., gums. Slowly degenerating matrices may also be incorporated into the formulation. Some enteric coatings also have a delayed release effect.
Another form of a controlled release of this therapeutic is by a method based on the Oros therapeutic system (Alza Corp.), i.e. the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects.
Other coatings may be used for the formulation. These include a variety of sugars which could be applied in a coating pan. The therapeutic agent could also be given in a film coated tablet and the materials used in this instance are divided into 2 groups. The first are the nonenteric materials and include methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone and the polyethylene glycols. The second group consists of the enteric materials that are commonly esters of phthalic acid.
A mix of materials might be used to provide the optimum film coating. Film coating may be carried out in a pan-coater or in a fluidized bed or by compression coating.
Pulmonary Delivery
Also contemplated herein is pulmonary delivery of a compound of the present invention, either alone, or in a pharmaceutical composition. The compound is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. Other reports of this include Adjei et al., 1990, Pharmaceutical Research, 7:565-569; Adjei et al., 1990, International Journal of Pharmaceutics, 63:135-144 (leuprolide acetate); Braquet et al., 1989, Journal of Cardiovascular Pharmacology, 13(suppl. 5):143-146 (endothelin-1); Hubbard et al., 1989, Annals of Internal Medicine, Vol. Ill, pp. 206-212 (al- antitrypsin); Smith et al., 1989, J. Clin. Invest. 84:1145- 1146 (a-1-proteinase); Oswein et al., 1990, "Aerosolization of Proteins", Proceedings of Symposium on Respiratory Drug Delivery II, Keystone, Colorado, March, (recombinant human growth hormone); Debs et al., 1988, J. Immunol. 140:3482-3488 (interferon-γ and tumor necrosis factor alpha) and Platz et al., U.S. Patent No. 5,284,656 (granulocyte colony stimulating factor). A method and composition for pulmonary delivery of drugs for systemic effect is described in U.S. Patent No. 5,451 ,569, issued September 19, 1995 to Wong et al.
Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Missouri; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colorado; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Massachusetts, to name only a few. All such devices require the use of formulations suitable for the dispensing a compound of the present invention. Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvants and/or carriers useful in therapy. Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated. Chemically modified compounds of the present invention may also be prepared in different formulations depending on the type of chemical modification or the type of device employed.
Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise a compound of the present invention dissolved in water at a concentration of about 0.1 to 25 mg of compound per mL of solution. The formulation may also include a buffer and a simple sugar (e.g., for stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a
surfactant, to reduce or prevent surface induced aggregation of the compound caused by atomization of the solution in forming the aerosol.
Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing a compound of the invention suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.
Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing a compound of the invention, and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation. The compound of the present invention should most advantageously be prepared in particulate form with an average particle size of less than 10 mm (or microns), most preferably 0.5 to 5 mm, for most effective delivery to the distal lung.
Nasal Delivery Nasal delivery of a compound of the present invention is also contemplated. Nasal delivery allows the passage of the compound to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran.
Transdermal Delivery
Various and numerous methods are known in the art for transdermal administration of a drug, e.g., via a transdermal patch, have applications in the present invention. Transdermal patches are described in for example, U.S. Patent No. 5,407,713, issued April 18, 1995 to Rolando et al.; U.S. Patent No. 5,352,456, issued October 4, 1004 to Fallon et al.; U.S. Patent No. 5,332,213 issued August 9, 1994 to D'Angelo et al.; U.S. Patent No. 5,336,168, issued August 9, 1994 to Sibalis; U.S. Patent No.
5,290,561, issued March 1, 1994 to Farhadieh et al.; U.S. Patent No. 5,254,346, issued October 19, 1993 to Tucker et al.; U.S. Patent No. 5,164,189, issued November 17, 1992 to Berger et al.; U.S. Patent No. 5,163,899, issued November 17, 1992 to Sibalis; U.S. Patent Nos. 5,088,977 and 5,087,240, both issued February 18, 1992 to Sibalis; U.S. Patent No. 5,008,110, issued April 16, 1991 to Benecke et al.; and U.S. Patent No. 4,921,475, issued May 1, 1990 to Sibalis, the disclosure of each of which is incorporated herein by reference in its entirety.
It can be readily appreciated that a transdermal route of administration may be enhanced by use of a dermal penetration enhancer, e.g., such as enhancers described in U.S. Patent No. 5,164,189 (supra), U.S. Patent No. 5,008,110 (supra), and U.S. Patent No. 4,879,119, issued November 7, 1989 to Aruga et al., the disclosure of each of which is incorporated herein by reference in its entirety.
Topical Administration
For topical administration, gels (water or alcohol based), creams or ointments containing compounds of the invention may be used. Compounds of the invention may also be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.
Rectal Administration
Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.
The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.
Furthermore, compounds according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or two doses per day.
Naturally, a patient in whom administration of a compound of the present invention is an effective therapeutic regimen is preferably a human, but can be any animal. Thus, as can be readily appreciated by one of ordinary skill in the art, the methods and pharmaceutical compositions of the present invention are particularly suited to administration to any animal, particularly a mammal, and including, but by no means limited to, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., avian species, such as chickens, turkeys, songbirds, etc., i.e., for veterinary medical use.
Preparation of Compounds of the Invention Compounds of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R.C.Larock in Comprehensive Organic Transformations, VCH publishers, 1989.
In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P.G.M.Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.
Compounds of formula (la) wherein R^, R4, RJ and n are as hereinbefore defined, Ri and R^ are both hydrogen and is a single bond, represented by formula (IX), may be prepared as shown in
Scheme 1
(II) (III) (IV) (V)
( IX) (VIII) (VII) (VI)
Scheme 1
example compounds of formula (IX) may be prepared by:-
(i) treating compounds of formula (II) wherein R^ and n are as hereinbefore defined and P1 is a suitable protecting group, such as benzyloxycarbonyl, with a suitable base, such as lithium hexamethyldisilazane, in an inert solvent, such as tefrahydrofuran, and at a temperature at about -78°C, followed by reaction with N-phenyltrifluoromethane-sulfonimide to give compounds of formula (III) wherein R^, pi and n are as hereinbefore defined and Tf is - S02CF3;
(ii) reaction of triflates of formula (III) with an aryl boronic acid of formula (X):-
in the presence of an aqueous base such as sodium bicarbonate and a palladium catalyst such as palladium tetrakistriphenylphosphine, and at a temperature from about 80 to about 100°C, to give compounds of formula (IV) wherein R^, R->5 pi and n are as hereinbefore defined;
(iii) reduction of compounds of formula (IV) with sodium borohydride in ethanol to give compounds of formula(V) wherein R^, R55 pi and are as hereinbefore defined;
(iv) conversion of the hydroxymethyl group in compounds of formula (V) to an aminomethyl group which is suitably protected to facilitate the further processes described hereinafter - for example reaction of compounds of formula (V) with phosphorus tribromide in pyridine followed by treatment of the resultant bromomethyl intermediate with di-tert- butyliminodicarboxylate to give compounds of formula (VI) wherein R^, R , p and n are as hereinbefore defined and P^ and P^ are each tertiary-butyloxycarbonyl (a suitable protecting group that is stable under conditions for the subsequent removal of protecting group P*);
(v) removal of the protecting group pi in compounds of formula (VI), for example when pi is benzyloxycarbonyl and P^ and P^ are both tertiary-butyloxycarbonyl, the deprotection may conveniently be carried out by hydrogenation in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol to give compounds of formula (VII) wherein R^, R^ and n are as hereinbefore defined and P^ and P^ are as just defined;
(vi) reaction of compounds of formula (VII) with compounds of formula (XI):-
wherein R^ is as hereinbefore defined and X* is a hydroxy group, or a halogen, preferably chlorine, atom using standard coupling conditions [for example when χl is a hydroxy group
the reaction may be carried out using standard peptide coupling procedures for example coupling in the presence of 0-(7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate and triethylamine (or diisopropylethylamine) in tefrahydrofuran (or dimethylformamide), at room temperature; and when X* is a halogen atom the acylation reaction may be carried out with the aid of a base, such pyridine, preferably in a solvent such as tefrahydrofuran and at a temperature at about room temperature] to give compounds of formula (VHI) wherein R3, R , R^, n, P2 and P3 are as defined above;
(vii) removal of the protecting groups P2 and P3 in compounds of formula (VTII), for example when P2 and P3 are both tertiary-butyloxycarbonyl the reaction may conveniently be carried out in the presence of an acid such as trifluoracetic acid in an inert solvent, such as dichloromethane, or by treatment with hydrogen chloride in methanol.
Compounds of formula (la) wherein R1, R2, R3, R4, R5 and n are as hereinbefore defined and is a single bond, represented by formula (XVI), may be prepared as shown in scheme 2.
(XII) (XIV)
(XVI) (XV)
Scheme 2
ple compounds of formula (XVI) may be prepared by:- reaction of compounds of formula (II) wherein R4 and n are as hereinbefore defined and P1 is a suitable protecting group, such as benzyloxycarbonyl, with an aryl boronate of formula (XVII):-
wherein R1, R2, P2 and P3 are as hereinbefore defined in the presence of potassium carbonate and a palladium catalyst such as [l,l'-bis-(diphenylphosphino)ferroceno]-dichloropalladium (IΙ)-dichloromethane complex in an inert solvent, such as dimethylsulfoxide, and at a temperature at about 80°C to give compounds of formula (XII) wherein R^ , R2, R4, R^, n, pi,
P2 and P3 are as hereinbefore defined; alternatively compounds of formula (XII) may be prepared by reaction of compounds of formula (II) with bis(pinacolato)boron in the presence of potassium acetate, (diphenylphosphino)-ferrocene and [1,1 '-bis- (diphenylphosphino)ferroceno]-dichloropalladium (II), in an inert solvent, such as dioxane, and at a temperature at about 80°C followed by reaction of the intermediate boronate of formula (XIII) with compounds of formula (XVIII):-
(XVIII)
wherein R , R , P* and P2 are as hereinbefore defined in the presence of potassium carbonate and a palladium catalyst such as [l,r-bis-(diphenylphosphino)ferroceno]-dichloropalladium (IΙ)-dichloromethane complex in an inert solvent, such as dimethylsulfoxide, and at a temperature at about 80°C ];
(ii) removal of the protecting group P* in compounds of formula (XII), for example when pi is benzyloxycarbonyl and P2 and P3 are both tertiary-butyloxycarbonyl, the deprotection may conveniently be carried out by hydrogenation as described hereinabove to give compounds of formula (XIV) wherein R1, R2, R4, R5, n, P2 and P3 are as just defined;
(iii) reaction of compounds of formula (XIV) with compounds of formula (XI) wherein Ri is as hereinbefore defined and X* is a hydroxy group, or a halogen, preferably chlorine, atom using standard coupling conditions [for example those described hereinabove] to give compounds of formula (XV) wherein R1, R2, R3, R4, R^, n, P2 and P3 are as defined above;
(vii) removal of the protecting groups P2 and P3 in compounds of formula (XV), using standard coupling conditions [for example those described hereinabove].
Compounds of formula (la) wherein Rl, R2, R3, R4, R^ and n are as hereinbefore defined and is a single bond, represented by formula (XVI), may also be prepared using resin technology as shown in scheme 3:-
(XIX) (TFP resin) (Resin 1)
(XVI) (XV)
Scheme 3
example compounds of formula (XVI) may be prepared by:- (i) Coupling of the resin ( XIX, an aminomethylated styrene/divinylbenzene copolymer), where
represents the polymeric core (comprising polystyrene crosslinked with 1% to
2% divinylbenzene), with 4-hydroxy-2,3,5,6-tetrafluorobenzoic acid, according to the
procedure described by LM.Salvino et. al. in International Patent Application Publication No.
WO 99/67228, to give TFP resin wherein is as hereinbefore defined;
(ii) treatment of TFP resin with acids of formula (XI) wherein R3 is as hereinbefore defined and χl is hydroxy, in the presence of diisopropyl carbodiimide and dimethylaminopyridine, in an inert solvent, such as dimethylformamide, and at a temperature at about room temperature, to
give resin 1 wherein R3 and are hereinbefore defined;
(iii) treatment of resin 1 with compounds of formula (XIV) wherein Rl, R2, R4, R^, n, pi and P2 are as defined immediately hereinbefore, in an inert solvent, such as dichloromethane, and at a temperature at about room temperature, to give compounds of formula (XV);
(iv) removal of the protecting groups in compounds of formula (XV), for example when P2 and
P3 are both tertiary-butyloxycarbonyl the reaction may conveniently be carried out in the presence of an acid such as trifluoracetic acid in an inert solvent, such as dichloromethane, or by treatment with hydrogen chloride in methanol.
Compounds of formula (lb), wherein R3 and R^ are as hereinbefore defined and R4 is cyano attached at the 4 position of the piperidine ring, represented by formula (XX), may be prepared as shown in scheme 4:-
(XXV)
(XXVII) (XX)
Scheme 4 ple compounds of formula (XX) may be prepared by:- Reacting a benzyl bromide of formula (XXI) wherein R^ is as hereinbefore defined, with sodium cyanide, in the presence of a phase transfer catalyst, such as tefrabutylammonium bromide, in a mixture of water and an inert solvent, such as dichloromethane, and at a temperature at about room temperature to give compounds of formula (XXII) wherein R-> is as hereinbefore defined;
(ii) treatment of the benzylcyanides of formula (XXII) with a suitably protected bis-(2-haloethyl)amine of formula (XXVIII):-
(XXVIII)
wherein X is halo, preferably chloro, and pi is a suitable protecting group, such as tertiary- butyloxycarbonyl, in the presence of sodium hydride and in an inert solvent, such as dimethylformamide, and at a temperature at about room temperature, to give compounds of formula (XXIII) wherein R^ and pi are as hereinbefore defined;
(iii) hydrogenation of compounds of formula (XXIII) in the presence of hydrochloric acid in ethanol and under pressure to give compounds of formula (XXIV) wherein R^ and P* are as hereinbefore defined;
(iv) protection of the amino group in compounds of formula (XXIV) with a suitable protecting group, for example with a benzyloxycarbonyl group, to give compounds of formula (XXV) wherein R^, pi and P2 are as hereinbefore defined;
(v) removal of the protecting group P n compounds of formula (XXV) to give compounds of formula (XXVI) wherein R^ and P2 are as hereinbefore defined;
(vi) reaction of compounds of formula (XXVI) with compounds of formula (XI) wherein R* is as hereinbefore defined and X1 is a hydroxy group, or a halogen, preferably chlorine, atom using standard coupling conditions [for example those described hereinabove] to give compounds of formula (XXVII) wherein R^ and P2 are as defined above;
(vii) removal of the protecting groups P2 in compounds of formula (XXVII), using standard coupling conditions [for example those described hereinabove].
Compounds of formula (la) wherein R3, R4, R5 and n are as hereinbefore defined, R* and R2 are both hydrogen and is a double bond, represented by formula (IX), may be prepared by removal of the pl protecting group in compounds of formula (VI) followed by acylation with compounds of formula (XI) and subsequent removal of the P2 and P3 protecting groups.
Compounds of formula (la) wherein R*, R2, R3, R4, R and n are as hereinbefore defined and is a double bond, represented by formula (XVI), may be prepared by removal of the P protecting group in compounds of formula (XII) followed by acylation with compounds of formula (XI) and subsequent removal of the P2 and P3 protecting groups.
According to a further feature of the present invention, compounds of the invention may be prepared by interconversion of other compounds of the invention.
As an example of the interconversion process, compounds of formula (la) wherein R1, R2, R4, R^ and n are as hereinbefore defined and R3 contains an optionally substituted alkylene linkage, may be prepared by hydrogenation of the corresponding compounds of formula (la) in which R3 contains the corresponding optionally substituted alkenylene or alkynylene linkage. The hydrogenation may be carried out using hydrogen (optionally under pressure) in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol, and at a temperature at about room temperature.
As another example of the interconversion process, compounds of the invention containing a heterocyclic group wherein the heteroatom is a nitrogen atom may be oxidized to their corresponding N-oxides. The oxidation may conveniently be carried out by means of reaction with a mixture of hydrogen peroxide and an organic acid, e.g. acetic acid, preferably at or above room temperature, for example at a temperature of about 60-90°C. Alternatively, the oxidation may be carried out by reaction with a peracid, for example peracetic acid or m-chloroperoxybenzoic acid, in an inert solvent such as chloroform or dichloromethane, at a temperature from about room temperature to reflux, preferably at elevated temperature. The oxidation may alternatively be carried out by reaction with hydrogen peroxide in the presence of sodium tungstate at temperatures between room temperature and about 60°C.
As another example of the interconversion process, compounds of formula (la) containing sulfone linkages may be prepared by the oxidation of corresponding compounds containing -S- or sulfoxide linkages. For example, the oxidation may conveniently be carried out by means of reaction with a
peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature.
It will be appreciated that compounds of the present invention may contain asymmetric centers. These asymmetric centers may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds the present invention. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates.
According to a further feature of the invention, acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
The acid addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.
The starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.
Aryl boronates of formula (XVII) wherein R*, R2, P2 and P3 are as hereinbefore defined may be prepared by reaction of compounds of formula (XVIII) wherein R , R2, P2 and P3 are as hereinbefore defined, with bis(pinacolato)boron in the presence of potassium acetate and [1,1 '-bis- (diphenylphosphino)ferroceno]-dichloropalladium (II) in an inert solvent, such as dioxane, at and at a temperature at about 80°C.
Compounds of formula (XVTfi) wherein Ri and R2 are as hereinbefore defined and P2 and P3 are both tertiary-butoxycarbonyl may be prepared by reaction of compounds of formula (XXIX):-
wherein R* and R2 are as hereinbefore defined with sodium hydride and di-tertiary- butyliminodicarboxylate, in an inert solvent, such as tefrahydrofuran, and at a temperature at about room temperature.
Intermediates of formulae (VIII) and (XV) are novel compounds and, as such, they and their processes described herein for their preparation constitute further features of the present invention.
The present invention is further Exemplified but not limited by the following illustrative Examples and Reference Examples.
In the nuclear magnetic resonance spectra (NMR) the chemical shifts are expressed in ppm relative to tetramethylsilane. Abbreviations have the following significances: br = broad, dd = double doublet, s = singlet; m = multiplet.
High Pressure Liquid Chromatography/ Mass Spectrometry (LC-MS) conditions for determination of retention times (R- ) were as follows: 3 micron Luna C18 (2) HPLC column (30mm x 4.6mm) eluting with (i) mixture of 0.05% trifluoroacetic acid in acetonitrile and 0.05% trifluoroacetic acid in water (1 :19, v/v) for 2 minutes, (ii) mixture of 0.05% trifluoroacetic acid in acetonitrile and 0.05%) trifluoroacetic acid in water (1:19 to 19:1, v/v) gradient elution over 10 minutes, (iii) mixture of 0.05% trifluoroacetic acid in acetonitrile and 0.05% trifluoroacetic acid in water (19:1, v/v) for 2 minutes, (iv) mixture of 0.05% trifluoroacetic acid in acetonitrile and 0.05% trifluoroacetic acid in water (1 : 19 to 1 : 19, v/v) gradient elution over 2 minutes; flow rate 2ml/minute with approximately 200μl/minute split to the Mass Spectrometer; injection volume 10-40μl; in line Diode Array (220- 450nm), in line Evaporative light scattering (ELS) detection ELS - temperature 50°C, Gain 8 - 1.8ml/minute; Source temperature 150°C.
The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate particular embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.
In the nuclear magnetic resonance spectra (NMR), reported infra, the chemical shifts are expressed in ppm relative to tetramethylsilane. Abbreviations have the following significances: br = broad, dd = double doublet, s = singlet; m = multiplet.
Moreover, in the Examples, High Pressure Liquid Chromatography/ Mass Spectrometry (LC-MS) conditions for determination of retention times (Rp) were as follows: 3 micron Luna C18 (2) HPLC column (30mm x 4.6mm) eluting with (i) mixture of 0.05% trifluoroacetic acid in acetonitrile and 0.05% trifluoroacetic acid in water (1:19, v/v) for 2 minutes, (ii) mixture of 0.05% trifluoroacetic acid in acetonitrile and 0.05% trifluoroacetic acid in water (1:19 to 19:1, v/v) gradient elution over 10 minutes, (iii) mixture of 0.05%) trifluoroacetic acid in acetonitrile and 0.05% trifluoroacetic acid in water (19:1, v/v) for 2 minutes, (iv) mixture of 0.05% trifluoroacetic acid in acetonitrile and 0.05% trifluoroacetic acid in water (1 : 19 to 1:19, v/v) gradient elution over 2 minutes; flow rate 2ml/minute with approximately 200μl/minute split to the Mass Spectrometer; injection volume 10-40μl; in line Diode Array (220-450nm), in line Evaporative light scattering (ELS) detection ELS - temperature 50°C, Gain 8 - 1.8ml/minute; Source temperature 150°C.
EXAMPLE 1 3-[l-(5-Phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(5-phenylethynyl-pyridin-3-yl)-methanone) di- hydrochloride)
A. J-?-{3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-pinacolato-boron
A solution of 3-bromobenzylbromide (7.5g, 30mmol) and di-tert-butyliminodicarboxylate (6.5g, 30mmol) in anhydrous tefrahydrofuran (80ml) was freated portionwise with sodium hydride (1.2g,
60%) dispersion in mineral oil). After stirring at ambient temperature for 7 hours the reaction mixture was partitioned between saturated aqueous ammonium chloride solution (90ml) and ethyl acetate (2 lots of 250ml). The combined organic layers were washed with brine (75ml), then dried over magnesium sulfate and then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with a mixture of pentane and dichloromethane (2:1, v/v) to give 3-[N,N-bis-(tert-butoxycarbonyl)aminomethyl]-bromobenzene as a pale yellow oil (9.52g). A sample
of this material (2.0g, 5.2mmol) was dissolved in anhydrous dimethylsulfoxide (30ml) and the solution was treated with potassium acetate (1.52g, 15.5mmol), bis(pinacolato)diboron (1.45g, 5.7mmol), and [l, -bis-(diphenylphosphino)ferroceno]-dichloropalladium (IΙ)-dichloromethane complex (0.13g, 0.16mmol). This mixture was stirred at 80°C under an atmosphere of nitrogen for 5 hours, then cooled and then partitioned between water ( 100ml) and diethyl ether (4 lots of 75ml). The combined organic layers were washed twice with brine (75ml), then dried over magnesium sulfate and then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with a mixture of pentane and dichloromethane (2:1, v/v) to give -Z?-{3-[N,N-bis-(tg t-butoxycarbonyl)-aminomethyl]- phenyll-pinacolato-boron as a colorless oil (1.08g). 1HΝMR (CDC13, 500 MHz): δ 7.78 (s, 1H), 7.70 (m, 1H), 7.39 (m, 1H), 7.30 (m, 1H), 4.79 (s, 2H), 1.27 (s, 18H), 1.35 (s, 12H). MS(EI): 434(M++H).
B. 4-{3-[NJN-Bis-(tert-butoxycarbonyl)aminomethyl]-phenyl}-piperidine
A solution of lithium diisopropylamine (54mmol) in anhydrous tefrahydrofuran (50ml), at -78°C, was treated dropwise with a solution of benzyl 4-oxo-l-piperidinecarboxylate (11.4g, 49mmol) in anhydrous tefrahydrofuran (50ml). This mixture was stirred at -78°C for 20 minutes and then freated with a solution of Ν-phenyltrifluoromethanesulfonimide (19.26g, 54mmol) in anhydrous tefrahydrofuran (55ml). The resultant orange suspension was warmed to 0°C, then stirred at 0°C for 2 hours and then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with dichloromethane to yield benzyl l,2,3,6-tetrahydro-4-(trifluoromethylsulphonyloxy)- pyridine- 1 -carboxylate as a yellow oil (11.34g). A portion of this material (0.84g, 2.3mmol) was dissolved in anhydrous dimethylformamide (20ml) and the solution was freated with 5-{3-[N,N-bis- (tert-butoxycarbonyl)aminomethyl]-phenyl-pinacolato-boron (l.Og, 2.3mmol), potassium carbonate (0.96g, 6.7mmol) and [l, -bis-(diphenylphosphino)ferroceno]dichloropalladium (IΙ)-dichloromethane complex (O.lg, 0.14mmol). This mixture was heated at 80°C under an atmosphere of nitrogen for 18 hours, then cooled and then concentrated under vacuum. The residue was partitioned between ethyl acetate (2 lots of 100ml) and water (100ml) containing concentrated ammonium hydroxide (6ml). The combined organic extracts were dried over magnesium sulfate and then concentrated under vacuum. The resultant oil was subjected to chromatography on silica gel eluting with a mixture of ethyl acetate and pentane (1:4, v/v) to yield a yellow oil (0.9g). This material was dissolved in ethanol (20ml) and the solution was treated with 10% palladium on carbon (20 mg) then stirred at ambient temperature under an atmosphere of hydrogen for 5 hours. The reaction mixture was filtered through a short pad of hyflo and the filtrate was concentrated under vacuum to give 4-{3-[N,N-bis-(tert- butoxycarbonyl)aminomethyl]-phenyl}-piperidine as colorless oil (0.54g). 1H ΝMR (CDCI3, 500 MHz): δ 7.10 (m, 4H), 4.80 (s, 2H), 4.45 (br m,lH), 3.20 (br m, 1H), 2.98 (br m, 1H), 2.75 (br m, 1H), 1.90 (m, 1H), 1.75-1.60 (m, 3H), 1.42 (s, 18H). MS(EI): 391(M++H).
C. N,N-Bis-(tgrt-butoxycarbonyl)-3-[l-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]- benzylamine
A solution of 5-phenylethynyl-pyridine-3-carboxylic acid (0.25g, l.lmmol) in anhydrous dimethylformamide (5ml) was treated with 0-(7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (0.42g, l.lmmol) and diisopropylethylamine (0.5ml, 3mmoI). This mixture was stirred 15 minutes at ambient temperature and then freated with a solution of 4-{3-[N,N-Bis-(tert- butoxycarbonyl)aminomethyl]-phenyl} -piperidine (0.39g, l.Ommol) in dimethylformamide (5ml). After stirring at ambient temperature for 18 hours the reaction mixture was concentrated under vacuum. The residue was partitioned between ethyl acetate (50ml) and saturated aqueous sodium bicarbonate (15ml). The organic layer was dried over magnesium sulfate and then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with a mixture of dichloromethane and methanol (49:1, v/v) to give N,N-bis-(tert-butoxycarbonyl)-3 - [ 1 -(5 - phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine as a yellow oil (0.25g). 1H ΝMR [(CD3)2SO, 500 MHz]: δ 8.82 (s, IH), 8.62 (s, IH), 8.02 (s, IH), 7.61 (m, 2H), 7.45 (m, 3H), 7.30 (m,
IH), 7.20 (m, IH), 7.15 (m, IH), 7.04 (m, IH), 4.68 (s, 2H), 4.62 (br , IH), 3.60 (br m, IH), 3.23 (br m, IH), 2.85 (m, 2H), 1.83 (br m, IH), 1.65 (m, 3H), 1.39 (s, 18H). MS(EI): 596(M++H).
P. 3-[l-(5-Phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride A solution of 3-[l-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzonitrile (0.15g,
0.25mmol) in ethyl acetate (20ml) was cooled to 0°C and then saturated with hydrogen chloride gas. The reaction mixture was stirred at ambient temperature for 4 hours and then concentrated to dryness under vacuum. The residue was freated with ethyl acetate (10ml) and the solvent removed under vacuum. This process was repeated twice to give 3 - [ 1 -(5-phenylethynyl-pyridine-3 -carbonyl)- piperidin-4-yl]-benzylamine di-hydrochloride as a white solid (0.1 lg). 1HΝMR [(CD3)2SO, 500
MHz]: δ 8.83 (s, IH), 8.63 (s, IH), 8.08 (s, IH), 7.61 (m, 2H), 7.45 (m, 3H), 7.44 (s, IH), 7.37 (m, 3H), 4.64 (br m, IH), 4.00 (m, 2H), 3.62 (br m, IH), 3.25 (br m, IH), 2.90 (br m, 2H), 1.88 (br m, IH), 1.70 (m, 3H). MS(EI): 396(M++H).
EXAMPLE 2
3-ri-(5-Phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(5-phenethyl-pyridin-3-yl)-methanone di- hydrochloride)
A. 5-Phenylethyl-pyridine-3-carboxylic acid
A solution of 5-phenylethynyl-pyridine-3-carboxylic acid (2g, 8.9mmol) in tefrahydrofuran (50ml) was treated with 10% palladium on carbon (200 mg) and stirred at ambient temperature under an atmosphere of hydrogen for 5 hours. The reaction mixture was filtered through a short pad of hyflo and the filtrate was concentrated under vacuum to give 5-phenylethyl-pyridine-3-carboxylic acid as white solid (2g). 1H NMR [(CD3)2SO, 500 MHz]: δ 8.90 (m, IH), 8.60 (m, IH), 8.12 (m, IH), 7.21 (m, 5H), 3.38 (br s, IH), 2.95 (m, 4H).
B. N,N-Bis-(tgrt-butoxycarbonyl)-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]- benzylamine By proceeding in a similar manner to the method described in EXAMPLE IC, but using of 5- phenylethyl-pyridine-3-carboxylic acid in place of 5-phenylethynyl-pyridine-3-carboxylic acid, there was prepared N,N-bis-(tgrt-butoxycarbonyl)-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]- benzylamine as a white amorphous solid. 1H ΝMR [(CD3)2SO, 500 MHz]: δ 8.50 (s, IH), 8.41 (s,
IH), 7.61 (m, IH), 7.30-7.05 (m, 9H), 4.68 (s, 2H), 4.62 (br m, IH), 3.48 (br m, IH), 3.35 (s, 4H), 3.18 (br m, IH), 2.85 (m, 2H), 1.82 (br m, IH), 1.65 (br m, IH), 1.58 (br m, 2H), 1.39 (s, 18H). MS(EI):
600(M++H).
C. 3-[l-(5-Phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride By proceeding in a similar manner to the method described in EXAMPLE ID, but using N,N-bis-(tert- butoxycarbonyl)-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine in place of N,N-Bis-(tert-butoxycarbonyl)-3-[l-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]- benzylamine, there was prepared 3 - [ 1 -(5-pheny lethyl-pyridine-3 -carbonyl)-piperidin-4-yl]- benzylamine di-hydrochloride as a white solid. 1H ΝMR [(CD3)2SO, 500 MHz]: δ 8.90 (m, 2H), 8.42
(s, IH), 7.58 (m, IH), 7.38-7.20 (m, 8H), 4.62 (br m, IH), 4.00 (m, 2H), 3.45 (br m, IH), 3.20 (br m, IH), 3.17 (m, 2H), 3.00 (m, 2H), 2.90 (br m, 2H), 1.88 (br m, IH), 1.70 (br m, 3H). MS(EI):
400(M++H).
EXAMPLE 3 3 - [ 1 -( 1 -oxy-5 -phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(l-oxy-5-phenethyl-pyridin-3-yl)-methanone hydrochloride)
A solution of N,N-Bis-(tgrt-butoxycarbonyl)-3 - [ 1 -(5-pheny lethyl-pyridine-3 -carbonyl)-piperidin-4-yl]- benzylamine (lOOmg, 0.17mmol, EXAMPLE 2B) in dichloromethane (10ml) was treated with meta- chloroperbenzoic acid (80%, 80mg, 0.37mmol). After stirring for 18 hours at ambient temperature the reaction mixture was diluted with dichloromethane (40ml) and then washed three times with saturated
aqueous sodium bicarbonate solution (20ml). The organic phase was dried over magnesium sulfate and then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with a mixture of dichloromethane and methanol (98:2, v/v) to give N,N-bls-(tert- butoxycarbony l)-3 - [ 1 -( 1 -oxy-5-phenylethyl-pyridine-3 -carbony l)-piperidin-4-yl]-benzylamine as a colorless oil (70mg). This material was dissolved in ethyl acetate (10ml) and the solution was cooled to 0°C, then saturated with hydrogen chloride gas, then stirred at ambient temperature for 4 hours and then concentrated to dryness under vacuum. The residue was treated with ethyl acetate (10ml) and the solvent removed under vacuum. This process was repeated twice to leave the title compound as a white solid (45mg). 1HNMR [(CD3)2SO, 500 MHz]: δ 8.39 (s, IH), 8.30 (s, IH), 7.45 (s, IH), 7.40 (s, IH), 7.38-7.18 (m, 8H), 4.59 (br m, IH), 4.00 (m, 2H), 3.50 (br m, IH), 3.20 (br m, IH), 2.98 (s, 4H), 2.85 (br m, 2H), 1.84 (br m, IH), 1.68 (br m, 3H). MS(EI): 416(M++H).
EXAMPLE 4 3-[l-(Quinoline-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin- l-yl]-quinolin-3-yl-methanone di-hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 1, but using quinoline-3- carboxylic acid in place of 5-phenylethynyl-pyridine-3-carboxylic acid, there was prepared the title compound as a white amorphous solid. 1HNMR [(CD3)2SO, 500 MHz]: δ 9.10 (s, IH), 8.78 (s, IH),
8.20 (m, 2H), 7.98 (m, IH), 7.80 (m, IH), 7.50 (s, IH), 7.35 (m, 3H), 4.72 (br m, IH), 4.00 (m, 2H), 3.80 (br m, IH), 3.30 (br m, IH), 2.90 (br m, 2H), 1.90 (br m, IH), 1.75 (br m, 3H). MS(EI):
346(M++H).
EXAMPLE 5 3-[l-(3-Phenylethynyl-benzoyl)-piperidin-4-yll-benzylamine hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(3-phenylethynyl-phenyl)-methanone hydrochloride)
A. N,N-Bis-(tert-butoxycarbonyl)-3 - [ 1 -(3 -ethynyl-benzoyl)-piperidin-4-yl] -benzylamine By proceeding in a similar manner to the method described in EXAMPLE IC, but using of 3-ethynyl- benzoic acid [prepared according to the procedure described by C. Eabom et al., J. Chem. Soc. C, 1967, (15), pages 1364- 1366] in place of 5-phenylethynyl-pyridine-3 -carboxylic acid, there was prepared N,N-bis-(tgrt-butoxycarbonyl)-3-[l-(3-ethynyl-benzoyl)-piperidin-4-yl]-benzylamine as a white amorphous solid. 1H ΝMR (CDC1 , 500 MHz): δ 7.76 (m, 2H), 7.40 (m, 2H), 7.25 (m, 2H),
7.10 (m, 4H), 4.95 (br m,lH), 4.79 (s, 2H), 3.80 (br m, IH), 3.10 (br m, IH), 2.84 (br m, IH), 2.78 (br m, IH), 1.90 (m, IH), 1.75 (m, 3H), 1.42 (s, 18H). MS(EI): 541(M++Νa).
B. N,N-Bis-(tgrt-butoxycarbonyl)-3-[l-(3-phenylethynyl-benzoyl)-piperidin-4-yl]-benzylamine A mixture of NN-bis-(tgrt-butoxycarbonyl)-3-[l-(3-ethynyl-benzoyl)-piperidin-4-yl]-benzylamine (0.24g, 0.46mmol), iodobenzene (95mg, 0.46mmol), dichlorobis(triphenylphosphine)palladium (II) (35mg, 0.05mmol), copper (I) iodide (26mg, 0.14mmol), friethylamine (0.57ml, 4.1mmol) and anhydrous dimethylformamide (8ml) was stirred at ambient temperature under nitrogen for 18 hours. The solvent was removed under vacuum and the residue was partitioned between ethyl acetate (3 lots of 50ml) and water (20ml). The combined organic layers were washed with brine (50ml), then dried over magnesium sulfate and then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with a mixture of cyclohexane and ethyl acetate (3 :2, v/v) to give N,N-bis-(tgrt-butoxycarbonyl)-3-[l-(3-phenylefhynyl-benzoyl)-piperidin-4-yl]-benzylamine as a yellow oil (0.23g). ^ ΝMR ^DC^, 500 MHz): δ 7.58 (m, 4H), 7.40 (m, 5H), 7.25 (m, 1H), 7.10
(m, 3H), 4.90 (br m,lH), 4.79 (s, 2H), 3.80 (br m, IH), 3.15 (br m, IH), 2.84 (br m, IH), 2.78 (br m,
IH), 1.95 (m, IH), 1.80 (m, 3H), 1.42 (s, 18H). MS(EI): 617(M++Νa).
C . 3 - [ 1 -(3 -Pheny lethyny l-benzoyl)-piperidin-4-yl] -benzylamine hydrochloride A solution ofN,N-Bis-(tgrt-butoxycarbonyl)-3-[l-(3-phenylethynyl-benzoyl)-piperidin-4-yl]- benzylamine (lOOmg, 0.17mmol) in methanol (10ml), cooled to 0 °C, was saturated with hydrogen chloride gas. The mixture was stirred at ambient temperature for 4 hours then concentrated to dryness under vacuum. The residue was triturated with a mixture of dichloromethane and diethyl ether to give 3-[l-(3-phenylethynyl-benzoyl)-piperidin-4-yl]-benzylamine hydrochloride as a white amorphous solid (46mg). !H ΝMR [(CD3)2SO, 500 MHz]: δ 7.61-7.30 (m, 13H), 4.62 (br m, IH), 4.00 (s, 2H),
3.62 (br m, IH), 3.25 (br m, IH), 2.85 (br m, 2H), 1.88 (br m, IH), 1.70 (br m, 3H). MS(EI):
395(M++H).
EXAMPLE 6 2- { 3 - [4-(3 -Aminomethyl-phenyl)-piperidine- 1 -carbonyl]-phenyl} - 1 -(4-hydroxyphenyl)-ethanone (A.K.A. 2-{3-[4-(3-Aminomethyl-phenyl)-piperidine-l-carbonyl]-phenyl}-l-(4-hydroxy-phenyl)- ethanone hydrochloride)
A. N,N-Bis-(tgrt-butoxycarbonyl)-3-{l-[3-(4-hydroxyphenyl)ethynyl-benzoyl]-piperidin-4-yl}- benzylamine
By proceeding in a similar manner to the method described in EXAMPLE 5B, but using 4-iodoρhenol in place of iodobenzene, there was prepared N,N-bis-(tgrt-butoxycarbonyl)-3-{l-[3-(4- hydroxyphenyl)ethynyl-benzoyl]-piperidin-4-yl}-benzylamine as a yellow amorphous solid. 1H ΝMR
(CDCI3, 500 MHz): δ 7.58 (m, 2H), 7.40 (m, 4H), 7.25 (m, IH), 7.15 (m, 3H), 6.80 (m, 2H), 4.90 (br m,lH), 4.79 (s, 2H), 3.90 (br m, IH), 3.15 (br m, IH), 2.84 (br m, IH), 2.78 (br m, IH), 1.98 (m, IH), 1.80 (m, 3H), 1.42 (s, 18H). MS(EI): 633(M++Na).
B. 2-{3-[4-(3-Aminomethyl-phenyl)-piperidine-l-carbonyl]-phenyl}-l-(4-hydroxyphenyl)-ethanone hydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 5C but using N,N-bis-(tert- butoxycarbonyl)-3-{l-[3-(4-hydroxyphenyl)ethynyl-benzoyl]-piperidin-4-yl}-benzylamine, there was prepared 2-{3-[4-(3-aminomethyl-phenyl)-piperidine-l-carbonyl]-phenyl}-l-(4-hydroxyphenyl)- . ethanone hydrochloride as a white amoφhous solid. 1H ΝMR [(CT>3)2SO, 500 MHz]: δ 7.92 (m,
2H), 7.40-7.28 (m, 8H), 6.82 (m, 2H), 4.60 (br m, IH), 4.38 (s, 2H), 4.00 (s, 2H), 3.62 (br m, IH), 3.18
(br m, IH), 2.80 (br m, 2H), 1.88 (br m, IH), 1.70-1.60 (br m, 3H), MS(EI): 429(M++H).
EXAMPLE 7 3- { l-[3-(6-Amino-pyridin-3-yl)ethynyl-benzoyl]-piperidin-4-yl}-benzylamine hydrochloride
( A.K. A. [4-(3 - Aminomethy 1-pheny l)-piperidin- 1 -yl]- [3 -(6-amino-pyridin-3 -ylethynyl)-pheny 1]- methanone hydrochloride)
A. 3-Iodo-6-(tgrt-butoxycarbonylamino)pyridine A stirred solution of 6-amino-3-iodopyridine (0.44g, 2.0mmol) in anhydrous tefrahydrofuran (7ml), under nitrogen, was freated dropwise with a solution of sodium bis(frimethylsilyl)amide (1M, 4.4ml, 4.4mmol). After stirring for a further 15 minutes the mixture was treated with a solution of di-tert- butyldicarboxylate (440 mg, 2mmol) in anhydrous tefrahydrofuran (3ml). The resulting thick slurry was stirred at ambient temperature for 18 hours then partitioned between ethyl acetate (3 lots of 50ml) and water (50ml). The combined organics were dried over sodium sulfate then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with a mixture of cyclohexane and ethyl acetate (9:1, v/v) to give 3-iodo-6-(tgrt-butoxycarbonylamino)pyridine as a white solid (0.56g). !H ΝMR (CDCI3, 500MHz) δ8.50 (s, IH), 7.92 (m, IH), 7.85 (m, IH), 1.58 (s,
9H). MS(EI): 319(M+- H).
B . N)N-Bis-(tgrt-butoxycarbony l)-3 - { 1 - [3 -(6-tgrt-butoxycarbonylamino-pyridm-3 -yl)ethyny 1- benzoyl]-piperidin-4-yl}-benzylamine
By proceeding in a similar manner to the method described in EXAMPLE 5B, but using 3-iodo-6- (tert-butoxycarbonylamino)pyridine in place of iodobenzene, there was prepared N,N-bis-(tert- butoxycarbonyl)-3-{l-[3-(6-tgrt-butoxycarbonylamino-pyridin-3-yl)ethynyl-benzoyl]-piperidin-4-yl}-
benzylamine as a yellow amoφhous solid. 1H NMR (CDCI3, 500MHz): δ 8.41 (s, IH), 7.99 (m, IH),
7.80 (m, IH), 7.61 (s, IH), 7.59 (m, 2H), 7.40 (m, 2H), 7.23 (m, IH), 7.12 (m, 3H), 4.90 (br m,lH), 4.79 (s, 2H), 3.84 (br m, IH), 3.15 (br m, IH), 2.84 (br m, IH), 2.78 (br m, IH), 1.95 (m, IH), 1.80 (m,
3H), 1.55 (s, 9H), 1.42 (s, 18H). MS(EI): 710(M+).
C. 3-{l-[3-(6-Amino-pyridin-3-yl)ethynyl-benzoyl]-piperidin-4-yl}-benzylamine hydrochloride By proceeding in a similar manner to the method described in EXAMPLE 5C but using N,N-bis-(tert- butoxycarbonyl)-3 - { 1 - [3-(6-tgrt-butoxycarbonylamino -pyridin-3 -yl)efhynyl-benzoyl]-piperidin-4-yl } - benzylamine, there was prepared 3 - { 1 - [3 -(6- Amino-pyridin-3 -yl)ethynyl-benzoyl]-piperidin-4-yl} - benzylamine hydrochloride as a white amoφhous solid. ). 1H MR [(CD3)2SO, 500 MHz]: δ 8.22
(s, IH), 8.15 (br s, 2H), 7.90 (m, IH), 7.60-7.41 (m, 5H), 7.30 (m, 3H), 6.93 (m, IH), 4.60 (br m, IH), 4.00 (m, 2H), 3.62 (br m, IH), 3.25 (br m, IH), 2.85 (br m, 2H), 1.84 (br m, IH), 1.60 (br m, 3H).
MS(EI): 411(M++H).
EXAMPLE 8
3-{l-[3-(4-hydroxymethylphenyl)ethynyl-benzoyl]-piperidin-4-yl}-benzylamine hydrochloride
(A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-[3-(4-hydroxymethyl-phenylethynyl)-phenyl]- methanone hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 5, but using 4- iodobenzylalcohol (prepared according to the procedure described by D.S.Tan et al., J. Am. Chem.
Soc, 1998, 120(33), pages 8565-8566) in place of iodobenzene, there was prepared the title compound as a white amoφhous solid. lH NMR [(CD )2SO, 500 MHz]: δ 7.61-7.25 (m, 12H), 5.33 (m, IH), 4.62 (br m, IH), 4.58 (m, 2H), 4.00 (s, 2H), 3.62 (br m, IH), 3.20 (br m, IH), 2.83 (br m, 2H), 1.84 (br m, IH), 1.72-1.62 (br m, 3H). MS(EI): 425(M++H).
EXAMPLE 9
3-[l-(3-Phenylethyl-benzoyl)-piperidin-4-yl]-benzylamine hydrochloride
(A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(3-phenethyl-phenyl)-methanone hydrochloride)
A solution of N,N-bis-(tgrt-butoxycarbonyl)-3-[l-(3-phenylethynyl-benzoyl)-piperidin-4-yl]- benzylamine (1 lOmg, O.lδmmol, EXAMPLE 5B) in ethanol (10ml) was freated with 10% palladium on carbon (20mg) and then stirred at ambient temperature under an atmosphere of hydrogen for 8 hours. The reaction mixture was filtered through a short pad of hyflo and then concentrated under vacuum to give a white amoφhous solid (0.54g). This material was treated with methanolic hydrogen chloride according to the procedure described in EXAMPLE 5C to give the title compound as white amoφhous solid (25mg). 1H ΝMR [(CD3)2SO, 500 MHz]: δ 7.40-7.15 (m, 13H), 4.62 (br m, IH),
4.00 (s, 2H), 3.60 (br m, IH), 3.10 (br m, IH), 2.80 (br m, 2H), 1.85 (br m, IH), 1.60 (br m, 3H), MS(EI): 399(M++H).
EXAMPLE 10 3-{ l-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine hydrochloride
(A.K.A. [4-(3-Aminomethyl-phenyl)-ρiρeridin-l-yl]-{3-[2-(4-hydroxy-phenyl)-ethyl]-phenyl}- methanone hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 9, but using N,N-bis-(tert- butoxycarbonyl)-3-{l-[3-(4-hydroxyphenyl)ethynyl-benzoyl]-piperidin-4-yl}-benzylamine (EXAMPLE 6A), there was prepared the title compound as a white amoφhous solid. 1H ΝMR
[(CD3)2SO, 500 MHz]: δ 9.18 (br s, IH), 7.41 (s, IH), 7.35 (m, 5H), 7.20 (m, 2H), 6.98 (m, 2H), 6.60
(m, 2H), 4.82 (br m,lH), 4.00 (m, 2H), 3.80 (br m, IH), 3.10 (br m, IH), 2.80 (m, 6H), 1.82 (br m,
IH), 1.70 (br m, IH), 1.60 (br m, 2H). MS(EI): 415(M++ H).
EXAMPLE 11
3- { 1 -[3-(6-amino-pyridin-3-yl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine hydrochloride
(A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-{3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl}- methanone hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 9, but using N,N-bis-(tert- butoxycarbonyl)-3-{l-[3-(6-tgrt-butoxycarbonylamino-pyridin-3-yl)ethynyl-benzoyl]-piperidin-4-yl}- benzylamine (EXAMPLE 7B), there was prepared the title compound as a white amoφhous solid. 1H ΝMR [(CD3)2SO, 500 MHz]: δ 7.90 (br s, 2H), 7.85 (m, IH), 7.76 (s, IH), 7.43 (s, IH), 7.40-7.30
(m, 5H), 7.24 (m, 2H), 6.93 (m, IH), 4.61 (br m, IH), 4.00 (m, 2H), 3.60 (br m, IH), 3.15 (br m, IH), 2.92 (br m, 6H), 1.90 (br m, IH), 1.70 (br m, IH), 1.60 (br m, 2H). MS(EI): 415( M++H).
EXAMPLE 12
3-[l-(4-Phenylethyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(4-phenethyl-thiophen-2-yl)-methanone hydrochloride) By proceeding in a similar manner to the method described in EXAMPLE 1, but using 4-phenylethyl- thiophene-2-carboxylic acid (prepared according the procedure described by S.Gronowitz et al., Heterocycles, 1981, 15(2), pages 947-959) in place of 5-ρhenylethynyl-pyridine-3-carboxylic acid, there was prepared the title compound as a white amoφhous solid. ^H ΝMR [(CD3)2SO, 500 MHz]: δ 7.41-7.18 (m, 1 IH), 4.37 (br m, IH), 4.00 (m, 2H), 3.05 (br m, 2H), 2.98 (s, 4H), 2.85 (br m, 2H), 1.90 (br m, 2H), 1.60 (br m, 2H), MS(EI): 405(M++H).
EXAMPLE 13 3-[l-(5-Phenylethyl-thiophene-2-carbonyl)-piperidin-4-yll-benzylamine hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(5-phenethyl-thiophen-2-yl)-methanone hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 2, but using 5- phenylethynyl-thiophene-2-carboxylic acid in place of 5-phenylethynyl-pyridine-3-carboxylic acid, there was prepared the title compound as a white amoφhous solid. 1H NMR [(CU3)2SO, 500 MHz]: δ 7.41 (s, IH), 7.38-7.20 (m, 9H), 6.83 (s, IH), 4.40 (br m, IH), 4.00 (br s, 2H), 3.12 (m, 2H), 3.08 (br m, 2H), 2.98 (m, 2H), 2.85. (br m, 2H), 1.82 (br m, 2H), 1.60 (br m, 2H), MS(EI): 405(M++H).
EXAMPLE 14 3-{l-[3-(Benzooxazo-2-yl)-benzoyl]-piperidin-4-yl}-benzylamine hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(3-benzoxazol-2-yl-phenyl)-methanone hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 1 , but using 3-(benzooxazo- 2-yl)-benzoic acid (prepared according to the procedure described by V.F.Bysfrov et al., Zh. Obshch. Khim., 1968, 38(5), pages 1001-1005) in place of 5-phenylethynyl-pyridine-3 -carboxylic acid, there was prepared the title compound as a white amoφhous solid. *H NMR [(CU3) SO, 500 MHz]: δ 8.28 (m, IH), 8.19 (s, IH), 7.81 (m, 2H), 7.50 (m, 2H), 7.43 (m, 3H), 7.30 (m, 3H), 4.66 (br m, IH),
4.00 (m, 2H), 3.70 (br m, IH), 3.25 (br m, IH), 2.92 (br m, IH), 2.82 (br m, IH), 1.90 (br m, IH), 1.70
(br m, 3H), MS(EI): 412(M++H).
EXAMPLE 15 3 - [ 1 -(3-Phenoxymethyl-benzoyl)-piperidin-4-yl]-benzylamine hydrochloride
(A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(3-phenoxymethyl-phenyl)-methanone hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 1, but using 3- phenoxymethyl-benzoic acid (prepared according to the procedure of H.Oelschlaeger et al., Arch. Pharm. (Weinheim, Ger.), 1978, 311(2), pages 81-97) in place of 5-phenylethynyl-pyridine-3- carboxylic acid, there was prepared the title compound as a white amoφhous solid. 1H NMR [(CD3) SO, 500 MHz]: δ 7.58-7.25 (m, 10H), 7.00 (m, 2H), 6.96 (m, IH), 5.18 (s, 2H), 4.62 (br m, IH), 4.00 (m, 2H), 3.62 (br m, IH), 3.18 (br m, IH), 2.82 (br , 2H), 1.88 (br m, IH), 1.65 (br m, 3H),
MS(EI): 401(M++H).
EXAMPLE 16 3-{l-[3-(2-£'-Phenylethenyl)-benzoyl]-piperidin-4-yl}-benzylamine hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl]-[3-((E)-styryl)-phenyl]-methanone hydrochloride) By proceeding in a similar manner to the method described in EXAMPLE 1, but using 3-(2-E- phenylethenyl)-benzoic acid (prepared according to the procedure of N.A.Bumagin et al., Zh. Org. Khim., 1995, 31(4), pages481-487) in place of 5-phenylethynyl-pyridine-3 -carboxylic acid, there was prepared the title compound as a white amoφhous solid. 1H NMR [(CU3)2SO, 500 MHz] : δ 7.71
(m, IH), 7.63 (m, 3H), 7.50 (m, 2H), 7.40-7.25 (m, 9H), 4.63 (br m, IH), 4.00 (s, 2H), 3.71 (br m, IH),
3.10 (br m, IH), 2.84 (br m, 2H), 1.88 (br m, IH), 1.70 (br m, 3H), MS(EI): 397(M++H).
EXAMPLE 17 4-Fluoro-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride (A.K.A. [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-l-yl]-(5-phenethyl-pyridin-3-yl)-methanone di-hydrochloride)
A. 4-(Pinacolatoboronyl)- 1 ,2,3 ,6-tetrahydro-pyridine trifluoroacetate
A solution of lithium diisopropylamine (59mmol) in anhydrous tefrahydrofuran (50ml) at -78°C was freated dropwise with a solution of tgrt-butyl 4-oxo-l-piperidinecarboxylate (10.7g, 54mmol) in anhydrous tefrahydrofuran (70ml). After stirring at -78°C for a further 20 minutes the reaction mixture was treated with a solution of N-phenyltrifluoromethanesulfonimide (21.2g, 59mmol) in anhydrous tefrahydrofuran (90ml). The resultant orange suspension was warmed to 0°C, then stirred at 0°C for 3 hours and then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with a mixture of pentane and dichloromethane (1:1, v/v) and then subjected to chromatography on alumina eluting with a mixture of pentane and ethyl acetate (9: 1, v/v) to yield tert- butyl l,2,3,6-tetrahydro-4-(trifluoromethylsulphonyloxy)-pyridine-l-carboxylate as a yellow oil (15g). A portion of this material (1.72g, 5.2mmol) was dissolved in anhydrous dioxane (30ml) and the solution was treated with bis(pinacolato)diboron (1.46g, 5.75mmol), potassium acetate (1.54g, 15.7mmol), (diphenylphosphino)-ferrocene (86mg, O.lδmmol) and [1,1 '-bis- (diphenylphosphino)ferroceno]-dichloropalladium (II) (114mg, 0.16mmol). The reaction mixture was heated at 80°C under an atmosphere of nitrogen for 18 hours, then cooled and then concentrated under vacuum. The residue was partitioned between ethyl acetate (2 lots of 100ml) and water (100ml). The combined organic extracts were dried over magnesium sulfate then concentrated under vacuum. The resultant oil was subjected to chromatography on silica gel eluting with a mixture of ethyl acetate and pentane (1:8, v/v) to yield a yellow oil (1.4g). A solution of this material in dichloromethane (10ml), cooled to 0°C, was freated with trifluoracetic acid (3.9ml). The mixture was stirred at ambient temperature for 2 hours then concentrated under vacuum to leave 4-(pinacolatoboronyl)- 1 ,2,3,6-
tetrahydro-pyridine trifluoroacetate as a brown oil. 1H NMR [(CX>3) SO, 500 MHz]: δ 8.76 (br s, 2H), 6.39 (br s, IH), 3.61 (br m, 2H), 3.11 (br m, 2H), 2.23 (br m, 2H), 1.20 (s 12H). MS(EI): 210(M++ H).
B. l-(5-Phenylethyl-pyridine-3-carbonyl)-4-(pinacolatoboronyl)-l,2,3,6-tetrahydro-pyridine A solution of 5-phenylethyl-pyridine-3 -carboxylic acid (0.46g, 2.0mmol, EXAMPLE 2A) in anhydrous dimethylformamide (9ml) was freated with 0-(7-azabenzotriazol- 1-yl)- 1,1, 3,3- tetramethyluronium hexafluorophosphate (0.87g, 2.2mmol) and diisopropylethylamine (1.7ml, lOmmol). This mixture was stirred at ambient temperature for 10 minutes then treated with a solution of 4-(pinacolatoboronyl)- 1,2,3 ,6-tetrahydro-pyridine trifluoroacetate (0.81g, 2.5mmol) in dimethylformamide (9ml). The reaction mixture was stirred at ambient temperature for 18 hours and then concentrated under vacuum. The residue was partitioned between dichloromethane (2 lots of 50ml) and saturated aqueous sodium bicarbonate (15ml). The combined organic layers were dried over magnesium sulfate and then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with ethyl acetate to give l-(5-phenylethyl-pyridine-3-carbonyl)-
4-(pinacolatoboronyl)- 1 ,2,3 ,6-tetrahydro-pyridine as a brown amoφhous solid (0.73g). *H NMR [(CD3)2SO, 500 MHz]: δ 8.49 (s, IH), 8.40 (s, IH), 7.61 (s, IH), 7.20 (m, 5H), 6.48 (br s, IH), 4.18
(br m, IH), 3.83 (br m, IH), 3.62 (br m, IH), 3.23 (br m, IH), 2.98 (m, 4H), 2.17 (br m, 2H), 1.20 (s,
12H). MS(EI): 441(M++Na).
C. N-(tgrt-Butoxycarbonyl)-3-bromo-4-fluoro-benzylamine
A mixture of 3-bromo-4 fluoro-benzylamine hydrochloride (2.41g, lOmmol), triethylamine (2.8ml, 20mmol), and di-tgrt-butoxycarbonate (1.8g, 10.3mmol) in dichloromethane (20ml) was stirred at ambient temperature for 18 hours then washed with water (20ml). The organic phase was dried over magnesium sulfate and then concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with a mixture of cyclohexane and ethyl acetate (3:1, v/v) to give N-(tgrt-butoxycarbonyl)-3-bromo-4-fluoro-benzylamine as a white solid (1.4g). *H NMR (CDCI3, 500 MHz): δ 7.45 (m, IH), 7.20 (m, IH), 7.08 (m, IH), 4.85 (br s, IH), 4.21 (m, 2H), 1.42 (s, 9H).
D. N-(tg?-t-Butoxycarbonyl)-4-fluoro-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-l,2,3,6-tetrahydro- pyridin-4-yl]-benzylamine
A mixture of Ν-(tgrt-butoxycarbonyl)-3-bromo-4-fluoro-benzylamine (0.28g, 0.92mmol), anhydrous dimethylformamide ( 10ml), 1 -(5 -phenylethyl-pyridine-3 -carbonyl)-4-(pinacolatoboronyl)- 1 ,2,3 ,6- tetrahydro-pyridine (0.37g, 0.88mmol), potassium carbonate (0.36g, 2.6mmol) and [1,1 '-bis- (diphenylphosphino)ferroceno]dichloropalladium (IΙ)-dichloromethane complex (43 mg, 0.05mmol)
was heated at 80°C under an atmosphere of nitrogen for 18 hours. The reaction mixture was cooled to room temperature and then concentrated under vacuum. The residue was partitioned between ethyl acetate (2 lots of 50ml) and water (10ml). The combined organic extracts were dried over magnesium sulfate and then concentrated under vacuum. The resultant oil was subjected to chromatography on silica gel eluting with ethyl acetate to yield N-(tgrt-butoxycarbonyl)-4-fluoro-3-[l-(5-phenylethyl- pyridine-3-carbonyl)-l,2,3,6-tetrahydro-pyridin-4-yl]-benzylamine as a pale yellow oil (0.18g). *H NMR (CDC13, 500 MHz): δ 8.58 (s, IH), 8.50 (s, IH), 7.51 (s, IH), 7.25 (m, 2H), 7.18 (m, 5H), 7.00
(m, IH), 6.01 (br s, IH), 4.83 (br s, IH), 4.38 (br m, IH), 4.27 (m, 2H), 3.98 (br m, 2H), 3.50 (br m, IH), 2.99 (m, 4H), 2.60 (br m, IH), 2.50 (br m, IH). MS(EI): 538(M++ Na).
E. 4-Fluoro-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride A solution of N-(tert-butoxycarbonyl)-4-fluoro-3 - [ 1 -(5-phenylethyl-pyridine-3 -carbonyl)- 1,2,3,6- tetrahydro-pyridin-4-yl]-benzylamine in ethanol (12ml) was freated with 10% palladium on carbon (75mg) and the mixture was stirred at ambient temperature under an atmosphere of hydrogen for 72 hours. The reaction mixture was filtered through a short pad of hyflo and the filtrate was concentrated under vacuum to give N-(tgrt-butoxycarbonyl-4-fluoro-3-[l-(5-phenylethyl-pyridine-3-carbonyl)- piperidin-4-yl]-benzylamine as colorless oil (85mg). This material was dissolved in methanol (10ml) and the solution was cooled to 0°C and then saturated with hydrogen chloride gas. This mixture was stirred at ambient temperature for 4 hours and then concentrated to dryness under vacuum. The residue was triturated with a mixture of dichloromethane and diethyl ether to give 4-fluoro-3-[l-(5- phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride as a white amoφhous solid (50mg). iHΝMR [(CD )2SO, 500 MHz]: δ 8.60 (s, IH), 8.58 (s, IH), 7.83 (s, IH), 7.60 (m,
IH), 7.38 (m, IH), 7.20 (m, 6H), 4.61 (br m, IH), 4.00 (m, 2H), 3.50 (br m, IH), 3.20 (br m, 2H), 2.99
(m, 2H), 2.95 (m, 2H), 2.90 (br m, IH), 1.82 (br m, IH), 1.65 (br m, 3H). MS(EI): 418(M++H).
EXAMPLE 18 4-Methyl-3- [ 1 -(5-phenylethyl-pyridine-3 -carbonyl)-piperidin-4-yl] -benzylamine di-hydrochloride (A.K.A. [4-(5-Aminomethyl-2-methyl-phenyl)-piperidin-l-yl]-(5-phenethyl-pyridin-3-yl)-methanone di-hydrochloride)
A. 4-[N,N-Bis-(tgrt-butoxycarbonyl)aminomethyl]-2-bromo-toluene
A solution of 4-methyl-3-bromobenzylbromide (1.63g, 6.2mmol, prepared according to the procedure described in International Patent Application No. WO 0009475) and di-tgrt-butyliminodicarboxylate (1.48g, 6.8mmol) in anhydrous tefrahydrofuran (15ml) was treated portionwise with sodium hydride (0.27g of 60%) dispersion in mineral oil, 6.8mmol). The mixture was stirred at ambient temperature for
18 hours then partitioned between saturated aqueous ammonium chloride solution (20ml) and ethyl acetate (3 lots of 80ml). The combined organic layers were washed with brine (80ml), then dried over magnesium sulfate and concentrated under vacuum. The residue was subjected to chromatography on silica gel eluting with a mixture of cyclohexane and diethyl ether (9:1, v/v) to give 4-[N,N-bis-(tgrt- butoxycarbonyl)aminomethyl]-2-bromo-toluene as a pale yellow oil (2.4g). 1H ΝMR (CDCI3, 500 MHz): δ 7.45 (s, IH), 7.18 (m, 2H), 4.71 (s, 2H), 2.38 (s, 3H), 1.43 (s, 18H).
B. 4-Methyl-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride By proceeding in a similar manner to the method described in EXAMPLE 17, but using 4-[NN-bis- (tgrt-butoxycarbonyl)aminomethyl]-2-bromo-toluene in place of Ν-(tgrt-butoxycarbonyl)-3-bromo-4- fluoro-benzylamine, there was prepared 4-methyl-3 - [ 1 -(5 -pheny lethy l-pyridine-3 -carbonyl)-piperidin-
4-yl]-benzylamine di-hydrochloride as a white amoφhous solid. 1H NMR [(CU3) SO, 500 MHz]: δ
8.60 (m, 2H), 7.83 (s, IH), 7.41 (s, IH), 7.20 (m, 7H), 4.62 (br m, IH), 3.98 (m, 2H), 3.45 (br m, IH), 3.20 (br m, IH), 3.07 (m, 2H), 3.00 (m, 2H), 2.95 (m, 2H), 2.32 (s, 3H), 1.80 (br m, IH), 1.70 (br m, 3H). MS(EI): 414(M++H).
EXAMPLE 19 3-{ l-[3-(5-Phenyl-l,3,4-oxadiazol-2-yl)-phenylcarbonyl]-piperidin-4-yl}-benzylamine hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-[3-(5-phenyl-l,3,4-oxadiazol-2-yl)-phenyl]- methanone hydrochloride)
A. 3-(5-Phenyl-l,3,4-oxadiazol-2-yl)-benzoic acid
A mixture of methyl hydrogen isopthalalate (1.8g, lOmmol), benzoic hydrazide (1.4g, lOmmol) and phosphorous oxychloride (20ml), under an atmosphere of nifrogen, was heated at 120°C for 18 hours, then cooled to room temperature and then poured into ice water (500ml). This mixture was treated with solid sodium carbonate until the aqueous layer was basic (pH 8 -9) and the resultant pink solid was filtered. This material was freated with 100ml methanol and the suspension was freated with sodium hydroxide solution (30ml, 1M). The reaction mixture was heated at reflux for 4 hours, then cooled and then concenfrated to dryness. The residue was dissolved in water (100ml) and the solution was acidified to pH 3 by addition of concentrated hydrochloric acid. The resultant precipitate was filtered, then dried and then subjected to chromatography on silica gel eluting with a mixture of dichloromethane and methanol (98:2, v/v) to yield 3-(5-phenyl-l,3,4-oxadiazol-2-yl)-benzoic acid as a white solid (600mg). 1HNMR [(CD3) SO, 500 MHz]: δ 8.80 (s, IH), 8.38 (m, IH), 8.18 (m, 3H),
7.78 (m, IH), 7.62 (m, 3H). MS(EI): 265(M+- H).
B. 3-{ l-[3-(5-Phenyl-l,3,4-oxadiazol-2-yl)-phenylcarbonyl]-piperidin-4-yl}-benzylamine hydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 1 , but using 3-(5-phenyl- l,3,4-oxadiazol-2-yl)-benzoic acid in place of 5-phenylethynyl-pyridine-3-carboxylic acid, there was prepared 3 - { 1 - [3 -(5-phenyl- 1 ,3 ,4-oxadiazol-2-yl)-phenylcarbony 1] -piperidin-4-y 1 } -benzylamine hydrochloride as a pale yellow amoφhous solid. 1H NMR [(CD3)2SO, 500 MHz]: δ 8.21 (m, IH),
8.20 (m, 3H), 7.75 (m, 2H), 7.68 (m, 3H), 7.50 (s, IH), 7.37 (m, 3H), 4.70 (br m, IH), 4.00 (m, 2H), 3.70 (br m, IH), 3.25 (br m, IH), 2.90 (br m, IH), 2.85 (br m, IH), 1.88 (br m, IH), 1.70 (m, 3H),
MS(EI): 439(M++H).
EXAMPLE 20
3-[l-(Indole-6-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate
(A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(lH-indol-6-yl)-methanone trifluoroacetate)
A solution of diisopropylamine in dimethylformamide (1ml, 180μM) in a glass vial was treated with a solution of 0-(7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate in dimethylformamide (1ml, 60μM) followed by a solution of indole-6-carboxylic acid in dimethylformamide (1ml, 60μM). After standing at ambient temperature for 15 minutes the mixture was freated with a solution of 4-{3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidine in dimethylformamide(lml, 60μM, EXAMPLE IB). The reaction mixture was allowed to stand at ambient temperature for 18 hours then evaporated. The residue was freated with chloroform (5ml) and aqueous sodium carbonate solution (5%). This mixture was shaken gently for 30 minutes, poured into a fritted polypropylene tube and the organic layer which passes through the frit collected in a glass vial. The chloroform was evaporated under vacuum and the residue was treated with a mixture of trifluoroacetic acid, dichloromethane and water (4ml, 55/40/5, v/v/v). This mixture was shaken gently for 2 hours and then evaporated to leave the title compound as a yellow oil. LC-MS: R- = 3.43 minutes (>96% by ELSD); MS (ES+), 334 (MH+).
EXAMPLE 21 3-[l-(Coumarm-3-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate (A.K.A. 3-[4-(3-Aminomethyl-phenyl)-piperidine-l-carbonyl]-l-benzopyran-2-one trifluoroacetate) By proceeding in a similar manner to the method described in EXAMPLE 20, but using coumarin-3- carboxylic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC-MS: Rτ = 3.15 minutes (>86% by ELSD); MS (ES+), 363 (MH+).
EXAMPLE 22
3 - [ 1 -(Naphthyl-2-carbonyl)-piperidin-4-y 1] -benzylamine trifluoroacetate
(A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-naphthalen-2-yl-methanone trifluoroacetate) By proceeding in a similar manner to the method described in EXAMPLE 20, but using 2-naphthoic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC- MS: RT = 3.66 minutes (100% by ELSD); MS (ES+), 345 (MH+).
EXAMPLE 23 3-{l-[3-(2-Naphthylthio)propionyl]-piperidin-4-yl}-benzylamine trifluoroacetate (A.K. A. 1 - [4-(3 - Aminomethy l-phenyl)-piperidin- 1 -yl]-3 -(naphthalen-2-ylsulfanyl)-propan- 1 -one trifluoroacetate)
By proceeding in a similar manner to the method described in EXAMPLE 20, but using 3-(2- naphthylthio)propionic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC-MS: Rτ = 4.00minutes (>95% by ELSD); MS (ES+), 405(MH+).
EXAMPLE 24
3-{l-[4-(Indol-3-yl)butanoyl]-piperidin-4-yl}-benzylamine trifluoroacetate
(A.K.A. l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-4-(lH-indol-3-yl)-butan-l-one trifluoroacetate) By proceeding in a similar manner to the method described in EXAMPLE 20, but using 4-(indol-3- yl)butanoic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC-MS: Rτ = 3.64 minutes (>90% by ELSD); MS (ES+), 376(MH+).
EXAMPLE 25 3- { 1 -[4-(4-Biphenyl)-4-ketobutanoyl]-piperidin-4-yl}-benzylamine trifluoroacetate (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-biphenyl-4-yl-methanone trifluoroacetate) By proceeding in a similar manner to the method described in EXAMPLE 20, but using 4-(4- biphenyl)-4-ketobutanoic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC-MS: Rτ = 4.00 minutes (100% by ELSD); MS (ES+), 427(MH+).
EXAMPLE 26 3-[l-(3-Benzyloxybenzoyl)-piperidin-4-yl]-benzylamine trifluoroacetate
(A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(3-benzyloxy-phenyl)-methanone trifluoroacetate)
By proceeding in a similar manner to the method described in EXAMPLE 23, but using 3- benzyloxybenzoic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC-MS: Rτ = 3.87 minutes (100% by ELSD); MS (ES+), 401 (MH+).
EXAMPLE 27 3-[l-(5-Phenylethynyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl]-(5-phenylethynyl-thiophen-2-yl)-methanone trifluoroacetate)
By proceeding in a similar manner to the method described in EXAMPLE 20, but using 5- phenylethynyl-thiophene-2-carboxylic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC-MS: R = 4.09 minutes (>97% by ELSD); MS(ES+), 410(MH+).
EXAMPLE 28
3-[l-(4-Phenylethynyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate
(A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(4-phenylethynyl-thiophen-2-yl)-methanone trifluoroacetate)
By proceeding in a similar manner to the method described in EXAMPLE 20, but using 4- phenylethynyl-thiophene-2-carboxylic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC-MS: Rτ = 4.08 minutes (>96% by ELSD); MS(ES+), 401(MH+).
EXAMPLE 29 3-(l-Benzoyl-piperidin-4-yl)-benzylamine trifluoroacetate (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-phenyl-methanone trifluoroacetate)
By proceeding in a similar manner to the method described in EXAMPLE 20, but using benzoic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC-MS:
RT = 3.39 minutes (>95% by ELSD); MS(ES+) 295(MH+).
EXAMPLE 30
3-[l-(4-N)N-Dimethylaminobenzoyl)-piperidin-4-yl]-benzylamine trifluoroacetate
(A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(4-dimethylamino-phenyl)-methanone trifluoroacetate)
By proceeding in a similar manner to the method described in EXAMPLE 20, but using 4-NN- dimethylaminobenzoic acid in place of indole-6-carboxylic acid, there was prepared the title compound as a yellow oil. LC-MS: Rτ = 3.32 minutes (100% by ELSD); MS(ES+) 338(MH+).
EXAMPLE 31 6-Fluoro-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride
(A.K.A. [4-(3-Aminomethyl-4-fluoro-phenyl)-piperidin-l-yl]-(5-phenethyl-pyridin-3-yl)-methanone di-hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 17, but using 3-bromo-6- fluoro-benzylamine in place of 3-bromo-4-fluoro-benzylamine, there was prepared the title compound as a pale yellow oil. *H NMR [(CD3)2SO, 500 MHz]: δ 8.44 (m, 2H), 7.61 (s, IH), 7.40 (m, IH),
7.20 (m, 6H), 7.05 (m, IH), 4.62 (br m, IH), 3.98 (m, 2H), 3.45 (br m, IH), 3.20 (br m, IH), 3.07 (m,
2H), 3.00 (m, 2H), 2.95 (m, 2H) 1.80 (br m, IH), 1.70 (br m, 3H). MS(EI): 418(M++H).
EXAMPLE 32 l-{3-[l-(5-Phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-phenyl)ethylamine di-hydrochloride (A.K.A. {4-[3-(l-Amino-ethyl)-phenyl]-piperidin- 1 -yl} -(5-phenethyl-pyridin-3-yl)-methanone di- hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 17, but using l-(3-bromophenyl)efhylamine (prepared according to the procedure of C.P.Chen et al., Tetrahedron Letters, 199, 32(49), pages 7175-7178) in place of 3-bromo-4-fluoro-benzylamine, there was prepared the title compound as a white solid. 1H NMR[(CD3)2SO, 500 MHz]: δ 8.62 (m, 2H), 7.95 (s, IH),
7.50 (s, IH), 7.20 (m, 8H), 4.62 (br m, IH), 4.38 (t, J= 6 Hz, IH), 3.50 (m, IH), 3.45 (br m, IH), 3.20 (br m, IH), 3.07 (m, 2H), 3.00 (m, 2H), 2.95 (m, 2H), 1.87 (br m, IH), 1.65 (br m, 3H), 1.50 (d, J= 6
Hz, 3H). MS(EI): 414(M++H).
EXAMPLE 33
3 - [ 1 -(4-Hydroxy-quinoline-3 -carbonyl)-piperidin-4-yl]-benzylamine (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(4-hydroxy-quinolin-3-yl)-methanone) By proceeding in a similar manner to the method described in EXAMPLE 1, but using 4-hydroxy- quinoline-3 -carboxylic acid (prepared according to the procedure of K.J.Shah, and E.A.Coats, J. Med. Chem. , 1977, 20(8), pages 1001-1006) in place of 5-phenylethynyl-pyridine-3 -carboxylic acid, there was prepared the title compound as a white amoφhous solid. 1H NMR[(CD3)2SO, 500 MHz]: δ 8.10
(m, 2H), 7.68 (m, IH), 7.59 (m, IH), 7.36 (m, 3H), 7.22 (m, 2H), 4.65 (br m, IH), 4.00 (m, 2H), 3.80 (br m, IH), 3.35 (br m, IH), 3.10 (br m, IH), 3.00 (br m, IH), 1.90-1.75 (br m, 4H). MS(EI): 362(M++H).
EXAMPLE 34 3-[l-(6-Phenyl-quinoline-3-carbonyl)-piperidin-4-yl]-benzylamine di-hydrochloride (A.K.A. [4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-(6-phenyl-quinolin-3-yl)-methanone di- hydrochloride)
By proceeding in a similar manner to the method described in EXAMPLE 1, but using 6-phenyl- quinoline-3-carboxylic acid [prepared according to the procedure of J.Biwersi et al., Am. J. Physiol., 1992, 262(1, Pt. 1), C243-C250] in place of 5-phenylethynyl-pyridine-3-carboxylic acid, there was prepared the title compound as a white amoφhous solid. *H NMR[(CD3)2SO, 500 MHz]: δ 9.00 (s, IH), 8.59 (s, IH), 8.41 (s, IH), 8.10 (m, 2H), 7.85 (m, 2H), 7.58 (m, 2H), 7.45 (m, 2H), 7.34 (m, 3H), 4.75 (br m, IH), 4.00 (m, 2H), 3.80 (br m, IH), 3.35 (br m, IH), 3.00 (br m, IH), 2.90 (br m, IH),
1.90- 1.75 (br m, 4H). MS(EI): 422(M++H).
EXAMPLE 35 4-(3-Aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonifrile
A. 3-Cyanobenzylcyanide
To a solution of 9.8g (200 mmole) of sodium cyanide and 1.61g (5 mmole) of tefrabutylammonium bromide in 50 ml of water was added a solution of 19.61g (100 mmole) of α-bromo-m-tolunifrile in 150 ml of dichloromethane. The mixture was stirred at room temperature for 24 hours. To this mixture was added 6.2 ml (100 mmole) of iodomethane. The mixture was stirred at room temperature for 3 hours. The layers were separated and the organic layer was dried over magnesium sulfate and was filtered. The filtrate was evaporated and the residue was triturated with petroleum ether and the insoluble material was collected to give 14.5g of a white solid, mp-66-9°C; 100%) yield: Η-NMR (300 MHz, CDC13) δ (TMS) 3.80-3.90(s, 2H), 7.49-7.72(m, 4H).
B . N-tgrt-Butoxycarbonyl-bis(2-chloroethyl)amine
To a mixture of 17.85g (100 mmole) of bis(2-chloroethyl)amine hydrochloride and 24.0g (110 mmole) of di-tgrt-butyl dicarbonate in 100 ml of dichloromethane was added a solution of 15.3 ml (110 mmole) of frietylamine in 50 ml of dichloromethane dropwise over 30 minutes. The mixture was stirred at room temperature for 24 hours and was poured into water. The organic layer was dried over magnesium sulfate and was filtered. The filtrate was evaporated to give 24g of an oil, 100% yield: Η-NMR (300 MHz, CDCL3) δ (TMS) 1.37-1.56 (m, 9H), 3.50-3.62 ( , 8H); MS (ESI) m/e 242 (M+H)+.
C. 4-(3-Cyanophenyl)-l-tg t-butoxycarbonyl-piperidine-4-carbonitrile
To a solution of 2.8g (19.7 mmole) of 3-cyanobenzylnifrile and 4.77g (19.7 mmole) of N-tgrt- butylcarbonyl-bis(2-chloroethyl)amine in 100 ml of anhydrous DMF was added 2.36g (59.1 mmole) of 60% sodium hydride in portions over 10 minutes. The mixture was stirred at room temperature for 3 days and was poured into water and was extracted with ether. The ether layer was dried over magnesium sulfate and was filtered. The filtrate was evaporated and the residue was purified by flash
chromatography using 4:1 hexane:ethyl acetate to give the product as a white solid: Η-NMR (300 MHz, CDC13) δ (TMS) 1.45(s, 9H), 1.85-2.0(m, 2H), 2.0-2.28(m, 2H), 3.05-3.30(m, 2H), 4.12-4.4(m, 2H), 7.53-7.80(m, 4H).
D. 4-(3-Aminomethyl-phenyl)-l-tgrt-butoxycarbonyl-piρeridine-4-carbonitrile
To a mixture of 0.31g (1 mmole) of 4-(3-cyanophenyl)-l-tgrt-butoxycarbonyl-piperidine-4-carbonifrile in 30 ml of absolute ethanol was added 0.08ml (1 mmole) of cone, hydrochloric acid followed by 30mg of 5% Pd/C. The mixture was agitated in a Parr shaker for 3 hours at 30 lbs. of pressure of hydrogen. The mixture was filtered through celite and the filtrate was evaporated. The residue was freated with ether and was stirred for 30 minutes and was filtered. The filter cake was freated with aqueous sodium carbonate and was extracted with dichloromethane to give 0.2g of product: 1H-NMR (300 MHz, CDCI3) δ(TMS) 1.38-1.60(m, 9H), 1.88-2.18(m, 4H), 3.05-3.30(m, 4H), 3.79-4.0(m, 2H), 7.22-7.85(m, 4H); MS (ESI) m/e 316 (M+H)+.
E. 4-(3-Benzyloxycarbonylaminomethyl-phenyl)-l-tgrt-butoxycarbonyl-piperidine-4-carbonitrile
To a solution of 0.2g of 4-(3-Aminomethyl-phenyl)-l-tgrt-butoxycarbonyl-piperidine-4-carbonitrile in 15 ml of dichloromethane was added a few drops of triethylamine followed by a few drops of benzyl chloroformate. The mixture was stirred for 1 hour at room temperature and was poured into aqueous sodium carbonate and was extracted with dichloromethane. The organic layer was dried over magnesium sulfate and was filtered. The filtrate was evaporated and the residue was used directly in the next step without further purification : !H-NMR (300 MHz, CDCL3) δ (TMS) 1.39-1.52 (m, 9H), 1.80-2.16(m, 4H), 3.08-3.42(m, 4H), 4.19-4.50(m, 2H), 5.08-5.13(d, 2H), 7.28-7.79(m, 9H); MS (ESI) m/e 450 (M+H)+.
F. 4-(3-Benzyloxycarbonylaminomethyl-phenyl)-piperidine-4-carbonitrile
The residue from the previous step was dissolved in dichloromethane containing 1 ml of trifluoroacetic acid and the solution was stirred at room temperature for 45 minutes. The solution was poured into aqueous sodium carbonate and was extracted with dichloromethane. The organic layer was dried and evaporated and the residue was purified by flash chromatography using 7:3 hexane:ethyl acetate to give the product: Η-NMR (300 MHz, CDCL3) δ (TMS) 1.80-2.18(m, 4H), 3.07-3.35(m, 4H), 4.28- 4.50(m, 2H), 5.09-5.13(d, 2H), 7.10-7.77(m, 9H); MS (ESI) m/e 349 (M+H)+.
G. 4-(3-Benzyloxycarbonylaminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4- carbonitrile To a solution of 0.15 g (0.33 mmole) of 4-(3 -benzyloxycarbonylaminomethyl-phenyl)-piperidine-4- carbonitrile in 20 ml of acetonitrile was added 0.038g (0.33 mmole) of N-ethylmopholine followed by
0.1 lg (0.33 mmole) of TBTU. To this solution was added 0.075g (0,33 mmole) of 5- phenethylpyridine-3-carboxylic acid in portions over 10 minutes. The mixture was stirred for 2 hours. The solution was concenfrated and the residue was purified by flash chromatography using 95:5 dichloromethane:methanol to provide 0.2g of product: Η-NMR (300 MHz, CDCL3) δ (TMS) 1.79- 2.20 (m, 4H), 2.70-2.82 (m, 4H), 2.90-3.07 (m, 2H), 3.15-3.70 (m, 2H), 4.35-4.40 (d, 2H), 5.07-5.25 (d, 2H), 7.10-7.50 (m, 15H), 8.42-8.58 (m, 2H); MS (ESI) m/e 559 (M+H)+.
H. 4-(3-Aminomethyl-ρhenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile
To a solution of 0.15g of 4-(3-benzyloxycarbonylaminomethyl-phenyl)-l-(5-phenethyl-pyridine-3- carbonyl)-piperidine-4-carbonitrile in 5 ml of glacial acetic acid was added 1 ml of 30% HBr in acetic acid. The solution was stirred at room temperature for 2 hours. The solution was poured into a saturated sodium carbonate solution and was extracted with dichloromethane. The organic layer was dried over magnesium sulfate and was filtered and evaporated. The residue was purified by Rainin HPLC using 10-100% (acetonitrile-0.1% aqueous TFA) to yield 16 mg of product isolated as the trifluoroacetic acid salt^H-NMR (300 MHz, DMSO-d6) δ (TMS); 1.95-2.30 (m, 4H), 2.45-2.62(m, 2H), 2.88-3.12(m, 4H), 3.70-4.20 (m, 2H), 7.12-7.38(m, 4H), 7.45-7.82(m, 6H), 8.50-8.65(m, 2H); MS (ESI) m/e 425 (M+H)+.
EXAMPLE 36 [4-(3-Aminomethylphenyl)piperidin- 1 -yl]-(3,4-dichlorophenyl)methanone trifluoroacetate
TFP resin (125mg of 1.25mmol/g resin, with 100% loading of acid, 156mmol, prepared according to the procedure described by LM.Salvino et. al. in International Patent Application Publication No. WO 99/67228) was swollen in dichloromethane (2.5mL) for 15 minutes then treated with a solution of 4- (3-aminomethylphenyl)piperidine (40mg, lOOm ol) in dichloromethane (2.5mL). The mixture was sealed in the reaction vessel then left shaking for 8 hours. The resin was filtered, then washed with dichloromethane (2mL) [TLC (5% MeOH / EtOAc) showed single product spot (no baseline amine)] and then freated with trifluoroacetic acid (0.5mL). After shaking for 2 hours TLC showed no residual intermediate and the reaction mixture was evaporated. The residue [ 97% purity by HPLC: R = 7.32 minutes; 10 micron Ci g reverse phase column (4.6mm x 10cm) eluting with 10-100% acetonitrile and water containing 0. l%trifluoroacetic acid] was dissolved in water (50mL) and the solution was lyophilized to give the title compound as an amorphous solid. 1H NMR [(CD3)2SO]: δ 8:15 (br s, 3H),
7.72-7.69 (m, 2H), 7.40 (dd, IH), 7.36-7.25 (m, 4H), 4.66-4.51 (m, IH), 4.05-3.96 (m, 2H), 3.69-3.48 (m, IH), 3.30-3.11 (m, IH), 2.91-2.73 (m, 2H), 1.90-1.54 (m, 4H). MS(Ion spray): 363 and
365(M++1).
EXAMPLE 37
1 -[4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 -(2-phenoxy-phenyl)-methanone trifluoroacetate By proceeding in a similar manner to the method described in EXAMPLE 36, but using the 2- phenoxybenzoic acid derived TFP resin in place of the 3,4-dichlorobenzoic acid TFP resin, there was prepared the title compound as a white amoφhous solid. 1H NMR [(CD3)2SO]: δ 8.11 (br s, 3H, NH3 +); 7.43-7.04 (m, 10H); 7.02-6.85 (m, 3H); 4.65-4.52 (m, H); 4.05-3.90 (m, 2H); 3.62-3.49 (m, H);
3.21-3.05 (m, H); 2.86-2.66 (m, 2H); 1.87-1.30 (m, 4H). MS(Ion spray): 587 (M++l).
EXAMPLE 38 1 - { 1 - [4-(3 -Aminomethyl-phenyl)-piperidin- 1 -yl]-methanoyl } -3 -methylsulfanyl-6,7-dihydro-5H- benzo [c]thiophen-4-one trifluoroacetate
2-(lH-Benzotriazol-l-yl)-l,l,3,3-tetramethyluronium tetrafluoroborate (TBTU) (120mg, 0.38mmol) was added to a room temperature solution of 3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydro- benzo[c]thiophene-l -carboxylic acid (88mg, 0.36mmol) and diisopropylethylamine (140mg, 1.08mmol) in dimethylformamide (2mL), under nifrogen. The reaction mixture was stirred for 10 minutes at room temperature before adding a solution of 4-[3-(N,N-di-tert- butoxycarbonylaminomethyl)phenyl]piperidine (140mg, 0.36mmol) and diisopropylethylamine (140mg, l.OSmmol) in dimethylfoπnamide (2mL). The reaction mixture was stirred at room temperature for 16 hours, concentrated to dryness in vacuo, and subjected to dry flash column chromatography on silica with 50:50, dichloromethane: ethyl acetate. l-{l-[4-(3-(N,N-di-tert- butoxycarbonylaminomethyl)phenyl)-piperidin-l-yl]-methanoyl}-3-methylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one was isolated as a colorless oil (177mg). The intermediate was dissolved in dichloromethane (20mL), cooled at 0°C, and freated with trifluoroacetic acid (2mL). The reaction mixture was stirred at room temperature under nitrogen for 2 hours, and concentrated to dryness in vacuo. The residue was dissolved in 20% acetonitrile/water [containing 0.1% trifluoroacetic acid] (9mL) and purified by preparative reverse-phase HPLC (C- 18, 10 micron reverse-phase column), eluting with 10% to 100% acetonitrile / water (containing 0.1% trifluoroacetic acid). The product fractions were combined and the acetonitrile removed in vacuo. The aqueous residue was frozen and lyophilized to give the title compound as an amoφhous white solid (122mg, 64%). 1HNMR [(CD3)2SO]: δ 8.16 (br s, 3H, NH3 +); 7.41-7.24 (m, 4H); 4.21 (br d, 2H); 4.03 (q, 2H); 3.18-3.02 (m, 2H); 2.91-2.72 (m, 3H); 2.59 (s, 3H); 2.53-2.41 (m, 2H); 1.98-1.90 (m, 2H); 1.90-1.79 (m, 2H); 1.68- 1.50 (m, 2H). MS(Ion spray): 415 (M++l).
EXAMPLE 39 1 - 4-(3-Aminomethyl-phenyl)-piperidin- 1-yl]- 1 -(6-chloro-benzo[b]thiophen-2-yl)-mefhanone trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 6- chlorobenzo[b]thiophene-2-carboxylic acid (prepared according to the procedure described in International Patent Application No. WO 0107436) in place of 3-methylsulfanyl-4-oxo-4,5,6,7- tetrahydro-benzo[c]thiophene-l -carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1HNMR [(CD3)2SO]: δ 8.17 (d, H); 8.14 (br s, 3H, NH3 +); 7.91 (d, H); 7.73 (s, H); 7.45 (dd, H); 7.37 (s, H); 7.35-7.24 (m, 3H); 4.42 (br s, 2H); 4.00 (q, 2H); 3.12 (br s, 2H); 2.93- 2.79 (m, H); 1.89-1.77 (m, 2H); 1.70-1.55 (m, 2H). MS(Ion spray): 385 and 387 (M++1).
EXAMPLE 40 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(5-chloro-lH-indol-2-yl)-methanone trifluoroacetate By proceeding in a similar manner to the method described in EXAMPLE 38, but using 5-chloro-lH- indole-2-carboxylic acid in place of 3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene-l- carboxylic acid, there was prepared the title compound as an amoφhous white solid. *H NMR [(CD3)2SO]: δ 11.78 (s, H); 8.14 (br s, 3H, NH3 +); 7.63 (s, H); 7.43-7.22 (m, 5H); 7.16 (dd, H); 6.76 (s, H); 4.55 (br d, 2H); 4.00 (q, 2H); 3.14 (br s, 2H); 2.94-2.80 (m, H); 1.90-1.79 (m, 2H); 1.73-1.54 (m, 2H); MS(Ion spray): 368 and 370 (M++1).
EXAMPLE 41 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(8-chloro-4H-l,5-dithia-cyclopenta[a]naphthalen-2- yl)-methanone trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 8-chloro-4H- l,5-difhiacyclopenta[a]naphthalene-2-carboxylic acid in place of 3-methylsulfanyl-4-oxo-4,5,6,7- tetrahydro-benzo[c]thiophene-l-carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3)2SO]: δ 8.14 (br s, 3H, NH3 +); 7.52 (d, H); 7.44-7.23 (m, 7H); 4.45 (s, 2H); 4.43 (br d, 2H); 4.00 (q, 2H); 3.12 (br s, 2H); 2.95-2.80 (m, H); 1.90-1.78 (m, 2H); 1.72- 1.56 (m, 2H). MS(Ion spray): 453 and 455 (M++1).
EXAMPLE 42 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl1-l-(2',4'-difluoro-4-hydroxy-biphenyl-3-yl)-methanone trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using diflunisal in place of 3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene-l-carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CL>3)2SO]: δ 10.15 (s, H, OH);
8.15 (br s, 3H, NH3 +); 7.56-7.46 (m, H); 7.40-7.22 (m, 7H); 7.13 (td, H); 6.97 (d, H); 4.64 (br s, H);
3.98 (q, 2H); 3.51 (br s, H); 3.10 (br s, H); 2.88-2.71 (m, H); 1.90-1.46 (m, 4H). MS(Ion spray): 423 and 424 (M++1).
EXAMPLE 43 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(3-methylsulfanyl-6,7-dihydro-benzo[c]thiophen-l- yl)-methanone trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 3- methylsulfanyl-6,7-dihydro-benzo[c]thiophene-l -carboxylic acid in place of 3-methylsulfanyl-4-oxo- 4,5,6,7-tetrahydro-benzo[c]thiophene-l-carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1HNMR [CDC13]: δ 8.13 (br s, 3H, NH3 +); 7.38-7.30 (m, H); 7.27-7.18 (m,
3H); 6.68 (d, H); 6.11-6.04 (m, H); 4.52-4.25 (br m, 2H); 4.01-3.93 (br m, 2H); 3.40-3.38 (m, H); 3.12- 2.97 (m, H); 2.90-2.75 (m, H); 2.75 (t, 2H); 2.43 (s, 3H); 2.37-2.28 (m, 2H); 1.97-1.81 (m, 2H); 1.89-
1.60 (m, 2H). MS(Ion spray): 400 (M++1).
EXAMPLE 44 l-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-6,6-dimethyl-3-methylsulfanyl-6,7- dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 6,6-dimethyl-
3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene-l -carboxylic acid in place of 3- methylsulfanyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene- 1 -carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3)2SO]: δ 8.16 (br s, 3H, NH3 +); 7.40-7.34
(m, 2H); 7.32-7.26 (m, 2H); 4.20 (br d, 2H); 4.01 (br s, 2H); 3.20-3.06 (m, 2H); 2.93-2.80 (m, H); 2.67 (s, 2H); 2.60 (s, 3H); 2.38 (3, 2H); 1.89-1.78 (m, 2H); 1.67-1.50 (m, 2H); 0.98 (s, 6H). MS(Ion spray):
444 (M++1).
EXAMPLE 45 l-[4-(3-Aminomethyl-phenyl)-piperidm-l-yl]-l-(6-bromo-pyridin-3-yl)-methanone bisfrifluoroacetate
A. 6-Bromonicotinic acid hydrochloride 72-Butyllithium (8.0 mL of 2.5M in hexanes, 20 mmol) was added dropwise to a stirring solution of 2,5-dibromopyridine (4.74 g, 20 mmol) in THF (100 mL) at -100 °C, under nifrogen. The reaction mixture was left at this temperature for 30 minutes before bubbling anhydrous carbon dioxide gas through the reaction mixture (for 20 minutes), and leaving to warm to-20 °C. Quenched with IN HCl (20 mL) and brine (20 mL), and extracted into ethyl acetate, dried over magnesium sulfate, concentrated to dryness. 6-Bromonicotinic acid hydrochloride was isolated as a pale yellow powder
(3.8 g, 16 mmol). 1H NMR [CDCI3+CD3OD]: δ 8.86 (d, 1H), 8.07 (dd, IH), 7.52 (d, IH). MS(Ion spray): 202 and 204 (M++l).
B. 1 - [4-(3-Aminomethyl-phenyl)-piperidin- 1-yl]- 1 -(6-bromo-pyridin-3-yl)-methanone bisfrifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 6- bromonicotinic acid hydrochloride in place of 3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydro- benzo[c]thiophene-l -carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [CD3OD]: δ 8.48 (d, H); 7.89 (dd, H); 7.82 (d, H); 7.48-7.30 (m, 4H); 4.90-4.81 (m, H); 4.15 (s, 2H); 3.84 (br d, H); 3.46-3.36 (m, H); 3.11-2.91 (m, 2H); 2.13-1.68 (m, 4H). MS(Ion spray): 374 and 376 (M++1).
EXAMPLE 46 6-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-2,3-dihydro-thiazolo[3,2-a]pyrimidin-5- one
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 5-oxo-2,3- dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acid in place of 3-methylsulfanyl-4-oxo-4,5,6,7- tetrahydro-benzo[c]thiophene-l-carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1HNMR [CD3OD]: δ 7.97 (s, H); 7.44-7.29 (m, 4H); 4.76 (br d, H); 4.59-4.51 (m, 2H); 4.07 (s, 2H); 3.83 (br d, H); 3.69-3.57 (m, 2H); 3.41-3.21 (m, H); 3.02-2.85 (m, 2H); 2.05-
1.67 (m, 4H). MS(Ion spray): 371 (M++1).
EXAMPLE 47 1 - [4-(3- Aminomethy l-phenyl)-piperidin- 1 -yl] - 1 -(3 -chloro-phenyl)-methanone trifluoroacetate By proceeding in a similar manner to the method described in EXAMPLE 38, but using 3- chlorobenzoic acid in place of 3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene-l- carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3)2SO]: δ 8.14 (br s, 3H, NH3 +); 7.57-7.43 (m, 3H); 7.40-7.22 (m, 5H); 4.70-4.56 (m, H); 4.01 (q,
2H); 3.64-3.56 (m, H); 3.23-3.10 (m, H); 2.91-2.79 (m, 2H); 1.92-1.52 (m, 4H). MS(Ion spray): 329 and 331 (M++l).
EXAMPLE 48 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(4-chloro-phenyl)-methanone trifluoroacetate By proceeding in a similar manner to the method described in EXAMPLE 38, but using 4- chlorobenzoic acid in place of 3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene-l-
carboxylic acid, there was prepared the title compound as an amoφhous white solid. *H NMR [(CD3)2SO]: δ 8.15 (br s, 3H, NH3 +); 7.53 (d, 2H); 7.44 (d, 2H); 7.40-7.23 (m, 4H); 4.64-4.56 (m, H); 4.02 (q, 2H); 3.72-3.58 (m, H); 3.24-3.10 (m, H); 2.95-2.89 (m, 2H); 1.90-1.50 (m, 4H). MS(Ion spray): 329 and 331 (M++1).
EXAMPLE 49 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[5-(2-chloro-phenyl)-[l,3,4]oxadiazol-2-yl]- phenyl}-methanone trifluoroacetate
A. 3-[5-(2-Chlorophenyl)-[l,3,4]oxadiazol-2-yl]-benzoic acid methyl ester
3-(2H-Tetrazol-5-yl)-benzoic acid methyl ester (204mg, lmmol) (prepared by the method of Tanaka et al, J. Med. Chem., 1998, 41(13), 2406) and 2-chlorobenzoyl chloride (175mg, lmmol) were combined in anisole (lOmL) at room temperature and 2,4,6-collidine (121mg, lmmol) in anisole (lmL) was added. The reaction mixture was heated at 100°C for 1 hour followed by 120°C for 15 minutes, monitoring the evolution of gas by balloon [volume of gas evolved was measured by positive displacement of water, total = 22mL]. Cooled reaction mixture to room temperature, and concenfrated to dryness in vacuo. The residue was subjected to flash column chromatography on silica with gradient dilution 5% to 40% ethyl acetate / heptane. 3-[5-(2-Chlorophenyl)-[l,3,4]oxadiazol-2-yl]-benzoic acid methyl ester was isolated as a colorless powder (229mg, 73%). ΪHNMR [CDC13]: δ 8.79 (s, H); 8.36 (d, H); 8.25 (d, H); 8.14 (d, H); 7.72-7.57 (m, 2H); 7.57-7.41 (m, 2H); 4.00 (s, 3H). MS(Ion spray):
SlS and Sπ ^+l).
B . 1 - [4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl] - 1 - {3- [5-(2-chloro-phenyl)- [ 1 ,3 ,4] oxadiazol-2-y 1]- phenylj-methanone trifluoroacetate IN Sodium hydroxide (2mL, 2mmol) was added to a solution of 3-[5-(2-chlorophenyl)-
[l,3,4]oxadiazol-2-yl]-benzoic acid methyl ester (113mg, 0.36mmol) in methanol (5mL) and THF (2mL), and the reaction mixture stirred at room temperature for 2h, before neutralizing to pH 7 with IN hydrochloric acid. The solution was concentrated to dryness in vacuo and placed under high vacuum overnight. Crude material was used directly without purification [MS(Ion spray): 301 and 303 (M++l); LC/ MS purity > 95%>, only major impurity is sodium chloride]. 2-(lH-Benzofriazol-l-yl 1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) (116mg, 0.36mmol) was added to a room temperature solution / suspension of crude 3-[5-(2-chlorophenyl)-[l,3,4]oxadiazol-2-yl]-benzoic acid and diisopropylethylamine (150mg, 1.14mmol) in dimethylformamide (2mL), under nifrogen. The reaction mixture was stirred for 10 minutes at room temperature before adding a solution of 4-[3-(N,N- di-tert-butoxycarbonylaminomethyl)phenyl]piperidine (78mg, 0.2mmol) and diisopropylethylamine
(150mg, 1.14mmol) in dimethylformamide (2mL). The reaction mixture was stirred at room temperature for 16 hours, concentrated to dryness in vacuo, and subjected to dry flash column chromatography on silica with 50:50, dichloromethane:ethyl acetate. l-{4-[3-(N,N-di-tert- butoxycarbonylaminomethyl)phenyl]-piperidin-l-yl}-l-{3-[5-(2-chloro-phenyl)-[l,3,4]oxadiazol-2- yl]-phenyl}-methanone was isolated as a colorless oil, which was dissolved in dichloromethane
(lOmL), cooled at 0°C, and treated with trifluoroacetic acid (ImL). The reaction mixture was stirred at room temperature under nitrogen for 2 hours, and concentrated to dryness in vacuo. The residue was dissolved in 20% acetonitrile/water [containing 0.1% trifluoroacetic acid] (9mL) and purified by preparative reverse-phase HPLC (C-18, 10 micron reverse-phase column), eluting with 20% to 60% acetonitrile / water (containing 0.1%) trifluoroacetic acid). The product fractions were combined and concenfrated to dryness in vacuo. The title compound was isolated as an amoφhous white glass solid
(98mg, 83%>). iH MR [(CD3)2SO]: δ 8.16 (br s, 3H, NH3 +) overlapped with 8.22-8.16 (m, 2H) and
8.13 (s, H); 7.79-7.72 (m, 3H); 7.69 (td, H); 7.62 (td, H); 7.41 (s, H); 7.39-7.27 (m, 3H); 4.64 (br d, H); 4.03 (q, 2H); 3.79-3.63 (m, H); 3.28-3.20 (m, H); 3.03-2.80 (m, 2H); 1.96-1.57 (m, 4H). MS(Ion spray): 473 and 475 (M++1).
EXAMPLE 50 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(5-pyridin-3-yl- l,3,4]oxadiazol-2-yl)-phenyl]- methanone bistrifluoroacetate
A. 3-(5-Pyridin-3-yl-[l,3,4]oxadiazol-2-yl)-benzoic acid methyl ester
Prepared in a similar manner to the method described in EXAMPLE 49A, but using nicotinoyl chloride hydrochloride instead of 2-chlorobenzoyl chloride, 2mmol of 2,4,6-collidine, and heating at 110°C instead of 100°C. The residue was subjected to flash column chromatography on silica with ethyl acetate and 5% methanol / ethyl acetate. 3-(5-Pyridin-3-yl-[l,3,4]oxadiazol-2-yl)-benzoic acid methyl ester was isolated as a colorless powder (84mg, 30%). 1H NMR [CDC13]: δ 9.40 (s, H); 8.84- 8.80 (m, H); 8.80-8.78 (m, H); 8.47 (dt, H); 8.38 (dt, H); 8.26 (dt, H); 7.67 (t, H); 7.52 (dd, H); 4.00 (s, 3H). MS(Ion spray): 282 (M++1).
B. l-[4-(3-Ammomethyl-phenyl)-piperidin-l-yl]-l-[3-(5-pyridin-3-yl-[l,3,4]oxadiazol-2-yl)-phenyl]- methanone bistrifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 49B, but using 3-(5-pyridin- 3-yl-[l,3,4]oxadiazol-2-yl)-benzoic acid methyl ester in place of 3-[5-(2-chlorophenyl)- [l,3,4]oxadiazol-2-yl]-benzoic acid methyl ester, there was prepared the title compound as an amoφhous white glass solid. 1H NMR [(CD3) SO]: δ 9.37 (br s, H); 8.86 (br s, H); 8.55 (d, H); 8.28-
8.23 (m, H); 8.20 (s, H); 8.16 (br s, 3H, NH3 +); 7.79-7.65 (m, 3H); 7.41 (s, H); 7.39-7.26 (m, 3H); 4.63 (br d, H); 4.09-4.00 (m, 2H); 3.80-3.62 (m, H); 3.37-3.16 (m, H); 3.02-2.80 (m, 2H); 1.98-1.55 (m,
4H). MS(Ion spray): 441 (M++1).
EXAMPLE 51 l-{ l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-ethylsulfanyl-6,6-dimethyl-6,7- dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 49B, but using 3- ethylsulfanyl-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene- 1 -carboxylic acid methyl ester in place of 3-[5-(2-chlorophenyl)-[l,3,4]oxadiazol-2-yl]-benzoic acid methyl ester, there was prepared the title compound as an amoφhous white glass solid. 1H NMR [(CU3) SO]: δ 8.16 (br s, 3H, NH3 +);
7.40-7.33 (m, 2H); 7.32-7.26 (m, 2H); 4.30-4.00 (m, 4H); 3.21-3.10 (m, 2H); 3.06 (q, 2H); 2.92-2.80 (m, H); 2.66 (s, 2H); 2.38 (s, 2H); 1.90-1.78 (m, 2H); 1.68-1.50 (m, 2H); 0.98 (s, 6H). MS(Ion spray):
458 (M++1).
EXAMPLE 52
1 - { 1 - [4-(3 -Aminomethyl-phenyl)-piperidin- 1 -yl]-methanoyl} -3-propylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 49B, but using 4-oxo-3- propylsulfanyl-4,5,6,7-tetrahydro-benzo[c]thiophene-l-carboxylic acid ethyl ester in place of 3-[5-(2- chlorophenyl)-[l,3,4]oxadiazol-2-yl]-benzoic acid methyl ester, there was prepared the title compound as an amoφhous white glass solid. 1HNMR [(CD )2SO]: δ 8.14 (br s, 3H, NH3 +); 7.41-7.23 (m, 4H); 4.21 (br d, 2H); 4.08-3.99 (m, 2H); 3.39-2.99 (m, 4H); 2.94-2.71 (m, 3H); 2.54-2.49 (m, 2H); 2.02- 1.90 (m, 2H); 1.90-1.70 (m, 4H); 1.70-1.51 (m, 2H); 1.03 (t, 3H). MS(Ion spray): 443 (M++1).
EXAMPLE 53 l-{ l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-isopropylsulfanyl-6,7-dihydro-5H- benzo [c]thiophen-4-one trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 49B, but using 3- isopropylsulfanyl-4-oxo-4,5,6,7-tefrahydro-benzo[c]thiophene- 1 -carboxylic acid ethyl ester in place of 3-[5-(2-chlorophenyl)-[l,3,4]oxadiazol-2-yl]-benzoic acid methyl ester, there was prepared the title compound as an amoφhous white glass solid. ΪHNMR [(CD3)2SO]: δ 8.14 (br s, 3H, NH3 +); 7.43-
7.23 (m, 4H); 4.30-4.16 (m, 2H); 4.09-3.98 (m, 2H); 3.53 (septet, H); 3.22-3.03 (m, 2H); 2.93-2.72 (m, 3H); 2.54-2.47 (m, 2H); 2.02-1.86 (m, 4H); 1.70-1.51 (m, 2H); 1.42 (d, 6H). MS(Ion spray): 443 (M++1).
EXAMPLE 54 3-{ l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro- benzo[c]thiophene-l-carbonitrile trifluoroacetate By proceeding in a similar manner to the method described in EXAMPLE 49B, but using 3-cyano-6,6- dimethyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene-l -carboxylic acid ethyl ester in place of 3-[5-(2- chlorophenyl)-[l,3,4]oxadiazol-2-yl]-benzoic acid methyl ester, there was prepared the title compound as an amorphous white glass solid. 1HNMR [(CD3)2SO]: δ 8.14 (br s, 3H, NH3 +); 7.41-7.33 (m, 2H);
7.32-7.26 (m, 2H); 4.30-3.90 (br m, 2H); 4.04-3.98 (m, 2H); 3.30-3.01 (m, 2H); 2.93-2.80 (m, H); 2.71 (s, 2H); 2.54 (s, 2H); 1.89-1.76 (m, 2H); 1.73-1.51 (m, 2H); 1.01 (s, 6H). MS(Ion spray): 423 (M++1).
EXAMPLE 55 3-{ l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-5,5-dimethyl-7-oxo-4,5,6,7-tefrahydro- benzo[c]thiophene- 1 -carboxylic acid trifluoroacetate The title compound was isolated as a by-product from the reaction carried out to synthesize 3-{l-[4-(3- aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro- benzo[c]thiophene-l-carbonitrile trifluoroacetate, in EXAMPLE 54. ]H NMR [(CD3)2SO]: δ 9.70 (s,
H, OH); 8.11 (br s, 3H, NH3 +); 7.42-7.26 (m, 4H); 4.28-3.96 (br m, 2H); 4.03-3.99 (m, 2H); 3.27-3.06 (m, 2H); 2.96-2.85 (m, H); 2.70 (s, 2H); 2.63 (s, 2H); 1.93-1.72 (m, 2H); 1.69-1.52 (m, 2H); 1.01 (s, 6H). MS(Ion spray): 442 (M++1).
EXAMPLE 56 3-{ l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-5,5-dimethyl-7-oxo-4,5,6,7-tefrahydro- benzo[c]thiophene-l -carboxylic acid methyl ester trifluoroacetate The title compound was isolated as a by-product from the reaction carried out to synthesize 3-{ l-[4-(3- aminomethyl-phenyl)-ρiperidin-l-yl]-methanoyl}-5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro- benzo[c]thiophene-l-carbonitrile trifluoroacetate, in EXAMPLE 54. lH NMR [(CD3)2SO]: δ 8.16 (br s, 3H, NH3 +); 7.41-7.34 (m, 2H); 7.33-7.27 (m, 2H); 4.30-3.95 (br m, 2H); 4.06-4.00 (m, 2H); 3.84 (s, 3H); 3.25-3.04 (m, 2H); 2.94-2.80 (m, H); 2.71 (s, 2H); 2.51 (s, 2H); 1.90-1.78 (m, 2H); 1.71-1.51 (m, 2H); 1.00 (s, 6H). MS(Ion spray): 456 (M++1).
EXAMPLE 57 l-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-methoxy-6,6-dimethyl-6,7-dihydro-
5H-benzo[c]thiophen-4-one.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 3-Methoxy- 6,6-dimethyl-4-oxo-4,5,6,7-tefrahydro-benzo[c]thiophene-l-carboxylic acid, there was prepared the
title compound as an amoφhous white solid. 1H NMR [(CI>3)2SO]: δ 8.22 (br s, 3H, NH3 +), 7.54-7.27
(m, 4H), 4.29-4.22 (m, 2H), 4.14 (s, 3H), 4.13-4.02 (m, 2H), 3.26-3.08 (m, 2H), 3.04-2.86 (m, IH), 2.71 (s, 2H), 2.37 (s, 2H), 2.02-1.84 (m, 2H), 1.79-1.54 (m, 2H), 1.04 (s, 6H). MS(Ion spray): 427.3
(M++1). EXAMPLE 58 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(4-pyrrol-l-yl-phenyl)-methanone-trifluoroacetate. By proceeding in a similar manner to the method described in EXAMPLE 38, but using 4-(lH-Pyrrol- 1-yl) benzoic acid in place of 3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene-l- carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3OD]: δ 7.62-7.51 (m, 4H), 7.41-7.22 (m, 6H), 6.32-6.28 (m, 2H), 4.85-4.66 (m, 2H), 4.08 (s,
2H), 4.03-3.88 (m, IH), 3.15-2.86 (m, 2H), 2.11-1.62 (m, 4H). MS(Ion spray): 360 (M++1).
EXAMPLE 59 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl1-l-benzo[b]thiophen-2-yl-methanone-trifluoroacetate. By proceeding in a similar manner to the method described in EXAMPLE 38, but using benzo(b)- thiophene-2-carboxylic acid in place of 3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydro-benzo[c]thiophene-
1-carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3OD]: δ 7.98-7.81 (m, 2H), 7.62 (s, IH), 7.45-7.32 (m, 5H), 7.31-7.22 (m, IH), 4.80-4.40 (m, 2H), 4.10 (s, 2H), 3.28-3.05 (m, IH), 3.02-2.90 (m, 2H), 2.02-1.88 (m, 2H), 1.86-1.65 (m, 2H). MS(Ion spray): 351 (M++1 ).
EXAMPLE 60 (E)- 1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]-3 -(3 -methoxy-phenyl)-propenone-trifluoroacetate . By proceeding in a similar manner to the method described in EXAMPLE 38, but using 3- methoxycinnamic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3OD]: δ 7.56 (d, IH), 7.45-7.25 (m, 5H), 7.23-7.13 (m, 3H), 6.98-6.90 (m, IH), 4.85-4.70 (m, IH), 4.50-4.35 (m, IH), 4.08 (s, 2H), 3.83 (s, 3H), 3.40-3.32 (m, IH), 3.01-2.75 (m, 2H), 2.08-1.83 (m, 2H), 1.81-1.61 (m, 2H). MS(Ion spray): 351 (M++1).
EXAMPLE 61 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(3-ethoxy-fhiophen-2-yl)-methanone-trifluoroacetate. By proceeding in a similar manner to the method described in EXAMPLE 38, but using 3- ethoxythiophene-2-carboxylic acid, there was prepared the title compound as an amoφhous white solid. iH NMR [(CD3OD]: δ 7.53 (d, IH), 7.46-7.22 (m, 4H), 6.94 (d, IH), 4.60-4.21 (br.m., 2H),
4.19 (q, 2H), 4.08 (s, 2H), 3.18-2.98 (m, IH), 2.96-2.85 (m, 2H), 2.0-1.86 (m, 2H), 1.84-1.65 (m, 2H), 1.37 (t, 3H). MS(Ion spray): 345 (M++1).
EXAMPLE 62 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-2-indan-2-yl-ethanone-trifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 2- indanylacetic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3OD]: δ 7.45-7.25 (m, 4H), 7.18-7.15 (m, 2H), 7.14-7.04 ( , 2H), 4.78-4.65 (m, IH), 4.18-4.11
(m, IH), 4.08 (s, 2H), 3.28-3.08 (m, 2H), 2.95-2.76 (m, 2H), 2.74-2.58 (m, 6H), 2.01-1.85 (m, 2H), 1.75-1.51 (m, 2H). MS(Ion spray): 349 (M++1).
EXAMPLE 63 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[5-(3-chloro-phenyl)-pyridin-3-yl]-methanone- ditrifluoroacetate.
A. 5-(3-chlorophenyl)-nicotinic acid
A three neck flask was charged with 5-bromonicotinic acid (2 g, 9.90 mmol), 3-chlorophenylboronic acid (1.55 g, 9.90 mmol), a 0.4 M solution of sodiumcarbonate in water (37 mL, 14.8 mmol) and Acetonitrile (37 mL). The solution was degassed under vacuum and tefrakistriphenylphoshine Pd(0) (0.57 g, 0.495 mmol) was added and the reaction refluxed overnight under nifrogen. The reaction was cooled to room temperature and filtered through a celite pad. The filtrate was partially evaporated under reduced pressure and the remaining solution acidified to pH=2 with IN HCl. The resulting solid was collected by filtration and dried under vacuum. 1H NMR [(CD3)2SO]:_δ 9.15-9.05 (m, 2H), 8.45
(s, IH), 7.85 (s, IH), 7.80-7.65 (m, IH), 7.60-7.42 (m, 2H).
B . 1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl] - 1 - 5-(3 -chloro-phenyl)-pyridin-3 -yl]-methanone- ditrifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 5-(3- chlorophenyl)-nicotinic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3)2SO]:_δ 8.99 (s, IH), 8.65 (s, IH), 8.18 (s, IH), 8.13 (br.s., 3H, NH3 +), 7.88 (s, IH), 7.76 (d, IH), 7.58-7.45 (m, 2H), 7.40-7.20 (m, 4H), 4.80-4.58 (m, IH), 3.98 (q, 2H), 3.78-3.55 (m, IH),
3.33-3.18 (m, IH), 2.98-2.71 (m, 2H), 1.95-1.52 (m, 4H). MS(Ion spray): 406 (M++1).
EXAMPLE 64 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(5-chloro-benzo[b]thiophen-2-yl)-methanone- trifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 5-chloro- benzo(b)thiophene-2-carboxylic acid, prepared as in WO 0107436, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3)2SO]:_δ 8.08 (br.s., 3H, NH3 +), 8.05 (d, IH),
8.01 (s, IH), 7.68 (s, IH), 7.47 (d, IH), 7.40-7.21 (m, 4H), 4.41 (br.s., 2H), 3.99, (q, 2H), 3.30-3.15 (m, 2H), 2.95-2.78 (m, IH), 1.90-1.75 (m, 2H), 1.73-1.52 (m, 2H). MS(Ion spray): 385 (M++1).
EXAMPLE 65 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-2-(3,4-dichloro-phenyl)-ethanone-frifluoroacetate. By proceeding in a similar manner to the method described in EXAMPLE 38, but using 3,4- dichlorophenyl acetic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3)2SO]:_δ 8.08 (br.s., 3H, NH3 +), 7.56 (d, IH), 7.48 (s, IH), 7.38-7.15 (m, 5H), 4.58-4.45 (m, IH), 4.15-3.92 (m, 3H), 3.85-3.65 (m, 2H), 3.18-3.03 (m, IH), 2.85-2.55 (m, 2H), 1.80-1.65 (m, 2H), 1.55-1.32 (m, 2H). MS(Ion spray): 376 (M++1).
EXAMPLE 66 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-2-(5-chloro-pyridin-3-yloxy)-ethanone- ditrifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using (5-chloro- pyridin-3-yloxy)-acetic acid, prepared as in WO 0107436, there was prepared the title compound as an amoφhous white solid. 1HNMR [(CD3)2SO]:_δ 8.28-8.21 (m, 2H), 8.15 (br.s., 3H, NH3 +), 7.58 (s,
IH), 7.40-7.20 (M, 4H), 5.01 (s, 2H), 4.52-4.38 (m, IH), 3.98 (q, 2H), 3.93-3.80 (m, IH), 3.22-3.05
(m, IH), 2.88-2.58 (m, 2H), 1.88-1.35 (m, 4H). MS(Ion spray): 360 (M++1).
EXAMPLE 67 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-2-(6-chloro-pyridin-2-yloxy)-ethanone- ditrifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using (6-chloro- pyridin-2-yloxy)-acetic acid, prepared as in WO 0107436, there was prepared the title compound as an amorphous white solid. 1HNMR [(CD3)2SO]:_δ 8.10 (br.s., 3H, NH3 +), 7.81-7.71 (m, IH), 7.41-7.18 (m, 4H), 7.08 (d, IH), 6.88 (d, IH), 5.15-4.92 (m, 2H), 4.50-4.31 (m, IH), 4.08-3.81 (m, 3H), 3.27- 3.08 (m, IH), 2.92-2.76 (m, IH), 2.75-2.60 (m, IH), 1.90-1.58 (m, 2H), 1.57-1.35 (m, 2H). MS(Ion spray): 360 (M++1).
EXAMPLE 68
(E)-l-f4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-(5-chloro-thiophen-2-yl)-propenone- trifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 3-(5-chloro- thiophen-2-yl)-acrylic acid, prepared as in WO 0107436, there was prepared the title compound as an amorphous white solid. 1H NMR [(CD3)2SO]:_δ 8.08 (br.s., 3H, NH3 +), 7.56 (d, IH), 7.40-7.28 (m,
3H), 7.26-7.18 (m, 2H), 7.12 (d, IH), 6.92 (d, IH), 4.70-4.50 (m, IH), 4.41-4.21 (m, IH), 3.98 (q, 2H), 3.28-3.05 (m, IH), 2.90-2.63 (m, 2H), 1.91-1.72 (m, 2H), 1.65-1.35 (m, 2H). ). MS(Ion spray): 361
(M++1).
EXAMPLE 69
(E)-l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-(4-chloro-thiophen-2-yl)-propenone- trifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 3-(4-chloro- thiophen-2-yl)-acrylic acid, prepared as in WO 0107436, there was prepared the title compound as an amorphous white solid. 1H NMR [(CD3)2SO]:_δ 8.06 (br.s., 3H, NH3 +), 7.65 (s, IH), 7.60-7.48 (m,
2H), 7.40-7.20 (m, 4H), 7.08 (d, IH), 4.70-4.51 (m, IH), 4.42-4.25 (m, IH), 4.05-3.93 (m, 2H), 3.28-
3.08 (m, IH), 2.90-2.63 (m, 2H), 1.90-1.65 (m, 2H), 1.63-1.40 (m, 2H). MS(Ion spray): 361 (M++1).
EXAMPLE 70 1 - [4-(3- Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 -(4,5,6,7-tetrahydro-benzo[c]thiophen- 1 -yl)- methanone-trifluoroacetate .
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 4,5,6,7- tetrahydro-benzo(c)thiophene-l -carboxylic acid, prepared as in JOC V62#6 1997 p. 1599, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3) SO]:_δ 8.13 (br.s, 3H, NH3 +), 7.40-7.33 (m, 2H), 7.31-7.25 (m, 2H), 7.20 (s, IH), 4.35-4.15 (m, 2H), 4.03 (q, 2H), 3.17-2.98 (m, 2H), 2.95-2.78 (m, IH), 2.73-2.58 (m, 4H), 1.90-1.78
(m, 2H), 1.75-1.63 (m, 4H), 1.61-1.42 (m, 2H). MS(Ion spray): 355 (M++1).
EXAMPLE 71 1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl] - 1 -(5 -chloro-4-methoxy-thiophen-3 -yl)-methanone- frifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 2-chloro-3- methoxy-thiophene-4-carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3)2SO]: δ 8.13 (br.s, 3H, NH3 +), 7.57 (s, IH), 7.40-7.22 (m, 4H), 4.70-4.58 (m,
IH), 4.05 (q, 2H), 3.85 (s, 3H), 3.75-3.60 (m, IH), 3.25 (m, IH), 2.95-2.78 (m, 2H), 1.93-1.70 (m, 2H), 1.68-1.45 (m, 2H). MS(Ion spray): 365 (M++1).
EXAMPLE 72 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(lH-indol-3-yl)-methanone-trifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using Indole-3- carboxylic acid, there was prepared the title compound as an amoφhous white solid. *H NMR [(CD3)2SO]:_δ 8.13 (br.s, 3H, NH3 +), 7.78-7.63 (m, 2H), 7.52-7.20 (m, 6H), 7.20-7.03 (m, 2H), 4.57-
4.38 (m, 2H), 4.03 (q, 2H), 3.17-3.02 (m, 2H), 2.95-2.75 (m, IH), 1.90-1.78 (m, 2H), 1.75-1.57 (m, 2H). MS(Ion spray): 334 (M++1).
EXAMPLE 73 l-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-l-yl]-l-(5-phenethyl-pyridin-3-yl)-methanone- ditrifluoroacetate .
A. 4-(3-Cyano-phenyl)-4-hydroxy-piperidine-l -carboxylic acid-tgrt-butyl ester. A solution of 3-Bromobenzonitrile (0.48 g, 2.64 mmol) in THF (20 mL) was stirred under nitrogen at - 78°C. To this was added dropwise a solution of 2.0M nBuLi in hexanes (1.38 mL, 2.72 mmol). The solution was allowed to warm to -15°C over 1.5 hours. The solution was recooled to -78°C and a solution of N-Boc-4-piperidone (0.53 g, 2.64 mmol) in THF (5 mL) was added dropwise. The reaction mixture was allowed to warm to -10°C and stirred at this temperature for three hours. The reaction was quenched with '/_ saturated ammonium chloride solution (30 mL) and stirred 15 minutes. The THF was removed by evaporation and the residue extracted with methylene chloride (3 X 50 mL). The organic extracts were combined, dried over sodium sulfate, evaporated to give an orange oil which was purified by flash chromatography 3:5:2 methylene chloride: heptane: ethyl acetate to give the title compound (0.30 g) as a clear oil. 1HNMR [(CDCl3]:_δ 7.82 (s, IH), 7.72 (d, IH), 7.58 (d, IH), 7.55-
7.42 ( , IH), 4.20-3.95 (m, 2H), 3.35-3.10 (m, 2H), 2.08-1.83 (m, 2H), 1.80-1.66 (m, 2H), 1.51 (s, 9H).
B. 4-[3-(Benzyloχycarbonylamino-methyl)-phenyl]-4-hydroxy-piperidine-l-carboxylic acid-tgrt- butyl ester.
A solution of 4-(3-Cyano-phenyl)-4-hydroxy-piperidine-l -carboxylic acid-tgrt-butyl ester (0.30 g, 0.99 mmol) in 7N ammonia/methanol (25 mL) and 5%>Rhodium on alumina (0.15 g) was hydrogenated overnight on a Parr apparatus (45 psi). The reaction was filtered through celite, evaporated, and azeotroped with MeOH:toluene 1:1 (2 X 30 mL) to give 4-(3-Aminomethyl-phenyl)-4-hydroxy-
piperidine- 1 -carboxylic acid-tert-butyl ester as a foam. This compound was used directly in the next step.
To a stirred mixture of 4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidine-l-carboxylic acid-tgrt-butyl ester (0.30 g, 0.99 mmol), methylene chloride (10 mL) and water (10 mL) was added potassium carbonate (0.28 g, 2.02 mmol) followed by benzylchloroformate (0.34 g, 2.02 mmol). The reaction stirred overnight at room temperature. The reaction was extracted with methylene chloride (3 X 30 mL). The organic extracts were combined, dried over sodium sulfate and evaporated to give a tan oil. Purification by flash chromatography 40%) Ethyl acetate: Heptane yielded 4-[3- (Benzyloxycarbonylamino-methyl)-phenyl] -4-hydroxy-piperidine- 1 -carboxylic acid-tgrt-butyl ester (0.40 g). 1HNMR [(CDC13]: δ 7.45-7.18 (m, 9H), 5.15 (s, 2H), 5.08 (br.s, IH, NH), 4.40 (d, 2H),
4.15-3.93 (m, 2H), 3.35-3.15 (m, 2H), 2.08-1.90 (m, 2H), 1.75-1.62 (m, 2H), 1.50 (s, 9H).
C.l-[4-(3-Aminomethyl-phenyl)-4-hydroxy-ρiperidin-l-yl]-l-(5-phenethyl-pyridin-3-yl)-methanone- difrifluoroacetate. To a stirred solution of 4-[3-(Benzyloxycarbonylamino-methyl)-phenyl]-4-hydroxy-piperidine-l- carboxylic acid-tgrt-butyl ester (0.38 g, 0.86 mmol) and methylene chloride (15 mL) at 0°C was added trifluoroacetic acid (5 mL). The reaction was allowed to warm to room temperature, stirred one hour and was evaporated to dryness to give [3-(4-(Hydroxy-piperidin-4-yl)-benzyl]-carbamic acid benzyl ester which was used directly in the next step.
To a stirred solution of 5-phenethyl-pyridin-3 -carboxylic acid (0.027 g, 0.1 mmol) and DMF (10 mL) was added diisopropylethyl amine (0.014 g, 0.11 mmol) followed by TBTU (0.0353 g, 0.11 mmol). This stirred for five minutes before adding a solution of [3-(4-(Hydroxy-piperidin-4-yl)-benzyl]- carbamic acid benzyl ester (0.045 g, 0.1 mmol), DMF (2 mL) and Diisopropylethylamine (0.039 g, 0.3 mmol). The reaction stirred overnight at room temperature. The solvent was removed by evaporation and the remaining residue partitioned between ethylacetate (50 mL) and saturated sodium bicarbonate (10 mL). The organic phase was separated, washed again with saturated sodium bicarbonate (10 mL) and dried over magnesium sulfate. Evaporation followed by purification by flash chromatography (100% ethylacetate) gave (3-{4-Hydroxy-l-[-l-(5-phenethyl-pyridin-3-yl)-methanoyl]-piperidin-4-yl}- benzyl)-carbamic acid benzyl ester (0.030 g) as a clear oil. Hydrogenation with Methanol (10 mL), Acetic acid (1 mL) and a catalytic amount of 10% Palladium on Carbon overnight followed by filtration through celite gave the crude product which was purified by HPLC as in Example 38 to give the title compound as an amoφhous solid (9.1 mg). 1HNMR [(CI 3)2SO]:_δ 8.58-8.42 (m, 2H), 8.15
(br.s, 3H, NH3 +), 7.73 (s, IH), 7.63-7.51 (m, 2H), 7.40 (t, IH), 7.38-7.25 (m, IH), 7.23-7.10 (m, 5H), 4.58-4.38 (m, IH), 4.03 (q, 2H), 3.60-3.10 (m, 3H), 3.05-2.86 (m, 4H), 2.06-1.80 (m, 2H), 1.78-1.63
(m, IH), 1.62-1.42 (m, IH). MS(Ion spray): 416 (M++1).
EXAMPLE 74 1 - [4-(3-Aminomethyl-phenyl)-piperidin- 1 -y 1]- 1 -( 1 -methyl- 1 H-indol-3 -yl)-methanone-trifluoroacetate . By proceeding in a similar manner to the method described in EXAMPLE 38, but using 1 -Methyl- 1H- indole-3 -carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [CDCl3]:_δ 8.63 (br.s, 3H, NH3 +), 7.60 (d, IH), 7.51 (s, IH), 7.41-7.18 (m, 5H), 7.15-7.05 (m,
2H), 4.55-4.35 (m, 2H), 4.01 (br.s, 2H), 3.78 (s, 3H), 3.18-2.95 (m, 2H), 2.80-2.61 (m, IH), 1.85-1.45 (m, 4H). MS(Ion spray): 348 (M++1).
EXAMPLE 75
1 -(3- { 1 -[4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl]-methanoyl} -indol- 1 -yl)-ethanone-trifluoroacetate. By proceeding in a similar manner to the method described in EXAMPLE 38, but using 1 -Acetyl- 1H- indole-3 -carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [(CD3)2SO]:_δ 8.39 (d, IH), 8.21 (br.s, 3H, NH3 +), 8.13 (s, IH), 7.70 (d, IH), 7.68-7.25 (m,
6H), 4.40 (br.s, 2H), 4.15-4.02 (m, 2H), 3.15-3.03 (m, 2H), 2.99-2.80 (m, IH), 2.71 (s, 3H), 1.95-1.76 (m, 2H), 1.74-1.55 (m, 2H). MS(Ion spray): 376 (M++1).
EXAMPLE 76 1 -[4-(3-Aminomethyl-phenyl)-piperidin- 1-yl]- 1 -(5 -methoxy- 1 -methyl- lH-indol-3 -yl)-methanone- trifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 5-Methoxy-l- methyl-lH-indole-3-carboxylic acid, prepared as in WO 9522524, there was prepared the title compound as an amoφhous white solid. *H NMR [(CD3)2SO]:_δ 8.13 (br.s, 3H, NH3 +), 7.71 (s, IH), 7.51-7.23 (m, 5H), 7.20 (s, IH), 6.83
(dd, IH), 4.53-4.40 (m, 2H), 4.13-3.95 (m, 2H), 3.80 (s, 3H), 3.76 (s, 3H), 3.18-3.01 (m, 2H), 2.95-
2.75 (m, IH), 1.95-1.76 (m, 2H), 1.75-1.52 (m, 2H). MS(Ion spray): 378 (M++1).
EXAMPLE 77 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(2-trifluoromethyl-phenylethynyl)-phenyl]- methanone trifluoroacetate
A. 4-{3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidine
As an alternative route, a one-pot cross coupling process was applied to the preparation of the title compound. A solution of 3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-bromobenzene (EXAMPLE
1A) (7.7 g, 20 mmol) in anhydrous DMF (60 ml) was treated with potassium acetate (5.9 g, 60 mmol), bis(pinacolato)diboron (5 g, 20 mmol), and [l,l '-bis-(diphenylphosphino) ferroceno]- dichloropalladium (IΙ)-dichloromethane complex (0.49 g, 0.60 mmol). This mixture was stirred at 80°C under an atmosphere of nitrogen for 4 hours, then benzyl l,2,3,6-tetrahydro-4- (trifluoromethylsulphonyloxy)-pyridine-l -carboxylate (EXAMPLE IB) (9.2 g, crude, < 25 mmol) was added, followed by aq Na2C03 (2M, 60 mL). The mixture was heated at 80°C under an nitrogen for another 2 hours and then concenfrated. The cross coupling product (2.2 g) was obtained after purification (as described in EXAMPLE IB). Further reduction (as described in EXAMPLE IB) yielded title compound. B . 1 - [4-(3- Aminomethyl-phenyl)-piperidin- 1 -yl] - 1 - [3 -(2-trifluoromethyl-phenylethynyl)-phenyl]- methanone trifluoroacetate
By proceeding in a similar manner to the coupling method described in EXAMPLE 5B, but using 2- iodobenzotrifluoride, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid.'H NMR [CD3OD]: δ 7.80-7.30 (m, 12H), 4.81 (br, IH), 4.10 (s, 2H), 3.87 (br IH), 3.30 (br, IH), 2.97 (m, 2H), 2.05-1.60 (br, 4H). MS (Ion spray): 463 (M+l).
EXAMPLE 78 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(2-methyl-phenylethynyl)-phenyl]-methanone trifluoroacetate By proceeding in a similar manner to the coupling method described in EXAMPLE 5b, but using 2- iodotoluene, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid. 'HNMR [CDJOD]: δ 7.66-7.16 (m, 12H), 4.81 (br, IH),
4.11 (s, 2H), 3.87 (br IH), 3.30 (br, IH), 2.97 (m, 2H), 2.51 (s, 3H), 2.05-1.60 (br, 4H). MS (Ion spray): 409 (M+l).
EXAMPLE 79 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(4-chloro-ρhenylethynyl)-phenyl]-methanone trifluoroacetate
By proceeding in a similar manner to the coupling method described in EXAMPLE 5b, but using 1- chloro-4-iodobenzene, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid. Η NMR [CD3OD]: δ 7.68-7.28 (m, 12H), 4.82 (br,
IH), 4.11 (s, 2H), 3.87 (br IH), 3.30 (br, IH), 2.97 (m, 2H), 2.05-1.60 (br, 4H). MS (Ion spray): 429 and 431 (M+l).
EXAMPLE 80 1 - [4-(3 -Am inomethyl-phenyl)-piperidin- 1 -yl]- 1 - [3 -(2-chloro-phenylethynyl)-phenyl] -methanone trifluoroacetate
By proceeding in a similar manner to the coupling method described in EXAMPLE 5b, but using 1- chloro-2- iodobenzene, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid. !HNMR [CD3OD]: δ 7.69-7.28 (m, 12H), 4.82 (br, IH), 4.11 (s, 2H), 3.87 (br IH), 3.30 (br, IH), 2.97 (m, 2H), 2.05-1.60 (br, 4H). MS (Ion spray): 429 and 431 (M+l).
EXAMPLE 81 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(2-fluoro-phenylethynyl)-phenyl]-methanone trifluoroacetate
By proceeding in a similar manner to the coupling method described in EXAMPLE 5b, but using 1- fluoro-2- iodobenzene, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid. !H NMR [CD3OD]: δ 7.69-7.16 (m, 12H), 4.80 (br,
IH), 4.10 (s, 2H), 3.84 (br IH), 3.30 (br, IH), 2.96 (m, 2H), 2.05-1.60 (br, 4H). MS (Ion spray): 413
(M+l).
EXAMPLE 82 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(3-fluoro-phenylethynyl)-phenyl1-methanone trifluoroacetate
By proceeding in a similar manner to the coupling method described in EXAMPLE 5b, but using 1- fluoro-3-iodobenzene, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid. ΗNMR [CD3OD]: δ 7.67-7.10 (m, 12H), 4.80 (br, IH), 4.10 (s, 2H), 3.85 (br IH), 3.30 (br, IH), 2.95 (m, 2H), 2.05-1.60 (br, 4H). MS (Ion spray): 413 (M+l).
EXAMPLE 83 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(4-fluoro-phenylethynyl)-phenyl]-methanone trifluoroacetate
By proceeding in a similar manner to the coupling method described in EXAMPLE 5b, but using 1- fluoro-4-iodobenzene, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid. *H NMR [CD3OD] : δ 7.64-7.10 (m, 12H), 4.80 (br, IH), 4.10 (s, 2H), 3.85 (br IH), 3.30 (br, IH), 2.97 (m, 2H), 2.05-1.60 (br, 4H). MS (Ion spray): 413 (M+l).
EXAMPLE 84 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[2-(2-fluoro-phenyl)-ethyl]-phenyl}-methanone trifluoroacetate
By proceeding in a similar manner to the reduction method described in EXAMPLE 9, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid. Η NMR [CD3OD]: δ 7.43-6.96 (m, 12H), 4.78 (br, IH), 4.11 (s, 2H), 3.72 (br IH), 3.18 (br, IH), 3.02-2.86 (m, 6H), 2.05-1.50 (br, 4H). MS (Ion spray): 417 (M+l).
EXAMPLE 85 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[2-(3-fluoro-phenyl)-ethyl]-phenyl}-methanone trifluoroacetate
By proceeding in a similar manner to the reduction method described in EXAMPLE 9, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid. *H NMR [CD3OD]: δ 7.43-6.80 (m, 12H), 4.78 (br, IH), 4.11 (s, 2H), 3.70 (br IH), 3.18 (br, IH), 3.02-2.85 (m, 6H), 2.05-1.50 (br, 4H). MS (Ion spray): 417 (M+l).
EXAMPLE 86 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[2-(4-fluoro-phenyl)-ethyl]-phenyl}-methanone trifluoroacetate By proceeding in a similar manner to the reduction method described in EXAMPLE 9, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amoφhous off-white solid. Η NMR [CD3OD]: δ 7.43-6.88 (m, 12H), 4.78 (br, IH), 4.10 (s, 2H), 3.69 (br IH), 3.18 (br, IH), 3.00-2.85 (m, 6H), 2.05-1.50 (br, 4H). MS (Ion spray): 417 (M+l).
EXAMPLE 87 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[2-(6-amino-pyridin-3-yl)ethynyl]-phenyl}- methanone tri-trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using (6-tert- butoxycarbonylamino-pyridin-3-yl)ethynyl-pyridine-3-carboxylic acid (prepared according to the method described in EXAMPLE 7), the title compound was prepared as an amoφhous off-white solid.
'H NMR [CD3OD]: δ 8.82 (s, IH), 8,66 (s, IH), 8.17 (s, IH), 8.07 (s, IH), 8.02 (d, IH), 7.43-7.27 (m,
4H), 7.05 (d, IH), 4.81 (br, IH), 4.10 (s, 2H), 3.79 (br IH), 3.37 (br, IH), 2.97 (m, 2H), 2.05-1.70 (br,
4H). MS (Ion spray): 412 (M+l).
EXAMPLE 88 l-[4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 - {3- [2-(6-amino-pyridin-3-yl)-ethyl]-phenyl } - methanone tri-trifluoroacetate
By proceeding in a similar manner to the reduction method described in EXAMPLE 9, and the deprotection method described in EXAMPLE 38, the title compound was prepared as an amorphous off-white solid. 1H NMR [CD3OD]: δ 8.60 (m, 2H), 7.94 (s, IH), 7.89 (d, IH), 7.61 (s, IH), 7.45-7.28 (m, 4H), 6.97 (d, IH), 4.80 (br, IH), 4.11 (s, 2H), 3.76 (br IH), 3.10-2.90 (m, 7H), 2.05-1.60 (br, 4H). MS (Ion spray): 416 (M+l).
EXAMPLE 89 1 -[4-(3-Ammomethyl-phenyl)-piperidin- 1 -yl]- 1 -(6-chloro-thieno[3 ,2-6]thiophen-2-yl)-methanone trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 6-chloro- thieno[3,2- >]thiophene-2-carboxylic acid, the title compound was prepared as an amoφhous off-white solid. ΗNMR [CD3OD]: δ 7.60 (s, IH), 7.47 (s, IH), 7.33-7.18 (m, 4H), 4.50 (br, 2H), 3.98 (s, 2H), 3.12 (br, 2H), 2.86 (m, IH), 1.85 (b, 2H), 1.67 (m, 2H). MS (Ion spray): 391 and 393 (M+l).
EXAMPLE 90 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(5-fluoro-thieno[3,2- ']thiophen-2-yl)-methanone trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 5-fluoro- thieno[3,2- >]thiophene-2-carboxylic acid, the title compound was prepared as an amoφhous off-white solid. JHNMR [CD3OD]: δ 7.65 (s, IH), 7.44-7.17 (m, 4H), 7.03 (s, IH), 4.60 (br, 2H), 4.12 (s, 2H), 3.22 (br, 2H), 2.97 (m, IH), 1.97 (b, 2H), 1.78 (m, 2H). MS (Ion spray): 375 (M+l).
EXAMPLE 91 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(5-methyl-thieno[3,2-t]thiophen-2-yl)-methanone trifluoroacetate By proceeding in a similar manner to the method described in EXAMPLE 38, but using 5-methyl- thieno[3,2-ό]thiophene-2-carboxylic acid, the title compound was prepared as an amoφhous off-white solid. !HNMR [CD3OD]: δ 7.60 (s, IH), 7.42-7.30 (m, 4H), 7.07 (s, IH), 4.63 (br, 2H), 4.11 (s, 2H), 3.21 (br, 2H), 2.97 (m, IH), 2.60 (s, 3H), 1.96 (b, 2H), 1.78 (m, 2H). MS (Ion spray): 371 (M+l).
EXAMPLE 92
l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(5-chloro-thieno[3,2-6]thioρhen-2-yl)-methanone trifluoroacetate
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 5-chloro- thieno[3,2- >]thiophene-2-carboxylic acid, the title compound was prepared as an amoφhous off-white solid. !H NMR [CD3OD]: δ 7.63 (s, IH), 7.42-7.29 (m, 5H), 4.60 (br, 2H), 4.11 (s, 2H), 3.12 (br, 2H), 2.97 (m, IH), 1.97 (b, 2H), 1.78 (m, 2H). MS (Ion spray): 391
In a similar manner to the methods described above, the following compounds are prepared:
EXAMPLE 93 l-{4-[3-(l - Aminoethyl)phenyl] -piperidin-l-yl}-l-(5 -phenylethyl-pyr idin-3 -yl)-methanone di- hydrochloride
A. [l-(3-Bromophenyl)ethyl]-carbamic acid tert-butyl ester 3-Bromoacetophenone oxime (23.4 mmol) was stirred in glacial acetic acid (150mL) at room temperature under nifrogen, and zinc dust (94mmol) added portionwise. The reaction mixture was stirred at room temperature for 24 hours, filtered off the solids and concentrated the filtrate to dryness. The residue was diluted with water, acidified to pH 5 with IN HCl, and washed with ethyl acetate. The aqueous was basified with sodium hydrogen carbonate, extracted into ethyl acetate, dried over magnesium sulfate, and concenfrated to dryness. The residue was dissolved in dimethylformamide (30mL) and triethylamine (36.9mmol) added. To this solution was added, dropwise, a solution of di- tert-butyldicarbonate (32.4mmol) in DMF (lOmL). The reaction mixture was stirred at room temperature for 6 hours, and left standing for 24 hours before concentrating to dryness. The residue was partitioned between water and ethyl acetate, and the aqueous phase extracted with ethyl acetate. The combined organic phase was washed with brine, dried over magnesium sulfate, and concentrated to dryness. The residue was purified by column chromatography on silica gel with dichloromethane as eluent, to give [l-(3-bromophenyl)ethyl]-carbamic acid tert-butyl ester as a pale yellow oil which crystallized upon standing. MS(EI): 300 and 302 (M++H).
B . 1 - {4- [3 -( 1 -Aminoethyl)phenyl] -piperidin- 1 -yl } - 1 -(5 -phenylethyl-pyridin-3 -yl)-methanone di- hydrochloride
By proceeding in a manner similar to the method described in EXAMPLE 17D, but using [l-(3- bromophenyl)ethyl]-carbamic acid tert-butyl ester in place of N-(tert-butoxycarbonyl)-3-bromo-4- fluorobenzylamine, there was prepared [l-(3-{l-[l-(3-phenethyl-phenyl)-methanoyl]-l,2,3,6- tetrahydro-pyridin-4-yl}-phenyl)-ethyl]-carbamic acid tert-butyl ester. This material was subjected to the same conditions as described in EXAMPLE 2A, but using [l-(3-{ l-[l-(3-phenethyl-phenyl)- methanoyl]-l,2,3,6-tefrahydro-pyridin-4-yl}-phenyl)-ethyl]-carbamic acid tert-butyl ester in place of 5-
phenylethynylpyridine-3-carboxylic acid. The crude product from this reaction was purified by column chromatography on silica gel, before being subjected to the same conditions as described in EXAMPLE ID, but using [l-(3-{l-[l-(3-phenethylphenyl)-methanoyl]-piperidin-4- yl}phenyl)ethyl]carbamic acid tert-butyl ester in place of 3-[l-(5-phenylethynylpyridine-3- carbonyl)piperidin-4-yl]benzonifrile. 1 - {4-[3-( 1 -Aminoethy l)phenyl]-piperidin- 1 -yl}- 1 -(5- phenylethyl-pyridin-3-yl)-methanone di-hydrochloride was isolated as a pale yellow solid. MS(EI):
414 (M++H).
EXAMPLE 94 1 -[4-(5-Aminomethyl-3-hydroxyphenyl)-piperidin- 1 -yl]- 1 -(5-phenylethyl-pyridin-3-yl)-methanone di- hydrochloride
A. 3-Bromo-N,N-(bis-tert-butoxycarbonyl)-5-(tert-butyldimethylsilyloxy)benzylamine (3-Bromo-5-methyl-phenoxy)-tert-butyldimethylsilane (3.32mmol) [prepared according to the procedure of J. E. Baldwin et al, Tetrahedron, 1991, 47(29), 5603], N-bromosuccinimide (3.65mmol), and benzoyl peroxide (0.332mmol) were dissolved in dichloromethane (lOmL) and the reaction mixture irradiated for 4 hours. Diluted with dichloromethane and washed with water, dried over magnesium sulfate and concenfrated to dryness. The crude material was purified by column chromatography on silica gel with 10% ethyl acetate / cyclohexane to give (3-bromo-5-bromomethyl- phenoxy)-tert-butyldimethylsilane as a colorless oil. This material was subjected to the conditions described in the first part of EXAMPLE 1A, but using (3-bromo-5-bromomethyl-phenoxy)-tert- butyldimethylsilane in place of 3-bromobenzylbromide, to give 3-bromo-N,N-(bis-tert- butoxycarbonyl)-5-(tert-butyldimethylsilyloxy)benzylamine as a colorless oil. MS (El) 516 and 518
(M++H).
B_;_l-(5-Phenylethynylpyridine-3-carbonyl)-4-(pmacolatoboronyl)-l,2,3,6-tetrahydropyridme By proceeding in a manner similar to the method described in EXAMPLE 17B, but using 5- phenylethynylpyridine-3-carboxylic acid in place of 5-phenethylpyridine-3-carboxylic acid , there was prepared l-(5-phenylethynylpyridine-3-carbonyl)-4-(pinacolatoboronyl)-l,2,3,6-tetrahydropyridine as a pale yellow solid. MS (El) 415 (M++H).
C. 1 - {4-[3-(N,N-bis-tert-Butoxycarbonyl)aminomethyl-5-hydroxyphenyl]-3,6-dihydro-2H-pyridin- 1- yl}-l-(5-phenylethynylpyridin-3-yl)methanone
By proceeding in a manner similar to the method described in EXAMPLE 17D, but using 3-bromo- N,N-(bis-tert-butoxycarbonyl)-5-(tert-butyldimethylsilyloxy)benzylamine in place of N-(tert- butoxycarbonyl)-3-bromo-4-fluorobenzylamine and 1 -(5-phenylethynylpyridine-3-carbonyl)-4-
(pinacolatoboronyI)-l,2,3,6-tetrahydropyridine in place of l-(5-phenylethylpyridine-3-carbonyl)-4- (pinacolatoboronyl)-l,2,3,6-tetrahydropyridine, there was prepared l-{4-[3-(N,N-bis-tert- Butoxycarbonyl)aminomethyl-5-hydroxyphenyl]-3,6-dihydro-2H-pyridin-l-yl}-l-(5- phenylethynylpyridin-3-yl)methanone as a pale brown solid. MS (El) 610 (M++H). The tert-butyl- dimethylsilyl moiety had unexpectedly been removed during this procedure.
D. 1 - [4-(5- Am inomethyl-3 -hydroxyphenyl)-piperidin- 1 -yl] - 1 -(5-pheny lethyl-pyridin-3 -yl)-methanone di-hydrochloride
By proceeding in a manner similar to the method described in EXAMPLE 2A, but using l-{4-[3-(N,N- bis-tert-butoxycarbonyl)aminomethyl-5-hydroxyphenyl]-3,6-dihydro-2H-pyridin-l-yl}-l-(5- phenylethynylpyridin-3-yl)methanone in place of 5-phenylethynylpyridine-3 -carboxylic acid, there was prepared l-{4-[3-(N,N-bis-tert-butoxycarbonyl)aminomethyl-5-hydroxy-phenyl]piperidin-l-yl}-l- (5-phenethylpyridin-3-yl)methanone. The crude product from this reaction was purified by column chromatography on silica gel, before being subjected to the same conditions as described in EXAMPLE ID, but using l-{4-[3-(N,N-bis-tert-butoxycarbonyl)aminomethyl-5-hydroxy- phenyl]piperidin-l-yl}-l-(5-phenethylpyridin-3-yl)methanone in place of 3-[l-(5- phenylethynylpyridine-3-carbonyl)piperidin-4-yl]benzonitrile. l-[4-(5-Aminomethyl-3- hydroxyphenyl)-piperidin-l-yl]-l-(5-phenylethyl-pyridin-3-yl)-methanone di-hydrochloride was isolated as a pale yellow solid. MS(EI): 416 (M++H).
EXAMPLE 95
1 - [4-(5-Aminomethyl-2-hydroxyphenyl)-piperidin- 1 -yl]- 1 -(5-phenylethyl-pyridin-3-yl)-methanone di- hydrochloride A. 4-Benzyloxy-3-bromobenzyl carbamic acid tgrt-butyl ester 3-Bromo-4-flurobenzonifrile (3.00 g, 15 mmol), benzyl alcohol (1.71 ml, 16.5 mmol) and THF (40 ml) are combined and treated with 60 %> sodium hydride in oil (0.66 g, 16.5 mmol). The reaction mixture is heated to reflux under nifrogen for 3 hours. Aqueous workup and chromatographic purification (cyclohexane:dichloromethane, 3:1) yields 4-benzyloxy-3-bromobenzonifrile as a white solid (3.88 g, 13.5 mmol). A portion of this material (2.64 g, 9.16 mmol) in THF (25 ml) is freated with a 1 M solution of borane in THF (18.3 ml, 18.3 mmol). After the exotherm subsides the reaction is refluxed a couple of days under nifrogen. The excess borane is destroyed by the addition of methanol and 4- benzyloxy-3-bromobenzylamine is precipitated as the hydrochloride salt (1.58 g, 4.8 mmol). This material is suspended in dichloromethane (30 ml) and freated successively with triethyl amine (1.68 ml, 12.02 mmol) and di-tgrt-butyl dicarbonate (1.26 g, 5.77 mmol). The reaction mixture is stirred under nitrogen four hours; aqueous workup and chromatographic purification (ethyl
acetate: cyclohexane, 3:7) yields the title compound as a white solid (1.69 g, 4.3 mmol). MS(EI): 394(M+).
B. 4-Benzyloxy-3- { 1 -[ 1 -(5-phenylethylpyridin-3-yl)methanoyl]-l ,2,3,6-tetrahydropyridin-4-yl}- benzyl carbamic acid tg?*t-butyl ester l-(5-Phenylethylpyridine-3-carbonyl)-4-(pinacolatoboronyl)-l,2,3,6-tetrahyropyridine (0.628 g, 1.5 mmol) as prepared in EXAMPLE 17B, 4-benzyloxy-3-bromobenzyl carbamic acid tgrt-butyl ester (0.62 g, 1.58 mmol), dichlorobis(friphenylphosphine)palladium (II) (0.074, 0.08 mmol), potassium carbonate (0.622 g, 4.5 mmol) and DMF (15 mL) are heated to 80 °C under nifrogen for 3 hours. The DMF is removed in vacuo, the residue is subjected to an aqueous workup and the organic residue is purified by chromatography to give a gray foam (0.45 g, 0.75 mmol).
C. 3-Hydroxy-2-{l-[l-(5-phenylethylpyridin-3-yl)methanoyl]-piperidin-4-yl}-benzyl carbamic acid tgrt-butyl ester . 4-Benzyloxy-3-{l-[l-(5-phenylethylpyridin-3-yl)methanoyl]-l,2,3,6-tetrahydropyridin-4-yl}-benzyl carbamic acid tgrt-butyl ester (0.34 g , 0.56 mmol) is hydrogenolyzed with hydrogen gas and 10% P/C to give the title compound as a white foam (0.27 g, 0.52 mmol). MS(EI): 515(M+).
D. 1 - [4-(5-Aminomethyl-2-hydroxyphenyl)-piperidin- 1 -yl]- 1 -(5-phenylethyl-pyridin-3 -yl)-methanone di-hydrochloride
3-Hydroxy-2-{l-[l-(5-phenylethylpyridin-3-yl)methanoyl]-piperidin-4-yl}-benzyl carbamic acid tgrt- butyl ester (0.09 g, 0.175 mmol) is converted to the title compound (0.053 g, 0.11 mmol) by the procedure described in EXAMPLE 5C. MS(EI): 416(M++H).
EXAMPLE 96 l-[4-(5-Aminomethyl-2-benzyloxyphenyl)-3,6-dihydro-2H-pyridin-l-yl]-l-(5-phenylethyl-pyridin-3- yl)-methanone di-hydrochloride
4-Benzyloxy-3- { 1 -[ 1 -(5-phenylethylpyridin-3-yl)methanoyl]- 1 ,2,3 ,6-tefrahydropyridin-4-yl} -benzyl carbamic acid tgrt-butyl ester (0.11 g, 0.184 mmol) is converted to the title compound (0.080 g, 0.15 mmol) by the procedure described in EXAMPLE 5C. MS(EI): 504(M++H).
EXAMPLE 97 l-[4-(3-Aminomethylphenyl)-piperidin- 1 -yl]- 1 -(4-phenylethyl-phenyl)-methanone hydrochloride A. 4-Phenylethynylbenzoic acid. 4-Phenylethynylbenzaldehylde (1.01 g, 4.85 mmol) is added to a suspension of silver oxide (0.56 g, 2.43 mmol) in water (15 ml) and sodium hydroxide (0.97 g, 24.3 mmol). The reaction mixture is
heated to 90 °C for 1.5 hours cooled and acidified. The aqueous mixture is exfracted with ethyl acetate and the organic layer is concentrated. The resultant solid is partitioned between ether and 0.1 M sodium hydroxide solution. The aqueous layer is acidified and the precipitated title compound (0.55g, 2.5 mmol) is collected. M.P. 224-225 °C; MS(EI): 222(M+)
B. l-[4-(3-Aminomethylphenyl)-piperidin-l-yl]-l-(4-phenylethyl-phenyl)-methanone hydrochloride By proceeding in similar manner to the method described in EXAMPLE IC but using 4-phenylethynyl benzoic acid, NN-bis-(tgrt-butoxycarbonyl)-3-[l-(4-phenylethynyl-benzoyl)-piperidin-4-yl]- benzylamine was prepared. The title compound is subsequently prepared by applying in sequence the methods described in EXAMPLE 9. MS(EI): 399(M++H).
EXAMPLE 98 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[2-(2-hydroxy-phenyl)-ethyl]-phenyl}-methanone hydrochloride By proceeding in a similar manner to the method described in EXAMPLE 10 but using N,N-bis-(tert- butoxycarbonyl)-3-{l-[3-(2-hydroxyphenyl)ethynyl-benzoyl]-piperidin-4-yl}-benzylamine, which was prepared in a similar manner to the method described in EXAMPLE 6a but using 2-iodophenol, there was prepared the title compound as a white amoφhous solid. MS(EI): 415 (M+H).
EXAMPLE 99 l-[4-(5-Aminomethyl-2-hydroxymethylphenyl)-3,6-dihydro-2H-pyridin-l-yl]-l-(5-phenylethyl- pyridin-3-yl)-methanone
A. Acetic acid 4-(Ν,Ν-bis-tert-butoxycarbonyl)aminomethyl-2-bromobenzyl ester 2-Bromo-4-(bromomethyl)benzylbromide (2.91mmol) [prepared according to the procedure of Bridger et al, J. Med. Chem. 1995, 38(2), 366] and di-tert-butyliminodicarboxylate (2.91mmol) were dissolved in tefrahydrofuran (lOmL), and sodium hydride (60%) in mineral oil, 2.9 lmmol) added at room temperature under argon. The reaction mixture was stirred at room temperature for 4 days, quenched with saturated aqueous ammonium chloride, exfracted into ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated to dryness. The crude residue was purified by column chromatography .on silica gel with cyclohexane:ethyl acetate = 9:1. 3-bromo-4-bromomethyl-(N,N-bis- tert-butoxycarbonyl)benzylamine was isolated as a white solid. A portion of 3-bromo-4-bromomethyl- (N,N-bis-tert-butoxycarbonyl)benzylamine (1.88mmol) was dissolved in acetonitrile (15mL), and to this was added potassium acetate (3.7mmol) and 18-crown-6 (0.095mmol). The reaction mixture was stirred at room temperature for 16 hours, concentrated to dryness, exfracted into ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated to dryness. Purification was carried out by
column chromatography on silica gel with diethyl ether: cyclohexane = 1:1. Acetic acid 4-(N,N-bis- tert-butoxycarbonyl)aminomethyl-2-bromobenzyl ester was isolated as a colorless solid. MS (El) 458 and 460 (M++H).
B. l-{4-[5-(N,N-bis-tert-Butoxycarbonyl)aminomethyl-2-acetoxymethylphenyl]-3,6-dihydro-2H- pyridin- 1 -yl} - 1 -(5-phenethylpyridin-3 -y l)methanone
By proceeding in a manner similar to the method described in EXAMPLE 17D, but using acetic acid 4-(N,N-bis-tert-butoxycarbonyl)aminomethyl-2-bromobenzyl ester in place of N-(tert- butoxycarbonyl)-3-bromo-4-fluorobenzylamine, there was prepared l-{4-[5-(N,N-bis-tert- butoxycarbonyl)aminomethyl-2-acetoxymethylphenyl]-3,6-dihydro-2H-pyridin-l-yl}-l-(5- phenethylpyridin-3-yl)methanone. MS (El) 670 (M++H).
C. 1 - [4-(5-Aminomethyl-2-hydroxymethylphenyl)-3 ,6-dihydro-2H-pyridin- 1 -yl]- 1 -(5-phenylethyl- pyridin-3-yl)-methanone 1 - {4-[5-(N,N-bis-tert-Butoxycarbonyl)aminomethyl-2-acetoxymethylphenyl]-3,6-dihydro-2H-pyridin- l-yl}-l-(5-phenethylpyridin-3-yl)methanone (0.3mmol) was dissolved in methanol (10mL) and cooled at 0°Cwhilst adding potassium carbonate (0. lmmol). Left at room temperature for 16 hours, concentrated to dryness and used crude residue directly in the next step. By proceeding in a manner similar to the method described in EXAMPLE ID, but using l-{4-[5-(N,N-bis-tert- butoxycarbonyl)aminomethyl-2-hydroxymethylphenyl]-3,6-dihydro-2H-pyridin-l-yl}-l-(5- phenethylpyridin-3-yl)methanone in place of 3-[l-(5-phenylethynylpyridine-3-carbonyl)piperidin-4- yljbenzonifrile, there was prepared l-[4-(5-aminomethyl-2-hydroxymethylphenyl)-3,6-dihydro-2H- pyridin-l-yl]-l-(5-phenylethyl-pyridin-3-yl)-methanone as a pale yellow solid. MS(EI): 428 (M++H).
EXAMPLE 100 l-[4-(5-Aminomethyl-thiophen-2-yl)-piperidin-l-yl]-(5-phenylethyl-pyridin-3-yl)-methanone di- hydrochloride
A. 2-[NJN-Bis-(tgrt-butoxycarbonyl)aminomethyl]-4-bromo-thiophene
By proceeding in a similar manner to the method described in EXAMPLE 1 A but using 4-bromo-2- bromomethyl-thiophene, which was simply prepared from reduction of 4-bromo-thiophene-2- carbaldehyde and subsequent bromonation of the alcohol, there was prepared the title compound.
B. l-[4-(5-Aminomethyl-thiophen-2-yl)-piperidin-l-yl]-(5-phenylethyl-pyridin-3-yl)-methanone di- hydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 93 but using 2-[N,N-bis- (tgrt-butoxycarbonyl)aminomethyl]-4-bromo-thiophene, there was prepared the title compound as a white amoφhous solid. MS(EI): 406(M+H).
EXAMPLE 101 [4-(5-Aminomethyl-pyridin-3-yl)-piperidin-l-yl]-l-(5-phenylethyl-pyridin-3-yl)-methanone tri- hydrochloride
A. 3-Bromo-5-(N,N-bis-tert-butoxycarbonyl)aminomethylpyridine
3-Bromo-5-hydroxymethylpyridine (16. lmmol) [prepared according to the procedure of Ashimori et al, Chem. Pharm. Bull. 1990, 38(9), 2446] and pyridine (32.3mmol) were dissolved in acetonitrile (32mL) and cooled to 0°C. Dibromofriphenylphosphorane (20.9mmol) added, and left reaction mixture to warm to room temperature in stoppered flask for 4 hours. The crude reaction mixture was purified by column chromatography directly on silica gel with diethyl ether:cyclohexane = 1:1. 3-Bromo-5- bromomethylpyridine was isolated as a pale brown solid. 3-Bromo-5-bromomethylpyridine (7.7mmol) and di-tert-butyliminodicarboxylate (lOmmol) were dissolved in tefrahydrofuran (20mL), and sodium hydride (60% in mineral oil, lOmmol) added at room temperature under argon. The reaction mixture was stirred at room temperature for 16 hours, quenched with saturated aqueous ammonium chloride, exfracted into ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated to dryness. The crude residue was purified by column chromatography on silica gel with cyclohexane:diethyl ether = 2:1. 3-bromo-5-(N,N-bis-tert-butoxycarbonyl)aminomethylpyridine was isolated as a pale yellow solid. MS (El) 387 and 389 (M++H).
B. [4-(5-Aminomethyl-pyridin-3-yl)-piperidin-l-yl]-l-(5-phenylethyl-pyridin-3-yl)-methanone fri- hydrochloride
By proceeding in a manner similar to the method described in EXAMPLE 17D, but using 3-bromo-5- (N,N-bis-tert-butoxycarbonyl)aminomethylpyridine in place of N-(tert-butoxycarbonyl)-3-bromo-4- fluorobenzylamine and l-(5-phenylethynylpyridine-3-carbonyl)-4-(pinacolatoboronyl)-l,2,3,6- tetrahydropyridine in place of l-(5-phenylethylpyridine-3-carbonyl)-4-(pinacolatoboronyl)-l,2,3,6- tefrahydropyridine, there was prepared l-[5-(N,N-bis-tert-butoxycarbonyl)aminomethyl-3',6'-dihydro- 2'H-[3,4']bipyridinyl- -yl]-l-(5-phenylethynylpyridin-3-yl)methanone. This material was subjected to the same conditions as described in EXAMPLE 2A, but using l-[5-(N,N-bis-tert- butoxycarbonyl)aminomethyl-3',6'-dihydro-2'H-[3,4,]bipyridinyl- 1 '-yl]- 1 -(5-phenylethynylpyridin-3- yl)methanone in place of 5-phenylethynylpyridine-3-carboxylic acid. The crude product from this reaction was purified by column chromatography on silica gel, before being subjected to the same conditions as described in EXAMPLE ID, but using {4-[5-( N,N-bis-tert- butoxycarbonyl)aminomethylpyridin-3-yl]-piperidin-l-yl}-l-(5-phenylethyl-pyridin-3-yl)-methanone in place of 3-[l-(5-phenylethynylpyridine-3-carbonyl)piperidin-4-yl]benzonifrile. [4-(5-Aminomethyl-
pyridin-3-yl)-piperidin- 1 -yl]- 1 -(5-phenylethyl-pyridin-3-yl)-methanone tri-hydrochloride was isolated as a pale yellow solid. MS(EI): 401 (M++H).
EXAMPLE 102 1 - [4-(3 -Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 -( 1 -ethyl- 1 H-indol-3 -yl)-methanone-trifluoroacetate.
A. l-Ethyl-lH-indole-3-carboxylic acid methyl ester.
A flask was charged with lH-indole-3-carboxylic acid methyl ester ( 2g, 11.41 mmol) and iodoethane (4.4g, 28.5 mmol) in dry THF ( 25 mL). The mixture was stirred in a water bath and a 60%> dispersion of sodium hydride (0.68g, 17.12 mmol) in mineral oil was added in portions over 5 minutes. The reaction stirred for 48 hours and was quenched by careful addition of water. The mixture was exfracted with dichloromethane (2 X 100 mL), dried over sodium sulfate and evaporated under reduced pressure. The crude product was purified by silica flash chromatography (10% ethyl acetate/heptane) to give 1- ethyl-lH-indole-3-carboxylic acid methyl ester (1.8g). !H NMR [CDC13]: δ 8.22-8.15 (m, IH), 7.87 (s, IH), 7.42-7.33 (m, IH), 7.31-7.25 (m, 2H), 4.22 (q, 2H), 3.92 (s, 3H), 1.52 (t, 3H).
B. 1 -Ethyl- lH-indole-3 -carboxylic acid.
A solution of 1 -ethyl- lH-indole-3 -carboxylic acid methyl ester ( 1.8g, 8.8 mmol) was stirred in a 1:1 mixture of THF:MeOH (40mL), and to this was added 2N NaOH (20 mL). The reaction was heated at reflux for 4 hours. The reaction mixture was partially evaporated to remove the THF, MeOH and the remaining material diluted with water ( 20 mL) and acidified to pH=2 with IN HCl. The mixture was exfracted with dichloromethane (100 mL), dried over sodium sulfate and evaporated under reduced pressure to give the title compound as a white solid, which was used directly in the next step.
C . 1 - [4-(3- Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 -( 1 -ethyl- 1 H-indol-3 -yl)-methanone- trifluoroacetate.
By proceeding in a similar manner to the method described in EXAMPLE 38, but using 1-ethyl-lH- indole-3-carboxylic acid, there was prepared the title compound as an amoφhous white solid. 1H NMR [CD3OD]: δ 7.75-7.63 (m, 2H), 7.52 (d, IH), 7.43-7.36 (m, 3H), 7.35-7.15 (m, 3H), 4.63-4.51 (m, 2H), 4.30 (q, 2H), 4.11 (s, 2H), 3.30-3.13 (m, 2H), 3.03-2.85 (m, IH), 2.00-1.86 (m, 2H), 1.85- 1.68 (m, 2H), 1.49 (t, 3H). MS (ion spray): 362 (M++1).
A. 4-Hydroxy-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester To a solution of ethyl 4-piperidone-3-carboxylate hydrochloride (5g, 24.05mmol) in THF (70mL) and water (35mL) at 0°C, was added triethylamine (8.7mL, 62.5 mmol), followed by N-
(benzyloxycarbonyloxy)succinimide (7.79g, 31.27mmol). The reaction mixture was stirred and
allowed to warm to room temperature. After 3 hours the reaction mixture was diluted with water (50mL) and ethyl acetate (lOOmL) added. The aqueous phase was exfracted into ethyl acetate (2χl00mL). The organic phases were combined, washed with brine (50mL), dried (MgS04), and the solvent removed in vacuo. The crude product was purified by column chromatography on silica gel (eluent, ethyl acetate : pentane = 1 :5) to give 4-hydroxy-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester as a colorless oil (7.26g, 94%). MS (El) 305 ( *).
B. 4-Trifluoromethanesulfonyloxy-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-benzyl ester 3- ethyl ester 4-Hydroxy-5,6-dihydro-2H-pyridine- 1 ,3-dicarboxylic acid 1 -benzyl ester 3-ethyl ester (15.94g,
52.5mmol) was dissolved in anhydrous THF (150mL) under nifrogen and cooled at -78°C during the addition of sodium bis(frimethylsilyl)amide (1M in THF; 68mL, 68mmol) via cannula. After stirring for 30 minutes at this temperature a solution of N-phenyltrifluoromethanesulfonimide (22.42g, 62.8mmol) in THF (230mL) was added dropwise via cannula. The reaction mixture was stirred at this temperature for 10 minutes before warming to 0°C and stirring for 2 hours. After 48h the reaction mixture was quenched with water, exfracted into DCM, dried (MgS0 ) and concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel (eluent; ethyl acetate: pentane = 4:1) to give 4-trifluoromethanesulfonyloxy-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester as colorless oil (18.59g, 81%). This material decomposed to a deep red material upon standing so was stored under nifrogen at 0°C in the dark. MS (El) 437 (TVT).
C. 4-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1- benzyl ester 3-ethyl ester 4-Trifluoromefhanesulfonyloxy-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester (200mg, 0.458mmol) was dissolved in anhydrous dioxane (6mL), and added dropwise, via cannula, to a mixture of potassium acetate (135mg, 1.374mmol), l,r-bis(diphenylphosphino)ferrocene (8mg, 0.014mmol), [l,r-bis(diphenylphosphino)ferroceno]dichloropalladium-dichloromethane complex (lOmg, 0.014mmol), and bis-pinnacolato diborane (116mg, 0.458mmol), under nifrogen. The mixture was heated at 80°C overnight, cooled to room temperature and partitioned between DCM and water. The aqueous phase was extracted with DCM, and the organic phases combined and dried (MgS0 ). Th crude product was purified by flash column chromatography on silica gel (eluent; pentane:ethyl acetate = 5:1) to afford 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-5,6-dihydro-2H- pyridine-l,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester as a colorless oil (94mg, 50%). MS (El) 415 (M÷).
P. 4-{3-[(N,N-Bis-tert-butoxycarbonyl)aminomethyllphenyl}-5,6-dihydro-2H-pyridine- 1 ,3- dicarboxylic acid 1 -benzyl ester 3-ethyl ester
A solution of 3-[N,N-bis-(tert-butoxycarbonyl)aminomethyl]bromobenzene (3.51g, 9.1mmol) [prepared by the method in Example 1A] and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-5,6- dihydro-2H-pyridine-l,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester (3.6g, 8.67mmol) in DMF ( 120mL) were added, via cannula, to a mixture of [ 1 , 1' - bis(diphenylphosphino)ferroceno]dichloropalladium-dichloromethane complex (425mg, 0.52mmol) and potassium carbonate (3.59g, 26mmol) under nitrogen. The reaction mixture was heated at 80°C overnight, concenfrated to dryness in vacuo, and the residue partitioned between DCM and water. The aqueous phase was exfracted with DCM, the organic phases combined, washed with brine, and dried (MgS0 ). The crude material was purified by column chromatography on silica gel (eluent; pentane : ethyl acetate = 6:1) to give 4-{3-[(N,N-bis-tert-butoxycarbonyl)aminomethyl]phenyl}-5,6-dihydro-2H- pyridine-l,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester as a colorless oil (2.27g, 44%). MS (El) 594 (M-).
E. (3S, 4S) and (3R,4R) 4-{3-[(N,N-Bis-tert-butoxycarbonyl)aminomethyl]phenyl}-piperidine-3- carboxylic acid ethyl ester
Solid carbon dioxide (lg) was added to a solution of 4-{3-[(N,N-bis-tert- butoxycarbonyl)aminomethyl]phenyl}-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester (2.07g, 3.48mmol) in IMS (20mL). 10% palladium on carbon (200mg) was added and the reaction mixture stirred at room temperature, under an atmosphere of hydrogen, for 4 hours. The palladium on carbon was filtered off through celite to give a 1 : 1 mixture of (3S, 4S) and (3R,4R) 4-{3- [(N,N-Bis-tert-butoxycarbonyl)aminomethyl]phenyl}-piperidine-3-carboxylic acid ethyl ester as a pale grey/brown oil (1.35g, 84%), which was pure enough for use in the subsequent reaction. MS (El) 462 (M÷).
F. (3S,4S) and (3R,4R)-4-{3-[(Bis-tert-butoxycarbonyl)aminomethyl]phenyl}-l-(5-phenethylpyridine-
3-carbonyl)piperidine-3-carboxylic acid ethyl ester
By proceeding in a similar manner to the method described in EXAMPLE 2B, but using a 1 : 1 mixture of (3S, 4S) and (3R,4R) 4-{3-[(N,N-Bis-tert-butoxycarbonyl)aminomethyl]phenyl}-piperidine-3- carboxylic acid ethyl ester instead of 4-{3-[N,N-bis(tert- butoxycarbonyl)aminomethyl]phenyl}piperidine, there was prepared a 1:1 mixture of (3S,4S) and
(3R,4R)-4-{3-[(Bis-tert-butoxycarbonyl)aminomethyl]ρhenyl}-l-(5-phenethylpyridine-3- carbonyl)piperidine-3 -carboxylic acid ethyl ester as a colorless glassy solid (414mg, 0.62mmol). MS
(El) 671 (M*).
G. (3S,4S) and (3R, 4R)-4-(3-Aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine- 3 -carboxylic acid ethyl ester dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE ID, but using a 1:1 mixture of (3S,4S) and (3R,4R)-4-{3-[(Bis-tert-butoxycarbonyl)aminomethyl]phenyl}-l-(5-phenethylpyridine- 3-carbonyl)piperidine-3-carboxylic acid ethyl ester instead of N,N-bis-(tert-butoxycarbonyl)-3-[l-(5- phenylethynylpyridine-3-carbonyl)piperidin-4-yl]benzylamine, there was prepared a 1:1 mixture of (3S,4S) and (3R, 4R)-4-(3-Aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3- carboxylic acid ethyl ester dihydrochloride as a white solid. MS (El) 471 (M1").
EXAMPLE 104 (3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3- carboxylic acid ethyl ester dihydrochloride
A. (3R,4S) and (3S,4R)-4-{3-[(tert-Butoxycafbonyl)aminomethyl]phenyl}-l-(5-phenethylpyridme-3- carbonyl)-piperidine-3-carboxylic acid ethyl ester
Sodium hydride (lOmg, 60% in mineral oil, 0.25mmol) was added to ethanol (lOmL), and after the effervescence had subsided a 1:1 mixture of (3S,4S) and (3R,4R)-4-{3-[(bis-tert- butoxycarbonyl)aminomethyl]phenyl}-l-(5-phenethylpyridine-3-carbonyl)piperidine-3-carboxylic acid ethyl ester (lOOmg) was added at room temperature. After 1 hour the solvent was removed in vacuo, and the residue partitioned between DCM and water. The aqueous phase was extracted with DCM, the combined organic phase washed with brine and dried (MgS0 ). The crude material was purified by column chromatography on silica gel (eluent; DCM:MeOH = 10:1) to give a 1:1 mixture of (3R,4S) and (3S,4R)-4-{3-[(tert-butoxycarbonyl)aminomethyl]phenyl}-l-(5-phenethylpyridme-3- carbonyl)-piperidine-3-carbQxylic acid ethyl ester as a pale yellow glassy solid (43mg, 51%>). MS (El) 571 (M1-).
B. (3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine- 3 -carboxylic acid ethyl ester dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE ID, but using a 1:1 mixture of(3R,4S) and (3S,4R)-4-{3-[(tert-butoxycarbonyl)aminomethyl]phenyl}-l-(5-phenethylpyridine-3- carbonyl)-piρeridine-3-carboxylic acid ethyl ester instead of N,N-bis-(tert-butoxycarbonyl)-3-[l-(5- phenylethynylpyridine-3-carbonyl)piperidin-4-yl]benzylamine, there was prepared a 1 :1 mixture of (3R,4S) and (3S, 4R)-4-(3-aminomethyl-ρhenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3- carboxylic acid ethyl ester dihydrochloride as a white solid. MS (El) 471 (M+).
EXAMPLE 105 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-r5-(4-bromo-2-fluoro-benzylamino)-pyridin-3-yl]- methanone trihydrochloride
A. 5-tgrt-Butoxycarbonylamino-nicotinic acid
To a solution of diethyl 3,5-pyridinedicarboxylate [prepared according to the procedure of J. C. Speelman and R. M. Kellogg, J. Org. Chem, 1990, 55 (2), pages 647-653; 64.19 g, 0.248 mol] in ethanol (650 mL) were added KOH pellets (14.56 g, 0.260 mol). The reaction mixture was stirred overnight at ambient temperature. Evaporation of solvent afforded a white solid that was rinsed with dichloromethane, and then dissolved in water. The aqueous solution was extracted with ether, and then acidified to pH 3. The resultant white precipitate was collected by filtration and dried to afford pyridine-3,5-dicarboxylic acid monomethyl ester (33.70 g). A portion of this material (10.00 g, 51.3 mmol) was dissolved in dry tgrt-butanol (300 mL) and treated sequentially with triethylamine (7.85 mL, 56.4 mmol) and diphenyl phosphoryl azide (11.5 mL, 53.4 mmol). The mixture was refluxed for 90 minutes, and then stirred at ambient temperature overnight. Solvent was removed under reduced pressure and the residue was partitioned between water and dichloromethane. The layers were separated and the aqueous phase was exfracted twice with dichloromethane. The combined organic phases were dried and concentrated. Chromatography on silica gel eluting with a mixture of pentane and ethyl acetate (3:1, v/v) gave 5-tert-butoxycarbonylamino-nicotinic acid ethyl ester (4.79 g). This ester was dissolved in methanol (45 mL) and freated with 1 N NaOH (54 mL, 54 mmol). After stirring 2 hours, volatiles were evaporated under reduced pressure and the residue was freated with 1 N HCl until the resultant slurry reached pH 3. The precipitate was collected by filtration, washed with water, and dried to afford 5-tgrt-butoxycarbonylamino-nicotinic acid (4.21 g): 1H NMR (300 MHz, DMSO- d6) δ 13.39 (br s, IH), 9.82 (s, IH), 8.78 (d, J=2.5 Hz, IH), 8.69 (d, J=1.9 Hz, IH), 8.45-8.50 (m, IH),
1.50 (s, 9H); 13C NMR (75 MHz, DMSO-dό) δ 166.2, 152.7, 143.4, 143.2, 136.2, 126.3, 124.9, 80.0, 27.9; MS (ESI) m/z 239 (M+H).
B. {5-[l-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)methanoyl]- pyridin-3-yl} carbamic acid tert-butyl ester
To a 0 °C solution of 4-{3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidine (0.1545 g, 0.3956 mmol, EXAMPLE IB), 5-tgrt-butoxycarbonylamino-nicotinic acid (0.0966 g, 0.4055 mmol), 1 -hydroxy- 7-azabenzotriazole (0.0290 g, 0.2131 mmol), and l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (0.1500 g, 0.7824 mmol) in dimethylformamide (5.0 mL) was added pyridine (0.065 mL, 0.8037 mmol). The reaction mixture was stirred 30 minutes at 0 °C, then allowed to warm to room temperature under inert atmosphere. After 16 hours at ambient temperature the reaction solution was diluted with ethyl acetate (30 mL), washed with saturated ammonium chloride (2 x 15 mL), saturated sodium bicarbonate (15 mL), and brine (15 mL). The organic phase was dried over magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by silica gel chromatography eluting with a mixture of ethyl acetate and methylene chloride (1:1, v/v) to give {5-[l-
(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)methanoyl]-pyridin-3- yl} carbamic acid tgrt-butyl ester as a colorless oil (0.1812 g): TLC, 50:50-methylene chloride:ethyl acetate, Rf = 0.20. 1H ΝMR (300 MHz, CDC13) δ 8.67 (d, J=2.6 Hz, IH), 8.34 (d, J=1.4 Hz, IH), 8.09 (s, IH), 7.93 (s, IH), 7.21-7.35 (m, IH), 7.08-7.18 (m, 3H), 4.81-4.93 (m, IH), 4.78 (s, 2H), 3.81-3.93 (br m, IH), 3.11-3.28 (br m, IH), 2.70-2.96 (m, 2H), 1.51 (s, 9H), 1.45 (s, 18H), 1.40-2.02 (m partially obscured, 4H); 13C ΝMR (75 MHz, CDCI3) δ 167.5, 152.6, 152.5, 144.8, 141.3, 141.0, 138.9, 135.7,
131.8, 128.5, 125.6, 125.3, 125.2, 124.1, 82.4, 81.0, 77.2, 49.3, 42.5, 28.1, 27.8; MS (CI) m/z 611 (M+H).
C. (4-Bromo-2-fluoro-benzyl)-{5-[l-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}- piperidin-l-yl)-methanoyl]-pyridin-3-yl}-carbamic acid dimethyl-ethyl ester To a solution of {5-[l-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l- yl)methanoyl]-pyridin-3-yl}carbamic acid tgrt-butyl ester (0.0745 g, 0.1220 mmol) in dimethylformamide (2.0 mL) was added sodium hydride (61% suspension in mineral oil, 0.0216 g, 0.5499 mmol). Deprotonation was allowed to occur over 3 minutes while stirring under inert atmosphere. 4-Bromo-2-fluorobenzyl bromide (0.1559 g,0.5819 mmol) was added to the anion solution. The mixture was stirred an additional 10 minutes, then quenched with water (5.0 mL). The reaction solution was exfracted with ethyl acetate (15 mL), and the organic phase was washed with brine (2 x 10 mL), dried over magnesium sulfate, filtered, and evaporated to dryness. Purification of the residue on silica gel eluting first with ethyl acetate/methylene chloride/hexane (1:1 :2, v/v/v) and then with ethyl acetate and methylene chloride (1:1, v/v) afforded (4-bromo-2-fluoro-benzyl)- { 5 - [ 1 -(4- {3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)-methanoyl]-pyridin-3-yl}- carbamic acid dimethyl-ethyl ester as a colorless oil (0.0917 g): TLC, 50:50-methylene chloride: ethyl acetate, Rf = 0.59. 1HΝMR (300 MHz, CDCI3) δ 8.47-8.51 (m, 2H), 7.61 (br s, IH), 7.07-7.32 (m, 7H), 4.89 (s, 2H), 4.78 (s, 2H), 4.77-4.92 (m partially obscured, IH), 3.68-3.83 (br m, IH), 3.09-3.24 (br m, IH), 2.70-2.97 (m, 2H), 1.45 (s, 18H), 1.44 (s, 9H), 1.30-2.04 (m partially obscured, 4H); 13C NMR (75 MHz, CDCI3) δ 167.0, 160.4 (d, 250.8), 154.0, 152.7, 148.5, 144.9, 139.0, 138.7, 132.2,
131.9, 130.7, 129.7, 127.9 (d, 3.4), 125.8, 125.7, 125.3, 123.8 (d, 14.5), 121.8 (d, 9.7), 119.3 (d, 24.8), 82.5, 82.2, 49.5, 46.9, 42.6, 32.8 (br), 28.4, 28.2, 28.0; *9p NMR (282 MHz, CDCI3) δ -114.9; MS (CI) m/z 797 (M+H).
D. l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[5-(4-bromo-2-fluoro-benzylamino)-pyridin-3-yl]- niethanone frihydrochloride
(4-Bromo-2-fluoro-benzyl)-{5-[l-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}- piperidin-l-yl)-methanoyl]-pyridin-3-yl}-carbamic acid dimethyl-ethyl ester (0.0806 g, 0.1010 mmol)
was freated with 4 MHCl in 1,4-dioxane (2.0 mL, 8.0 mmol) and stirred at ambient temperature. After 25 minutes the reaction mixture was diluted with isopropyl alcohol (0.5 mL) and stirring was continued for an additional 2.5 hours. Dripping the reaction solution into ether (40 mL) with vigorous stirring afforded a white precipitate which was collected by filtration, washed with fresh ether (3.0 mL), and dried to afford l-[4-(3-aminomethyl-phenyl)-piperidin-l-yl]-l-[5-(4-bromo-2-fluoro- benzylamino)-pyridin-3-yl1-methanone trihydrochloride (0.0563 g): ΪH MR (300 MHz, DMSO-dό) δ 8.39 (br s, 2H), 8.16 (d, J=2.7 Hz, IH), 8.08 (s, IH), 7.16-7.70 (m, 8H), 4.49-4.64 (br m, IH), 4.46 (s, 2H), 4.05-4.30 (m, IH), 4.00 (AB q, J=5.7 Hz, 2H), 3.01-3.25 (m, IH), 2.77-2.95 (m, 2H), 1.75- 1.92 (m, IH), 1.45-1.75 (br m, 3H); 19F NMR (282 MHz, DMSO-dό) δ -114.1; MS (ESI) m/z 497 (M+H).
EXAMPLE 106 1 - [4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl] - 1 -(5-benzy lammo-pyridin-3 -yl)-methanone frihydrochloride
A. Benzyl- { 5-[ 1 -(4- {3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl} -piperidin- 1 -yl)- methanoyl]-pyridin-3-yl}-carbamic acid dimethyl-ethyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using benzyl bromide in place of 4-bromo-2-fluorobenzyl bromide, there was prepared benzyl-{5-[l-(4-{3-[N,N-bis- (tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidm-l-yl)-methanoyl]-pyridin-3-yl}-carbamic acid dimethyl-ethyl ester as a yellow oil. TLC, 50:50-methylene chloride:ethyl acetate, Rf = 0.48. 1HΝMR (300 MHz, CDCI3) δ 8.52 (d, J=2.2 Hz, IH), 8.46 (d, J=1.2 Hz, IH), 7.56 (s, IH), 7.04-7.38 (m, 9H), 4.89 (s, 2H), 4.78 (s, 2H), 4.75-4.90 (m partially obscured, IH), 3.63-3.88 (br m, IH), 3.00-3.19 (br m, IH), 2.68-2.90 (m, 2H), 1.45 (s, 18H), 1.44 (s, 9H), 1.37-2.04 (m, 4H); 13C NMR (75 MHz, CDCI3) δ 167.0, 154.1, 152.6, 148.4, 144.8, 144.5, 138.9, 137.5, 132.0, 131.5, 128.6, 128.5, 127.5, 127.2, 125.7, 125.5, 125.2, 82.4, 81.6, 53.4, 49.4, 42.5, 33.8, 28.3, 28.1, 27.9; MS (CI) m/z 701 (M+H).
B. l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl1-l-(5-benzylamino-pyridin-3-yl)-methanone frihydrochloride By proceeding in a similar manner to the method described in EXAMPLE 105D, but using benzyl-{5- [l-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)-methanoyl]-pyridin-3- yl} -carbamic acid dimethyl-ethyl ester, there was prepared 1 - [4-(3 -aminomethyl-phenyl)-piperidin- 1 - yl]- 1 -(5-benzylamino-pyridin-3-yl)-methanone frihydrochloride as a white solid. 1H ΝMR (300 MHz, DMSO-d6) δ 8.45 (br s, 2H), 8.13 (d, J=2.5 Hz, IH), 8.08 (d, J=1.0 Hz, IH), 7.54 (s, IH), 7.47 (s, IH), 7.18-7.45 (m, 8H), 4.50-4.63 (br m, IH), 4.45 (s, 2H), 4.02-4.12 (m, IH), 3.99 (AB q, J=5.5 Hz, 2H),
3.05-3.25 (m, IH), 2.70-2.95 (m, 2H), 1.75-1.90 (br m, IH), 1.50-1.70 (br m, 3H); MS (ESI) m/z 401 (M+H).
EXAMPLE 107 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{5-[(naphthalen-2-ylmethyl)-amino]-pyridin-3-yl}- methanone frihydrochloride
A. {5-[l-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)-methanoyl}- pyridin-3-yl}-naphthalen-2-ylmethyl-carbamic acid dimethyl-ethyl ester By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 2-
(bromomethyl)naphthalene in place of 4-bromo-2-fluorobenzyl bromide, there was prepared {5-[l-(4- {3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)-methanoyl}-pyridin-3-yl}- naphthalen-2-ylmethyl-carbamic acid dimethyl-ethyl ester as a colorless oil. TLC, 50:50-methylene chloride:ethyl acetate, Rf = 0.42. 1H ΝMR (300 MHz, CDCI3) δ 8.55 (d, J=1.8 Hz, IH), 8.13 (d, J=187.5 Hz, IH), 7.68-7.83 (m, 3H), 7.60 (s, IH), 7.54 (br s, IH), 7.35-7.49 (m, 3H), 7.21-7.29 (m partially obscured, IH), 7.16 (d, J=7.7 Hz, IH), 7.08 (s, IH), 7.01 (d, J=7.7 Hz, IH), 5.00-5.08 (m,
2H), 4.77 (s, 2H), 3.48-3.62 (br m, IH), 2.59-3.03 (m, 3H), 1.45 (s, 27H), 1.27-1.95 (m, 4H); 13C ΝMR (75 MHz, CDCl3) δ 166.9, 154.3, 152.6, 148.6, 144.8, 144.7, 138.9, 138.8, 134.9, 133.3, 132.8, 132.2, 131.6, 128.6, 127.7, 126.3, 126.2, 126.0, 125.8, 125.5, 125.3, 125.2, 82.4, 81.8, 53.6, 49.4, 42.5, 33.2, 28.4, 28.2, 28.0; MS (CI) m/z 752 (M+H).
B. l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{5-[(naphthalen-2-ylmethyl)-amino]-pyridin-3-yl}- methanone frihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using {5-[l-(4- {3-[N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)-methanoyl}-pyridin-3-yl}- naphthalen-2-ylmethyl-carbamic acid dimethyl-ethyl ester, there was prepared l-[4-(3-aminomethyl- phenyl)-piperidin- 1 -yl]- 1 - { 5 - [(naphthalen-2-ylmethyl)-amino]-pyridin-3 -yl } -methanone frihydrochloride as a as a white solid. 1H ΝMR (300 MHz, DMSO-d6) δ 8.34 (br s, 2H), 8.17 (s, IH), 8.03 (s, IH), 7.75-7.97 (m, 4H), 5.58-7.77 (m, IH), 7.25-7.57 (m, 6H), 7.22 (d, J=7.2 Hz, IH), 4.61 (s, 2H), 4.50-4.68 (m partially obscured, IH), 4.10-4.35 (m, IH), 4.00 (AB q, J=5.7 Hz, 2H), 2.91-3.12 (m, IH), 2.66-2.90 (m, 2H), 1.70-1.89 (m, IH), 1.36-1.69 (m, 3H); MS (ESI) m/z 451 (M+H).
EXAMPLE 108 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[5-(4-bromo-benzylamino)-pyridin-3-yl]-methanone frihydrochloride
A. (4-Bromobenzyl)-{5-[l-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l- yl)-methanoyl]-pyridin-3-yl}-carbamic acid dimethyl-ethyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 4- bromobenzyl bromide in place of 4-bromo-2-fluorobenzyl bromide, there was prepared (4- bromobenzyl)- {5-[l-(4-{3- [N,N-bis-(tgrt-butoxycarbonyl)amino-methyl] -phenyl } -piperidin- 1 -yl)- methanoyl]-pyridin-3-yl}-carbamic acid dimethyl-ethyl ester as a colorless oil. TLC, 50:50-methylene chloride:ethyl acetate, Rf = 0.41. lR ΝMR (300 MHz, CDCI3) δ 8.45-8.51 (m, 2H), 7.56 (br s, IH), 7.43 (d, J=8.4 Hz, 2H), 7.24-7.30 (m partially obscured, IH), 7.11 (d, J=8.4 Hz, 2H), 6.96-7.17 (m partially obscured, 3H), 4.83 (s, 2H), 4.77 (s, 2H), 4.75-4.87 (m partially obscured, IH), 3.65-3.80 (br m, IH), 3.05-3.23 (br m, IH), 2.69-2.91 (m, 2H), 1.45 (s, 18H), 1.43 (s, 9H), 1.30-2.00 (m, 4H); 13C ΝMR (75 MHz, CDCl3) δ 166.8, 154.0, 152.5, 148.4, 144.7, 138.9, 138.7, 136.5, 132.1, 131.8, 131.7, 131.5, 129.0, 128.6, 125.7, 125.5, 125.2, 121.4, 82.4, 81.9, 52.8, 49.3, 42.5, 33.5, 28.3, 28.1, 27.9; MS (CI) m/z 781 (M+H).
B. l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[5-(4-bromo-benzylamino)-pyridin-3-yl]- methanone frihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using (4- bromobenzyl)-{5-[l-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)- methanoyl]-pyridin-3-yl}-carbamic acid dimethyl-ethyl ester, there was prepared l-[4-(3- aminomethyl-phenyl)-piperidin- 1 -yl]- 1 - [5-(4-bromo-benzylamino)-pyridin-3 -yl]-methanone frihydrochloride as a cream-colored solid. 1H ΝMR (300 MHz, DMSO-d6) δ 8.34 (br s, 2H), 8.11 (d, J=2.5 Hz, IH), 8.04 (s, IH), 7.52 (d, J=8.5 Hz, 2H), 7.34 (d, J=8.5 Hz, 2H), 7.15-7.67 (m, 5H), 4.49- 4.64 (br m, IH), 4.42 (s, 2H), 4.05-4.15 (m, IH), 4.01 (AB q, J=5.7 Hz, 2H), 3.00-3.20 (m, IH), 2.70- 2.90 (m, 2H), 1.72-1.88 (m, IH), 1.45-1.70 (m, 3H); MS (ESI) m/z 479 (M+H).
EXAMPLE 109 3-[(5-{l-[4-(3-Aminomethyl-phenyl)piperidin-l-yl]-methanoyl}-pyridin-3-ylamino)-methyl]- benzonitrile frihydrochloride
A. {5-[l-(4-{3-rN,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)-methanoyl]- pyridin-3-yl}-(3-cyano-benzyl)-carbamic acid dimethyl-ethyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but -bτomo-m- tolunifrile in place of 4-bromo-2-fluorobenzyl bromide, there was prepared {5-[l-(4-{3-rN,N-bis-(tgrt- butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)-methanoyl]-pyridin-3-yl}-(3-cyano-benzyl)- carbamic acid dimethyl-ethyl ester as a yellow oil. TLC, 50:50-methylene chloride: ethyl acetate, Rf =
0.44. !H NMR (300 MHz, CDCI3) δ 8.46-8.52 (m, 2H), 7.51-7.65 (m, 3H), 7.36-7.50 (m, 2H), 7.24- 7.31 (m partially obscured, IH), 7.03-7.18 (m, 3H), 4.92 (s, 2H), 4.79-4.92 (m partially obscured, IH), 4.78 (s, 2H), 3.70-3.85 (br m, IH), 3.10-3.28 (br m, IH), 2.71-2.99 (m, 2H), 1.45 (s, 18H), 1.44 (s,
9H), 1.30-2.05 (m partially obscured, 4H); 13C NMR (75 MHz, CDCI3) δ 166.7, 153.8, 152.5, 148.1, 145.2, 144.7, 139.2, 138.9, 138.7, 132.1, 131.9, 131.5, 131.2, 130.6, 129.6, 128.6, 125.6, 125.5, 125.2, 118.3, 112.9, 82.4, 80.6, 52.8, 49.3, 42.4, 33.5, 28.3, 28.0, 27.9; MS (CI) m/z 727 (M+H).
B. 3-[(5-{l-[4-(3-Aminomethyl-phenyl)piperidin-l-yl]-methanoyl}-pyridin-3-ylamino)-methyl]- benzonifrile frihydrochloride By proceeding in a similar manner to the method described in EXAMPLE 105D, but using {5-[l-(4- {3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)-methanoyl]-pyridin-3-yl}- (3-cyano-benzyl)-carbamic acid dimethyl-ethyl ester, there was prepared 3-[(5-{ l-[4-(3-aminomethyl- phenyl)piperidin-l-yl]-methanoyl}-pyridin-3-ylamino)-methyl]-benzonitrile frihydrochloride as a white solid. 1H ΝMR (300 MHz, DMSO-d6) δ 8.33 (br s, 2H), 8.13 (d, J=2.5 Hz, IH), 8.02 (s, IH), 7.80-7.91 (m, IH), 7.63-7.75 (m, 2H), 7.42-7.58 (m, 2H), 7.20-7.7.41 (m, 4H), 4.51 (s, 2H), 4.40-4.62 (m partially obscured, IH), 4.10-4.25 (m, IH), 4.00 (AB q, J=5.7 Hz, 2H), 2.90-3.20 (m, IH), 2.72- 2.93 (m, 2H), 1.75- 1.90 (br m, IH), 1.45- 1.70 (br m, 3H); MS (ESI) m/z 426 (M+H).
EXAMPLE 110 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[5-(2-chloro-4-fluoro-benzylamino)-pyridin-3-yl]- methanone frihydrochloride
A. {5-[l-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)-methanoyl]- pyridin-3-yl}-(2-chloro-4-fluoro-benzyl)-carbamic acid dimethyl-ethyl ester By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 2-chloro-4- fluorobenzyl bromide in place of 4-bromo-2-fluorobenzyl bromide, there was prepared {5-[l-(4-{3- [N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)-methanoyl]-pyridin-3-yl}-(2- chloro-4-fluoro-benzyl)-carbamic acid dimethyl-ethyl ester as a colorless oil. TLC, 50:50-methylene chloride:ethyl acetate, Rf = 0.48. 1H ΝMR (300 MHz, CDCI3) δ 8.51 (d, J=2.2 Hz, IH), 8.46 (d, J=1.8 Hz, IH), 7.62 (s, IH), 7.24-7.34 (m, 2H), 7.04-7.19 (m, 4H), 6.97 (td, J=8.2, 2.5 Hz, IH), 4.96 (s, 2H), 4.77 (s, 2H), 4.75-4.90 (m partially obscured, IH), 3.70-3.85 (br m, IH), 3.05-3.25 (br m, IH), 2.70-
2.90 (m, J=21.45, s Hz, 18H), 1.44 (s, 9H), 1.30-2.05 (m, 4H); 13C NMR (75 MHz, CDCI3) δ 166.9, 161.8 (d, 250.1), 153.8, 152.6, 148.1, 144.7, 144.6, 138.9, 138.6, 133.6 (d, 9.7), 131.8, 131.7, 130.8 (d, 3.4), 129.8 (d, 7.6), 128.6, 125.7, 125.6, 125.2, 117.0 (d, 24.9), 114.3 (d, 21.4), 82.4, 82.1, 50.3, 49.4, 42.5, 33.8, 28.3, 28.1, 27.9; 19p NMR (282 MHz, CDCI3) δ -112.0; MS (CI) m/z 754 (M+H).
B. l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[5-(2-chloro-4-fluoro-benzylamino)-pyridin-3-yl]- methanone frihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using{5-[l-(4-{3- [N,N-bis-(tgrt-butoxycarbonyl)aminomethyl]-phenyl}-piperidin-l-yl)-methanoyl]-pyridin-3-yl}-(2- chloro-4-fluoro-benzyl)-carbamic acid dimethyl-ethyl ester, there was prepared l-[4-(3-aminomethyl- phenyl)-piperidin-l-yl]-l-[5-(2-chloro-4-fluoro-benzylamino)-pyridin-3-yl]-methanone frihydrochloride as a white solid. 1H ΝMR (300 MHz, DMSO-d6) δ 8.34 (br s, 2H), 8.15 (d, J=2.5 Hz, IH), 8.07 (s, IH), 7.12-7.55 (m, 8H), 4.50-4.65 (br m, IH), 4.46 (s, 2H), 4.12-4.24 (br m, IH), 4.00 (AB q, J=5.8 Hz, 2H), 3.05-3.20 (br m, IH), 2.70-2.90 (m, 2H), 1.72-1.90 (br m, IH), 1.48-1.73
(br m, 3H); 19F ΝMR (282 MHz, DMSO-d6) δ -112.6; MS (ESI) m/z 453 (M+H).
EXAMPLE 111 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[5-(4-trifluoromethoxy-benzylamino)-pyridin-3-yl]- methanone frihydrochloride
A. {5-[l-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)-methanoyl]- pyridin-3-yl}-(4-frifluoromethoxy-benzyl)-carbamic acid dimethyl-ethyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 4- (trifluoromethoxy)benzyl bromide in place of 4-bromo-2-fluorobenzyl bromide, there was prepared { 5- [ 1 -(4- {3 - [N,N-bis-(tgrt-butoxycarbonyl)amino-methyl] -phenyl } -piperidin- 1 -yl)-methanoyl]- pyridin-3-yl}-(4-frifluoromethoxy-benzyl)-carbamic acid dimethyl-ethyl ester as a colorless oil. TLC,
50:50-methylene chloride:ethyl acetate, Rf = 0.48. 1H ΝMR (300 MHz, CDCI3) δ 8.45-8.53 (m, 2H), 7.60 (s, IH), 7.20-7.30 (m, 3H), 7.05-7.20 (m, 5H), 4.88 (s, 2H), 4.77 (s, 2H), 4.75-4.90 (m partially obscured, IH), 3.70-3.84 (br m, IH), 3.08-3.24 (br m, IH), 2.70-2.93 (m, 2H), 1.45 (s, 18H), 1.44 (s,
9H), 1.35-2.05 (m, 4H); 13C MR (75 MHz, CDCI3) δ 166.9, 154.0, 152.6, 148.3, 144.7, 144.6, 138.9, 138.8, 136.3, 132.2, 131.9, 128.7, 128.6, 125.7, 125.6, 125.2, 121.2, 120.1 (q, 262), 82.4, 82.0, 52.7, 49.4, 42.5, 32.3, 28.3, 28.1, 27.9; 19F NMR (282 MHz, CDCI3) δ -57.4; MS (CI) m/z 786 (M+H).
B . 1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl] - 1 - [5-(4-trifluoromethoxy-benzylamino)-pyridin-3 - yl]-methanone frihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using{5-[l-(4-{3- [N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)-methanoyl]-pyridin-3-yl}-(4- trifluoromethoxy-benzyl)-carbamic acid dimethyl-ethyl ester, there was prepared l-[4-(3-
aminomethyl-phenyl)-piperidin-l-yl1-l-[5-(4-frifluoromethoxy-benzylamino)-pyridin-3-yl]-methanone frihydrochloride as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 8.35 (br s, 2H), 8.12 (d, J=2.8 Hz, IH), 8.05 (s, IH), 7.20-7.75 (m, 9H), 4.50-4.65 (m, IH), 4.48 (s, 2H), 4.05-4.20 (m, IH), 4.00 (AB q, J=5.9 Hz, 2H), 3.05-3.25 (m, IH), 2.70-2.90 (m, 2H), 1.75-1.90 (m, IH), 1.50-1.70 (br m, 3H); 19F NMR (282 MHz, DMSO-d6) δ -56.3; MS (ESI) m/z 485 (M+H).
EXAMPLE 112 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{5-[(pyridin-3-ylmethyl)-amino]-pyridin-3-yl}- methanone tetrahydrochloride
A. { 5- 1 -(4- { 3 - [N, N-Bis-(tgrt-butoxycarbonyl)amino-methy 1] -phenyl } -piperidin- 1 -yl)-methanoyl] - pyridin-3-yl}-pyridin-3-ylmethyl-carbamic acid dimethyl-ethyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 3- (chloromethyl)pyridine hydrochloride in place of 4-bromo-2-fluorobenzyl bromide, there was prepared {5-[l-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)-methanoyl]- pyridin-3-yl}-pyridin-3-ylmethyl-carbamic acid dimethyl-ethyl ester as a colorless oil. TLC, 15:85- isopropyl alcoho methylene chloride, Rf = 0.54. !H ΝMR (300 MHz, CDCI3) δ 8.46-8.56 (m, 4H),
7.53-7.62 (m, 2H), 7.22-7.31 (m partially obscured, 2H), 7.05-7.18 (m, 3H), 4.90 (s, 2H), 4.77 (s, 2H), 4.75-4.99 (m partially obscured, IH), 3.69-3.83 (br m, IH), 3.05-3.25 (br m, IH), 2.70-2.96 (m, 2H), 1.45 (s, 18H), 1.44 (s, 9H), 1.20-2.03 (m, 4H); 13C ΝMR (75 MHz, CDCI3) δ 166.8, 154.0, 152.6,
149.1, 149.0, 148.6, 144.9, 144.7, 138.9, 138.7, 135.1, 133.1, 132.4, 131.9, 128.7, 125.7, 125.6, 125.3, 123.6, 82.5, 82.2, 51.2, 49.4, 42.6, 33.9, 28.4, 28.2, 28.0; MS (CI) m/z 702 (M+H).
B. l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{5-[(pyridin-3-ylmethyl)-amino]-pyridin-3-yl}- methanone tetrahydrochloride
{5-[l-(4-{3-[N,N-Bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)-methanoyl]- pyridin-3-yl}-pyridin-3-ylmethyl-carbamic acid dimethyl-ethyl ester (0.0250 g, 0.0356 mmol) was treated with 5-6 M HCl in isopropanol (1.0 mL, 8.0 mmol) and stirred at ambient temperature. After 90 minutes the reaction mixture was diluted with methyl alcohol (0.5 mL) and stirring was continued for an additional 75 minutes. Dripping the reaction solution into ether (40 mL) with vigorous stirring afforded a white precipitate which was collected by filtration, washed with fresh ether (3.0 mL), and dried to afford 1 - [4-(3 -aminomethyl-phenyl)-piperidin- 1 -yl] - 1 - { 5- [(pyridin-3 -ylmethyl)-amino]- pyridin-3-yl}-methanone tetrahydrochloride (0.0160 g): 1H NMR (300 MHz, DMSO-d6) δ 8.60-8.95 (m, 2H), 8.39 (br s, 2H), 8.29 (d, J=8.0 Hz, IH), 7.97-8.25 ( , 2H), 7.65-7.85 (m, 2H), 7.47 (d, J=8.0 Hz, 2H), 7.20-7.38 (m, 3H), 4.63 (s, 2H), 4.43-4.61 (m partially obscured, IH), 4.00 (AB q, J=5.8 Hz,
2H), 3.05-3.25 (m partially obscured, IH), 2.72-2.95 (m, 2H), 1.80-1.88 (m, IH), 1.47-1.77 (m, 3H); MS (CI) m/z 402 (M+H).
EXAMPLE 113 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{5-[(pyridin-2-ylmethyl)-amino]-pyridin-3-yl}- methanone tetrahydrochloride
A. { 5- [ 1 -(4- { 3 - [N, N-B is-(tgrt-butoxycarbonyl)amino-methyl]-phenyl} -piperidin- 1 -yl)-methanoyl] - pyridin-3-yl}-pyridin-2-ylmethyl-carbamic acid dimethyl-ethyl ester By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 2-
(chloromethyl)pyridine hydrochloride in place of 4-bromo-2-fluorobenzyl bromide, there was prepared {5-[l-(4-{3-[NJN-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)-methanoyl]- pyridin-3-yl}-pyridin-2-ylmethyl-carbamic acid dimethyl-ethyl ester as a colorless oil. TLC, 50:50- methylene chloride:ethyl acetate, Rf = 0.09. 1H ΝMR (300 MHz, CDCI3) δ 8.67 (d, J=2.3 Hz, IH), 8.52 (d, J=4.7 Hz, IH), 8.44 (d, J=1.8 Hz, IH), 7.81 (s, IH), 7.59-7.72 (m, IH), 7.22-7.31 (m partially obscured, 2H), 7.00-7.20 (m, 4H), 4.97 (s, 2H), 4.77 (s, 2H), 4.72-4.90 (m partially obscured, IH), 3.74-3.89 (br m, IH), 3.04-3.25 (br m, IH), 2.69-2.94 (m, 2H), 1.45 (s, 18H), 1.41 (s, 9H), 1.23-2.03 (m partially obscured, 4H); MS (CI) m/z 702 (M+H).
B . 1 - [4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 - { 5- [(pyridin-2-ylmethyl)-amino]-pyridin-3 -yl } - methanone tetrahydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 112B, but using{5-[l-(4-{3- [N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidin-l-yl)-methanoyl]-pyridin-3-yl}- pyridin-2-ylmethyl-carbamic acid dimethyl-ethyl ester, there was prepared l-[4-(3-aminomethyl- phenyl)-piperidin- 1 -yl] - 1 - { 5 - [(pyridin-2-ylmethyl)-amino]-pyridin-3 -yl} -methanone tetrahydrochloride as a white solid. MS (ESI) m/z 402 (M+H).
In a similar manner to the methods described in EXAMPLES 105 and 112, the following compounds are prepared: EXAMPLE 114 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{5-[(pyridin-4-ylmethyl)-amino]-pyridin-3-yl}- methanone tetrahydrochloride;
EXAMPLE 115 . l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(3-benzylamino-phenyl)-methanone dihydrochloride;
A. [3-(4-{3-[N)N-Bis-(tert-butoxycarbonyl)amino-methyll-phenyl}-piperidine-l-carbonyl)-phenyl]- carbamic acid tgrt-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105B, but using 3-(Boc- amino)benzoic acid in place of 5-tgrt-butoxycarbonylamino-nicotinic acid, there was prepared [3-(4-
{3-[N,N-bis-(tert-butoxycarbonyl)amino-methyl1-phenyl}-piperidine-l-carbonyl)-phenyl]-carbamic acid tgrt-butyl ester as a white solid. 1H ΝMR (300 MHz, CDCI3) δ 7.40-7.50 (m, 2H), 7.22-7.37 (m, 2H), 7.04-7.15 (m, 4H), 4.77-4.90 (br m, IH), 4.76 (s, 2H), 3.81-3.96 (br m, IH), 3.05-3.20 (br m, IH), 2.68-2.90 (m, 2H), 1.52 (s, 9H), 1.45 (s, 18H), 1.35-1.85 (m partially obscured, 4H) ); MS (CI) m/z 610 (M+H).
B. Benzyl-[3-(4-{3-[N,N-Bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)- phenyl]-carbamic acid tgrt-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using benzyl bromide in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-(tert- butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-carbamic acid tgrt-butyl ester, there was prepared benzyl-[3-(4-{3-[N,N-Bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine- l-carbonyl)-phenyl]-carbamic acid tert-butyl ester as a white solid. 1H MR (300 MHz, CDCI3) δ
7.03-7.34 (m, 13H), 4.84 (br s, 2H), 4.78-4.90 (m partially obscured, IH), 4.77 (s, 2H), 3.69-3.85 (br m, IH), 2.90-3.10 (br m, IH), 2.65-2.88 (m, 2H), 1.45 (s, 18H), 1.41 (s, 9H), 1.35-1.95 (m partially obscured, 4H) ); MS (CI) m/z 700 (M+H).
C . 1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 -(3 -benzylamino-phenyl)-methanone dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using prepared benzyl-[3-(4-{3-[N,N-Bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)- phenylj-carbamic acid tgrt-butyl ester, there was prepared l-[4-(3-aminomethyl-phenyl)-piperidin-l- yl]-l-(3-benzylamino-phenyl)-methanone dihydrochloride as a white solid. MS (ESI) m/z 400 (M+H).
EXAMPLE 116 1 - {4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 - { 3 - [(naphthalen-2-ylmethyl)-amino]-phenyl } - methanone dihydrochloride;
A. [3-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]- naρhthalen-2-ylmethyl-carbamic acid tgrt-butyl ester By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 2-
(bromomethyl)naphthalene in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-
(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine- 1 -carbonyl)-phenyl]-carbamic acid tgrt-butyl ester, there was prepared [3-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l- carbonyl)-phenyl]-naphthalen-2-ylmethyl-carbamic acid tgrt-butyl ester as a white solid. MS (ESI) m/z 650 (M+H).
B. l-{4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[(naphthalen-2-ylmethyl)-amino]-phenyl}- methanone dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using [3-(4-{3- [N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-naphthalen-2- ylmethyl-carbamic acid tgrt-butyl ester, there was prepared 1 - { 4-(3-aminomethyl-phenyl)-piperidin- 1 - yl]-l-{3-[(naphthalen-2-ylmethyl)-amino]-phenyl}-methanone dihydrochloride as a white solid. MS (ESI) m/z 450 (M+H).
EXAMPLE 117 3 - [(3 - { 1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]-methanoyl } -phenylamino)-methy l]-benzonifrile dihydrochloride;
A. [3-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-(3- cyano-benzyl)-carbamic acid tgrt-butyl ester By proceeding in a similar manner to the method described in EXAMPLE 105C, but using α-bromo- /w-tolunitrile in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-(tert- butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-carbamic acid tgrt-butyl ester, there was prepared [3-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l- carbonyl)-phenyl]-(3-cyano-benzyl)-carbamic acid tert-butyl ester as a white solid. MS (CI) m/z 725 (M+H).
B . 3 - [(3 - { 1 - [4-(3 - Ammomethyl-phenyl)-piperidm- 1 -yl] -methanoyl} -phenylamino)-methyl]- benzonitrile dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but [3-(4-{3-[N,N- bis-(tgrt-butoxycarbonyl)amino-methyl]-ρhenyl}-piperidine-l-carbonyl)-phenyl]-(3-cyano-benzyl)- carbamic acid tgrt-butyl ester, there was prepared 3-[(3-{ l-[4-(3-aminomethyl-phenyl)-piperidin-l-yl]- methanoyl} -phenylamino)-methyl] -benzonitrile dihydrochloride as a white solid. MS (ESI) m/z 425 (M+H).
EXAMPLE 118 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(4-bromo-benzylamino)-phenyl]-methanone dihydrochloride;
A. (4-Bromo-benzyl)-[3-(4-{3-[NJN-bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l- carbonyl)-phenyl]-carbamic acid tert-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 4- bromobenzyl bromide in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-(tert- butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-carbamic acid tgrt-butyl ester, there was prepared (4-bromo-benzyl)-[3-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}- piperidine-l-carbonyl)-phenyl]-carbamic acid tgrt-butyl ester as a clear oil. MS (CI) m/z 778 (M+H).
B. l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(4-bromo-benzylamino)-phenyl]-methanone dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using (4-bromo- benzyl)-[3-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)- phenyl]-carbamic acid tgrt-butyl ester, there was prepared l-[4-(3-aminomethyl-phenyl)-piperidin-l- yl]- 1 -[3-(4-bromo-benzylamino)-phenyl1-methanone dihydrochloride as a white solid. MS (ESI) m/z 480 (M+H).
EXAMPLE 119 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[(pyridin-2-ylmethyl)-amino]-phenyl}-methanone trihydrochloride;
A. [3-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]- pyridin-2-ylmethyl-carbamic acid tert-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 2-picolyl chloride hydrochloride in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-(tert- butoxy carbony l)amino-methyl] -phenyl} -piperidine- 1 -carbonyl)-pheny l]-carbamic acid tert-butyl ester, there was prepared [3-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l- carbonyl)-phenyl]-pyridin-2-ylmethyl-carbamic acid tgrt-butyl ester as a white solid. 1H ΝMR (300 MHz, CDCI3): δ 8.53 (d, IH), 7.60-7.70 (m, 2H), 7.29-7.37 (m, 4H), 7.08-7.24 (m, 5H), 4.97 (s, 2H), 4.70-4.90 (m partially obscured, IH), 4.77 (s, 2H), 3.75-3.95 (br m, IH), 2.65-3.20 (br m, 3H), 1.40- 2.00 (m partially obscured, 4H), 1.45 (s, 18H), 1.39 (s, 9H). MS (ESI): m/z 701 (M+H).
B . 1 - {4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 - {3- [(pyridin-2-ylmethyl)-amino]-phenyl } - methanone frihydrochloride By proceeding in a similar manner to the method described in EXAMPLE 105D, but using [3-(4-{3- [N, N-Bis-(tert-butoxycarbony l)amino-methyl] -phenyl} -piperidine- 1 -carbonyl)-phenyl] -pyridin-2-
ylmethyl-carbamic acid tgrt-butyl ester, there was prepared 1 - {4-(3-aminomethyl-phenyl)-piperidin- 1 - yl]-l-{3-[(pyridin-2-ylmethyl)-amino]-phenyl}-methanone frihydrochloride as a light yellow solid. 1H NMR [300 MHz, (CD3)2SO]: δ 8.69 (d, IH), 8.34 (br s, 3H), 8.19 (tr, IH), 7.73 (d, IH), 7.63 (tr, IH), 7.25-7.42 (m, 4H), 7.14 (tr, IH), 6.68 (d, IH), 6.61 (m, 2H), 4.40-4.70 (br m partially obscured, IH), 4.61 (s, 2H), 4.01 (q, 2H), 3.70-3.95 (br m partially obscured, IH), 2.90-3.15 (br m, IH), 2.65-2.90 (br m, 2H), 1.35-1.95 (br m, 4H). MS (ESI): m/z 401 (M+H).
EXAMPLE 120 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[(pyridin-3-ylmethyl)-amino]-phenyl}-methanone frihydrochloride;
A. [3-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]- pyridin-3-ylmethyl-carbamic acid tgrt-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 3-picolyl chloride hydrochloride in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-(tert- butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-carbamic acid tgrt-butyl ester, there was prepared [3 -(4- { 3 - [N, N-bis-(tert-butoxycarbonyl)amino-methyl] -phenyl } -piperidine- 1 - carbonyl)-phenyl]-pyridin-3-ylmethyl-carbamic acid tgrt-butyl ester as a cream oil. 1H ΝMR (300 MHz, CDCI3): δ 8.49 (br s, 2H), 7.57 (d, IH), 7.33 (m, IH), 7.07-7.24 (m, 8H), 4.70-4.95 (m partially obscured, IH), 4.85 (s, 2H), 4.77 (s, 2H), 3.65-3.90 (br m, IH), 2.65-3.15 (br m, 3H), 1.40-2.00 (m partially obscured, 4H), 1.45 (s, 18H), 1.41 (s, 9H). MS (ESI): m/z 701 (M+H).
B. l-{4-(3-Ammomethyl-phenyl)-piperidin-l-yl]-l-{3-[(pyridin-3-ylmethyl)-amipo]-phenyl}- methanone frihydrochloride By proceeding in a similar manner to the method described in EXAMPLE 105D, but using [3-(4-{3- [N)N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-pyridin-3- ylmethyl-carbamic acid tert-butyl ester, there was prepared 1 - {4-(3-aminomethyl-phenyl)-piperidin- 1 - yl]-l-{3-[(pyridin-3-ylmethyl)-amino]-phenyl}-methanone frihydrochloride as a light yellow solid. 1H ΝMR [300 MHz, (CD3)2SO]: δ 8.81 (s, IH), 8.70 (d, IH), 8.34 (m, 4H), 7.86 (tr, IH), 7.25-7.41 (m, 4H), 7.14 (tr, IH), 6.67 (d, IH), 6.59 (m, 2H), 4.40-4.70 (br m partially obscured, IH), 4.50 (s, 2H), 4.01 (q, 2H), 3.70-3.90 (br m partially obscured, IH), 2.90-3.15 (br m, IH), 2.65-2.90 (br m, 2H), 1.35-1.95 (br m, 4H). MS (ESI): m/z 401 (M+H).
EXAMPLE 121 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[(pyridin-4-ylmethyl)-amino]-phenyl}-methanone frihydrochloride.
A. [3-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl1-phenyl}-ρiperidine-l-carbonyl)-phenyl]- pyridin-4-ylmethyl-carbamic acid tgrt-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 4-picolyl chloride hydrochloride in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-(tert- butoxycarbonyl)amino-methyl]-phenyl}-piperidine- 1 -carbonyl)-phenyl]-carbamic acid tgrt-butyl ester, there was prepared [3-(4-{3-[NN-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l- carbonyl)-phenyl]-ρyridin-4-ylmethyl-carbamic acid tert-butyl ester as a cream oil. 1H ΝMR (300 MHz, CDCI3): δ 8.55 (br d, 2H), 7.33 (q, 2H), 7.06-7.26 (m, 8H), 4.70-4.90 (m partially obscured, IH), 4.84 (s, 2H), 4.77 (s, 2H), 3.70-3.90 (br, IH), 268-3.15 (br m, 3H), 1.40-2.00 (m partially obscured, 4H), 1.45 (s, 18H), 1.41 (s, 9H). MS (ESI): m/z 701 (M+H).
B. l-{4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[(pyridin-4-ylmethyl)-amino]-phenyl}- methanone frihydrochloride By proceeding in a similar manner to the method described in EXAMPLE 105D, but using [3-(4-{3- [N,N-Bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-pyridin-4- ylmethyl-carbamic acid tert-butyl ester, there was prepared 1 - {4-(3-aminomethyl-phenyl)-piperidin- 1 - yl]- 1 - {3- [(pyridin-4-ylmethyl)-amino]-pheny 1} -methanone frihydrochloride as a cream solid. 1H ΝMR [300 MHz, (CD3)2SO]: δ 8.76 (br s, 2H), 8.33 (br s, 3H), 7.87 (d, 2H), 7.24-7.41 (m, 4H), 7.13 (tr, IH), 6.65-7.00 (br, IH), 6.56-6.64 (m, 3H), 4.40-4.70 (br m partially obscured, IH), 4.61 (s, 2H), 4.01 (q, 2H), 3.70-3.90 (br m partially obscured, IH), 2.90-3.15 (br m, IH), 2.65-2.90 (br m, 2H), 1.35-1.95 (br m, 4H). MS (ESI): m/z 401 (M+H).
EXAMPLE 122 3-[l-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate
A. 4-oxo-piperidine-l -carboxylic acid (trimethylsilyl) ethyl ester
A solution of 4-piperidone monohydrate. Hydrochloride (13.55g, 88mmol) 2-frimethylsilylethyl-p- nitrophenylcarbonate (25.00g, 88mmol) in acetonitrile (300 ml) was freated with triethylamine (50 ml, 359 mmol) and dimethyl-aminopyridine (10.78g, 88mmol) and heated to reflux for 2 hours. The solution was cooled and concentrated to an oil. The residue was dissolved in dichloromethane (300ml) and washed twice with 1M hydrochloric acid and twice with 1M sodium hydroxide until all of the yellow color was removed from the organics. The organics were then washed with brine, dried over magnesium sulfate and concenfrated under vacuum to give 4-oxo-piperidine-l -carboxylic acid (trimethylsilyl) ethyl ester as colorless oil. (19.35g) 1H ΝMR (CDCI3, 30° MHz): δ 4-24 (2H> 3-78 (4H, t), 2.45 (4H, t), 1.05 (2H, t), 0.05 (9H, s) MS (El) 284(M+CH3CΝ)
B. 4-(3-Cyano-phenyl)-3,6-dihydro-2H-pyridine-l-carboxylic acid 2-trimethylsilanyl-ethyl ester A solution of lithium hexamethyldisilazide (60 mmol) in anhydrous tefrahydrofuran (150 ml), at - 78°C, was treated dropwise with a solution of 4-oxo-piperidine-l -carboxylic acid (trimethylsilyl) ethyl ester (13.30g, 55mmol) in anhydrous tefrahydrofuran (50ml). The addition was over 20 minutes maintaining the internal temperature at -65 to -70°C. This solution was stirred at -78°C for 45 minutes and then freated with a solution of N-phenyltrifluoromethanesulfonimide (19.65g, 55mmol) in anhydrous tefrahydrofuran (75ml). The solution was warmed to 0°C, then stirred at 0°C for 3 hours and then concenfrated under vacuum. The residue was dissolved in dichloromethane and washed with water, dried over magnesium sulfate and concenfrated to give 2-(trimethylsilyl) ethyl 1,2,3,6- tetrahydro-4- (frifluoromethylsulphonyloxy)-pyridine-l -carboxylate as a yellow oil (22. lg). The material is used crude, as column chromatography on silica gel or alumina caused the material to deteriorate. A portion of this material (20.65g, 55mmol) was dissolved in acetonitrile (300 ml) and the solution was freated with 3-cyanoboronic acid (8.90g, 60mmol), 2M sodium carbonate (82.5ml, 165mmol) and lithium chloride (6.98g, 165mmol). The non-homogenous mixture was stirred vigorously and flushed with nifrogen for 5 minutes, then tetrakistriphenylphospine palladium (0) (3.10g, 3mmol). The mixture was heated to reflux (90°C oil bath) for 90 minutes, then cooled and filtered. The red filtrate was concenfrated and the residue was partitioned between dichloromethane (3 lots 100ml) and 2M sodium carbonate (200ml). The combined organic extracts were dried over magnesium sulfate and then concenfrated under vacuum. The resultant oil was subjected to chromatography silica gel eluting with a mixture of ethyl acetate, heptane and dichloromethane (1:5:1, v/v) to yield 4-(3-cyano-phenyl)-3,6-dihydro-2H-pyridine-l-carboxylic acid 2-trimethylsilanyl-ethyl ester as a yellow oil (10.46g). 1HNMR (CDC13, 300 MHz): δ 7.40-7.65 (m, 4H), 6.10 (m, IH), 4.23
(t, 2H), 4.15 (d, 2H), 3.70 (t, 2H), 2.45 (m, 2H), 1.12 (t, 2H), 0.05 (s, 9H).
C. 4-(3-Aminomethyl-phenyl)-piperidine-l-carboxylic acid 2-trimethylsilanyl-ethyl ester hydrochloride 4-(3-Cyanophenyl)-3,6-dihydro-2H-pyridine-l-carboxylic acid 2-trimethylsilanyl-ethyl ester (10.40g, 32mmol) was dissolved in ethanol (250ml), concentrated hydrochloric acid (3ml, 35mmol) and 10% palladium on carbon (50% wet, 5.0g) was added. The mixture was hydrogenated at 50 psi for 4 hours then filtered through celite and concenfrated. The oily solid obtained was triturated with ether/pentane and 4-(3-aminomethyl-phenyl)-piperidine-l -carboxylic acid 2-frimethylsilanyl-ethyl ester hydrochloride was obtained as a white solid (7.10g). 1H NMR [(CD3)2SO, 300 MHz]: δ 8.38 (br s,
2H), 7.20-7.40 (m, 4H), 4.10 (t, 4H), 3.98 (s, 2H), 2.63-3.00 (m, 3H), 1.75 (m, 2H), 1.50 (m, 2H), 0.94 (t, 2H), 0.02 (s, 9H). LC-MS (ES) 335 (M +H), 93% TIC.
D. (3-Piperidin-4-yl-benzyl) carbamate Wang resin p-Nitrophenyl carbonate Wang resin (l l.OOg, 15mmol) and anhydrous dimethylformamide (100ml) were placed in a peptide synthesis vessel and the resin was allowed to swell for 15 minutes. This was then treated with 4-(3-aminomefhyl-phenyl)-piperidine-l-carboxylic acid 2-trimethylsilanyl-ethyl ester hydrochloride (7.50g, 2 lmmol) in 50ml dimethylformamide, dimethylaminopyridine (0.72, 6mmol) and diisopropylethyl-amine. The peptide vessel was shaken at room temperature for 24 hours, then washed thoroughly with dimethylformamide (x5), methanol (x2), dimethylformamide (x2), methanol (x2), dichloromethane (x3), methanol (x2), dichloromethane (x2), methanol (x3), and dried. The resin was then treated with tefrahydrofuran to swell the resin and then allowed to drain. Then anhydrous tefrahydrofuran (100ml) and tefrabutylammonium fluoride (75ml, 1M in tefrahydrofuran) were added and the resin shaken for 18 hours. The resin was drained and washed with tefrahydrofuran (x5), methanol (x3), dichloromethane (x3), methanol (x3), dichloromethane (x3), methanol (x3) and dried to give (3-piperidin-4-yl-benzyl) carbamate Wang resin (12.30g).
E. 3-[l-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate
(3-Piperidin-4-yl-benzyl) carbamate Wang resin (60mg, 0.075mmol) suspended in dimethylformamide (3ml) and 5-phenylethynyl-furan 2 carboxylic acid (80mg, 0.38mmol), diisopropylcarbodiimide (48mg, 0.38mmol) and 1-hydroxybenzotriazole (50mg, 0.38mmol) were added. The mixture was shaken at room temperature overnight and washed with dimethylformamide (x5), methanol (x5), dichloromethane then methanol (repeat 5 times). The resin was treated with trifluoroacetic acid and dichloromethane (1 :1 v/v, 4ml) for 45 minutes and filtered. The filtrate was concentrated to give 3-[l- (5-phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate as a pale yellow oil (30mg). LC-MS (ES) 385 (M÷+H) 100% TIC.
In a similar manner to the methods described in EXAMPLE 112, the following compounds set forth in Table 5 were prepared as the trifluoroacetate salts:
TABLE 5
By proceeding in a similar manner to the method described in EXAMPLE 36, but using the appropriate carboxylic acid derived TFP resin in place of the 3,4-dichlorobenzoic acid TFP resin, the following compounds set forth in Table 6 were prepared as the frifluoroacetate salts:
TABLE 6
EXAMPLE 344 [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]- [ 1 , 1 ' ;4 ' , 1 "]terphenyl-3 -yl-methanone hydrochloride
A. {4-[3-N,N-Di-(tert-butoxycarbonyl)aminomethyl)-phenyl]-piperidin-l-yl}-(3-bromo-phenyl)- methanone
By proceeding in a similar manner to the method described in EXAMPLE 105B, but using 3- bromobenzoic acid in place of 5-tert-butoxycarbonylamino-nicotinic acid, there was prepared {4-[3-
N,N-di-(tert-butoxycarbonyl)aminomethyl)-phenyl]-piperidin-l-yl}-(3-bromo-phenyl)-methanone as a colorless oil. MS (CI) m/z 573 (M+H).
B . { 4- [3 -N, N-Di-(tgrt-butoxycarbonyl)aminomethyl)-phenyl] -piperidin- 1 -yl) -[ 1 , 1' ;4' , 1 "]terphenyl-3 - yl-methanone
By proceeding in a similar manner to the method described in EXAMPLE 17D, but using 4- biphenylboronic acid in place of l-(5-phenylethyl-pyridine-3-carbonyl)-4-(pinacolatoboronyl)-l,2,3,6- tetrahydro-pyridine and {4-[3-N,N-di-(tert-butoxycarbonyl)aminomethyl)-phenyl]-piperidin-l-yl}-(3- bromo-phenyl)-mefhanone in place of Ν-(tert-butoxycarbonyl)-3-bromo-4-fluoro-benzylamine, there was prepared {4-[3-N,N-di-(tgrt-butoxycarbonyl)aminomethyl)-phenyI|-piperidin-l-yl}- [ 1 , 1 ' ;4 ' , 1 "1terphenyl-3 -yl-methanone as a yellow oil- MS (CI) m/z 647 (M+H).
C . [4-(3 -Aminomethy l-phenyl)-piperidin- 1 -yl]- [ 1 , 1' ;4 ' , 1 "]terphenyl-3 -yl-methanone hydrochloride By proceeding in a similar manner to the method described in EXAMPLE 105D, but using {4-[3-N,N- di-(tert-butoxycarbonyl)aminomethyl)-phenyl]-piperidin- 1 -yl } - [ 1 , 1 ' ;4 ' , 1 "]terphenyl-3 -yl-methanone,
there was prepared [4-(3-aminomethyl-phenyl)-piperidin-l-yl]-[l, ;4',l"]terphenyl-3-yl-methanone hydrochloride as a cream-colored solid. MS (CI) m/z 447 (M+H).
EXAMPLE 345 3 - [ 1 -(6-Chloroquinoline-3 -carbony l)-piperidin-4-yl] -benzylamine di-hydrochloride
A. Ethyl 6-chloroquinoline-3-carboxylate
Ethyl 4,6-Dichloroquinoline-3-carboxylate [prepared as described in C. C. Price and R. M. Roberts J. Amer. Chem. Soc. 68, 1204 (1964); C. J. Ohnmacht, Jr. J. Med. Chem. 14, 17 (1971) ] (2.0 g, 7.4 mmol) was added portionwise to a solution of sodium borohydride (1.2 g, 3 lmmol) in 15 ml of methoxyethanol at about 0°C. The reaction mixture was warmed to room temperature over 3 hours then diluted with ethyl acetate. After standard aqueous workup (dil HCl; saturated NaHC03) the organic layer was dried (NaS04) and concentrated to a residue. The residue was exposed to air oxidation (about 14 days) and exfracted repeatedly with boiling heptane. The heptane was removed in vacuo to yield ethyl 6-chloroquinoline-3-carboxylate as a beige solid. 1H NMR [(CDCI3), 300 MHz]: δ 9.38 (bs, IH), 8.68 (s, IH), 8.05 (d, IH), 7.83 (s, 2H), 7.69 (d, IH), 4.40 (q, 2H), 1.39 (t, 3 H).
MS(EI): 236(M++ H).
B. 6-Chloroquinoline-3-carboxylic acid Ethyl 6-chloroquinoline-3 -carboxylate (0.19 g, 0.81 mmol) was saponified by freatment with dioxane (10 ml) and 10% aqueous sodium hydroxide (10 ml) at reflux for 3 hours. The dioxane was removed under vacuo; the aqueous solution remaining was acidified with HCl. The precipitated product was collected and washed with water to isolate 6-chloroquinoline-3 -carboxylic acid as an off-white solid
(0.14 g, 0.67 mmol). 1H NMR [(CD3OD), 300 MHz]: δ 9.35 (s, IH), 8.95 (s, IH), 8.17 (s, IH), 8.1 (d, 2H), 7.87 (d, IH).
C. N,N-bis-(tgrt-butoxycarbonyl)-3-[l-(6-chloroquinoline-3-carbonyl)-piperidin-4-yl] benzylamine By proceeding in a similar manner to the method described in EXAMPLE IC, but using 6- chloroquinoline-3-carboxylic acid in place of 5-phenylethynyl-pyridine-3-carboxylic acid, crude title compound was prepared. The crude product was purified by flash chromatography (25-50%> ethyl acetate/Heptane) to yield the title compound as a white amorphous solid. 1H ΝMR[(CDCl3), 300
MHz]: δ 8.98 (bs, IH), 8.20 (s, IH), 8.05 (d, IH), 7.88 (s, IH), 7.72 (d, IH), 7.08-7.31 (m, 4H), 4.93 (br m, IH), 4.78 (s, 2H), 3.90 (br m, IH), 3.27 (br m, IH), 3.95 (br m, IH), 2.82 (m, IH), 1.6-2.1 (br m, 4H), 1.47 (s, 18H).
D. 3-[l-(6-Chloroquinoline-3-carbonyl)-piperidin-4-yl]-benzylamine
N)N-bis-(tert-butoxycarbonyl)-3-[l-(6-Chloroquinoline-3-carbonyl)-piperidin-4-yl] benzylamine (0.055 g, 0.095 mmol) was freated with a solution of 15% trifluoroacetic acid in methylene chloride (5 ml) at 0°C. The reaction was warmed to ambient temperature over 2.5 hr and the solvents were removed in vacuo. The residue was triturated with ether to yield the title compound (0.033 g,
0.087mmol) as an amorphous solid. 1H ΝMR[(CD3)2SO, 500 MHz]: δ 8.95 (s, IH), 8.44 (s, IH), 8.20
(s, IH), 8.07 (d, IH), 7.84 (d, 2H), 7.23-7.40 (m, 4H), 4.67 (m, IH), 7.34 (m, 3H), 4.75 (br m, IH), 4.05 (m, 2H), 3.75 (br m, IH), 3.30 (br , IH), 2.80-3.00 (br m, 2H), 1.90 (br m, IH), 1.6-1.8 (br m,
3H). MS(EI): 380(M++H).
EXAMPLE 346 l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(3-benzylamino-phenyl)-methanone dihydrochloride
A. r3-(4-{3-[N,N-Bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]- carbamic acid tgrt-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105B, but using 3-(Boc- amino)benzoic acid in place of 5-tgrt-butoxycarbonylamino-nicotinic acid, there was prepared [3-(4- {3-[N,N-bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-carbamic acid tgrt-butyl ester as a white solid. 1H ΝMR (300 MHz, CDCI3): δ 7.40-7.50 (m, 2H), 7.22-7.37 (m, 2H), 7.04-7.15 (m, 4H), 4.75-4.90 (br m, IH), 4.76 (s, 2H), 3.80-3.96 (br m, IH), 3.00-3.25 (br m, IH), 2.68-2.95 (m, 2H), 1.40-2.05 (m partially obscured, 4H), 1.52 (s, 9H), 1.45 (s, 18H). MS (CI): m/z 610 (M+H).
B. Benzyl-[3-(4-{3-[N,N-Bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)- phenyfj-carbamic acid tgrt-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using benzyl bromide in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-(tert- butoxycarbonyl)amino-methyl]-phenyl} -piperidine- 1 -carbonyl)-phenyl]-carbamic acid tgrt-butyl ester, there was prepared benzyl- [3 -(4- { 3- [N,N-Bis-(tert-butoxycarbonyl)amino-methyl] -phenyl } -piperidine- l-carbonyl)-phenyl]-carbamic acid tgrt-butyl ester as a white solid. 1H ΝMR (300 MHz, CDCI3): δ 7.03-7.34 (m, 13H), 4.75-4.90 (m partially obscured, IH), 4.84 (br s, 2H), 4.77 (s, 2H), 3.69-3.85 (br m, IH), 2.90-3.10 (br m, IH), 2.65-2.90 (m, 2H), 1.40-2.00 (m partially obscured, 4H), 1.45 (s, 18H), 1.41 (s, 9H). MS (CI): m/z 700 (M+H).
C . 1 - [4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl] - 1 -(3 -benzylamino-phenyl)-methanone dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using prepared benzyl-[3-(4-{3-[N,N-Bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)- phenyl]-carbamic acid tgrt-butyl ester, there was prepared l-[4-(3-aminomethyl-phenyl)-piperidin-l- yl]- 1 -(3-benzylamino-phenyl)-methanone dihydrochloride as a white solid. 1H ΝMR [300 MHz, (CD3)2SO]: δ 8.26 (br s, 3H), 7.20-7.55 (m, 9H), 7.11 (tr, IH), 6.66 (d, IH), 6.57 (m, 2H), 4.40-4.70 (br m, IH), 4.30 (s, 2H), 4.15 (m, IH), 4.01 (q, 2H), 2.90-3.15 (br m, IH), 2.65-2.90 (br m, 2H), 1.35- 1.95 (br m, 4H). MS (ESI): m/z 400 (M+H).
EXAMPLE 347 l-{4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[(naphthalen-2-ylmethyl)-amino]-phenyl}- methanone dihydrochloride
A. [3-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]- naphthalen-2-ylmethyl-carbamic acid tgrt-butyl ester By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 2-
(bromomethyl)naphthalene in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis- (tert-butoxycarbonyl)amino-methyl]-phenyl} -piperidine- 1 -carbonyl)-phenyl]-carbamic acid tgrt-butyl ester, there was prepared [3-(4- {3- [N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl} -piperidine- 1 - carbonyl)-phenyl]-naphthalen-2-ylmethyl-carbamic acid tert-butyl ester as a white solid. 1H ΝMR (300 MHz, CDCI3): δ 7.61-7.80 (m, 4H), 7.38-7.45 (m, 3H), 6.99-7.34 (m, 8H), 5.00 (br s, 2H), 4.70- 4.90 (m partially obscured, IH), 4.76 (s, 2H), 3.55-3.75 (br m, IH), 2.70-2.95 (br m, 2H), 2.55-2.70 (m, IH), 1.40-1.95 (m partially obscured, 4H), 1.45 (s, 18H), 1.42 (s, 9H). MS (ESI): m/z 650 (M+H).
B. l-{4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[(naphthalen-2-ylmethyl)-amino]-phenyl}- methanone dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using [3-(4-{3- [N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-naphthalen-2- ylmethyl-carbamic acid tert-butyl ester, there was prepared 1 - { 4-(3 -aminomethy l-phenyl)-piper idin- 1 - yl] - 1 - {3 - [(naphthalen-2-ylmethyl)-amino]-phenyl } -methanone dihydrochloride as a white solid. 1H ΝMR [300 MHz, (CD3)2SO]: δ 8.22 (br s, 3H), 7.81-7.88 (m, 4H), 7.11-7.54 (m, 8H), 6.69 (d, IH), 6.59 (s, IH), 6.54 (d, IH), 4.45-4.65 (m partially obscured, IH), 4.47 (s, 2H), 4.01 (q, 2H), 3.60-3.80 (m partially obscured, IH), 2.85-3.05 (br m, IH), 2.65-2.85 (br m, 2H), 1.30-1.95 (br m, 4H). MS (ESI): m/z 450 (M+H).
EXAMPLE 348 3 - [(3 - { 1 - |"4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]-methanoyl } -pheny lamino)-methyl]-benzonifrile dihydrochloride
A. [3-(4-{3-[N,N-Bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-(3- cyano-benzyl)-carbamic acid tert-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using α-bromo- ffz-tolunitrile in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-(tert- butoxycarbonyl)amino-methyl]-phenyl}-piperidine- l-carbonyl)-phenyl]-carbamic acid tgrt-butyl ester, there was prepared [3-(4-{3-[N,N-bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l- carbonyl)-phenyl]-(3-cyano-benzyl)-carbamic acid tgrt-butyl ester as a white solid. 1H ΝMR (300 MHz, CDCI3): δ 7.06-7.55 (m, 12H), 4.70-4.90 (m partially obscured, IH), 4.86 (s, 2H), 4.77 (s, 2H),
3.70-3.90 (br m, IH), 2.95-3.20 (br m, IH), 2.65-2.95 (br m, 2H), 1.40-2.00 (m partially obscured,
4H), 1.45 (s, 18H), 1.41 (s, 9H). MS (CI): m/z 725 (M+H).
B . 3 - [(3 - { 1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]-methanoyl} -pheny lamino)-methyl]- benzonitrile dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but [3-(4-{3-[NN- bis-(tgrt-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)-phenyl]-(3-cyano-benzyl)- carbamic acid tert-butyl ester, there was prepared 3-[(3-{ l-[4-(3-aminomethyl-phenyl)-piperidin-l-yl]- methanoyl}-phenylamino)-methyl]-benzonifrile dihydrochloride as a white solid. 1HΝMR [300 MHz, (CD3)2SO]: δ 8.18 (br s, 3H), 7.75 (s, IH), 7.65 (m, 2H), 7.49 (tr, IH), 7.21-7.35 (m, 4H), 7.08 (tr, IH), 6.61 (d, IH), 6.52 (m, 2H), 4.40-4.70 (br m, IH), 4.33 (s, 2H), 3.98 (q, 2H), 3.50-3.70 (m partially obscured, IH), 2.85-3.10 (br m, IH), 2.65-2.85 (br m, 2H), 1.30-1.90 (br m, 4H). MS (ESI): m/z 425 (M+H).
EXAMPLE 349
1 - [4-(3 -Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 - [3 -(4-bromo-benzylamino)-phenyl] -methanone dihydrochloride
A. (4-Bromo-benzyl)- [3-(4- {3 - [N,N-bis-(tert-butoxycarbonyl)amino-methyl] -phenyl } -piperidine- 1 - carbonyl)-phenyl]-carbamic acid tert-butyl ester
By proceeding in a similar manner to the method described in EXAMPLE 105C, but using 4- bromobenzyl bromide in place of 4-bromo-2-fluorobenzyl bromide and using [3-(4-{3-[N,N-bis-(tert- butoxycarbonyl)amino-methyl]-phenyl} -piperidine- l-carbonyl)-ρhenyl]-carbamic acid tert-butyl ester, there was prepared (4-bromo-benzyl)-[3-(4-{3-[N,N-bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-
piperidine- l-carbonyl)-phenyl]-carbamic acid tert-butyl ester as a clear oil. 1H NMR (300 MHz, CDCI3): δ 7.41 (d, 2H), 7.06-7.38 (m, 8H), 7.10 (d, 2H), 4.70-4.90 (br m, partially obscured, IH), 4.78 (s, 2H), 4.77 (s, 2H), 4.25-4.45 (br m, IH), 3.70-3.85 (br , IH), 2.90-3.15 (br m, IH), 2.65-2.90 (br m, 2H), 1.40-2.00 (m partially obscured, 4H), 1.45 (s, 18H), 1.41 (s, 9H). MS (CI): m/z 778 (M+H).
B . 1 - [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 - [3 -(4-bromo-benzylamino)-pheny l]-methanone dihydrochloride
By proceeding in a similar manner to the method described in EXAMPLE 105D, but using (4-bromo- benzyl)-[3-(4-{3-[N,N-bis-(tert-butoxycarbonyl)amino-methyl]-phenyl}-piperidine-l-carbonyl)- phenyl]-carbamic acid tert-butyl ester, there was prepared 1 - [4-(3 -ammomethyl-phenyl)-piperidin- 1 - yl]- 1 -[3-(4-bromo-benzylamino)-phenyl]-methanone dihydrochloride as a white solid. ^H ΝMR [300 MHz, (CD3)2SO]: δ 8.28 (br s, 3H), 7.25-7.66 (m, 8H), 7.11 (tr, IH), 6.64 (d, IH), 6.55 (m, 2H), 4.45- 4.70 (br m, IH), 4.28 (s, 2H), 4.15 (m, IH), 4.01 (q, 2H), 2.90-3.15 (br m, IH), 2.65-2.90 (br m, 2H), 1.30-1.95 (br m, 4H). MS (ESI): m/z 480 (M+H).
EXAMPLE 350 [4-(3 -Aminomethy l-phenyl)-piperidin- 1 -yl]- [ 1 , 1 ' ;4 ' , 1 "]terphenyl-3 -yl-methanone hydrochloride
A. {4-[3-N,N-Di-(tert-butoxycarbonyl)aminomethyl)-phenyl]-piperidin-l-yl}-(3-bromo-phenyl)- methanone
By proceeding in a similar manner to the method described in EXAMPLE 105B, but using 3- bromobenzoic acid in place of 5-tert-butoxycarbonylamino-nicotinic acid, there was prepared {4-[3- N,N-di-(tert-butoxycarbonyl)aminomethyl)-phenyl]-piperidin- 1 -yl} -(3-bromo-phenyl)-m ethanone as a colorless oil. 1H ΝMR (300 MHz, CDCI3): δ 7.55 (m, 2H), 7.24-7.37 (m, 2H), 7.08-7.16 (m, 4H),
4.75-4.92 (br m, IH), 4.77 (s, 2H), 3.75-3.90 (br m, IH), 3.00-3.25 (br m, IH), 2.70-3.00 (br m, 2H), 1.50-2.00 (m partially obscured, 4H) 1.45 (s, 18H). MS (CI): m/z 573 (M+H).
B . {4- [3 -N,N-Di-(tgrt-butoxycarbonyl)aminomethyl)-phenyl]-piperidin- 1 -yl} - [ 1 , 1' ;4 ' , 1 "] terphenyl-3 - yl-methanone
By proceeding in a similar manner to the method described in EXAMPLE 17D, but using 4- biphenylboronic acid in place of l-(5-phenylethyl-pyridine-3-carbonyl)-4-(pinacolatoboronyl)-l,2,3,6- tetrahydro-pyridine and {4-[3-N,N-di-(tert-butoxycarbonyl)aminomethyl)-phenyl]-piperidin- l-yl}-(3- bromo-phenyl)-methanone in place of Ν-(tgrt-butoxycarbonyl)-3-bromo-4-fluoro-benzylamine, there was prepared {4-[3-N,N-di-(tgrt-butoxycarbonyl)aminomethyl)-phenyl]-piperidin-l-yl}-
[1,1' ;4',rηte henyl-3-yl-meihanone as a yellow oil. 1H ΝMR (300 MHz, CDCI3): δ 7.61-7.71 (m,
8H), 7.34-7.53 (m, 6H), 7.14 (m, 3H), 4.80-5.00 (m, IH), 4.77 (s, 2H), 3.85-4.05 (br m, IH), 3.00-3.25 (br m, IH), 2.70-3.00 (br m, 2H), 1.50-2.05 (m, 4H), 1.44 (s, 18H). MS (CI): m/z 647 (M+H).
C . [4-(3 - Aminomethyl-phenyl)-piperidin- 1 -yl]- [ 1 , 1 ' ;4 ' , 1 "]terphenyl-3 -yl-methanone hydrochloride By proceeding in a similar manner to the method described in EXAMPLE 105D, but using {4-[3-N,N- di-(tgrt-butoxycarbonyl)aminomethyl)-phenyl]-piperidin- 1 -y 1 } - [ 1 , 1 ' ;4 ' , 1 "]terphenyl-3 -yl-methanone, there was prepared [4-(3 -aminomethyl-phenyl)-piperidin- l-yl]-[l,l';4',l "]terphenyl-3 -yl-methanone hydrochloride as a cream-colored solid. ^ΝMR [300 MHz, (CD3)2SO]: δ 8.24 (br s, 3H), 7.73-7.84 (m, 8H), 7.29-7.61 (m, 9H), 4.55-4.80 (br m, IH), 4.01 (q, 2H), 3.65-3.85 (br m, IH), 2.75-3.05 (br m, 2H), 1.50-2.00 (br m, 4H). MS (CI): m/z 447 (M+H).
EXAMPLE 351 4-(3-Aminomethyl-phenyl)-piperidine-l -carboxylic acid (3 ,4-dichloro-phenyl)-amide frifluoroacetate 3,4-Dichlorophenyl isocyanate (60mg, 0.319mmol) was added to a stirring solution of 4-[3-(Ν,Ν-di- tert-butoxycarbonylaminomethyl)phenyl]piperidine (lOOmg, 0.256mmol) in DCM (5mL) at room temperature. After 16 hours the reaction was quenched with water (5mL) and separated, and exfracted the aqueous phase with DCM (5mL). The combined organics were dried over anhydrous sodium sulfate, and concenfrated to dryness. The residue was purified by dry flash column chromatography on silica with 50:50, dichloromethane:ethyl acetate. 4-[3-(N,N-di-tert- butoxycarbonylaminomethyl)phenyl]-piperidine-l -carboxylic acid (3,4-dichloro-phenyl)-amide was isolated as a colorless oil, which was dissolved in dichloromethane (25mL), cooled at 0°C, and treated with trifluoroacetic acid (3mL). The reaction mixture was stirred at room temperature under nitrogen for 2 hours, and concentrated to dryness in vacuo. The residue was dissolved in 20% acetonifrile/water [containing 0.1% trifluoroacetic acid] (9mL) and purified by preparative reverse-phase HPLC (C-18, 10 micron reverse-phase column), eluting with 10% to 100% acetonitrile / water (containing 0.1% trifluoroacetic acid). The product fractions were combined and the acetonitrile removed in vacuo. The aqueous residue was frozen and lyophilized to give the title compound as an amorphous white solid
(68mg, 53%). NMR [(CD3)2SO]: δ 8.82 (s, H, NH); 7.88 (s, H); 7.84 (br s, 3H, NH3 +); 7.46 (s, H); 7.37-7.22 (m, 5H); 4.24 (br d, 2H); 3.99 (s, 2H); 2.89 (br t, 2H); 2.83-2.70 (m, H); 1.82-1.71 (m, 2H);
1.60-1.44 (m, 2H). MS(Ion spray): 378 and 380 (M++1).
EXAMPLE 352 4-(3-Aminomethyl-phenyl)-piperidine- 1 -carboxylic acid 2,3 -dimethoxybenzylamide-frifluoroacetate. (3-Piperidin-4-yl-benzyl) carbamate Wang resin (EXAMPLE 122D) (60μmol) was suspended in dichloromethane (2mL) and added diisopropylethylamine (0.66 mmol) followed by phosgene (0.6
mmol of a 20%> solution in toluene). The reaction mixture was shaken for 5 minutes before washing the resin with toluene (x8). The resin was suspended in DMF (2mL) and to this was added a solution of 2,3-dimethoxybenzylamine (O.δmmol) in DMF (1.5mL) and the reaction mixture shaken for 5 minutes before washing the resin with DMF (x3). The resin was then suspended in dichloromethane (2mL) and freated with TFA (0.5mL). The reaction mixture was shaken for 5 minutes, before the resin was filtered off and the filfrate concenfrated to dryness to give the title compound (48μmol) as a pale yellow solid. MS (El) 383 (M+).
By proceeding in a similar manner to the method described in EXAMPLES 351 AND 352, the following compounds set forth in Table 7 were prepared, as the trifluoroacetate salts:
TABLE 7
IN VITRO TEST PROCEDURE
Since all the actions of tryptase, as described in the background section, are dependent on its catalytic activity, then compounds that inhibit its catalytic activity will potentially inhibit the actions of tryptase. Inhibition of this catalytic activity may be measured by the in vitro enzyme assay and the cellular assay.
Tryptase inhibition activity is confirmed using either isolated human lung tryptase or recombinant human β tryptase expressed in yeast cells. Essentially equivalent results are obtained using isolated native enzyme or the expressed enzyme. The assay procedure employs a 96 well microplate (Costar 3590) using L-pyroglutamy]-L-prolyl-L-arginine-/rørø-nifroanilide (S2366: Quadratech) as substrate (essentially as described by McEuen et. al. Biochem Pharm, 1996, 52, pages 331-340). Assays are performed at room temperature using 0.5mM substrate (2 x Km) and the microplate is read on a microplate reader (Beckman Biomek Plate reader) at 405nm wavelength. The inhibition constant (Ki) for particular compounds of the present invention is set forth in Table 8. It was determined using the procedure set forth herein.
Materials and Methods for Tryptase primary screen (Chromogenic assay)
Assay buffer 50 mM Tris (pH 8.2), 100 mM NaCl, 0.05% Tween 20, 50 ug/ml heparin. Substrate
S2366 (Stock solutions of 2.5 mM).
Enzyme Purified recombinant beta Tryptase Stocks of 310 ug/ml. Protocol (Single point determination) • Add 60 ul of diluted substrate (final concentration of 500 uM in assay buffer) to each well
• Add compound in duplicates , final concentration of 20 uM, volume 20 ul
• Add enzyme at a final concentration of 50 ng/ml in a volume of 20 ul
• Total volume for each well is 100 ul
• Agitate briefly to mix and incubate at room temp in the dark for 30 minutes • Read absorbencies at 405 nM
Each plate has the following controls -
Totals : 60 ul of substrate, 20 ul of buffer (with 0.2% final concentration of DMSO), 20 ul of enzyme
Non-specific: 60 ul of substrate, 40 ul of buffer (with 0.2% DMSO)
Totals: 60 ul of substrate, 20 ul of buffer (No DMSO), 20 ul of enzyme
Non-specific: 60 ul of substrate, 40 ul of buffer (No DMSO)
Protocol (IC50 and Ki determination)
The protocol is essentially the same as above except that the compound is added in duplicates at the following final concentrations: 0.01, 0.03, 0.1, 0.3, 1, 3, 10 uM (All dilutions carried out manually). For every assay, whether single point or IC50 determination, a standard compound is used to derive IC5o for comparison. From the IC 50 value, the Ki can be calculated using the following formula: Ki = IC50/(1 + [Substrate]/Km).
Using this procedure, Ki values with respect to tryptase for particular compounds of the present invention are set forth in Table 8 below:
TABLE S
This data clearly shows that compounds of the present invention exhibit tryptase inhibition activity. Consequently, compounds of the present invention readily have applications in pharmaceutical compositions for freating a wide variety of tryptase related conditions, and naturally, in methods for treating such conditions in patients.
The present invention is not to be limited in scope by the specific embodiments describe herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.
Claims (1)
- WHAT IS CLAIMED IS:1. A compound of formula (I):such that Ar is an aryl group or a heteroa ryl group, and the group is beta to theT ^ group on the aryl, wherein:- is a single or a double bond; Ri and R2 are each independently hydrogen or lower alkyl;R3 is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R", -OR", -S(0)mR" or-C(=0)-R6; R4 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=0)-NYlγ2 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy,-S(0)m-alkyl or - ^Y2;R5 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, frifluoromethyl, -C(=0)-NY1 Y2, - ^Y2, -Z1-C2_6alkylene-R7 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido, -C(=0)-NYlY2, -SO2-Nγl Y2, -S(0)m-alkyl or -NY^Y2;R6 is aryl or heteroaryl;R7 is hydroxy, alkoxy, ureido, -C(=0)-Nγ!γ2, -S02-NY1Y2, -S(0)m-alkyl or -Nγ!γ2; R^ is hydrogen or lower alkyl; γl and Y2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; or the group -NY* Y2 may form a cyclic amine;Z^s O, S(0)m or NR8; m is zero or an integer 1 to 2; n is zero or an integer 1 to 4; an N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, and a hydrate of said compound. ,2. The compound of Claim 1, wherein R1 and/or R2 is hydrogen, and R3 is an aryl or an heteroaryl.3. The compound of Claim 2, wherein said R3 aryl comprises a phenyl or a naphthyl.4. The compound of Claim 2, wherein said R3 aryl is substituted with at least one substituent.5. The compound of Claim 4, wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by heteroaryl, an arylalkynyl, a heteroarylalkynyl, an aryl, a heteroaryl, an arylalkenyl and an arylalkyloxy.6. The compound of Claim 5, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.7. The compound of Claim 2, wherein said heteroaryl comprises a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.8. The compound of Claim 7, wherein said heteroaryl is substituted with at least one substituent.9. The compound of Claim 8, wherein said substituent comprises an alkyl, an alkyl substituted by an aryl, an alkyl substituted by an aryloxy, an alkyl substituted by an aroyl, an alkyl substituted heteroaryl, an arylalkynyl, a heteroarylalkynyl, a heteroaryl, an arylalkenyl or an arylalkyoxy.10. The compound of Claim 9, wherein said aryl of said substituent is further substituted by at least one aryl substituent.11. The compound of Claim 1, wherein R comprises hydrogen or a cyano group. The compound of Claim 1, wherein R5 comprises a hydrogen, a lower alkyl, or a halo.The compound of Claim 1 , wherein is a single bond.The compound of Claim 1, wherein n=2.The compound of Claim 1, wherein: Ar comprises a phenyl group; R1 =R2 = hydrogen;R3 comprises an aryl, a naphthyl, or a heteroaryl;R4 comprises hydrogen or a cyano group;R5 comprises hydrogen, a lower alkyl, or a halo; represents a single bond; and n=2.The compound of Claim 15, wherein said aryl or said naphthyl of R3 is substituted with at least one substituent comprising a halo atom, an alkyl substituted by aryl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by a heteroaryl, an arylalkynyl, a heteroarylalkynyl, an aryl, a heteroaryl, an arylalkenyl, or an arylalkyloxy.The compound of Claim 16, wherein said aryl or said heteroaryl of said substituent is further substituted by at least one aryl substituent.The compound of Claim 15, wherein said heteroaryl of R3 is substituted by at least one substituent comprising a pyridyl, a quinolinyl, a thienyl a furanyl, or an indolyl.The compound of Claim 18, wherein said substituent of said heteroaryl is further substituted by at least one moiety comprising an alkyl substituted by an aryl, an alkyl substituted by an aryloxy, an alkyl substituted by an aroyl, an alkyl substituted heteroaryl, an arylalkynyl, a heteroarylalkynyl, a heteroaryl, an arylalkenyl, or an arylalkyloxy.The compound of Claim 19, wherein an aryl of said moiety is further substituted by at least one aryl substituent.A compound of formula (la): whereinR? is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alky loxycarbony lam ino, cycloalkyl, heterocycloalkyl, R", -OR^, -S(0)mR" or-C(=O)-R6;R4 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=0)-Nγlγ2 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy,-S(0)m-alkyl or -Nγ!γ2; andR is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, trifluoromethyl, -C(=0)-NY1Y2, -Nγ!γ2, -Z1-C2_6alky1ene-R7 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido, -C(=O)-Nγlγ2, -SO2-NY1 Y2, -S(0)m-alkyl or -Nγ!γ2> and> a corresponding N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, an N-oxides and prodrugs.22. The compound of Claim 21 , wherein R3 is an aryl comprising a phenyl or a naphthyl.23. The compound of Claim 22, wherein said aryl is substituted by at least one substituent comprising a halo atom, an alkyl substituted by an aryl, an alkyl substituted by a heteroaryl.24. The compound of Claim 23, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.25. The compound of Claim 21, wherein R3 comprises phenylCι _3alkylpyridyl [e.g. 5- phenylethyl-pyrid-3-yl], phenylC 1.3 alky Ithienyl [e.g. 5-phenylethyl-thien-2-yl] or indolyl [e.g. indol-6-ylJ.26. The compound of Claim 21, wherein R3 is a heteroaryl comprising a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.27. The compound of Claim 26, wherein said heteroaryl is substituted by at least one substituent comprising an alkyl substituted by an aryl, or an alkyl substituted by a heteroaryl.28. The compound of Claim 27, wherein said aryl and said heteroaryl of said substituent are further substituted by at least one aryl group substituent.29. The compound of Claim 28, wherein R3 comprises phenylC 1.3 alkylpyridyl [e.g. 5- phenylethyl-pyrid-3-yl], phenylC 1.3 alky Ithienyl [e.g. 5-phenylethyl-thien-2-yl], or indolyl [e.g. indol-6-yl].30. The compound of Claim 21, wherein R4 comprises a hydrogen or a cyano.31. The compound of Claim 21, wherein R5 comprises a hydrogen, a lower alkyl or a halo.32. The compound of Claim 31, wherein R5 comprises a methyl or a fluoro.33. The compound of Claim 31 , wherein R5 is attached to the phenyl ring of formula (la) in the position para to the CH2NH2 group.34. The compound of Claim 21 , wherein:R is a phenyl, a naphthyl, a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, a phenyl substituted by at least one substituent, a naphthyl substituted by at least one substituent, or a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, that is substituted by at least one substituent, wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, and alkyl substituted heteroaryl, wherein the aryl or heteroaryl groups are further substituted by one or more aryl group substituents;R4 comprises hydrogen or a cyano; and R5 comprises hydrogen, a lower alkyl or a halo.35. The compound of Claim 34, wherein:R3 comprises phenylC 1.3 alkylpyridyl [e.g. 5-phenylethyl-pyrid-3-yl], phenylC 1.3 alky Ithienyl[e.g. 5-phenylethyl-thien-2-yl] or indolyl [e.g. indol-6-yl; R4 comprises a hydrogen or a cyano; andR5 comprises a methyl or a fluoro, and is attached to the phenyl ring of formula (lb) in the position para to the CH2NH2 group.36. A compound of formula (lb):whereinR? is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R >, -OR^, -S(0)mR^ or-C(=0)-R6;R4 is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=0)-NY^Y2 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, -S^m-alkyl or -NYiY2; andRp is hydrogen, acyl, alkoxy, alkyloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, frifluoromethyl, -C(=0)-NY1 Y2, -NY^Y2, -Z1-C2_6alkylene-R7 or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido,-C(=0)-NY1Y2, -S02-NY1Y2 -S(0)m-alkyl or -NY1 Y2> and> a corresponding N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, an N-oxides and prodrugs.37. The compound of Claim 36, wherein R is an aryl comprising a phenyl or a naphthyl.38. The compound of Claim 37, wherein said aryl is substituted by at least one substituent comprising a halo atom, an alkyl substituted by an aryl, an alkyl substituted by a heteroaryl.39. The compound of Claim 38, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.40. The compound of Claim 36, wherein R3 is a heteroaryl comprising a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.41. The compound of Claim 41, wherein said heteroaryl is substituted by at least one substituent comprising an alkyl substituted by an aryl, or an alkyl substituted by a heteroaryl.42. The compound of Claim 42, wherein said aryl and said heteroaryl of said substituent are further substituted by at least one aryl group substituent.43. The compound of Claim 36, wherein R3 comprises phenylC .3 alkylpyridyl [e.g. 5-phenylethyl- pyrid-3-yl], phenylC 1.3 alkylthienyl [e.g. 5-phenylethyl-thien-2-yl], or indolyl [e.g. indol-6-yl].44. The compound of Claim 36, wherein R4 comprises a hydrogen or a cyano.45. The compound of Claim 36, wherein R5 comprises a hydrogen, a lower alkyl or a halo.46. The compound of Claim 45, wherein R5 comprises a methyl or a fluoro.47. The compound of Claim 45, wherein R5 is attached to the phenyl ring of formula (lb) in the position para to the CH2NH2 group.48. The compound of Claim 36, wherein: R3 is a phenyl, a naphthyl, a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, a phenyl substituted by at least one substituent, a naphthyl substituted by at least one substituent, or a heteroaryl selected from the group consisting a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl, that is substituted by at least one substituent, wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, and alkyl substituted heteroaryl, wherein the aryl or heteroaryl groups are further substituted by one or more aryl group substituents;R4 comprises hydrogen or a cyano; andR5 comprises hydrogen, a lower alkyl or a halo.49. The compound of Claim 48, wherein:R3 comprises phenylC 1.3 alkylpyridyl [e.g. 5-phenylethyl-pyrid-3-yl], phenylC 1.3 alkylthienyl[e.g. 5-phenylethyl-thien-2-yl] or indolyl [e.g. indol-6-yl; R4 comprises a hydrogen or a cyano; and R5 comprises a methyl or a fluoro, and is attached to the phenyl ring of formula (lb) in the position para to the CH2NH2 group.50. The compound of Claim 1, selected from the group consisting of: 3-[l-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine; 3-[l-(3-phenylethyl-benzoyl)-piperidin-4-yl]-benzylamine;3-{ l-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine;3-{l-[3-(6-amino-pyridin-3-yl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine;3-[l-(5-phenylethyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine;4-fluoro-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine; 4-methyl-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;3-[l-(indole-6-carbonyl)-piperidin-4-yl]-benzylamine;4-(3-aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile[4-(3-aminomethylphenyl)piperidin-l-yl]-(3,4-dichlorophenyl)methanone; l-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-methylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one frifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(3-methylsulfanyl-6,7-dihydro-benzo[c]thiophen-l- yl)-methanone trifluoroacetate;1 - { 1 - [4-(3 -Aminomethyl-phenyl)-piperidin- 1 -yl]-mefhanoyl } -3 -ethylsulfanyl-6,6-dimethyl-6,7- dihydro-5H-benzo[c]thiophen-4-one frifluoroacetate; 1 - { 1 - [4-(3 -Aminomethyl-phenyl)-piperidin- 1 -yl]-methanoyl } -3 -propylsulfanyl-6,7-dihydro-5H- benzo[c]thioρhen-4-one frifluoroacetate; l-{ l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-isopropylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one frifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-benzo[b]thiophen-2-yl-methanone-frifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-l-yl]-l-(5-phenethyl-pyridin-3-yl)-methanone- ditrifluoroacetate;1 - [4-(3 -Am inomethyl-phenyι)-piperidin- 1 -yl]- 1 -( 1 -methyl- 1 H-indol-3 -y l)-methanone-trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-[3-(2-fluoro-phenylethynyl)-phenyl]-methanone frifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[2-(2-fluoro-phenyl)-ethyl]-phenyl}-methanone trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl}- methanone tri-trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(6-chloro-thieno[3,2-έ]thiophen-2-yl)-methanone frifluoroacetate; (3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3- carboxylic acid ethyl ester dihydrochloride;3-[l-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate;4-(3-Aminomethyl-phenyl)-piperidine-l-carboxylic acid (3 ,4-dichloro-phenyl):amide trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(2,3-dihydro-benzofuran-5-yl)-methanone; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(5,6-dichloro-pyridin-3-yl)-methanone; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(3-bromo-4-fluoro-phenyl)-methanone;(E)-l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-(2-nitro-phenyl)-propenone;1 -[4-(3-Aminomethyl-phenyl)-piperidin- 1-yl]- l-(3-bromo-5-iodo-phenyl)-methanone; and(E)-l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-phenyl-propenone.51. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier thereof.52. The pharmaceutical composition of Claim 51, wherein said compound is selected from the group consisting of:3-[l-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine; 3 - [ 1 -(3 -phenylethy l-benzoyl)-piperidin-4-yl] -benzylamine; 3-{l-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl}-benzylamine; 3- { 1 -[3-(6-amino-pyridin-3-yl)ethyl-benzoyl]-piperidin-4-yl} -benzylamine; 3 - [ 1 -(5-phenylethy l-thiophene-2-carbonyl)-piperidin-4-y 1] -benzylamine;4-fluoro-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine; 4-methyl-3-[l-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine; 3-[l-(indole-6-carbonyl)-piperidin-4-yl]-benzylamine;4-(3-aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile[4-(3-aminomethylphenyl)piperidin-l-yl]-(3,4-dichlorophenyl)methanone;1 - { 1 -[4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl]-methanoyl} -3-methylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(3-methylsulfanyl-6,7-dihydro-benzo[c]thiophen-l- yl)-methanone trifluoroacetate; l-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-ethylsulfanyl-6,6-dimethyl-6,7- dihydro-5H-benzo[c]thiophen-4-one frifluoroacetate; l-{l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-methanoyl}-3-propylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one trifluoroacetate;1 - { 1 -[4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl]-methanoyl} -3-isopropylsulfanyl-6,7-dihydro-5H- benzo[c]thiophen-4-one trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-benzo[b]thiophen-2-yl-methanone-trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-l-yl]-l-(5-phenethyl-pyridin-3-yl)-methanone- difrifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(l-methyl-lH-indol-3-yl)-methanone-trifluoroacetate;1 - [4-(3-Aminomethyl-phenyl)-piperidin- 1 -yl]- 1 - [3-(2-fluoro-phenylethynyl)-phenyI]-methanone trifluoroacetate; 1 - [4-(3-Aminomethy l-phenyl)-piperidin- 1 -yl]- 1 - {3 - [2-(2-fluoro-phenyl)-ethyl] -phenyl } -methanone frifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-{3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl}- methanone tri-trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(6-chloro-thieno[3,2-&]thiophen-2-yl)-methanone frifluoroacetate;(3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-l-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3- carboxylic acid ethyl ester dihydrochloride;3-[l-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate;4-(3-Aminomethyl-phenyl)-piperidine-l-carboxylic acid (3,4-dichloro-phenyl)-amide trifluoroacetate; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(2,3-dihydro-benzofuran-5-yl)-methanone; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(5,6-dichloro-pyridin-3-yl)-methanone; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(3-bromo-4-fluoro-phenyl)-methanone;(E)-l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-(2-nitro-phenyl)-propenone; l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-l-(3-bromo-5-iodo-phenyl)-methanone; (E)-l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-phenyl-propenone; and l-[4-(3-Aminomethyl-phenyl)-piperidin-l-yl]-3-cyclohexyl-propan-l-one.53. A pharmaceutical composition comprising a compound of Claim 21 and a pharmaceutically acceptable carrier thereof.54. A pharmaceutical composition comprising a compound of Claim 36 and a pharmaceutically acceptable carrier thereof.55. A method for treating a patient suffering from, or subject to, a condition that can be ameliorated by the administration of an inhibitor of tryptase, wherein the method comprises administering to the patient an effective amount of a compound of Claim 1.56. The method of Claim 55, wherein the condition comprises inflammatory disease, a disease of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, an interstitial lung disease, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, a neurofibroma, a hypertrophic scar, a dermatological condition, a condition related to atherosclerotic plaque rupture, periodontal disease, diabetic retinopathy, tumor growth, anaphylaxis, multiple sclerosis, a peptic ulcer, or a syncytial viral infection.57. The method of Claim 56, wherein the inflammatory disease comprises joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, or osteoarthritis; the dermatological condition comprises atopic dermatitis or psoriasis; and the condition related to atherosclerotic plaque rupture comprises myocardial infarction, stroke, or angina.58. A method for treating a patient suffering from, or subject to, a condition that can be ameliorated by the administration of an inhibitor of tryptase, wherein the method comprises administering to the patient an effective amount of a compound of Claim 21.59. The method of Claim 58, wherein the condition comprises inflammatory disease, a disease of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, an interstitial lung disease, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, a neurofibroma, a hypertrophic scar, a dermatological condition, a condition related to atherosclerotic plaque rupture, periodontal disease, diabetic retinopathy, tumor growth, anaphylaxis, multiple sclerosis, a peptic ulcer, or a syncytial viral infection.60. The method of Claim 59, wherein the inflammatory disease comprises joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, or osteoarthritis; the dermatological condition comprises atopic dermatitis or psoriasis; and the condition related to atherosclerotic plaque rupture comprises myocardial infarction, stroke, or angina.61. A method for freating a patient suffering from, or subject to, a condition that can be ameliorated by the administration of an inhibitor of tryptase, wherein the method comprises administering to the patient an effective amount of a compound of Claim 36.62. The method of Claim 61, wherein the condition comprises inflammatory disease, a disease of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, an interstitial lung disease, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, a neurofibroma, a hypertrophic scar, a dermatological condition, a condition related to atherosclerotic plaque rupture, periodontal disease, diabetic retinopathy, tumor growth, anaphylaxis, multiple sclerosis, a peptic ulcer, or a syncytial viral infection.63. The method of Claim 62, wherein the inflammatory disease comprises joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, or osteoarthritis; the dermatological condition comprises atopic dermatitis or psoriasis; and the condition related to atherosclerotic plaque rupture comprises myocardial infarction, stroke, or angina.64. A pharmaceutical composition comprising a compound of Claim 1 and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti- inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.65. The pharmaceutical composition of Claim 64, wherein the beta andrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenaline; the anticholinergic comprises iprafropium bromide; the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.66. A pharmaceutical composition comprising a compound of formula 21 and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti- inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.67. The pharmaceutical composition of iim 66, wherein the beta andrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenaline; the anticholinergic comprises iprafropium bromide; the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.68. A pharmaceutical composition comprising a compound Claim 36 and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti- inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.69. The pharmaceutical composition of Claim 66, wherein the beta andrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenaline; the anticholinergic comprises iprafropium bromide; the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.70. A method for freating a patient suffering from asthma, comprising administering to the patient a combination of a compound of Claim 1, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent71. A method for freating a patient suffering from asthma, comprising administering to the patient a combination of a compound of Claim 21, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent.72. A method for treating a patient suffering from asthma, comprising administering to the patient a combination of a compound of Claim 36, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti- inflammatory corticosteroid, and an anti-inflammatory agent.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0012362.0 | 2000-05-22 | ||
| GBGB0012362.0A GB0012362D0 (en) | 2000-05-22 | 2000-05-22 | Chemical compounds |
| US09/843,126 US6977263B2 (en) | 2000-05-22 | 2001-04-26 | Chemical compounds |
| US09/843,126 | 2001-04-26 | ||
| PCT/US2001/013811 WO2001090101A1 (en) | 2000-05-22 | 2001-04-27 | Arylmethylamine derivatives for use as tryptase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001257413A1 true AU2001257413A1 (en) | 2002-02-21 |
| AU2001257413B2 AU2001257413B2 (en) | 2007-01-18 |
Family
ID=26244322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001257413A Ceased AU2001257413B2 (en) | 2000-05-22 | 2001-04-27 | Arylmethylamine derivatives for use as tryptase inhibitors |
| AU5741301A Pending AU5741301A (en) | 2000-05-22 | 2001-04-27 | Arylmethylamine derivatives for use as tryptase inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU5741301A Pending AU5741301A (en) | 2000-05-22 | 2001-04-27 | Arylmethylamine derivatives for use as tryptase inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050228018A1 (en) |
| EP (1) | EP1296972B1 (en) |
| KR (1) | KR100858642B1 (en) |
| CN (1) | CN1230431C (en) |
| AR (1) | AR033525A1 (en) |
| AU (2) | AU2001257413B2 (en) |
| BR (1) | BR0111206A (en) |
| CA (1) | CA2409827C (en) |
| DZ (1) | DZ3347A1 (en) |
| HR (1) | HRP20020926B1 (en) |
| HU (1) | HU227630B1 (en) |
| IL (1) | IL152830A0 (en) |
| MA (1) | MA25809A1 (en) |
| MX (1) | MXPA02011400A (en) |
| NO (1) | NO327378B1 (en) |
| OA (1) | OA12274A (en) |
| PL (1) | PL360495A1 (en) |
| WO (1) | WO2001090101A1 (en) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04010441A (en) * | 2002-04-23 | 2005-02-14 | Shionogi & Co | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME. |
| CN100439337C (en) | 2002-11-26 | 2008-12-03 | 辉瑞产品公司 | Phenyl-substituted piperidine compounds as PPAR activators |
| GB0308613D0 (en) * | 2002-12-26 | 2003-05-21 | Aventis Pharma Inc | 4-(3-Aminomethylphenyl) piperidin-1-yl- 5-(2-fluorophenylethynyl) furan-2-yl- methanone as an inhibitor of mast cell tryptase |
| EP3178816A1 (en) | 2003-04-11 | 2017-06-14 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease |
| EP1620405A2 (en) * | 2003-05-01 | 2006-02-01 | Abbott Laboratories | Pyrazole-amides and sulfonamides as sodium channel modulators |
| GEP20094675B (en) | 2003-07-24 | 2009-05-10 | Euro Celtique Sa | Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain |
| EP1571150A1 (en) * | 2004-03-02 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Process for the preparation of tryptase inhibitors |
| KR101182690B1 (en) * | 2004-03-02 | 2012-09-14 | 아벤티스 파마슈티칼스 인크. | Process for the preparation of tryptase inhibitors |
| ES2332184T3 (en) | 2004-03-22 | 2010-01-28 | ELI LILLY & COMPANY | DERIVATIVES OF PIRIDILO AND ITS USE AS ANTAGONIST OF THE MGLU5 RECEPTOR |
| DOP2005000039A (en) * | 2004-03-26 | 2005-10-31 | Aventis Pharma Inc | HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE |
| JP4810426B2 (en) | 2004-07-01 | 2011-11-09 | 第一三共株式会社 | Thienopyrazole derivative having PDE7 inhibitory action |
| US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
| AU2005295730A1 (en) * | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| US7880007B2 (en) | 2004-11-29 | 2011-02-01 | Vertex Pharmaceuticals Incorporated | Bicyclic substituted phenyl piperidine modulators of muscarinic receptors |
| CA2587664A1 (en) * | 2004-12-21 | 2006-06-29 | Devgen N.V. | Compounds with kv4 ion channel activity |
| US7576218B2 (en) * | 2005-10-11 | 2009-08-18 | Chemocentryx, Inc. | 4-phenylpiperdine-pyrazole CCR1 antagonists |
| CA2630468C (en) | 2005-12-05 | 2015-01-20 | Otsuka Pharmaceutical Co., Ltd. | Medicinal drug |
| CN101505739A (en) | 2006-03-30 | 2009-08-12 | Ptc医疗公司 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith |
| US8115005B2 (en) | 2006-08-04 | 2012-02-14 | Decode Genetics Ehf. | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation |
| UA95978C2 (en) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Stat3/5 activation inhibitor |
| TW200833663A (en) * | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| WO2008075077A1 (en) * | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Piperidine derivatives for the treatment of obesity |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| WO2009044403A2 (en) * | 2007-10-05 | 2009-04-09 | Juvenis Ltd. | Injectable biodegradable polymer compositions for soft tissue repair and augmentation |
| CA2706391A1 (en) | 2007-11-21 | 2009-05-28 | Janssen Pharmaceutica N.V. | Spiropiperidines for use as tryptase inhibitors |
| EP2234485B1 (en) * | 2007-12-20 | 2013-11-13 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| RS54413B1 (en) | 2008-08-22 | 2016-04-28 | Sanofi | [4- (5-AMINOMETHYL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - [7-FLUORO-1- (2-METHOXY-ETHYL) -4TRIFLUOROMETOXY-1H-INDOL-3-IL] METHANONE AS INHIBITOR MASTOCYT TRIPTASES |
| EA020548B1 (en) | 2008-12-19 | 2014-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
| FR2955324A1 (en) * | 2010-01-15 | 2011-07-22 | Sanofi Aventis | DISUBSTITUTED 4- (5-AMINOMETHYL-PHENYL) -PIPERIDIN-1-YL] -1H-INDOL-3-YL] -METHANONES |
| ME01908B (en) | 2009-12-17 | 2014-12-20 | Boehringer Ingelheim Int | New ccr2 receptor antagonists and uses thereof |
| KR20120097410A (en) * | 2009-12-23 | 2012-09-03 | 사노피 | Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors |
| RS53456B (en) * | 2009-12-23 | 2014-12-31 | Sanofi | [4 [4- (5-AMINOMETHYL-2-FLUOR-PHENYL) -PIPERIDIN-1-IL] - (1H-Pyrrolo-pyridin-IL) -METHANONE AND THEIR SYNTHESIS |
| CN102770431A (en) * | 2009-12-23 | 2012-11-07 | 赛诺菲 | [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof |
| CA2785434A1 (en) * | 2009-12-23 | 2011-06-30 | Sanofi | Treatment for inflammatory bowel disease |
| WO2011079103A1 (en) * | 2009-12-23 | 2011-06-30 | Sanofi | Spiropiperidine benzylamines as beta-tryptase inhibitors |
| PT3002008T (en) * | 2010-03-11 | 2018-12-24 | Univ New York | Amido compounds as roryt modulators and uses thereof |
| US8877745B2 (en) | 2010-05-12 | 2014-11-04 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| EP2694707B1 (en) | 2011-04-07 | 2018-08-15 | Cornell University | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
| JP6203194B2 (en) * | 2012-11-30 | 2017-09-27 | 協和発酵キリン株式会社 | Nitrogen-containing heterocyclic compounds |
| TW201441193A (en) | 2012-12-06 | 2014-11-01 | Kyowa Hakko Kirin Co Ltd | Pyridone compound |
| BR112016011079A2 (en) | 2013-11-15 | 2017-12-05 | Wistar Inst | ? ebna1 inhibitors and their method of use? |
| TWI636978B (en) | 2014-03-06 | 2018-10-01 | 美商Ptc治療公司 | 1,2,4-oxadiazole benzoic acid salt and pharmaceutical composition |
| MX2017014550A (en) | 2015-05-14 | 2018-02-26 | Wistar Inst | Ebna1 inhibitors and methods using same. |
| AU2016287584B2 (en) | 2015-07-02 | 2020-03-26 | Centrexion Therapeutics Corporation | (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
| KR20180081516A (en) | 2015-10-30 | 2018-07-16 | 피티씨 테라퓨틱스, 인크. | How to treat epilepsy |
| CN112543634A (en) | 2018-05-17 | 2021-03-23 | 威斯达研究所 | Crystalline forms of an EBNA1 inhibitor and methods of making and using the same |
| WO2020163689A1 (en) | 2019-02-08 | 2020-08-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 20-hete formation inhibitors |
| CN110357833B (en) * | 2019-06-03 | 2022-05-24 | 杭州维坦医药科技有限公司 | Aromatic Heteroacetamide Derivatives and Their Preparation and Application |
| TW202115086A (en) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk inhibitors |
| BR112022024300A2 (en) * | 2020-06-04 | 2023-01-24 | Pillai Universal Llc | SMALL MOLECULES FOR TARGETED DEGRADATION OF UNTARGETED KRAS IN CANCER THERAPY |
| WO2025195508A1 (en) * | 2024-03-22 | 2025-09-25 | 润尔眼科药物(广州)有限公司 | Phenyl heterocyclic compound and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4407139A1 (en) * | 1994-03-04 | 1995-09-07 | Thomae Gmbh Dr K | New amino-alkylene(oxy) substd. aryl-aza:cycloalkane derivs. |
| US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
-
2001
- 2001-04-27 HU HU0302485A patent/HU227630B1/en not_active IP Right Cessation
- 2001-04-27 WO PCT/US2001/013811 patent/WO2001090101A1/en not_active Ceased
- 2001-04-27 PL PL36049501A patent/PL360495A1/en not_active Application Discontinuation
- 2001-04-27 BR BR0111206-6A patent/BR0111206A/en not_active IP Right Cessation
- 2001-04-27 AU AU2001257413A patent/AU2001257413B2/en not_active Ceased
- 2001-04-27 OA OA1200200357A patent/OA12274A/en unknown
- 2001-04-27 CA CA2409827A patent/CA2409827C/en not_active Expired - Lifetime
- 2001-04-27 CN CNB018119522A patent/CN1230431C/en not_active Expired - Lifetime
- 2001-04-27 MX MXPA02011400A patent/MXPA02011400A/en active IP Right Grant
- 2001-04-27 AR ARP010102009A patent/AR033525A1/en active IP Right Grant
- 2001-04-27 DZ DZ013347A patent/DZ3347A1/en active
- 2001-04-27 AU AU5741301A patent/AU5741301A/en active Pending
- 2001-04-27 IL IL15283001A patent/IL152830A0/en unknown
- 2001-04-27 EP EP01930925A patent/EP1296972B1/en not_active Expired - Lifetime
- 2001-04-27 KR KR1020027015683A patent/KR100858642B1/en not_active Expired - Fee Related
- 2001-04-27 HR HR20020926A patent/HRP20020926B1/en not_active IP Right Cessation
-
2002
- 2002-11-21 NO NO20025601A patent/NO327378B1/en not_active IP Right Cessation
- 2002-11-21 MA MA26919A patent/MA25809A1/en unknown
-
2005
- 2005-02-14 US US11/057,809 patent/US20050228018A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2409827C (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| AU2001257413A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| JP4796732B2 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| JP4323169B2 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists | |
| JP4563800B2 (en) | 1- (4-Piperidinyl) benzimidazolone as a histamine H3 antagonist | |
| EP1492785B9 (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
| JP4104983B2 (en) | Acylated piperidine derivatives as melanocortin-4 receptor agonists | |
| JP4980928B2 (en) | G protein-coupled receptor (GPR116) agonist and use thereof for the treatment of obesity and diabetes | |
| JP2006502180A (en) | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | |
| HK1087702B (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| JP2007197428A (en) | Pharmaceutical composition | |
| WO2004060884A1 (en) | [4-(3-aminomethylphenyl) piperidin-1-yl]- [5-(2-fluorophenylethynyl)furan-2-yl]-methanone as an inhibitor of mast cell tryptase | |
| JP2006045208A (en) | Piperidine compounds and process for producing the same | |
| HK1057899B (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| HK1120512A (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
| HK1071360B (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors |